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II. ABSTRACT 
 
Chapter One provides a general introduction into the biology and chemistry of nitric 
oxide, with particular focus on the role of nitric oxide in cardiovascular disease, cancer 
and hypoxia. It also details the types of organic functional groups used as nitric oxide 
donors, with detailed discussion of nitrate esters, furoxans and sydnonimines. 
 
Chapter Two discusses prostate cancer. It provides an overview into the development 
of prostate cancer, prostate cancer staging, and treatment. The key molecular aspects of 
prostate cancer are detailed, and the types of treatment available outlined. 
 
Chapter Three details the synthesis and activity of NCX-1102, a nitric oxide-donating 
analogue of the non-steroidal anti-inflammatory drug sulindac, and the synthetic work 
in the preparation of analogues of NCX-1102, using nitrate esters, furoxans and 
sydnonimines as nitric oxide-donating functional groups. The compounds prepared 
were tested against a prostate cancer cell line (PC3) and the cytotoxicity results are 
presented. 
 
Chapter Four describes the synthesis of nitric-oxide donating analogues of abiraterone, 
a CYP17 inhibitor for the treatment of prostate cancer. The results of cytotoxicity 
assays against PC3 cells are detailed. 
 
Chapter Five discusses the application of nitric oxide-donating functional groups in 
tandem with biologically active motifs. The synthesis of nitric oxide-donating amino 
acids, and their application to the preparation of nitric oxide-donating RGD peptides 
and prostate-specific membrane antigen inhibitors is presented, along with 
representative biological evaluation.  
 
Chapter Six introduces possible future work for the continuation of the project, 
suggesting the synthesis of fluorinated sydnonimines, prostate-specific membrane 
antigen inhibitors combined with for prostate cancer imaging and a “tool-box” of nitric 
oxide-donating bioconjugation reagents. 
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CHAPTER 1: NITRIC OXIDE 
Nitric oxide (NO) is a pleiotropic diatomic molecule, which plays diverse roles in 
chemistry and biology. It is a radical, with a single unpaired electron in a π* 
antibonding orbital (Figure 1). This electron is located on the nitrogen atom (Figure 1). 
Until 1986, the only known function of NO was as a toxic gas produced from the 
process of internal combustion in automobiles.1 However, more recently, this free 
radical has been implicated in the control of blood pressure,2 neurotransmission,3 
inhibition of platelet aggregation and immune regulation.4 It is also implicated in 
cytostasis and cytotoxicity in cancer,5 amongst other biological processes.  
                                                                	  	  	  	  	  	  	  	  	  
Figure 1: Lewis structure and ground state molecular orbital diagram of NO. 
 
Extensive and diverse research programmes have developed exploring the role of NO 
and its use as a therapeutic agent. In 1992 the journal Science named NO molecule of 
the year,6 and in 1998 its role in the relaxation of smooth muscle in the cardiovascular 
system was the subject of the Nobel Prize for Medicine.7 
2s 
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NO is sparingly soluble in water, where a maximum concentration of 2-3 mM can be 
achieved.8 It is unstable to many oxidising conditions, and its gaseous native state 
makes it difficult to introduce into biological systems. As such, efforts have focussed on 
developing compounds that will release NO through a variety of chemical and 
enzymatic methods. 
The biosynthesis of endogenous NO is regulated by a series of NO synthase (NOS) 
enzymes. There are three such synthases,9 which are characterised by their localisation 
of expression in cells. 
• Endothelial NOS (eNOS) is responsible for generating NO in the endothelium. 
The endothelium is the layer of cells which forms the inner layer in blood and 
lymph vessels. eNOS is also expressed in the kidneys, heart and brain, and is the 
principle NOS enzyme for regulating NO function in the vascular system. 
• Inducible NOS (iNOS) is expressed in macrophage cells and areas of the 
cardiovascular system in an oxidising environment. iNOS has roles in host 
immunity, anti-microbial properties, and macrophage oxidative burst. 
• Neural NOS (nNOS) is found in brain tissues in the central and peripheral 
nervous system and has roles in cell communication and in interactions with 
plasma membranes. 
 
Two NOS variants are also known, mitochondrial NOS (mtNOS) and bacterial NOS 
(bNOS).9 
The NOS enzymes are responsible for the catabolism of L-arginine (Arg) 1 to L-
citrulline 2 (Scheme 1).9 The guanidine moiety of 1 is hydroxylated to the intermediate 
N-ω-hydroxy-L-arginine 3, which remains in the enzyme active site. This requires a 
stoichiometric quantity of oxygen and nicotinamide adenine dinucleotide phosphate in 
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its reduced form (NADPH). In the second step, N-hydroxy-L-arginine 3 is oxidised to 
the amino acid L-citrulline 2 and NO, upon consumption of oxygen and half an 
equivalent of NADPH (Scheme 1). 
 
Scheme 1: Pathway for the endogenous biosynthesis of NO.  
 
The endogenous production of NO has diverse roles in biology, acting as a regulator in 
the  cardiovascular system, neurotransmission, inflammation and cell migration. Some 
these roles of NO summarised below, below with a focus on showing the activity of NO 
is based on its chemistry. 
 
1.1 BIOLOGICAL ROLES OF NO. 
1.1.1 NO IN THE CARDIOVASCULAR SYSTEM, AND ACTIVATION 
OF SOLUBLE GUANYLATE CYCLASE. 
The cardiovascular system is a network of vessels responsible for the distribution of 
blood, and its components, around the body. Blood vessels are constructed of four main 
parts as show in Figure 2.10 
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Figure 2: Anatomy of blood vessels. 
 
The interior “hollow” space where blood flows is the lumen, and the interior layer of 
cells facing into the lumen is the endothelium. Surrounding this in the walls of the 
vessels are layers of smooth muscle. It is the smooth muscle layer, and its ability to 
contract and relax, which enlarges the lumen to allow increased blood flow, and vice- 
versa to constrict blood flow. The smooth muscle layer is encased in a layer of collagen. 
In the cardiovascular system, NO induces the relaxation of the smooth muscle layer.11 
Furchgott identified that relaxation of smooth muscle is not a direct result of 
acetylcholine signaling, but due to an unknown messenger molecule, which was coined 
“endothelium-derived relaxing factor” (EDRF).12 However, the identification of EDRF 
eluded scientists for many years, as it was produced with a plethora of other products in 
nanogram quantities in endothelial cells. Glyceryl trinitrate (GTN) 4 and sodium 
nitroprusside (SNP) 5, had both been long used clinically for the treatment for 
angina13,14 without knowledge of a direct mode of action. It was subsequently elucidated 
by groups led by Louis Ignarro15 and Salvador Moncada,16 that EDRF was NO, and that 
GTN 4 and SNP 5 were both exogenous donors of NO.15,16  
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The production of NO in the endothelium is responsible for the signaling cascade 
regulating the conversation of guanosine-5-triphosphate (GTP) 6 to cyclic guanosine-
3,5-monophosphate (cGMP) 7.17–19 This process initiates a cascade of reactions that 
results in protein phosphorylation and relaxation of smooth muscle. The transformation 
of GTP 6 to cGMP 7 is catalysed by soluble guanylate cyclase (sGC) (Scheme 2) and 
sGC is recognised as a receptor for NO.20 
 
Scheme 2: Enzymatic conversion of GTP to cGMP. 
 
sGC is found in the cytoplasm of most mammalian cells, and it is predominantly located 
in the brain and lungs.21 sGC is a heterodimer of α and β subunits, the β subunit 
containing a haem component coordinated to a histidine residue at position 105 (His-
105).22 It has been determined spectroscopically that the iron atom in the haem is in the 
Fe (II) oxidation state,23 analogous to deoxyhaemoglobin.24 The binding of NO to this 
haem is responsible for activation of sGC. This event is consistent with the coordination 
chemistry of NO. 
NO is a π-acid ligand, analogous to the archetypal co-ordinating ligand carbon 
monoxide. When CO coordinates to a metal centre a σ bond is formed through overlap 
between the filled non-bonding orbital containing the lone pair of electrons on CO, and 
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an empty σ orbital on the metal. In low oxidation state metals, e.g. 2+ or lower, the 
metal pushes electron density from filled dxy, dxz and dyz orbitals into the empty π*-
orbital on CO, in a process described as synergic back-bonding. The overlap of these 
orbitals results in coordination of CO, with a metal-CO angle of 180° (Figure 3).25  
 
 
Figure 3: σ and π bonding modes in CO metal coordination. 
 
The ability of a ligand to undergo this type of π-bonding is called π-acidity. Unlike 
carbon monoxide which has an empty antibonding orbital, NO has one electron in the 
π*-antibonding orbital, and as such, would be less able to accept a π back-bond. 
However, NO can lose, or gain electron density as it binds to a metal.26 As a result, NO 
co-ordinates between the extremes of NO+ and NO-.26 NO+ is isoelectronic to CO, and 
NO+ coordination is analogous to CO, giving linear complexes with a strong metal-N 
bond. 
In contrast, NO- contains a half-filled π* anti-bonding orbital and cannot undergo π-
back bonding with a metal centre. Instead, it forms a σ-bond from an sp2 hybridised 
orbital. The shape of this orbital results in the ligand becoming bent with respect to the 
metal, at an angle of approximately 120° (Figure 4).26 This σ bond is still very strong, as 
NO- is isoelectronic to molecular dioxygen, which binds to metals in the same way. 
 
M C O M C O
M C O M C O
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Figure 4: σ-bonding in NO metal coordination 
 
Complexes with linearly bound NO+ are usually five coordinate, trigonal bipyramidal, 
with NO in an equatorial orientation,26 whereas NO- coordinated complexes are square 
pyramidal with NO in the apical position (Figure 5).26 
 
Figure 5: Geometry of five-coordinate NO complexes. 
 
The ability of NO to coordinate between these two extremes provides the metal with an 
“electron sink” in the case of NO+ coordinated ligands. In substitution reactions, a 
linearly coordinated NO+ ligand can temporarily accept electron density from a metal 
centre, becoming a bent NO- ligand, giving the metal two fewer electrons and allowing 
it to accept an incoming ligand.26 
The binding characteristics of NO can be used to explain the biologically observed 
activation of sGC. As the haem ring is fixed in a square planar geometry, the NO can 
only bind to give an octahedral complex; NO will bind in bent fashion. However, when 
NO is bound as NO-, any ligand trans to NO will share a bonding orbital on the metal. 
There is a very strong donation of electrons via the σ-bond from the nitrogen to the 
metal. However, due to the bent geometry, there is poor overlap between the d-orbitals 
and the π-orbitals, and the metal cannot redistribute this electron density via π back-
donation. As such, any ligand trans to NO- would have to donate electron density the 
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same σ orbital on the metal as NO- and the coordination would be very weak. When NO 
binds to the Fe porphyrin, the Fe—His-105 bond is weakened, such that it is 
enthalpically favoured for His-105 to dissociate, activating sGC. This hypothesis was 
proven experimentally by Dierks et al. through metalloporphyrin reconstitution 
experiments.27 By changing the Fe (II) ligand for Mn (II) and Co (II), they demonstrated 
that the trans-effect of the nitrosyl ligand was weakened by Mn (II) and increased by Co 
(II). This NO coordination and release of His-105 moves the Fe atom out of the plane of 
the porphyrin, exposing the active site and allowing GTP to enter.28  
The activation of sGC in smooth muscle is responsible for observed cardiovascular 
reactions including vasodilation, inhibition of platelet aggregation and activation, 
inhibition of cell adhesion molecule expression, lipid scavenging, and reduction of 
tissue factor expression.29 sGC has been identified as a therapeutic target for 
cardiovascular disease.30 
These biological functions have been exploited in medicine to use NO release as a 
method to modulate diseases such as angina and clotting disorders.31,32  
 
1.1.2 NO IN HYPOXIA 
Cells which lack sufficient oxygen are described as being hypoxic.33 In this state, they 
undergo a series of biochemical responses to compensate. Many cells, such as those 
found in solid tumours, experience oxygen deprivation in both acute and chronic 
hypoxic conditions.34,35 Acute hypoxia arises as a result of poor perfusion to the tumour, 
and as a result, oxygen delivery is low.36 Chronic hypoxia develops as a consequence of 
tumour growth beyond the limit of diffusion from tumour vasculature to cells within the 
tumour.37 Hypoxia in the cancer microenvironment is associated with increased 
invasiveness, metastases, and resistance to radio- and chemotherapy, and is a prognostic 
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marker for poor clinical outcomes.37,38 Cells in chronic hypoxic conditions, rather than 
activating pathways associated with programmed cell death, undergo the “hypoxic 
response”, where the cells adapt to the hypoxic environment and trigger a survival 
mechanism.39 The hypoxic response is regulated by expression of Hypoxia-Inducible 
Factor 1α (HIF-1α).39 HIF-1α is the only DNA regulatory element truly regulated by 
oxygen.40 The hypoxic response is summarised in Figure 6. 
HIF-1α is one of two HIF subunits, which when dimerised with HIF-1β form the HIF 
transcription factor (Figure 6).41  
 
Figure 6: Hypoxia and HIF-1α. The fate of cellular HIF-1α is determined by the oxygen content 
of the cells (Permissions requested, Carroll and Ashcroft).42 
 
Under normoxic conditions, HIF-1α is expressed, but it is rapidly degraded. Two 
proline residues in the oxygen-dependent domain of HIF-1α are modified by a family of 
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HIF-prolyl and arginyl hydroxylases.43 This modified protein then undergoes 
ubiquitination, mediated by the product of the von Hippel-Lindau (pVHL) tumour 
suppressor gene, and subsequent degradation.43 Under hypoxic conditions, the prolyl 
and arginyl hydroxylase activity is blocked, and as such, HIF-1α is not recognised by 
the pVHL and accumulates, translocates to the nucleus and interacts with HIF-1β, 
promoting gene transcription.44,45 The list of genes activated by HIF-1 is ever 
expanding, but they can be sub-grouped into classes. Many of the genes are related to 
adapting to reduced oxygen availability, by increased glucose uptake and glycolysis 
(GLUT1 and lactate dehydrogenase A).39 Other genes increase oxygen transport by 
promoting red blood cell maturation (Epo, transferrin)46 and angiogenesis (VEGF).47 
HIF-1 also has a role in cell apoptosis and necrosis.47,48 The combination of hypoxia-
induced gene expression, and genetic instability of cancer cells accounts for the 
observed radio- and chemo-resistance of hypoxic tumours.38 
It was shown by the group of Salvador Moncada that NO regulates the levels of HIF-1α 
by two separate mechanisms, one of which is dependent on the mitochondrial electron 
transport chain.49 Mitochondria are the major oxygen-consuming components of the cell 
and it has been reported that regulation of HIF-1α activity is dependent on 
mitochondrial function.50,51  
At high concentrations (> 1 µM), NO is responsible for stabilisation of HIF-1α under 
hypoxic and normoxic conditions; this effect is independent of mitochondrial activity. 
At low concentrations (< 400 nM), NO prevents the accumulation of HIF-1α in 
hypoxia, by inhibiting complex IV of the mitochondrial respiration chain.49 This 
reduced accumulation of NO is a result of increased degradation of the HIF-1α protein, 
not by a reduction in HIF-1α synthesis.49 It was shown that under pathophysiological 
hypoxic conditions with the addition of NO, molecular oxygen is redistributed from 
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cytochrome C oxidase in the electron transport chain, as the binding site of O2 is 
occupied by NO.49 This creates a situation where increased O2 is available for prolyl 
and arginyl hydroxylases and degradation of HIF-1α.52 
Reversing the hypoxic response with NO has been identified as a potential treatment for 
disease states where hypoxia is implicated, such as infant respiratory distress syndrome 
and neonatal hypoxia respiratory failure.53–55  
 
1.1.3 NITRIC OXIDE IN CANCER 
In contrast to cardiovascular disease, where the role of NO has been precisely defined in 
relation to the activation of sGC, the role of NO in cancer is much more diverse. 
NO has been identified as a cytoprotective, carcinogenic and cytotoxic agent in cancer, 
depending on the concentration within the tumour. NO has also been used as a cancer 
therapeutic. There is extensive literature on each subject,56,57 and some key aspects are 
discussed in this section. 
 
1.1.3.1 NO CYTOPROTECTION AND TUMOUR PROGRESSION 
The role of NO as a cytoprotective agent is closely related to its action as a carcinogen. 
NO is a free radical, and as such it readily interacts with other free radicals, such as 
molecular oxygen, and metals in biological systems. Low concentrations of NO have 
been shown to protect the cells from treatment by peroxides58,59 by preventing cell 
injury from lipid oxidation and subsequent endothelial damage.60 In these systems, NO 
acts a chain-breaking antioxidant, scavenging peroxide radicals.60  
Recently, the group of Wogan at MIT reported that endogenously produced NO is a 
factor in chemoresistance of melanoma cells towards cisplatin treatment.61 The role of 
NO in the nitrosylation of the proapoptotic enzyme caspase-3 was proposed as the 
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mechanism of this cytoprotection.61 Treatment with PTIO, an NO scavenger, or with S-
nitrosothiol scavengers reversed the cytoprotection.61 
 
PTIO 
 
The over-expression of NOS enzymes and subsequent increased production of NO has 
been identified as a factor in tumour growth. Malignant glioblastoma are aggressive 
brain tumours, with limited options for therapy and extremely poor prognosis, with a 
median survival of under 15 months.62 Eyler et al. reported that increased proliferation 
of glioma stem cells and tumour growth arises as a result of overexpression of NOS-2, a 
nitric oxide synthase isoform.63 Increased iNOS expression has also been examined as a 
cause of breast cancer metastasis.64 Large scale studies have revealed that the increased 
NOS production in breast cancers emerges as a result of upregulation of NOS in the 
tumour cells, not in the surrounding stromal tissue; and that increased NOS expression 
was associated with tumour invasion and microvessel density.65,66 Increased iNOS gene 
expression is reported in tumours of the brain, head, neck, oesophagus, lung, prostate, 
bladder, pancreatic and Kaposi’s sarcoma.67 
 
1.1.3.2 NO AS A CARCINOGEN AND CYTOTOXIC AGENT 
NO acts as a carcinogen due to its free radical chemistry and resultant DNA damage. 
There are three putative mechanisms which have been discussed for how NO induces 
DNA damage:68 
 
 
N
N
O
O
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(1) Formation of nitrosoamines and DNA base deamination. 
(2) Direct modification of DNA by reactive nitrogen/oxygen species. 
(3) Inhibition of DNA repair mechanisms. 
 
Nitrosoamines are chemical intermediates associated with nitrosative stress and are 
potentially carcinogenic.69 The mechanism of nitrosoamine formation has been 
proposed based on the gas-phase reactivity of NO.69 
2NO + O2 ⟶ 2NO2                   (1) 
NO + NO2 ⇌ N2O3                       (2) 
2NO2 ⇌ N2O4                                   (3) 
In the gas phase, NO reacts with O2 to give NO2 (1).69 In an environment with sufficient 
oxygen, this proceeds to completion and is irreversible.69 NO2 is in equilibrium with 
N2O3 (dinitrogen trioxide) (2) and N2O4 (dinitrogen tetroxide) (3). N2O3 is a potent 
nitrosating agent. In vivo, the primary substrates for nitrosation are the DNA bases 
adenine 8, guanine 9 and cytosine 10 (Scheme 3). The putative mechanism for DNA 
base nitrosation is shown in Scheme 3.68 Nitrosation of exocyclic amines 8-10 is 
proposed to form primary nitrosoamines 11-13 (Scheme 3).68 These decompose via the 
N-hydroxy species 14-16 with loss of nitrogen to give the deaminated products 17-19 
(Scheme 3).68 Adenine 8 is converted to hypoxanthine 17, guanine 9 to xanthine 18, and 
cytosine 10 to uracil 19. The conversion of these base pairs results in DNA mismatches 
in Watson-Crick base pairing as shown in Table 1. 
Original Base Pairs with  New Base Pairs with 
Adenine 8 Thymine Deaminates to Hypoxanthine 17 Cytosine 
Guanine 9 Cytosine Xanthine 18 Thymine 
Cytosine 10 Guanine Uracil 19 Adenine 
 
Table 1: Products of DNA base deamination. 
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Scheme 3: Deamination of DNA bases by dinitrogen trioxide.  
 
Single strand DNA is more susceptible to this process than double strand DNA.68 DNA 
deamination takes place more prevalently in replication and transcription of DNA. In 
tandem with other genetic mutations these DNA lesions can be carcinogenic. The 
nitrosation of secondary amines results in the formation of N-nitrosoamines which 
cannot undergo deamination, due to having two alkyl/aryl groups. These are implicated 
as nitrosyl transfer agents to primary amines. In addition to the deamination of DNA 
bases, DNA can be directly modified by the action of reactive nitrogen/oxygen species, 
specifically peroxynitrite (ONOO−).70 
Superoxide (O2−) is a common radical in biological systems. In vivo superoxide and 
NO react to give the peroxynitrite ion. This occurs at a rate of 7 x 109 M-1 s-1, near the 
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diffusion controlled limit.71 The reaction of NO with superoxide is faster than the rate of 
reaction of NO with haem centres, and of superoxide with superoxide dismutase.72,73 In 
biological systems, peroxynitrite reacts with carbon dioxide to give 
peroxynitrosocarbonate (ONOOCO2−), this decomposes to give CO3− and NO2 
radicals, and it is these radicals, along with peroxynitrite which cause DNA damage.74 
The mechanism of peroxynitrite induced DNA damage was exquisitely elucidated by 
Niles et al.70 Their main finding revealed that the predominant type of DNA damage 
involved modification at guanine 9 via oxidation reactions. The main products were 
identified as 20-25, summarised in Scheme 4 and 5.70 
 
Scheme 4: Summary of main peroxynitrite oxidation products of guanine.70 
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Scheme 5: DNA damage products from guanine.70 
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In addition to intramolecular reactions, guanine radical 27 can also react with thymidine 
bases 28 to result in cross-linked G-T 22.74 These DNA modifications, as with 
deamination, give rise to degraded DNA, which can lead to cancer formation.  
Interestingly, the chemistry of peroxynitrite in DNA has been exploited for the 
treatment of cancers where faulty DNA repair mechanisms have been proposed to lead 
to genetic instability.75 
The poly(ADP-ribose) polymerase (PARP) family of enzymes, responsible for DNA 
repair, is also inhibited by NO. The PARP enzymes contain a zinc finger motif, which is 
critical for DNA binding.76 These zinc fingers contain four cysteine residues responsible 
for binding the zinc atom.76 Sulfur atoms have a good affinity for NO, and S-
nitrosothiols are well documented. 
Upon exposure to NO, two nitrosative processes can take place.75 In the first, nitrosation 
of one of the key cysteine residues by N2O3, results in zinc expulsion. In the second, 
oxidation of a pair of cysteine residues by nitrite or peroxynitrite gives rise to a 
disulfide bridge, again with release of zinc. This reactivity with zinc finger enzymes has 
been documented in other enzymes with this DNA binding motif.77,78  
As described in this section, NO has many different roles in cancer. As a consequence, 
the development of NO as a therapeutic remains a challenging area of research. In 2004, 
Jones et al. identified that the NO released from (S)-nitroso-N-acetyl penicillamine 
(SNAP) 29 affected tumour angiogenesis in a dose-dependent manner.79  
 
At 26 µM nitrite, angiogenesis was increased by up to 46%; however, a ten fold 
increase of NO to 281 µM resulted in an 80% inhibition of angiogenesis.79 In addition 
OH
O
HN
SNO
O
29
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to angiogenesis reduction, a number of kinases were also inhibited at increased NO 
concentration.79 
This observation has led to the development of NO-drug hybrids. The combination of a 
known drug, with an established bioactivity against a therapeutic target, with an NO 
release functionality, adds an NO “warhead”.  
This leads us to consider the organic chemistry of NO-releasing functional groups. 
 
1.2 NITRIC OXIDE DONORS 
Since the 1980’s, organic chemists have developed a range of NO donors, such as those 
which release NO spontaneously or donate NO at a controlled rate, and to some 
extent.80 There are three main NO-release mechanisms,80 despite the variety of 
structural differences between precursor motifs. These are: 
1.) Thermal or photochemical decomposition. 
2.) Chemical induced release under acidic or basic conditions, or with a metal or 
thiol. 
3.) Enzyme activated decomposition. 
 
The currently developed NO donors, and their mechanism of NO release, is summarised 
in Table 2. 
In addition to molecules which directly release NO, there are many pharmaceuticals 
which work by an NO-dependent mechanism. A good example is the antiogensin-
converting enzyme (ACE) inhibitors such as Captopril.  
 
Captopril 
HS O
N
O
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ACE inhibitors inhibit the degradation of bradykinin, a peptide responsible for 
vasodilation and as a result, lower blood pressure.81 One of the ways that bradykinin 
achieves this is by the activation of NOS.82 The calcium channel blocker, amlodipine, 
also works by stimulation of NOS.83 Drugs of this type, in which part of their 
mechanism of action is the endogenous release of NO are called ‘NO stimulators’.80  
A detailed discussion on the nitrate esters, furoxans and sydnonimines follows, with 
discussion on their synthesis, biological properties and use in NO-hybrids. These motifs 
are directly relevant to this thesis. 
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Chemical Class Representative 
Compound 
Pathway of NO generation 
Non-Enzymatic Enzymatic 
Organic Nitrate84 
 
 
Thiol CYP450, GST etc 
Organic Nitrite85 
  
Hydrolysis, trans-
nitrosation, thiol, hν, 
heat 
Xanthine oxidase etc 
Metal-NO complex26 
 
 
Light, thiols, reductants, 
nucleophiles 
Membrane bound 
enzyme 
N-Nitrosamine86 
 
 
Hydroxide, hν CYP450 enzyme 
N-Hydroxyl 
Nitrosoamine87 
  
hν, heat Peroxidases 
Nitrosoimine88 
  
Thiols, hν Unknown enzymes 
Nitrosothiol89 
 
 
Spontaneous, enhanced 
by thiols, light, metal 
ions 
Unknown enzymes 
C-Nitroso90 
  
hν, heat Unknown mechanism 
Diazetine dioxide91 
 
 
Spontaneous, thiols Unknown mechanism 
Furoxan92 
 
 
Thiols Unknown enzymes 
Oxatriazole-5-imine93 
 
 
Thiols Unknown enzymes 
Sydnonimine94 
 
 
Spontaneous, enhanced 
by hν, oxidants, pH >5 
Prodrugs require 
hydrolysis 
Oxime95 
 
 
Spontaneous, O2/FeIII-
porphyrin 
CYP450 
Hydroxyamine96 
  
Auto-oxidation 
enhanced by metal ions 
Catalase/H2O2 
N-Hydroxy 
guanidine and 
Guanidine97 
  
Oxidants NOS, CYP450 
Hydroxyurea98 
 
 
H2O2/metalloenzyme 
Haem 
Peroxidase 
Hydroxamic acid99 
 
 
Unknown sGC 
Table 2: Nitric oxide donors 	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1.2.1 NITRATE ESTERS 
The earliest class of NO donors are the organic nitrates (Figure 7),84 which are esters of 
nitric acid with alcohols: GTN 4, isosorbide dinitrate (ISDN) 30 and pentaerithrityl 
tetranitrate (PETN) 31 and nicorandil 32 are examples of this class,84GTN, ISDN and 
nicorandil are used clinically.100  
 
Figure 7: General structure of nitrate esters. 
 
The nitrate ester functional group is widely used in pharmaceuticals,101 polymers,102 
propellants103 and explosives.104 The lower nitrate esters are colourless liquids with a 
“sweetish” smell,84 analogous to the corresponding carboxylic acid esters. They are 
generally insoluble in water. Nitrate esters are generally prepared by one of two 
methods, these are: esterification of the appropriate alcohol with nitric acid or they are 
formed nucleophilic substitution on carbon with a source of nitrate.84 
Alcohol esterification provides the most common method for the preparation of nitrate 
esters. In general, it involves the use of equal volumes of nitric and sulfuric acid as a 
nitrating mixture. The combination of these two acids generates the nitronium anion, 
which upon addition of an alcohol, is quenched to form the corresponding nitrate ester 
(Scheme 6). 
 
Scheme 6: Reagents and conditions: HNO3, H2SO4, 0 °C. 
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The reaction is carried under cooled conditions as the formation of the nitronium ion 
and reaction with an alcohol are highly exothermic processes.105 This method of nitrate 
ester formation was used by Serkov and Bezuglov in their preparation of the amino acid 
33 from L-threonine 34 (Scheme 7).106 
 
 
Scheme 7: Reagents and conditions: a.) i. HNO3, CH2Cl2, 0 °C, 1 h; ii. Ac2O, 0 °C to r.t., 45 
min, 63%. 
 
While this is an effective method for the preparation of nitrate esters, and uses readily 
available acids, it is only useful for nitrate esters of acid stable substrates. Complex 
molecules are unlikely to survive the highly acidic nitrating mixture. As a result an 
alternative mild method involving nucleophilic substitution has also developed. 
Nucleophilic substitution of an alkyl halide with silver nitrate offers an effective 
preparation (Scheme 8).107  
 
 
Scheme 8: Reagents and conditions: AgNO3, CH3CN, r.t. to reflux, Hal = Cl, Br, I. 
 
Advantages of this method are neutral reaction conditions and a wide functional group 
tolerance. In general, the reaction is carried out using acetonitrile as a solvent due to the 
relatively high solubility of AgNO3, but poor solubility of the silver halide salts that are 
formed.108,109 Dry solvent is required to avoid solvolysis of the ester.110 Alkyl iodides and 
bromides are generally most reactive under these conditions, and tertiary, allylic or 
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benzylic alkyl chlorides are also reactive. However alkyl chlorides require pre-
activation using a Finkelstein reaction.108 NaNO3, KNO3 and Bu4NNO3 have also been 
used in nitrate substitution reactions where the leaving group is mesylate or  
tosylate.111–113 Once prepared, nitrate esters are generally stable to most reaction 
conditions. They are unstable towards strong alkali conditions, and readily undergo 
direct SN2 substitution, α-hydrogen elimination of nitrite and β-hydrogen of nitrate, 
respectively (Scheme 9) with C-O and N-O solvolysis.110,114–116 The SN2 reaction has 
been shown to be predominant. 
 
Scheme 9: Reactions of nitrate esters in aqueous base. 	  
1.2.1.1 NITRIC OXIDE RELEASE FROM NITRATE ESTERS 
NO release from nitrate esters has been extensively researched, with a number of 
mechanisms being proposed.117 The chemical conversion of an organic nitrate to NO 
involves a three electron reduction. 
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RONO2 + e- ⟶ RONO + e- + H+ ⟶ ROH + NO2-      (1) 
NO2- + e- + H+ ⟶ HO- + NO, or                          (2) 
NO2- + Mn+ ⟶ M(n-1) + O + NO                          (3) 
 
A single electron is responsible for the reduction of the nitrate ester to the 
corresponding nitrite ester (1). The second, for further reduction and hydrolysis to the 
alcohol and nitrite (NO2-) (1). From here, nitrite can acquire a further electron and a 
proton to give NO and hydroxide (2), or interaction with a redox active metal Mn+ 
resulting in metal oxidation M(n-1) and the formation of NO and an oxygen radical (3). A 
number of metabolic enzymes appear to be involved in the de-nitrative metabolism of 
organic nitrates. These include aldehyde dehydrogenase 2,118 xanthine oxidoreductatase 
119 and glutathione-S-transferase (GST).120 No enzyme has yet been proposed to catalyse 
the three electron reduction of nitrate to NO.121 
Ignarro suggested that the initial two electron reduction was due to reaction of thiol 
residues, specifically thiolate cysteine 35 as illustrated in Scheme 10 to generate a 
thionitrate ester 36.117  
 
 
Scheme 10: Proposed mechanisms for nitrate ester reduction through a thionitrate ester 36. 	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From here, two reaction mechanisms were proposed: The first, (pathway A, Scheme 
10), involves the formation of a disulfide bond between thionitrate ester 36 and another 
cysteine 35, to liberate disulfide and nitrite.  The seconds (pathway B, Scheme 10), 
involves metal complex 37, whereby a redox active metal, chelated between 
heteroatoms to activate the sulfur residue to attack from another cysteine 35, also 
generating disulfide and NO.117 Yeates proposed that the intermediate thionitrate 36 can 
undergo a radical homolysis of the S-N bond as illustrated in Scheme 11, to give RS 38 
and NO2 39, with the radical localised on oxygen in the latter case (Scheme 11).122 
These combine to give the sulfenyl intermediate 40 and would rearrange to the sulfinyl 
species 41 (Scheme 11). Radical breakdown of either of these adducts would provide 
the sulfoxide radical 42 and NO. 122 
 
 
Scheme 11: Proposed mechanism for thionitrate ester decomposition. 
 
Yeates proposed a key role of glutathione-S-transferase in the catalysis of these 
reactions.122 Formation of the cysteine anion (RS-) is crucial for the mechanisms 
proposed, as nitrate esters are poor electrophiles for thiols (RSH) at physiological pH.123 
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1.2.1.2 BIOLOGICAL ACTIVITY OF NITRATE ESTERS 
The biological activity of nitrate esters is inherently linked to its NO release properties. 
Organic nitrates are used in the treatment of a range of cardiovascular diseases such as 
angina, myocardial infarction, congestive heart failure and the control of blood 
pressure.117  
Nitrate esters have been used as an effective way of preparing NO-hybrid drugs. Recent 
examples include the preparation of carnosine analogues e.g. 43.124  
 
Analogues such as 43 were able to trap toxic aldehydes and chelate copper acting as 
NO-donating antioxidants.124 The preliminary pharmacological activity suggests 43 has 
a potential for the treatment of complex vascular and neurodegenerative diseases where 
a reduction of NO availability and oxidative stress is implicated in disease progression.  
Qin et al. recently developed an “NO-chimera”, a molecule containing an NO release 
mechanism and also acting as a GABA mimetic e.g. 44.125 
 
These “nomethiazoles” showed good biological activity in Alzheimer’s disease models, 
citing that the novel scaffold was able to restore both synaptic function and cognition in 
mice.125 
Nitrate esters have also been shown to enhance the biological activity of natural 
products. For example, vincamine 45 is a potent vasodilator,126 and its semisynthetic 
derivative, vinpocetine 46 has been used in the treatment of cerebrovascular disease.126 
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Nitrate ester derivative 47 was shown to significantly increase cerebral blood flow 
without affecting blood pressure in comparison to vinpocetine 46.127 
 
 
1.2.2 FUROXANS 
Furoxan is the colloquial name given to the 1,2,5-oxadiazole-2-oxide heterocyclic 48. 
First synthesised in the early 1900’s,128 the biological activity of the furoxan was not 
investigated until the middle of the 20th century. NMR spectroscopy and X-ray 
crystallography were used to confirm the widely argued structure.128  
The furoxan structure was first proposed by Wieland in 1908.129 The position of the N-
oxide is indicated as 2-, N- or N2-oxide, based on an anticlockwise numbering of the 
atoms from the ring oxygen (O1), with the pentavalent nitrogen as N2. 
                                                      
The unsubstituted 1,2,5-oxadiazole-2-oxide 48 was synthesised in 1994 by Godovikova 
et al. by the action of dinitrogen tetroxide on glyoxime 49 (Scheme 12).130  
 
 
 
Scheme 12: Reagents and conditions, N2O4 (1 mol), dichloromethane, 35-38 °C, 45%.130 
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A colourless, stable liquid at room temperature, X-ray analysis shows that 48 is planar 
and has typical features common to many other furoxans, namely a short N2-O (exo) 
bond (1.240 Å) with a corresponding strong IR stretching frequency of 1620 cm-1, the 
O(1)-N(2) bond is longer at 1.44 Å.130  
A variety of methodologies exist to prepare furoxans, taking advantage of their potential 
to substitution reactions at the 3- and 4-positions. Contrary to other N-oxide systems 
(e.g. pyridine N-oxide, N-methylmorpholine-N-oxide), furoxans are not prepared by 
direct oxidation of the parent 1,2,5-oxadiazole-2-oxide (furazan) 50.  
 
 
The synthetic routes to furoxans 51 vary depending on the substitution required. 
Commonly used approaches involve cyclisation of a nitro-nitrene intermediates 
generated from azidonitroolefins,131,132 oxidative cyclisation of 1,2-dioximes,133  
dehydrative cyclisation of α-nitrooximes,134  or by nitrile oxide cycloadditions (Scheme 
13).135 
 
Scheme 13: Synthetic routes to furoxans. R, R1 = Aryl, SO2Ph.108,131,133–135 
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Furoxans e.g. 51 undergo deoxygenation with loss of the N-oxide to provide the furazan 
52 when treated with phosphites (Scheme 14).136  
 
     
Scheme 14: Reagents and conditions: P(OEt)3, 150 °C, 5 h, 53%, R = R1 = Ph.136  
 
Furoxans are useful starting materials for a number of chemical transformations, some 
of which retain the furoxan structure while others utilise the furoxan as a synthetic 
equivalent of the nitrile oxide for further reaction. For example, Whitney and Nicholas 
report the use of bis(phenylsulfonyl)furoxan 53 as a source of phenylsulfonyl nitrile 
oxide 54 during the preparation of dehydroisoxazoles 55-58 and isoxazole 59 (Scheme 
15, Table 3).137 The yields were modest, but the products were readily isolated and the 
starting material was easily prepared as described vida infra. 
 
Scheme 15: Dipolarophile (1 equiv.), 53 (4 equiv.), xylene, 3-7 h.137 
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Entry Dipolarophile Cycloadduct Yield 
1 
  
 
55 
46 
2 
   
56 
48 
3 
   
57 
34 
4 
   
58 
50 
5 
   
59 
52 
 
Table 3: Summary of cycloadditions with nitrile oxide surrogate. 
 
Furoxans are deactivated towards electrophilic substitution and are acid (H+) stable.128 
The furoxan ring is however, is susceptible to nucleophilic attack. Halides, nitro and 
sulfonyl groups in positions 3 and 4 can undergo nucleophilic substitution. 
Interestingly, bis(phenylsulfonyl)furoxan 53 undergoes substitution with oxygen 
nucleophiles in the 4-position very selectively due to its increased electrophilicity, to 
provide furoxan ethers 60 (Scheme 16).138 The use of functionalised nucleophiles 
allows the furoxan to be linked to other chemical entities.  
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Scheme 16: Reagents and conditions: a.) ROH, base (e.g. NaOH, tBuOK, DBU). R = alkyl, aryl. 
 
1.2.2.1 NITRIC OXIDE RELEASE FROM FUROXANS 
Although the furoxan was first identified in 1903, it was not until 1992 when Feelisch 
and colleagues reported the release of NO from the furoxan under physiological 
conditions.139 With this development, the furoxan presented itself as a bench stable, 
easily synthesised unit from which to develop new NO donors.139  
Feelisch determined that NO release from furoxans requires interactions with thiols. In 
biological systems, the two most prevalent thiol species are proteomic cysteine residues, 
and glutathione,139 both of which have been demonstrated in biological tests to initiate 
the breakdown of furoxans to release NO, with maximum NO release achieved with a 
50-fold excess of thiol.139 The products observed from the reaction of furoxan with an 
excess of glutathione were nitrite and nitrate, the final oxidation products of NO under 
aqueous aerobic conditions.140 
Feelish proposed a mechanism to account for the observed reaction products based on 
the reaction with thiolate species. The proposed mechanism implies the attack of 
thiolate onto the 3- or 4-position of the furoxan ring, producing intermediates, which 
decompose with the release of nitroxyl anion. This can then be oxidised to NO, and in 
turn, to nitrite and nitrate (Scheme 17).139 
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Scheme 17: Thiolate mediated NO release from furoxans. 
 
Attack of thiolate at the 3- or 4-position is dependent on the appended substituents.139 
The NO-release from furoxans in vivo, however, is a much more complicated process. 
NO-release may be thiol induced, but a possible enzymatic activation cannot be ruled 
out. This aspect of the furoxan pharmacochemistry has received little attention to date. 
 
1.2.2.2 BIOLOGICAL ACTIVITY OF FUROXANS. 
Furoxan hybrid drugs have been examined and researched extensively and have 
displayed a wide variety of bioactivities, in many cases greater than the parent drug they 
are conjugated to.92 Table 4 summarises a selection of the wealth of furoxan hybrids that 
have been prepared to modulate the biological activity of a bioactive compound. 
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Bioactivity Parent Drug Study 
   
α1- antagonists Prazosin Fruttero et al., 1995 141 
β1- antagonists Propranolol Boschi et al., 1997 142 
Ca2+ channel blockers 1,4-Dihydropyridines Cena et al., 2001 143 
K+ channel activators Nicorandil Mu et al., 2000 144 
NSAID conjugates Aspirin, Ibuprofen Turnbull et al., 2006; 145,	  Lolli 
et al., 2001 146 
Ca2+ channel activators (S)-Isradipine Visentin et al., 1999 147 
Anti-H.pylori Metronidazole Bertinaria et al., 2003 148 
H2-antagonist Lamtidine Bertinaria et al., 2000 149 
H3-antagonists Imoproxifan Tosco et al., 2004 150 
Anticancer 5-Fluoro-2′-deoxyuridine 
(osteosarcoma, mammary, 
murine sarcoma) 
Moharram et al., 2004 151 
 Thalidomide (hepatoma, lung 
carcinoma, prostate) 
Wang et al., 2009 152 
 Pemetrexed (lung carcinoma, 
gastric adenocarcinoma, 
hepatoma, leukaemia) 
Min et al., 2009 153 
 Glycyrrhetinic acid 
(hepatocellular carcinoma) 
Lai et al., 2010 154 
β2- agonists Fenoterol Busonsanti et al., 2007 155 
Bone resorption inhibition Bisphosphonates Lolli et al., 2010 156 
 
Table 4: Summary of furoxan hybrid drugs in the literature and the bioactivities they modulate. 
 
More recently, it was shown by Schiefer et al. that NO release from furoxans could be 
used as a neuroprotective and procognitive agent by activation of the sGC signaling 
cascade.157 
 
Peptidomimetic 61 restored synaptic function to hippocampal slices treated with an 
oligomeric amyloid-β peptide, the major component of amyloid plaques which impair 
synaptic function.157,158 This treatment could have use in the treatment of 
neurodegenerative diseases such as Alzheimer’s disease. 
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Collaborative research between the groups of Megson and Gasco led to the preparation 
and analysis of (R)-roscovitine analogue 62.159 It was shown to be pro-apoptotic for 
human neutrophils, and that it was more active than the parent (R)-roscovitine 63 in 
termination of the inflammatory response. 
 
 
 
1.2.3 SYDNONIMINES 
Sydnonimines 64 are 5-membered mesoionic heterocyclic rings containing an unusual 
O-N-N bond motif and an exo-imino group.160 
 
Mesoionic is an amalgamation of the terms mesomeric and ionic; and recognises that a 
mesoionic structure cannot be drawn without the use of a formal positive and negative 
charge. This distinguishes sydnonimines from other ionic species in organic chemistry 
such as zwitterions and ylides.161  
Syndnonimines were first synthesised in the 1950’s independently by two groups; 
Brookes and Walker160 in London and by Ohta and colleagues in Japan.162 Both 
laboratories followed a similar synthetic route involving an acid-catalysed cyclisation of 
an N-substituted N-nitrosoglycinonitrile 65. These were prepared by nitrosation of a N-
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substituted glycinonitrile with nitrous acid (Scheme 18). Protonation of the nitrile by 
strong acid is followed by concomitant cyclisation followed by elimination of an α-
proton to give the sydnonimine 64. 
 
 
Scheme 18: Mechanism of formation of sydnonimines. 
 
A highly-effective procedure for the synthesis of sydnonimine hydrochloride salts was 
reported by Turnbull and Beal in 1992.94 This describes a high yielding (>80%),  “one-
pot” procedure from an N-substituted glycinonitrile. The procedure uses isopentyl nitrite 
as the nitrosating agent and dry HCl gas to catalyse ring closure (Scheme 19). 
 
 
Scheme 19: Reagents and conditions: 1.) isopentyl nitrite, Et2O, 2-12 h, ii.) HCl (g), 5-10 mins, 
71-93%, R = alkyl, aryl, R1 = H.94 
 
The preparation outlines the use of isopentyl nitrite as the nitrosation agent in diethyl 
ether, followed by direct cyclisation catalysed by dry HCl gas. The advantage of this 
procedure is that the intermediate carcinogenic N-nitrosoamine 6569,163 species is not 
isolated. Upon isolation of the sydnonimine 64 further functionalisation can be readily 
achieved from the exo-cyclic nitrogen (Scheme 20) or electrophilic aromatic 
substitution on the ring. (Scheme 20, 21).164–167  
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Scheme 20: Elaboration of sydnonimine motif 64. R = Alkyl, Aryl, R1 = Alkyl, Aryl 
 
Once a substitutent has been placed onto the exo-imino position, then the 4-position of 
the ring can be substituted. Halogenation with chlorine, bromine and iodine proceeds 
smoothly using the appropriate N-halosuccinimide (Scheme 21).94,168,169 Halogenation 
with fluorine has not been reported. 
 
Scheme 21: C4 Halogenation of sydnonimines. 	  
1.2.3.1 NITRIC OXIDE RELEASE FROM SYDNONIMINES 
As in the case furoxans, sydnonimines can act as an exogenous source of NO,140 
however, the chemical mechanism of NO release from the sydnonimine moiety is not 
well understood.170 The mechanism is believed to begin with the hydrolysis of the N-
acyl unit of the sydnonimine 67 (Scheme 22, A). 140 probably by an enzymatic process, 
although chemical hydrolysis has not be ruled out.  
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Scheme 22: Hydrolysis of sydnonimines to release NO. 
 
Unsubstituted sydnonimines 64 are unstable as the free base, exposure to oxygen, or 
enzyme hydrolyses ring opening to give the N-nitroso species 65 (Scheme 22, B). which 
can be oxidised to NO. 
Khmel’nitskaya et al. studied the mechanism of NO release from a number of 
sydnonimines by chemical hydrolysis and found that substitution at the 3-position with 
a dialkylamino group increased NO production ten-fold with a maximum of 31 ± 2% of 
available NO reported.171 Alkyl substitututed sydnonimines were poor NO donors under 
the chemical assay. The working hypothesis proposes that dialkylamino substituents 
lower the activation energy of NO release by stabilising the cation formed (Scheme 23).  
 
   
Scheme 23: Resonance stabilisation of dialkylamino substitutents by 1,3-hydride shift. R = 
alkyl. 
 
Clearly the pathways of NO release in vitro and in vivo may not be the same.172 It 
appears that in vivo release is enhanced by enzymatic degradation. For example, the 
monoamine oxidase (MAO) inhibitor sydnophen 68 with a 1-phenylpropan-2-yl side 
chain has been shown to be an active NO generator in vivo, but in the Khmel’nitskaya 
assay it showed only 1% NO release.171  
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1.2.3.2 BIOLOGICAL ACTIVITY OF SYDNONIMINES 
The reported bioactivity for sydnonimines is extensive with the parent heterocycles or 
minor derivatives, demonstrating anti-tumour,173 anti-inflammatory164 and spasmolytic 
(muscle relaxant) activity.174 For example, Yashunskii et al. reported an extensive 
number of 3- and 4-substituted alkyl, aryl and aralkyl sydnonimines demonstrating 
reversible inhibitory properties of MAO and peripheral sympathomimetic CNS 
activation.175  
 
Figure 8: Increased inhibition of MAO of alkyl chain sydnonimines. 
 
Sydnonimines have shown significant promise as cardiovascular therapeutics. These are 
exemplified in three key compounds, SIN-1 69, Molsidomine 70 and CAS-936 71.  
 
Molsidomine 70 is an antihypertensive, long acting vasodilation drug used clinically for 
the treament of stable, moderate angina pectoris. It is a prodrug for SIN-1 69 and 
derives its activity from the release of NO.176 CAS-936 71 is structurally similar to 
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molsidomine 70 and acts as an antiischemic agent. However, while molsidomine 70 
requires liver metabolism to generate its active component, CAS-936 71 is believed to 
possess a vasodilating activity of its own. CAS-936 71 is not used clinically.177 
Soulère et al. developed a series of sydnonimines 73-77 as potential trypanocidal agents 
against Trypanosoma equiperdum,178 with compound 75 showing improved activity 
compared to cymelarsan 77178 an arsenic based drug for the treatment of African 
trypanosomiasis (Scheme 24).179  
 
 
Scheme 24: Reagents and conditions: a.) 4-Nitrophenyl chloroformate, pyridine, 25 °C, 16 h, 
70%; b.) 73, EtOH, reflux, 3.5 h, 83%; 74: t-BuOH, reflux, 18 h, 70%; 75: 2,4-[(4,6-diamino-
1,3,5-triazin-2-yl)amino]phenyl-1-ethanol, CH3CN, 82 °C, 4 h, 26%; 76: 2′,3′-O-isopropylidene-
adenosine, CH3CN, 4 h, 50%.178 
 
Cai et al.180 developed a series of glycoside based sydnonimines 82-83 (Scheme 25). 
These carbohydrate conjugated sydnonimines could be deprotected to give the parent 
sugar. NO was catalysed by the action of glycosidases.180 
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Scheme 25: Reagents and conditions: a.) 4-Nitrophenylchloroformate, Et3N, CH2Cl2, r.t., 4.5 h, 
80 = 90% , 81 = 88%, (1:3 α/β); b.) 69, pyridine, r.t., 12 h, 82 = 35% (α), 10% (β), 83 = 40% 
(α+β).180 
 
Perflurophenyl carbamate 84 was also successful for the synthesis of active esters of β-
lactam cephalosporins (Scheme 26).181 Coupling of 84 with SIN-1 69 furnished 
sydnonimine 85 in a 4:1 inseparable mixture of 3’- and 2’- position isomers in 42% 
yield (Scheme 26). The release of NO from 85 was catalysed by penicillinase.181  
 
 
Scheme 26: Reagents and conditions: a.) 69, pyridine, 42%. 
 
1.3 MEASURING NO RELEASE. 
Measuring the concentration of NO in samples of air or biological milieu is difficult. 
The rapid oxidation of NO to nitrite (NO2-) and nitrate (NO3-) by oxygen, and its 
reaction with superoxide to give peroxynitrite (ONOO-) results in a very short half-life 
for NO. A number of assays have been developed measure NO, however, they are 
indirect assays generally measuring oxidation products or NO-adducts. 
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NO is a radical and EPR spectroscopy can be used to detect its presence. However, the 
direct detection of NO directly by EPR is not possible, as the relaxation time of the 
stimulated electron is too rapid to be detected.182 In order to detect NO by EPR, 
nitroxide spin traps such as 2-methyl-2-nitrosopropane 86 or 3,5-dibromo-4-
nitrosobenzenesulfonic acid 87 are required.183   
 
Haemoglobin (Hb) has also been used as a spin trap where the nitrosyl-Hb adduct is 
readily measurable by EPR.184 This method has been used to detect NO production from 
arterial rings184 and for the investigation of the production of nitrosyl-Hb in septic 
shock.185,186 
Hb can also be used to detect NO spectrophotometrically when it reacts with 
oxohaemoglobin (Hb(Fe2+)O2) to give nitrate and methemoglobin (Hb(Fe3+))15 the latter 
can be observed at 406 nm.15 The reaction of NO with Hb occurs in less than 100 ms,187 
and as such it is useful for determining the production of NO from a biological sample 
over an extended period. The disadvantage of this technique is commercially available 
haemoglobin must first reduced be with dithionite, and purified by gel 
chromatography.187 
A second widely used spectrophotometric analysis is the Griess test.188 It is generally 
accepted that the complete exclusion of oxygen from biological samples or buffers is 
virtually impossible, and that any oxygen present will rapidly oxidise NO to nitrite, and 
then from nitrite to nitrate. The oxidation of nitrite to nitrate is much slower, and as 
such, there is a build up of nitrate. Griess developed a diazotisation method for the 
N O
NO
Br Br
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detection of nitrite, and this has been adopted as a proxy measurement for the 
production of NO (Scheme 27).188  
 
Scheme 27: Reactions of the Griess test for nitrite determination. 
 
In this assay, a sample is incubated with sulfanilamide 88 in the presence of an acid, 
usually phosphoric acid. This generates the nitrosonium ion, which reacts with 
sulfanilamide 88 to give diazonium 89. Following incubation, N-(1-
naphthyl)ethylenediamine 90 is added, and the sample is further incubated. During this 
time, coupling between the diazonium 89 the amine 90 generates the diazo compound 
91 that can be detected spectrophotometrically between 550 and 570 nm. The Griess 
test is the most widely used assay for detection of NO. It is easy to perform, and the 
materials required are commercially available in kit form. The method can be adapted 
such that NO release can is assessed in samples in 96-well plate format using a 
microplate reader, allowing for high-throughput analysis of NO production.188 In 
addition to the detection of NO by spectrophotometric methods, NO can be detected by 
chemiluminescence. The chemiluminescence assay was first developed to assay the 
concentration of NO in atmospheric samples.189 NO reacts with ozone to generate light 
((1) and (2)), which can be detected by a sensitive photomultiplier tube.  
NO + O3 ⟶ NO2 + O2               (1) 
NO2 ⟶ NO2 + hν                      (2) 
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This assay can be modified to detect NO in solution by driving solubilised NO into the 
gas phase by bubbling helium through the solution. The chemiluminescence assay 
detects NO production to a level of 10-13 M (100 fM).189 This technique detects oxygen 
metabolites of NO through the use of an acidifircation step; however this process can 
result in an over-estimation of NO levels.190 
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CHAPTER TWO: PROSTATE CANCER 
 
In the United Kingdom, prostate cancer (PCa) accounts for 13% of male cancer deaths 
and represents 25% of all new male cancers diagnosed. In 2010, this equated to 40,975 
new cases, which is approximately 134 cases per 100,00 men in the UK. PCa 
commonly affects men over the age of 50, and as a consequence presents significant 
challenge in diagnosis and prognosis for clinicians, as progression from a localised 
tumour to metastatic disease can be rapid, and currently there are no tumour markers 
known to identify aggressive forms of the disease. 
 
2.1 THE PROSTATE 
The prostate is an exocrine gland of the male reproductive system. It is found in the 
majority of mammals. In humans the prostate is found in the lower abdomen and 
surrounds the urethra. Anatomically, the prostate is divided into sections, described as 
zones or lobes. It consists of epithelial glands and is encased in a fibromuscular stroma; 
the prostatic capsule.191  
The role of the prostate is to store and secrete prostatic fluid, a component of semen. 
These secretions are alkaline and are generally composed of basic sugars, zinc and 
proteolytic enzymes. Prostatic fluid also contains prostatic acid phosphatase and 
prostate-specific antigen (PSA); both of which are elevated in PCa and are used as 
diagnostic markers.192 
The prostate is regulated by specific androgens produced by the body.193 The main 
regulatory androgen is testosterone 92, a C19 steroid produced in the testes under the 
control of pituitary hormones.194 
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Testosterone 92 is then converted into dihydrotestosterone 93 (DHT) by the action of 5-
alpha reductase. DHT can then act through the androgen receptor (AR) in prostate 
tissue.195 
 
2.2 PROSTATE CANCER 
Tumours of the prostate have been shown to develop over 20-30 years or more, and up 
to 10% are based on an inherited genetic predisposition to prostate tumourigenesis.196 
Post-mortem data estimates that approximately 50% of all men in their fifties have 
histological evidence of PCa. This rises to 80% by age 80.197 
PCa arises in the epithelial or progenitor cells within the prostate and is initially an 
adenocarcinoma.198 The discovery of the requirement for androgens for PCa growth was 
the topic of pioneering work by the Nobel Prize (1966, Physiology or Medicine) 
laureate Charles Huggins.198 
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Figure 9: Pathology of prostate cancer (Image from National Cancer Institute Library) 
 
Stage I of PCa involves the accumulation of malignant cells within otherwise normal 
prostate glands (Figure 9). Stage I is regarded as a carcinoma in situ. Due to the 
complex biochemistry within the tumour, genetic markers to gauge the innate malignant 
potential of the tumour, at this stage, have yet to be identified.199–201 Diagnosis of PCa at 
Stage I rare as the tumour presents only in small pockets within the prostate, and cannot 
be identified by a digital rectal exam. 
Further growth of the tumour to the point it can be palpated upon examination, but 
remains within the gland, is characteristic of a Stage II carcinoma. At this stage, the 
tumour may have spread bilaterally to both lobes of the prostate (Figure 9).202 Further 
diagnosis of the tumour is based on a patients PSA level, the rate of change of PSA 
level and the Gleason score; a measurement of cell abnormality based on histology.203 A 
combination of these results provides critical information to clinicians regarding 
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anticipated tumour behaviour. Up to this point, the PCa can still be treated surgically; 
this is discussed in detail (vida infra). 
Once the tumour advances through the prostatic capsule, the cancer has reached stage 
III. Stage III tumours are associated with metastases that remain within the pelvis 
(Figure 9).202 From Stage III onwards there is a marked change in overall patient 
prognosis. Metastases further than the prostate represent Stage IV (Figure 9). Prostate 
metastases are found in the bones in up to 80% of cases,204 with lung, liver, pleural and 
adrenal metastasis also common.205 Post-mortem analysis has indicated that metastasis 
occurs through the spinal veins, and through the vena cava.205 In general, treatment at 
this stage with androgen ablation therapy is effective in the majority of patients, 
however, they experience disease recurrence in a median of 12-18 months. This 
represents Stage IVa of prostate cancer progression, termed castration-resistant prostate 
cancer (CRPa). At this advances stage, tumour growth is independent of androgens and 
treatment options are limited, metastases are extensive and the prognosis is poor. 
 
2.3 GENETIC PREDISPOSITION TO PROSTATE CANCER 
Familial studies on PCa have consistently shown a strong hereditary component in PCa 
risk, greater than any other type of cancer.196 Men with PCa were more likely to report 
having a brother or father with PCa than the family of their spouses.206 An early study 
on the molecular genetics of familial PCa identified a chromosomal region, which has 
gone on to be named the hereditary prostate cancer gene (HPC1).207 However, further 
studies into the effect of the HPC1 gene on PCa have produced ambiguous results.208–211 
To date, no oncogene has been linked conclusively with the initiation or early 
progression of PCa.212 However, a number of classical oncogenes have been researched 
in PCa to further understand the molecular progression of carcinogenesis and the 
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clinical impact on prognosis.213 Most recently, it was identified that germline mutations 
in BRCA1/2 are responsible for more aggressive PCa phenotypes, distant metastases and 
a higher probability of lymph node involvement,214 with overall poor patient prognosis. 
This suggests that the BRCA1/2 genes could be used as prognostic markers for PCa in 
the same way they are used in breast and ovarian carcinoma.215,216  
While the number of individual mutations examined are too great to describe in detail, a 
paradigm of progression has been established, which correlates the most common 
molecular changes in PCa throughout its growth (Figure 10).217 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Molecular progression in PCa (adapted from Karayi)217 
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2.4 MOLECULAR FEATURES OF PROSTATE CANCER 
A number of key molecular architectures in PCa have been used to identify the 
molecular mechanisms at play during its progression, and have been identified as targets 
for treatment and diagnosis. Detailed below are key molecular features which contribute 
to the progression and treatment of prostate cancer. 
 
2.4.1 THE ANDROGEN RECEPTOR 
The androgen receptor is a nuclear receptor responsible for the binding of testosterone 
or dihydrotestosterone (Figure 11).218 It is composed of amino-terminal and carboxy-
terminal ligand binding domains, and a DNA-binding domain containing two zinc 
fingers.219,220   
 
Figure 11: Crystal structure of the androgen receptor (rainbow helices) complex with 
testosterone (white sticks). Created using PyMol based on PBD crystallographic structure 
2AM9.219 
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Like other DNA-binding proteins, it is chaperoned by heat shock proteins when free 
from a ligand.221  
The main function of the androgen receptor is as a DNA-binding transcription factor. 
Upon ligand binding, the AR sheds its molecular chaperones and translocates to the 
nucleus, it then dimerises and results in regulation of androgen response genes. The AR 
also interacts with other proteins in the nucleus to regulate gene transcription.  
Male development is dependent on the action of the androgen receptor.222 After puberty, 
the androgen-receptor is responsible for the regulation of genes related to male sexual 
characteristics, and for growth-quiescent maintenance of the prostate epithelial tissue 
(where the AR is widely expressed) and for increased production of PSA. 
Prostate epithelial tissue is the main tissue type which is transformed into prostate 
adenocarcinoma.223 Genetic faults in these growth-quiescence elements results in PCa 
progression which is regulated by the supply of androgens within the cell. The act of 
androgens alone interacting with the androgen receptor alone does not appear to 
promote carcinogenesis in humans. 
 
2.4.2 ANDROGEN RECEPTOR IN PROSTATE CANCER 
The AR is heterogeneously expressed throughout primary prostate tumours, and 
androgen receptor expression has no correlation with a patient’s response to androgen 
ablation therapy.224 Anti-androgen therapy directly blocks the activity of the AR, and 
consequentially begins the cascade to induce apoptosis.225 While AR inhibition is 
effective in treatment at Stage IV of the disease, the AR is implicated in the 
development of CRPa. In most cases of CRPa, the expression and activity of the 
androgen receptor are maintained,226 and the receptor drives the progression of the 
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disease in castration-levels of testosterone.227 A number of mechanisms have been 
suggested for this activity. 
The first is a hypersensivity pathway. This mechanism suggests that the prostate cancer 
has a lower threshold for androgen activity and can be activated in castration-levels of 
testosterone.228 One postulated mechanism is the overexpression of the AR gene.229 AR 
overexpression results in increased sequestration of the remaining low levels of 
testosterone, allowing growth at castration-levels of testosterone. Approximately 30% 
of CRPa tumours overexpress the AR after androgen ablation,230 although mutation may 
be independent of selective pressure of androgen blockade.231 Amplification can be a 
result of clonal selection of the cells which will proliferate in the low levels of 
androgen.232 The hypersensitivity pathway has also shown that local production of DHT 
can account for proliferation in CRPa.233 Increased 5a-reducatase activity may account 
for the observed increased levels of DHT in castration-levels of testosterone.195 
The second pathway has been coined “the promiscuous pathway”.228 Somatic mutations 
in the AR gene result in mutations in the AR binding site, such that it can be activated 
by other ligands such as non-androgens,234–236 antiandrogens,237,238 or in the absence of 
a ligand.239 Genetic changes can also result in overexpression of the androgen receptor 
itself, either in a wild type, or mutant form. A study by Shi et al. examined the function 
of the androgen receptor in CRPa tumours.240 The results are shown in Table 5. In 
summary, they found that 77% of tumours had AR activity at partial or increased levels 
to wild type.240  
Androgen Receptor Activity Percentage 
Loss of function 16 
Wild Type function 7 
Partial function 32 
Gain of function 45 
 
Table 5: Androgen receptor function in CRPa tumours.240 
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In the absence of AR mutation, CRPa may be driven by ligand-independent 
mechanisms. Such pathways have been classed as “outlaw pathways”. Outlaw pathways 
are the induction of AR activity through androgen-independent mechanisms. AR 
activation by growth factors,239 receptor tyrosine-kinases (e.g. HER-2/neu)241 and 
aberrant Akt signaling242 have been identified in the literature. 
These examples show that the AR plays a key role in the progression of early PCa 
cancer and the progression from metastatic disease to CRPa. 
 
2.4.3 PROSTATE-SPECFIC ANTIGEN 
Prostate-specific antigen (PSA) is a serine protease produced by prostatic tissue and is 
used as a clinical test for prostate cancer.192 A glycoprotein, it consists of a 237 amino 
acid protein appended with a carbohydrate chain.243 In normal prostate tissue, PSA is 
secreted into the glandular ducts, where it is highly concentrated. PSA only reaches 
circulation if there is “leaking backwards” from the duct into the extracellular fluid and 
into circulatory plasma.244 In prostate cancer, the structure of the prostate is changed 
and malformed. As a result, there is an increased amount of PSA directly secreted into 
the extracellular fluid and, as such, into the plasma.244  
PSA level has long been used as a clinical test for prostate cancer, however, in recent 
years there has been less reliance on PSA level as an indicator for prostate disease. 244 
The United States Preventive Services Task Force recently ruled that the PSA level 
should not be used as a disease marker for prostate cancer, as it results in an 
overdiagnosis of otherwise asymptomatic PCa.245 A PSA level of between 4-10 ng/mL 
is reported as “suspicious” and warrants further assessment.218 More often, the PSA 
velocity is considered. The velocity is the rate of change of PSA levels, which is most 
relevant once a tumour reaches the size when it requires vascularisation for continued 
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growth, approximately 1-3 mm in diameter.246 From this point, direct blood supply 
access to the tumour increases the relevance of the PSA test. PSA level is a clinical 
indication of AR activity247 not for the presence of prostate cancer.  
 
2.4.4 PROSTATE-SPECIFIC MEMBRANE ANTIGEN 
Prostate-specific membrane antigen (PSMA) is a folate hydrolase that is expressed in 
primary and metastatic prostate cancer.248 Expression is further upregulated in CRPa 
and in aggressive high-grade tumours.249,250 PSMA is not expressed in the vasculature 
of healthy non-prostatic tissue. The crystal structure for PSMA was solved by Davis et 
al. in 2005, revealing a zinc binding site and a substrate binding arginine patch (Figure 
12).251 
 
Figure 12: Crystal Structure of PSMA. A.) Ribbon diagrams of side and top view of PSMA with 
NAAG 94 and methotrexate bound; B.) Overlay of zinc binding site of PSMA with similar 
enzymes; C.) Proposed role of Zn in a-NAAG cleavage. Adapted from Davis M. I. et al, Proc. 
Natl. Acad. Sci. 2005, 102, 5981-5986. Copyright held by The National Academy of Sciences of 
the United States of America, 2005. 
A! B!
C!
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The physiological role of PSMA in the prostate is not known. However, it is known to 
cleave glutamate from N-acetylaspartyl glutamate 94 (NAAG) (Scheme 28).252,251 
  
Scheme 28: Hydrolysis of NAAG 94 to acetyl aspartate 95 and glutamate 96. 
 
PSMA shuttles between the cell interior and cell surface for further internalisation.253 
The combination of these attributes has led to PSMA being identified as a potential 
target for tumour targeted drug delivery, and as a prognostic biomarker. 
Currently, an indium-111 labelled anti-PSMA antibody is used to detect soft tissue 
metastasis and disease recurrence, which targets PSMA while internalised.254 
Radiolabelled monoclonal antibodies have also been shown to target cell surface 
PMSA,255 but their long-circulating half-life and poor tumour penetration limit their 
clinical effectiveness. 
In light of this, Kozikowski et al.256 developed a series of dipeptide PSMA inhibitors 
97, which, rather than being traditional amide (C-N) linked dipeptides, they are linked 
by a urea (N-(CO)-N).256  
 
 
Maresca et al.257 developed a Glu-Lys conjugate, introducing radiolabelled iodine-123 
and iodine-121 isotopes for imaging and therapy respectively (Scheme 29, 100), by 
radioiododestannylation (Scheme 29).257 These two molecules demonstrated high 
affinity for PSMA in LNCaP cells.257 
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Scheme 29: Reagents and conditions: a.) [121/123I]NaI, H2SO4, AcOH, H2O2; b.) TFA/CH2Cl2, 
>90% radiolabelled product (over two steps). 
 
2.5 TREATMENT OF PROSTATE CANCER 
The treatment strategies for PCa can be divided into five categories, however, not all are 
available to patients at each stage of the disease. In this section, each treatment option is 
detailed. 
 
2.5.1 WATCHFUL WAITING 
For some patients in the early stages of the disease where the tumour remains isolated in 
the prostate, there is often no treatment prescribed. A course of “watchful waiting” is 
more often undertaken. In this instance, the patient is closely monitored by a general 
practitioner to evaluate the disease progression. This is most often prescribed to elderly 
patients, or those who are considered high-risk candidates for surgery or 
radiotherapy.258  
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2.5.2 SURGERY  
At present there remains two key surgical options for PCa patients; Radical 
prostatectomy is a treatment option for patients in Stages I and II of PCa, where the 
carcinoma remains confined to the prostate. Radical prostatectomy has been reported as 
a treatment for PCa since 1904,259 although it is associated with significant morbidity 
and mortality. In 1947, Millin described the radical retropubic prostatectomy which was 
undertaken with a single incision.260 This procedure was the standard of care until the 
late 1990s and was curative in most men.261 Modern prostatectomies are carried out 
laparoscopically, and increasingly with the use of robotics. On average, the 5-year 
biochemical-free survival rate, that is without increased levels of PSA, is 94%.262 
Surgery is also an option for androgen ablation therapy. Bilateral orchiectomy, the 
surgical removal of the testes, has shown to be an effective treatment for stage IV 
metastatic disease.263 
 
2.5.3 RADIOTHERAPY 
The treatment of PCa using radiation is offered to patients in Stages II and III of the 
disease, where the PCa is still confined to the pelvic region. Traditional external beam 
radiotherapy has been used extensively for the treatment of localised PCa,264 but in 
recent years, new radio-therapeutic options are becoming available.265 For example, 
conformal radiotherapy uses beams of different shapes to minimize the impact on 
healthy tissues. The use of 3D MRI and CT imaging allows the tumour to be mapped in 
three dimensions. Intensity-modulated radiation therapy uses beams of radiation with 
different applied dosage, to vary the dose delivered to different parts of the tumour.266 
In addition to external radiotherapy, radiation can be delivered internally in the form of 
brachytherapy. In permanent brachytherapy radioactive seeds are implanted into the 
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prostate gland and low dose radiation (2 Gy h-1) is released over a period of weeks. In 
general, brachytherapy uses isotopes with a long half-life, preferably a few weeks. After 
this time, the non-radioactive material remains in the patient. Isotopes with short half 
lives are sometimes used for high-dose (12 Gy h-1), temporary therapy. Following 
temporary treatment, the radiation source is removed. Iodine-125 (t1/2 = 59.6 d),267 
palladium-103 (t1/2 = 17 d)268 and caesium-131 (t1/2 = 9.7 d)269 are used for permanent 
brachytherapy, and iridium-192 (t1/2  = 74 d)270 is used for temporary brachytherapy. 
For advanced PCa with bone metastases, the radiopharmaceutical radium-223 (t1/2 =11/4 
days) (Alpharadin) is undergoing clinical trials.271,272 Radium-223 naturally self-
localises to bone metastases as a calcium-mimic.271 Administered monthly for four to 
six months, Ra223 resulted in an increased survival rate of 4.5 months in endocrine 
resistant tumours.271 
 
2.5.4 ANDROGEN ABLATION THERAPY  
Prostatectomy and radiotherapy are not treatment options when PCa has metastasised 
beyond the pelvis. At this point, androgen ablation therapy (AAT) is the primary 
treatment. As previously indicated in Chapter Two, PCa is an endocrine tumour, 
requiring testosterone and its metabolite dihydrotestosterone, to continue to grow. 
AAT’s work by suppressing testosterone activity in tumour growth, either by blocking 
its production or its activity. AAT can be achieved surgically or medically. Bilateral 
orchiectomy, the surgical removal of the testes, was the “gold standard” in androgen 
ablation therapy until the 1980’s.273 As the testes are the main source of testosterone 
production, their removal results in a rapid and permanent reduction in testosterone 
levels, with a median increase in survival rate of up to 36 months. The advantages of 
Chapter Two 
 
	   58	  
orchiectomy are its cost compared to long-term medical options, however, potential 
physical and psychological side-effects led to the development of medical alternatives. 
The production of testosterone by Leydig cells in the testes is in response to lutenising 
hormone (LH). LH secretion is stimulated in response to the secretion of gonadotropin-
releasing hormone (GnRH) by the hypothalamus. However, continuous production of 
GnRH has the opposite effect, it inhibits the release of LH from the pituitary gland, and, 
as a result, testosterone production from the testes ceases.274 GnRH agonists are 
synthetic peptides based on natural GnRH. They act by binding to the GnRH receptor, 
activating production of LH. However, synthetic modifications result in slow 
dissociation from the GnRH receptor, resulting in continuous LH production and the 
subsequent inhibition of testosterone production.233 GnRH agonists are decapeptides, 
with synthetic modifications in the tenth and/or sixth position (Table 6).275 
Agonist Sequence 
GnRH pyroGlu His Trp Ser Tyr Gly Leu Arg Pro Gly-NH2 
Leuprolide pyroGlu His Trp Ser Tyr D-Leu Leu Arg Pro NHEt 
Buserelin pyroGlu His Trp Ser Tyr D-Ser(OtBu) Leu Arg Pro NHEt 
Nafarelin pyroGlu His Trp Ser Tyr D-Naphyl Leu Arg Pro Gly-NH2 
Histrelin pyroGlu His Trp Ser Tyr D-His(N-Bn) Leu Arg Pro NHEt 
Goselerin pyroGlu His Trp Ser Tyr D-Ser(OtBu) Leu Arg Pro NHNHCO2NH2 
 
Table 6: GnRH agonists, position 6 and 10 highlighted. 
 
GnRH agonists have the same clinical efficacy as surgery, however, the early stages of 
GnRH agonist treatment are associated with “tumour flare”. The initial surge of 
testosterone production results in a rapidly growing tumour, which is associated with 
pain, urinary tract blockages and potential spinal compression.276 As a result of this, 
GnRH agonists are often prescribed in conjunction with a second class of androgen 
ablation therapy; anti-androgens. 
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Anti-androgens are androgen receptor antagonists.277 The binding of anti-androgens 
halts the cascade of biochemical signals that result in tumour growth. Four key anti-
androgens are used clinically, cyprostat 101, bicalutamide 102, flutamide 103 and 
nilutamide 104.278 
 
 
Cyprostat 101 is a synthetic derivative of 17-hydroxyprogesterone.279 Key 
modifications to the steroid backbone include a C2-C3 cyclopropanation, chlorination at 
C5, with corresponding C5-C6 oxidation to the alkene, and acetylation of the alcohol at 
C17. These modifications furnish cyprostat 101 with potent antagonist activity for the 
androgen receptor the drug shows limited metabolism. Cyprostat 101 also displays 
inhibitory activity in the biosynthesis of endogenous corticosteroids.280 
The aryl amides bicalutamide 102,281 flutamide 103 282 and nilutamide 104283 act as 
pure anti-androgens by competitive inhibition of the androgen receptor. bicalutamide 
102 also accelerates the degradation of the androgen receptor and has replaced 
flutamide 103 and nilutamide 104 in most instances. 
Key to each structure is the electron-withdrawing aromatic ring, containing a 
trifluoromethyl and nitro or nitrile group. This is required for efficient binding to AR.284 
The hydroxyl group of bicalutamide 102 (and the active metabolite of flutamide 103) is 
responsible for a key interaction with the AR. 285 Anti-androgens are widely used for the 
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treatment of Stage IV metastatic disease, either as a mono-therapy or in conjunction 
with GnRH agonists. However, patients with advanced PCa eventually develop 
resistance to anti-androgens. 
In addition to the above described treatments for PCa, two new mechanisms for 
androgen ablation are reaching the clinic. The first is the use of a GnRH antagonist, the 
second, CYP17 inhibition. 
GnRH antagonists bind to the GnRH receptor.286 However, while GnRH agonists rely 
on the body’s biochemical response to massive LH production, and subsequent 
desensitisation to its effects, GnRH antagonists competitively and reversibly bind to the 
GnRH receptor, blocking the release of LH. The biological response also results in 
suppression of testosterone production. The advantage of GnRH antagonists is that they 
have an immediate action of lowering testosterone production, without the associated 
“tumour flare”. Currently, only one GnRH antagonist is marketed, degarelix 105. 
Degarelix 105 is a synthetic decapeptide containing six non-proteinogenic amino 
acids.287  
 
CYP17 inhibition is the most promising recent advance in the treatment of advanced 
PCa, and CRPa.288 CYP17 is a cytochrome P450 enzyme involved in the biosynthesis 
of testosterone from cholesterol.289 Inhibition of this enzyme prevents the biosynthesis 
of testosterone in any cell throughout the body, and is not limited to those generally 
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associated with testosterone production.288 CYP17 inhibition is most effective in CRPa, 
where one of the postulated mechanisms for its development is increased testosterone 
production from previously low contributors, such as the adrenal glands.290 The CYP17 
inhibitor abiraterone 106 is currently marketed for the treatment of CRPa.291 The 
development and detailed mechanism of action of abiraterone 106 is discussed 
extensively in Chapter Four. 
 
Androgen ablation therapy results in a 90-95% decrease of testosterone levels in the 
blood292  and up to 90% reduction in intraprosatic levels of DHT, and is effective in up 
to 80% of patients.293 This reduction in DHT results in apoptosis of prostate cancer 
cells, and prostate epithelial progenitor cells. In addition, ablation therapy results in the 
apoptosis and degeneration of prostatic capillaries, and constriction of larger blood 
vessels supplying the prostate preceding apoptosis. Tumour vasculature survival is 
regulated by paracrine growth factor regulation between epithelial stromal cells.294 As 
such, while blood vessel growth does not require androgens, their growth is regulated 
by basic fibroblast growth factor and VEGF, which in turn, is regulated by the AR.294 
Inhibition of AR activity consequentially results in local vasculature apoptosis, 
compounding the prostate cancer apoptosis.295 
 
2.5.5 CHEMOTHERAPY 
Patients who fail to respond to initial androgen therapy, or who relapse with CRPa have 
limited treatment options after abiraterone. Cytotoxic chemotherapeutic agents remain 
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the mainstay of treatment at this stage, with mitoxantrone 107, docetaxel 108, epirubicin 
109 and estramustine 110 often prescribed.296,297  
 
 
 
2.6 SUMMARY 
Prostate cancer continues to be a challenging disease and developing effective 
treatments is at the forefront of modern medicine. The absence of definitive biomarkers 
for disease identification and progression result in difficulties for diagnosis, prognosis 
and treatment. Key molecular architectures such as the androgen receptor, prostate 
specific antigen and prostate specific membrane antigen, present themselves as targets 
for improved treatment of prostate cancer. New pharmaceuticals such as abiraterone and 
degarelix aim to improve patient outcome when patients develop castration-resistant 
disease. 
The discovery of new drugs for the treatment of prostate cancer remains important, and 
the rest of this thesis will discuss the development of novel compounds that release 
nitric oxide as potential agents for the treatment of prostate cancer.
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CHAPTER THREE: NITRIC OXIDE-DONATING ANALOGUES OF 
SULINDAC 
 
In 2009, it was reported by Stewart et al., that an NO-donating analogue  (NCX-1102) 
111 of sulindac 112, a widely used non-steroidal anti-inflammatory drug, was cytotoxic 
against PC3 cells.298  
 
 
PC3 is a human prostate cancer cell line of hormone insensitive, metastatic disease, 
isolated from a bone metastasis of a human male.299 It represents prostate cancer in 
stage IV, castration resistant disease. Cells at this stage of progression have a high 
metastatic potential.300  
It was reported that the NO-donating analogue NCX-1102 111, has a pro-apoptotic, 
cytotoxic, and anti-invasive effect on PC3 cells.298 In addition, a des-nitrato analogue, 
NCX-112 113, where the nitrate ester of NCX-1102 111 is hydrolysed, was more active 
that sulindac 112, but had decreased activity in comparison to NCX-1102 111. The 
cytotoxicity of NCX-1102 111 was conserved under normoxic and hypoxic conditions.  
An investigation into the mechanism of this activity revealed that NCX-1102 111 was 
able to reverse the hypoxic response. HIF-1α expression was downregulated under 
hypoxic conditions upon treatment with NCX-1102 111,298 also under hypoxic 
conditions, HIF-1α expression was equally expressed when treated with sulindac 112, 
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and a DMSO  control.298 NCX-1102 111 is predicted to function as an NO-donor and as 
such, the observed increase in cytotoxicity is attributed to ‘NO bioactivity’. However, 
NO in isolation appears ineffective, as the use of sodium nitroprusside, an NO donor, 
showed no cytotoxicity.298 
Interestingly, when experiments were conducted with a proteasome inhibitor, the 
observed reduction in HIF-1α expression was maintained. This suggests that the 
mechanism of HIF-1α reduction reported by Hagen et al.,52 of oxygen redistribution to 
allow HIF-1α proteosomal degradation, as a result of NO inhibition of mitochondrial 
activity,52 is not at play in this system. In addition to reduced HIF-1α expression, a 
reduction in Akt phosphorylation was observed and suggested that the PI3K-Akt-mTOR 
signal transduction pathway is one of the mechanisms operating for the observed 
activity of NCX-1102 111. Previous studies301–303 have demonstrated a link between 
this pathway and HIF-1α expression under hypoxic conditions.  
Subsequent observations revealed that in addition to inhibition of the hypoxic response 
and cytotoxicity, NCX-1102 111 mediated a radiosensitisation effect on prostate cancer 
under varying oxygen conditions. The mechanism of radiosensitisation was  found to be 
due to increased DNA double strand breaks, together with fixation of the radiation-
induced damage in DNA, which otherwise would be repaired.304 It was noted that the 
concentration required to induce radiosensitisation of the PC3 cells were relatively high 
(IC50 values ranging from 10 to 50 µM) suggesting a limited clinical applicability of 
NCX-1102.304,305  
Consequently the synthesis of analogues of NCX-1102 111 that could deliver NO with 
improved activity for both cytotoxicity and radiosensitisation potential are of interest. 
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3.1 AIMS 
The aim of this work was to design and synthesise a series of NCX-1102 111 analogues 
utilising nitrate esters, furoxans and sydnonimines as NO-donating functional groups. 
These motifs would be appended via esters and amides through the sulindac 112 
carboxylic acid through a by of linkers. The oxidation state of sulfur will also be 
changed to assess its affect on activity. 
The target molecules have a generic structure based on 114. 
 
 
 
3.2 RESULTS AND DISCUSSION 
An approach into the re-targeting of sulindac 112 for other therapeutic applications has 
shown that varying the oxidation state of the sulfoxide 112, to both the sulfide 115 and 
sulfone 116 can affect the biological properties of the compounds.306,307  
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To this end, NO-donating analogues of the sulfoxide 112, sulfide 115 and sulfone 116 
were prepared. The sulfide 115 and sulfone 116 oxidation states could be accessed 
readily and in high yield from the commercially available sulfoxide 112.308 
 
3.2.1 PREPARATION OF SULINDAC SULFIDE AND SULFONE 
The reduction of sulindac sulfoxide 112 to sulfide 15 has been reported by Folgi et al. 
(Scheme 30).308 using triphenylphosphine and titanium (IV) chloride, based on a 
method developed by Kikuchi et al.309 
 
 
Scheme 30: Reagents and conditions: a.) Ph3P, TiCl4, THF, r.t., 24 h, 75%.308 
 
The proposed mechanism of this triphenylphosphine/Lewis acid deoxygenation is 
illustrated in Scheme 31.309  
 
Scheme 31: Proposed mechanism of PPh3/TiCl4 mediated sulfoxide deoxygenation.309 
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In the event a polymer supported triphenylphosphine was used. Upon consumption of 
the sulfoxide 112, the reaction mixture was filtered through a pad of Celite to remove 
the polymer supported reagent (Scheme 32). 
 
 
 
Scheme 32: Reagents and conditions: a.) PS-PPh3, TiCl4, THF, r.t., 24 h, 94%. 
 
This was effective in providing the desired sulfide 115 in 94% yield. 31P NMR 
spectroscopy confirmed that there was no residual phosphorus residues in the product. 
While this was effective in providing the first sample of sulfide, it was not suitable for 
larger quantities due to the high cost of polymer supported triphenylphosphine.310 
As such standard triphenylphosphine was used, using the procedure reported by Fogli et 
al.308 However, following work-up, 1H and 31P NMR spectroscopy confirmed the 
presence of both triphenylphosphine and triphenylphosphine oxide in the samples 
prepared, which could not be fully removed by trituration or column chromatography. 
 As such an alternative reduction method was sought. The deoxygenation of sulfinyl 
groups has been reported to proceed under a variety of conditions,311 a similar ‘low 
valent’ titanium (II), with zinc as the reductant was chosen.97  
The addition of sulindac sulfoxide 112 to a solution of TiCl4 and zinc powder resulted 
in complete reduction to the sulfide 115 within 30 minutes and after work up the sulfide 
115 was recovered in quantitative yield with no further purification required. 
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Scheme 33: Reagents and conditions: a.) TiCl4, Zn, THF, r.t., 0.5 h, quantitative. 
 
Folgi et al. also describe the preparation of sulfone 116.308 Oxidation of the sulfoxide 
using Oxone® under aqueous conditions furnished the desired sulfone, in quantitative 
yield on a 1 mmol scale also without the need for further purification (Scheme 34).  
 
 
 
Scheme 34: Reagents and conditions: a.) Oxone®, 1:1 MeOH:H2O, r.t., 1 h, quantitative. 
 
Scaling this reaction to 2.4 mmol (1 g scale) required column chromatography to purify 
the product 116, however this and gave a slightly lower yield (50-70%). 
The formation of the oxidation states sulindac sulfoxide 112, sulfide 115 and sulfone 
116 was easily determined by using 1H NMR as shown in Figure 13. The chemical shift 
of the methyl group attached to the sulfur group shifts depending upon the oxidation 
state. For the sulfoxide 112, the SOCH3 is a singlet at 2.81 ppm. The sulfone 116, is 
shifted downfield to 3.14 ppm and reduction to the sulfide 15 results in an upfield shift 
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to 2.55 ppm. Chemical shift changes are were also observed in the 13C NMR signal for 
the methyl group (sulfide, 15 ppm, sulfoxide 44 ppm and sulfone 46 ppm).  Similar 
changes are also observed in the 19F NMR (Figure 13). 
 
 
Figure 13: 1H and 19F {1H} NMR (CDCl3) comparison of sulindac sulfoxide 112, sulfide 115 and 
sulfone 116.  
 
3.2.2 NITRATE ESTER-SULINDAC ANALOGUES 
The initial task to prepare corresponding 4-nitrooxybutyl and 4-hydroxybutyl esters, 
analogous of sulfide 115 and sulfone 116, analogous to NCX-1102 111 and NCX-112 
113. In addition, samples of NCX-1102 111 and NCX-112 113 were required to be used 
as positive controls for in vitro analysis. 
The reported method for preparing the 4-nitrooxybutyl ester of NCX-1102 111, is the 
formation of the 4-bromobutyl ester followed by nitrate displacement. This was 
replaced with a Steglich esterification312 using 4-nitrooxybutanol 120. This limits the 
sulindac 112 
sulindac sulfide 115  
sulindac sulfone 116 
1H NMR 400 MHz 19F {1H} NMR 376 MHz 
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possibility of silver residues contaminating the final product. The required 4-
nitrooxybutanol 120 was prepared based a literature procedure (Scheme 35).313,314  
 
 
 
Scheme 35: Reagents and conditions: a.) NaI, TBDMSCl, THF, 55 °C, 18 h, quant.; b.) i.) 
AgNO3, CH3CN, 1.25 h, ii.) H2O, 1 h, 27% 
 
Ring opening of THF with sodium iodide, and trapping of the alkoxide as its TBDMS 
ether, proceeded in quantitative yield. Immediate treatment of the purified iodide with 
silver nitrate, followed by acidolysis provided 4-nitrooxybutanol 120 in 27% yield. 
Previous work in the group315 into the preparation of sulindac esters used 
dicyclohexylcarbodiimide (DCC) as the activating agent in a Steglich esterification. 
While the esterification was effective the formation of the dicyclohexylurea product was 
a problem and residues were retained after purification. As such, EDCI.HCl was used as 
the urea by-product is both water soluble, and easily removed on work-up with an acid 
wash. In the event the desired esters 111, 123 and 124 were prepared in good yields 
from the corresponding carboxylic acids 112, 115 and 116 (Scheme 36). 
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Scheme 36: Reagents and conditions: a.) 120, EDCI.HCl, DMAP, CH2Cl2, r.t., 3 h, 111 = 91%, 
123 = 95%, 124 = 73%. 
 
In order to prepare the 4-hydroxybutyl esters, 1,4-butanediol 125 was mono-protected 
as its TBDMS-ether 126 based on a procedure of Taillier et al. This used an excess of 
1,4-butanediol 125 to drive mono-protection (Scheme 37).316 
 
 
Scheme 37: Reagents and conditions: a.) TBDMSCl, Et3N, CH2Cl2, r.t., 18 h, 68%. 
 
Steglich esterification with carboxylic acids 112, 115 and 116 furnished the desired 
TBDMS esters 127-129, respectively. Deprotection with CSA/MeOH furnished the 
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desired 4-hydroxybutyl esters 113, 130 and 131 in good yields after chromatography 
(Scheme 38).317 
 
 
Scheme 38: Reagents and conditions: a.) 126, EDCI.HCl, DMAP, CH2Cl2, r.t., 3 h, 126 = 85%, 
128 = 98%, 129 = 89%; b.) 10-CSA, CH2Cl2:MeOH (1:1), r.t., 3 h, 113 = 63%, 130 = 82%, 131 = 
75%. 
 
In addition to the 4-nitrooxybutyl esters of sulindac 112, sulfide 115, and sulfone 116 a 
series of alternate nitrate ester alcohols were prepared to investigate the effect of chain 
length, and nitrate content. 
Commercially available bromoalcohols 132-135 were treated with silver nitrate in 
acetonitrile under reflux, to furnish nitrate esters 136-139  (Scheme 39, Table 7). 
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Scheme 39: Reagents and conditions: a.) AgNO3, CH3CN, reflux, 8 h; b.) AgNO3, CH3CN, r.t., 7 
days. See Table 7 for yields. 
 
Alcohol Product Yield (%) 
132 136 85 
133 137 90 
134 138 88 
135 139 26 
 
Table 7: Yields of different nitrate ester alcohols. 
 
Alcohols 136-139 are known127,318,319 in the literature. Alcohol 139 is known from the 
de-nitration of PETN 31 with hydrazine hydrate100 or by hydrolysis of a single nitrate 
ester with rubidium hydroxide.320 Given the explosive nature of 31, neither method was 
used to prepare alcohol 139. Rather, pentaerythritol tribromide 135 was treated with a 
excess of silver nitrate at room temperature over 7 days. After this time, alcohol 139 
was isolated in 26% yield after chromatography. While there is limited evidence100 to 
suggest that alcohol 139 is explosive, as a precaution it was stored at -20 °C and was not 
prepared on large scale. With alcohols 136-139, in hand they were coupled to sulindac 
112 and its sulfide 115 and sulfone 116. Steglich esterification with alcohols 136-139 
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furnished the desired esters 140-151 in acceptable to excellent yields (Scheme 40, Table 
8). 
 
Scheme 40: Reagents and conditions: a.) 136-139, EDCI.HCl, DMAP, CH2Cl2, r.t., 3 h, 
Linker Product Yield (%) Product Yield (%) Product Yield (%) 
136 140 44 144 82 148 90 
137 141 66 145 95 149 90 
138 142 80 146 85 150 92 
139 143 86 147 92 151 88 
 
Table 8: Nitrate ester analogues of sulindac. 
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3.2.3 FUROXAN-SULINDAC ANALOGUES 
It was envisioned that the furoxan heterocycle could be linked to sulindac 112 by 
synthesising a series of furoxan alcohols for preparation of sulindac esters. The most 
widely used furoxan in the literature321 is bis(phenylsulfonyl)furoxan 53 and this has 
shown NO release properties in in vitro and in vivo models, so it was chosen as the 
furoxan motif used for this research.  
 
 
Bis(phenylsulfonyl)furoxan can undergo selective substitution at the 4-position with 
alcohols and diols.321 It was prepared in three steps following a literature 
procedure.152,322 Alkylation of thiophenol 152 with chloroacetic acid furnished 
(phenylthio)acetic acid 153 in 97% yield.152 This was then oxidised using Oxone® in 
aqueous methanol to provide sulfone 154 (Scheme 41).322 
 
        
Scheme 41: Reagents and conditions: a) Chloroacetic acid, NaOH, Na2CO3, 95% aq. EtOH, 
r.t., 18  h, 97%; b) Oxone®, 1:1 MeOH:H2O, r.t., 1 h, 95%. 
 
The oxidation state was confirmed to be the sulfone, rather than the sulfoxide by 
comparison to 1H NMR data in the literature and by mass spectrometry.323 Oxidation of 
thioether 153 was conducted on a 1 g scale to provide sulfone 154 without the need for 
further purification. On scales larger than 1 g, the product required recrystallisation 
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which consequently affected the overall yield. The average yield for the oxidation on a 
1 g scale was ~95%. 
With the furoxan precursor in hand, cyclisation to bis(phenylsulfonyl)furoxan 53 was 
undertaken. As such, heating a nitrating mixture of fuming HNO3 and acetic acid 
furnished the desired furoxan in 50% yield.152 
 
 
Scheme 42: Reagents and conditions: a.) fuming HNO3, AcOH, reflux, 1.5 h, 50%. 
 
A putative mechanism for the reaction involves an α-nitration to give nitroacid 154, 
followed by decarboxylation to the aci-nitrosulfone 156. Loss of water from 157 
generates the nitrile oxide 54, and this species this dimerises by a [3+2] dipolar 
cycloaddition to the furoxan 53 (Scheme 43). The reaction generates large quantities of 
deep red “nitrous” fumes for the duration of the reaction.  
 
Scheme 43: Mechanism for the formation of bis(phenylsulfonyl)furoxan 53. 
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Quenching the reaction mixture into ice-water, precipitated the product as a pale off-
white amorphous solid and recrystallisation from isopropanol provided the desired 
furoxan 53 as white needles. The average yield for this transformation was 50% on a   
25 g scale. The literature suggest that reaction times longer than 2 hours result in 
electrophilic nitration on one of the phenyl rings321 so this was avoided. 
Bis(phenylsulfonyl)furoxan 53 could then be selectively substituted in the 4-position 
with diols. In total nine diols were chosen link the heterocycles with sulindac. In the 
event, seven diols generated the desired furoxan alcohols 166-172 in 33-87% yields 
(Scheme 44, Table 9).  Diols 158 and 161 did not give the desired product.              
 
Scheme 44: Reagents and conditions: a.) Diol 158-165, 50% w/w aq. NaOH, THF, r.t., 1 h.  
Linker Product Yield (%) 
159 166 67 
125 167 50 
160 168 39 
162 169 82 
163 170 33 
164 171 33 
165 172 54 
 
Table 9: Synthesis of furoxan linkers. 
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Furoxans 166-169 are reported in the literature,152 but were fully characterised in this 
study. Alkene furoxan 170 is reported as a mixture of isomers.152 The two aromatic 
linker units 171 and 172 could be prepared in good yield and are the first examples of 
aromatic linked furoxans. Purification of 172 was only partly successful, however, 
trituration with chloroform precipitated the starting diol, which could be removed by 
filtration. 3-Hydroxybenzyl alcohol 164 has two possible alcohol moieties which could 
potentially give furoxans 171 and 173. However, only a single phenol adduct 171 was 
observed.  
 
Two diols, 158 and 161, did not provide the desired furoxan as expected. No product 
was observed with ethylene glycol 158. (2-Ethyoxy)ethoxyethanol 161 furnished a 
mixture of products with the same mass, presumed to be 3- and 4- position isomers.  
Preparation of the furoxans 174 and 175, from diols 158 and 161, required selective 
mono-silyl protection with a tert-butyldimethylsilyl group to give 176 and 177. 324,325 
This was achieved using an excess of diol relative to tert-butyldimethylsilyl chloride 
(Scheme 45). Homologation of the protected diols 176 and 177 with 
bis(phenylsulfonyl)furoxan 53 furnished the desired products. The TBDMS ether was 
then deprotected by methanolysis (Scheme 45). 
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Scheme 45: Reagents and conditions: a.) TBDMSCl, Et3N, DMAP, CH2Cl2, 0 °C to r.t., 16 h, 
74%. b.) TBDMSCl, imidazole, CH2Cl2, 0 °C to r.t., 16 h, 50%; c.) i. Diol 176 or 177, 50% w/w 
aq. NaOH, THF, r.t., 1 h; ii. 10-CSA, MeOH, 0.5 h, r.t., 174 = 60%, 175 = 46%. 
 
With the furoxan alcohols in hand, the final step in the synthesis required the 
conjugation to the various oxidation states of sulindac 112, 115 and 116, respectively 
(Scheme 46).  
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Scheme 46: Reagents and conditions: a.) 166-172, 174, 175, EDCI.HCl, DMAP, CH2Cl2, r.t., 2 
h.  
Linker Product Yield (%) Product Yield (%) Product Yield (%) 
174 178 89 187 46 196 25 
166 179 85 188 46 197 77 
167 180 57 189 32 198 26 
168 181 83 190 80 199 71 
175 182 34 191 41 200 62 
170 183 93 192 55 201 53 
169 184 68 193 56 202 32 
171 185 68 194 65 203 66 
172 186 54 195 49 204 50 
Table 10: Summary of sulindac-furoxan ester yields. 
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In total, 27 sulindac-furoxan hybrids 178-204 were prepared for biological evaluation, 
using the 9 furoxan linkers, and the 3 oxidation states of sulindac. The hybrid esters 
were isolated as yellow solids or gums. 
 
3.2.4 SYDNONIMINE-SULINDAC ANALOGUES 
Two key synthetic targets were identified for the conjugation of a sydnonimine to 
sulindac 112. These were direct sulindac amides, and attached with a linker between the 
units. 
The sydnonimine chosen was substituted with a phenyl group in the 3-position. This 
was selected, as it is structurally analogous to the phenyl in the furoxans. The phenyl 
group should stabilise the cation 205a-d formed from NO release in a similar manner to 
a dialkylamino group (Scheme 47). 
 
 
 
Scheme 47: Stabilisation of phenyl aminoacetonitrile cation 105 by resonance. 
 
The desired sydnonimine 206 was prepared from aniline 207 in two steps (Scheme 48). 
Aniline was alkylated with bromoacetonitrile based on a literature procedure,326 
providing the desired phenylaminoacetonitrile 208 in 87% yield as transparent crystals. 
 
 
Scheme 48: Reagents and conditions: a.) BrCH2CN, K2CO3, NaI, CH3CN, reflux, 18 h, 87% 
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Phenylaminoacetonitrile 208 was nitrosated with isopentyl nitrite (1.5 equiv., 2 h) in 
diethyl ether following the procedure reported of Beal and Turnbull.94 Dry HCl gas was 
then bubbled through the solution to promote ring closure. This generated a pale pink 
solid (Scheme 49). 
 
Scheme 49: Reagents and conditions: a.) i. Isopentyl nitrite (1.25 equiv.), Et2O, 2 h, ii. dry HCl 
(g), 15 min. 
 
1H NMR analysis of the product indicated this to be a 1:1 mixture of the desired 3-
phenylsydnonimine HCl salt 206 and phenylaminoacetonitrile HCl salt 208. This 
mixture of products could clearly arise be due to the breakdown of the intermediate N-
nitrosoamine, before HCl addition, as they have been reported to be light sensitive.80 
The Beal and Turnbull procedure was modified increasing the equivalents of isopentyl 
nitrite (3 equiv.) and time (16 h) in the absence of light. This protocol provided the 
desired 3-phenylsydnonimine hydrochloride in 94% yield (Scheme 50). 
 
 
Scheme 50: Reagents and conditions: a.) i.) Isopentyl nitrite (3.0 equiv), Et2O, 16 h, ii) dry HCl 
(g), 15 min, 94%. 
 
The acylation onto sulindac 112 was now considered. While acylation of sydnonimines 
onto acyl chlorides has precidence in the literature,165 there are no reported examples of 
preparing the acyl chloride of sulindac. Attempts by Halder et al.327 to prepare this acyl 
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chloride using Vilsmeier conditions (oxalyl chloride/DMF) resulted in formation of 
sulindac sulfide lactone 209 as the sole product (Scheme 51). This was rationalised as a 
long-range vinylogous Pummerer rearrangement.327 In the light of this, a carbodiimide 
coupling strategy was chosen. 
 
Scheme 51: Reagents and conditions: a.) (COCl)2, Et3N, EtOH, CH2Cl2, r.t. 66%.327 
 
Under the previously optimised conditions for esterification (EDCI/DMAP/CH2Cl2) the 
reaction was slow and after extended reaction time (18 h) mainly starting material 
remained (Table 11). 
 
 
Scheme 52: Reagents and conditions: see Table 11. 
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entry Amine 
eq. 
Solvent Additive T/ °C t/ h Yield (%) 
1 1.1 CH2Cl2 EDCI.HCl r.t. 2 No 
reaction 
2 1.1 CH2Cl2 EDCI.HCl reflux 2 No 
reaction 
3 1.1 CH2Cl2 EDCI.HCl + 
Et3N 
r.t. 2 No 
reaction 
4 1.1 DMF EDCI.HCl r.t. 2 35%a 
5 1.1 CH2Cl2:DMF 
(10:1) 
EDCI.HCl r.t. 2 50%a 
6 1.1 CH2Cl2:CH3CN 
(8:2) 
EDCI.HCl r.t. 2 88% 
a.) contaminated with DMF 
Table 11: Optimisation of conditions for amide 210 formation. 
 
3-Phenylsydnonimine hydrochloride 206 was poorly soluble in dichloromethane and 
this presented a problem. Addition of 1 equivalent of triethylamine did not improve the 
reaction. Sydnonimines are poor nucleophiles and are unstable as the free base.328 It is 
presumed that the rate of breakdown of the sydnonimine was greater than the rate of 
acylation. By changing the sovlent to DMF, the solubility improved and the reaction 
proceeded to give the desired product 210 in ca. 35% yield, however removal of DMF 
on work up proved problematic. 
A co-solvent mixture of 10:1 CH2Cl2/DMF increased the yield to 50%. In this instance, 
the solubilty problem was solved, but again, residual DMF contaminated the product 
after chromatography. Switching from DMF to acetonitrile as a co-solvent 
(CH2Cl2:CH3CN, 8:2) improved the yield (88%) significantly. With these optimised 
conditions, the sydnonimine amides of sulindac sulfide 115 and sulindac sulfone 116 
were also prepared in 70% and 75% yields respectively (Scheme 53). 
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Scheme 53: Reagents and conditions: a.) EDCI.HCl, DMAP, CH2Cl2/CH3CN (8:2), 2 h, 210 = 
88%, 211 = 70%, 212 = 75%. 
 
The preparation of these amides with sulindac represents the first use of a carbodiimide 
to prepare sydnonimine amides; upto this point the only reported amides were prepared 
using acid chlorides. A strategy was now devised for the preparation of sulindac 
sydnonimine conjugates using a linker. 
The first linker considered was the amino acid, β-alanine 213. It was envisaged that this 
3-carbon unit could be attached to the sydnonimine 206 as an amide. β-Alanine 213 was 
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protected as an ethyl ester 214 and purified by recrystallisation from ethanol and diethyl 
ether (Scheme 54).329 
 
Scheme 54: Reagents and conditions: a.) SOCl2, EtOH, reflux, 4 h, quant., b.) DCC, Et3N, 
CH2Cl2, reflux, 4 h, 91%; c.) LiOH, THF:H2O (4:1), 16 h, r.t., 76%. 
 
Coupling to sulindac 112 was achieved using DCC with the addition of triethylamine 
and DMAP to give amide 215 (Scheme 54). Deprotection with aqueous base furnished 
the homologated carboxylic acid 216 (Scheme 54).  
Attempts to form a sydnonimine amide of carboxylic acid 216 using the previous EDCI 
conditions (EDCI, DMAP, CH2Cl2/CH3CN) were unsuccesful. From here, a series of  
conditions using a variety of coupling reagents (EDCI.HCl, T3P, HATU, and PyBoP) 
were screened. However, these did not furnish the desired amide. Attempts to make the 
acyl chloride using Vilsmeier conditions (oxalyl chloride/DMF) or the Ghosez reagent 
were also unsuccessful. With nowhere reasonable to go, the β-alanine homologation 
was abandoned.  
Given the known reactivity of sydnonimines an alternative strategy was implemented. 
This involved acylating the sydnonimine with an acyl chloride to generate an amide, 
containing a functionality that can be used to create a linker. Thus, treatment of 3-
phenylsydnonimine 206 with 2-bromoacetyl chloride and an excess of triethylamine 
(2.6 equivalents), furnished an acylated species in 66% yield. However the product was 
not the desired α-bromoamide but the α-chloroamide 217 (Scheme 55).  
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Scheme 55: Reagents and conditions: a.) Bromoacetyl chloride, Et3N, CH2Cl2, -20 °C to r.t., 14 
h, 66%. 
 
This unexpected halogen exchange is clearly due to an in situ Finkelstein reaction with 
free chloride ion. In the event, this chloride could not be displaced by suitable amine 
nucleophiles. As a result, an alternative acyl chloride was explored, containing a similar 
bifunctionality. 4-Nitrophenyl chloroformate178,180 was reacted 3-phenylsydnonimine 
hydrochloride 206 and this generated the 4-nitrophenyl carbamate 218 as a white solid 
(64% yield) (Scheme 56), which was remarkably stable at room temperature. 
 
Scheme 56: Reagents and conditions: a.) 4-Nitrophenyl chloroformate, Et3N, CH2Cl2,  -20 °C to 
r.t., 14 h, 64%. 
 
A number of amides were prepared from the acids 112, 115 and 116 using ethanolamine 
219 and ethylenediamine 220 to link with 218. The use of both a carbamate- and urea-
linked sydnonimines allows comparisons to be made regarding NO release from these 
structures. Ureas are more hydrolytically stable than carbamates, and as such a 
concomitant hydrolysis and loss of CO2 is more likely to occur in the carbamate.  Pre-
formation of the activated imidazolide with carbonyldiimidazole (CDI), followed by 
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addition of an excess of ethanolamine 219 or ethylenediamine 220 furnished the desired 
amides 221-226 (Scheme 57). The yields for each amide are summarised in Table 12. 
 
Amine Product Yield % Product Yield % Product Yield % 
 
221 88 223 85 225 90 
 
222 81 224 89 226 83 
 
Table 12: Summary of yields for the prepared sulindac amides 221-226. 
 
 
Scheme 57: Reagents and conditions: a.) 1.) CDI, CH2Cl2, r.t., 3 h; 2.) 219 or 220, r.t., 14 h. 
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Condensation of alcohols 221, 223 and 225 or amines 222, 224 and 226 with carbamate 
217 furnished the requisite carbamates 227, 229 and 231 and ureas 228, 230 and 232 
(Scheme 58). 
 
Scheme 58: Reagents and conditions: a.) 218, CH3CN, reflux, 16 h, 17-90%, 
 
Product Yield % Product Yield Product Yield 
227 17 229 56 231 49 
228 86 230 86 232 90 
 
Table 13: Summary of the yields of sulindac carbamates and ureas 227-232. 
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With the nine sydnonimines in hand, the potential NO-donating analogues of sulindac 
were subjected to cytotoxicity assays. 
 
3.3 CYTOTOXICITY RESULTS 
The nitrate ester, furoxan, and sydnonimine analogues of sulindac were assayed at the 
University of Edinburgh for cytotoxicity against PC3 cells using a crystal violet assay. 
Crystal violet (CV) is a triphenylmethane dye which binds to DNA and is an indicator 
of cell proliferation. The results are presented as a percentage of cells remaining after 
treatment with a sulindac analogue. The bound CV gives a strong purple colour that can 
be examined spectrophotometrically at an optical density of 570 nm. The cell growth 
percentage is calculated using the following equation: 
 
%  𝐶𝑒𝑙𝑙𝑠  𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 =    𝑂𝐷!"#  𝑜𝑓  𝑡𝑒𝑠𝑡  𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑𝑂𝐷!"#  𝑜𝑓  𝐷𝑀𝑆𝑂  𝑐𝑜𝑛𝑡𝑟𝑜𝑙   ×  100 
 
The compounds were screened against PC3 cells under normoxic conditions and at a 
concentration of 50 µM of the sulindac analogue. The results are summarised in Tables 
14-17. Data for compounds which showed statistically significant reduction in cell 
population are highlighted in bold. Cytotoxicity assays and statistical analyses were 
conducted by Mr James Black at the University of Edinburgh. 
Reference compounds of sulindac 112 its sulfide 115 and sulfone 116 were assayed 
along with their corresponding 4-nitrooxybutyl and 4-hydroxybutyl esters, 111, 123- 
124 and 113, 130-131, respectively (Table 14).  
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 % Cells alive at time point after treatment at 50 μMb 
Entry 24 h 48 h 72 h 
DMSO 0.05%a 99.1 ± 9.9 100.9 ± 4.9 95.7 ± 7.7 
NCX-1102a 58.8 ± 8.2 35.5 ± 5.3 24.5 ± 3.9 
112 87.3 ± 5.6 101.0 ± 2.4 89.3 ± 7.4 
115 99.2 ± 2.9 93.7 ± 5.8 105.4 ± 3.0 
116 87.8 ± 2.5 91.0 ± 3.5  83.5 ± 4.9 
111 72.2 ± 9.2 43.9 ± 2.9 41.0 ± 4.0 
123 49.4 ± 2.3 28.4 ± 2.5 17.1 ± 3.6 
124 68.7 ± 4.1 52.9 ± 0.7 54.7 ± 3.5 
113 96.6 ± 3.4 76.9 ± 3.9 96.5 ± 3.6 
130 98.2 ± 5.8 80.5 ± 6.9 84.0 ± 5.1 
131 87.4 ± 7.0 81.5 ± 5.0 86.6 ± 5.3 
a. Mean of all CV experiments conducted, b. Mean of triplicate repeat. 
Table 14: Summary of CV cytotoxicity assays of the control compounds. 
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Sulindac 112 had no cytotoxic effect on PC3 cells, in agreement with the previously 
reported data by Stewart et al.298 This is also the case for the corresponding sulfide 115 
and sulfone 116. In addition, the 4-hydroxybutyl esters 113, 130-131 did not have any 
significant cytotoxicity, however, the corresponding 4-nitrooxybutyl esters 111, 123-
124 all showed a statistically significant cytotoxic effect, sulindac sulfide 4-
nitrooxybutyl ester 123 showed an improved activity over NCX-1102 111. 
Synthetically prepared 111 and NCX-1102 111 provided by the company NiCOX had 
different profiles in vitro. They were both cytotoxic, but NCX-1102 111 had in 
improved activity in the CV assay. The reason for this is unknown.  
Table 15 summarises the nitrate ester analogues 140-151. 
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 % Cells alive at time point after treatment at 50 μMb 
Entry 24 h 48 h 72 h 
DMSO 0.05%a 99.1 ± 9.9 100.9 ± 4.9 95.7 ± 7.7 
NCX-1102a 58.8 ± 8.2 35.5 ± 5.3 24.5 ± 3.9 
140 73.1 ± 24.3 54.9 ± 6.8 35.5 ± 4.2 
144 95.6 ± 0.8 120.0 ± 13.6 91.2 ± 5.6 
148 84.4 ± 16.3 96.2 ± 14.4 84.4 ± 2.7 
141 105.0 ± 9.1 72.7 ± 9.3 88.1 ± 22.9 
145 92.4 ± 5.1 85.1 ± 8.7 103.7 ± 5.4 
149 93.3 ± 17.2 59.0 ± 4.7 64.0 ± 8.0 
142 46.5 ± 2.6 44.9 ± 10.3 30.2 ± 4.5 
146 91.2 ± 4.6 92.3 ± 1.5 93.6 ± 8.5 
150 88.0 ± 11.9 89.0 ± 9.0 89.4 ± 1.2 
143 86.0 ± 5.3 79.9 ± 6.4 89.6 ± 6.3 
137 88.3 ± 3.6 101.2 ± 6.9 110.4 ± 1.3 
151 100.6 ± 8.0 84.5 ± 10.9 95.3 ± 10.0 
a. Mean of all CV experiments conducted, b. Mean of triplicate repeat. 
Table 15: Summary of CV cytotoxicity assays for nitrate ester analogues. 
 
When the range of nitrate esters was expanded to change the length of the linker, and 
introduce more nitrate ester functionalities, the assays indicated that the majority of the 
compounds had no significant effect on cell growth. Only two compounds showed a 
statistically significant reduction in cell growth. These were 2-nitrooxyethyl ester 140 
F O
O
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Chapter Three 
 
	   94	  
and dinitrate ester 142. They had an overall reduction in cell growth to 35.5 % ± 4.2 and 
30.2 % ± 4.5, respectively. However, given the overall poor activity of this series, none 
of the compounds emerged as candidates further testing. 
The cytotoxicity of the furoxan analogues 178-204 is summarised in Table 16. 
In contrast to the nitrate ester analogues, the furoxan analogues were a much more 
promising series of compounds. At 50 µM, 13 of the 27 compounds tested showed 
complete cell death after 24 hours. A further 11 compounds displayed a significant 
reduction in cell growth after 72 hours. Only three compounds had no significant 
activity. 
In the sydnonimine series, of the nine compounds tested, 7 had a significant reduction in 
cell population after 72 hours. These were amide 210, the carbamates 227, 229, 231 and 
the ureas 228, 230, 232. In particular, the activity of amide 210, carbamate 229 and urea 
230 was similar to NCX-1102. Amides 221 and 212 showed no statistical reduction in 
cell growth.  
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 % Cells alive at time point after treatment at 50 μMb 
Entry 24 h 48 h 72 h 
DMSO 0.05%a 99.1 ± 9.9 100.9 ± 4.9 95.7 ± 7.7 
NCX-1102a 58.8 ± 8.2 35.5 ± 5.3 24.5 ± 3.9 
178 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
187 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
196 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
179 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
188 34.9 ± 4.7 21.2 ± 4.0 15.7 ± 2.5 
197 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
180 32.3 ± 4.9 21.8 ± 1.8 16.5 ± 3.1 
189 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
198 67.9 15.4 49.9 3.7 38.8 ± 3.3 
181 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
190 57.2 ± 5.2 41.7 ± 8.4 29.2 ± 5.3 
199 42.4 ± 2.4 24.2 ± 4.8 15.4 ± 1.3 
182 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
191 55.2 ± 6.0 71.0 ± 5.3 50.8 ± 5.7 
200 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
183 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
192 25.4 ± 5.2 20.8 ± 2.0 15.0 ± 2.9 
201 36.5 ± 5.1 38.0 ± 5.6 27.3 ± 6.9 
184 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
193 30.6 ± 2.7  31.4 ± 6.1 20.6 ± 3.3 
202 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
185 71.8 ± 4.1 56.2 ± 2.3 51.9 ± 1.0 
194 101.9 ± 4.0 79.7 ± 4.6 82.7 ± 3.8 
203 88.3 ± 3.2 67.7 ± 9.0 63.6 ± 0.7 
186 73.9 ± 3.57  67.7 ± 11.1 66.3 ± 10.4 
195 81.1 ± 3.1 88.3 ± 5.3 80.6 ± 3.0 
204 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
a. Mean of all CV experiments conducted, b. Mean of triplicate repeat. 
Table 16: Summary of CV data for furoxan analogues. 
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 % Cells alive at time point after treatment at 50 μMb 
Entry 24 h 48 h 72 h 
DMSO 0.05%a 99.1 ± 9.9 100.9 ± 4.9 95.7 ± 7.7 
NCX-1102a 58.8 ± 8.2 35.5 ± 5.3 24.5 ± 3.9 
210 64.6 ± 16.7 29.8 ± 0.5 20.6 ± 1.9 
211 89.0 ± 4.9 90.8 ± 2.7 77.0 ± 2.5 
212 107.8 ± 21.0 74.5 ± 6.1 81.1 ± 7.4 
227 76.7 ± 0.8 46.4 ± 2.7 41.4 ± 3.6  
229 57.7 ± 5.8 27.1 ± 1.3 17.7 ± 1.3 
231 76.5 ± 2.0 45.9 ± 2.6 37.3 ± 4.4 
228 74.0 ± 4.5 46.7 ± 1.2 36.3 ± 2.7 
230 66.5 ± 6.0 34.7 ± 1.6 21.3 ± 1.8 
232 86.1 ± 14.2 58.2 ± 5.1 55.5 ± 2.5 
a. Mean of all CV experiments conducted, b. Mean of triplicate repeat. 
Table 17: Summary of CV data for sydnonimine analogues. 
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3.4 SUMMARY 
In total, fifty-three analogues of sulindac were prepared using three NO-donor 
functionalities; nitrate esters, furoxans and sydnonimines. Thirty six of these showed a 
statistical increase in cytotoxic effect relative to control compounds against PC3 cells at 
a concentration of 50 µM. 
After further in vitro study (James Black, University of Edinburgh) furoxans 181 and 
183 were identified as lead compounds for further study. To this effect, a scale-up for 
the synthesis of these two compounds will be undertaken to prepare sufficient material 
for the use in mouse model studies. 
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CHAPTER FOUR: NITRIC OXIDE-DONATING ANALOGUES OF 
ABIRATERONE 
 
This chapter describes the development of NO drug conjugates of the drug abiraterone 
106. 
 
It has been known since the work of Charles Huggins in 1941 that prostate cancer 
growth is driven by androgens.198 As a result of this, the mainstay treatment of 
advanced metastatic disease is androgen-ablation therapy as described in Chapter 
Two.330 However, within 18-24 months, CRPCa develops driven by adaptive 
mechanisms distinct from androgen receptor signaling.331 Upon development of CRPCa 
the main treatment options of chemotherapy are mainly palliative and the prognosis is 
terminal. In light of this, new mechanisms for the treatment of CRPCa were sought in 
the early 1990s to account for adaptive mechanisms of the androgen receptor, in 
particular, mechanisms indicating hypersensitivity to castration levels of testosterone 
and those implicating endogenous production of testosterone by the tumour. It was 
recognised that the ideal therapeutic would give global androgen blockade in any cell 
capable of biosynthesizing testosterone, and CYP17 was identified as a potential 
clinical target. CYP17 is an enzyme involved in testosterone biosynthesis from 
cholesterol 233 (Figure 14).332 It is a c-P450 responsible for hydroxylation at the 17-
position of pregnenolone 234 and progesterone 235 in both the testes and adrenal 
glands. Following hydroxylation to the steroids 236 and 237, CYP17 cleaves the acetyl 
side chain at C-17, generating the 17-keto functionality found in 
dehydroepiandrosterone 238 and androstenedione 239.  
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Figure 14: Biosynthetic pathway of cholesterol 233 to testosterone 92. 
 
These metabolites are intermediates on the pathway to testosterone 92. Inhibition of this 
enzyme would clearly prevent the biosynthesis of testosterone in all cells producing it. 
The antifungal agent ketoconazole 240 has also been shown to inhibit CYP17 when 
administered in high doses. This compound has been trialled for the treatment of 
prostate cancer.333 However, its short half-life in vivo, undesirable side-effects and 
intensive treatment regime ruled ketoconazole out as an effective treatment for CRPCa. 
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Early results from McCague et al. identified that 4-pyridylacetic acid esters 241a-e were 
effective inhibitors of the hydroxylase-lyase enzyme isolated from rat testes; however, 
they were unselective, showing potency against the aromatase enzyme also. The esters 
241 were prepared by trans-esterification of methyl 4-pyridyl acetate 242 with the 
lithium alkoxide of a range of alcohols (Scheme 59).334 
 
 
Scheme 59: Reagents and conditions: a.) ROH, THF, n-butyllithium, -78 °C- r.t., 4-16 h, 11-
96%.  R = see Table 18. 
 
Compounds with 4-substituted cyclohexyl esters, or bulkier lipophilic esters e.g. 
borneyl, isopinocampheyl and adamantyl demonstrated an increased activity for the 
inhibition of hydroxylase-lyase over the aromatase (Table 18). This selectivity was 
rationalised as a difference in the hydrophobic pockets available in each active site.335 
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 IC50, μM  
Entry R human 
placental 
aromatase 
C17-20 lyase 17α-hydroxylase 
ratio of 
lyase/aromatase 
potency 
241a 
 
0.30 20 15 67 
241b 
 0.15 4.4 4.2 29 
241c 
 
0.097 2.2 1.5 23 
241d 
 
0.096 1.8 1.7 19 
241e 
 
0.089 0.61 0.56 6.9 
 
Table 18: Activities of 4-pyridyl acetic acid esters 241a-e against rat C17-20 lyase and 17α-
hydroxylase.334 
 
Molecular modelling has indicated that bulky esters which display increased lyase and 
hydroxylase inhibition are acting as bioisosteres of a steroid motif and could enter a 
larger hydrophobic pocket than is present in the aromatase.335 
This led to the preparation of steroids substituted at the 17-position with pyridyl groups. 
It was postulated from molecular modelling335 that the pyridyl nitrogen coordinates the 
iron in the haem cofactor and that a nitrogen in the 2- or 3-position would give optimum 
coordination geometry.  The haem is critical for both the activity of the hydroxylase and 
lysase. The proposed mechanism is shown in Scheme 60.  
O
O
O
O
O
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Scheme 60: Mechanism of CYP17 oxidation. Adapted from Potter et al.291 
 
A key aspect of the process is a Baeyer-Villeger rearrangement of peroxyhemiacetal D 
to liberate the haem species and generate a 17-O-acetyloxy steroid F.336 This 
decomposition occurs with  the loss of acetic acid to generate the 17-keto functionality 
G.336 Coordination of the pyridyl nitrogen as a sixth ligand to the haem iron prevents 
the access of molecular oxygen and this inhibits both steps of the enzyme, arresting 
androgen biosynthesis. 
A series of 17-pyridyl steroids was designed and prepared by Potter et al. based on the 
pregnenolone skeleton, the preferred substrate for the human enzyme.337 The pyridyl 
nitrogen was placed sequentially at the 2-, 3- and 4-positions. The three target steroids 
were prepared from dehydroepiandrosterone 3-acetate (Scheme 61). Preparation of the 
relevant enol triflate and subsequent cross-coupling with the desired pyridyl unit 
furnished the steroid acetates. These were then deprotected under basic conditions.291 
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Scheme 61: Reagents and conditions: 2,6-di-tert-butyl-4-methylpyridine, Tf2O, CH2Cl2, 58%; b.) 
2-position: 2-pyridylzinc chloride, bromo(isoprenyl)-bis(triphenylphosphine)palladium (II), THF, 
245 = 74%; 3-position: diethyl(3-pyridyl)borane, Pd(PPh3)2Cl2, THF, 2 M Na2CO3, 246 =  84%; 
4-position: lithium trimethoxy(4-pyridyl)boronate, Pd(PPh3)2Cl2, THF, 2 M Na2CO3; c.) NaOH, 
H2O, MeOH, 248 = 78%, 106 = 79%, 249 = 53 % (over two steps). 
 
The ability of 106, 248, 249 to inhibit CYP17 lyase and hydroxylase activities was 
assayed using ketoconazole as a positive control. Steroid 106 emerged the most potent 
activity in vitro showing an IC50 of 2.9 nM and 4 nM against the lyase and hydroxylase 
respectively, a greater than 10-fold increase in activity compared to ketoconazole. 
Compound 246, the acetate protected steroid 106, was tested in vivo in mice; and it 
displayed an excellent ability to reduce testosterone to an undetectable level, as well as 
reducing the mass of androgen dependent organs.291 
Compound 106, now referred to as abiraterone 106 progressed into human clinical trials 
and was recently approved for use by the NHS for the treatment of advanced CRPa. 
Abiraterone 106 is the first in a new class of drugs to be used for the treatment of CRPa. 
While the clinical trial data demonstrated that abiraterone 106 is effective for the 
treatment of CRPa, the median radiographic progression-free time was found to be 5.6 
months, with a median overall survival of 3.9 months (compared to placebo).338 In 
AcO
O
H
H H
AcO
OTf
H
H H
AcO
H
H H
N
HO
H
H H
N
a.) b.)
c.)
243 244
245, N2
246, N3
247, N4
248, N2
106, N3
249, N4
Chapter Four 
 
	   104	  
addition, 3-50% of patients exhibited a primary resistance to abiraterone 106 after 
beginning treatment and all patients ultimately exhibited resistance.339  
As such, there is potential to improve the activity of the drug and this is the focus of this 
aspect of the thesis. Following on from the reported bioactivity of nitric oxide in the 
sulindac 112 compounds, a series of NO-donating analogues of abiraterone 106 was 
proposed. Abiraterone 106 is delivered clinically as the acetate prodrug 246, requiring 
an in vivo hydrolysis to release the drug. As such, by changing the acetate ester to an 
ester linked to an NO donating unit, abiraterone 106 and the NO functionality should 
reasonably be targeted to the site of hydrolysis.  
 
4.1 AIMS 
The aim of this aspect of the research was to prepare a series of NO-donating analogues 
of abiraterone 106. The new constructs will be assayed along with an appropriate 
control. An immediate objective was prepare a series of NO-donating carboxylic acids 
and the appropriate abiraterone esters. Thus the structures 250-254 emerged as synthesis 
targets. 
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4.2 RESULTS AND DISCUSSION 
The synthesis of abiraterone 106 reported by Potter et al. starts from 
dehydroepiandrosterone 3-acetate 243.291 As this material was unavailable, 
commercially available dehydroepiandrosterone 238 was chosen as the starting 
material. This was converted to abiraterone in four-steps based on known literature 
procedures.291 This synthesis was accomplished in a 61% overall yield (Scheme 62).  
 
Scheme 62: Reagents and conditions: a.) Ac2O, BF3.(OEt)2, CH2Cl2, r.t., 4 h, quant.; b.) 2,6-di-
tert-butyl-4-methylpyridine, Tf2O, CH2Cl2, r.t., 18 h, 58%; b.) diethyl(3-pyridyl)borane, 
Pd(PPh3)2Cl2, THF, 2 M Na2CO3, reflux, 1.5 h, 87%; c.) 10% KOH in MeOH, MeOH, 0 °C, 1 h, 
quant. 
 
Acetylation at the 3-position with acetic anhydride and catalytic BF3.(OEt)2 furnished 
the protected acetate 243 in quantitative yield (Scheme 62). Treatment with 
trifluoromethanesulfonic anhydride using 2,6-di-tert-butyl-4-methyl pyridine as a base 
furnished the desired enol triflate 244 (58%) (Scheme 62). A quantity of the undesired 
triene 255 was also isolated along with another minor impurity. This accounted for 
approximately 10% of the mass balance isolated.  
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Palladium catalysed Suzuki cross-coupling using Pd(PPh3)2Cl2, diethyl(3-
pyridyl)borane and aqueous  Na2CO3 in THF provided the desired abiraterone acetate 
246 (Scheme 62). This was deprotected based on an alternative procedure used to 
prepare a benzimidazole analogue of abiraterone.340 Treatment with methanolic KOH in 
methanol furnished abiraterone 106 in quantitative yield, without the need for 
chromatography (Scheme 62). 
The 13C NMR spectrum of enol triflate 244, abiraterone acetate 246 and abiraterone 106 
are reported for the first time due to incomplete data in the literature. In addition, the 
use of HSQC correlation spectroscopy allowed for the steroid backbone protons to be 
unambiguously assigned in the 1H and 13C NMR spectrum; for example Figure 15. 
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Figure 15: HSQC spectrum of abiraterone acetate 246 (1H 500 MHz, 13C 75 MHz, CDCl3) 
 
Esterification of abiraterone 106 with butyric acid furnished the butyrate ester in 79% 
yield as a white solid (Scheme 63). This material was prepared as a control compound 
as a non-NO donating ester. 
 
 
Scheme 63: Reagents and conditions: a.) Butyric acid, EDCI.HCl, DMAP, CH2Cl2, r.t., 18 h, 
79%. 
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This ester 250 has an alkyl chain, which does not link to an NO-donating functionality. 
On the other hand the three proposed targets 251, 253 and 254 have an alkyl linker 
which terminates with an NO-donating functionality. Ester 250 will serve as a control 
with a longer alkyl chain to that of acetate 246. 
Target 251 combined the nitrate ester with abiraterone 106. The initial synthesis of 251 
involved a two-step process. Initially abiraterone 106 was esterified using 4-
bromobutyric acid 256 to furnish the bromobutyrate 257. This was followed by bromide 
substitution with nitrate (Scheme 64).  
 
Scheme 64: Reagents and conditions: a.) 4-Bromobutyric acid, EDCI.HCl, DMAP, CH2Cl2, r.t., 
18 h, 79%; b.) AgNO3, CH3CN, 90 °C, 18 h, 18%. 
 
Treatment of 257 with silver nitrate resulted in a low conversion to the nitrate ester by 
1H NMR. Heating the reaction to 90 °C resulted in the complete consumption of starting 
however, the isolated yield was only 18%. Disappointingly, elemental analysis showed 
that the material was impure. This is likely to be due to residual silver impurities in the 
product. Given the low yield of nitrate 251, an alternative route was devised. This 
involved coupling of 4-(nitrooxy)butyric acid 258 to abiraterone 106. 4-
(Nitrooxy)butyric acid 258 was prepared from 4-bromobutyric acid (Scheme 65). 
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Scheme 65: Reagents and conditions: a.) AcCl, MeOH, 0 °C to r.t., 18 h, quant.; b.) AgNO3, 
CH3CN, 90 °C, 18 h, 97%; c.) LiOH, MeOH, 5 °C, 18 h, 77%. 
 
4-Bromobutyric acid 256 was converted to the corresponding methyl ester 259. 
Treatment with silver nitrate furnished methyl 4-(nitrooxy)butyrate 260 in good yield. 
While this material was of relatively high purity, purification by chromatography was 
carried out to remove any residual silver salts. Finally, saponification of the methyl ester 
260 with aqueous lithium hydroxide at 5 °C provided the required 4-(nitrooxy)butyric 
acid 258 in 77% yield. 
Finally, coupling of abiraterone 106 with 4-(nitrooxy)butyric acid 258 using EDCI and 
stoichiometric DMAP gave the desired 4-(nitrooxy)butyrate ester 251 in 95% yield 
(Scheme 66). 
 
 
Scheme 66: Reagents and conditions: a.) 258, EDCI.HCl, DMAP, CH2Cl2, r.t., 4 h, 95%. 
 
A second nitrate ester 252 was prepared. This was the direct O-nitrate ester at the 3-
position of abiraterone 106. This was accomplished using zinc nitrate and EDCI.HCl, 
based on conditions reported by Sarma341 for the formation of the 3-O-nitrate of 
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cholesterol 233. The reaction occurs with retention of configuration at C3. The reaction 
proved straight forward with abiraterone 106, and gave the desired nitrate ester 252, 
which was isolated in 35% yield (88% b.r.s.m). 
 
Scheme 67: Reagents and conditions: a.) Zn(NO3)2.(H2O)6, EDCI.HCl, DMAP, CH3CN:CH2Cl2 
(1:1), r.t., 18 h, 35%. 
 
Steroid 252 shows a 1H NMR NOE between CH-3 and the protons in the CH2-2 and 
CH2-4 positions: There is no NOE correlation to CH3-19, which would be expected if 
there had been an inversion of the configuration upon nitrate ester formation the 
stereochemistry of this position had been inverted.  
In order to prepare furoxan target 253, carboxylic acid 261 was prepared from alcohol 
167 following a literature procedure.342 The preparation of 167 is reported vide supra in 
Chapter Three.  
 
Scheme 68: Reagents and conditions: a.) 2.5 M Jones reagent, acetone, 0 °C to r.t., 0.5 h, 
23%. 
 
Oxidation of 167 was accomplished with Jones reagent, however on work up the 
desired acid was isolated in a low, 23% yield. As a result, an improved method was 
sought. To this end, tert-butyl 4-hydroxybutanoate 262 was prepared in two steps from 
succinic anhydride 263 (Scheme 69). 
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Scheme 69: Reagents and conditions: a.) tert-BuOH, Et3N, HOSu, DMAP, toluene, reflux, 18 h, 
77%; b.) BH3.Me2S, r.t., 18 h, quant. 
 
Ring opening of succinic anhydride 263 with tert-butanol furnished the tert-butyl hemi 
succinate 264 in 77% yield after recrystallization from petroleum ether (Scheme 69). 
Selective reduction of the carboxylic acid was achieved using BH3.Me2S to provide the 
desired alcohol 262 in quantitative yield (Scheme 69). 
Sulfonyl substitution with alcohol 262 onto bis(phenylsulfonyl)furoxan 53 using DBU, 
furnished the desired ether 265 in 95% yield (Scheme 70). Deprotection with 
trifluoroacetic acid gave carboxylic acid 261 in quantitative yield. (Scheme 70). 
Although this protocol involved an extra two steps, the route avoids the use of toxic 
chromium, and provided 261 in a 73% overall yield. This can be compared very 
favourably with 11.5% over two steps using the Jones oxidation. 
 
Scheme 70: Reagents and conditions: a.) DBU, CH2Cl2, r.t., 2 h, 95%; b.) TFA, CH2Cl2, r.t., 16 
h, quant. 
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With carboxylic acid 261 in hand, attention was drawn to preparing target 253. 
Esterification using previously established conditions, furnished the desired abiraterone 
ester 253 in 92% yield (Scheme 71). 
 
Scheme 71: Reagents and conditions: a.) 261, EDCI.HCl, DMAP, CH2Cl2, r.t., 18 h, 92%. 
 
A sydnonimine carboxylic acid 266 was also prepared using the methodology 
developed in Chapter Three.  
 
Scheme 72: Reagents and conditions: a.) CH3CN, reflux, 18 h, 70%; b.) TFA, CH2Cl2 r.t., 18 h, 
quant. 
 
Acylation of alcohol 262 with p-nitrophenolate 215 resulted in the tert-butyl protected 
sydnonimine carbamate 267 in 70% yield. Deprotection of the tert-butyl ester with 
trifluoroacetic acid furnished the sydnonimine acid 266 in quantitative yield. Coupling 
of this acid to abiraterone 106 proved to be sluggish, requiring 48 hours to proceed to 
completion, however the desired ester 254 was isolated in an 88% yield. 
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Scheme 73: Reagents and conditions: a.) 266, EDCI.HCl, DMAP, CH2Cl2, r.t., 48 h, 88%. 
 
4.3 CYTOTOXICITY RESULTS 
In total, seven abiraterone based compounds were evaluated for cytotoxicity against 
PC3 cells at the University of Edinburgh, using the same assay described in Chapter 
Three. Abiraterone 106 and abiraterone acetate 246 were used as positive controls The 
esters 251-254 were all designed as NO-donating compounds. Butyrate ester 250 was 
tested as a further control as a longer chain, non-NO-donating analogue. 
The crystal violet assay was carried out by Mr James Black of the University of 
Edinburgh. The compounds were screened against PC3 cells under normoxic conditions 
at a concentration of 50 µM. The results are summarised in Table 19. 
Of the seven compounds screened, five showed a statistically significant reduction in 
cell growth compared to the DMSO control. Of these, two were abiraterone acetate 246 
and abiraterone 106. A significant level of activity was expected for these two 
molecules based on their already established clinical use. Of the NO-donating series, 
nitrate ester 251 and furoxan 253 showed significant activity. Furoxan 253 showed a 
higher activity than NCX-1102 111. Interestingly butyrate ester 250 was cytotoxic 
indicating that longer esters (than acetate 246) also increase activity. 
These initial results suggest that NO-donating analogues of abiraterone are active 
against PC3 cells with furoxan 253 emerging as a lead compound for further 
investigation. 
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 % Cells alive at time pointb 
Entry 24 h 48 h 72 h 
DMSO 0.05%a 99.1 ± 9.9 100.9 ± 4.9 95.7 ± 7.7 
NCX-1102 111a 58.8 ± 8.2 35.5 ± 5.3 25.5 ± 3.9 
 
246 
0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
 
106 
54.6 ± 8.5 57.7 ± 14.1 34.7 ± 4.0 
 
250 
68.1 ± 13.9 59.0 ± 14.0 32.8 ± 4.0 
 
251 
76.6 ± 8.5 56.6 ± 13.1 35.6 ± 3.34 
 
252 
86.3 ± 7.4 92.2 ± 15.0 70.6 ± 2.8 
 
253 
48.0 ± 12.6 27.5 ± 10.9 12.8 ± 3.4 
 
254 
89.8 ± 12.5 99.1 ± 16.3 83.8 ± 12.4 
a. Mean of all CV experiments conducted, b. Mean of triplicate repeat. 
Table 19: Summary of CV results for abiraterone series. 
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4.4 SUMMARY 
 
Abiraterone 106 was prepared in four steps from the commercially available steroid 
238. A series of NO-donating carboxylic acids were prepared and abiraterone analogues 
prepared using an EDCI.HCl coupling to furnish the esters. In total, four analogues of 
abiraterone were prepared using three NO-donor functionalities; nitrate esters, furoxans 
and sydnonimines. Two of these showed a statistical increase in cytotoxic effect relative 
to control compounds against PC3 cells at a concentration of 50 µM. 
Further in vitro study (James Black, University of Edinburgh) is underway to 
investigate the activity of the compounds in the LnCAP cell line, a hormone-sensitive 
prostate cancer cell line.  
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CHAPTER FIVE: TARGETING NITRIC OXIDE RELEASE WITH 
AMINO ACIDS AND PEPTIDES 
 
This Chapter details the development of NO-releasing amino acids, and their 
applications in bioactive peptide assembly. 
 
The development of new drugs by medicinal chemists hinges on their ability to 
recognise and capitalise on the molecular recognition of a small molecule with the 
desired target. By identifying key molecular interactions between biological substrates 
and designed molecules, the potency and specificity of new molecular entities is 
enhanced. 
This design process is extensive, involving organic synthesis, in silico modeling,343 and 
more recently, library and fragment-based screening.344 
In contrast, molecular recognition in biology has evolved a series of highly conserved 
motifs which have begun to be exploited by medicinal chemists as a way of targeting 
drug delivery, often in oncology therapies. Many drugs are effective, however their 
related toxicity to healthy tissues reduces their clinical effectiveness due to adverse side 
effects.345 By developing a conjugate between a molecular recognition motif and the 
drug, the altered vector can help to circumvent the associated side effects. 
Many of these motifs are highly specific for a distinct cellular target, such as a receptor 
or protein surface, and they display a high affinity and specificity in vivo. Examples of 
these include biotin 267,346 folate 268,347 octreotide (OctR) 269348 and Arg-Gly-Asp 
(RGD) 270,349 as well as larger units such as antibodies, oligonucleotide sequences350 
and antibody-fusion proteins.351 
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These recognition motifs have been exploited for a large variety of uses in chemical 
biology. For example, Ting et al. demonstrated that biotinylation of an 18F labelled 
aryltrifluoroborate (ArBF3-) ligand 271 was able to localise the distribution of the ligand 
to bladder, stomach, liver and salivary glands in mice; in contrast to the localization of 
free fluoride to the bone.352 
 
 
 
 
 
 
 
 
Figure 16: Reprinted (adapted) with permission from Ting et al. J. Am. Chem. Soc., 2008, 130, 
12045-12055. Copyright 2008 American Chemical Society. 
 
HN
N N
N N
H
N
H
O O OH
O
OH
H2N
O
NHHN
S
O
HH
O
OH
HN N
H
NH
S S
NH
O
H
N
O NH
O
O
OH
O
NH2
O
NH2
NHO
N
H
HO
HO
N
H
OH
O
OH
O
OH
N
O
NH2H
NH2N
NH
267
268
270
269
Biotin Injected Mouse Biotin-Avicin Injected 
Mouse 18 minutes 
Salivary Gland 
Stomach 
Liver 
NHHN
S
O
HH
O
H
N
271
N
O F
F
F
KF3B
Chapter Five 
 
	   118	  
Peptide based recognition units OctR 269 and RGD 270 have been used as targeting 
anchors for drug conjugation.348,353 Pacitaxel was conjugated to OctR through a 
succinate linker to develop an OctR-Taxol conjugate 272.348 
 
 
Conjugate 272 was shown to be exclusively toxic to cells expressing endogenous 
somatostatin G-protein coupled receptors (SSTRs), with reduced toxicity to low SSTRs 
expressing cells, demonstrating cell selectivity and targeting of taxol.348 
The RGD sequence is a cell adhesion sequence discovered in fibronectin by 
Pierschbacher & Ruoslahti,354 which binds to receptor proteins called integrins. After 
much scepticism it was confirmed that this three amino acid sequence plays a central 
role in adhesion biology, with RGD being the prototypical adhesion signal. As such, it 
has been widely exploited in medicinal chemistry as a targeting motif. Cell adhesion 
plays a crucial role in a variety of basic biological processes, such as cell migration, cell 
anchorage, proliferation, differentiation and apoptosis.355 In cancer, changes in cell 
adhesion have roles in metastasis, tumour angiogenesis and in the evasion of 
apoptosis.356 
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The RGD sequence can easily be introduced into peptides to develop synthetic RGDs, 
which can act in two different ways:357 On the surface of cells, the RGD sequence 
promotes cell adhesion, and in solution, they act as a decoy, preventing adhesion by 
binding to soluble integrin fragments and disrupting cell signalling..357 Up to twelve of 
the twenty known integrins recognise the RGD sequence in their respective ligands, and 
the RGD sequence has been identified in a large number of adhesion proteins.349 
Tumour cell expression of the integrins αvβ3, αvβ5, α5β1, α6β4 and αvβ6 is correlated with 
cancer progression and has led to intense study.358 For example, the αvβ3 is widely 
expressed in the blood vessels of human tumours, as confirmed by biopsy, however, it 
is not expressed in the vessels of normal tissue. The over expression of αvβ3 has been 
identified to be correlated to a number of disease markers. 
In breast cancer and prostate cell carcinoma, αvβ3 integrin expression is correlated with 
bone metastasis due to an association between integrins and the processes of cell 
migration and adhesion involving osteopontin,359–361 a bone sialoprotein found in bone 
tissue. The αvβ3 integrin is overexpressed in the invasive margins of glioblastoma in 
conjunction with increased levels of fibronectin,361 it is associated with enhanced cell 
motility and resistance to apoptosis.361 In pancreatic cancer, αvβ3 is associated with 
lymph node metastasis.362 
Because of the widespread overexpression of the αvβ3 integrin in cancer, the RGD 
sequence has been exploited as a mechanism to target cancer cells. For example, 
coinjection of RGD peptides with tumour cells into the blood stream prevents the 
subsequent growth of tumour nodules in other tissues,363 effectively acting as an anti-
metastatic agent. Spontaneous metastasis of tumours has also been halted using this 
type of treatment.364 RGD peptides have been shown to inhibit tumour cell invasion in 
vitro.365 
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Development of synthetic RGD peptides has added a new dimension to this therapy. By 
adding a cytotoxic or radiolabelled group to a RGD peptide, this warhead can be 
delivered effectively to antigenic cells.356 
One example of the use of this is in imaging technologies. Cheng et al. were able to 
track αvβ3 expression in living xenograft mice (U87MG) using an RGD conjugate 273 
with a near-infrared fluorescent (NIRF) dye, Cy5.5.366 
 
 
The mice were injected with human glioblastoma cells at 4-6 weeks of age, and 
subsequently imaged at 14-21 days after implant, when the tumour had reached a 
diameter of 400-600 mm. Following injection with RGD-NIRF dye 273, they were able 
to observe αvβ3 distribution using a tungsten-halogen lamp to excite the dye at 610-665 
nm, and the dye showed a high selectivity for tumour tissue in living in vivo model and 
later dissection analysis.366 
Synthetic work in the O’Hagan laboratory has been focussed on the use of RGD 
peptides as a tool in positron emission tomography using 18-fluorine. The fluorosugar 
18-FDR 274 has been successfully bioconjugated to c(RGDfC) 275 using a cysteine 
maleimide conjugation to give 276 and then oxime trapping of the fluorosugar to give 
FDR-conjugate 277 (Scheme 74).367  
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Scheme 74: Reagents and conditions: a.) aminooxyhexylmaleimide, H2O, r.t., 20 min; b.) 274, 
NH4OAc buffer, r.t., 30 min, 86% (“cold reaction”).367 
 
The exquisite selectivity of the RGD sequence is also evident in the delivery of 
chemotherapy agents. Mukhopadhyay et al. developed a series of platinum (IV)-RGD 
complexes, e.g. 278 which were specifically cytotoxic to cell lines containing the αvβ3 
and αvβ5 integrins, with toxicities approaching that of cisplatin 279.368 
 
 
It was shown that the linear RGD containing Pt(IV) complexes e.g. 278 were equally 
effective as the cyclic RGD peptides in cytotoxicity and specificity.368 
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Dal Pozzo et al. generated a series of RGD conjugates with the quinolone alkaloid 
camptothecin 280, a known inhibitor of the DNA enzyme, topoisomerase I.369 In 
preliminary clinical trials, camptothecin displayed good anticancer activity, but had 
poor solubility and adverse side effects. As such, namitecan 281, a 7-position modified 
hydrophilic analogue, was developed.353 
 
The synthetic RGD-camptothecin analogues, e.g. 282 were both cytotoxic and selective 
to cells expressing αvβ3 and αvβ5 integrins, identifying this strategy as a possible 
mechanism to improve the selectivity of camptothecin analogues.353 
 
 
In the light of the recent developments with the RGD motif it became an objective to 
explore the preparation of a series of NO-donating amino acids, which could be 
incorporated into the appropriate peptide constructs. 
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One widely used NO-donating amino acid is SNAP 29.89 SNAP 29 is an S-nitrosothiol 
and has long had use in biochemistry as a positive control for NO release. 
 
Its stability is solution is dependent of temperature, buffer composition and metal 
content, and as such, conditions can be tuned to alter its half-life from seconds to hours. 
Due to this instability SNAP 29 is not used clinically. 
Amino acids provide the basic building blocks for many aspects of synthetic chemistry, 
from natural product total synthesis, to combinatorial synthesis of oligopeptides. By 
developing a number of amino acids with the potential for orthogonal protecting group 
manipulation it was envisaged that they could be used in chemical biology as targeted 
NO-donors, in combination with known recognition sequences. 
To develop these amino acids, it was chosen to chemically modify naturally occurring 
amino acids, in this way the absolute configuration would be immediately introduced 
without the need for an asymmetric synthesis. 
 
5.1 NITRIC OXIDE-DONATING AMINO ACIDS- RESULTS AND DISCUSSION 
Four amino acid scaffolds were chosen, these were tyrosine 283, 4-aminophenylalanine 
284, serine 285 and 2,3-diaminopropionic acid 286.  
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The NO donors chosen were the heterocyclic furoxan and sydnonimines. Following the 
earlier work, these were to be introduced using bis(phenylsulfonyl)furoxan 53 and p-
nitrophenyl carbamate 218. As such, the target amino acids are 287-291 respectively. 
 
 
 
The amine and acid functionalities of tyrosine were protected based on literature 
procedures.370,371 Tyrosine 283 was protected as its methyl ester 292 using MeOH/HCl 
in quantitative yield. Amine protection with di-tert-butyl dicarbonate (Boc2O) provided 
the tert-butoxycarbonyl methyl ester 293 (Scheme 75).  
 
 
Scheme 75: Reagents and conditions: a.) AcCl, MeOH, reflux, 18 h, quant.; b.) Boc2O, 
NaHCO3, EtOH, r.t., 18 h, 80%. 
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4-Aminophenylalanine 284 was prepared from its nitro precursor 294. A two step 
protection of 4-nitrophenylalanine 294 provided the tert-butoxycarbonyl methyl ester 
296. This was then efficiently reduced with palladium on carbon and ammonium 
formate to provide the aniline 297 (Scheme 76). 
 
 
Scheme 76: Reagents and conditions: a.) SOCl2, MeOH, 0 °C to r.t., 18 h, quant.; b.) Boc2O, 
Et3N, CH2Cl2, r.t., 18 h, quant.; c.) 10% Pd/C, ammonium formate, MeOH, r.t., 3 h, quant. 
 
In order to prepare the protected amino acids with the sydnonimine heterocycle 
appended, 293 and 297 were treated with p-nitrophenyl carbamate 128 under the 
previously determined conditions. This furnished the desired carbamate 298 and urea 
299 in excellent yields (Scheme 77). 
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Scheme 77: Reagents and conditions: a.) 218, CH3CN, reflux, 18 h, 298 = 89%, 299 = 85%. 
 
Investigations were made to introduce the furoxan moiety into amino acids 293 and 
297. A modification of the conditions established by Fruttero was used.372 The Fruttero 
conditions called for the use of 3 equiv. of alcohol, 2 equiv. of DBU and 1 equiv. of 
bis(phenylsulfonyl)furoxan 53. However, the alcohols used were typically aliphatic 
alcohols, which could be removed on aqueous workup. Given that the tyrosine 
derivative 293 is not water soluble, it was chosen to use equimolar quantities of 293 and 
bis(phenylsulfonyl)furoxan 53. In the event, treatment of phenol 293 with DBU, 
followed by addition of bis(phenylsulfonyl)furoxan 53 provided the desired furoxan 
ether 300 in 86% yield (Scheme 78).  
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Scheme 78: Reagents and conditions: a.) 53, DBU, CH2Cl2, r.t., 2 h, 86%. 
 
Repeating these conditions with aniline 297 gave no reaction. In retrospect, there are no 
literature reports of bis(phenylsulfonyl)furoxan 53 reacting with nitrogen nucleophiles, 
and this reaction was unlikely to be successful. 
In addition to tyrosine-derived sydnonimines, the methodology was extended to serine 
285 and 2,3-diaminopropionic acid 286. The protected substrates 301 and 302 were 
prepared using standard literature methods.373,374 
For serine 285, protection as the methyl ester 303 with in situ generated HCl proceeded 
in quantitative yield, this was followed by tert-butoxycarbonyl protection with Boc2O 
and triethylamine to give 301 (Scheme 79). 
 
 
Scheme 79: Reagents and conditions: a.) SOCl2, MeOH, 0 °C to r.t., 18 h, b.) Boc2O, Et3N, 
CH3CN, r.t., 18 h, quant. 
 
For 2,3-diaminopropionic acid 286, commercially available (S)-2-[(tert-
butoxycarbonyl)amino]-3-aminopropionic acid 304 was protected as its methyl ester  
302 using TMS-diazomethane (Scheme 80).  
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Scheme 80: Reagents and conditions: a.) TMS-diazomethane, CH2Cl2, MeOH, r.t., 3 h, quant. 
 
Substrates 301 and 302 were successfully acylated to give carbamate 305 and urea 306 
in 60% and 55% yield, respectively (Scheme 81). 
 
 
Scheme 81: Reagents and conditions: a.) 218, CH3CN, reflux, 18 h, 305 = 60%, 306 = 55%. 
 
With five amino acid scaffolds in hand methods for achieving orthogonal deprotections 
were explored. Deprotections of 298 are summarised in Scheme 82. 
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Scheme 82: Reagents and conditions: a.) 4 M HCl in dioxane, CH2Cl2, r.t., 1 h, quant.; b.) 
NaOH, THF:H2O (1:1), r.t., 15 min, 95%; c.) i. NaOH, THF:H2O (1:1), r.t., 15 min, ii. 4 M HCl in 
dioxane, CH2Cl2, r.t., 1 h, 77%. 
 
tert-Butoxycarbonyl deprotection of 298 with HCl furnished the desired amine 
hydrochloride salt 307 in quantitative yield. Deprotection of the methyl ester was 
accomplished with NaOH in 1:1 THF:H2O, providing carboxylic acid 308 after an 
acidic workup in good yield. A one-pot procedure combining these two steps, methyl 
ester deprotection and tert-butoxycarbonyl deprotection, furnished the free amino acid 
hydrochloride 287 in 77% overall yield. Application of these deprotection methods to 
urea 299, furnished the amine hydrochloride 309, acid 310 and amino acid 388 as 
anticipated (Scheme 83). 
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Scheme 83: Reagents and conditions: a.) 4 M HCl in dioxane, CH2Cl2, r.t., 1 h, quant.; b.) 
NaOH, THF:H2O (1:1), r.t., 15 min, 88%; c.) i. NaOH, THF:H2O (1:1), r.t., 15 min, ii. 4 M HCl in 
dioxane, CH2Cl2, r.t., 1 h, 75%. 
 
The ether 300 could also be selectively deprotected to the amine hydrochloride 311, 
carboxylic acid 312, and amino acid 289 under the similar reaction conditions (Scheme 
84). 
 
 
Scheme 84: Reagents and conditions: a.) 4 M HCl in dioxane, CH2Cl2, r.t., 1 h, quant.; b.) 
NaOH, THF:H2O (1:1), r.t., 15 min, 90%; c.) i. NaOH, THF:H2O (1:1), r.t., 15 min, ii. 4 M HCl in 
dioxane, CH2Cl2, r.t., 1 h, 80%. 
 
tert-Butoxycarbonyl deprotections of 305 and 306 under acidic conditions gave the  
desired amine hydrochlorides 313 and 314 (Scheme 85) in a straight forward manner. 
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However, ester hydrolysis of 305 with NaOH generated the dehydroalanine carboxylic 
acid 315. A similar reaction with 306 did not give any recoverable material (Scheme 
85). 
 
Scheme 85: Reagents and conditions: a.) 4 M HCl in dioxane, CH2Cl2, r.t. 1 h, 313 = 314 = 
quant. 
 
Scheme 86: Reagents and conditions: a.) NaOH, THF:H2O, r.t., 15 min, 315 = yield not 
determined, 316 = no product isolated. 
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To access the desired free carboxylic acid derivative of 305, serine 285 was protected as 
its tert-butoxycarbonyl tert-butyl ester 317 (Scheme 87). Acylation with p-nitrophenyl 
carbamate 218 provided sydnonimine 318 in 60% yield and then global deprotection 
with trifluoroacetic acid furnished the amino acid trifluoroacetate 319. N-Protection 
with Boc2O then gave the desired free carboxylic acid 320 (Scheme 87).  
 
Scheme 87: Reagents and conditions: a.) i. Boc2O, NaOH, dioxane, 18 h; ii. DMF-DBA, 
toluene, reflux, 18 h, 65%; b.) 218, CH3CN, reflux, 18 h, 60%; c.) TFA, CH2Cl2, r.t., 16 h, quant.; 
d.) Boc2O, NaHCO3, H2O:dioxane (1:1), r.t., 16 h, 72%. 
 
While the tert-butoxycarbonyl group is a robust protecting group for amines, it is not 
always compatible with further synthetic chemistry. Its sensitivity towards acid 
precludes its use with other acid sensitive protecting groups such 2,2,4,6,7-pentamethyl-
dihydrobenzofuran-5-sulfonyl (Pbf) and tert-butyl ether/esters, where selective 
protection is required. To allow for the amino acid to be used in further chemistry, 298 
and 300 were orthoganally with two different groups, Fmoc and Alloc. Deprotection of 
298 with HCl furnished the amine hydrochloride 307 as previously described (Scheme 
82). The amine hydrochloride salt 307 was then treated with Fmoc-Cl or Alloc-Cl in 
THF to re-protect the free amine providing the Fmoc 321 and the Alloc 322 amino acid 
(Scheme 88). These two amino acids were deprotected with NaOH to provide the free 
carboxylic acids 323 and 324, respectively (Scheme 88). 
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Scheme 88: Reagents and conditions: a.) 4 M HCl in dioxane, CH2Cl2, r.t., 1 h, quant.; b.) 
Fmoc-Cl, Et3N, THF, 0 °C to r.t., 1 h, 90%; c.) Alloc-Cl, Et3N, THF, 0 °C to r.t., 1 h, 85%; d.) 
NaOH, THF:H2O, r.t., 15 min, 323 = 80%,  324 = 80%. 
 
The same conditions were applied to amino acid 300 to furnish Fmoc 325 and Alloc 
326 amino acid, along with the free carboxylic acids 327 and 328 after methyl ester 
deprotection (Scheme 89). 
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Scheme 89: Reagents and conditions: a.) 4 M HCl in dioxane, CH2Cl2, r.t., 1 h, quant.; b.) 
Fmoc-Cl, Et3N, THF, 0 °C to r.t., 1 h, 90%; c.) Alloc-Cl, Et3N, THF, 0 °C to r.t., 1 h, 81%; d.) 
NaOH, THF:H2O, r.t., 15 min, 327 = 80%, 328 = 77%. 
 
5.1.1 NITRIC OXIDE RELEASE 
The Griess test was used to measure the NO release from amino acids 287 and 289, as 
they are the precursor building blocks for further chemistry. The Griess test is a 
colourimetric assay for nitrite, one of the oxidation products of NO (see Chapter One 
for detailed description).188 While the measurement of nitrite is not a direct measure of 
NO, it is a reliable proxy measure due to the rapid oxidation of NO. For furoxans, it has 
previously been reported that the formation of nitrite (NO2-), is a reliable measure of the 
NO release, in the presence of excess thiol.139 Equimolar production of superoxide 
(O2), along with NO is reported, for sydnonimines.140 To this affect, the Griess assay 
for NO2- was used to determine the production of NO from amino acids 287 and 289, 
and as a control, L-tyrosine 283. Amino acids 287 and 289 (1 mmol, [final], 400 µM) in 
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a solution of DMSO: H2O (2:8) were incubated with a glutathione (GT) buffer 
containing superoxide dismutase (SOD) ([GT] 6 mmol, final [GST] 600 µM, pH 7.6, 
[SOD] 4557 U mL-1). Amino acids 287 and 289 showed an NO2- release of 30.4 ± 3.9 
µmol and 44.8 ± 3.2 µmol, respectively. (Table 20) The amount of NO required to 
induce a cellular response is at the picomolar to nanomolar range. Control incubations 
performed under identical conditions in the absence of GT and SOD did not give 
significant NO production. This is in agreement with the reported release of NO from 
furoxans and sydnonimines in aqueous conditions,139,140 No measureable NO production 
was observed from tyrosine 283. 
Compound NO2- production 
(μmol)  (GT 
buffer) 
NO2- production 
as % 
(GST buffer) 
 
NO2- production 
(μmol)  (pH 7.6 
buffer) 
NO2- production 
as % 
(pH 7.6 buffer) 
 
287 30.4 (± 3.9) 7.5 3.2 (± 1.1) <1% 
289 44.8 (± 3.2) 11.2 5.2 (± 5.5) 1.3 % 
293 0.0 (± 0.1) 0 0.0 (± 0.1) 0 
 
Table 20: NO release from amino acids 287 and 289. 
 
To demonstrate the synthetic utility of these amino acids, 287 and 289 were 
incorporated into tripeptide sequences (Scheme 90). 
Amide formation between 308 with L-Val-OMe and L-Phe-OMe with HATU in DMF 
provided the dipeptides 329 and 330 in >99:1 d.r. and in 91% and 95% yields, 
respectively (Scheme 90). Deprotection with HCl provided the hydrochloride salt, 
which was not characterised, but immediately to couple to Fmoc-Arg(Pbf)-OH and 
Fmoc-Asp(OtBu)-OH to provide the tripeptides 331 and 332 (Scheme 90). The 
conditions were applicable to amino acid 312 to furnish dipeptides 333 and 334, and 
tripeptides 335 and 336 (Scheme 90). 
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Scheme 90: Reagents and conditions: a.) L-Val-OMe, HATU, (iPr)2EtN, DMF, 0 °C to r.t., 16 h, 
329 = 91%; b.) 4 M HCl in dioxane, CH2Cl2, 1 h; c.) Fmoc-L-Arg(Pbf)-OH, HATU, (iPr)2EtN, 
DMF, 0 °C to r.t., 16 h, 331 = 88%; d L-Phe-OMe, HATU, (iPr)2EtN, DMF, 0 °C to r.t., 16 h, 330 
= 95%; e.) Fmoc-L-Asp(OtBu)-OH, HATU, (iPr)2EtN, DMF, 0 °C to r.t., 16 h, 332 = 85%; f.) L-
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Val-OMe, HATU, (iPr)2EtN, DMF, 0 °C to r.t., 16 h, 333 = 95%; g.) Fmoc-L-Asp(OtBu)-OH, 
HATU, (iPr)2EtN, DMF, 0 °C to r.t., 16 h, 335 = 80%; h.) L-Phe-OMe, HATU, (iPr)2EtN, DMF, 0 
°C to r.t., 16 h, 334 = 95%; i.) Fmoc-L-Arg(Pbf)-OH, HATU, (iPr)2EtN, DMF, 0 °C to r.t., 16 h, 
336 = 88%. 
 
With the development of protecting group strategies for the amino acid series, attention 
turned to their integration into biologically relevant peptides. The RGD peptide 
sequence was identified as a suitable framework. NO-RGD peptides could clearly target 
nitric oxide delivery to the surface of cancer cells. Given the previously reported 
findings that the hypoxic response is reversed in prostate cancer cells upon treatment 
with nitric oxide NSAIDs,298 an NO-RGD peptide may allow for a more targeted 
delivery of NO to a cell, rather than from a compound such as NCX-1102 111, not a 
prostate specific compound. NO-RGD peptides also have the potential for use in 
cardiovascular disease. It has been reported that the tetrapeptide RGD peptide 337, 
containing an S-nitrosothiol-derived cysteine residue, was a more effective 
antithrombotic agent than the RGD sequence alone.375 RGD-SNO peptide 337 is also a 
vasodilatory peptide, due to the release of NO. RGD alone did not cause vasodilation.375 
 
 
Two types of NO-RGD peptides were designed for synthesis. The first are linear 
peptides: containing the RGD sequence with an NO-release functionality. The second, a 
cyclic RGD pentapeptide containing amino acid 287. Cyclic RGD peptides 
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conformationally lock the RGD sequence and in general have a greater affinity for 
integrin binding and increased in vivo stability. 
 
5.2 NITRIC OXIDE-DONATING RGD PEPTIDES- RESULTS AND 
DISCUSSION 
A solution phase Fmoc/tBu peptide coupling strategy was chosen for the preparation of 
the linear RGD peptides. This strategy would assemble the RGD sequence first, 
followed by coupling of the desired carboxylic acid. Global deprotection would then  
provide the peptide. 
The desired RGD sequence was prepared based on the procedure reported by Welsh and 
Smith,376 starting from di-tert butyl ester protected aspartic acid 338. This was carried 
out in two steps from commercially available N-Cbz-aspartic acid 339 (Scheme 91). 
 
 
Scheme 91: Reagents and conditions: a.) tert-Butyl acetate, BF3(OEt2), r.t., 18 h, 60%; b.) i. 
NH4CO2H, 10% Pd/C, THF/MeOH (1:1), r.t., 18 h, ii.) sat. HCl in EtOAc, 1 h, -20 °C, 80%. 
 
Protection of the free carboxylic acid groups of 339 was accomplished using tert-butyl 
acetate and boron trifluoride (Scheme 91).377 Workup using aqueous NaOH allowed for 
the unreacted starting material and mono-protected acid to be extracted into the aqueous 
layer, such that the isolated fully protected 340 required no further purification.  
Deprotection of the Cbz group was accomplished by transfer hydrogenation with 
ammonium formate and palladium on carbon.377 The free base was converted to its 
hydrochloride salt 338 by the addition of a saturated solution of HCl in ethyl acetate to a 
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solution of the amine in ethyl acetate. The overall yield of the two steps was 48%, and 
the reaction could be carried out on a 10 g scale. 
The synthesis of NH2-RGD 341 was undertaken as reported by Welsh and Smith 
(Scheme 92).376 
 
 
Scheme 92: Reagents and conditions: a.) T3P®, (iPr)2EtN, CH2Cl2, 0 °C, 16 h, 95%; b.) 
piperidine, CH2Cl2, 0 °C to r.t., 2 h, 87%; c.) T3P®, (iPr)2EtN, CH2Cl2, 0 °C, 16 h, 90%; d.) 
piperidine, DMF, 0 °C to r.t., 0.5 h, 85%. 
 
Peptide coupling between the prepared di-tert butyl aspartic acid 338 and Fmoc-Gly-
OH 341 using T3P® furnished dipeptide 343 in 95% yield.376 The observed optical 
rotation of this material was +23.0 (c = 1.0, CHCl3), in accordance with the reported 
value +22.9 (c = 1.0, CHCl3).376 Deprotection of the Fmoc group was carried out using 
piperidine to give amine 344.376 Homologation of amine 344 with commercially 
available Fmoc-Arg(Pbf)-OH furnished tripeptide 345.376 The crude material was a 99:1 
mixture of diastereoisomers based on 1H NMR; and it was possible to separate the 
undesired diastereoisomer by chromatography and isolate the desired tripeptide 345 in 
85% yield. 
Fmoc deprotection of 345 following the literature method376 resulted in a 70% 
racemisation of the arginine stereogenic centre (Figure 17).  
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Changing the deprotection solution from 20% piperidine in dichloromethane to 10% 
piperidine in DMF arrested the racemisation and generated diasteromerically pure 341. 
With amine 341 in hand it was coupled to the Boc-protected amino acids 308 and 312 
using HATU as the coupling reagent, to generate tetrapeptides 346 and 347 in excellent 
yield and as single diastereoisomers after column chromatography (Scheme 93). 
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Figure 17: 1H NMR (500 MHz, CDCl3) 
comparison of Fmoc deprotection of 
345.  
A = 20% piperidine in CH2Cl2, 
B = 10% piperidine in DMF. 
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Scheme 93: Reagents and conditions: a.) HATU, DMF, (iPr)2EtN, 0 °C to r.t., 18 h, 346 = 70%, 
347 = 69%. 
 
The acid labile Boc, Pbf and tert-butyl esters were then globally deprotected by 
treatment with a cocktail of TFA, triisopropylsilane (TIPS) and water (95:2.5:2.5). This 
furnished the tetrapeptides 348 and 349 as their trifluoroacetate salts after 
lyophilisation. 
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Scheme 94: Reagents and conditions: a.) TFA:TIPS:H2O, r.t., 2 h, 348 = 92%, 349 = 90%. 
 
By using Fmoc-protected amino acid 321 the tetrapeptide 350 could also be accessed 
under the same coupling conditions (Scheme 95).  
 
Scheme 95: Reagents and conditions: a.) HATU, DMF, (iPr)2EtN, 0 °C to r.t., 18 h, 76%; b.) 
piperidine, DMF, 0 °C to r.t., 0.5 h, 90%, 
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The use of the Fmoc allowed for selective deprotection at the N-terminus furnishing the 
free amine 351 for use in further chemistry (Scheme 95). To demonstrate this, the NO-
RGD peptide 351 was linked to abiraterone 106 via a succinate linker. This molecule 
combines the bioactive properties of abiraterone 106, an NO release unit, and an RGD 
targeting sequence. 
Abiraterone hemisuccinate 352 was prepared in two steps using previously prepared 
tert-butyl hemisuccinate 264 (Scheme 96).  
 
Scheme 96: Reagents and conditions: a.) 264, EDCI.HCl, DMAP, CH2Cl2, r.t., 16 h, 95%; b.) 
TFA, CH2Cl2, r.t., 16 h, quant. 
 
tert-Butyl ester 353 was prepared in 95% yield from abiraterone 106 and tert-butyl 
hemisucinate with EDCI.HCl and DMAP (Scheme 96). Deprotection of 353 with 
trifluoroacetic acid furnished hemisuccinate 352 in quantitative yield (Scheme 96). 
Attempts to prepare 352 directly from abiraterone 106 were investigated, however the 
reaction with succinic anhydride 263 was slow, and purification of the product proved 
difficult. 
With hemisuccinate 352 in hand, this was coupled to amine 351 to provide the RGD-
abiraterone conjugate 354 (Scheme 97). 
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Scheme 97: Reagents and conditions: a.) HATU, DMF, (iPr)2EtN, 0 °C to r.t., 18 h, 83%. 
 
The 1H and 13C resonances of conjugate 354 could be fully assigned using 2D COSY, 
HSQC and HMBC analysis. Deprotection of the conjugate with the TFA cocktail, 
followed by trituration with diethyl ether, and then lyophilisation, gave the final 
conjugate 355 (Scheme 98). 
 
Scheme 98: Reagents and conditions: a.) TFA:TIPS:H2O, r.t., 2 h, 75%,  
 
RGD amine 341 was also coupled with carboxylic acids 258, 261 and 266. These were 
prepared earlier in Chapter Three. Peptide coupling using HATU as the activation 
reagent furnished the peptides 356-357 in good yields (Scheme 99). Finally, subsequent 
deprotection and lyophilisation furnished peptides 359-361 (Scheme 100). 
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Scheme 99: Reagents and conditions: a.) HATU, DMF, (iPr)2EtN, 0 °C to r.t., 18 h, 358 = 65%, 
359 = 76%, 360 = 80%. 
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Scheme 100: Reagents and conditions: a.) TFA:TIPS:H2O, r.t., 2 h, 359 = 85%, 360 = 90%, 
361 = 88%. 
 
5.2.1 NITRIC OXIDE RELEASE 
The Griess test was used to determine the level of NO release from the NO-RGD 
peptides.188 Solutions of RGD peptides 348, 349, 355, 359-361 (1 mmol, [final], 400 
µM) in DMSO: H2O (1:9) were incubated with a GT buffer containing SOD ([GT] 6 
mmol, final [GT] 600 µM, pH 7.6, [SOD] 4557 U mL-1). RGD was used as a control. 
The data are summarized in Table 21. 
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Compound NO2- production 
(μmol)  (GT 
buffer) 
NO2- production 
as % 
(GST buffer) 
 
NO2- production 
(μmol)  (pH 7.6 
buffer) 
NO2- production 
as % 
(pH 7.6 buffer) 
 
359 32.2 ± 2.5 8.1 2.1 ± 0.4 <1.0 
360 41.4 ± 1.1 10.4 1.6 ± 1.1 <1.0 
361 29.6 ± 6.6  7.4 3.1 ± 2.3 <1.0 
348 40.8 ± 2.7 10.2 4.0 ± 1.6 1.0 
349 52.5 ± 5.4 13.1 1.0 ± 0.7 <1.0 
355 31.6 ± 4.8 7.9 2.4 ± 1.1 <1.0 
270 2.6 ± 0.6 <1.0 2.2 ± 0.7 <1.0 
 
Table 21: NO release from RGD peptides. Data are the averages of triplicate experiments 
 
All of the prepared NO-RGD peptides demonstrated GT dependent NO release in the 
Griess assay. The RGD sequence  270 alone did not show any NO-release in GT or pH 
7.6 buffer. The highest levels of NO release were observed from the furoxan RGD 
peptides 349 and 360. The levels of NO release were 41.4 ± 1.1 µmol and 52.5 ± 5.1 
µmol (10.4 and 13.1%) respectively. Sydnonimine RGD peptide 348 had a similar level 
of NO release (40.8 ± 2.7 µmol, 10.2 %) to furoxan RGD peptides 349 and 360. Nitrate 
ester 359 and abiraterone conjugate 355 had comparable levels of NO release (32.2 ± 
2.5 µmol and 31.6 ± 4.8 µmol) 
 
 5.2.2 αvβ3 INTEGRIN AFFINITY EVALUATION 
The RGD peptide conjugates were submitted to integrin binding assays to measure their 
affinity for the αvβ3 integrin. These assays were conducted by Dr Ian Fleming at the 
University of Aberdeen, Biomedical Imaging Centre. 
The competitive affinity of RGD peptides 348, 349, 355, 359-361 were calculated based 
on their affinity towards an immobilized αvβ3 integrin receptor and a biotinylated 
c[RGDfK]-(PEG)2. Commercially available RGD 270 and GRGDSPK were used as 
reference sequences. IC50 values were calculated for each peptide, and were normalized 
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with respect to the IC50 of RGD to allow comparisons between experiments. The results 
are summarised in Table 22. 
Compound IC50 / μm Q 
RGD 8.5 ± 3.1 1 
GRGDSPK 6.4 ± 1.3 0.75 
359 5.6 ± 0.5 0.66 
360 4.7 ± 0.7 0.56 
361 6.2 ± 0.2 0.73 
348 6.0 ± 0.3 0.70 
349 5.8 ± 1.6 0.68 
355 107.6 ± 45.7 12.6 
 
Table 22: Inhibition of biotinylated c[RGDfK]-(PEG)2 binding to immobilized αvβ3 integrin. Data 
are the averages of triplicate experiments. Q = normalized activity as ratio 
IC50(peptide)/IC50(RGD) 
 
The highest affinity (4.8 µM) was observed for furoxan RGD peptide 360. This was 
nearly two-fold higher affinity than RGD 360, and nearly 1.5 fold higher affinity than 
GRGDSPK. RGD peptides 359, 361, 348, 349 all displayed greater affinity for αvβ3 
compared to RGD, and they had a comparable activity to GRGDSPK. 
Abiraterone conjugate 355, displayed an integrin binding affinity of 107.6 µM, an 
approximately 13-fold decrease in affinity compared to RGD. The lower affinity of 355 
might be the result of the increased structural complexity of the molecule, allowing 
fewer degrees of freedom of rotation while maintaining integrin binding. 
The integrin binding studies suggest that the addition of a single amino acid residue, or 
a heterocycle appended chain onto the N-terminus of the peptide has little affect on the 
affinity of the peptide to αvβ3. However, installation of a large group on the N-terminus 
as shown with peptide 355 results in a decreased affinity towards the αvβ3 integrin when 
a linear chain is used. 
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5.3 STUDIES TOWARDS THE SYNTHESIS OF A NITRIC OXIDE-DONATING 
CYCLIC RGD PEPTIDE 
Cyclic RGD peptides generally have an improved integrin binding affinity compared to 
linear RGD sequences. Macrolactamisation of the RDG sequence entropically favours 
RGD binding by pre-organisation of the recognition sequence. In addition, cyclic 
RGD’s have improved metabolic stability and these are attractive targets. Cyclic RGD 
362 was proposed as a synthetic target. 
 
 
 
The retrosynthetic strategy towards peptide 362 is based on the macrolactamisation of 
acyclic peptide 373. This can be prepared in a convergent approach from two fragments. 
Fragment A is the tripeptide 374 with a free amine functionality; Fragment B is the 
carboxylic acid 375 (Scheme 101). 
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Scheme 101: Retrosynthetic analysis of cRGD 362. 
 
Fragment A 364 was prepared in five steps from glycine 366 as illustrated in Scheme 
102. 
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Scheme 102: Reagents and conditions: a.) Allyl alcohol, p-TsOH, toluene, reflux (Dean-Stark), 
16 h, 90%; b.) Fmoc-Arg(Pbf)-OH, HOBt, EDCI.HCl, DMF, 0 °C to r.t., 18 h, 89%; c.) piperidine, 
DMF, r.t. 0.25 h, 95%; d.) 321, HATU, CH2Cl2, r.t. 18 h, 87%; e.) piperidine, DMF, r.t. 0.5 h, 
82%. 
 
Glycine 366 was protected as its allyl ester 377 in a condensation reaction using allyl 
alcohol, and p-TsOH in toluene under Dean-Stark conditions (Scheme 102).378 
Purification by recrystallisation from dichloromethane furnished allyl glycine 377 as the 
tosylate salt in 90% yield. Amide coupling with Fmoc-Arg(Pbf)-OH using EDCI.HCl 
and HOBt in DMF allowed the preparation of dipeptide 368 in 89% yield with an 
optical rotation of -5.3° (c = 1, CHCl3) (Scheme 102). Deprotection of the Fmoc group 
of 368 using piperidine in DMF furnished amine 369 in 95% yield. Further coupling 
with Fmoc-amino acid 321 using HATU provided tripeptide 370 in 87% yield. This was 
efficiently deprotected to give the free amine 364 in 82% yield (Scheme 102). 
Fragment B 365, was prepared following the literature procedure of Carpino et al 
(Scheme 103).379,380  
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Scheme 103: Reagents and conditions: a.) Allyl alcohol, p-TsOH, toluene, reflux (Dean-Stark), 
16 h, 81%; b.) Cyanuric fluoride, pyridine, 0 °C to r.t., 4 h, 94%; c.) 372, (iPr)2EtN, CH2Cl2,, 0 °C 
to r.t., 16 h, 68%; d.) 10% Pd/C, ammonium formate, r.t., 3 h, 85%. 
 
Thus, D-phenylalanine 371 was converted to its benzyl ester 372 (Scheme 103).378 
Activation of Fmoc-Asp(OtBu)-OH 373 to the corresponding acyl fluoride using 
cyanuric fluoride provided 374 in 94% (Scheme 103). The formation of the acyl 
fluoride was confirmed by 19F NMR with a signal at +28.2 ppm. A condensation could 
then be achieved between amino acids 372 and 374 to furnish dipeptide 375 (68% yield) 
(Scheme 103). Dipeptide 375 could also be prepared using HOBt and EDCI in DMF. 
The yield for both methods is similar. The sequence was completed with a transfer 
hydrogenation using ammonium formate and Pd/C which furnished carboxylic acid 365 
in 85% yield after chromatography (Scheme 103). 
With the two fragments in hand, dipeptide 375 and tripeptide 374 were coupled together 
using HATU to provide the peptapeptide 376. This coupling was achieved in 82% yield 
and as single diastereoisomer after chromatography (Scheme 104). 
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Scheme 104: Reagents and conditions: a.) HATU, CH2Cl2, (iPr)2EtN, 0 °C to r.t., 18 h, 82%. 
 
With the protected linear pentapeptide 376 in hand, deprotection of the allyl ester was 
considered. The deprotection was explored using Pd(PPh3)4 and morpholine as an allyl 
scavenger based on conditions previously reported for deprotection of similar glycyl 
allyl esters in peptides.381,382 This did not however yield the desired product. 
Consumption of the starting ester was observed, but the carboxylic acid could not be 
isolated. The use of morpholine as the allyl scavenger was identified as the problem in 
this reaction, as morpholine can also be used to deprotect Fmoc groups. As such 
dimedone was explored as an alternative allyl scavenger. 
Two model substrates were used to explore the using dimedone/Pd(PPh3)4 deprotection 
these were the dipeptide 368 and tripeptide 370 (Scheme 105).  
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Scheme 105: Reagents and conditions: Dimedone, Pd(PPh3)4, dry THF, r.t., 3-5 h, 377 = 95%, 
378 = 88%. 
 
These two peptides appeared appropriate as they possess the same sequence of amino 
acids as found in pentapeptide 376. Fortuitously when they were treated with dimedone 
(3-5 molar equiv.) and Pd(PPh3)4 (5-8 mol%) in dry THF, the expected carboxylic acids 
were isolated in 95% and 88% yield respectively, with no observed racemisation. These 
conditions were applied to pentapeptide 376 and this also proved successful furnishing 
the pentapeptide acid 379 in a 77% yield (Scheme 106). 
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Scheme 106: Reagents and conditions: Dimedone, Pd(PPh3)4, dry THF, r.t., 3-5 h, 77%. 
 
With carboxylic acid 379 in hand, attention turned to deprotection and then 
macrolactamisation. The literature reports many examples of peptide 
macrolactamisation in natural product total synthesis.383–385 It was chosen to mediate the 
Fmoc deprotection using piperidine in DMF, and then use the unpurified material 
directly in the macrolactamisation reaction (Scheme 107, Table 23, Entry 1). 
 
Scheme 107: Reagents and conditions: see Table 23. 
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Entry Fmoc deprotection 
conditions 
Macrolactamisation conditions Outcome 
1 Piperidine/DMF, 0.5 h HATU, CH2Cl2, 
0.01 M, 36 h 
9-methylenefluorene 
isolated 
2 Et2NH/CH3CN, 3 h N/A no product isolated 
3 Piperdine/CH2Cl2, 0.5 
h 
HATU, HOAt, DMF, 0.01 M, 24 h no product isolated 
4 Piperidine/CH2Cl2, 
0.5 h 
HATU, HOAt, CH2Cl2, 0.001 M, 
36 h 
9-methylenefluorene 
isolated 
5 Piperidine/CH2Cl2, 
0.5 h 
T3P®, (iPr)2NEt, CH2Cl2, 0.001 
36 h 
9-methylenefluorene 
isolated 
6 PS-Piperazine, 
CH2Cl2, 24 h 
T3P®, (iPr)2NEt, CH2Cl2, 0.001 
M, 72 h 
no product isolated 
 
Table 23: Conditions explored for the macrolactamisation of 379. 
 
Deprotection of the Fmoc group was monitored by thin-layer chromatography, but the 
corresponding product could not be observed on TLC. 1H NMR indicated some 
“peptide-like” signals, and as such the crude reaction product was subjected to 
macrolactamisation conditions with HATU, but only 9-methylenefluorene 381 could be 
isolated. 
 
 
Based on this result a series of attempts were made to isolated the intermediate amino 
acid and purify it by column chromatography (Table 23, Entry 2). However in all cases 
the product could not be isolated. The presence of the amino acid could not be 
determined by thin-layer chromatography, UV or ninhydrin visualisation on normal or 
C18 reverse-phase silica plates. As a result the deprotection and macrolactamisation 
381
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were undertaken without any purification of the intermediate amino acid, beyond 
solvent evaporation and drying under vacuum. A solution of piperidine in 
dichloromethane was identified as the optimum conditions for Fmoc deprotection 
(Table 23, Entry 3-5), as the residual solvent was readily removed. Three 
macrolactamisation conditions were trialled using HATU and T3P®; but the product 
was not observed in either case. Polymer-supported piperazine was also explored used 
in place of piperidine (Table 23, Entry 6). Deprotection of the Fmoc group was 
apparent, however when subjected to macrolactamisation the lactam was not formed.  
Macrolactamisation of peptide 389 is clearly proving difficult and could not be achieved 
during the course of this research.  
 
5.4 NITRIC OXIDE DONATING PSMA INHIBITORS-RESULTS AND 
DISCUSSION 
Chapter Two described the use of a simple heterodimeric urea scaffold to target and 
inhibit PSMA for radioimaging.256,257 This urea was identified as a potential homing 
unit for drug delivery and NO location. We sought to prepare similar urea-based PSMA 
inhibitors appended with our NO release units previously described i.e. nitrate esters, 
furoxans and sydnonimines. In addition, we aimed to combine a PSMA inhibitor with 
the CYP17 inhibitor, abiraterone, and an NO release sydnonimine. 
The Glu-Lys urea 382 was prepared from commercially available di-tert butyl protected 
glutamic acid 383, and ε-Cbz tert-butyl lysine 384 in a protocol similar to that reported 
by Maresca et al. (Scheme 108).257 Generation of the isocyanate of 384 followed by its 
reaction with 383 generated protected urea 382. Hydrogenolysis of the Cbz group was 
carried out in a flow reactor (H-Cube) in order to furnish the amine 385 in quantitative 
yield (Scheme 108). 
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Scheme 108: Reagents and conditions: a.) Triphosgene, (iPr)2EtN, dry CH2Cl2, -20 °C, 1 h; b.) 
383, (iPr)2EtN, 2 h, -20 °C to r.t., 78%; c.) H-Cube, 1 atm pressure, 1 mL/min, r.t., 10% Pd/C 
cartridge, quant.. 
 
Maresca et al. have reported the use of amine 385 in reductive aminations, isocyanate 
condensation and sulfonamide preparation.257 We chose this amine to link to carboxylic 
acids 258, 261 and 266 as previously described in Chapter Three. 
 
 
 
To this effect, amide coupling between acids 258, 261 and 266 with amine 385 using 
HATU as a coupling reagent furnished the desired amides 386-388 in excellent yield 
(Scheme 309). 
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Scheme 309: Reagents and conditions: a.) 258, HATU, (iPr)2EtN, DMF, r.t. 18 h, 70%; b.) 261, 
HATU, (iPr)2EtN, DMF, r.t. 18 h, 72%; c.) 266, HATU, (iPr)2EtN, DMF, r.t. 18 h, 66%. 
 
Deprotection of the tert-butyl esters 386-388 using TFA and purification by trituration 
with acetonitrile provided the carboxylic acids 389-391 (Scheme 310). These PSMA 
inhibitors were insoluble in all solvents, apart from TFA and DMSO and as a result it 
was not possible to obtain optical rotations on these molecules. The poor solubility also 
has implications for their potential use as NO donors in a clinical setting. Their may be 
improved by replacing the amide with a bioisostere with greater solubilising potential, 
such as a sulfonamide or secondary amine. The solubility may also be improved by 
adding appropriate groups to the appended carboxylic acids. These avenues remain to 
be explored. 
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Scheme 310: Reagents and conditions: a.) TFA, CH2Cl2, 0 °C, to r.t., 18 h, 389 = 90%, 390 = 
92%, 391 = 80%. 
 
In addition to the NO-conjugates 389-391, the PSMA inhibitor motif was also 
developed as a component in an NO and abiraterone 106 conjugate. 
Conversion of amino acid 321, as previously prepared in Chapter Five, to the 
corresponding acyl fluoride 392, and subsequent condensation with amine 385, 
provided the Fmoc-protected peptide 393. Fmoc deprotection with piperidine furnished 
amine 394, which was then linked with abiraterone hemisuccinate 352 to furnish amide 
395. Finally, TFA deprotection followed by purification by trituration with acetonitrile 
gave the tris-acid 396 (Scheme 311). 
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Scheme 311: Reagents and conditions: a.) Cyanuric fluoride, pyridine, CH2Cl2, 0 °C to r.t., 4 h, 
quant., b.) 385, (iPr)2EtN, CH2Cl2,, 0 °C to r.t., 16 h, 78%; c.) Piperdine, DMF, 0 °C to r.t., 0.5 h, 
90%; d.) 352, HATU, (iPr)2EtN, DMF, r.t. 18 h, 91%; e.) TFA, CH2Cl2, 0 °C to r.t., 18 h, 88%. 
 
5.4.1 NITRIC OXIDE RELEASE 
The Griess test was used to determine the level of NO release from the NO-PSMA 
inhibitors and the results are summarised in Table 24.188 PSMA inhibitors 389-391 and 
396 (1 mmol, [final], 400 µM) in of DMSO were incubated with a GT buffer containing 
SOD ([GT] 6 mmol, final [GT] 600 µM, pH 7.6, [SOD] 4557 U mL-1). 
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Compound NO2- production 
(μmol)  (GST 
buffer) 
NO2- production 
as % 
(GST buffer) 
 
NO2- production 
(μmol)  (pH 7.6 
buffer) 
NO2- production 
as % 
(pH 7.6 buffer) 
 
389 47.7 ± 2.2 11.4 2.9 ± 1.6 <1.0 
390 57.2 ± 4.4 14.3 3.3 ± 1.0 <1.0 
391 22.0 ± 2.9 5.5 1.9 ± 0.4 <1.0 
396 33.9 ± 6.1 8.5 1.8 ± 0.5 <1.0 
 
Table 24: NO release from PSMA inhibitors. Data are the averages of triplicate experiments 
 
PSMA inhibitors 389-391 and 396 all displayed NO release properties in the presence 
of GT. The highest level of NO released was observed from furoxan 390 (57.2 ± 4.4 
µM, 14.3 %) released. The NO release from the abiraterone conjugate 396 was also 
significant (33.9 ± 6.1 µM, 8.5%). NO release in pH 7.6 buffer was less than 1% in each 
case.  
The targeting of NO delivery with PSMA inhibitors presents as an attractive option for 
prostate cancer therapy and these initial studies pave the way for future work on 
compound optimisation. 
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CHAPTER SIX: CONCLUSIONS AND FUTURE WORK 
 
Through the course of this thesis NO-donating functionalities have been applied in the 
synthesis of an array of bioactive molecules, varying from conjugation with drug 
molecules to installation in amino acids and peptides. 
A total of 47 analogues of NCX-1102 were prepared, using nitrate esters, furoxans and 
sydnonimines as NO-donating functional groups. These were screened for cytotoxic 
activity at the University of Edinburgh, and two lead compounds, 181 and 183 were 
identified for further test in a mouse model of prostate cancer, the work on the sulindac 
series of compounds has been submitted for publication in Bioorganic and Medicinal 
Chemistry. This strategy was then applied to abiraterone, a CYP17 inhibitor recently 
licenced for the treatment of CRPCa; in this study, a furoxan analogue 253 was selected 
as a lead compound. Further biological evaluation is underway on this series of 
compounds at the University of Edinburgh. 
In addition to NO-drug hybrids, the concept was extended to amino acid motifs. With a 
series of tyrosine and serine derived NO-donating amino acids prepared. This work was 
published in Organic and Biomolecular Chemistry in 2013.386 These amino acids were 
employed in the synthesis of NO-donating RGD peptides, and PSMA inhibitors. The 
linear RGD peptides displayed NO release in the presence of glutathione, and had 
similar affinity towards the αvβ3 integrin. Further biological assays into the potential 
cytotoxicity of these peptides are being undertaken at the University of Aberdeen. 
Overall this research has examined the delivery of NO using drug hybrids and through 
more targeted means, such as amino acids and peptides. The delivery of NO to a target 
organ is a diffult task. The appending of NO release units to known molecules, with 
known activities is at first glance, an easy way of delivering NO along with the drug 
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molecule. But this is not guaranteed, NO release is difficult to control and this is the 
main challenge for developing targeted therapies. 
 
The final part of this thesis discusses the possible future work that could be undertaken 
to continue this research. 
Three possible aspects of work have been described herein, these are: 
1.) Fluorinated sydnonimines 
2.) Imaging PSMA expression with positron emission tomography. 
3.) Simple highly-functionalised NO-donating linkers for bioconjugation. 
 
6.1 FLUORINATED SYDNONIMINES 
As shown in Chapter 1, halogenation of the C4 position of the sydnonimine ring is 
easily accomplished for chlorine, bromine and iodine using the corresponding N-
halogen succinimide (Chapter 1, Scheme 21, page 36).169 Installation of a fluorine atom 
in C4 is not known. Given the prevalence of fluorinated molecules in organic chemistry, 
particularly in relation to pharmaceuticals, a fluorinated syndonimine would be a 
valuable functional group. To this end, the synthesis of two fluorinated sydnonimines is 
proposed (Scheme 312). 
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Scheme 312: Fluorination of sydnonimines. Proposed reagents and conditions: a.) i.) n-BuLi,; 
ii.) NFSI; b.) NIS; c.) CF3SO2Cl, Ru(phen)3, hν; d.) NaSO2CF3 (Langois reagent), tBuOOH, 
CH2Cl2:H2O. 
 
Sydnonimine 397 has been previously prepared in our group. In this proposed synthesis, 
the fluorination of 397 is proposed by lithiation and fluorination of the anion with an 
electrophilic fluorination reagent such as NFSI to provide fluorosydnonimine 398. 
Trifluoromethylation of 397 is forseen to occur in a two-step process; initial iodination 
with NIS to sydnonimine 399, followed by trifluoromethylation by photoredox catalysis 
to give trifluoromethylsydnonimine 400, based on the work of MacMillan.387 This 
method of trifluoromethylation has been shown to work with a wide range of aromatic 
and heteroaromatic systems; and could be easily applied using commercially available 
reagents. Direct trifluromethylation of 397 may also be possible using the 
trifluoromethylation conditions developed by Baran using the Langois reagent 
(NaSO2CF3).388 
With these in hand, it would be interesting to examine the kinetics of hydrolysis to 
release NO with the fluorinated sydnonimines 298 and 400, and parent sydnonimine 
397. This could be undertaken using 1H and 19F NMR spectroscopy. 
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6.2 IMAGING PSMA EXPRESSION WITH POSITRON EMISSION 
TOMOGRAPHY 
 
Positron emission tomography (PET) is a developing technique for medical imaging. As 
described in Chapter Five, research within the group has focused on the use of fluorine 
as a radiotracer for PET imaging, using the RGD sequence to image integrin expression 
with fluorodeoxyribose as the source of fluorine.367,389,390 The PSMA inhibitor motif 
described in Chapter Five has been used as a method of imaging PSMA expression in 
prostate cancer tumour tissue. This has involved using radiolabelled iodine,257 
technetium391 and rhenium.392 Based on work in the group, a four-step synthesis is 
proposed to develop a labeled PSMA inhibitor using FDR as the fluorine source 
(Scheme 313). Conversion of the amine 385, prepared previously, to the 
triphenylpyrillium salt 401 gives a leaving group suitable to be substituted with N-Boc 
hydroxylamine to give tert-butoxycarbonyl protected material 402 (Scheme 313). 
Global deprotection of the tert-butoxycarbonyl and tert-butyl esters with TFA would 
provide 403. This would be a suitable precursor for oxime bioconjugation with FDR to 
give labelled inhibitor 404 (Scheme 313). 
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Scheme 313: Synthesis of fluorinated PSMA inhibitor. Proposed reagents and conditions: a.) 
Ethanol, Δ; b.) N-Boc hydroxylamine; c.) TFA; d.) 274 (FDR), Buffer. 
 
6.3 SIMPLE HIGHLY-FUNCTIONALISED NO-DONATING LINKERS FOR 
BIOCONJUGATION. 
 
Bioconjugation reactions represent a simple method of the post-translational 
modification of biomolecules. To this effect, the development of a “tool-box” of 
bifunctionalised linkers is proposed. These would contain an NO-release unit and a 
reactive site for bioconjugation. These would all be accessed from a series of amines, 
with nitrate ester, furoxan and sydnonimine functionalities (Scheme 314). 
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Scheme 314: Proposed reagents and conditions: a.) HNO3, Ac2O; b.) Boc2O, Et3N, 
CHCl3; c.) 218, CH3CN, Δ; d.) 53, DBU; e.) TFA, CH2Cl2. 
 
Nitrate ester 406 could be prepared based on a literature procedure393 from 2-
(aminoethoxy)ethanol 405 (Scheme 314). Boc-protected amine 408394 could be used to 
access sydnonimine 411 and furoxan 413. Amines 406, 411 and 413 could be 
functionalised to the corresponding azide using TfN3. The corresponding alkynes 414-
416 could be prepared via an amide coupling between amine 406, 411 or 413 and the 
second generation di-fluoro cyclooctyne 417 developed by Bertozzi et al.395 These 
azides and alkynes could be used in azide-alkyne Huisgen cycloadditions. 
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Scheme 315: Proposed reagents and conditions: a.) EDCI.HCl, CH2Cl2. 
 
In a similar fashion, the N-hydroxysuccinyl carbamates could be prepared for lysine 
ligation. 
In combination, this “tool-box” would allow for a wide variety of bioconjugation 
reactions to take place on a range of chemical functional groups. While it would be 
possible to prepare similar linkers with a maleimide functional group for thiol-ene type 
ligation, this would be counterproductive for bioconjugation with these groups, as the 
sulfhydryl groups are required for the reaction with the NO-donating functional group 
to release NO. 
However, this reactivity could be used to develop a bioconjugation reaction that 
released NO upon bioconjugation. For example, thiophilic bioactivation of furoxans 
generates a covalent C-S bond in the NO release mechanism.139 It has been 
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demonstrated that electron-withdrawing groups promote the reaction with thiolate 
ions,157 and as such, a furoxan with an increased number of electron-withdrawing 
groups, such as fluorine groups e.g 418-421, could be an alternative to maleimides for 
bioconjugation chemistry, combined with release of nitric oxide. 
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APPENDIX: EXPERIMENTAL SECTION 
 
A.1 GENERAL EXPERIMENTAL PROCEDURES 
  
For anhydrous reactions, glassware was flame dried under high vacuum. Reactions were carried 
out under an atmosphere of argon, unless otherwise noted. Compressed argon was passed 
through a drying column packed with 4 Å molecular sieves, potassium hydroxide and self-
indicating desiccant, before reaching a double manifold.  Dry CH2Cl2 and THF were obtained 
by sequential passage through drying columns, followed by dispensing under an atmosphere of 
argon from an mBRAUN SPS-800 solvent purification machine, THF was used unstabilised. 
Dry acetonitrile was obtained by drying over CaH2 followed by distillation under argon and 
stored over CaH2. Dry solvents were used when indicated in the procedure. 
All chemicals were purchased from: Sigma Aldrich, Alfa Aesar, Fluorochem, TCI Europe or 
Fisher Scientific. Silica Gel 60 (240–400 mesh) was purchased from Merck. Glass-backed TLC 
plates with 254 nm indicator were also purchased from Merck. Flash column chromatography 
was carried out following the procedure reported by Still et al.396 
Triethylamine, diisopropylamine and piperidine were distilled from KOH before use and stored 
over KOH. Any chemicals requiring further purification were purified by the literature 
method.397 
 
1H NMR spectra were recorded 300, 400 or 500 MHz Bruker Avance/Avance II/Avance III 
spectrometers. All spectra were acquired in deuterated solvents, and calibrated to the residual 
chemical shift of that solvent. Chemical shifts are given in δ as in units of parts per million 
(ppm) relative to tetramethylsilane. Proton assignments are made according to chemical shift, 
multiplicity and 2D NMR experiments and are reported to 2 decimal place. Coupling constants 
(J) are reported to nearest 0.1 Hz. NMR spectra were interpreted using TopSpin v3.0.  
 
13C NMR spectra were recorded at 75, 101, 126 MHz on Bruker Avance/Avance II/Avance III 
spectrometers. Resonances were assigned by reference to DEPTQ, HMBC and HSQC spectra 
and are reported to 1 decimal place with coupling constants reported to nearest 0.1 Hz.  
 
19F NMR spectra were recorded at 376 MHz on Bruker Avance II spectrometer. Fluorine 
assignments are made according to chemical shift, multiplicity, and reference to the literature. 
Coupling constants are reported to 0.1 Hz and are averaged for coupling nuclei. 
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Multiplicities are as follows: s – singlet, br s – broad singlet, m – multiplet, d – doublet, dd – 
doublet of doublets, ddd – doublet of doublet of doublets, dt – doublet of triplets, t – triplet, q – 
quartet. 
 
Under reduced pressure refers to the use of a KNF diaphragm pump or Büchi V-700 vacuum 
pump to remove solvent under reduced pressure on a Büchi Rotavapour R-210 apparatus, with a 
water bath at 40 ºC and a Büchi V-850 pressure regulator. The bath temperature was reduced to 
0 ºC with ice when removing solvents from volatile compounds. Drying under vacuum refers to 
the use of an Edwards RV-3 rotary vane oil pump at a pressure of <0.1  mbar.  
 
Lyophilisation refers to the removal of water by sublimation on a Christ Alpha 1-2 LD plus 
freeze dryer equipped with an Edwards RV-3 two stage rotary vane oil pump.  
 
Optical rotations were recorded on a Perkin Elmer model 341 polarimeter with a cell 
pathlength of 1 dm. Samples were recorded at 589 nm (sodium D-line). Concentrations are 
reported in g/100 mL and specific optical rotations are denoted as [α]!!" in the implied units of 
10-1 deg cm3 g-1.  
 
TLC plates were visualised under UV light (254 or 365 nm) and/ or stained with the appropriate 
staining solution The staining solution is reported when used: either basic aqueous potassium 
permanganate or ethanolic cerium phosphomolybdate. 
 
Melting points were measured using a Gallenkap Griffin MPA350 melting point apparatus and 
are uncorrected. 
 
Mass Spectroscopic analyses at the School of Chemistry were conducted by Mrs Caroline 
Horsburgh on a Micromass LCT electrospray time of flight mass spectrometer. Samples sent to 
the EPSRC mass spectrometry service in Swansea were analysed on a Thermofisher LTQ 
Orbitrap XL mass spectrometer using electrospray ionisation (ES). m/z values are reported in 
Daltons. 
 
IR spectra were recorded a Perkin Elmer Spectrum GX FT-IR machine as either a KBr disk, or 
as thin films on NaCl plates. 
 
Elemental microanalyses were performed on a Carlo-Erba EA 1108 with PC based data 
system, Eager 200 for Windows and a Sartorious Ultra Micro Balance, 4504MP8 at the UCL 
London School of Pharmacy. 
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Miscellaneous Brine refers to a saturated solution of sodium chloride in distilled water.  	  	  
A.2 COMPOUND NUMBERING 
Compounds based on the sulindac 112 core structure are numbered in the experimental 
section based on the style reported by Douglas.398 Primes are used when necessary. 
 
 
Compounds based on the abiraterone 106 core structure are numbered in the 
experimental section based IUPAC nomenclature for steroids. Primes are used when 
necessary. 
 
Amino acids and peptides are numbered on the structures sequentially, not based on 
IUPAC nomenclature, for ease. Primes are used when necessary. 
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A.3 GENERAL PROCEDURES 
 
General procedure A 
 
EDCI.HCl (1-2 equiv.), the alcohol (1 equiv.) and DMAP (10 mol%) were added to a solution 
of sulindac derivative (sulfoxide, sulfide or sulfone, 1 equiv.) in dichloromethane (10 mL) and 
stirred for 4 h at room temperature. The solution was partitioned with aq. HCl solution (2 N, 10 
mL). The organic layer was separated and washed with aq. HCl solution (2 N, 5 mL) and brine 
(10 mL). The organic layer was dried over MgSO4 and the solvent removed under reduced 
pressure to yield the crude material. This crude material was purified by silica gel 
chromatography to give the desired ester. 
 
General Procedure B 
 
HATU (3 equiv.) was added to a solution of amine (1 equiv.) and acid (1.5 equiv.) in dry DMF 
(5 mL) cooled to 0 °C. The solution was stirred for 15 min and diisopropylethylamine (distilled, 
4 equiv.) was added. The solution was allowed to warm to room temperature and stirred for 
18 h. The resultant solution was diluted with ethyl acetate (50 mL) and water (50 mL). The 
organic layer was separated and washed with aq. HCl (2 N, 20 mL), aq. Na2CO3 (saturated, 20 
mL) and brine (20 mL). The organic layer was separated and dried over Na2SO4, filtered and the 
solvent removed under reduced pressure. The resultant residue was uptaken in dichloromethane 
and adsorbed onto silica gel. Purification by silica gel chromatography provided the desired 
amide. 
 
General procedure C 
 
RGD peptide (upto 100 mg) was dissolved in a deprotecting cocktail of TFA:TIPS:H2O 
(700  µL, 95:2.5:2.5) and stirred for 2 h. The solvent was removed under reduced pressure and 
the residue triturated with cold diethyl ether. The residue was dissolved in tert-butanol:H2O (5 
mL, 1:4), snap-frozen and lyophilised to give the trifluoroacetate salt. 
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A.4 EXPERIMENTAL PROCEDURES FOR CHAPTER THREE 
 
(Z)-2-(5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetic acid 
(sulindac sulfide), 115308 
 
 
 
Titanium (IV) chloride (1.0 M in CH2Cl2 solution, 1.5 mmol, 1.5 mL) and PS-
triphenylphosphine (3.00 mmol/g loading, 1.5 g, 1.5 mmol) were added to a solution of sulindac 
112 (356 mg, 1.00 mmol) in dry tetrahydrofuran (20 mL) at 0 °C. The mixture was allowed to 
warm to room temperature and stirred for 24 h. After this time, the suspension was filtered 
through Celite and the resulting solution quenched with aq. NaHCO3 solution (saturated, 
100  mL). The aqueous layer was extracted with diethyl ether (3 × 30 mL). The combined ether 
layers were washed with brine (50 mL), dried over Na2SO4, filtered and the solvent removed 
under reduced pressure to yield (Z)-2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-
inden-3-yl)acetic acid, sulindac sulfide 115, (320 mg, 94%, 0.94 mmol) as a yellow solid, which 
was used without any further purification: m.p. 186-188 °C, [Lit.308 186-190 °C]; νmax  (thin 
film)/cm−1 2926, 1702, 1557, 1601, 1491, 1048; 1H NMR (500 MHz; CDCl3) δ 7.44 (2H, d, J 
8.2 Hz, CH-2′,6′), 7.36 (1H, dd, J 8.4, 5.3 Hz, CH-7), 7.29 (2H, d, J 8.2 Hz, CH-3′,5′), 7.15 (1H, 
s, CH-α), 6.88 (1H, dd, J 8.9, 2.1 Hz, CH-6), 6.58 (1H, ddd, J 8.9, 8.8, 2.1 Hz, CH-4), 3.59 (2H, 
s, 3-CH2), 2.55 (3H, s, SCH3) and 2.20 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 175.3 
(quat., carboxyl), 163.1 (quat., d, J 246.1 Hz, C-5), 146.2 (quat., d, J 8.4 Hz, C-8), 140.0 (quat., 
C-1), 139.2 (quat., C-4′), 138.8 (quat., C-2), 132.9 (quat., C-3), 130.2 (quat., C-1′), 130.0 (CH, 
C-α), 129.9 (CH × 2, C-2′,6′), 129.7 (quat., C-9), 125.9 (CH × 2, C-3′,5′), 123.8 (CH, d, J 8.9 
Hz, C-7), 110.7 (CH, d, d, J 22.7 Hz, C-6), 105.7 (CH, d, J 24.3 Hz, C-4), 31.3 (CH2, 3-CH2), 
15.4 (CH3, SCH3) and 10.6 (CH3, 2-CH3); 19F {1H} (376 MHz; CDCl3) -114.2 (CF); m/z (ES+) 
363 ([M+Na]+, 100%); HRMS m/z (ES)+ calcd. for C20H17FNaO2S  [M+Na]+ requires 363.0831, 
found 363.0839; CHN Anal. calcd. for  C20H17FO2S: C, 70.57; H, 5.03. Found C, 70.61; H, 
5.11. The data were in agreement with the literature values.308 
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OR 
 
Titanium (IV) chloride (1.0 M solution in CH2Cl2, 8.4 mmol, 8.4 mL) was added to a 
suspension of zinc dust (1.1 g, 16.8 mmol) in tetrahydrofuran (20 mL) cooled in an ice/acetone 
bath and the resulting suspension stirred for 10 min. A suspension of sulindac 112  (1.0 g, 
2.8 mmol) in dichloromethane (20 mL) was added dropwise via syringe pump over 0.5 h and 
the resultant suspension stirred for 2 h, maintaining cooling. The suspension was filtered 
through a pad of Celite and the resulting solution was quenched with aq. HCl solution (3 N, 
100 mL), the solution was extracted with dichloromethane (3 × 60 mL) and the organics 
combined and dried over Na2SO4, filtered and the solvent removed  under reduced pressure to 
yield (Z)-2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetic acid, 
sulindac sulfide 115 (952 mg, 1.00 mmol, quant.) as a yellow solid, which was used without any 
further purification. The data were in agreement with the literature values and those reported 
previously.308 
 
(Z)-2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetic 
acid. (sulindac sulfone), 116308 
 
 
 
Oxone® (3.08 g, 5.0 mmol) was added to a solution of sulindac 112 (356 mg, 1.0 mmol) in a 
mixture of tetrahydrofuran: MeOH: water. (3:1:1, 20 mL) and stirred for 1 hour at room 
temperature. The suspension was concentrated under reduced pressure to half of its original 
volume. Water (50 mL) was added and the precipitate collected by vacuum filtration to yield 
(Z)-2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetic acid, sulindac 
sulfone 116 (372 mg, 1.0 mmol, quant.) as a yellow solid, which was used without any further 
purification: m.p. 196–198 °C, [Lit.308 199-200 °C,]; νmax  (thin film)/cm−1 2078, 1720, 1493, 
1400, 1255, 1147, 1048; 1H NMR (300 MHz; CDCl3) δ 8.00 (2H, d, J 8.4 Hz, CH-3′,5′), 
7.70  (2H, d, J 8.4 Hz, CH-2′,6′), 7.14 (1H, s, CH-α), 7.10 (1H, dd, J 5.1, 8.4 Hz, CH-7), 
6.89  (1H, dd, J 8.8, 2.4 Hz, CH-6), 6.58 (1H, ddd, J 8.9, 8.8, 2.4 Hz, CH-4), 3.60 (2H, s, 3-
6
5
4
8
9
7
3
2
1
α
1'
6'
5'
4'
3'
2'
S
SO2CH3
2-CH3
F
3-CH2 Cbx
O
OH
O O
Appendix: Experimental 
 
	   177	  
CH2), 3.14 (3H, s, SO2CH3) and 2.21 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 174.6 
(quat., carboxyl), 162.3 (quat., d, J 247.0 Hz, C-5), 146.6 (quat., d, J 9.1 Hz, C-8), 142.5 (quat., 
C-4′), 142.2 (quat., C-1′), 139.9 (quat., C-1), 138.5 (quat., C-2), 131.6 (quat., C-3), 130.2 (CH × 
2, C-2′,6′), 129.7 (quat., C-9), 129.2 (CH, C-α), 127.2 (CH × 2, C-3′,5′), 123.8 (CH, d, J 8.4 Hz, 
C-7), 111.1 (CH, d, J 22.6 Hz, C-6), 106.3 (CH, d, J 24.2 Hz, C-4), 44.5 (CH3, SO2CH3), 31.2 
(CH2, 3-CH2) and 10.5 (CH3, 2-CH3); 19F {1H} (376 MHz; CDCl3) δ -112.7 (CF); m/z (ES+) 395 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C20H17FO4NaS [M+Na]+ requires 395.0729, 
found 395.0722; CHN Anal. calcd. for  C20H17FO4S: C, 64.50; H, 4.60. Found C, 64.59; H, 
4.70. The data were in agreement with the literature values.308 
 
tert-Butyl(4-iodobutoxy)dimethylsilane, 122313 
 
 
 
THF (8.2 mL, 100 mmol) was added to dry acetonitrile (80 mL), followed by addition of 
sodium iodide (12.0 g, 80.0 mmol) and tert-butyldimethylsilyl chloride (6.03 g, 40.0 mmol) and 
the solution heated at 55 °C for 18 h. Water was added (150 mL) and the suspension extracted 
with petroleum ether/diethyl ether (9:1, 3 × 100 mL).  The combined organic extracts were 
washed with saturated sodium hydrogen sulfite solution (100 mL) and brine (100 mL), dried 
over Na2SO4, filtered and the solvent removed under reduced pressure to give tert-butyl(4-
iodobutoxy)dimethylsilane 122 (12.5 g, 40.0 mmol, quant.) as a colorless liquid, which was 
used without any further purification: 1H NMR (300 MHz; CDCl3) δ 3.64 (2H, t, J 6.2 Hz, CH2-
1), 3.22 (2H, t, J 6.9 Hz, CH2-4), 1.91 (2H, quint, J 6.9 Hz, CH2-2), 1.66-1.51 (2H, m, CH2-3), 
0.89 (9H, s, CH3 × 3, SiC(CH3)3) and 0.05 (6H, s, CH3 × 3, Si(CH3)2); 13C NMR (100 MHz; 
CDCl3) δ 62.4 (CH2, C-1), 33.9 (CH2, C-4), 30.6 (CH2, C-2), 26.4 (CH3 × 3, SiC(CH3)3), 18.7 
(quat., SiC(CH3)3), 7.5 (CH2, C-3) and -4.9 (CH3 × 2, Si(CH3)2); m/z (ES+) 337 ([M+Na]+, 
100%). The data were in agreement with the literature values.313 
 
4-Nitrooxybutan-1-ol, 120314 
 
 
 
Silver nitrate (1.3 g, 7.65 mmol) was added to a solution of tert-butyl(4-
iodobutoxy)dimethylsilane 122 (1.2 g, 3.82 mmol) in dry acetonitrile (20 mL) at -10 °C in the 
absence of light. After 15 min, the solution was allowed to warm to room temperature and 
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stirred for a further hour. The suspension was filtered and water was added (2 mL) and the 
solution was stirred for a further hour. The solution was partitioned between ethyl acetate (40 
mL) and water (30 mL), the organic layer was separated and dried over Na2SO4 and the solvent 
removed under reduced pressure to yield 4-nitrooxybutanol 120 (150 mg, 1.11 mmol, 29%) as a 
pale yellow oil, which was used without any further purification: 1H NMR (300 MHz; CDCl3) δ 
4.50 (2H, t, J 6.7 Hz, CH2-4), 3.69 (2H, t, J 6.1 Hz, CH2-1), 1.89-1.79 (2H, m, CH2-3), 1.75 
(1H, s, br, OH) and 1.72-1.62 (2H, m, CH2-2); 13C NMR (100 MHz; CDCl3) δ 73.1 (CH2, C-4), 
61.9 (CH2, C-1), 28.6 (CH2, C-3) and 23.1 (CH2, C-2); m/z (ES−) 118 ([M-H]−, 100%). The data 
were in agreement with the literature values.314 
 
(Z)-4-(Nitrooxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-
inden-3-yl)acetate, 111 
 
 
 
Following general procedure A with sulindac 112 (47 mg, 0.13 mmol) and 4-(nitrooxy)butanol 
120 (15 mg, 0.13 mmol), purification by flash chromatography, eluting with dichloromethane 
and methanol (99:1), furnished (Z)-4-(nitrooxy)butyl 2-(5-fluoro-2-methyl-1-(4-
(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate 111 (58 mg, 0.12 mmol, 91%) as a yellow 
solid: Rf 0.48 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate);  m.p. 60-62 °C; νmax (thin 
film)/cm−1 1732, 1626, 1466, 1280, 1161, 1047, 967, 863, 820; 1H NMR (400 MHz; CDCl3) δ 
7.73 (2H, d, J 8.5 Hz, CH-3′,5′), 7.68 (2H, d, J 8.5 Hz, CH-2′,6′), 7.18 (1H, s, CH-α), 7.16 (1H, 
dd, J 5.4, J 8.5 Hz, CH-7), 6.88 (1H, dd, J 8.9, 2.9 Hz, CH-4), 6.58 (1H, ddd, J 8.9, 8.2, 2.9 Hz, 
CH-6), 4.40 (2H, t, J 5.3 Hz, CH2-4′′), 4.16 (2H, t, J 5.6 Hz, CH2-1′′), 3.58 (2H, s, 3-CH2), 2.82 
(3H, s, SOCH3), 2.22 (3H, s, 2-CH3) and 1.76-1.73 (4H, m, CH2 × 2); 13C NMR (100 MHz; 
CDCl3) δ 170.1 (quat., carboxyl), 162.9 (quat., d, J 244.9 Hz, C-5), 146.6 (quat., d, J 9.0 Hz, C-
8), 145.6 (quat., C-4′), 141.6 (quat., C-1), 139.6 (quat., C-1′), 138.2 (quat., C-2), 131.7 (quat., C-
3), 130.3 (CH × 2, C-2′,6′), 129.5 (quat., C-9), 128.4 (CH, C-α), 123.9 (CH × 2, C-3′,5′), 123.8 
(CH, d, J 9.2 Hz, C-7), 110.9 (CH, d, J 22.5 Hz, C-6), 106.1 (CH, d, J 23.9 Hz, C-4), 72.5 (CH2, 
C-4′′), 64.2 (CH2, C-1′′), 43.9 (CH3, SOCH3), 31.8 (CH2, 3-CH2), 24.9 (CH2, C-2′′), 23.6 (CH2, 
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C-3′′) and 10.5 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -113.4 (CF); m/z (ES+) 473 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C24H24FNNaO6S [M+Na]+ requires 473.1308 
found 473.1300; CHN Anal. calcd. for C24H24FNO6S: C, 60.88; H, 5.11; N, 2.96. Found C, 
60.94; H, 5.09; N, 3.00. 
 
(Z)-4-(Nitrooxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-
3-yl)acetate, 123 
 
 
 
Following general procedure A with sulindac sulfide 115 (45 mg, 0.13 mmol) and 4-
(nitrooxy)butanol 120 (15 mg, 0.13 mmol), purification by flash chromatography, eluting with 
dichloromethane and methanol (99:1), furnished (Z)-4-(nitrooxy)butyl 2-(5-fluoro-2-methyl-1-
(4-(methylthio)benzylidene)-1H-inden-3-yl)acetate 123 (58 mg, 0.13 mmol, 95%) as a yellow 
solid: Rf 0.92 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate);  m.p. 54-57 °C; νmax (thin 
film)/cm−1 1746, 1633, 1450, 1270, 1160, 1051, 870, 820; 1H NMR (400 MHz; CDCl3) δ 7.45 
(2H, d, J 8.3 Hz, CH-3′,5′), 7.38 (1H, dd, J 8.4 5.3 Hz, CH-7), 7.30 (2H, d, J 8.3 Hz, CH-2′,6′), 
7.16 (1H, s, CH-α), 6.88 (1H, dd, J 9.0, 2.5 Hz, CH-4), 6.60 (1H, ddd, J 9.0, 8.9, 2.5 Hz, CH-6), 
4.40 (2H, t, J 6.1 Hz, CH2-4′′), 3.63 (2H, t, J 5.9 Hz, CH2-1′′), 3.58 (2H, s, 3-CH2), 2.56 (3H, s, 
SCH3), 2.22 (3H, s, 2-CH3) and 1.76-1.73 (4H, m, CH2 × 2); 13C NMR (100 MHz; CDCl3) δ 
170.3 (quat., carboxyl), 163.0 (quat., d, J 247.5 Hz, C-5), 146.4 (quat., d, J 9.3 Hz, C-8), 140.0 
(quat., C-1), 139.2 (quat., C-4′), 138.5 (quat., C-2), 132.9 (quat., C-3), 130.6 (CH, C-α), 130.1 
(quat., C-1′), 129.9 (CH × 2, C-2′,6′), 129.8 (quat., C-9), 126.0 (CH × 2, C-3,5′), 123.8 (CH, d, J 
8.8 Hz, C-7), 110.6 (CH, d, J 22.9 Hz, C-6), 105.7 (CH, d, J 23.7 Hz, C-4), 72.5 (CH2, C-4′′), 
64.1 (CH2, C-1′′), 31.9 (CH2, 3-CH2), 25.0 (CH2, C-3′′), 25.1 (CH2, C-2′′), 15.4 (CH3, SCH3) 
and 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -114.4 (CF); m/z (ES+) 457 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C24H24FNNaO5S [M+Na]+ requires 457.1359 
found 457.1360; CHN Anal. calcd. for C24H24FNO5S: C, 63.00; H, 5.29; N, 3.06. Found C, 
63.04; H, 5.35; N, 3.09. 
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(Z)-4-(Nitrooxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-
inden-3-yl)acetate, 124 
 
 
 
Following general procedure A with sulindac sulfone 116 (49 mg, 0.13 mmol) and 4-
(nitrooxy)butanol 120 (15 mg, 0.13 mmol), purification by flash chromatography, eluting with 
dichloromethane and methanol (99:1), furnished (Z)-4-(nitrooxy)butyl 2-(5-fluoro-2-methyl-1-
(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetate 124 (48 mg, 0.10 mmol, 73%) as a 
yellow solid: Rf 0.68 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 65-69 °C; 
νmax (thin film)/cm−1 1751, 1620, 1454, 1271, 1174, 105, 892, 815; 1H NMR (400 MHz; CDCl3) 
δ 8.01 (2H, d, J 8.4 Hz, CH-3′,5′), 7.70 (2H, d, J 8.4 Hz, CH-2′,6′), 7.14 (1H, s, CH-α), 7.10 
(1H, dd, J 8.4, 5.4 Hz, CH), 6.87 (1H, dd, J 8.8, 2.4 Hz, CH-4), 6.58 (1H, ddd, J 8.8, 8.8, 2.4 
Hz, CH-6), 4.40 (2H, t, J 6.1 Hz, CH2-4′′), 4.15 (2H, q, J 6.1 Hz, CH2-1′′), 3.57 (2H, s, 3-CH2), 
3.14 (3H, s, SO2CH3), 2.21 (3H, s, 2-CH3) and 1.76-1.73 (4H, m, CH2 × 2); 13C NMR (100 
MHz; CDCl3) δ 170.0 (quat., carboxyl), 163.4 (quat., d, J 247.2 Hz, C-5), 146.7 (quat., d, J 8.4 
Hz, C-8), 142.5 (quat., C-4′), 142.3 (quat., C-1′), 139.9 (quat., C-1), 138.1 (quat., C-2), 132.2 
(quat., C-3), 130.2 (CH × 2, C-2′,6′), 129.3 (quat., C-9), 127.6 (CH × 2, C-3,5′), 127.4 (CH, C-
α), 123.8 (CH, d, J 9.8 Hz, C-7), 111.0 (CH, d, J 22.6 Hz, C-6), 106.3 (CH, d, J 24.9 Hz, C-4), 
72.5 (CH2, C-4′′), 64.2 (CH2, C-1′′), 44.5 (CH3, SO2CH3), 31.8 (CH2, 3-CH2), 24.9 (CH2, C-2′′), 
23.6 (CH2, C-3′′) and 10.5 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -112.9 (CF); m/z 
(ES+) 489 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C24H24FNNaO7S [M+Na]+ requires 
489.1258 found 489.1256. CHN Anal. calcd. for C24H24FNO7S: C, 59.89; H, 4.29; N, 2.86. 
Found C, 59.91; H, 4.35; N, 3.00. 
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4-((tert-Butyldimethylsilyl)oxy)butan-1-ol, 126316 
 
 
 
Triethylamine (7.26 g, 10.0 mL, 73.4 mmol) and TBDMSCl (7.38 g, 4.89 mmol) were added to 
a solution of 1,4-butanediol 125 (22.4 g, 22.0 mL, 245 mmol) in CH2Cl2 (300 mL) and the 
resultant solution stirred overnight at room temperature. The solution was poured into brine 
(100 mL) and the organic layer was separated and washed with distilled water (100 mL) and 
brine (75 mL). The organic layer was dried over Na2SO4, filtered and the solvent removed under 
reduced pressure to give a pale yellow oil. This oil was purified by silica gel chromatography, 
eluting with petroleum ether and ethyl acetate (99:1), to afford 4-((tert-
butyldimethylsilyl)oxy)butan-1-ol 126 (6.80 g, 3.32 mmol, 68%) as a colourless liquid: Rf 0.30 
(70:30, PE:EtOAc, cerium phosphomolybdate); 1H NMR (400 MHz; CDCl3) δ 3.64-3.58 (4H, 
m, CH2-1,4), 2.68 (1H, t, J  5.8, OH), 1.65-1.60 (4H, m, CH2-2,3), 0.90 (9H, s, SiC(CH3)3) and 
0.05 (6H, s, Si(CH3)2); 13C NMR (100 MHz; CDCl3) δ 63.2 (CH2), 62.7 (CH2), 30.0 (CH2), 29.7 
(CH2), 25.9 (CH3 × 3, SiC(CH3)3), 18.3 (quat., SiC(CH3)3) and -5.5 (CH3 × 2, Si(CH3)2); m/z 
(ES+) 227 ([M+Na]+, 100%). The data were in agreement with the literature values.316 
 
(Z)-4-((tert-Butyldimethylsilyl)oxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)-
benzylidene)-1H-inden-3-yl)acetate, 127 
 
 
 
Following general procedure A with sulindac 112 (172 mg, 0.49 mmol) and 4-((tert-
butyldimethylsilyl)oxy)butan-1-ol 126 (100 mg, 0.49 mmol), purification by flash 
chromatography, eluting with dichloromethane and methanol (99:1), furnished (Z)-4-((tert-
butyldimethylsilyl)oxy)butyl-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)-benzylidene)-1H-inden-
3-yl)acetate 127 (226 mg, 0.42 mmol, 85%) as a yellow solid: Rf 0.56 (95:5, CH2Cl2:MeOH, 
UV/cerium phosphomolybdate);  m.p. 59-61 °C; νmax (thin film)/cm−1 2869, 1745, 1601, 1591, 
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1491, 1466, 1317, 1256, 1185, 1092, 810; 1H NMR (400 MHz; CDCl3) δ 7.72 (2H, d, J 8.4 Hz, 
CH-3′,5′), 7.67 (2H, d, J 8.4 Hz, CH-2′,6′), 7.15 (1H, s, CH-α), 7.14 (1H, dd, J  8.4, 5.0 Hz, CH-
7), 6.89 (1H, dd, J 8.9, 2.4 Hz, CH-4), 6.55 (1H, ddd, J 8.9, 8.9, 2.4 Hz, CH-6), 4.13 (2H, t, J 
6.6 Hz, CH2-1′′, 3.61 (2H, t, J 6.2 Hz, CH2-4′′), 3.56 (2H, s, 3-CH2), 2.81 (3H, s, SOCH3), 2.21 
(3H, s, 2-CH3), 1.71-1.65 (2H, m, CH2-2′′), 1.56-1.50 (2H, m, CH2-3′′), 0.89 (9H, s, SiC(CH3)3) 
and 0.04 (6H, s, Si(CH3)2); 13C NMR (100 MHz; CDCl3) δ 170.3 (quat., carboxyl), 163.4 (quat., 
d, J 248.7 Hz, C-5), 146.8 (quat., d, J 8.7 Hz, C-8), 145.5 (quat., C-4′), 141.7 (quat., C-1), 139.7 
(quat., C-1′), 138.1 (quat., C-2), 132.0 (quat., C-3), 130.3 (CH × 2, C-2′,6′), 129.5 (quat., C-9), 
128.1 (CH, C-α), 123.8 (CH × 2, C-3,5′), 123.6 (CH, d, J 8.8 Hz, C-7), 110.7 (CH, d, J 22.7 Hz, 
C-6), 106.2 (CH, d, J 23.9 Hz, C-4), 65.1 (CH2, C-1′′), 62.5 (CH2, C-4′′), 43.9 (CH3, SOCH3), 
31.9 (CH2, 3-CH2), 29.1 (CH2, C-2′′), 25.9 (CH3 × 3, SiC(CH3)3), 25.3 (CH2, C-3′′), 18.3 (quat., 
SiC(CH3)3), 10.6 (CH3, 2-CH3) and -5.3 (CH3 × 2, Si(CH3)2); 19F {1H} NMR (376 MHz; 
CDCl3) δ -113.4 (CF); m/z (ES+) 565 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C30H39FNaO4SSi [M+Na]+ requires 565.2220, found 565.2219. 
 
(Z)-4-((tert-Butyldimethylsilyl)oxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylthio)-
benzylidene)-1H-inden-3-yl)acetate, 128 
 
 
 
Following general procedure A with sulindac sulfide 115 (163 mg, 0.49 mmol) and 4-((tert-
butyldimethylsilyl)oxy)butan-1-ol 126 (100 mg, 0.49 mmol), purification by flash 
chromatography, eluting with dichloromethane, furnished (Z)-4-((tert-
butyldimethylsilyl)oxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetate 128 (253 mg, 0.48 mmol, 98%) as a yellow solid: Rf 0.90 (95:5, CH2Cl2:MeOH, 
UV/cerium phosphomolybdate); m.p. 64-65 °C; νmax (thin film)/cm−1 2954, 2927, 1734, 1622, 
1602, 1491, 1467, 1317, 1255, 836, 810; 1H NMR (400 MHz; CDCl3) δ 7.45 (2H, d, J 8.4 Hz, 
CH-3′,5′), 7.36 (1H, dd, J  8.4, 5.2 Hz, CH-7), 7.30 (2H, d, J 8.4 Hz, CH-2′,6′), 7.14 (1H, s, CH-
α), 6.90 (1H, dd, J 9.0, 2.4 Hz, CH-4), 6.58 (1H, ddd, J 9.0, 8.8, 2.4 Hz, CH-6), 4.13 (2H, t, J 
6.5 Hz, CH2-1′′), 3.61 (2H, t, J 6.2 Hz, CH2-4′′), 3.56 (2H, s, 3-CH2), 2.56 (3H, s, SCH3), 2.21 
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(3H, s, 2-CH3), 1.74-1.65 (2H, m, CH2-2′′), 1.58-1.49 (2H, m, CH2-3′′), 0.89 (9H, s, SiC(CH3)3) 
and 0.04 (6H, s, Si(CH3)2); 13C NMR (100 MHz; CDCl3) δ 170.4 (quat., carboxyl), 163.4 (quat., 
d, J  245.5 Hz, C-5), 146.5 (quat., d, J  8.7 Hz, C-8), 140.2 (quat., C-1), 139.1 (quat., C-4′), 
138.6 (quat., C-2), 133.1 (quat., C-3), 130.9 (quat., C-1′), 129.9 (CH × 2, C-2′,6′), 129.8 (quat., 
C-9), 131.0 (CH, C-α), 126.0 (CH × 2, C-3,5′), 123.6 (CH, d, J 8.7 Hz, C-7), 110.5 (CH, d, J 
22.5 Hz, C-6), 105.8 (CH, d, J 23.9 Hz, C-4), 65.0 (CH2, C-1′′), 62.5 (CH2, C-4′′), 31.9 (CH2, 3-
CH2), 29.1 (CH2, C-2′′), 25.9 (CH3 × 3, SiC(CH3)3), 25.2 (CH2, C-3′′), 18.3 (quat., SiC(CH3)3), 
15.4 (CH3, SCH3), 10.6 (CH3, 2-CH3) and -5.3 (CH3 × 2, Si(CH3)2); 19F {1H} NMR (376 MHz; 
CDCl3) δ -114.4 (CF); m/z (ES+) 549 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C30H39FNaO3SSi [M+Na]+ requires 549.2271, found 549.2269. 
 
(Z)-4-((tert-Butyldimethylsilyl)oxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)-
benzylidene)-1H-inden-3-yl)acetate, 129 
 
 
 
Following general procedure A with sulindac sulfone 116 (182 mg, 0.49 mmol) and 4-((tert-
butyldimethylsilyl)oxy)butan-1-ol 126 (100 mg, 0.49 mmol), purification by flash 
chromatography, eluting with dichloromethane and methanol (99:1), furnished 2-(5-fluoro-2-
methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetate 129 (244 mg, 0.44 mmol, 89%) 
as a yellow solid: Rf 0.69 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 67-68 
°C; νmax (thin film)/cm−1 2928, 2858, 1734, 1604, 1592, 1470, 1389, 1311,1255, 1150, 973, 833, 
770; 1H NMR (400 MHz; CDCl3) δ 8.01 (2H, d, J 8.4 Hz, CH-3′,5′), 7.70 (2H, d, J 8.4 Hz, CH-
2′,6′), 7.12 (1H, s, CH-α), 7.10 (1H, dd, J 8.3, 5.1 Hz, CH-7), 6.89 (1H, dd, J 8.9, 2.4 Hz, CH-
4), 6.57 (1H, ddd, J  17.4, 8.9, 2.4 Hz, CH-6), 4.14 (2H, t, J 6.6 Hz, CH2-1′′), 3.61 (2H, t, J 6.1 
Hz, CH2-4′′), 3.56 (2H, s, 3-CH2), 3.14 (3H, s, SO2CH3), 2.21 (3H, s, 2-CH3), 1.75-1.65 (2H, m, 
CH2-2′′), 1.59-1.50 (2H, m, CH2-3′′), 0.89 (9H, s, SiC(CH3)3) and 0.04 (6H, s, Si(CH3)2); 13C 
NMR (100 MHz; CDCl3) δ 170.2 (quat., carboxyl), 163.7 (quat., d, J 246.7 Hz, C-5), 146.9 
(quat., d, J 8.8 Hz, C-8), 142.6 (quat., C-4′), 141.7 (quat., C-1′), 139.9 (quat., C-1), 138.0 (quat., 
C-2), 132.6 (quat., C-3), 130.2 (CH × 2, C-2′,6′), 129.3 (quat., C-9), 127.6 (CH × 2, C-3′,5′), 
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127.0 (CH, C-α), 123.7 (CH, d, J 9.1 Hz, C-7), 110.9 (CH, d, J 22.7 Hz, C-6), 106.4 (CH, d, J 
24.2 Hz, C-4), 65.2 (CH2, C-1′′), 62.5 (CH2, C-4′′), 44.5 (CH3, SO2CH3), 31.9 (CH2, 3-CH2), 
29.1 (CH2, C-2′′), 25.9 (CH3 × 3, SiC(CH3)3), 25.3 (CH2, C-3′′), 18.3 (quat., SiC(CH3)3), 10.5 
(CH3, 2-CH3) and -5.3 (CH3 × 2, Si(CH3)2);19F {1H} NMR (376 MHz; CDCl3) δ -112.9 (CF); 
m/z (ES+) 581 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C30H39FNaO5SSi [M+Na]+ 
requires 581.2169, found 581.2170. 
 
(Z)-4-Hydroxybutyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-
inden-3-yl)acetate, 113 
 
 
 
10-Camphorsulfonic acid (2 mg, 0.01 mmol) was added to a solution of sulindac TBDMS ester 
127 (50 mg, 0.09 mmol) in CH2Cl2:MeOH (1:1, 4 mL) and the solution stirred for 3 h. Water 
(5 mL) was added and the solution extracted with CH2Cl2 (4 mL). The organic layer was 
separated, washed with brine (3 mL), dried over anhydrous Na2SO4, filtered and the solvent 
removed under reduced pressure to give the crude residue. Purification by silica gel 
chromatography, eluting with dichloromethane and methanol (99:1), to give (Z)-4-hydroxybutyl 
2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate 113 (32 mg, 0.06 
mmol, 63%) as a yellow solid: Rf 0.38 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); 
m.p. 72-74 °C; 3402, 2941, 1730, 1622, 1601, 1591, 1491, 1466, 1437, 1257, 1092, 811; 1H 
NMR (400 MHz; CDCl3) δ 7.72 (2H, d, J 8.5 Hz, CH-3′,5′), 7.66 (2H, d, J 8.5 Hz, CH-2′,6′), 
7.16 (1H, s, CH-α), 7.15 (1H, dd, J 8.3, 5.2 Hz, CH-7), 6.89 (1H, dd, J 9.0, 2.4 Hz, CH-4), 6.55 
(1H, ddd, J 9.0, 8.9, 2.4 Hz, CH-6), 4.15 (2H, t, J 6.4 Hz, CH2-1′′), 3.63 (2H, q, J 6.1 Hz, CH2-
4′′), 3.56 (2H, s, 3-CH2), 2.81 (3H, s, SOCH3), 2.21 (3H, s, 2-CH3), 1.77-1.68 (2H, m, CH2-2′′), 
1.63-1.54 (2H, m, CH2-3′′) and 1.25 (1H, t, J 6.1, OH); 13C NMR (100 MHz; CDCl3) δ 170.3 
(quat., carboxyl), 163.2 (quat., d, J 245.0 Hz, C-5), 146.7 (quat., d, J 8.3 Hz, C-8), 145.5 (quat., 
C-4′), 141.7 (quat., C-1), 139.7 (quat., C-1′), 138.2 (quat., C-2), 131.9 (quat., C-3), 130.3 (CH × 
2, C-2′,6′), 129.5 (quat., C-9), 128.2 (CH, C-α), 123.8 (CH × 2, C-3,5′), 123.7 (CH, d, J 9.2 Hz, 
C-7), 110.8 (CH, d, J 23.3 Hz, C-6), 106.2 (CH, d, J 23.3 Hz, C-4), 65.0 (CH2, C-1′′), 62.3 
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(CH2, C-4′′), 43.9 (CH3, SOCH3), 31.9 (CH2, 3-CH2), 29.1 (CH2, C-2′′), 25.1 (CH2, C-3′′) and 
10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -113.4 (CF); m/z (ES+) 451 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C24H25FNaO4S [M+Na]+ requires 451.1355 found 
451.1352; CHN Anal. calcd. for C24H25FO4S: C, 67.27; H, 5.88. Found C, 67.30; H, 5.92. 
 
(Z)-4-Hydroxybutyl 2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-
3-yl)acetate, 130 
 
 
 
10-Camphorsulfonic acid (2 mg, 0.01 mmol) was added to a solution of sulindac TBDMS ester 
128 (50 mg, 0.10 mmol) in CH2Cl2:MeOH (1:1, 4 mL) and the solution stirred for 3 h. Water (5 
mL) was added and the solution was extracted with CH2Cl2 (4 mL). The organic layer was 
separated and washed with brine (3 mL), dried over anhydrous Na2SO4, filtered and the solvent 
removed under reduced pressure to give the crude residue, which was purified by silica gel 
chromatography eluting with dichloromethane and methanol (99:1), to give (Z)-4-hydroxybutyl 
2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetate 130 (32 mg, 0.08 
mmol, 82%) as a yellow solid: Rf 0.12 (CH2Cl2); m.p. 59-60 °C; νmax (thin film)/cm−1 3400, 
2928, 1730, 1603, 1591, 1467, 1310, 1150, 957, 855, 770; 1H NMR (400 MHz; CDCl3) δ 7.45 
(2H, d, J 8.1 Hz, CH-3′,5′), 7.37 (1H, dd, J 8.4, 5.2 Hz, CH-7), 7.30 (2H, d, J 8.1 Hz, CH-2′,6′), 
7.15 (1H, s, CH-α), 6.90 (1H, dd, J 9.0, 2.4 Hz, CH-4), 6.59 (1H, ddd, J 9.0, 8.9, 2.4 Hz, CH-6), 
4.15 (2H, t, J 6.5 Hz, CH2-1′′), 3.63 (2H, q, J 6.2 Hz, CH2-4′′), 3.57 (2H, s, 3-CH2), 2.56 (3H, s, 
SCH3), 2.22 (3H, s, 2-CH3), 1.77-1.67 (2H, m, CH2-2′′), 1.62-1.53 (2H, m, CH2-3′′) and 1.27 
(1H, t, J 6.1, OH). 13C NMR (100 MHz; CDCl3) δ 170.4 (quat., carboxyl), 163.1 (quat., d, J 
245.3 Hz, C-5), 146.5 (quat., d, J 8.1 Hz, C-8), 140.1 (quat., C-1), 139.2 (quat., C-4′), 138.4 
(quat., C-2), 133.0 (quat., C-3), 131.9 (CH, C-α), 130.8 (quat., C-1′), 129.9 (CH × 2, C-2′,6′), 
129.8 (quat., C-9), 126.0 (CH × 2, C-3,5′), 123.7 (CH, d, J 9.4 Hz, C-7), 110.5 (CH, d, J 22.3 
Hz, C-6), 105.8 (CH, d, J 24.0 Hz, C-4), 64.9 (CH2, C-1′′), 62.3 (CH2, C-4′′), 31.9 (CH2, 3-
CH2), 29.1 (CH2, C-2′′), 25.1 (CH2, C-3′′), 15.4 (CH3, SCH3) and 10.6 (CH3, 2-CH3); 19F {1H} 
NMR (376 MHz; CDCl3) δ -114.4 (CF); m/z (ES+) 435 ([M+Na]+, 100%); HRMS m/z (ES+) 
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calcd. for C24H25FNaO3S [M+Na]+ requires 435.1406 found 435.1400; CHN Anal. calcd. for 
C24H25FO3S: C, 69.88; H, 6.11. Found C 69.93; H, 6.18. 
 
(Z)-4-Hydroxybutyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-
inden-3-yl)acetate, 131 
 
 
 
10-Camphorsulfonic acid (2 mg, 0.010 mmol) was added to a solution of sulindac TBDMS ester 
129 (50 mg, 0.09 mmol) in CH2Cl2:MeOH (1:1, 4 mL) and the solution stirred for 3 h. Water (5 
mL) was added and the solution was extracted with CH2Cl2 (4 mL). The organic layer was 
separated and washed with brine (3 mL), dried over anhydrous Na2SO4, filtered and the solvent 
removed under reduced pressure to give the crude residue, which was purified by silica gel 
chromatography, eluting with dichloromethane and methanol (99:1), to give (Z)-4-hydroxybutyl 
2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetate 131 (30 mg, 0.07 
mmol, 75%) as a yellow solid: Rf 0.32 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); 
m.p. 81-82 °C; νmax (thin film)/cm−1 3345, 3063, 2938, 1736, 1606, 1592, 1468, 1299, 1181, 
967; 1H NMR (400 MHz; CDCl3) δ 8.01 (2H, d, J 8.4 Hz, CH-3′,5′), 7.71 (2H, d, J 8.4 Hz, CH-
2′,6′), 7.13 (1H, s, CH-α), 7.10 (1H, dd, J 8.4, 5.1 Hz, CH-7), 6.90 (1H, dd, J 8.8, 2.3 Hz, CH-
4), 6.58 (1H, ddd, J 8.9, 8.8, 2.3 Hz, CH-6), 4.16 (2H, t, J 6.5 Hz, CH2-1′′), 3.65 (2H, q, J 6.1 
Hz, CH2-4′′), 3.57 (2H, s, 3-CH2), 3.14 (3H, s, SO2CH3), 2.22 (3H, s, 2-CH3), 1.78-1.69 (2H, m, 
CH2-2′′) and 1.63-1.54 (2H, m, CH2-3′′); 13C NMR (100 MHz; CDCl3) δ 170.1 (quat., 
carboxyl), 163.4 (quat., d, J 245.0 Hz, C-5), 146.8 (quat., d, J 8.1 Hz, C-8), 142.5 (quat., C-4′), 
141.4 (quat., C-1′), 139.9 (quat., C-1), 138.0 (quat., C-2), 132.4 (quat., C-3), 130.2 (CH × 2, C-
2′,6′), 129.3 (quat., C-9), 127.6 (CH × 2, C-3,5′), 127.2 (CH, C-α), 123.7 (CH, d, J 9.8 Hz, C-7), 
110.9 (CH, d, J 22.4 Hz, C-6), 106.4 (CH, d, J 22.4 Hz, C-4), 65.0 (CH2, C-1′′), 62.3 (CH2, C-
4′′), 44.5 (CH3, SO2CH3), 31.9 (CH2, 3-CH2), 29.1 (CH2, C-2′′), 25.1 (CH2, C-3′′) and 10.5 
(CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -112.9 (CF); m/z (ES+) 467 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C24H25FNaO5S [M+Na]+ requires 467.1304 found 
467.1309; CHN Anal. calcd. for C24H25FO5S: C, 64.85; H, 5.67. Found C, 64.90; H, 5.75. 
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2-(Nitrooxy)ethanol, 136318 
 
 
 
Silver nitrate (2.07 g, 13.2 mmol) was added to a solution of 2-bromoethanol 132 (500 mg, 4.00 
mmol), in CH3CN (15 mL) and stirred for 8 h under reflux. The mixture was poured onto brine 
(20 mL), and the precipitate was filtered. The filtrate was extracted with diethyl ether (5 × 20 
mL), dried over MgSO4, filtered and the solvent was removed under reduced pressure to yield 
2-nitrooxyethanol 136 (364 mg, 3.40 mmol mmol, 85%) as a colourless oil, which was used 
without any further purification: 1H NMR (400 MHz; CDCl3) δ 4.59 (2H, t, J 4.6 Hz, CH2-2), 
3.92 (2H, t, J 4.6 Hz, CH2-1); 13C NMR (100 MHz; CDCl3) δ 74.3 (CH2, C-1), 59.2 (CH2, C-
2); m/z (ES+) 130 ([M+Na]+, 100%). The data were in agreement with the literature values.318 
 
6-(Nitrooxy)hexan-1-ol, 137319 
 
 
Silver nitrate (698 mg, 4.11 mmol) was added to a solution of 6-bromohexan-1-ol 133 (500 mg, 
2.76 mmol) in CH3CN (15 mL) and stirred for 8 h under reflux. The mixture was poured onto 
brine (20 mL), and the precipitate was filtered. The filtrate was extracted with diethyl ether (5 × 
20 mL), and dried over MgSO4, filtered and the solvent was removed under reduced pressure to 
yield 6-(nitrooxy)hexan-1-ol 137 (405 mg, 2.48 mmol, 90%) as a clear pale yellow oil, which 
was used without any further purification: Rf 0.29 (30:70 EtOAc:PE, KMnO4); 1H NMR (400 
MHz; CDCl3) δ 4.45 (2H, t, J 6.7 Hz, CH2-6), 3.65 (2H, t, J 6.5 Hz, CH2-1), 1.70-1.78 (2H, m, 
CH2-5), 1.54-1.62 (2H, m, CH2-2), 1.38-1.48 (5H, m, 2 × CH2-3, 4, OH); 13C NMR (100 
MHz;CDCl3) δ 73.4 (CH2, C-6), 62.6 (CH2, C-1), 32.5 (CH2, C-2), 26.8 (CH2, C-5), 25.6, 25.4 
(CH2 × 2, C-3, 4); m/z (ES+) 164 ([M+H]+, 100%). The data were in agreement with the 
literature values.319 
 
1,3-Di(nitrooxy)-2-propanol, 138127 
 
 
 
Silver nitrate (1.80 g, 10.7 mmol) was added to a solution of 1,3-dibromo-2-propanol 134 (500 
mg, 2.30 mmol) in CH3CN (15 mL) and stirred for 8 h under reflux. The mixture was poured 
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onto brine (20 mL), and the precipitate was filtered. The filtrate was extracted with diethyl ether 
(5 × 20 mL), dried over MgSO4, filtered and the solvent was removed under reduced pressure to 
yield 1,3-di(nitrooxy)-2-propanol 138 (367 mg, 2.02 mmol, 88%) as a pale yellow oil, which 
was used without any further purification: Rf 0.50 (30:70 EtOAc:PE, KMnO4); 1H NMR (400 
MHz; CDCl3) δ 4.58 (2H, dd, J 11.7, 4.5 Hz, 2 × CHAHB-2), 4.51 (2H, dd, J 11.7, 6.0 Hz, 2 × 
CHAHB-2), 4.23-4.29 (1H, m, CH-2); 13C NMR (100 MHz; CDCl3) δ 72.6 (CH2 × 2, C-2), 65.3 
(CH, C-1); m/z (ES+) 205 ([M+H]+, 100%). The data were in agreement with the literature 
values.127 
 
3-Nitrooxy-2,2-bis(nitrooxymethyl)propan-1-ol, 139 
 
 
 
Silver nitrate (8.50 g, 50 mmol) was added to a solution of pentaerythritol tribromide 135 (1.00 
g, 3.10 mmol), in CH3CN (25 mL) and stirred at room temperature for 7 days. The solution was 
poured onto brine (25 mL) and the solid was removed by filtration. The filtrate was extracted 
with diethyl ether (6 × 20 mL) and washed with water (50 mL). The organic layer was dried 
over MgSO4, filtered and the solvent was removed under reduced pressure. The residue was 
purified by flash column chromatography, eluting with ethyl acetate and hexane (5:95 to 20:90) 
to furnish 3-nitro-2,2-bis(nitromethyl)propan-1-ol 139 (220 mg, 0.80 mmol, 26%) as a 
colourless oil: Rf 0.67 (30:70 EtOAc:PE, KMnO4); 1H NMR (400 MHz; CDCl3) δ 4.57 (6H, s, 
3 × CH2-3), 3.75 (2H, d, J 4.8 Hz, CH2-1), 2.45-2.53 (1H, m, OH); 13C NMR (100 MHz; 
CDCl3) δ 69.7 (CH2 × 3, C-3), 60.3 (CH2, C-1), 43.4 (quat., C-2); m/z (ES+) 294 ([M+H]+, 
100%). The data were in agreement with the literature values.100 
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(Z)-2-(Nitrooxy)ethyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-
inden-3-yl)acetate, 140 
 
 
 
Following general procedure A with sulindac 112 (50 mg, 0.14 mmol) and 2-(nitrooxy)ethanol 
136 (17 mg, 0.15 mmol), purification by flash chromatography, eluting with dichloromethane 
and methanol (99:1), furnished (Z)-2-(nitrooxy)ethyl 2-(5-fluoro-2-methyl-1-(4-
(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate 140 (27.1 mg, 0.06 mmol, 44%) as a yellow 
solid: Rf 0.38 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 102-104 °C; νmax 
(thin film)/cm−1 1635, 1467, 1414, 1372, 1294, 1169; 1H NMR (300 MHz; CDCl3) δ 7.73 (2H, 
d, J 8.4 Hz, CH-3′,5′), 7.67 (2H, d, J 8.4 Hz, CH-2′,6′), 7.18 (1H, s, CH-α), 7.16 (1H, dd, J 8.5, 
5.1 Hz, CH-7), 6.86 (1H, dd, J 8.9, 2.4 Hz, CH-4), 6.56 (1H, ddd, J 8.9, 8.8, 2.4 Hz, CH-6), 
4.63-4.69 (2H, m, CH2-2′′), 4.37-4.42 (2H, m, CH2-1′′), 3.62 (2H, s, 3-CH2), 2.80 (3H, s, 
SOCH3), and 2.20 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.9 (quat., carboxyl), 163.5 
(quat., d, J 246.7 Hz, C-5), 146.5 (quat., d, J 8.7 Hz, C-8), 145.7 (quat., C-4′), 141.6 (quat., C-
1), 139.7 (quat., C-1′), 138.7 (quat., C-2), 131.2 (quat., C-3), 130.4 (CH × 2, C-3′,5′), 129.6 
(quat., C-9), 128.6 (CH, C-α), 123.9 (CH × 2, C-2′,6′), 123.8 (CH, d, J 8.8 Hz, C-7), 111.0 (CH, 
d, J 22.2 Hz, C-6), 106.1 (CH, d, J 24.0 Hz, C-4), 70.3 (2 × CH2, C-2′′), 61.0 (CH, C-1′′), 44.1 
(CH3, SOCH3), 31.5 (CH2, 3-CH2), 10.7 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -
113.3 (CF); m/z (ES+) 468 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C22H20FNNaO6S 
[M+Na]+ requires 468.0893, found 468.0878; CHN Anal. calcd. for C22H20FNO6S: C, 59.32; H, 
4.53; N, 3.14 Found C, 59.82; H, 4.62; N, 3.22. 
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(Z)-6-(Nitrooxy)hexyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-
inden-3-yl)acetate, 141 
 
 
 
Following general procedure A with sulindac 112 (50 mg, 0.14 mmol) and 6-(nitrooxy)hexan-1-
ol 137 (24 mg, 0.15 mmol), purification by flash chromatography, eluting with dichloromethane 
and methanol (99:1), furnished (Z)-6-(nitrooxy)hexyl 2-(5-fluoro-2-methyl-1-(4-
(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate 141 (47 mg, 0.09 mmol, 66%) as a viscous 
yellow oil: Rf 0.45 (95:5 CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax (thin film)/cm−1 
1626, 1467, 1278, 1162; 1H NMR (300 MHz; CDCl3) δ 7.72 (2H, d, J 8.4 Hz, CH-3′,5′), 7.66 
(2H, d, J 8.4 Hz, CH-2′,6′), 7.16 (1H, s, CH-α), 7.18-7.12 (1H, m, CH-7), 6.89 (1H, dd, J 8.9, J 
2.4 Hz, CH-4), 6.56 (1H, ddd, J 9.0, 8.9, 2.5 Hz, CH-6), 4.39 (2H, t, J 6.6 Hz, CH2-6′′), 4.11 
(2H, t, J 6.4 Hz, CH2-1′′), 3.56 (2H, s, 3-CH2), 2.81 (3H, s, SOCH3), 2.21 (3H, s, 2-CH3); 1.56-
1.73 (4H, m, 2 × CH2-2′′, 5′′) and 1.30-1.43 (4H, m, 2 × CH2-3′′, 4′′); 13C NMR (100 MHz; 
CDCl3) δ 170.4 (quat., carboxyl), 163.4 (quat., d, J 246.5 Hz, C-5), 146.8 (quat., d, J 8.7 Hz, C-
8), 145.7 (quat., C-4′), 141.7 (quat., C-1), 139.8 (quat., C-1′), 138.3 (quat., C-2), 132.0 (quat., C-
3), 130.4 (CH × 2, C-3′,5′), 129.6 (quat., C-9), 128.4 (CH, C-α), 124.0 (CH × 2, C-2′,6′), 123.8 
(CH, d, J 8.8 Hz, C-7), 110.9 (CH, d, J 22.7 Hz, C-6), 106.3 (CH, d, J 23.8 Hz, C-4), 73.7 (CH2, 
C-6′′), 64.9 (CH2, C-1′′), 44.1 (CH3, SOCH3), 32.1 (CH2, 3-CH2), 28.5 (CH2, C-5′′), 26.8 (CH2, 
C-2′′), 25.6 (CH2, C-4′′), 25.4 (CH2, C-3′′) 10.7 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; 
CDCl3) δ -113.5 (CF); m/z (ES+) 524 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C26H28FNNaO6S [M+Na]+ requires 524.1519, found 524.1511; CHN Anal. calcd. for 
C26H28FNO6S: C, 62.26; H, 5.63; N, 2.79. Found C, 62.31; H, 5.71; N, 2.84. 
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(Z)-1,3-Bis(nitrooxy)propan-2-yl 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzyl-
idene)-1H-inden-3-yl)acetate, 142 
 
 
 
Following general procedure A with sulindac 112 (50 mg, 0.14 mmol) and 1,3-di(nitrooxy)-2-
propanol 138 (27 mg, 0.15 mmol), purification by flash chromatography, eluting with 
dichloromethane and methanol (99:1), furnished (Z)-1,3-bis(nitrooxy)propan-2-yl-2-(5-fluoro-
2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate 142 (58 mg, 0.11 mmol, 
80%) as a yellow solid: Rf 0.41 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 84-
86 °C; νmax (thin film)/cm−1 1743, 1646, 1603, 1467, 1275, 1151; 1H NMR (300 MHz; CDCl3) δ 
7.73 (2H, d, J 8.4 Hz, CH-3′,5′), 7.67 (2H, d, J 8.4 Hz, CH-2′,6′), 7.16 (1H, s, CH-α), 7.16 (1H, 
dd, J 8.4, 5.1 Hz, CH-7), 6.84 (1H, dd, J 8.8, 2.4 Hz, CH-4), 6.58 (1H, ddd, J 8.9, 8.9, 2.4 Hz, 
CH-6), 5.31-5.42 (1H, m, CH-1′′) 4.75 (2H, dd, J 12.6, 4.8 Hz, 2 × CHAHB-2), 4.55 (2H, dd, J 
12.6, 5.8 Hz, 2 × CHAHB-2), 3.62 (2H, s, 3-CH2), 2.80 (3H, s, SOCH3), and 2.20 (3H, s, 2-CH3); 
13C NMR (100 MHz; CDCl3) δ 169.3 (quat., carboxyl), 163.5 (quat., d, J 246.7 Hz, C-5), 146.3 
(quat., d, J 8.8 Hz, C-8), 145.8 (quat., C-4′), 141.6 (quat., C-1), 139.7 (quat., C-1′), 139.0 (quat., 
C-2), 131.6 (quat., C-3), 130.4 (CH × 2, C-3′,5′), 129.6 (quat., C-9), 128.9 (CH, C-α), 124.0 
(CH × 2, C-2′,6′), 123.6 (CH, d, J 8.8 Hz, C-7), 111.2 (CH, d, J 22.5 Hz, C-6), 106.0 (CH, d, J 
24.4 Hz, C-4), 69.5 (CH2 × 2, C-2′′), 67.3 (CH, C-1′′), 44.1 (CH3, SOCH3), 31.5 (CH2, 3-CH2), 
10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -113.2 (CF); m/z (ES+) 543 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C23H21FN2NaO9S [M+Na]+ requires 543.0850, found 
543.0840; CHN Anal. calcd. for C23H21FN2O9S: C, 53.08; H, 4.07; N, 5.38. Found C, 53.38; H, 
4.18; N, 5.80. 
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(Z)-3-(Nitrooxy)-2,2-bis((nitrooxy)methyl)propyl 2-(5-fluoro-2-methyl-1-(4- 
(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate, 143 
 
 
 
Following general procedure A with sulindac 112 (50 mg, 0.14 mmol) and 3-nitrooxy-2,2-
bis(nitrooxymethyl)propan-1-ol 139 (41 mg, 0.15 mmol), purification by flash chromatography, 
eluting with dichloromethane and methanol (99:1), furnished (Z)-3-(nitrooxy)-2,2-
bis((nitrooxy)methyl)propyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetate 143 (70 mg, 0.12 mmol, 86%) as a yellow gum: Rf 0.39 (95:5, CH2Cl2:MeOH); νmax 
(thin film)/cm−1 1733, 1652, 1467, 1415, 1273, 1150, 1088;  1H NMR (300 MHz; CDCl3) δ 7.73 
(2H, d, J 8.4 Hz, CH-3′,5′), 7.67 (2H, d, J 8.4 Hz, CH-2′,6′), 7.20 (1H, s, CH-α), 7.18 (1H, dd, J 
8.4, 5.1 Hz, CH-7), 6.85 (1H, dd, J 8.8, 2.4 Hz, CH-4), 6.60 (1H, ddd, J 8.9, 8.9, 2.4 Hz, CH-6), 
4.56 (6H, s, 3 × CH2-3′′), 4.21 (2H, s, CH2-1′′), 3.63 (2H, s, 3-CH2) 2.81 (3H, s, SOCH3), and 
2.21 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.1 (quat., carboxyl), 163.4 (quat., d, J 
247.8 Hz, C-5), 146.1 (quat., d, J 8.7 Hz, C-8), 145.9 (quat., C-4′), 141.2 (quat., C-1), 139.5 
(quat., C-1′), 138.7 (quat., C-2), 130.8 (quat., C-3), 130.4 (CH × 2, C-3′,5′), 129.6 (quat., C-9), 
129.4 (CH, C-α), 124.0 (CH × 2, C-2′,6′), 123.9 (CH, d, J 9.0 Hz, C-7), 111.4 (CH, d, J 22.5 
Hz, C-6), 105.8 (CH, d, J 24.0 Hz, C-4), 69.2 (3 × CH2, C-3′′),  61.9 (CH2, C-1′′), 44.1 (CH3, 
SOCH3), 42.2 (quat., C-2′′), 31.6 (CH2, 3-CH2), 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; 
CDCl3) δ -113.0 (CF); m/z (ES+) 543 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C25H24FN3NaO12S [M+Na]+ requires 632.0962, found 632.0972; CHN Anal. calcd. for 
C25H24FN3NaO12S: C, 49.26; H, 3.97; N, 6.89. Found C, 49.36; H, 4.00; N, 6.91. 
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(Z)-2-(Nitrooxy)ethyl 2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-
3-yl)acetate, 144 
 
 
 
Following general procedure A with sulindac sulfide 115 (50 mg, 0.15 mmol) and 2-
(nitrooxy)ethanol 132 (17 mg, 0.15 mmol), purification by flash chromatography, eluting with 
dichloromethane and methanol (99:1), furnished(Z)-2-(nitrooxy)ethyl 2-(5-fluoro-2-methyl-1-(4-
(methylthio)benzylidene)-1H-inden-3-yl)acetate 144 (52 mg, 0.12 mmol, 82%) as a yellow 
solid: Rf 0.86 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate);  m.p. 79-80 °C; νmax (thin 
film)/cm−1 1741, 1636, 1602, 1567, 1404, 1280, 1151, 1092, 855; 1H NMR (400 MHz; CDCl3) 
δ 7.45 (2H, d, J 8.4 Hz, CH-3′,5′), 7.37 (1H, dd, J 8.4, 5.2 Hz, CH-7), 7.29 (2H, d, J 8.4 Hz, 
CH-2′,6′), 7.15 (1H, s, CH-α), 6.86 (1H, dd, J 9.0, J 2.4 Hz, CH-4), 6.59 (1H, ddd, J 9.0, 9.0, 
2.4 Hz, CH-6), 4.67-4.64 (2H, m, CH2-2′′), 4.40-4.37 (2H, m, CH2-1′′), 3.60 (2H, s, 3-CH2), 
2.55 (3H, s, SCH3), 2.20 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 170.0 (quat., 
carboxyl), 163.1 (quat., d, J 242.9 Hz, C-5), 146.2 (quat., d, J 8.7 Hz, C-8), 140.0 (quat., C-1), 
139.2 (quat., C-2), 138.8 (quat., C-1′), 132.9 (quat., C-3), 130.2 (CH, C-α), 130.0 (quat., C-9), 
129.9 (CH × 2, C-2′,6′), 129.8 (quat., C-4′), 125.9 (CH × 2, C-3,5′), 123.7 (CH, d, J 8.5 Hz, C-
7), 110.6 (CH, d, J 22.4 Hz, C-6), 105.6 (CH, d, J 23.6 Hz, C-4), 70.2 (CH2, C-2′′), 60.7 (CH2, 
C-1′′), 31.4 (CH2, 3-CH2), 15.4 (CH3, SCH3) 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; 
CDCl3) δ -114.2 (CF); m/z (ES+) 452 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C22H20FNaO5S [M+Na]+ requires 452.0944, found 452.0940; CHN Anal. calcd. for 
C22H20FO5S: C, 61.53; H, 4.69; N, 3.26. Found C, 61.55; H, 4.73; N, 3.30. 
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(Z)-6-(Nitrooxy)hexyl 2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-
inden-3-yl)acetate, 145 
 
 
 
Following general procedure A with sulindac sulfide 115 (50 mg, 0.15 mmol) and 6-
(nitrooxy)hexan-1-ol 137 (24 mg, 0.15 mmol), purification by flash chromatography, eluting 
with dichloromethane and methanol (99:1), furnished (Z)-6-(nitrooxy)hexyl 2-(5-fluoro-2-
methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetate 145 (68 mg, 0.140 mmol, 95%) as 
a yellow gum: Rf 0.62 (95:5, CH2Cl2:MeOH); νmax (thin film)/cm−1 2940, 1732, 1627, 1466, 
1279, 1158, 1092, 1021, 976, 864; 1H NMR (400 MHz; CDCl3) δ 7.44 (2H, d, J 8.2 Hz, CH-
3′,5′), 7.36 (1H, dd, J 8.2, 5.2 Hz, CH-7), 7.29 (2H, d, J 8.2 Hz, CH-2′,6′), 7.14 (1H, s, CH-α), 
6.89 (1H, dd, J 9.0, 2.4 Hz, CH-4), 6.58 (1H, ddd, J  17.6, 9.0, 2.4 Hz, CH-6), 4.38 (2H, t, J 6.6 
Hz, CH2-6′′), 4.10 (2H, t,  J 6.5, 3-CH2), 3.62 (2H, s, 3-CH2), 2.55 (3H, s, SCH3), 2.21 (3H, s, 2-
CH3), 1.70-1.58 (4H, CH2-2′′, 5′′), 1.40-1.28 (4H, CH2-3′′, 4′′); 13C NMR (100 MHz; CDCl3) δ 
170.4 (quat., carboxyl), 163.0 (quat., d, J 244.5 Hz, C-5), 146.5 (quat., d, J 8.7 Hz, C-8), 140.1 
(quat., C-1), 139.2 (quat., C-2), 138.4 (quat., C-1′), 133.0 (quat., C-3), 129.8 (CH, C-α), 130.8 
(quat., C-9), 129.9 (CH × 2, C-2′,6′), 129.0 (quat., C-4′), 126.0 (CH × 2, C-3,5′), 123.7 (CH, d, J 
9.0 Hz, C-7), 110.6 (CH, d, J 23.1 Hz, C-6), 105.8 (CH, d, J 23.1 Hz, C-4), 73.1 (CH2, C-6′′), 
64.8 (CH2, C-1′′), 32.0 (CH2, 3-CH2), 28.4 (CH2, C-5′′), 26.7 (CH2, C-2′′), 25.5 (CH2, C-4′′), 
25.3 (CH2, C-3′′), 15.4 (CH3, SCH3) 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) 
δ -114.5 (CF); m/z (ES+) 508 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C26H28FNNaO5S 
[M+Na]+ requires 508.1570, found 508.1577; CHN Anal. calcd. for C26H28FNO5S: C, 64.31; H, 
5.81; N, 2.88. Found C, 64.37; H, 5.86; N, 2.91. 
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(Z)-1,3-Bis(nitrooxy)propan-2-yl 2-(5-fluoro-2-methyl-1-(4-(methylthio)benzyl-
idene)-1H-inden-3-yl)acetate, 146 
 
 
 
Following general procedure A with sulindac sulfide 115 (50 mg, 0.15 mmol) and 1,3-
di(nitrooxy)-2-propanol 138 (27 mg, 0.15 mmol), purification by flash chromatography, eluting 
with dichloromethane furnished (Z)-1,3-bis(nitrooxy)propan-2-yl 2-(5-fluoro-2-methyl-1-(4-
(methylthio)benzylidene)-1H-inden-3-yl)acetate 146 (63 mg, 0.125 mmol, 85%) as a yellow 
solid: Rf 0.67 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 141-142 °C; νmax 
(thin film)/cm−1 2959, 1741, 1638, 1600, 1465, 1312, 1280, 1153, 1091, 854; 1H NMR (400 
MHz; CDCl3) δ 7.45 (2H, d, J 8.3 Hz, CH-3′,5′), 7.38 (1H, dd, J 8.5, 5.2 Hz, CH-7), 7.29 (2H, 
d, J 8.3 Hz, CH-2′,6′), 7.16 (1H, s, CH-α), 6.84 (1H, dd, J 9.0, 2.4 Hz, CH-4), 6.60 (1H, ddd, J 
9.0, 9.0, 2.4 Hz, CH-6), 5.38 (1H, tt, J 5.7, 4.1 Hz, CH-1′′), 4.74 (2H, dd, J 12.6, 4.1 Hz, 
CHAHB-2′′), 4.55 (2H, dd, J 12.7, 5.7 Hz, CHAHB-2′′), 3.62 (2H, s, 3-CH2), 2.55 (3H, s, SCH3), 
2.20 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.3 (quat., carboxyl), 163.1 (quat., d, J 
245.6 Hz, C-5), 145.9 (quat., d, J 8.7 Hz, C-8), 139.8 (quat., C-1), 139.3 (quat., C-2), 139.1 
(quat., C-1′), 132.8 (quat., C-3), 130.5 (CH, C-α), 129.3 (quat., C-9), 129.9 (CH × 2, C-2′,6′), 
129.7 (quat., C-4′), 125.9 (CH × 2, C-3,5′), 123.8 (CH, d, J 8.6 Hz, C-7), 110.7 (CH, d, J 22.5 
Hz, C-6), 105.4 (CH, d, J 23.6 Hz, C-4), 69.3 (CH2 × 2, C-2′′), 67.0 (CH2, C-1′′), 31.3 (CH2, 3-
CH2), 15.4 (CH3, SCH3) 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -114.2 (CF); 
m/z (ES+) 527 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C23H21FN2NaO8S [M+Na]+ 
requires 527.0900, found 527.0911; CHN  Anal. calcd. for C23H21FN2O7S: C, 54.76; H, 5.20; N, 
5.55. Found C, 54.84; H, 5.33; N, 5.70. 
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(Z)-3-(Nitrooxy)-2,2-bis((nitrooxy)methyl)propyl 2-(5-fluoro-2-methyl-1-(4-
(methylthio)benzylidene)-1H-inden-3-yl)acetate, 147 
 
 
 
Following general procedure A with sulindac sulfide 115 (50 mg, 0.14 mmol) 3-nitrooxy-2,2-
bis(nitrooxymethyl)propan-1-ol 139 (41 mg, 0.15 mmol), purification by flash chromatography, 
eluting with dichloromethane furnished (Z)-3-(nitrooxy)-2,2-bis((nitrooxy)methyl)propyl 2-(5-
fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetate 137 (80 mg, 0.135 mmol, 
92%) as a yellow gum: Rf 0.51 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax 
(thin film)/cm−1 2918, 1744, 1647, 1467, 1381, 1277, 1148, 997, 851, 749; 1H NMR (400 MHz; 
CDCl3) δ 7.45 (2H, d, J 8.2, CH-3′,5′), 7.41 (1H, dd, J 8.2, 5.2 Hz, CH-7), 7.30 (2H, d, J 8.3 Hz, 
CH-2′,6′), 7.18 (1H, s, CH-α), 6.84 (1H, dd, J 8.9, 2.4 Hz, CH-4), 6.62 (1H, ddd, J 8.9, 8.9, 2.4 
Hz, CH-6), 4.34 (6H, s,  3 × CH2-3′′), 4.20 (2H, s, CH2-1′′), 3.62 (2H, s, 3-CH2), 2.55 (3H, s, 
SCH3), 2.21 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.1 (quat., carboxyl), 163.1 
(quat., d, J 246.9 Hz, C-5), 145.8 (quat., d, J 8.3 Hz, C-8), 139.9 (quat., C-1), 139.5 (quat., C-2), 
138.8 (quat., C-1′), 132.6 (quat., C-3), 131.0 (CH, C-α), 130.9 (quat., C-9), 129.9 (CH × 2, C-
2′,6′), 129.6 (quat., C-4′), 126.0 (CH × 2, C-3,5′), 124.1 (CH, d, J 8.9 Hz, C-7), 111.0 (CH, d, J 
22.6 Hz, C-6), 105.3 (CH, d, J 23.8 Hz, C-4), 69.0 (CH2 × 3, C-3′′),  61.7 (CH2, C-1′′), 42.1 
(quat., C-2′′), 31.5 (CH2, 3-CH2), 15.4 (CH3, SCH3) 10.5 (CH3, 2-CH3); 19F {1H} NMR (376 
MHz; CDCl3) δ -113.9 (CF); m/z (ES+) 616 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C25H24FN3NaO11S [M+Na]+ requires 616.1013, found 616.1020; CHN Anal. calcd. for 
C25H24FN3O11S: C, 50.59; H, 4.08; N, 7.08. Found C, 50.66; H, 4.10; N, 7.13. 
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(Z)-2-(Nitrooxy)ethyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-
inden-3-yl)acetate, 148 
 
 
 
Following general procedure A with sulindac sulfone 116 (50 mg, 0.13 mmol) and 2-
(nitrooxy)ethanol 136 (16 mg, 0.14 mmol), purification by flash chromatography, eluting with 
dichloromethane and methanol (99:1), furnished(Z)-2-(nitrooxy)ethyl 2-(5-fluoro-2-methyl-1-(4-
(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetate 148 (56 mg, 0.12 mmol, 90%) as a yellow 
solid: Rf 0.67 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 141-142 °C; νmax 
(thin film)/cm−1 1740, 1635, 1591, 1370, 1310, 1281, 1149, 956, 855, 796; 1H NMR (300 MHz; 
CDCl3) δ 8.01 (2H, d, J 8.5 Hz, CH-3′,5′), 7.70 (2H, d, J 8.5 Hz, CH-2′,6′), 7.14 (1H, s, CH-α), 
7.10 (1H, dd, J 8.4, 5.2 Hz, CH-7), 6.86 (1H, dd, J 8.8, 2.3 Hz, CH-4), 6.58 (1H, ddd, J 8.9, 8.8, 
2.3 Hz, CH-6), 4.68-4.65 (2H, m, CH2-2′′), 4.42-4.39 (2H, m, CH2-1′′), 3.61 (2H, s, 3-CH2), 
3.14 (3H, s, SO2CH3), 2.20 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.7 (quat., 
carboxyl), 163.4 (quat., d, J 246.9 Hz, C-5), 146.5 (quat., d, J 9.3 Hz, C-8), 142.5 (quat., C-4′), 
142.3 (quat., C-1′), 139.9 (quat., C-1), 138.5 (quat., C-2), 131.6 (quat., C-3), 130.2 (CH × 2, C-
2′,6′), 129.4 (quat., C-9), 127.6 (CH × 2, C-3,5′), 127.5 (CH, C-α), 123.8 (CH, d, J 9.3 Hz, C-7), 
110.1 (CH, d, J 22.9 Hz, C-6), 106.2 (CH, d, J 24.1 Hz, C-4), 70.1 (CH2, C-2′′), 60.9 (CH2, C-
1′′), 44.5 (CH3, SO2CH3), 31.4 (CH2, 3-CH2), 10.5 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; 
CDCl3) δ -112.5 (CF); m/z (ES+) 484 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C22H20FNNaO7S [M+Na]+ requires 484.0842, found 484.0840; CHN Anal. calcd. for 
C22H20FNO7S: C, 57.26; H, 4.37; N, 3.04. Found C, 57.42; H, 4.44; N, 3.11. 
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(Z)-6-(Nitrooxy)hexyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-
inden-3-yl)acetate, 149 
 
 
 
Following general procedure A with sulindac sulfone 116 (50 mg, 0.14 mmol) and 6-
(nitrooxy)hexan-1-ol 137 (24 mg, 0.15 mmol), purification by flash chromatography, eluting 
with dichloromethane and methanol (99:1), furnished (Z)-6-(nitrooxy)hexyl 2-(5-fluoro-2-
methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetate 149 (63 mg, 0.122 mmol, 90%) 
as a yellow gum: Rf 0.52 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax (thin 
film)/cm−1 2866, 2087, 1722, 1628, 1466, 1310, 1280, 1150, 1087, 1021, 960, 864; 1H NMR 
(300 MHz; CDCl3) δ 8.00 (2H, d, J 8.2 Hz, CH-3′,5′), 7.69 (2H, d, J 8.2 Hz, CH-2′,6′), 7.13 
(1H, s, CH-α), 7.10 (1H, dd, J 8.4, 5.1 Hz, CH-7), 6.88 (1H, dd, J 8.7, 2.3 Hz, CH-4), 6.56 (1H, 
ddd, J 8.9, 8.7, 2.3 Hz, CH-6), 4.39 (2H, t,  J 6.6 Hz, CH2-6′′), 4.12 (2H, t,  J 6.4, 3-CH2), 3.56 
(2H, s, 3-CH2), 3.13 (3H, s, SO2CH3), 2.20 (3H, s, 2-CH3), 1.68-1.59 (4H, CH2-2′′, 5′′), 1.46-
1.39 (4H, CH2-3′′, 6′′); 13C NMR (100 MHz; CDCl3) δ 170.2 (quat., carboxyl), 163.5 (quat., d, J 
248.0 Hz, C-5), 146.8 (quat., d, J 8.7 Hz, C-8), 142.5 (quat., C-4′), 142.3 (quat., C-1′), 139.8 
(quat., C-1), 138.1 (quat., C-2), 132.4 (quat., d, J 1.7 Hz, C-3), 130.2 (CH × 2, C-2′,6′), 129.3 
(quat., d, J 2.8 Hz, C-9), 127.6 (CH × 2, C-3,5′), 127.2 (CH, C-α), 123.7 (CH, d, J 9.1 Hz, C-7), 
110.9 (CH, d, J 22.6 Hz, C-6), 106.4 (CH, d, J 23.8 Hz, C-4), 73.0 (CH2, C-6′′), 64.9 (CH2, C-
1), 44.5 (CH3, SO2CH3), 31.9 (CH2, 3-CH2), 28.3 (CH2, C-5′′), 26.7 (CH2, C-2′′), 23.5 (CH2, C-
4′′), 25.2 (CH2, C-3′′), 10.5 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -112.5 (CF); 
m/z (ES+) 540 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C26H28FNNaO7S [M+Na]+ 
requires 540.1468, found 540.1470. CHN Anal. calcd. for C26H28FNNaO7S: C, 60.34; H, 5.45; 
N, 2.71. Found C, 60.36; H, 5.49; N, 2.77. 
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(Z)-1,3-Bis(nitrooxy)propan-2-yl 2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)-
benzylidene)-1H-inden-3-yl)acetate, 150 
 
 
 
Following general procedure A with sulindac sulfone 116 (50 mg, 0.14 mmol) and 1,3-
di(nitrooxy)-2-propanol 138 (27 mg, 0.15 mmol), purification by flash chromatography, eluting 
with dichloromethane furnished (Z)-1,3-bis(nitrooxy)propan-2-yl 2-(5-fluoro-2-methyl-1-(4-
(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetate 150 (66 mg, 0.123 mmol, 92%) as a yellow 
solid: Rf 0.57 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 92-94 °C; νmax (thin 
film)/cm−1 2095, 1744, 1640, 1463, 1410, 1277, 1145, 1084, 1014, 963, 833; 1H NMR (300 
MHz; CDCl3) δ 8.00 (2H, d, J 8.4 Hz, CH-3′,5′), 7.71 (2H, d, J 8.4 Hz, CH-2′,6′), 7.15 (1H, s, 
CH-α), 7.10 (1H, dd, J 8.4, 5.0 Hz, CH-7), 6.84 (1H, dd, J 8.7, 2.3 Hz, CH-4), 6.58 (1H, ddd, J 
8.9, 8.7, 2.3 Hz, CH-6), 5.39 (1H, tt, J 5.8, 3.9 Hz, CH-1′′), 4.76 (2H, dd, J 12.7, 3.9, Hz, 
CHAHB-2′′), 4.56 (2H, dd, J 12.6, 5.8 Hz, CHAHB-2′′), 3.62 (2H, s, 3-CH2), 3.14 (3H, s, 
SO2CH3), 2.20 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.1 (quat., carboxyl), 163.4 
(quat., d, J 247.1 Hz, C-5), 146.3 (quat., d, J 8.9 Hz, C-8), 142.4 (quat., C-4′), 142.1 (quat., C-
1′), 139.9 (quat., C-1), 138.8 (quat., C-2), 131.0 (quat., d, J 1.8 Hz, C-3), 130.2 (CH × 2, C-
2′,6′), 129.1 (quat., J 2.6 Hz, C-9), 127.7 (CH, C-α), 127.6 (CH × 2, C-3,5′), 123.8 (CH, d, J 9.1 
Hz, C-7), 111.1 (CH, d, J 22.4 Hz, C-6), 106.0 (CH, d, J 24.1 Hz, C-4), 69.3 (CH2 × 2, C-2′′), 
67.2 (CH2, C-1′′), 44.5 (CH3, SO2CH3), 31.3 (CH2, 3-CH2), 10.5 (CH3, 2-CH3); 19F {1H} NMR 
(376 MHz; CDCl3) δ -112.7 (CF); m/z (ES+) 559 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C23H21FN2NaO10S [M+Na]+ requires 559.0799, found 559.0803; CHN Anal. calcd. for 
C23H21FN2O10S: C, 51.49; H, 3.95; N, 5.22. Found C, 51.55; H, 4.01; N, 5.28. 
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(Z)-3-(Nitrooxy)-2,2-bis((nitrooxy)methyl)propyl 2-(5-fluoro-2-methyl-1-(4-(methyl-
sulfonyl)benzylidene)-1H-inden-3-yl)acetate, 151 
 
 
 
Following general procedure A with sulindac sulfone 116 (50 mg, 0.14 mmol) and 3-nitrooxy-
2,2-bis(nitrooxymethyl)propan-1-ol 139 (41 mg, 0.15 mmol), purification by flash 
chromatography, eluting with dichloromethane, furnished  (Z)-3-(Nitrooxy)-2,2-
bis((nitrooxy)methyl)propyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-
3-yl)acetate 151 (74 mg, 0.118 mmol, 88%) as a yellow gum; Rf 0.59 (95:5, CH2Cl2:MeOH, 
UV/cerium phosphomolybdate); νmax (thin film)/cm−1 2912, 2551, 1744, 1646, 1468, 1398, 
1279, 1149, 1088, 955, 854, 760; 1H NMR (300 MHz; CDCl3) δ 8.02 (2H, d, J 8.3 Hz, CH-
3′,5′), 7.70 (2H, d, J 8.3 Hz, CH-2′,6′), 7.17 (1H, s, CH-α), 7.13 (1H, dd, J 8.4, 5.1 Hz, CH-7), 
6.85 (1H, dd, J 8.7, 2.2 Hz, CH-4), 6.60 (1H, ddd, J 8.9, 8.7, 2.2 Hz, CH-6), 4.37 (6H, s,  3 × 
CH2-3′′), 4.21 (2H, s, CH2-1′′), 3.63 (2H, s, 3-CH2), 3.14 (3H, s, SO2CH3), 2.20 (3H, s, 2-CH3); 
13C NMR (100 MHz; CDCl3) δ 168.9 (quat., carboxyl), 163.4 (quat., d, J 247.1 Hz, C-5), 146.3 
(quat., d, J 8.9 Hz, C-8), 142.2 (quat., C-4′), 141.8 (quat., C-1′), 140.0 (quat., C-1), 138.5 (quat., 
C-2), 131.2 (quat., d, C-3), 130.2 (CH × 2, C-2′,6′), 129.2 (quat., C-9), 128.1 (CH, C-α), 127.9 
(CH × 2, C-3,5′), 123.5 (CH, d, J 9.2 Hz, C-7), 111.4 (CH, d, J 22.4 Hz, C-6), 105.8 (CH, d, J 
23.8 Hz, C-4), 69.0 (CH2  × 3, C-3′′), 61.9 (CH2, C-1′′), 44.5 (CH3, SO2CH3), 42.0 (quat., C-2′′), 
31.5 (CH2, 3-CH2), 10.5 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -112.0 (CF); m/z 
(ES+) 648 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C25H24FN3NaO13S [M+Na]+ requires 
648.0912, found 648.0916; CHN Anal. calcd. for C25H24FN3O13S: C, 48.00; H, 3.87; N, 6.72. 
Found C, 48.12; H, 3.89; N, 6.75  
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2-(Phenylthio)acetic acid, 153152 
 
 
 
Thiophenol 152 (2.4 g, 2.3 mL, 22.0 mol) and sodium hydroxide (880 mg, 22.0 mol) in 95% aq. 
EtOH (11 mL) were added dropwise to a solution of chloroacetic acid (2.27 g, 24.0 mol) and 
sodium carbonate (1.27 g, 6.00 mmol) in distilled water (5 mL) and stirred for 18 h at room 
temperature. The solution was acidified to pH 2 with aq. HCl solution (3 N) and extracted with 
ethyl acetate (50 mL). The solvent was removed under reduced pressure to yield 2-
(phenylthio)acetic acid 153 (3.57 g, 97%, 21.2 mmol) as white crystals, which was used without 
any further purification: m.p. 60-63 °C; [Lit.152 60-62 °C]; 1H NMR (300 MHz; CDCl3) δ 7.42-
7.39 (2H, m, CH-3,5), 7.33-7.20 (3H, m, CH-1,2,6) and 3.66 (2H, s, CH2-7); 13C NMR (100 
MHz; CDCl3) δ 175.1 (quat., C-8), 134.5 (quat., C-4), 127.3 (CH, C-1), 130.1 (CH × 2, C-2,6), 
129.8 (CH × 2, C-3,5) and 36.6 (CH2, C-7); m/z (ES−) 167 ([M-H]−, 100%). The data were in 
agreement with the literature values.399 
 
2-(Phenylsulfonyl)acetic acid, 154152 
 
 
 
Oxone® (7.37 g, 12.0 mmol) in distilled water (10 mL) was added dropwise to a solution of 2-
(phenylthio)acetic acid 153 (1.00 g, 6.0 mmol) in methanol (40 mL) and the resultant 
suspension stirred for 3 h at room temperature. The volatile components were removed under 
reduced pressure and the residue was partitioned  between ethyl acetate and water (1:1, 100 
mL). The organic layer was separated and the solvent removed under reduced pressure to yield 
2-(phenylsulfonyl)acetic acid 154 (1.15 g, 5.75 mmol, 96%) as white crystals, which was used 
without any further purification: m.p. 110-113 °C, [Lit.152 112-113 °C]; 1H NMR (300 MHz; 
CDCl3) δ 7.98 (2H, dt, J 7.1, 2.5 Hz, CH-3,5), 7.70 (1H, tt, J 7.4, 2.5 Hz, CH-1), 7.60 (2H, tt, J 
7.4, 7.1 Hz, CH-2, 6) and 4.16 (2H, s, CH2-7); 13C NMR (100 MHz; CDCl3) δ 165.8 (quat., C-
8), 138.8 (quat., C-4), 135.0 (CH, C-1), 129.8 (CH × 2, C-2,6), 128.9 (CH × 2, C-3,5) and 60.9 
(CH2, C-7); m/z (ES−) 199 ([M-H]−, 100%). The data were in agreement with the literature 
values.399 
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3,4-Bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 53152 
 
 
 
Fuming nitric acid (27.0 g, 18 mL, 430 mmol) was added dropwise to a solution of 2-
(phenylsulfonyl)acetic acid 154 (12.0 g, 60.0 mmol) in glacial acetic acid (35 mL) at 0 °C with 
stirring. The resulting solution solution was stirred at 0 °C for 15 min, then heated to reflux for 
45 min, during which time the solution became a deep red colour. The solution was cooled to 
room temperature and poured onto ice, resulting in precipitation of crude product. The solid was 
collected by filtration and recrystallised from 2-propanol to yield 3,4-bis(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide 53 (2.88 g, 7.87 mmol, 26%) as white needles: m.p. (2-propanol) 154-155 
°C, [Lit., 154-156 °C152]; 1H NMR (500 MHz; CDCl3) δ 8.19-8.16 (4H, m, ArCH × 4), 7.83-
7.79 (2H, m, ArCH × 2) and 7.70-7.64 (4H, m, ArCH × 4) 13C NMR (100 MHz; CDCl3) δ 
155.6 (quat., C-2), 137.1 (quat.), 136.2 (quat.), 136.1 (CH), 135.9 (CH), 130.22 (CH × 2), 129.9 
(CH × 2), 129.2 (CH × 2) and 115.2 (quat., C-1); m/z (ES+), 389 ([M+Na]+, 100%). The data 
were in agreement with the literature values.152 
 
4-(3-Hydroxypropoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 166152  
 
 
 
1,3-Propanediol 159 (304 mg, 4.0 mmol) and 50% NaOH solution (w/w; 350 mg, 4.00 mmol) 
were added to a stirring solution of 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 53 (732 
mg, 2.00 mmol) in tetrahydrofuran (20 mL) and the resultant solution was stirred for 3 h. The 
solvent was removed under reduced pressure and the residue was partitioned between distilled 
water and dichloromethane (1:1, 100 mL). The organic layer was separated and the aqueous 
layer extracted with dichloromethane (2 × 30 mL). The organic layers were combined and dried 
over Na2SO4, filtered and the solvent removed under reduced pressure to give a brown solid. 
This solid was purified by silica gel chromatography, eluting with dichloromethane and 
methanol (100:0 to 99:1), to give 4-(3-hydroxypropoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-
oxide 166 (402 mg, 1.34 mmol, 67%) as a white powder: Rf 0.14 (70:30, PE: EtOAc, 
12
N
O
N
SS
O
O O O O
O
N+
54
N
O S
OO
6
O-
3
2
1
11
10
9
8
7
HO
Appendix: Experimental 
 
	   203	  
UV/KMnO4); m.p. 105-107 °C, [Lit.152 105-106 °C]; 1H NMR (400 MHz; CDCl3) δ 8.06 (2H, 
d, J 8.5 Hz, CH-7, 11), 7.77 (1H, tt, J 7.3, 1.2 Hz, CH-9), 7.63 (2H, t, J 7.4 Hz, CH-8,10), 4.60 
(2H, t, J 6.0 Hz, CH2-3), 3.89 (2H, t, J 6.0 Hz, CH2-1), 2.14 (2H, quintet, J 6.0 Hz, CH2-2) and 
1.75 (1H, s, br, OH), 13C NMR (100 MHz; CDCl3) δ 158.9 (quat., C-4′), 138.0 (quat., C-6), 
135.7 (CH, C-9), 129.7 (CH × 2, C-7,11), 128.6 (CH × 2, C-8,10), 112.2 (CH, C-5), 69.3 (CH2, 
C-3), 59.4 (CH2, C-1) and 31.3 (CH2, C-2); m/z (ES+) 323 ([M+Na]+, 100%). The data were in 
agreement with the literature values.152 
 
4-(4-Hydroxybutoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 167152 
 
 
 
1,4-Butanediol 125 (180 mg, 2.0 mmol) and 50% NaOH solution (w/w; 175 mg, 2.00 mmol) 
were added to a stirring solution of 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 53 (366 
mg, 1.00 mmol) in dry tetrahydrofuran (10 mL)  and the resultant solution was stirred for 3 h. 
The solvent was removed under reduced pressure and the residue was partitioned  between 
distilled water and dichloromethane (1:1, 100 mL). The organic layer was separated and the 
aqueous layer extracted with dichloromethane (2 × 30 mL). The organic layers were combined 
and dried over Na2SO4, filtered and the solvent removed under reduced pressure to give 4-(4-
hydroxybutoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 167 (143 mg, 50%) as a white 
solid which was used without any further purification: Rf 0.21 (70:30, PE: EtOAc, 
UV/KMnO4); m.p. 61-63 °C, [Lit.152 61-64 °C]; 1H NMR (300 MHz; CDCl3) δ 8.08-8.05 (2H, 
m, CH-8,12), 7.77-7.74 (1H, m, CH-10), 7.66-7.61 (2H, m, CH-9,11), 4.49 (2H, t, J 6.3, CH2-
4), 3.81-3.75 (2H, m, CH2-1), 2.05-1.99 (2H, m, CH2-3) and 1.81-1.74 (2H, m, CH2-2); 13C 
NMR (100 MHz; CDCl3) δ 159.0 (quat., C-5), 137.9 (quat., C-7), 135.6 (CH, C-10), 129.7 (CH 
× 2, C-9,11), 128.6 (CH × 2, C-8,12), 111.6 (quat., C-6), 71.5 (CH2, C-4), 62.0 (CH2, C-1), 28.9 
and 25.0 (CH2 × 2, C-2,3); m/z (ES+) 337 ([M+Na]+, 100%). The data were in agreement with 
the literature values.152 
 
 
 
 
 
 
O
N+
65
N
O S
OO
7
O-
4
3
2
12
11
10
9
8
1
HO
Appendix: Experimental 
 
	   204	  
4-(6-Hydroxyhexyloxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 168 
 
 
 
1,6-Hexanediol 160 (475 mg, 4.0 mmol) and 50% NaOH solution (w/w; 350 mg, 4.00 mmol) 
were added to a stirring solution of 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 53 (732 
mg, 2.00 mmol) in tetrahydrofuran (20 mL) and the resultant solution was stirred for 3 h. The 
solvent was removed under reduced pressure and the residue was partitioned between distilled 
water and dichloromethane (1:1, 100 mL). The organic layer was separated and the aqueous 
layer extracted with dichloromethane (2 × 30 mL). The organic layers were combined and dried 
over Na2SO4, filtered and the solvent removed under reduced pressure to give a white solid. 
This solid was purified by silica gel chromatography, eluting with dichloromethane, to give 4-
(6-hydroxyhexyloxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 168 (266 mg, 0.78 mmol, 
39%) as white crystals: m.p. 54-57 °C; Rf  0.33 (70:30, EtOAc:PE, UV/KMnO4); νmax (thin 
film)/cm−1 3438, 2921, 1611, 1552, 1491, 1164; 1H NMR (300 MHz; CDCl3) δ 8.07 (2H, d, J 
8.5 Hz, CH-10,14), 7.77 (1H, tt, J 8.5, 1.2 Hz, CH-12), 7.63 (2H, t, J 7.8 Hz, CH-11,13), 4.44 
(2H, t, J 6.5 Hz, CH2-6), 3.69 (2H, t, J 6.5 Hz, CH2-1), 1.94-1.87 (2H, m, CH2-5), 1.66-1.60 
(2H, m, CH2-2), 1.55 (1H, s, br, OH) and 1.52-1.47 (4H, m, CH2-3, 4); 13C NMR (300 MHz; 
CDCl3) δ 159.0 (quat., C-7), 138.1 (quat., C-9), 135.6 (CH, C-12), 129.7 (CH × 2, C-11,13), 
128.5 (CH × 2, C-10,14), 110.5 (quat., C-8), 71.6 (CH2, C-6), 62.7 (CH2, C-1), 32.5 (CH2, C-5), 
28.4 (CH2, C-2), 25.5 (CH2, C-4) and 25.3 (CH2, C-3); m/z (ES+) 365 ([M+Na]+, 100%); 
HRMS m/z (ES+) calcd. for C14H18N2NaO6S [M+Na]+ requires 365.0783, found 365.0790 
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4-((4-Hydroxybut-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 169 
 
 
 
But-2-yne-1,4-diol 162 (345 mg, 4.00 mmol) and 50% NaOH solution (w/w; 350 mg, 4.00 
mmol) were added to a stirring solution of 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 53 
(732 mg, 2.00 mmol) in tetrahydrofuran (20 mL) and the resultant solution was stirred for 3 h. 
The solvent was removed under reduced pressure and the residue was partitioned between 
distilled water and dichloromethane (1:1, 100 mL). The organic layer was separated and the 
aqueous layer extracted with dichloromethane (2 × 30 mL). The organic layers were combined 
and dried over Na2SO4, filtered and the solvent removed under reduced pressure to give a white 
residue. This residue was purified by silica gel chromatography, eluting with dichloromethane, 
to give 4-((4-hydroxybut-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 169 (204 
mg, 0.66 mmol, 33%) as a white solid: Rf 0.31 (30:70 EtOAc:PE, UV/KMnO4); m.p. 109-112 
°C, [Lit.152 110-112 °C]; 1H NMR (300 MHz; CDCl3) δ 8.09 (2H, d, J 8.0 Hz, CH-8,12), 7.78 
(1H, tt, J 7.5, 1.8 Hz, CH-10), 7.64 (2H, t, J 7.5 Hz, CH-9,11), 5.12 (2H, t, J 1.8 Hz, CH2-4), 
4.36 (2H, t, J 1.8 Hz, CH2-1) and 1.80 (1H, s, br, OH); 13C NMR (100 MHz; CDCl3) δ 158.0 
(quat., C-5), 137.8 (quat., C-7), 135.8 (CH, C-10), 129.7 (CH × 2, C-9,11), 128.2 (CH × 2, C-
8,12), 110.6 (quat., C-6), 88.1 (quat., C-3), 77.6 (quat., C-2), 58.8 (CH2, C-4) and 51.0 (CH2, C-
1); m/z (ES)+ 333 ([M+Na]+, 100%). The data were in agreement with the literature values.152 
 
(Z)-4-((4-Hydroxybut-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 
170 
 
(Z)-But-2-ene-1,4-diol 163 (352 mg, 4.0 mmol) and 50% NaOH solution (w/w; 350 mg, 4.00 
mmol) were added to a stirring solution of 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 53 
(732 mg, 2.00 mmol) in tetrahydrofuran (20 mL) and the resultant solution was stirred for 3 h. 
The solvent was removed under reduced pressure and the residue was partitioned between 
distilled water and dichloromethane (1:1, 100 mL). The organic layer was separated and the 
aqueous layer extracted with dichloromethane (2 × 30 mL). The organic layers were combined 
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and dried over Na2SO4, filtered and the solvent removed under reduced pressure to give a 
colourless solid. This solid was purified by silica gel chromatography, eluting with 
dichloromethane and methanol (100:0 to 99:1) to yield (Z)-4-((4-hydroxybut-2-en-1-yl)oxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 170 (515 mg, 1.64 mmol, 82%) as colourless crystals: 
Rf 0.21 (30:70, EtOAc:PE, UV/KMnO4); m.p.  58-60 °C; νmax  (thin film)/cm−1 3413, 1977, 
1909, 1615, 1542, 1449, 1257; 1H NMR (300 MHz; CDCl3) δ 8.06 (2H, d, J 8.3 Hz, CH-8,12), 
7.77 (1H, tt, J 8.7, 1.3 Hz, CH-10), 7.63 (2H, t, J 8.3 Hz, CH-9,11), 6.05-5.96 (1H, m, CH-3), 
5.86-5.78 (1H, m, CH-2), 5.08 (2H, d, J 6.7 Hz, CH2-4), 4.33 (2H, t, J 5.6 Hz, CH2-3) and 1.79 
(1H, t, J 5.7, OH) 13C NMR (300 MHz; CDCl3) δ 158.6 (quat., C-5), 137.9 (quat., C-7), 135.8 
(CH, C-3), 135.7 (CH, C-10), 129.7 (CH × 2, C-9,11), 128.6 (CH × 2, C-8,12), 123.5 (CH, C-
2), 110.6 (quat., C-6), 66.7 (CH2, C-4) and 60.4 (CH2, C-1); m/z (ES+) 335 ([M+Na]+, 100%); 
HRMS m/z (ES+) calcd. for C12H12N2NaO6S [M+Na]+ requires 335.0314, found 335.0322. 
 
4-(3-(Hydroxymethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 171 
 
 
 
3-(Hydroxy)benzyl alcohol 164 (497 mg, 4.00 mmol) and 50% NaOH solution (w/w; 350 mg, 
4.00 mmol) were added to a stirring solution of 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-
oxide 53 (732 mg, 2.00 mmol) in dry tetrahydrofuran (20 mL) and the resultant solution was 
stirred for 3 h. The solvent was removed under reduced pressure and the residue was partitioned  
between distilled water and dichloromethane (1:1, 100 mL). The organic layer was separated 
and the aqueous layer extracted with dichloromethane (2 × 30 mL). The organic layers were 
combined and dried over Na2SO4, filtered and the solvent removed under reduced pressure to 
give a white residue. This residue was purified by silica gel chromatography, eluting with 
dichloromethane to yield 4-(3-(hydroxymethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-
oxide 171 (376 mg, 1.08 mmol, 54%) as a colourless oil which solidified on standing to a off-
white solid: Rf 0.74 (30:70 EtOAc:PE, UV/KMnO4); m.p. 75-78 °C; νmax  (thin film)/cm−1 3268, 
1901, 1609, 1537, 1356, 1644, 1080; 1H NMR (500 MHz; CDCl3) δ 8.12 (2H, d, J 8.0 Hz, CH-
11,15), 7.81 (1H, tt, J 7.5, 1.8 Hz, CH), 7.67 (2H, t, J 7.5 Hz, CH-12,14), 7.45 (1H, t, J 7.9 Hz, 
CH-13), 7.36 (1H, s, CH), 7.32 (1H, d, J 7.9 Hz, CH), 7.25 (1H, dd, J 7.9, 2.2 Hz, CH) and 4.77 
(2H, s, CH2-1); 13C NMR (100 MHz; CDCl3) δ 158.1 (quat., C-8), 152.9 (quat., C-4), 143.6 
(quat., C-2), 138.0 (quat., C-10), 135.8 (CH, C-13), 130.1 (CH, C-6), 129.8 (CH × 2, C-12,14), 
128.7 (CH × 2, C-11,15), 124.9 (CH, C-6), 118.9 (CH, C-5), 118.0 (C-7), 110.6 (quat., C-9) and 
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64.4 (CH2, C-1); m/z (ES+) 371 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C15H12N2NaO6S 
[M+Na]+ requires 371.0314 found 371.0320. 
 
4-(3-Hydroxyphenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 172 
 
 
 
3-Hydroxyphenol 165 (440 mg, 4.00 mmol) and 50% NaOH solution (w/w; 350 mg, 
4.00  mmol) were added to a stirring solution of 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 
2-oxide 53 (732 mg, 2.00 mmol) in tetrahydrofuran (20 mL) and the resultant solution was 
stirred for 3 h. The solvent was removed under reduced pressure and the residue was partitioned 
between distilled water and dichloromethane (1:1, 100 mL). The organic layer was separated 
and the aqueous layer extracted with dichloromethane (2 × 30 mL). The organic layers were 
combined and dried over Na2SO4, filtered and the solvent removed under reduced pressure to 
give a deep red oil. Purification by silica gel chromatography, eluting with petroleum ether and 
ethyl acetate (90:10), yielded colourless glass. This glass was uptaken in chloroform (20 mL) 
and washed with distilled water (5 × 10 mL) dried over Na2SO4, filtered and the solvent 
evaporated under reduced pressure to yield 4-(3-hydroxyphenoxy)-3-(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide 172 (218 mg, 0.65 mmol, 33%) as a pale pink glass: Rf 0.40 (30:70 
EtOAc:PE, UV/KMnO4); m.p. 95-98 °C; νmax  (thin film)/cm−1 3487, 1614, 1533, 1483, 1432, 
1356, 1257, 1164, 997, 945; 1H NMR (400 MHz; CDCl3) δ 8.09 (2H, d, J 8.0 Hz, CH-10,14), 
7.79 (1H, t, J 7.3 Hz, CH-12), 7.67-7.62 (2H, m, CH-11,13), 7.29 (1H, t, J 8.2 Hz, CH-5), 6.87 
(1H, dd, J 8.2, 1.8 Hz, CH-6), 6.81 (1H, t, J 1.8 Hz, CH-2) and 6.78 (1H, dd, J 8.2, 1.8 Hz, CH-
4); 13C NMR (100 MHz; CDCl3) δ 158.2 (quat., C-3), 156.9 (quat., C-7), 153.5 (quat., C-1), 
137.9 (quat., C-9), 135.9 (CH, C-12), 130.7 (CH, C-5), 129.9 (CH × 2, C-10,14), 128.6 (CH × 
2, C-11,13), 113.9 (CH, C-6), 111.9 (CH, C-4), 110.8 (quat., C-8) and 107.4 (CH, C-2); m/z 
(ES+) 357 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C14H10N2NaO6S [M+Na]+ requires 
357.0157, found 357.0163 
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2-((tert-Butyldimethylsilyl)oxy)ethanol, 176324 
 
 
 
TBDMSCl (2.91 g, 19.3 mmol) was added over 1 h to a solution of ethylene glycol 158 (2.33 g, 
38.6 mmol), triethylamine (2.5 mL, 24.1 mmol), and DMAP (20 mg, 0.16 mmol) in 
dichloromethane (150 mL) at 0 °C. The solution was allowed to warm to room temperature and 
stirred for 16 h. The solution was diluted with dichloromethane (30 mL) and water (30 mL) was 
added. The biphasic mixture was washed successively with aq. NaHCO3 (saturated, 50 mL), 
NH4Cl solution (saturated, 50 mL), water (50 mL) and brine (50 mL), dried over MgSO4, 
filtered and evaporated under reduced pressure to give a pale yellow oil. This oil was purified 
by silica gel chromatography, eluting with EtOAc and PE (95:5 PE:EtOAc), to give 2-((tert-
butyldimethylsilyl)oxy)ethanol 176 (2.15 g, 11.9 mmol, 74%) as a colourless oil: Rf 0.71 
(70:30, PE:EtOAc, cerium phosphomolybdate); 1H NMR (300 MHz; CDCl3) δ 3.64-3.61 (2H, 
m, CH2), 3.58-3.54 (2H, m, CH2), 0.83 (9H, s, CH3 × 3) and 0.03 (6H, s, CH3 × 2); 13C NMR 
(100 MHz; CDCl3) δ 62.7 (CH2), 61.6 (CH2), 25.8 (CH3 × 3), 18.3 (quat.) and -5.4 (CH3 × 2); 
m/z ES− 175 ([M-H]−, 100%). The data were in agreement with the literature values.324 
 
4-(2-Hydroxyethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 174152 
 
 
 
2-((tert-Butyldimethylsilyl)oxy)ethanol 176 (352 mg, 2.0 mmol) and 50% NaOH solution (w/w; 
350 mg, 4.00 mmol) were added to a solution of 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-
oxide 53 (732 mg, 2.00 mmol) in tetrahydrofuran (20 mL) and the resultant solution was stirred 
for 3 h. The solvent was removed under reduced pressure and the residue was partitioned 
between distilled water and dichloromethane (1:1, 100 mL). The organic layer was separated 
and the aqueous layer extracted with dichloromethane (2 × 30 mL). The organic layers were 
combined and dried over Na2SO4, filtered and the solvent removed under reduced pressure to 
give a fawn coloured residue (400 mg). This residue was dissolved in methanol (10 mL) and 
10-camphorsulfonic acid (400 mg, 1.72 mmol) added. The resulting solution was stirred for 30 
min before being quenched with saturated sodium bicarbonate solution (10 mL) and extracted 
with ethyl acetate (15 mL). The solvent was removed under reduced pressure to give an off 
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white solid. This solid was purified by silica gel chromatography, eluting with dichloromethane, 
to give 4-(2-hydroxyethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 174 (340 mg, 0.23 
mmol, 60%) as a white solid: Rf  0.17 (70:30, PE: EtOAc, UV/KMnO4); m.p. 120-122 °C, 
[Lit.152 118-119 °C]; 1H NMR (300 MHz; CDCl3) δ 8.08 (2H, d, J 8.1 Hz, CH-7,9), 7.77 (1H, 
tt, J 6.7, J 1.3 Hz, CH-8), 7.63 (2H, tt, J 8.1, J 1.3 Hz, CH-6,10), 4.55 (2H, t, J 4.5 Hz, CH2-2), 
4.05 (2H, q, J 4.5 Hz, CH2-1) and 2.26 (1H, s, br, OH); 13C NMR (100 MHz; CDCl3) δ 159.0 
(quat., C-3), 137.9 (quat., C-5), 135.7 (CH, C-8), 129.7 (CH × 2, C-7, C-9), 128.6 (CH × 2, C-6, 
C-10), 109.9 (quat., C-4), 72.8 (CH2, C-2) and 60.5 (CH2, C-1); m/z (ES+) 309 ([M+Na]+, 
100%). The data were in agreement with the literature values.152 
 
2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethanol, 177325 
 
 
 
Imidazole (1.26 g, 18.5 mmol) was added to a solution of diethyleneglycol 161 (3.5 mL, 37.0 
mmol) in dichloromethane (40 mL) at 0 °C, and the resulting mixture was stirred 5 min. tert-
Butyldimethylsilyl chloride (2.79 g, 18.5 mmol) was added in one portion and the reaction 
stirred for 1 h at 0°C and then allowed to warmed to room temperature and stirred overnight. 
Distilled water  (20 mL) was added and the organic layer was washed with aq. HCl solution (1  
N, 15 mL), saturated sodium bicarbonate solution (15 mL) and with brine (20 mL). The organic 
layer was dried over MgSO4, and the solvent removed under reduced pressure to give the crude 
product. This product was purified by silica gel chromatography, eluting with ethyl acetate and 
petroleum ether (20:80) give 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethanol 177 (2.00 g, 
9.08 mmol, 50%) as a colourless oil: Rf 0.25 (70:30, PE: EtOAc, cerium phosphomolybdate); 
1H NMR  (300 MHz, CDCl3) δ 3.81-3.77 (2H, m, CH2-1), 3.74- 3.70 (2H, m, CH2-4), 3.64-3.60 
(4H, m, CH2-2, 3), 0.91 (9H, s, 3 × CH3, SiC(CH3)3) and 0.08 (6H, s, Si(CH3)2)); 13C NMR 
 (300 MHz, CDCl3) δ 72.6 (CH2), 72.4 (CH2), 62.9 (CH2), 62.0 (CH2), 25.9 (CH3 × 3), 18.4 
(quat.) and -5.3 (CH3 × 2); m/z (ES) − 219 ([M-H]−, 100%). The data were in agreement with the 
literature values.325 
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4-(2-(2-Hydroxyethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 175152 
 
 
 
2-(2-tert-Butyldimethylsiloxyethoxy)ethanol 177 (400 mg, 2.0 mmol) and 50% NaOH solution 
(w/w; 350 mg, 4.00 mmol) were added to a stirring solution of 3,4-bis(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide 53 (732 mg, 2.00 mmol) in tetrahydrofuran (20 mL) and the resultant 
solution was stirred for 3 h. The solvent was removed under reduced pressure and the residue 
was partitioned  between distilled water and dichloromethane (1:1, 100 mL). The organic layer 
was separated and the aqueous layer extracted with dichloromethane (2 × 30 mL). The organic 
layers were combined and dried over Na2SO4, filtered and the solvent removed under reduced 
pressure to give a colourless oil (415 mg). This oil was dissolved in methanol (10 mL) and 
10-camphorsulfonic acid (400 mg, 1.72 mmol) was added. The resulting solution was stirred for 
30 min before being quenched with saturated sodium bicarbonate solution (10 mL) and 
extracted with ethyl acetate (20 mL). The solvent was removed under reduced pressure to give 
an off-white solid. This solid was purified by silica gel chromatography, eluting with 
dichloromethane and methanol (100:0 to 99:1), to give 4-(2-(2-hydroxyethoxy)ethoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 175 (300 mg, 0.91 mmol, 46%) as a white solid: Rf 
0.13 (70:30, PE: EtOAc, UV/KMnO4);  m.p. 58-60 °C, [Lit.152 58-60 °C]; 1H NMR (300 MHz; 
CDCl3) δ 8.09-8.06 (2H, m, CH-8, 12), 7.76 (1H, tt, J 6.7, 1.3 Hz, CH-10), 7.66-7.60 (2H, m, 
CH-9,11), 4.61-4.58 (2H, m, CH2-4), 3.96-3.93 (2H, m, CH2-1), 3.82-3.77 (2H, m, CH2-3) and 
3.73-3.70 (2H, m, CH2-2); 13C NMR (100 MHz; CDCl3) δ 159.0 (quat., C-5), 141.1 (quat., C-
7), 135.7 (CH, C-10), 129.7 (CH × 2, C-9,11), 128.6 (CH × 2, C-8,12), 109.6 (quat., C-6), 72.7 
(CH2, C-4), 70.5 (CH2, C-3), 68.3 (CH2, C-1) and 60.4 (CH2, C-2); m/z (ES+) 353 ([M+Na]+, 
100%). The data were in agreement with the literature values.152 
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(Z)-4-(2-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 178 
 
 
 
Following general procedure A with sulindac 112 (62 mg, 0.18 mmol) and 4-(2-
hydroxyethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 174 (50 mg, 0.18 mmol), 
purification by flash chromatography, eluting with dichloromethane and methanol (95:5), 
furnished, (Z)-4-(2-(2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 178 (78 mg, 0.15 mmol, 89%) 
as a yellow solid: m.p. 59-61 °C; Rf 0.47 (95:5, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 2940, 1735, 1601, 1560, 1459, 1433, 1370, 1241, 
1166, 1080; 1H NMR (400 MHz; CDCl3) δ 8.07 (2H, d, J 7.9 Hz, CH-6′′,10′′), 7.79-7.56 (7H, 
m, CH-2′,3′,5′,6′,7′′,8′′,9′′), 7.16 (1H, s, CH-α), 7.15 (1H, dd, J 8.4, 5.1 Hz, CH-7), 6.88 (1H, dd, 
J 8.9, 2.5 Hz, CH-4), 6.56 (1H, ddd, J 8.9, 8.9, 2.5 Hz, CH-6), 4.55 (2H, t, J 4.5 Hz, CH2-1′′), 
4.04 (2H, t, J 4.5 Hz, CH2-2′′), 3.57 (2H, s, 3-CH2), 2.81 (3H, s, SOCH3) and 2.21 (3H, s, 2-
CH3); 13C NMR (100 MHz; CDCl3) δ 170.7 (quat., carboxyl), 163.2 (quat., d, J 248.1, C-5), 
158.4 (quat., C-3′′), 146.7 (quat., d, J 8.9, C-8), 145.5 (quat., C-4′), 142.3 (quat., C-1), 139.9 
(quat., C-1′), 138.2 (quat., C-2), 137.9 (quat., C-5′′), 135.7 (CH, C-8′′), 131.8 (quat., C-3), 130.3 
(CH × 2, C-3′,5′), 129.7 (CH × 2, C-7′′,9′′), 129.5 (quat., C-9), 128.2 (CH, C-α), 128.6 (CH × 2, 
C-2′′,6′′), 123.8 (CH × 2, C-3′,5′), 123.7 (CH, d, J 8.9, C-7), 110.8 (CH, d, J 22.5, C-6), 110.6 
(quat., C-4′′), 106.2 (CH, d, J 24.1, C-4), 72.8 (CH2, C-2′′), 60.4 (CH2, C-1′′), 43.9 (CH3, 
SOCH3), 31.6 (CH2, 3-CH2) and 10.5 (CH3, 2-CH3); 19F {1H} (376 MHz; CDCl3) δ -113.4 (CF); 
m/z (ES+) 647 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C30H25FN2NaO8S2 [M+Na]+ 
requires 647.0934, found 647.0929; CHN Anal. calcd. for C30H25FN2O8S2: C, 57.68; H, 4.03; 
N, 4.48. Found 57.85; H, 4.11; N, 4.51. 
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(Z)-4-(3-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 179 
 
 
Following general procedure A with sulindac 112 (60 mg, 0.17 mmol) and 4-(3-
hydroxypropoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 166 (50 mg, 0.17 mmol), 
purification by flash chromatography, eluting with dichloromethane, furnished (Z)-4-(3-(2-(5-
fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetoxy)propoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 179 (90 mg, 0.14 mmol, 85%) as a yellow solid:  
m.p. 104-106 °C; Rf 0.45 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax (thin 
film)/cm−1 3433, 2935, 1732, 1611, 1552, 1459, 1365, 1255, 1164, 1085; 1H NMR (500 MHz; 
CDCl3) δ 8.05 (2H, d, J 8.0 Hz, CH-7′′,11′′), 7.80-7.57 (7H, m, CH- 2′,3′,4′,5′,8′′,9′′, 10′′), 7.16 
(1H, s, CH-α), 7.14 (1H, dd, J 8.5, 5.1 Hz, CH-7), 6.83 (1H, dd, J 8.9, 2.4 Hz, CH-4), 6.54 (1H, 
ddd, J 8.9, 8.9, 2.4 Hz, CH-6), 4.40 (2H, t, J 6.0 Hz, CH2-1′′), 4.31 (2H, t, J 6.0 Hz, CH2-3′′), 
3.59 (2H, s, 3-CH2), 2.81 (3H, s, SOCH3) and 2.24-2.10 (5H, m, 2-CH3 and CH2-2′′); 13C NMR 
(100 MHz; CDCl3) δ 170.7 (quat., carboxyl), 163.0 (quat., d, J 246.9 Hz, C-5), 158.7 (quat., C-
4′′), 146.6 (quat., d, J 8.5 Hz, C-8), 145.6 (quat., C-4′), 141.5 (quat., C-1), 139.6 (quat., C-1′), 
138.3 (quat., C-2), 138.0 (quat., C-6′′), 135.7 (CH, C-9′′), 131.0 (quat., C-3), 130.3 (CH × 2, C-
2′,6′), 129.2 (CH, C-α), 129.7 (CH × 2, C-8′′,10′′), 129.5 (quat., C-9), 128.6 (CH × 2, C-7′′,11′′), 
123.9 (CH × 2, C-3′,5′), 123.8 (CH, d, J 8.6, C-7), 110.9 (CH, d, J 22.4 Hz, C-6), 110.4 (quat., 
C-5′′), 105.9 (CH, d, J 24.1 Hz, C-4), 67.7 (CH2, C-3′′), 60.8 (CH2, C-1′′), 43.9 (CH3, SOCH3), 
31.7 (CH2, 3-CH2), 27.8 (CH2, C-2′′) and 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) 
δ -113.5 (CF); m/z (ES+) 661 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C31H27FN2NaO8S2 
[M+Na]+ requires 661.1091, found 661.1087; CHN Anal. calcd. for C31H27FN2O8S2: C, 58.30; 
H, 4.26; N, 4.39. Found C, 58.51; H, 4.32; N, 4.45. 
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(Z)-4-(4-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)butoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 180 
 
 
 
Following general procedure A with sulindac 112 (50 mg, 0.14 mmol) and 4-(4-
hydroxybutoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 167 (50 mg, 0.15 mmol), 
purification by flash chromatography, eluting with dichloromethane and methanol (99.5:0.5), 
furnished (Z)-4-(4-(2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)butoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 180 (52 mg, 0.08 mmol, 57%) 
as a yellow solid: m.p. 80-82 °C; Rf  0.35 (95:5, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 2930, 1736, 1617, 1550, 1474, 1340, 1249, 1172, 
1085; 1H NMR (300 MHz; CDCl3) δ 8.04 (2H, d, J 8.1 Hz, CH-8′′,12′′), 7.70-7.57 (7H, m, CH-
2′,3′,5′,6′,9′′,10′,11′′), 7.17 (1H, s, CH-α), 7.16 (1H, dd, J 8.4, 5.1 Hz, CH-7), 6.90 (1H, dd, J 
8.9, 2.3 Hz, CH-4), 6.56 (1H, ddd, J 8.9, 8.9, 2.3 Hz, CH-6), 4.40 (2H, t, J 6.2 Hz, CH2-1′′), 
4.20 (2H, t, J 5.9 Hz, CH2-4′′), 3.60 (2H, s, 3-CH2), 2.81 (3H, s, SOCH3), 2.22 (3H, s, 2-CH3), 
2.05-1.96 (2H, m, CH2-2′′) and 1.87-1.76 (2H, m, CH2-3); 13C NMR (100 MHz; CDCl3) δ 170.4 
(quat., carboxyl), 163.6 (quat., d, J 245.0 Hz, C-5), 159.5 (quat., C-5′′), 146.5 (quat., d, J 8.9 Hz, 
C-8), 139.9 (quat., C-1), 141.0 (quat., C-4′), 139.2 (quat. × 2, C-7′′, C-1′), 138.4 (quat., C-2), 
135.6 (CH, C-10′′), 132.9 (quat., C-3), 129.9 (CH × 2, C-9′′,11′′), 129.0 (CH, C-α), 129.9 (CH × 
2, C-2′,6′), 129.7 (quat., C-9), 129.9 (CH × 2, C-8′′,12′′), 124.3 (CH × 2, C-3′,5′), 123.7 (CH, d, 
J 8.9, C-7), 112.8 (quat., C-6′′), 111.2 (CH, d, J 22.3 Hz, C-6), 106.5 (CH, d, J 23.1 Hz, C-4), 
71.3 (CH2, C-4′′), 64.6 (CH2, C-1′′), 44.3 (CH3, SOCH3), 32.2 (CH2, 3-CH2), 25.6 (CH2, C-3′′), 
25.4 (CH2, C-2′′) and 11.0 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -113.5, s (CF); 
m/z (ES+) 675 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C32H29FN2O8NaS2 [M+Na]+ 
requires 675.1247, found 675.1238. CHN Anal. calcd. for C32H29FN2O8S2: C, 58.88; H, 4.48; N, 
4.29. Found C, 58.95; H, 4.51; N, 4.30. 
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(Z)-4-((6-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 181 
 
 
Following general procedure A with sulindac 112 (52 mg, 0.15 mmol) and 4-((6-
hydroxyhexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 168 (50 mg, 0.15 mmol), 
purification by flash chromatography, eluting with dichloromethane and methanol (99:1), 
furnished (Z)-4-((6-(2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 181 (83 mg, 0.12 mmol, 
83%) as a yellow solid: m.p. 42-44 °C; Rf  0.40 (99:5, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 2926, 1734, 1614, 1552, 1464, 1447, 1356, 1260, 
1169, 1085; 1H NMR (400 MHz; CDCl3) δ, 8.05 (2H, d, J 8.5, CH-10′′,14′′), 7.76-7.72 (3H, m, 
CH-3′,5′, 12′′), 7.67 (2H, d, J 8.3 Hz, CH-2′,6′) 7.61 (2H, t, J 7.9 Hz, CH-11′′, 13′′), 7.17 (1H, s, 
CH-α), 7.16 (1H, dd, J 8.3, 5.2 Hz, CH-7), 6.90 (1H, dd, J 8.9, 2.4 Hz, CH-4), 6.56 (1H, ddd, J 
8.9, 8.9, 2.4 Hz, CH-6), 4.39 (2H, t, J 6.5 Hz, CH2-1′′), 4.14 (2H, t, J 6.5 Hz, CH2-6′′), 3.58 (2H, 
s, 3-CH2), 2.82 (3H, s, SOCH3), 2.22 (3H, s, 2-CH3), 1.87-1.80 (2H, m, CH2-2′′), 1.71-1.64 (2H, 
m, CH2-5′′) and 1.50-1.36 (4H, m, CH2 × 2, CH2-3′′, CH2-4′′); 13C NMR (100 MHz; CDCl3) δ 
170.5 (quat., carboxyl), 163.1 (quat., d, J 243.6 Hz, C-5), 159.0 (quat., C-7′′), 146.5 (quat., d, J 
8.4 Hz, C-8), 140.0 (quat., C-1), 139.2 (quat. × 2, C-2, C-4′), 138.4 (quat., C-1′), 138.1 (quat., 
C-9′′), 135.6 (CH, C-12′′), 132.9 (quat., C-3), 130.8 (CH, C-α), 129.9 (CH × 2, C-3′,5′), 129.8 
(quat., C-9), 129.6 (CH × 2, C-10′′,14′′), 128.5 (CH × 2, C-11′′,13′′), 125.9 (CH × 2, C-2′,6′), 
123.7 (CH, d, J 8.8 Hz, C-7), 110.5 (CH, d, J 22.6 Hz, C-6), 110.5 (quat., C-8′′), 105.8 (CH, d, J 
23.7 Hz, C-4), 71.4 (CH2, C-6′′), 64.8 (CH2, C-1′′), 32.0 (CH2, 3-CH2), 28.5 (CH2, C-5′′), 28.3 
(CH2, C-2′′), 25.5 (CH2, C-4′′), 25.2 (CH2, C-3′′), 15.4 (CH3, SCH3) and 10.6 (CH3, 3-CH3); 19F 
{1H} NMR (376 MHz; CDCl3) δ, -113.5 (CF); m/z (ES+) 703 ([M+Na]+, 100%); HRMS m/z 
(ES+) calcd. for C34H33FN2NaO8S2  [M+Na]+ requires 703.1560, found 703.1555; CHN Anal. 
calcd. for C34H33FN2O8S2: C, 59.99; H, 4.89; N, 4.12. Found C, 60.08; H, 5.00; N, 4.18. 
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(Z)-4-(2-(2-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 182 
 
 
Following general procedure A with sulindac 112 (51 mg, 0.16 mmol) and 4-(2-(3-
hydroxyethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 175 (50 mg, 0.15 mmol) 
purification by flash chromatography, eluting with dichloromethane and methanol (95:5), 
furnished, (Z)-4-(2-(2-(2-(5-fluoro-2-methyl-1-(4-(methyl-sulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)-ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 182 (36 mg, 0.10 mmol, 
38%) as a yellow solid: m.p. 56-58 °C; Rf 0.37 (95:5, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 2935, 1732, 1609, 1550, 1459, 1370, 1164; 1H NMR 
(300 MHz; CDCl3) δ 8.07-8.04 (2H, m, CH-8′′,12′′), 7.79-7.56 (7H, m, CH-2′,3′,5′,6′, 
9′′,10′′,11′′), 7.15 (1H, s, CH-α), 7.14 (1H, dd, J 8.4, 5.1 Hz, CH-7), 6.92 (1H, dd, J 9.0, J 2.4, 
CH-4), 6.54 (1H, ddd, J 9.0, 17.6, J 2.4, CH-6), 4.52-4.49 (2H, m, CH2-1′′), 4.33-4.30 (2H, m, 
CH2-4), 3.87-3.84 (2H, m, CH2-2′′), 3.80-3.77 (2H, m, CH2-3′′), 3.62 (2H, s, 3-CH2), 2.81 (3H, 
s, SOCH3) and 2.21 (3H, s, 2-CH3 ); 13C NMR (100 MHz; CDCl3) δ 170.2 (quat., carboxyl), 
163.4 (quat., d, J 244.5 Hz, C-5), 158.79 (quat., C-5′′), 146.7 (quat., d, J 8.8, C-8), 145.6 (quat., 
C-4′), 141.6 (quat., C-1), 139.6 (quat., C-1′), 138.4 (quat., C-2), 138.1 (quat., C-7′′), 135.6 (CH, 
C-10′′), 131.7 (quat., C-3), 130.3 (CH × 2, C-2′,6′), 129.7 (CH × 2, C-9′′,11′′), 129.3 (quat., C-
9), 128.6 (CH × 2, C-3′,5′), 128.4 (CH, C-α), 127.7 (CH × 2, C-8′′,12′′), 123.7 (CH, d, J 8.8, C-
7), 110.8 (CH, d, J 23.0 Hz, C-6), 110.5 (quat., C-6′′), 106.2 (CH, d, J 23.8 Hz, C-4), 70.5 (CH2, 
C-4′′), 69.4 (CH2, C-1′′), 68.3 (CH2, C-2′′), 64.0 (CH2, C-3′′), 43.9 (CH3, SOCH3), 31.7 (CH2, 3-
CH2) and 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -113.5 (CF); m/z (ES+) 691 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C32H29FN2NaO9S2, [M+Na]+ requires 691.1196, 
found 691.1200; CHN Anal. calcd. for C32H29FN2O9S2: C, 57.48; H, 4.37; N, 4.19. Found C, 
57.64; H, 4.40; N, 4.27. 
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4-(((Z)-4-(2-((Z)-5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)but-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 183 
 
 
Following general procedure A with sulindac 112 (57 mg, 0.17 mmol) and (Z)-4-((4-
hydroxybut-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 170 (50 mg, 0.17 
mmol), purification by flash chromatography, eluting with dichloromethane and methanol 
(99:1), furnished 4-(((Z)-4-(2-((Z)-5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-
inden-3-yl)acetoxy)but-2-en-1-yl)oxy)-3-(phenylsulf-onyl)-1,2,5-oxadiazole 2-oxide 183 (96 mg, 
0.15 mmol, 93%) as a yellow solid: m.p. 98-100 °C; Rf 0.36 (95:5 CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 3059, 2921, 1732, 1609, 1545, 1456, 1407, 1255, 
1159, 1083, 1046; 1H NMR (500 MHz; CDCl3) δ 8.05 (2H, d, J 8.2, CH-8′′,12′′), 7.78-7.57 
(7H, m CH-2′,3′,5′,6′,9′′,10′′,11′′), 7.15 (1H, s, CH-α), 7.15 (1H, dd, J 8.4, 5.1, CH-7), 6.87 (1H, 
dd, J 8.9, 2.4 Hz, CH-6), 6.56 (1H, ddd, J 8.9, 8.9, 2.5 Hz, CH-4), 5.92-5.88 (2H, m, CH-2′′,3′′), 
5.01 (2H, d, J 5.1 Hz, 3-CH2), 4.76 (2H, d, J 5.2 Hz, CH2-4), 3.60 (2H, s, 3-CH2), 2.81 (3H, s, 
SOCH3) and 2.21 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.9 (quat., carboxyl), 163.4 
(quat., d, J 245.8 Hz, C-5), 158.5 (quat., C-5′′), 146.6 (quat., d, J 8.8, C-8), 145.6 (quat., C-4′), 
141.6 (quat., C-1), 139.6 (quat., C-1′), 138.4 (quat., C-2), 138.0 (quat., C-7′′), 135.7 (CH, C-
10′′), 131.5 (quat., C-3), 130.3 (CH × 2, C-3′,5′), 130.0 (CH, C-3′′), 129.5 (quat., C-9), 129.7 
(CH × 2, C-9′′,11′′), 128.6 (CH × 2, C-8′′,12′′), 128.5 (CH, C-α), 126.2 (CH, C-2′′), 123.9 (CH × 
2, C-2′,6′), 123.8 (CH, d, J 9.8 Hz, C-7), 112.0 (quat., C-6′′), 110.9 (CH, d, J 22.9 Hz, C-6), 
106.1 (CH, d, J 23.8 Hz, C-4), 66.5 (CH2, C-4′′), 60.6 (C-1′′), 43.9 (CH3, SOCH3), 31.7 (CH2, 3-
CH2) and 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -112.8 (CF); m/z (ES+) 673 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C32H27FN2NaO8S2 [M+Na]+ requires 673.1091, 
found 673.1089; CHN Anal. calcd. for C32H27FN2O8S2: C, 59.07; H, 4.18; N, 4.31. Found C, 
59.20; H, 4.28; N, 4.36. 
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(Z)-4-((4-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)but-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 184 
 
 
Following general procedure A with sulindac 112 (57 mg, 0.17 mmol) and 4-((4-hydroxybut-2-
yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 169 (50 mg, 0.17 mmol), purification 
by flash chromatography, eluting with dichloromethane and methanol (99:1), furnished (Z)-4-
((4-(2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetoxy)but-2-yn-1-
yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 184 (71 mg, 0.11 mmol, 68%) as a yellow 
solid: m.p. 89-90 °C; Rf 0.29 (95:5 CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax (thin 
film)/cm−1 2926, 1732, 1614, 1552, 1469, 1452, 1359, 1255, 1155, 1080; 1H NMR (400 MHz; 
CDCl3) δ, 8.07 (2H, d, J 8.3 Hz, CH-8′′,12′′), 7.80-7.60 (7H, m, CH-2′,3′,5′,6′,9′′, 10′′,11′′), 7.18 
(1H, s, CH-α), 7.16 (1H, dd, J 5.2, 8.4 Hz, CH-7), 6.89 (1H, dd, J 8.9, 2.3 Hz, CH-6), 6.57 (1H, 
ddd, J 9.0, 8.9, 2.3, CH-4), 5.10 (2H, t, J 1.7 Hz, CH2-1′′), 4.78 (2H, t, J 1.7 Hz, CH2-4), 3.63 
(2H, s, 3-CH2), 2.82 (3H, s, SOCH3) and 2.22 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ, 
169.4 (quat., carboxyl), 163.4 (quat., d, J 246.5 Hz, C-5), 158.3 (quat., C-5′′), 146.6 (quat., d, J 
7.8 Hz, C-8), 145.6 (quat., C-4′), 141.5 (quat., C-1), 139.9 (quat., C-1′), 138.6 (quat., C-2), 
137.8 (quat., C-7′′), 135.7 (CH, C-10′′), 131.1 (quat., C-3), 130.3 (CH × 2, C-3′,5′), 129.7 (CH × 
2, C-8′′,12′′), 129.5 (quat., C-9), 128.7 (CH × 2, C-9′′,11′′), 128.6 (CH, C-α), 123.9 (CH × 2, C-
2′,6′), 123.7 (CH, d, J 9.4 Hz, C-7), 110.9 (CH, d, J 22.7 Hz, C-6), 110.6 (quat., C-6′′), 106.1 
(CH, d, J 24.0 Hz, C-4),  83.7 (quat., C-3′′), 78.9 (quat., C-2′′), 60.4 (CH2, C-4′′), 58.6 (CH2, C-
1′′), 44.0 (CH3, SOCH3), 31.5 (CH2, 3-CH2) and 10.6 (CH3, 3-CH3); 19F {1H} NMR (376 MHz; 
CDCl3) δ -113.4 (CF); m/z (ES+) 671 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C32H25FN2NaO8S2 [M+Na]+ requires 671.0934, found 671.0926; CHN Anal. calcd. for 
C32H25FN2O8S2: C, 59.25; H, 3.88; N, 4.32. Found C, 59.30; H, 4.00; N, 4.29. 
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(Z)-4-(3-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 186 
 
 
Following general procedure A with sulindac 112 (53 mg, 0.15 mmol) and 4-(3-
hydroxyphenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 172 (50 mg, 0.15 mmol), 
purification by flash chromatography, eluting with dichloromethane and methanol (99.5:0.5), 
furnished (Z)-4-(3-(2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene) 
-1H-inden-3-yl)acetoxy)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 186 (54 mg, 0.08 
mmol, 54%) as a yellow solid: m.p. 58-60 °C; Rf 0.42 (95:5, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 2921, 2305, 1754, 1616, 1530, 1437, 1260, 1169; 1H 
NMR (500 MHz; CDCl3) δ 8.07 (2H, d, J 8.0, CH-10′′,14′′), 7.77 (1H, t, J 7.3, CH-12′′), 7.74 
(2H, d, J 8.2 Hz, CH-3′,5′), 7.69 (2H, d, J 8.2, CH-2′,6′), 7.64 (2H, t, J 7.8 Hz, CH-11′′, 13′′), 
7.43 (1H, t, J 8.3 Hz, ArCH), 7.22-7.18 (3H, m, ArCH × 3), 7.13 (1H, t, J 2.0 Hz, CH-α), 7.06 
(1H, dd, J 8.3, 2.0 Hz, CH-7) 6.97 (1H, dd, J 8.6, 2.0 Hz, CH-6), 6.60 (1H, ddd, J 9.0, 8.9, 2.0 
Hz, CH-4), 3.81 (2H, s, 3-CH2), 3.8 (3H, s, SOCH3) and 2.29 (3H, s, 2-CH3), 13C NMR (100 
MHz; CDCl3) δ 168.1 (quat., carboxyl), 163.4 (quat., d, J 249.8 Hz, C-5), 157.9 (quat., C-7′′), 
152.7 (quat., C-3′′), 151.4 (quat., C-1′′), 146.3 (quat., d, J 8.7 Hz, C-8), 145.6 (quat., C-4′), 
141.5 (quat., C-1), 139.5 (quat., C-1′), 138.9 (quat., C-2),  137.8 (quat., C-9′′), 135.9 (CH, C-
12′′), 130.7 (CH, C-5′′), 130.4 (CH × 2, C-2′,6′), 130.3 (quat., C-3), 130.2 (CH × 2, C-11′′,13′′), 
129.8 (CH × 2, C-10, C-14′′), 129.5 (quat., C-9), 128.8 (CH, C-α), 123.9 (CH × 2, C-3′,5′), 
123.8 (CH, C-7), 119.4 (CH, C-4′′), 117.3 (CH, C-6′′), 113.7 (CH2, C-2′′),  111.1 (CH, d, J 22.9 
Hz, C-6), 110.6 (quat., C-8′′), 106.0 (CH, d, J 24.0 Hz, C-4), 43.9 (CH3, SOCH3), 31.9 (CH2, 3-
CH2) and 10.7 (CH3, 2-CH3), 19F {1H} NMR (376 MHz; CDCl3) δ -112.7 (CF); m/z (ES+) 695 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C34H25FN2NaO8S2 [M+Na]+ requires 695.0934, 
found 695.0927; CHN Anal. calcd. for C32H25FN2O9S2: C, 60.71; H, 3.75; N, 4.16. Found C, 
60.82; H, 3.88; N, 4.26. 
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(Z)-4-(3-((2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetoxy)methyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 185 
 
 
Following general procedure A with sulindac 112 (53 mg, 0.15 mmol), 4-(3-
(hydroxymethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 171 (50 mg, 0.15 
mmol) purification by flash chromatography, eluting with dichloromethane and methanol 
(99.5:0.5), furnished (Z)-4-(3-((2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-
inden-3-yl)acetoxy)methyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 185 (67 mg, 
0.10 mmol, 68%) as a yellow solid. m.p. 86-84 °C; Rf 0.50 (95:5 CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); ); νmax (thin film)/cm−1 2921, 1734, 1614, 1533, 1491, 1447, 1257, 1164, 
1048; 1H NMR (400 MHz; CDCl3) δ 8.10 (2H, d, J 8.5 Hz, CH-10′′,14′′), 7.80 (1H, tt, J 8.5, 1.2 
Hz, CH-12′′), 7.73 (2H, d, J 8.5 Hz, CH-3′,5′), 7.68-7.63 (4H, m, ArCH × 4), 7.42 (1H, t, J 7.9, 
ArCH), 7.28-7.24 (3H, m, ArCH × 3), 7.17 (1H, s, CH-α), 7.16 (1H, dd, J 8.4, 5.3, CH-7), 6.86 
(1H, dd, J 8.9, 2.5, CH-6), 6.54 (1H, ddd, J 9.0, 8.9, 2.5 Hz, CH-4), 5.18 (2H, s, CH2-α′), 3.64 
(2H, s, 3-CH2), 2.82 (3H, s, SOCH3) and 2.21 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 
169.9 (quat., carboxyl), 163.4 (quat., d, J 247.9 Hz, C-5), 158.3 (quat., C-7′′), 152.3 (quat., C-
3′′), 146.6 (quat., d, J 8.4 Hz, C-8), 145.5 (quat., C-4′), 141.5 (quat., C-1), 139.2 (quat., C-2), 
138.5 (quat., C-1′′), 138.2 (quat., C-1′), 137.9 (quat., C-9′′), 135.9 (CH, C-12′′), 131.4 (quat., C-
3), 130.3 (CH × 2, C-3′,5′), 130.2 (CH, C-5′′), 129.8 (CH × 2, C-10′′,14′′), 129.5 (quat., C-9), 
128.5 (CH, C-α), 128.7 (CH × 2, C-11′′,13′′), 126.2 (CH, C-6′′), 123.9 (CH × 2, C-2′,6′), 123.7 
(CH, d, J 9.4 Hz, C-7), 119.6 (CH, C-2′′), 119.4 (C-4′′), 110.8 (CH, d, J 22.5 Hz, C-6), 110.7 
(quat., C-8′′), 106.1 (CH, d, J 24.0 Hz, C-4), 65.8 (CH2, C-α′), 43.9 (CH3, SOCH3), 31.8 (CH2, 
3-CH2) and 10.6 (CH3, 3-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -113.4 (CF); m/z (ES+) 709 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C35H27FN2NaO8S2  [M+Na]+ requires 709.1091, 
found 709.1084; CHN Anal. calcd. for C35H27FN2O8S2: C, 61.21; H, 3.96; N, 4.08; Found C, 
61.35; H, 4.07; N, 4.15. 
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(Z)-4-(2-(2-(5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 187 
 
 
 
 
Following general procedure A with sulindac sulfide 115 (60 mg, 0.18 mmol) and 4-(2-
hydroxyethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 174 (50 mg, 0.18 mmol), 
purification by flash chromatography, eluting with dichloromethane, furnished (Z)-4-(2-(2-(5-
fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetoxy)ethoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 187 (39 mg, 0.08 mmol, 46%) as a yellow solid: m.p. 
115-118 °C; Rf 0.47 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax (thin 
film)/cm−1 2921, 1741, 1614, 1545, 1449, 1360, 1262, 1162, 1147, 825; 1H NMR (400 MHz; 
CDCl3) δ 8.05 (2H, d, J 8.2 Hz, CH-6′′,10′′), 7.73 (1H, tt, 2H, d, J 8.2, 6.8 Hz, CH-8′′), 7.57 
(2H, t, J 8.2 Hz, CH-7′′,9′′), 7.44 (2H, d, J 8.2 Hz, CH-3′,5′), 7.38 (1H, dd, J 8.3, 5.2 Hz, CH-7), 
7.29 (2H, d, J 8.2 Hz, CH-2′,6′), 7.17 (1H, s, CH-α), 6.87 (1H, dd, J 8.9, 2.4 Hz, CH-4), 6.58 
(1H, ddd, J 9.0, 8.9, 2.4 Hz, CH-6), 4.66-4.62 (2H, m, CH2-1′′), 4.56-4.52 (2H, m, CH2-2′′), 
3.66 (2H, s, 3-CH2), 2.56 (3H, s, SCH3) and 2.22 (3H, s, 2-CH3), 13C NMR (100 MHz; CDCl3) 
δ 170.1 (quat., carboxyl), 163.1 (quat., d, J 245.0, C-5), 158.7 (quat., C-3′′), 146.3 (quat., d, J 
8.5, C-8), 140.0 (quat., C-1), 139.2 (quat. × 2, C-2, C-4′), 139.8 (quat., C-1′), 138.0 (quat., C-
5′′), 135.6 (CH, C-8′′), 132.9 (quat., C-3), 130.3 (CH, C-α), 129.9 (CH × 2, C-2′,6′), 129.6 (CH 
× 2, C-7′′,9′′), 129.9 (quat., C-9), 128.7 (CH × 2, C-6′′,10′′), 125.9 (CH × 2, C-3′,5′), 123.8 (CH, 
d, J 9.0, C-7), 110.7 (CH, d, J 22.5, C-6), 110.5 (quat., C-4′′), 105.6 (CH, d, J 23.7, C-4), 68.8 
(CH2, C-2′′), 61.7 (CH2, C-1′′), 31.5 (CH2, 3-CH2), 15.4 (CH3, SCH3) and 10.6 (CH3, 2-CH3), 
19F {1H} (376 MHz; CDCl3) δ -114.3 (CF); m/z (ES+) 631 ([M+Na]+, 100%); HRMS m/z (ES+) 
calcd. for C30H25FN2NaO7S2, [M+Na]+ requires 631.0985, found 631.0980; CHN Anal. calcd. 
for C30H25FN2O7S2: C, 59.20; H, 4.14; N, 4.60. Found C, 59.30; H, 4.16; N, 4.65. 
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(Z)-4-(3-(2-(5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 188 
 
 
Following general procedure A with sulindac sulfide 115 (56 mg, 0.17 mmol) and 4-(3-
hydroxypropoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 166 (50 mg, 0.17 mmol), 
purification by flash chromatography, eluting with dichloromethane, furnished (Z)-4-(3-(2-(5-
fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetoxy)-propoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 188 (47 mg, 0.08 mmol, 46%) as a yellow solid: m.p. 
99-100 °C; Rf 0.93 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); H NMR (500 MHz; 
CDCl3) δ 8.04 (2H, d, J 8.3 Hz, CH-7′′,11′′), 7.73 (1H, tt, J 6.6, 1.6 Hz, CH-9′′), 7.62-7.57 (2H, 
m, CH-8′′,10′′), 7.43 (2H, d, J 8.2 Hz, CH-3′,5′), 7.36 (1H, dd, J 8.2, 2.4 Hz, CH-7), 7.29 (2H, 
d, J 8.2 Hz, CH-2′,6′), 7.14 (1H, s, CH-α), 6.82 (1H, dd, J 9.0, 2.4 Hz, CH-4), 6.56 (1H, ddd, J 
9.0, 8.9, 2.4 Hz, CH-6), 4.39 (2H, t, J 6.1 Hz, CH2-1′′), 4.30 (2H, t, J 6.1 Hz, CH2-3′′), 3.59 (2H, 
s, 3-CH2), 2.55 (3H, s, SCH3) and 2.23-2.15 (5H, m, 2-CH3 and CH2-2′′); 13C NMR (100 MHz; 
CDCl3) δ 170.2 (quat., carboxyl), 163.0 (quat., d, J 244.7 Hz, C-5), 158.7 (quat., C-4′′), 146.3 
(quat., d, J 8.6 Hz, C-8), 139.9 (quat., C-1), 139.3 (quat. × 2, C-2′, C-4′), 138.5 (quat., C-1′), 
138.0 (quat., C-6′′), 135.7 (CH, C-9′′), 132.9 (quat., C-3), 130.2 (CH × 2, C-3′,5′), 130.5 (CH, 
C-α), 129.9 (CH × 2, C-2′,6′), 129.7 (CH × 2, C-8′′,10′′), 129.3 (quat., C-9), 128.5 (CH × 2, C-
7′′,11′′), 123.8 (CH, d, J 9.0, C-7), 110.6 (CH, d, J 22.6 Hz, C-6), 110.4 (quat., C-5′′), 105.6 
(CH, d, J 23.8 Hz, C-4), 67.7 (CH2, C-3′′), 60.7 (CH2, C-1′′), 31.8 (CH2, 3-CH2), 27.8 (CH2, C-
2′′), 15.4 (CH3, SCH3) and 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -114.4 
(CF); m/z (ES+) 645 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C31H27FN2NaO7S2 [M+Na]+ 
requires 645.1141, found 645.1143; CHN Anal. calcd. for C31H27FN2O7S2: C, 59.79; H, 4.37; 
N, 4.50. Found C, 59.84; H, 4.41; N, 4.61. 
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(Z)-4-(4-(2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)butoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 189 
 
 
Following general procedure A with sulindac sulfide 115 (50 mg, 0.15 mmol) and 4-(4-
hydroxybutoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 167 (50 mg, 0.15 mmol), 
purification by flash chromatography, eluting with dichloromethane and methanol (99.5:0.5), 
furnished (Z)-4-(4-(2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)butoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 189 (30 mg, 0.05 mmol, 32%) 
as a yellow solid: m.p. 68-70 °C; Rf 0.88 (95:5, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 2600, 1738, 1605, 1555, 1498, 1450, 1362, 1250, 
1165, 1110; 1H NMR (500 MHz; CDCl3) δ 8.04 (2H, d, J 8.2 Hz, CH-8′′,12′′), 7.73 (1H, t, J 7.5 
Hz, CH-10′′), 7.59 (2H, t, J 7.5 Hz, CH-9′′,11′′), 7.44 (2H, d, J 8.2 Hz, CH-3′,5′), 7.37 (1H, dd, 
J 8.5, 5.3 Hz, CH-7), 7.27 (2H, t, J 8.3 Hz, CH-2′,6′), 7.15 (1H, s, CH-α), 6.90 (1H, dd, J 9.0, 
2.3 Hz, CH-4), 6.58 (1H, ddd, J 9.0, 9.0, 2.3 Hz, CH-6), 4.39 (2H, t, J 6.0 Hz, CH2-1′′), 4.20 
(2H, t, J 6.2 Hz, CH2-4′′), 3.59 (2H, s, 3-CH2), 2.55 (3H, s, SCH3), 2.22 (3H, s, 2-CH3), 1.93-
1.87 (2H, m, CH2-2) and 1.84-1.78 (2H, m, CH2-3); 13C NMR (100 MHz; CDCl3) δ 170.4 
(quat., carboxyl), 163.7 (quat., d, J 245.1 Hz, C-5), 158.9 (quat., C-5′′), 146.5 (quat., d, J 8.8 Hz, 
C-8), 139.9 (quat., C-1), 139.2 (quat., C-4′), 138.5 (quat., C-7′′), 138.0 (CH, C-10′′), 135.6 
(quat., C-2), 132.8 (quat., C-3), 130.6 (quat., C-1′), 130.1 (CH, C-α), 130.0 (CH × 2, C-9′′,11′′), 
129.9 (CH × 2, C-2′, C-5′), 129.7 (CH × 2, C-8′′,12′′), 128.5 (quat., C-9), 125.9 (CH × 2, C-
3′,5′), 123.7 (CH, d, J 8.9, C-7), 112.0 (quat., C-6′′), 110.6 (CH, d, J 22.3 Hz, C-6), 105.7 (CH, 
d, J 23.7 Hz, C-4), 70.9 (CH2, C-4′′), 64.2 (CH2, C-1′′), 31.9 (CH2, 3-CH2), 25.1 (CH2, C-3′′), 
25.0 (CH2, C-2′′), 15.4 (CH3, SCH3) and 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) 
δ -113.9 (CF); m/z (ES+) 658 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C32H29 FN2O7NaS2 
[M+Na]+ requires 659.1298, found 659.1302; CHN Anal. calcd. for C32H29FN2O8S2: C, 60.36; 
H, 4.59; N, 4.40. Found C, 60.42; H, 4.65; N, 4.48. 
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(Z)-4-((6-(2-(5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 190 
 
 
Following general procedure A with sulindac sulfide 115 (50 mg, 0.15 mmol) and 4-((6-
hydroxyhexyl)oxy)-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 168 (50 mg, 0.15 mmol), 
purification by flash chromatography, eluting with dichloromethane furnished (Z)-4-((6-(2-(5-
fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetoxy)-hexyl)oxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 190 (79 mg, 0.12 mmol, 80%) as a yellow solid: m.p. 
67-77 °C; Rf 0.40 (CH2Cl2, UV/cerium phosphomolybdate); νmax (thin film)/cm−1 2616, 1732, 
1611, 1550, 1488, 1456, 1356, 1257, 1169; 1H NMR (400 MHz; CDCl3) δ, 8.05 (2H, d, J 8.5 
Hz, CH-10′′,14′′), 7.73 (1H, tt, J 7.5, 1.7, CH-12′′), 7.60 (2H, t, J 7.5 Hz, CH-11′′,13′′), 7.44 
(2H, d, J 8.1 Hz, CH-3′,5′), 7.38 (1H, dd, J 8.4, 5.3 Hz, CH-7), 7.29 (2H, d, J 8.4 Hz, CH-2′,6′), 
7.15 (1H, s, CH-α), 6.91 (1H, dd, J 9.0, 2.5 Hz, CH-4), 6.59 (1H, ddd, J 9.0, 8.9, 2.5 Hz, CH-6), 
4.38 (2H, t, J 6.5 Hz, CH2-1′′), 4.14 (2H, t, J 6.5 Hz, CH2-6′′), 3.58 (2H, s, 3-CH2), 2.55 (3H, s, 
SCH3), 2.22 (3H, s, 2-CH3), 1.86-1.79 (2H, m, CH2-2′′), 1.70-1.63 (2H, m, CH2-5′′) and 1.49-
1.34 (4H, m, CH2 × 2, CH2-3′′, CH2-4′′); 13C NMR (100 MHz; CDCl3) δ 170.3 (quat., 
carboxyl), 163.3 (quat., d, J 246.6 Hz, C-5), 159.0 (quat., C-7′′), 146.8 (quat., d, J 8.6 Hz, C-8), 
145.4 (quat., C-4′), 141.6 (quat., C-1), 139.7 (quat., C-1′), 138.2 (quat., C-2), 138.1 (quat., C-
9′′), 135.6 (CH, C-12′′), 131.9 (quat., C-3), 130.3 (CH × 2, C-2′,6′), 129.7 (CH × 2, C-10′′,14′′), 
129.5 (quat., C-9), 128.5 (CH × 2, C-11′′,13′′), 128.3 (CH, C-α), 125.9 (CH × 2, C-3′,5′), 123.7 
(CH, d, J 9.0 Hz, C-7), 110.8 (CH, d, J 23.0 Hz, C-6), 110.5 (quat., C-8′′), 106.2 (CH, d, J 23.8 
Hz, C-4), 71.4 (CH2, C-6′′), 64.9 (CH2, C-1′′), 43.9 (CH3, SOCH3), 31.9 (CH2, 3-CH2), 28.4 
(CH2, C-5′′), 28.3 (CH2, C-2′′), 25.5 (CH2, C-4′′), 25.2 (CH2, C-3′′) and 10.6 (CH3, 3-CH3); 19F 
{1H} NMR (376 MHz; CDCl3) δ -114.4 (CF); m/z (ES+) 687 ([M+Na]+, 100%); HRMS m/z 
(ES+) calcd. for C34H33FN2NaO7S2 [M+Na]+ requires 687.1611, found 687.1615; CHN Anal. 
calcd. for C34H33FN2O7S2: C, 61.43; H, 5.00; N, 4.21. Found C, 61.51; H, 5.11; N, 4.24. 
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(Z)-4-(2-(2-(2-(5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 191 
 
 
Following general procedure A with sulindac sulfide 115 (50 mg, 0.15 mmol) and 4-(2-(3-
hydroxyethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 175 (50 mg, 0.15 mmol), 
purification by flash chromatography, eluting with dichloromethane, furnished (Z)-4-(2-(2-(2-
(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetoxy)ethoxy)ethoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 191 (41 mg , 0.06 mmol, 41%) as a yellow solid: 
m.p. 50-53 °C; Rf  0.83 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax (thin 
film)/cm−1 2931, 1729, 1609, 1550, 1491, 1449, 1638, 1260, 1088; 1H NMR (300 MHz; CDCl3) 
δ 8.05 (2H, d, J 8.2 Hz, CH-8′′,12′′), 7.72 (1H, tt, J 7.6, 1.1 Hz, CH-10′′), 7.58 (2H, t, J 7.7 Hz, 
CH-9′′,11′′), 7.42 (2H, d, J 8.1 Hz, CH-3′,5′), 7.35 (1H, dd, J 8.4, 5.3 Hz, CH-7), 7.28 (2H, d, J 
8.1 Hz, CH-2′,6′), 7.14 (1H, s, CH-α), 6.91 (1H, dd, J 9.0, 2.4 Hz, CH-4), 6.56 (1H, ddd, J 9.0, 
8.8, 2.4, CH-6), 4.50-4.48 (2H, m, CH2-1′′), 4.32-4.30 (2H, m, CH2-4′′), 3.84-3.82 (2H, m, 
CH2-2′′), 3.79-3.76 (2H, m, CH2-3), 3.61 (2H, s, 3-CH2), 2.55 (3H, s, SCH3) and 2.20 (3H, s, 2-
CH3); 13C NMR (100 MHz; CDCl3) δ 170.4 (quat., carboxyl), 163.1 (quat., d, J 249.0 Hz, C-5), 
158.9 (quat., C-5′′), 146.5 (quat., d, J 9.3 Hz, C-8), 140.0 (quat., C-1), 139.2 (quat. × 2, C-2, C-
4′), 138.6 (quat., C-1′), 138.1 (quat., C-7′′), 135.6 (CH, C-10′′), 132.9 (quat., C-3), 130.0 (quat., 
C-9), 129.9 (CH × 2, C-2′,6′), 129.6 (CH × 2, C-9′′,11′′), 128.6 (CH × 2, C-8′′,12′′), 128.4 (CH, 
C-α), 125.9 (CH × 2, C-3′,5′), 123.7 (CH, d, J 8.7, C-7), 110.6 (CH, d, J 23.4 Hz, C-6), 110.5 
(quat., C-6′′), 105.9 (CH, d, J 23.9 Hz, C-4), 70.5 (CH2, C-4′′), 69.4 (CH2, C-2′′), 68.4 (CH2, C-
5′′), 64.0 (CH2, C-1′′), 15.4 (CH3, SCH3), 31.8 (CH2, 3-CH2) and 10.6 (CH3, 2-CH3); 19F {1H} 
NMR (376 MHz; CDCl3) δ -114.2 (CF); m/z (ES+) 675 ([M+Na]+, 100%); HRMS m/z (ES+) 
calcd. for C32H29FN2NaO8S2 [M+Na]+ requires 675.1247, found 675.1239; CHN Anal. calcd. 
for C32H29FN2O8S2: C, 58.88; H, 4.48; N, 4.29. Found C, 58.98; H, 4.52; N, 4.33. 
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4-(((Z)-4-(2-((Z)-5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)but-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 192 
 
 
Following general procedure A with sulindac sulfide 115 (60 mg, 0.17 mmol) and (Z)-4-((4-
hydroxybut-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 170 (50 mg, 0.17 
mmol), purification by flash chromatography, eluting with dichloromethane and hexane (90:10), 
furnished 4-(((Z)-4-(2-((Z)-5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)but-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 192 (56 mg, 0.09 
mmol, 55%) as a yellow solid m.p. 84-86 °C; Rf 0.92 (95:5, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 2921, 1732, 1606, 1545, 1491, 1449, 1309; 1H NMR 
(500 MHz; CDCl3) δ 8.05 (2H, d, J 8.3 Hz, CH-8′′,12′′), 7.73 (1H, tt, J 7.5, 1.3 Hz, CH-10′′), 
7.60 (2H, t, J 8.1 Hz, CH-9′′,11′′), 7.44 (2H, d, J 8.2 Hz, CH-3′,5′), 7.36 (1H, dd, J 8.4, 5.3, CH-
7), 7.28 (2H, d, J 8.4 Hz, CH-2′,6′), 7.15 (1H, s, CH-α), 6.86 (1H, dd, J 9.0, 2.4 Hz, CH-6), 6.58 
(1H, ddd, J 9.0, 8.9, 2.4 Hz, CH-4), 5.94-5.83 (2H, m, CH-2′′, 3′′), 5.01 (2H, d, J 5.0 Hz, CH2-
1′′), 4.75 (2H, d, J 5.1 Hz, CH2-4′′), 3.59 (2H, s, 3-CH2), 2.55 (3H, s, SCH3) and 2.20 (3H, s, 2-
CH3); 13C NMR (100 MHz; CDCl3) δ 170.1 (quat., carboxyl), 163.1 (quat., d, J 244.6 Hz, C-5), 
158.5 (quat., C-5′′), 146.3 (quat., d, J 8.8 Hz, C-8), 139.9 (quat., C-1), 139.2 (quat. × 2, C-2, C-
4′), 138.7 (quat., C-1′), 138.0 (quat., C-7′′), 135.7 (CH, C-10′′), 132.9 (quat., C-3), 130.2 (CH × 
2, C-2′,6′), 130.4 (CH, C-α), 129.8 (CH × 2, C-9′′,11′′), 129.7 (CH, C-3′′), 129.7 (quat., C-9), 
128.6 (CH × 2, C-8′′,12′′), 126.1 (CH, C-2′′), 125.9 (CH × 2, C-3′,5′), 123.8 (CH, d, J 8.8 Hz, C-
7), 110.6 (CH, d, J 22.3 Hz, C-6), 110.5 (quat., C-6′′), 105.7 (CH, d, J 24.1 Hz, C-4), 66.6 (CH2, 
C-4′′), 60.5 (C-1′′), 31.7 (CH2, 3-CH2), 15.4 (CH3, SCH3) and 10.6 (CH3, 2-CH3); 19F {1H} 
NMR (376 MHz; CDCl3) δ -114.3 (CF); m/z (ES+) 657 ([M+Na]+, 100%); HRMS m/z (ES+) 
calcd. for C32H27FN2NaO7S2, [M+Na]+ requires 657.1141, found 657.1135; CHN Anal. calcd. 
for C32H27FN2O7S2: C, 60.56; H, 4.29; N, 4.41. Found C, 60.70; H, 4.40; N, 4.51. 
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(Z)-4-((4-(2-(5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)but-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 193 
 
 
Following general procedure A with sulindac sulfide 115 (60 mg, 0.17 mmol), 4-((4-
hydroxybut-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 169 (50 mg, 0.17 
mmol), purification by flash chromatography, eluting with dichloromethane, furnished (Z)-4-
((4-(2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetoxy)but-2-yn-1-
yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 193 (57 mg, 0.09 mmol, 56%) as a yellow 
solid: m.p. 79-80 °C; Rf 0.94 (95:5 CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax (thin 
film)/cm−1 2911, 1739, 1611, 1545, 1488, 1454, 1360, 1260, 1169, 822; 1H NMR (400 MHz; 
CDCl3) δ 8.07 (2H, d, J 8.5 Hz, CH-8′′,12′′), 7.75 (1H, tt, J 7.5, 1.1 Hz, CH-10′′), 7.62 (2H, t, J 
7.5 Hz, CH-9′′,11′′), 7.45 (2H, d, J 8.3 Hz, CH-3′,5′), 7.38 (1H, dd, J 8.4, 5.2 Hz, CH-7), 7.30 
(2H, d, J 8.4 Hz, CH-2′,6′), 7.17 (1H, s, CH-α), 6.89 (1H, dd, J 9.0, 2.4 Hz, CH-6), 6.59 (1H, 
ddd, J 9.0, 9.0, 2.4 Hz, CH-4), 5.10 (2H, t, J 1.6 Hz, CH2-1′′), 4.78 (2H, t, J 1.6 Hz, CH2-4), 
3.63 (2H, s, 3-CH2), 2.55 (3H, s, SCH3) and 2.22 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) 
δ, 169.6 (quat., carboxyl), 163.1 (quat., d, J 246.0 Hz, C-5), 157.9 (quat., C-5′′), 146.6 (quat., d, 
J 8.7 Hz, C-8), 139.9 (quat., C-1), 139.3 (quat., C-4′), 138.9 (quat., C-1′), 139.3 (quat., C-2), 
137.8 (quat., C-7′′), 135.7 (CH, C-10′′), 132.0 (quat., C-3), 130.3 (CH, C-α), 129.9 (CH × 2, C-
2′,6′), 129.8 (quat., C-9), 129.7 (CH × 2, C-8′′,12′′), 128.6 (CH × 2, C-3′′′, C-5′′′), 125.9 (CH × 
2, C-3′,5′), 123.7 (CH, d, J 9.0 Hz, C-7), 110.7 (CH, d, J 22.6 Hz, C-6), 110.6 (quat., C-6′′), 
105.7 (CH, d, J 24.1 Hz, C-4), 83.8 (quat., C-3′′), 78.8 (quat., C-2′′), 58.6 (CH2, C-4′′), 52.4 
(CH2, C-1′′), , 31.5 (CH2, 3-CH2), 15.4 (CH3, SCH3) and 10.6 (CH3, 3-CH3); 19F {1H} NMR 
(376 MHz; CDCl3) δ, -114.3 (CF); m/z (ES+) 655 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. 
for C32H25FN2NaO7S2 [M+Na]+ requires 655.0985, found 655.0980; CHN Anal. calcd. for 
C32H25FN2O7S2: C, 60.75; H, 3.98; N, 4.43. Found C, 60.84; H, 4.06; N, 4.50. 
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(Z)-4-(3-(2-(5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 195 
 
 
Following general procedure A with sulindac sulfide 115 (51 mg, 0.15 mmol), 4-(3-
hydroxyphenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 172 (50 mg, 0.15 mmol), 
purification by flash chromatography, eluting with dichloromethane and hexane (90:10), 
furnished (Z)-4-(3-(2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 195 (48 mg, 0.07 mmol, 49%) 
as a yellow solid: m.p. 59-61 °C; Rf 0.71 (CH2Cl2, UV/cerium phosphomolybdate); νmax (thin 
film)/cm−1 2070, 1750, 1620, 1530, 1490, 1395, 1156, 1120; 1H NMR (300 MHz; CDCl3) δ 
8.06 (2H, d, J 8.4 Hz, CH-10′′,14′′), 7.76 (1H, tt, J 7.3, 1.3 Hz, CH-12′′), 7.62 (2H, t, J 8.0 Hz, 
CH-11′′,13′′), 7.46 (2H, d, J 8.0 Hz, CH-3′,5′), 7.43-7.38 (2H, m, ArCH × 2), 7.30 (2H, d, J 8.4 
Hz, CH-2′,6′), 7.21-7.18 (2H, m, ArCH × 2), 7.11 (1H, t, J 2.3 Hz, ArCH), 7.05 (1H, ddd, J 8.2, 
2.2, 0.9 Hz, ArCH), 6.96 (1H, dd, J 9.0, 2.4 Hz, CH-6), 6.62 (1H, ddd, J 9.0, 8.9, 2.4 Hz, CH-
4), 3.80 (2H, s, 3-CH2), 2.55 (3H, s, SCH3) and 2.28 (3H, s, 2-CH3); 13C NMR (100 MHz; 
CDCl3) δ 168.3 (quat., carboxyl), 163.1 (quat., d, J 246.0 Hz, C-5), 157.9 (quat., C-7′′), 152.8 
(quat., C-3′′), 151.5 (quat., C-1′′), 146.2 (quat., d, J 8.7, C-8), 139.9 (quat., C-1), 139.4 (quat., 
C-1′), 139.2 (quat. × 2, C-2, C-4′), 137.9 (quat., C-9′′), 135.9 (CH, C-12′′), 132.8 (quat., C-3), 
130.5 (CH, C-5′′), 130.4 (CH, C-α), 129.9 (CH × 2, C-3′,5′), 129.8 (CH × 2, C-11′′,13′′), 129.6 
(quat., C-9), 128.6 (CH × 2, C-10′′, C-1′′), 125.9 (CH × 2, C-2′,6′), 123.9 (CH, d, J 9.2, C-7), 
119.9 (CH, C-4′′), 117.2 (CH, C-6′′), 113.7 (CH2, C-2′′),  112.2 (quat., C-8′′) 110.8 (CH, d, J 
22.6, C-6), 105.7 (CH, d, J 24.6, C-4), 31.9 (CH2, 3-CH2), 15.4 (CH3, SCH3) and 10.8 (CH3, 2-
CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -114.0 (CF); m/z (ES+) 679 ([M+Na]+, 100%); 
HRMS m/z (ES+) calcd. for C34H25FN2NaO7S2, 679.0985 found 679.0975; CHN Anal. calcd. 
for C32H25FN2O7S2: C, 62.18; H, 3.84; N, 4.27. Found C, 62.29; H, 3.95; N, 4.20. 
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(Z)-4-(3-((2-(5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetoxy)methyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 194 
 
 
Following general procedure A with sulindac sulfide 115 (50 mg, 0.15 mmol) and 4-(3-
(hydroxymethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 171 (50 mg, 0.15 
mmol) purification by flash chromatography, eluting with dichloromethane, furnished (Z)-4-(3-
((2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetoxy)methyl)phenoxy)-
3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 194 (64 mg, 0.10 mmol, 65%) as a yellow solid: 
m.p. 99-101 °C; Rf 0.56 (CH2Cl2, UV/cerium phosphomolybdate); νmax (thin film)/cm−1 2068, 
1749, 1623, 1533. 1442, 1260, 1166, 1122; 1H NMR (400 MHz; CDCl3) δ, 8.10 (2H, d, J 8.3, 
CH-10′′,14′′), 7.79 (1H, tt, J 7.5, 1.3 Hz, CH-12′′), 7.65 (2H, t, J 7.8 Hz, CH-11′′,13′′), 7.45 (2H, 
d, J 8.1 Hz, CH-3′,5′), 7.40 (1H, d, J 7.8 Hz, ArCH), 7.37 (1H, dd, J 8.4, 5.2 Hz, CH-7), 7.31-
7.29 (3H, m, ArCH × 3), 7.27-7.24 (2H, m, ArCH × 2), 7.15 (1H, s, CH-α), 6.86 (1H, dd, J 9.0, 
2.4 Hz, CH-6), 6.56 (1H, ddd, J 9.0, 8.8, 2.4 Hz, CH-4), 5.17 (2H, s, CH2-α′), 3.64 (2H, s, 3-
CH2), 2.62 (3H, s, SCH3) and 2.21 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ, 170.0 (quat., 
carboxyl), 163.0 (quat., d, J 244.9 Hz, C-5), 158.3 (quat., C-7′′), 152.6 (quat., C-3′′), 146.3 
(quat., d, J 8.7 Hz, C-8), 140.0 (quat., C-1), 139.2 (quat. × 2, C-2, C-4′), 138.7 (quat., C-1′′), 
138.3 (quat., C-1′), 137.9 (quat., C-9′′), 135.8 (CH, C-12′′), 132.9 (quat., C-3), 130.3 (CH, C-α), 
130.2 (CH, C-5′′), 129.9 (CH × 3, C-2′,6′, C-9), 129.8 (CH × 2, C-10′′,14′′), 128.6 (CH × 2, C-
11′′,13′′), 126.2 (CH, C-6′′), 125.9 (CH × 2, C-3′,5′), 123.7 (CH, d, J 9.0 Hz, C-7), 119.6 (CH, 
C-2′′), 119.4 (C-4′′), 110.7 (quat., C-8′′), 110.6 (CH, d, J 22.4 Hz, C-6), 105.7 (CH, d, J 23.3 
Hz, C-4), 65.7 (CH2, C-α′), 31.8 (CH2, 3-CH2), 15.4 (CH3, SCH3) and 10.6 (CH3, 3-CH3); 19F 
{1H} NMR (376 MHz; CDCl3) δ -114.4 (CF); m/z (ES+) 693 ([M+Na]+, 100%); HRMS m/z 
(ES+) calcd. for C35H27FN2NaO7S2 [M+Na]+ requires 693.1141, found 693.1135; CHN Anal. 
calcd. for C35H27FN2O7S2: C, 62.67; H, 4.06; N, 4.18; Found C, 62.71; H, 4.15; N, 4.15. 
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(Z)-4-(2-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 196 
 
 
Following general procedure A with sulindac sulfone 116 (65 mg, 0.18 mmol) and 4-(2-
hydroxyethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 174 (50 mg, 0.18 mmol),  
purification by flash chromatography, eluting with dichoromethane, furnished (Z)-4-(2-(2-(5-
fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetoxy)ethoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 196 (22 mg, 0.04 mmol, 25%) as a yellow solid: m.p. 
88-93 °C; Rf 0.84 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax (thin film)/cm−1 
2926, 1737, 1611, 1550, 1491, 1456, 1400, 1360, 1556, 1085; 1H NMR (400 MHz; CDCl3) δ 
8.04 (2H, d, J 8.2 Hz, CH-6′′,10′′), 8.00 (2H, d, J 8.2 Hz, CH-3′,5′), 7.74 (1H, t, J 7.5, CH-8′′), 
7.70 (2H, d, J 8.2 Hz, CH-2′,6′), 7.58-7.55 (2H, m, CH-7′′,9′′), 7.15 (1H, s, CH-α), 7.10 (1H, dd, 
J 8.7, 5.1, CH-7), 6.88 (1H, dd, J 9.0, 2.1 Hz, CH-4), 6.57 (1H, ddd, J 9/0, 9.0, 2.1 Hz, CH-6), 
4.65-4.63 (2H, m, CH2-1′′), 4.57-4.54 (2H, m, CH2-2′′), 3.66 (2H, s, 3-CH2), 3.14 (3H, s, 
SO2CH3) and 2.23 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.9 (quat., carboxyl), 
163.5 (quat., d, J 245.5 Hz, C-5), 158.5 (quat., C-3′′), 146.7 (quat., d, J 9.0 Hz, C-8), 142.5 
(quat., C-4′), 142.2 (quat., C-1′), 139.9 (quat., C-1), 138.6 (quat., C-2), 137.9 (quat., C-5′′), 
135.7 (CH, C-8′′), 131.7 (quat., C-3), 130.2 (CH × 2, C-2′,6′), 129.7 (CH × 2, C-7′′,9′′), 129.3 
(quat., C-9), 128.7 (CH × 2, C-3′,5′), 127.9 (CH, C-α), 127.7 (CH × 2, C-6′′,10′′), 123.8 (CH, d, 
J 9.3 Hz, C-7), 111.0 (CH, d, J 22.7 Hz, C-6), 110.5 (quat., C-4′′), 106.2 (CH, d, J 24.1, C-4), 
67.7 (CH2, C-2′′), 61.8 (CH2, C-1′′), 44.5 (CH3, SO2CH3), 31.6 (CH2, 3-CH2) and 10.6 (CH3, 2-
CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -112.8 (CF); m/z (ES+) 663 ([M+Na]+, 100%); 
HRMS m/z (ES+) calcd. for C30H25FN2NaO9S2 [M+Na]+ requires 663.0883, found 663.0889; 
CHN Anal. calcd. for C30H25FN2O9S2: C, 56.24; H, 3.93; N, 4.37. Found C, 56.36; H, 4.01; N, 
4.45. 
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(Z)-4-(3-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetoxy)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 197 
 
 
Following general procedure A with sulindac sulfone 116 (62 mg, 0.17 mmol) and 4-(3-
hydroxypropoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 166 (50 mg, 0.17 mmol), 
purification by flash chromatography, eluting dichoromethane, furnished (Z)-4-(3-(2-(5-fluoro-
2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetoxy)propoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 197 (85 mg, 0.13 mmol, 77%) as a yellow solid: m.p. 
108-110 °C; Rf 0.82 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax (thin 
film)/cm−1 2926, 1729, 1611, 1547, 1491, 1449, 1257, 1166, 1088; 1H NMR (500 MHz; CDCl3) 
δ 8.06-7.99 (4H, m, CH-3′,5′,7′′,11′′), 7.77-7.69 (3H, m, CH-2,6′,9′′), 7.64 (2H, t, J 8.0 Hz, CH-
8′′,10′′), 7.13 (1H, s, CH-α), 7.09 (1H, dd, J 8.4, 5.2 Hz, CH-7), 6.84 (1H, dd, J 8.8, 2.4 Hz, CH-
4), 6.55 (1H, ddd, J 8.9, 8.8, 2.4 Hz, CH-6), 4.40 (2H, t, J 6.1 Hz, CH2-1′′), 4.32 (2H, t, J 6.0 
Hz, CH2-3′′), 3.59 (2H, s, 3-CH2), 3.14 (3H, s, SO2CH3) and 2.24-2.16 (5H, m, 2-CH3 and CH2-
2′′); 13C NMR (100 MHz; CDCl3) δ 169.9 (quat., carboxyl), 163.0 (quat., d, J 247.0 Hz, C-5), 
158.7 (quat., C-4′′), 146.8 (quat., C-8), 142.4 (quat., C-4′), 142.2 (quat., C-1′), 139.9 (quat., C-
1), 138.2 (quat., C-2), 138.0 (quat., C-6′′), 135.7 (CH, C-9′′), 132.1 (quat., C-3), 130.3 (CH × 2, 
C-2′,6′), 129.7 (CH × 2, C-8′′,10′′), 129.3 (quat., C-9), 128.6 (CH × 2, C-3′,5′), 127.7 (CH × 2, 
C-7′′,11′′), 127.4 (CH, C-α), 123.8 (CH, d, J 9.3 Hz, C-7), 110.0 (CH, d, J 22.7 Hz, C-6), 110.4 
(quat., C-4′′), 106.2 (CH, d, J 23.4, C-4), 67.7 (CH2, C-3′′), 60.9 (CH2, C-1′′), 44.5 (CH3, 
SO2CH3), 31.7 (CH2, 3-CH2), 27.8 (CH2, C-2′′) and 10.2 (CH3, 2-CH3); 19F {1H} NMR (376 
MHz; CDCl3) δ -112.9 (CF); m/z (ES+) 677 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C31H27FN2NaO9S2 [M+Na]+ requires 677.1040, found 677.1045; CHN Anal. calcd. for 
C31H27FN2O9S2: C, 56.87; H, 4.16; N, 4.28. Found C, 56.92; H, 4.22; N, 4.29. 
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(Z)-4-(4-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetoxy)butoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 198 
 
 
Following general procedure A with sulindac sulfone 116 (50 mg, 0.13 mmol) and 4-(4-
hydroxybutoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 167 (50 mg, 0.15 mmol) 
purification by flash chromatography, eluting with dichloromethane and methanol (99.5:0.5), 
furnished (Z)-4-(4-(2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene) 
-1H-inden-3-yl)acetoxy)butoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 198 (23 mg, 0.04 
mmol, 26%) as a yellow solid: m.p. 64-68 °C; Rf 0.72 (95:5, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 2931, 1733, 1613, 1562, 1471, 1440, 1355, 1300, 
1140, 1088; 1H NMR (500 MHz; CDCl3) δ 8.02 (2H, d, J 8.3 Hz, CH-8′′,12′′), 7.93 (2H, d, J 
8.3 Hz, CH-3′,5′), 7.67 (1H, t, J 7.5 Hz, CH-10′′), 7.62 (2H, d, J 8.2 Hz, CH-2′,6′), 7.53 (2H, t, J 
8.0 Hz, CH- 9′′,11′′), 7.07 (1H, s, CH-α), 7.03 (1H, dd, J 8.4, 5.1 Hz, CH-7), 6.83 (1H, dd, J 8.8, 
2.3 Hz, CH-4), 6.50 (1H, ddd, J 8.9, 8.8, 2.3 Hz, CH-6), 4.33 (2H, t, J 6.1 Hz, CH2-1′′), 4.14 
(2H, t, J 6.2 Hz, CH2-4), 3.53 (2H, s, 3-CH2), 3.07 (3H, s, SO2CH3), 2.15 (3H, s, 2-CH3), 1.87-
1.82 (2H, m, CH2-2′′) and 1.78-1.73 (2H, m, CH2-3′′); 13C NMR (100 MHz; CDCl3) δ 169.1 
(quat., carboxyl), 162.4 (quat., d, J 246.4 Hz, C-5), 157.9 (quat., C-5′′), 145.8 (quat., d, J 8.8 Hz, 
C-8), 142.5 (quat., C-4′), 141.5 (quat., C-1′), 141.4 (quat., C-1), 139.7 (quat., C-7′′), 138.8 
(quat., C-2), 134.6 (CH, C-4′′′), 131.2 (quat., C-3), 127.5 (CH, C-α), 130.2 (CH × 2, C-2′,6′), 
129.7 (CH × 2, C-8′′,12′′), 128.6 (CH × 2, C-3′,5′), 128.3 (quat., C-9), 127.5 (CH × 2, C-
7′′,11′′), 122.7 (CH, d, J 9.1 Hz, C-7), 111.9 (quat., C-6′′) 109.9 (CH, d, J 22.4 Hz, C-6), 105.3 
(CH, d, J 23.9 Hz, C-4), 69.8 (CH2, C-4′′), 63.3 (CH2, C-1′′), 43.4 (CH3, SO2CH3), 30.9 (CH2, 3-
CH2), 24.2 (CH2, C-3′′), 24.0 (CH2, C-2′′) and 9.5 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; 
CDCl3) δ -114.4 (CF); m/z (ES+) 691 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C32H29FN2O9NaS2 [M+Na]+ requires 691.1196, found 691.1200; CHN Anal. calcd. for 
C32H29FN2O9S2: C, 57.48; H, 4.37; N, 4.19. Found C, 57.63; H, 4.46; N, 4.22. 
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(Z)-4-((6-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetoxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 199 
 
 
Following general procedure A with sulindac sulfone 116 (54 mg, 0.15 mmol) and 4-((6-
hydroxyhexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 168 (50 mg, 0.15 mmol), 
purification by flash chromatography, eluting with dichloromethane, furnished (Z)-4-((6-(2-(5-
fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetoxy)hexyl)oxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 199 (72 mg, 0.10 mmol, 71%) as a yellow solid: m.p. 
60-63 °C; Rf 0.33 (100% CH2Cl2, UV/cerium phosphomolybdate); νmax (thin film)/cm−1 2926, 
1734, 1614, 1552, 1469, 1449, 1358, 1309, 1149; 1H NMR (400 MHz; CDCl3) δ 8.05 (2H, d, J 
8.6 Hz, CH-10′′,14′′), 8.01 (2H, d, J 8.4 Hz, CH-3′,5′), 7.75 (1H, tt, J 7.6, 1.7 Hz, CH-12′′), 7.70 
(2H, d, J 8.0 Hz, CH-3′,5′), 7.61 (2H, t, J 7.7 Hz, CH-11′′,13′′), 7.14 (1H, s, CH-α), 7.11 (1H, 
dd, J 8.4, 5.1 Hz, CH-7), 6.91 (1H, dd, J 8.9, 2.4 Hz, CH-4), 6.57 (1H, ddd, J 9.0, 8.9, 2.4 Hz, 
CH-6), 4.39 (2H, t, J 6.6 Hz, CH2-1′′), 4.15 (2H, t, J 6.6 Hz, CH2-6), 3.58 (2H, s, 3-CH2), 3.14 
(3H, s, SO2CH3), 2.22 (3H, s, 2-CH3), 1.89-1.80 (2H, m, CH2-2′′), 1.72-1.65 (2H, m, CH2-5′′) 
and 1.50-1.36 (4H, m, CH2 × 2, CH2-3′′, CH2-4′′); 13C NMR (100 MHz; CDCl3) δ, 170.2 (quat., 
carboxyl), 163.4 (quat., d, J 247.3 Hz, C-5), 159.0 (quat., C-7′′), 146.9 (quat., d, J 8.8 Hz, C-8), 
142.5 (quat., C-4′), 142.3 (quat., C-1′), 139.9 (quat., C-1), 138.1 (quat. × 2, C-2, C-9′′), 135.6 
(CH, C-12′′), 132.4 (quat., C-3), 130.2 (CH × 2, C-3′,5′), 129.7 (CH × 2, C-10′′,14′′), 129.4 
(quat., C-9), 128.5 (CH × 2, C-2′,6′), 127.6 (CH × 2, C-11′′,13′′), 127.3 (CH, C-α), 123.7 (CH, 
d, J 9.0, C-7), 110.9 (CH, d, J 22.9 Hz, C-6), 110.5 (quat., C-8′′), 106.4 (CH, d, J 24.0 Hz, C-4), 
71.4 (CH2, C-6′′), 64.9 (CH2, C-1′′), 44.5 (CH3, SO2CH3), 31.9 (CH2, 3-CH2), 28.4 (CH2, C-5′′), 
28.3 (CH2, C-2′′), 25.5 (CH2, C-4′′), 25.2 (CH2, C-3′′) and 10.5 (CH3, 3-CH3); 19F {1H} NMR 
(376 MHz; CDCl3) δ -113.0 (CF); m/z (ES+) 719 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C34H33FN2NaO9S2 [M+Na]+ requires 719.1509, found 719.1501; CHN Anal. calcd. for 
C34H33FN2O9S2: C, 58.61; H, 4.77; N, 4.02. Found C, 58.72; H, 4.84; N, 4.08. 
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(Z)-4-(2-(2-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetoxy)ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 200 
 
 
Following general procedure A with sulindac sulfone 116 (55 mg, 0.15 mmol) and 4-(2-(3-
hydroxyethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 175 (50 mg, 0.15 mmol), 
purification by flash chromatography, eluting with dichloromethane, furnished (Z)-4-(2-(2-(2-
(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetoxy)ethoxy)ethoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 200 (63.2, 0.09 mmol, 62%) as a yellow solid: m.p. 
60-63 °C; Rf  0.67 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax (thin film)/cm−1 
2926, 1727, 1611, 1552, 1459, 1365, 1309, 1260, 1156, 1088; 1H NMR (300 MHz; CDCl3) δ 
8.09-8.04 (2H, m, CH-8′′,12′′), 8.00 (2H, d, J 8.4 Hz, CH-3′,5′), 7.76-7.53 (5H, m, CH-
2′,6′,9′′,10′′,11′′), 7.12 (1H, s, CH-α), 7.09 (1H, dd, J 8.4, 5.1 Hz, CH-7), 6.92 (1H, dd, J 8.9, 2.4 
Hz, CH-6), 6.55 (1H, ddd, J 9.0, 8.9, 2.4 Hz, CH-4), 4.53-4.49 (2H, m, CH2-1′′), 4.34-4.31 (2H, 
m, CH2-4′′), 3.87-3.84 (2H, m, CH2-2), 3.80-3.77 (2H, m, CH2-3), 3.62 (2H, s, 3-CH2), 3.14 
(3H, s, SO2CH3) and 2.20 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 170.1 (quat., 
carboxyl), 163.4 (quat., d, J 247.2 Hz, C-5), 158.79 (quat., C-5′′), 146.9 (quat., d, J 8.9 Hz, C-
8), 142.3 (quat., C-4′), 142.3 (quat., C-1), 139.9 (quat., C-1′), 138.3 (quat., C-2), 138.0 (quat., C-
7′′), 135.6 (CH, C-10′′), 132.2 (quat., C-3), 130.2 (CH × 2, C-2′,6′), 129.7 (CH × 2, C-9′′,11′′), 
129.4 (quat., C-9), 127.3 (CH, C-α), 127.6 (CH × 2, C-8′′,12′′), 123.9 (CH × 2, C-3′,5′), 123.7 
(CH, d, J 8.9 Hz, C-7), 110.9 (CH, d, J 22.8 Hz, C-6), 110.5 (quat., C-6′′), 106.2 (CH, d, J 24.4 
Hz, C-4), 70.5 (CH2, C-4′′), 69.4 (CH2, C-2′′), 68.3 (CH2, C-5′′), 64.1 (CH2, C-1′′), 44.5 (CH3, 
SO2CH3), 31.7 (CH2, 3-CH2) and 10.5 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -
113.0 (CF); m/z (ES+) 707 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C32H29FN2NaO10S2 
[M+Na]+ requires 707.1145, found 707.1139; CHN Anal. calcd. for C32H29FN2O10S2: C, 56.13; 
H, 4.27; N, 4.09. Found C, 56.20; H, 4.35; N, 4.20. 
 
 
 
6
5
4
8
9
7
3
2
1
α
1'
6'
5'
4'
3'
2'
SSO2CH3
2-CH3
F
3-CH2 Cbx
O
O
1"
2"
O
3"
4"
O 5"
N O
N
6"
S
7"
12"
11"
10"9"
8"
O
O O
O O
Appendix: Experimental 
 
	   234	  
4-(((Z)-4-(2-((Z)-5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetoxy)but-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 201 
 
 
Following general procedure A with sulindac sulfone 116 (60 mg, 0.17 mmol) and (Z)-4-((4-
hydroxybut-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 170 (50 mg, 0.17 
mmol) purification by flash chromatography, eluting with dichloromethane, furnished 4-(((Z)-4-
(2-((Z)-5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetoxy)but-2-en-1-
yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 201 (96 mg, 0.15 mmol, 93%) as a yellow 
solid: m.p. 109-110 °C; Rf 0.86 (95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); νmax 
(thin film)/cm−1 2921, 1732, 1611, 1547, 1447, 1365, 1260, 1166, 1083; 1H NMR (500 MHz; 
CDCl3) δ 8.06-7.99 (4H, m, CH-3′,5′,8′′,12′′), 7.78-7.68 (3H, m, CH-2′,6′,10′′), 7.60 (2H, t, J 8.0 
Hz, CH-9′′,11′′), 7.14 (1H, s, CH-α), 7.10 (1H, dd, J 8.4, 5.1 Hz, CH-7), 6.87 (1H, dd, J 8.8, 2.4 
Hz, CH-6), 6.57 (1H, ddd, J 8.9, 8.8, 2.4 Hz, CH-4), 5.96-5.84 (2H, m, CH-2′′, 3′′), 5.01 (2H, d, 
J 5.2 Hz, CH2-1′′), 4.77 (2H, d, J 5.3 Hz, CH2-4′′), 3.60 (2H, s, 3-CH2), 3.14 (3H, s, SO2CH3) 
and 2.21 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.8 (quat., carboxyl), 163.5 (quat., d, 
J 245.8 Hz, C-5), 158.5 (quat., C-5′′), 146.7 (quat., d, J 8.7 Hz, C-8), 142.5 (quat., C-4′), 142.3 
(quat., C-1′), 139.9 (quat., C-1), 138.3 (quat., C-2), 137.9 (quat., C-7′′), 135.7 (CH, C-10′′), 
132.0 (quat., C-3), 130.2 (CH × 2, C-3′,5′), 129.9 (CH, C-3′′), 129.3 (quat., C-9), 129.7 (CH × 2, 
C-9′′,11′′), 128.6 (CH × 2, C-8′′,12′′), 128.4 (CH × 2, C-2′,6′), 127.4 (CH, C-α), 126.2 (CH, C-
2′′), 123.8 (CH, d, J 9.2 Hz, C-7), 111.0 (CH, d, J 22.2 Hz, C-6), 110.6 (quat., C-6′′), 106.3 
(CH, d, J 23.7 Hz, C-4), 66.5 (CH2, C-4′′), 60.6 (C-1′′), 44.5 (CH3, SO2CH3), 31.7 (CH2, 3-CH2) 
and 10.6 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -112.8 (CF); m/z (ES+) 689 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C32H27FN2NaO9S2 [M+Na]+ requires 689.1040, 
found 689.1046; CHN Anal. calcd. for C32H27FN2O9S2: C, 57.65; H, 4.08; N, 4.20. Found C, 
57.72; H, 4.13; N, 4.26. 
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(Z)-4-((4-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetoxy)but-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 202 
 
 
Following general procedure A with sulindac sulfone 116 (55 mg, 0.17 mmol), 4-((4-
hydroxybut-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 169 (50 mg, 0.17 
mmol), purification by flash chromatography, eluting with dichloromethane, furnished (Z)-4-
((4-(2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetoxy)but-2-yn-1-
yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 202 (32 mg, 0.05 mmol, 32%) as a yellow 
solid: m.p. 99-100 °C; Rf 0.80 (95:5 CH2Cl2:MeOH); νmax (thin film)/cm−1 2921, 1739, 1609, 
1547, 1449, 1358, 1309, 1169, 1144; 1H NMR (400 MHz; CDCl3) δ 8.07 (2H, d, J 8.5 Hz, CH-
8′′,12′′), 8.01 (2H, d, J 8.4 Hz, CH-3′,5′), 7.89-7.59 (5H, m, CH-2′,6′,9′′,10′′,11′′), 7.15 (1H, s, 
CH-α), 7.10 (1H, dd, J 5.2, 8.4, CH-7), 6.88 (1H, dd, J 8.9, 2.4 Hz, CH-6), 6.57 (1H, ddd, J 9.0, 
8.9, 2.4, CH-4), 5.10 (2H, t, J 1.6 Hz, CH2-1′′), 4.78 (2H, t, J 1.6 Hz, CH2-4), 3.63 (2H, s, 3-
CH2), 3.14 (3H, s, SO2CH3) and 2.22 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.3 
(quat., carboxyl), 163.4 (quat., d, J 246.2 Hz, C-5), 157.9 (quat., C-5′′), 146.6 (quat., d, J 9.0 Hz, 
C-8), 142.4 (quat., C-4′), 142.2 (quat., C-1′), 139.9 (quat., C-1), 138.5 (quat., C-2), 137.8 (quat., 
C-7′′), 135.7 (CH, C-10′′), 131.6 (quat., C-3), 130.2 (CH × 2, C-3′,5′), 129.7 (CH × 2, C-
8′′,12′′), 128.7 (CH × 2, C-2′,6′), 129.3 (quat., C-9), 127.6 (CH × 2, C-9′′,11′′), 127.5 (CH, C-α), 
123.8 (CH, d, J 9.0 Hz, C-7), 111.0 (CH, d, J 22.8 Hz, C-6), 110.6 (quat., C-6′′), 106.3 (CH, d, J 
24.3 Hz, C-4),  83.7 (quat., C-3′′), 78.9 (quat., C-2′′), 60.4 (CH2, C-4′′), 58.5 (CH2, C-1′′), 44.5 
(CH3, SO2CH3), 31.4 (CH2, 3-CH2) and 10.6 (CH3, 3-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ 
-112.9 (CF); m/z (ES+) 687 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C32H25FN2NaO9S2  
[M+Na]+ requires 687.0883, found 687.0878; CHN Anal. calcd. for C32H25FN2O9S2: C, 57.82; 
H, 3.79; N, 4.21. Found C, 58.00; H, 3.84; N, 4.26. 
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(Z)-4-(3-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetoxy)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 204 
  
 
Following general procedure A with sulindac sulfone 116 (56 mg, 0.15 mmol) and 4-(3-
hydroxyphenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 172 (50 mg, 0.15 mmol), 
purification by flash chromatography, eluting with dichloromethane and hexane (90:10), 
furnished (Z)-4-(3-(2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetoxy)-phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 204 (52 mg, 0.08 mmol, 
50%) as a yellow solid: m.p. 62-64 °C; Rf  0.79 (95:5, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 2921, 1732, 1609, 1491, 1449, 1309, 1147, 1048; 1H 
NMR (500 MHz; CDCl3) δ 8.07 (2H, d, J 8.3, CH-10′′,14′′), 8.02 (2H, d, J 8.3 Hz, CH-3′,5′), 
7.77 (1H, t, J 7.5 Hz, CH-12′′), 7.72 (2H, d, J 8.0 Hz, CH-2′,6′), 7.63 (2H, t, J 7.9 Hz, CH-
11′′,13′′), 7.43 (1H, d, J 8.3 Hz, ArCH), 7.20 (1H, dd, J 8.3, 2.3 Hz, ArCH), 7.18 (1H, s, CH-α), 
7.15-7.12 (2H, m, ArCH × 2), 7.06 (1H, dd, J 8.2, 1.9 Hz, CH-7), 6.97 (1H, dd, J 8.8, 2.4 Hz, 
CH-6), 6.61 (1H, ddd, J 9.0, 8.8, 2.4 Hz, CH-4), 3.81 (2H, s, 3-CH2), 3.14 (3H, s, SO2CH3) and 
2.28 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 168.0 (quat., carboxyl), 163.5 (quat., d, J 
246.0 Hz, C-5), 157.9 (quat., C-7′′), 152.7 (quat., C-3′′), 151.3 (quat., C-1′′), 146.5 (quat., d, J 
8.7 Hz, C-8), 142.3 (quat., C-4′), 142.2 (quat., C-1′), 140.0 (quat., C-1), 138.8 (quat., C-2), 
137.8 (quat., C-9′′), 135.9 (CH, C-12′′), 131.3 (quat., C-3), 130.4 (CH, C-5′′), 130.2 (CH × 2, C-
3′,5′), 129.3 (quat., C-9), 129.8 (CH × 2, C-11′′,13′′), 128.6 (CH × 2, C-2′,6′), 127.8 (CH, C-α), 
127.7 (CH × 2, C-10′′,14′′), 123.9 (CH, d, J 9.2, C-7), 119.8 (CH, C-4′′), 117.3 (CH, C-6′′), 
113.7 (CH2, C-2′′), 111.2 (CH, d, J 22.8 Hz, C-6), 110.6 (quat., C-8′′), 106.2 (CH, d, J 23.9 Hz, 
C-4), 44.5 (CH3, SO2CH3), 31.9 (CH2, 3-CH2) and 10.7 (CH3, 2-CH3); 19F {1H} NMR (376 
MHz; CDCl3) δ -113.3 (CF); m/z (ES+) 711 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C34H25FN2NaO9S2 [M+Na]+ requires 711.0883, found 711.0878, CHN Anal. calcd. for 
C32H25FN2O9S2: C, 59.29; H, 3.66; N, 4.07; N, 4.27. Found C, 59.38; H, 3.70; N, 4.02. 
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(Z)-4-(3-((2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetoxy)methyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 203 
 
 
Following general procedure A with sulindac sulfone 116 (54 mg, 0.15 mmol) and 4-(3-
(hydroxymethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 171 (50 mg, 0.15 
mmol) purification by flash chromatography, eluting with dichloromethane and methanol 
(99.5:0.5), furnished (Z)-4-(3-((2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-
inden-3-yl)acetoxy)methyl)phenoxy)-3-(phenyl-sulfonyl)-1,2,5-oxadiazole 2-oxide 203 (69 mg, 
0.10 mmol, 66%) as a yellow solid: m.p. 119-120 °C; Rf 0.83 (95:5 CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); νmax (thin film)/cm−1 3068, 2926, 1734, 1616, 1533, 1442, 1306, 1159, 
1085; 1H NMR (400 MHz; CDCl3) δ 8.11 (2H, d, J 8.5 Hz, CH-10′′,12′′), 8.03 (2H, d, J 8.3 Hz, 
CH-3′,5′), 7.82 (1H, tt, J 7.5, 1.6 Hz, CH-12′′), 7.72 (2H, d, J 8.3 Hz, ArCH × 2), 7.67 (2H, t, J 
7.9 Hz, CH-11′′,13′′), 7.44 (1H, t, J 7.9 Hz, ArCH), 7.27-7.25 (3H, m, ArCH × 3), 7.16 (1H, s, 
CH-α), 7.12 (1H, dd, J 5.1, 8.4 Hz, CH-7), 6.88 (1H, dd, J 8.9, 2.4 Hz, CH-6), 6.56 (1H, ddd, J 
9.0, 8.9, 2.4 Hz, CH-4), 5.20 (2H, s, CH2- α′), 3.66 (2H, s, 3-CH2), 3.17 (3H, s, SO2CH3) and 
2.22 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 169.8 (quat., carboxyl), 163.3 (quat., d, J 
247.5 Hz, C-5), 158.3 (quat., C-7′′), 152.6 (quat., C-3′′), 146.6 (quat., d, J 8.5 Hz, C-8), 142.4 
(quat., C-4′), 142.3 (quat., C-1′), 139.9 (quat., C-1), 138.4 (quat., C-1′′), 138.2 (quat., C-2), 
137.9 (quat., C-9′′), 135.9 (CH, C-12′′), 131.9 (quat., C-3), 130.2 (CH × 3, C-3′,5′, C-5′′), 129.8 
(CH × 2, C-10′′,14′′), 129.3 (quat., C-9), 128.6 (CH, C-α), 128.6 (CH × 2, C-11′′,13′′), 128.4 
(CH × 2, C-2′,6′), 126.2 (CH, C-6′′), 123.7 (CH, d, J 9.0 Hz, C-7), 119.6 (CH, C-2′′), 119.3 (C-
4′′), 110.9 (CH, d, J 22.6 Hz, C-6), 110.7 (quat., C-8′′), 106.3 (CH, d, J 22.7, C-4), 65.8 (CH2, 
C-α′), 44.5 (CH3, SO2CH3), 31.8 (CH2, 3-CH2) and 10.6 (CH3, 3-CH3); 19F {1H} NMR (376 
MHz; CDCl3) δ -112.9 (CF); m/z (ES+) 725 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C35H27FN2NaO9S2 [M+Na]+ requires 725.1040, found 725.1038; CHN Anal. calcd. for 
C35H27FN2O9S2: C, 59.82; H, 3.87; N, 3.99; Found C, 60.00; H, 3.99; N, 4.06. 
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2-(Phenylamino)acetonitrile, 208 
 
 
Bromoacetonitrile (6.27 g, 3.64 mL, 52.0 mmol), potassium carbonate (8.3 g, 60.1 mmol) and 
sodium iodide (3.7 g, 24.7 mmol) were added to a solution of freshly distilled aniline 207 (4.55 
g, 4.5 mL, 48.9 mmol) in dry acetonitrile (100 mL) and the suspension stirred at room 
temperature overnight in the absence of light. The suspension was filtered and the filtrate 
partitioned between diethyl ether (100 mL) and distilled water (100 mL). The organic layer was 
separated and washed with distilled water (50 mL) and brine (50 mL), dried over Na2SO4, 
filtered and the solvent removed under reduced pressure to yield 3-(phenylamino)acetonitrile 
208 (5.62 g, 42.6 mmol, 87%) as a colourless oil which crystallised on standing, which was 
used without any further purification: m.p. 40-42 °C, [Lit.400 40 °C]; 1H NMR (300 MHz; 
CDCl3) δ 7.24-7.17 (2H, m, CH-3,5), 6.81 (1H, tt, J 8.4, 1.1 Hz, CH-1), 6.65-6.61 (2H, m, CH-
2,6) and 3.99-3.95 (3H, m, CH2, NH); 13C NMR (100 MHz; CDCl3) δ 145.3 (quat., C-4), 129.8 
(CH × 2, C-2, 6), 120.2 (CH, C-1), 117.3 (quat., C-7), 113.8 (CH × 2, C-3, 5) and 32.8 (CH2, C-
6); m/z (ES+) 155 ([M+Na]+, 100%). The data were in agreement with the literature values.400 
 
3-Phenylsydononimine hydrochloride, 20694 
 
 
Isopentyl nitrite (1.41 g, 1.6 mL, 12.0 mmol) was added to a stirring solution of 2-
(phenylamino)acetonitrile 208 (660 mg, 5.0 mmol) in diethyl ether (5 mL) and the resulting 
suspension was stirred for 16 h in the absence of light. Dry hydrogen chloride (gas) was 
bubbled through solution for 15 min. The suspension was cooled in an ice bath for 15 min and 
filtered. The residue was dried under vacuum to give 3-phenylsydononimine hydrochloride 208 
(927 mg, 4.70 mmol, 94%) as a pale pink solid, which was used without any further 
purification: m.p. 179-181, [Lit.164 180-181 °C]; νmax (thin film)/cm−1 2365, 1684, 1653, 1616, 
1288, 1111; 1H NMR (400 MHz; d6-DMSO) δ 10.10 (2H, s, NH.HCl), 8.71 (1H, s, CH-7), 8.06 
(2H, d, J 7.1 Hz, CH-3, 5) and 7.86-7.77 (3H, m, CH-1,2,6); 13C NMR (100 MHz; d6-DMSO) δ 
170.4 (quat., C-8), 134.5 (quat., C-4), 133.8 (quat.), 131.3 (CH × 2, C-3,5), 123.6 (CH × 2, C-
2,6) and 103.2 (CH, C-7); m/z (ES+) 162 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for 
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C8H8N3O [M+H]+ requires 162.0667, found 162.0663. The data were in agreement with the 
literature values.94,164 
 
(Z)-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetyl)(3-phenylsydnoniminyl)amide, 210 
 
 
Sulindac 112 (50 mg, 0.14 mmol), EDCI.HCl (38 mg, 0.20 mmol) and DMAP (5 mg, 
0.04  mmol) were added to a solution of 3-phenylsydnonimine 206 (28 mg, 0.14 mmol) in 
CH2Cl2:CH3CN (4:1, 10 mL) and the resultant solution stirred at room temperature for 2 h. The 
solution was washed with distilled water (5 mL) and brine (5 mL), dried over MgSO4, filtered 
and the solvent removed under reduced pressure to give crude product, which was purified by 
silica gel chromatography, eluting with dichloromethane and methanol (100:0 to 90:10), to 
afford (Z)-(2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetyl)(3-
phenylsydnoniminyl)amide 210 (52 mg, 0.10 mmol, 74%) as a yellow solid: Rf 0.17 (95:5, 
CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 68-71 °C; νmax (thin film)/cm−1 3052, 
1719, 1634, 1601, 1558, 1468, 1414, 1360, 1248, 1163, 1046, 967. 920, 734; 1H NMR (400 
MHz; CDCl3) δ 8.48 (1H, s, CH-2′′), 7.81 (2H, d, J 7.7 Hz, CH-3′,5′), 7.74-7.70 (3H, m, CH-
4′′,6′′,8′′), 7.68-7.65 (4H, m, CH × 2′,6′,5′′,7′′), 7.14-7.11 (2H, m, CH-7 and CH-α), 6.98 (1H, 
dd, J 8.9, 2.3 Hz, CH-4), 6.51 (1H, ddd, J 9.0, 8.9, 2.3 Hz, CH-6), 3.84 (2H, s, 3-CH2), 2.82 
(3H, s, SOCH3) and 2.25 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 178.2 (quat., C-1′′), 
173.0 (quat., carboxyl), 163.4 (quat., d, J 245.2 Hz, C-5), 147.6 (quat., d, J 9.0 Hz, C-8), 145.1 
(quat., C-4′), 142.1 (quat., C-1), 140.1 (quat., C-1′), 137.8 (quat., C-2), 133.6 (quat., C-3′′), 
133.4 (quat., C-3), 130.6 (CH × 2, C-2′,6′), 130.3 (CH × 2, C-4′′,8′′) 130.2 (quat., C-9), 129.7 
(CH, C-6′′), 127.3 (CH, C-α), 123.7 (CH × 2, C-3′,5′), 123.3 (CH, d, J 8.9 Hz, C-7), 121.6 (CH 
× 2, C-5′′,7′′), 110.4 (CH, d, J 22.6 Hz, C-6), 106.5 (CH, d, J 24.3 Hz, C-4), 105.0 (CH, C-2′′), 
43.9 (CH3, SOCH3), 31.4 (CH2, 3-CH2) and 10.6 (CH3, 2-CH3); 19F {1H} (376 MHz; CDCl3) -
113.2; m/z (ES+) 500 [M+H], 522 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C28H23FN3O3S 
[M+H]+ requires 500.1444, found 500.1446, C28H22FN3NaO3S [M+Na]+ requires 522.1264, 
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found 522.1263; CHN Anal. calcd. for C28H22FN3O3S: C, 67.32; H, 4.44; N, 8.41. Found C, 
67.30; H, 4.46; N, 8.35. 
 
(Z)-(2-(5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetyl)(3-
phenylsydnoniminyl)amide, 211 
 
 
 
Sulindac sulfide 115 (50 mg, 0.15 mmol), EDCI.HCl (38 mg, 0.20 mmol) and DMAP (5 mg, 
0.04 mmol) were added to a solution of 3-phenylsydnonimine 206 (30 mg, 0.15 mmol) in 
CH2Cl2:CH3CN (4:1, 10 mL) and the resultant solution stirred at room temperature for 2 h. The 
solution was washed with distilled water (5 mL) and brine (5 mL), dried over MgSO4, filtered 
and the solvent removed under reduced pressure to give crude product, which was purified by 
silica gel chromatography, eluting with dichloromethane and methanol (100:0 to 90:10), to 
afford (Z)-(2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetyl)-(3-
phenylsydnoniminyl)amide 211 (46 mg, 0.10 mmol, 70%) as a yellow solid: Rf 0.51 (95:5, 
CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 54-56 °C; νmax (thin film)/cm−1 1630, 
1600, 1552, 1467, 1360, 1319, 1163, 1092, 967; 1H NMR (400 MHz; CDCl3) δ 8.50 (1H, s, 
CH-2′′), 7.88 (2H, d, J 7.8 Hz, CH-4′′,8′′), 7.78 (1H, tt, J 7.4, 2.1 Hz, CH-6), 7.73-7.67 (2H, m, 
CH-5′′,7′′), 7.43 (2H, d, J 8.3 Hz, CH-3′,5′), 7.34 (1H, dd, J 8.4, 5.0 Hz, CH-7), 7.28 (2H, d, J 
7.8 Hz, CH-2′,6′), 7.12 (1H, s, CH-α), 6.97 (1H, dd, J 9.1, 2.4 Hz, CH-4), 6.53 (1H, ddd, J 9.0, 
9.0, 2.4 Hz, CH-6), 4.03 (2H, s, 3-CH2), 2.55 (3H, s, SCH3) and 2.24 (3H, s, 2-CH3); 13C NMR 
(100 MHz; CDCl3) δ 178.4 (quat., C-1′′), 173.2 (quat., carboxyl), 163.4 (quat., d, J 245.6 Hz, C-
5), 146.9 (quat., d, J 9.1 Hz, C-8), 140.4 (quat., C-1), 139.3 (quat., C-2), 139.2 (quat., C-1′), 
137.9 (quat., C-4′), 134.5 (CH, C-6′′), 133.3 (quat., C-3′′), 132.2 (quat., C-3), 131.2 (CH × 2, C-
4′′,8′′), 130.2 (CH × 2, C-2′,6′), 130.1 (quat., C-9), 129.7 (CH, C-α), 126.2 (CH × 2, C-3′,5′), 
123.8 (CH, d, J 8.6 Hz, C-7), 122.2 (CH × 2, C-5′′,7′′), 110.7 (CH, d, J 22.6 Hz, C-6), 106.4 
(CH, d, J 23.8 Hz, C-4), 106.7 (CH, C-2′′), 35.2 (CH2, 3-CH2), 15.7 (CH3, SCH3) and 11.1 
(CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) -114.2; m/z (ES+) 484 ([M+H]+, 100%); 
HRMS m/z (ES+) calcd. for C29H22FN3NaO2S [M+Na]+ requires 506.1314, found 506.1310; 
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CHN Anal. calcd. for C29H22FN3O2S: C, 69.55; H, 4.59; N, 8.69. Found C, 69.56; H, 4.59; N, 
8.72. 
 
(Z)-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetyl)(3-phenylsydnoniminyl)amide, 212 
 
 
 
Sulindac sulfone 116 (50 mg, 0.13 mmol), EDCI.HCl (38 mg, 0.20 mmol) and DMAP (5 mg, 
0.04 mmol) were added to a solution of 3-phenylsydnonimine 206 (28 mg, 0.14 mmol) in 
CH2Cl2::CH3CN (4:1, 10 mL) and the resultant solution stirred at room temperature for 2 h. The 
solution was washed with distilled water (5 mL) and brine (5 mL), dried over anhydrous 
MgSO4, filtered and the solvent removed under reduced pressure to give crude product which 
was purified by silica gel chromatography, eluting with dichloromethane and methanol (100:0 
to 90:10), to afford (Z)-(2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)-
acetyl)(3-phenylsydnoniminyl)amide 212 (64 mg, 0.13 mmol, 85%) as a yellow solid: Rf 0.52 
(95:5, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 62-65 °C; νmax (thin film)/cm−1 
3064, 1632, 1601, 1553, 1469, 1360, 1310, 1149, 964; 1H NMR (400 MHz; CDCl3) δ 8.46 (1H, 
s, CH-2′′), 7.97 (2H, d, J 8.4 Hz, CH × 3′,5′), 7.80-7.77 (2H, m, CH-4′′,8′′), 7.74-7.60 (5H, m, 
CH-2′,6′,5′′,6′′,7′′), 7.07 (1H, s, CH-α), 7.05 (1H, dd, J 8.3, 5.0 Hz, CH-7) 6.96 (1H, dd, J 9.1, 
2.4 Hz, CH-4), 6.49 (1H, ddd, J 9.1, 9.0, 2.4 Hz, CH-6), 3.82 (2H, s, 3-CH2), 3.12 (3H, s, 
SO2CH3) and 2.22 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 178.6 (quat., C-1′′), 173.4 
(quat., carboxyl), 162.9 (quat., d, J 246.1 Hz, C-5), 147.9 (quat., d, J 9.0 Hz, C-8), 143.0 (quat., 
C-4′), 143.1 (quat., C-1′), 139.8 (quat., C-1), 137.7 (quat., C-2), 135.2 (CH, C-6′′), 133.8 (quat., 
C-3′′), 133.6 (quat., C-3), 130.9 (CH × 2, C-2′,6′), 130.4 (CH × 2, C-4′′,8′′), 129.7 (quat., d, J 
2.8 Hz, C-9),  127.7 (CH × 2, C-3′,5′), 126.5 (CH, C-α), 123.6 (CH, d, J 9.0 Hz, C-7), 121.7 
(CH × 2, C-5′′,7′′), 110.7 (CH, d, J 22.8 Hz, C-6), 106.9 (CH, d, J 23.7 Hz, C-4), 105.1 (CH, C-
2′′), 44.7 (CH3, SO2CH3), 37.1 (CH2, 3-CH2) and 10.8 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; 
CDCl3) -113.2; m/z (ES+) 516 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C29H22FN3NaO4S 
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[M+Na]+ requires 538.1213, found 538.1219; CHN Anal. calcd. for C29H22FN3O4S: C, 65.23; 
H, 4.30; N, 8.15. Found C, 65.22; H, 4.34; N, 8.17. 
 
β-Alanine ethyl ester hydrochloride, 214329 
 
 
Thionyl chloride (21.4 g. 13 mL, 0.18 mol) was added dropwise to a solution of β-alanine 213 
(8.0 g, 0.09 mmol) in ethanol (200 mL) cooled in an ice bath. Following addition the solution 
was warmed to room temperature and stirred overnight. The solvent was removed under 
reduced pressure and the resulting solid was triturated with diethyl ether to provide β-alanine 
ethyl ester hydrochloride 214 (13.8 g, 0.09 mmol, quant) as a white solid, which was used 
without any further purification: m.p. 65-67 °C, [Lit.401 65-67 °C]; 1H NMR (400 MHz; d6-
DMSO) δ 8.09 (3H, s, NH2.HCl-1), 4.06 (2H, q, 3J 7.0, CH2-5), 3.02 (2H, t, 3J 6.8, CH2-2), 2.68 
(2H, t, 3J 6.8, CH2-3) and 1.17 (3H, t, 3J 7.0, CH3-6); 1H NMR (400 MHz; d6-DMSO) δ 170.9 
(quat., C-4), 61.1 (CH2, C-5), 35.1 (CH2, C-3), 31.7 (CH2, C-2) and 14.4 (CH3, C-6); m/z (ES+) 
118 ([M+H]+, 100%). The data were in agreement with the literature values.329,401 
 
(Z)-Ethyl 3-(2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetamido)propanoate, 215 
 
 
β-Alanine ethyl ester hydrochloride 214 (1.40 g, 9.00 mmol), dicyclohexylcarbodiimide (1.85 g, 
9.00 mmol) and DMAP (20 mg, 0.20 mmol) were added to a solution of sulindac 112 (3.00 g, 
8.42 mmol) and triethylamine (0.91 g, 1.26 mL, 9.00 mmol) in CH2Cl2 (30 mL) and the 
resultant solution was heated under reflux with stirring for 4 h. The solution was cooled, filtered 
and the residue triturated with ethyl acetate and cooled at 4 °C overnight. The solution was 
filtered and the filtrate washed with aq. HCl (2 N, 2 × 25 mL), The organic layer was separated 
and washed with distilled water (50 mL) and brine (50 mL), dried over MgSO4, filtered and the 
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solvent removed under reduced pressure to yield a yellow oil, which was purified by silica gel 
chromatography, eluting with dichloromethane and methanol (99:1), to yield (Z)-ethyl 3-(2-(5-
fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetamido)propanoate 215 
(3.49 g, 7.67 mmol, 91%) as a yellow crystalline solid: Rf 0.87 (90:10 CH2Cl2:MeOH); m.p. 59-
60 °C; νmax (thin film)/cm−1 3301, 2929, 1732, 1647, 1602, 1551, 1467, 1370, 1196, 1171, 1036, 
815; 1H NMR (400 MHz; CDCl3) δ 7.74 (2H, d, 3J 8.2, CH-3′,5′), 7.68 (2H, d, J 8.2, CH-2′,6′), 
7.19 (1H, s, CH-α), 7.17 (1H, dd, J 8.5, 5.5, Hz, CH-7), 6.82 (1H, dd, J 8.8, 2.4 Hz, CH-4), 6.58 
(1H, ddd, J 9.0, 8.8, 2.4 Hz, CH-6), 6.24 (1H, t, J 5.9 Hz, NH), 4.03 (2H, q, J 7.1 Hz, CH2-4′′), 
3.50 (2H, s, 2-CH2), 3.48 (2H, q, J 6.2 Hz, CH2-1′′), 2.82 (2H, s, SOCH3), 2.50 (2H, t, J 6.2 Hz, 
CH2-2′′), 2.20 (3H, s, 2-CH3) and 1.18 (3H, t, J 7.1 Hz, CH3-5′′); 13C NMR (100 MHz; CDCl3) 
δ 172.4 (quat., C-3′′), 169.4 (quat., carboxyl), 163.5 (quat., d, J 247.0 Hz, C-5), 146.6 (quat., d, 
J 8.5, C-8), 145.6 (quat., C-4′), 141.7 (quat., C-1), 139.7 (quat., C-1′), 138.8 (quat., C-2), 132.7 
(quat., C-3), 130.4 (CH × 2, C-2′,6′), 129.7 (quat., C-9), 128.7 (CH, C-α), 124.0 (CH × 2, C-
3′,5′), 123.8 (CH, d, J 9.4, C-7), 111.0 (CH, d, J 22.7 Hz, C-6), 106.1 (CH, d, J 23.9 Hz, C-4), 
60.8 (CH2, C-4′′),  44.0 (CH3, SOCH3), 35.3 (CH2, C-1′′), 34.0 (CH2, 3-CH2), 33.8 (CH2, C-2′′), 
14.2 (CH3, C-5′′) and 10.7 (CH3, 2-CH3); 19F {1H} (376 MHz; CDCl3) -112.4; m/z (ES+) 478 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C25H26FNNaO4S [M+Na]+ requires 478.1464, 
found 478.1460.  
 
(Z)-3-(2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetamido)propanoic acid, 216 
 
 
Lithium hydroxide (178 mg, 7.43 mmol) was added in a single portion to a solution of ethyl 
ester 215 (564 mg, 1.24 mmol) in THF:H2O (4:1, 20 mL) cooled in an ice bath. The resultant 
solution was stirred for one hour at 0 °C then stirred overnight at room temperature. The 
solution was cooled in an ice bath and aq. HCl (2 N, 10 mL) was added followed by extraction 
with dichloromethane (2 × 20 mL). The organic extracts were combined and washed with brine 
(25 mL), dried over MgSO4, filtered and the solvent removed under reduced pressure to yield 
(Z)-3-(2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetamido)-
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propanoic acid 216 (403 mg, 0.944 mmol, 76%) as a yellow crystalline solid: Rf 0.34 (90:10 
CH2Cl2:MeOH); m.p. 63-65 °C; νmax (thin film)/cm−1 3295, 3057, 2934, 1724, 1656, 1649, 
1467, 1322,, 1196, 815; 1H NMR (400 MHz; CDCl3) δ 7.77 (2H, d, J 8.6 Hz, CH-3′,5′), 7.72 
(2H, d, J 8.2 Hz, CH-2′,6′), 7.18 (1H, s, CH-α), 7.16 (1H, dd, J 8.6, 5.2 Hz, CH-7), 6.84 (1H, 
dd, J 8.8, 2.3 Hz, CH-4), 6.56 (1H, ddd, J 9.0, 8.8, 2.3 Hz, CH-6), 6.33 (1H, t, J 6.1 Hz, NH), 
3.52 (2H, s, 3-CH2), 3.48 (2H, q, J 6.1 Hz, CH2-1′′), 2.83 (2H, s, SOCH3), 2.54 (2H, t, 3J 6.2, 
CH2-2′′) and 2.20 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 175.3 (quat., C-3′′), 169.4 
(quat., carboxyl), 163.4 (quat., d, J 245.3 Hz, C-5), 146.3 (quat., d, J 9.0, C-8), 145.2 (quat., C-
4′), 141.5 (quat., C-1), 139.6 (quat., C-1′), 138.8 (quat., C-2), 132.7 (quat., C-3), 130.3 (CH × 2, 
C-2′,6′), 129.5 (quat., C-9), 128.6 (CH, C-α), 123.9 (CH × 2, C-3′,5′), 123.8 (CH, d, J 9.7, C-7), 
111.1 (CH, d, J 22.7, C-6), 106.0 (CH, d, J 24.4, C-4), 43.6 (CH3, SOCH3), 35.0 (CH2, C-1′′), 
33.6 (CH2, C-2′′), 33.2 (CH2, 3-CH2) and 10.5 (CH3, 2-CH3); 19F NMR {1H} (376 MHz; CDCl3) 
-112.8; m/z (ES+) 450 ([M+Na]+, 100%); m/z (ES−) 426 ([M-H]−, 100%); HRMS m/z (ES+) 
calcd. for C23H22FNNaO4S [M+Na]+ requires 450.1151, found 450.1154.  
 
N-(2-Chloroacetyl)-3-phenylsydnonimine, 217 
 
 
Triethylamine (236 mg, 325 µL, 2.33 mmol) was added to a solution of 3-phenylsydononimine 
hydrochloride 206 (200 mg, 1.02 mmol) and 2-bromoacetyl chloride (191 mg, 100 µL, 1.22 
mmol) in CH2Cl2 (25 mL) at -20 °C. The solution was allowed to warm to room temperature 
overnight with continued stirring. The solution was partitioned between dichloromethane (100 
mL) and distilled water (100 mL). The organic layer was separated and washed with distilled 
water (50 mL) and brine (50 mL), dried over Na2SO4, filtered and the solvent removed in vacuo 
to yield dark brown solid, which was purified by silica gel chromatography, eluting with 
dichloromethane and acetone (100:0 to 95:5), to provide N-(2-chloroacetyl)-3-
phenylsydnonimine 217 (160 mg, 0.78 mmol, 66%) as a fawn solid: Rf 0.61 (90:10, 
CH2Cl2:acetone); m.p. 99-100 °C; νmax (thin film)/cm−1 3121, 1647, 1556, 1468, 1400, 1362, 
1337, 1239, 1176, 974, 939, 821; 1H NMR (300 MHz; CDCl3) δ 8.51 (1H, s, CH-7), 7.84 (2H, 
d, J 7.8 Hz, CH-3,5), 7.79-7.67 (3H, m, CH-1,2,6) and 4.29 (2H, s, CH2-10); 13C NMR (100 
MHz; CDCl3) δ 175.0 (quat., C-8), 174.0 (quat., C-9), 148.1 (quat., C-4), 133.9 (CH, C-1), 
131.0 (CH × 2), 121.9 (CH × 2), 105.2 (CH, C-7) and 46.8 (CH2, C-10); m/z (ES+) 260 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C10H9N3O2Cl [M+H]+ requires 238.0385, found 
238.0383. 
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N-((4-Nitrophenoxy)carbonyl)-3-phenylsydnonimine, 218 
 
 
Triethylamine (1.18 g, 1.65 mL, 11.7 mmol) was added dropwise to a stirring solution of 3-
phenylsydononimine hydrochloride 206 (1.00 g, 5.07 mmol) and p-nitrophenyl chloroformate 
(1.53 g, 7.61 mmol) in dichloromethane (20 mL) at -20 °C. The solution was allowed to warm 
to room temperature overnight with continued stirring. The solution was partitioned between 
dichloromethane (100 mL) and distilled water (100 mL). The organic layer was separated and 
washed with distilled water (50 mL) and brine (50 mL), dried over Na2SO4, filtered and the 
solvent removed in vacuo to give a pale yellow solid which was purified by silica gel 
chromatography, eluting with dichloromethane and acetone (100:0 to 95:5), to provide N-((4-
nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 (1.04 g, 3.19 mmol, 64%) as pale yellow 
needles: Rf 0.69 (90:10, CH2Cl2:acetone, KMnO4); m.p. 198-200 °C (CH3CN); νmax (thin 
film)/cm−1 1700, 1671, 1587, 1576, 1513, 1490, 1345, 1276, 1216, 1187, 976, 765; 1H NMR 
(300 MHz; CDCl3) δ 8.27 (2H, d, J 9.0 Hz, CH-12,14), 8.20 (1H, s, CH-7), 7.84 (2H, d, J 8.4, 
CH-3,5), 7.79-7.76 (1H, m, CH-1), 7.73-7.20 (2H, m, CH-2,6) and 7.40 (2H, d, J 9.0 Hz, CH-
11,15); 13C NMR (100 MHz; CDCl3) δ 176.1 (quat., C-8), 159.3 (quat., C-9′′), 157.4 (quat., C-
10′′), 146.9 (quat., C-4′′), 144.9 (quat., C-13′′), 133.9 (CH, C-1′′), 131.1 (CH × 2) 125.3 (CH × 
2), 122.6 (CH × 2), 121.8 (CH × 2) and 103.9 (CH, C-7); m/z (ES+) 349 ([M+Na]+, 100%); 
HRMS m/z (ES+) calcd. for C15H10N4NaO5 [M+Na]+ requires 349.0549, found 349.0555. 
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(Z)-2-(5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)-N-(2-
hydroxyethyl)acetamide, 221 
 
 
 
Sulindac 112 (1.00 g, 2.81 mmol) was added to a stirring solution of carbonyl diimidazole (0.50 
g, 3.08 mmol) in dichloromethane (50 mL) and the solution stirred for 6 h with noticeable 
evolution of gas (CO2). The reaction mixture was concentrated to half its volume and added to a 
stirring solution of ethanolamine 219 (1.88 g, 1.86 mL, 30.8 mmol) in dichloromethane (100 
mL) and the resultant solution stirred overnight. This solution was washed with aq. NaOH (2 N, 
2 × 50 mL). The organic layer was separated, dried over MgSO4, filtered and the solvent 
removed under reduced pressure to give (Z)-2-(5-fluoro-2-methyl-1-(4-
(methylsulfinyl)benzylidene)-1H-inden-3-yl)-N-(2-hydroxyethyl)acetamide 221 (0.99 g, 2.47 
mmol, 88%), as a yellow crystalline solid, which was used without any further purification: Rf 
0.55 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 79-80 °C; νmax (thin 
film)/cm−1 3305, 3063, 1652, 1602, 1548, 1467, 1417, 1266, 1169, 1034, 815; 1H NMR (300 
MHz; CDCl3) δ 7.75 (2H, d, J 8.4 Hz, CH-3′,5′), 7.68 (2H, d, J 8.4 Hz, CH-2′,6′), 7.20 (1H, s, 
CH-α), 7.19 (1H, dd, J 8.5, 5.2 Hz, CH-7), 6.87 (1H, dd, J 8.7, 2.5 Hz, CH-4), 6.61 (1H, td, J 
8.9, 8.8, 2.4 Hz, CH-6), 6.05 (1H, t, br, J 5.8 Hz, NH), 3.70 (2H, t, J 5.1 Hz, CH2-2′′), 3.56 (2H, 
s, 3-CH2), 3.41 (2H, q, J 5.4 Hz, CH2-1′′), 2.82 (3H, s, SOCH3), 2.40 (1H, s, br, OH) and 2.23 
(3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 170.6 (quat., carboxyl), 163.4 (quat., d, J 247.0 
Hz, C-5), 146.0 (quat., d, J 9.0 Hz, C-8), 145.3 (quat., C-4′), 141.1 (quat., C-1), 139.7 (quat., C-
1′), 139.1 (quat., C-2), 132.6 (quat., C-3), 130.5 (CH × 2, C-2′,6′), 130.2 (quat., C-9), 129.0 
(CH, C-α), 124.3 (CH, d, J 9.0 Hz, C-7), 124.1 (CH × 2, C-3,5′), 111.7 (CH, d, J 22.1, C-6), 
106.3 (CH, d, J 23.9 Hz, C-4), 62.7 (CH2, C-2′′), 44.2 (CH3, SOCH3), 42.9 (CH2, C-2′′), 33.9 
(CH2, 3-CH2) and 10.9 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -112.7; m/z (ES+) 
422 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C22H22FNNaO3S [M+Na]+ requires 
422.1202, found 422.1211. 
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(Z)-N-(2-Aminoethyl)-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-
inden-3-yl)acetamide, 222 
 
 
Sulindac 112 (1.00 g, 2.81 mmol) was added to a stirring solution of carbonyl diimidazole (0.50 
g, 3.08 mmol) in dichloromethane (50 mL) and the solution stirred for 6 h with noticeable 
evolution of gas (CO2). The reaction mixture was concentrated to half its volume and added to a 
stirring solution of ethylenediamine 220 (1.85 g, 2.07 mL, 30.8 mmol) in dichloromethane (100 
mL) and the solution stirred overnight. The solution was washed with aq. NaOH (2 N, 2 × 50 
mL). The organic layer was separated, dried over MgSO4, filtered and the solvent removed 
under reduced pressure to give (Z)-N-(2-aminoethyl)-2-(5-fluoro-2-methyl-1-(4-
(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetamide 222 (0.90 g, 2.26 mmol, 81%), as a 
yellow crystalline solid, which was used without any further purification: Rf 0.59 (90:10, 
CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 78-79 °C; νmax (thin film)/cm−1 3278, 
3050, 1655, 1651, 1601, 1557, 1467, 1168, 1087, 1038, 956, 733; 1H NMR (300 MHz; CDCl3) 
δ 7.74 (2H, d, J 8.5 Hz, CH-3′,5′), 7.68 (2H, d, J 8.5 Hz, CH-2′,6′), 7.19 (1H, s, CH-α), 7.18 
(1H, dd, J 8.4, 5.1 Hz, CH-7), 6.88 (1H, dd, J 8.7, 2.3 Hz, CH-4), 6.59 (1H, ddd, J 8.9, 8.8, 2.5 
Hz, CH-6), 6.09 (1H, s, br, NH), 3.54 (2H, s, 3-CH2), 3.27 (2H, q, J 5.8 Hz, CH2-1′′), 2.83 (3H, 
s, SOCH3), 2.76 (2H, t, J 6.1 Hz, CH2-2′′) and 2.22 (3H, s, 2-CH3); 13C NMR (100 MHz; 
CDCl3) δ 169.8 (quat., carboxyl), 163.8 (quat., d, J 246.5 Hz, C-5), 147.1 (quat., d, J 8.7 Hz, C-
8), 145.3 (quat., C-4′), 141.5 (quat., C-1), 139.6 (quat., C-1′), 138.5 (quat., C-2), 132.8 (quat., d, 
J 2.2, C-3), 130.3 (CH × 2, C-2′,6′), 129.6 (quat., d, J 2.7 Hz, C-9), 128.4 (CH, C-α), 123.8 (CH 
× 2, C-3,5′), 123.6 (CH, d, J 9.3 Hz, C-7), 110.9 (CH, d, J 22.7 Hz, C-6), 106.0 (CH, d, J 23.9 
Hz, C-4), 43.8 (CH3, SOCH3), 42.4 (CH2, C-1′′), 41.3 (CH2, C-2′′), 33.6 (CH2, 3-CH2) and 10.6 
(CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -112.8; m/z (ES+) 421 ([M+Na]+, 100%); 
HRMS m/z (ES+) calcd. for C22H23FN2NaO2S [M+Na]+ requires 421.1362, found 421.1360. 
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(Z)-2-(5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)-N-(2-
hydroxyethyl)acetamide, 223 
 
 
 
Sulindac sulfide 115 (0.35 g, 1.03 mmol) was added to a stirring solution of carbonyl 
diimidazole (0.180 g, 1.10 mmol) in dichloromethane (50 mL) and the solution stirred for 6 h 
with noticeable evolution of gas (CO2). The reaction mixture was concentrated to half its 
volume and added to a stirring solution of ethanolamine 219 (1.02 g, 1.10 mL, 16.9 mmol) in 
dichloromethane (100 mL) and the solution stirred overnight. The solution was washed with aq. 
NaOH (2 N, 2 × 50 mL). The organic layer was separated, dried over MgSO4, filtered and the 
solvent removed under reduced pressure to give a yellow residue. This residue was purified by 
silica gel chromatography, eluting with dichloromethane and methanol (100:0 to 85:15), to 
afford (Z)-2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)-N-(2-
hydroxyethyl)acetamide 223 (0.34 g, 0.88 mmol, 85%) as a yellow solid: Rf 0.65 (90:10, 
CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 67-69 °C; νmax (thin film)/cm−1 3277, 
1652, 1601, 1543, 1307, 1145, 1088, 1066, 960; 1H NMR (300 MHz; d6-DMSO) δ 8.13 (1H, t, 
J 5.5 Hz, NH), 7.49 (2H, d, J 8.3 Hz, CH-3′,5′), 7.36-7.30 (3H, m, CH-2′,6′, 7), 7.26 (1H, s, CH-
α), 7.12 (1H, dd, J 9.5, 2.5 Hz, CH-4), 6.71 (1H, ddd, J 9.0, 8.5, 2.5 Hz, CH-6), 4.71 (1H, t, J 
5.1 Hz, OH), 3.44-3.88 (4H, m, 3-CH2, CH2-2′′), 3.13 (2H, q, J 6.0 Hz, CH2-1′′), 2.53 (3H, s, 
SCH3) and 2.16 (3H, s, 2-CH3); 13C NMR (d6-DMSO) δ 168.9 (quat., carboxyl), 162.4 (quat., d, 
J 243.4 Hz, C-5), 147.1 (quat., d, J 9.1 Hz, C-8), 139.2 (quat., C-1), 138.9 (quat., C-2), 137.8 
(quat., C-4′), 132.9 (quat., d, J 2.3 Hz, C-9), 132.7 (quat., C-3), 130.1 (quat., C-1′), 129.8 (CH × 
2, C-2′,6′), 129.6 (CH, C-α), 125.5 (CH × 2, C-3,5′), 122.9 (CH, d, J 9.1 Hz, C-7), 110.1 (CH, d, 
J 22.8 Hz, C-6), 106.0 (CH, d, J 23.7 Hz, C-4), 59.8 (CH2-4′′, C-2′′), 41.6 (CH2, C-1′′), 32.7 
(CH2, 3-CH2), 14.3 (CH3, SCH3) and 10.4 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) 
δ -114.6; m/z (ES+) 406 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C22H22FNNaO2S 
[M+Na]+ requires 406.1253, found 406.1255. 
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(Z)-N-(2-Aminoethyl)-2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-
3-yl)acetamide, 224 
 
 
Sulindac sulfide 115 (0.350 g, 1.03 mmol) was added to a stirring solution of carbonyl 
diimidazole (0.180 g, 1.10 mmol) in dichloromethane (50 mL) and the solution stirred for 6 h 
with noticeable evolution of gas (CO2). The reaction mixture was concentrated to half its 
volume and added to a stirring solution of ethylenediamine 220 (1.14 g, 1.10 mL, 16.9 mmol) in 
dichloromethane (100 mL) and the solution stirred overnight. The solution was washed with aq. 
NaOH (2 N, 2 × 50 mL). The organic layer was separated, dried over MgSO4, filtered and the 
solvent removed under reduced pressure to give a yellow residue. This residue was purified by 
silica gel chromatography, eluting with dichloromethane and methanol (100:0 to 85:15), to 
afford (Z)-N-(2-aminoethyl)-2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetamide 224 (0.35 g, 0.92 mmol, 89%) as a yellow solid: Rf 0.58 (90:10, CH2Cl2:MeOH, 
UV/cerium phosphomolybdate); m.p. 67-69 °C; νmax (thin film)/cm−1 3419, 2088, 1646, 1491, 
1465, 1320, 1262, 1170; 1H NMR (300 MHz; d6-DMSO) δ 8.46 (1H, t, J 5.4, NH), 7.48 (2H, d, 
J 8.3 Hz, CH-3′,5′), 7.36-7.30 (3H, m, CH- 2′,6′,7), 7.27 (1H, s, CH-α), 7.13 (1H, dd, J 9.4, 2.4 
Hz, CH-4), 6.72 (1H, ddd, J 9.0, 8.4, 2.4 Hz, CH-6), 3.46 (2H, s, 3-CH2), 3.25 (2H, q, J 6.2 Hz, 
CH2-1′′), 2.79 (2H, t, J 6.2 Hz, CH2-2′′), 2.53 (3H, s, SCH3) and 2.17 (3H, s, 2-CH3); 13C NMR 
(d6-DMSO) δ 169.4 (quat., carboxyl), 162.4 (quat., d, J 242.5 Hz, C-5), 147.1 (quat., d, J 9.1 
Hz, C-8), 139.2 (quat., C-1), 139.0 (quat., C-2), 138.0 (quat., C-4′), 132.6 (quat., C-9), 132.3 
(quat., C-3), 130.2 (quat., C-1′), 129.9 (CH × 2, C-2′,6′), 129.6 (CH, C-α), 125.5 (CH × 2, C-
3,5′), 122.9 (CH, d, J 9.3 Hz, C-7), 110.1 (CH, d, J 22.7 Hz, C-6), 106.1 (CH, d, J 23.7 Hz, C-
4), 38.6 (CH2, C-1′′), 38.0 (CH2, C-2′′), 32.7 (CH2, 3-CH2), 14.3 (CH3, SCH3) and 10.5 (CH3, 2-
CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -114.5; m/z (ES+) 405 ([M+Na]+, 100%); HRMS 
m/z (ES+) calcd. for C22H23FN2NaOS [M+Na]+ requires 405.1413, found 405.1409. 
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(Z)-2-(5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)-N-(2-
hydroxyethyl)acetamide, 225 
 
 
 
Sulindac sulfone 116 (0.35 g, 0.94 mmol) was added to a stirring solution of carbonyl 
diimidazole (0.18 g, 1.10 mmol) in dichloromethane (50 mL) and the solution stirred for 6 h 
with noticeable evolution of gas (CO2). The reaction mixture was concentrated to half its 
volume and added to a stirring solution of ethanolamine 219 (1.02 g, 1.10 mL, 16.9 mmol) in 
dichloromethane (100 mL) and the solution stirred overnight. The solution was washed with aq. 
NaOH (2 N, 2 × 50 mL). The organic layer was separated, dried over MgSO4, filtered and the 
solvent removed under reduced pressure to give a yellow residue. This residue was purified by 
silica gel chromatography, eluting with dichloromethane, methanol and triethylamine (100:0 to 
95:5), to afford (Z)-2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)-N-
(2-hydroxyethyl)acetamide 225 (0.35 g, 0.85 mmol, 90%) as a yellow solid: Rf 0.60 (90:10, 
CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 120-122 °C; νmax (thin film)/cm−1 3295, 
1644, 1600, 1548, 1491, 1466, 1262, 1169, 1092; 1H NMR (300 MHz; d6-DMSO) δ 8.16 (1H, t, 
J 5.6 Hz, NH), 8.03 (2H, d, J 8.4 Hz, CH-3′,5′), 7.85 (2H, d, J 8.4 Hz, CH-2′,6′), 7.35 (1H, s, 
CH-α), 7.14-7.09 (2H, m, CH-7, CH-4), 6.70 (1H, ddd, J 9.0, 8.9, 2.4 Hz, CH-6), 4.70 (1H, t, J 
5.3, OH), 3.44-3.40 (4H, m, 3-CH2 and CH2-2′′), 3.29 (3H, s, SO2CH3), 3.13 (2H, q, J 6.1 Hz, 
CH2-1′′) and 2.18 (3H, s, 2-CH3); 13C NMR (d6-DMSO) δ 168.7 (quat., carboxyl), 162.6 (quat., 
d, J 243.9 Hz, C-5), 147.4 (quat., d, J 9.6 Hz, C-8), 141.5 (quat., C-4′), 141.1 (quat., C-1′), 
140.1 (quat., C-1), 137.6 (quat., C-2), 134.2 (quat., C-3), 130.0 (CH × 2, C-2′,6′), 129.3 (quat., 
d, J 2.3 Hz, C-9), 128.3 (CH, C-α), 127.2 (CH × 2, C-3,5′), 123.1 (CH, d, J 9.3 Hz, C-7), 110.3 
(CH, d, J 22.7 Hz , C-6), 106.4 (CH, d, J 24.5 Hz, C-4), 59.8 (CH2, C-2′′), 43.4 (CH3, SO2CH3), 
41.6 (CH2, C-1′′), 32.7 (CH2, 3-CH2) and 10.3 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) 
δ -113.8; m/z (ES+) 438 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C22H22FNNaO4S 
[M+Na]+ requires 438.1151, found 438.1155. 
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(Z)-N-(2-Aminoethyl)-2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-
inden-3-yl)acetamide, 226 
 
 
 
Sulindac sulfone 116 (0.35 g, 0.94 mmol) was added to a stirring solution of carbonyl 
diimidazole (0.18 g, 1.10 mmol) in dichloromethane (50 mL) and the solution stirred for 6 h 
with noticeable evolution of gas (CO2). The reaction mixture was concentrated to half its 
volume and added to a stirring solution of ethylenediamine 220 (1.14 g, 1.10 mL, 16.9 mmol) in 
dichloromethane (100 mL) and the solution stirred overnight. The solution was washed with aq. 
NaOH (2 N, 2 × 50 mL). The organic layer was separated, dried over MgSO4, filtered and the 
solvent removed under reduced pressure to give a yellow residue. This residue was purified by 
silica gel chromatography, eluting with dichloromethane, methanol and triethylamine (100:0:0 
to 85:15:1), to afford (Z)-N-(2-aminoethyl)-2-(5-fluoro-2-methyl-1-(4-
(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetamide 226 (0.32 g, 0.78 mmol, 83%) as a 
yellow solid: Rf 0.43 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 128-130 °C; 
νmax (thin film)/cm−1 3285, 1651, 1601, 1548, 1306, 1148, 1089, 1016, 960; 1H NMR (300 
MHz; d6-DMSO) δ 8.16 (1H, t, J 5.7, NH), 8.02 (2H, d, J 8.5 Hz, CH-3′,5′), 7.88 (2H, d, J 8.5 
Hz, CH-2′,6′), 7.35 (1H, s, CH-α), 7.15-7.10 (2H, m, CH-4, 7), 6.70 (1H, ddd, J 9.0, 9.0, 2.4 Hz, 
CH-6), 3.44 (2H, s, 3-CH2), 3.29 (3H, s, SO2CH3), 3.09 (2H, q, J 6.3 Hz, CH2-1′′), 2.62 (2H, t, J 
6.3 Hz, CH2-2′′) and 2.18 (3H, s, 2-CH3); 13C NMR (100 MHz, d6-DMSO) δ 168.8 (quat., 
carboxyl), 162.8 (quat., d, J 243.6 Hz, C-5), 147.4 (quat., d, J 8.8 Hz, C-8), 141.5 (quat., C-4′), 
141.1 (quat., C-1′), 140.1 (quat., C-1), 137.0 (quat., C-2), 134.2 (quat., C-3), 130.4 (CH × 2, C-
2′,6′), 129.3 (quat., C-9), 128.4 (CH, C-α), 127.2 (CH × 2, C-3,5′), 123.1 (CH, d, J 9.2, C-7), 
110.4 (CH, d, J 22.7 Hz, C-6), 106.3 (CH, d, J 23.0 Hz, C-4), 43.4 (CH3, SO2CH3), 41.5 (CH2, 
NHC-1′′), 40.8 (CH2NH2, C-2′′), 32.7 (CH2, 3-CH2) and 10.4 (CH3, 2-CH3); 19F {1H} NMR 
(376 MHz; CDCl3) δ -113.8; m/z (ES+) 437 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C22H23FN2NaO3S [M+Na]+ requires 437.1311, found 437.1310. 
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N-(((2-(2-((Z)-5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetamido)ethoxy)carbonyl)-3-phenylsydnonimine, 227 
 
 
 
Alcohol 221 (100 mg, 0.25 mmol) and N-((4-nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 
(82 mg, 0.25) were dissolved in acetonitrile (10 mL) and heated under reflux for 24 h. The 
solvent was removed under reduced pressure and the residue purified by silica gel 
chromatography, eluting with dichloromethane and methanol (100: 0 to 90:10), to provide (Z)-
5-(((2-(2-((Z)-5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetamido)ethoxy)carbonyl)-3-phenylsydnonimine 227 (25 mg, 0.04 mmol, 17%) as a yellow 
solid: Rf 0.77 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. (acetone) 89-91 °C; 
νmax (thin film)/cm−1 3292, 3064, 1722, 1662, 1604, 1591, 1468, 1369, 1279, 1199, 1039, 969, 
858, 815, 733; 1H NMR (400 MHz; CDCl3) δ 8.08 (1H, s, CH-5′′), 7.80 (2H, d, J 8.0 Hz, CH-
3′,5′), 7.74-7.55 (7H, m, CH-2′,6′,7′′,8′′,9′′,10′′,11′′), 7.16 (1H, s, CH-α), 7.10 (1H, dd, J 8.4, 5.1 
Hz, CH-7), 6.84 (1H, dd, J 8.9, 2.4 Hz, CH-4), 6.47 (1H, ddd, J 9.0, 8.9, 2.4 Hz, CH-6), 6.46 
(1H, t, J 5.6 Hz, NH), 4.21 (2H, t, J 5.2 Hz, CH2-2′′), 3.58 (2H, q, J 5.2 Hz, CH2-1′′), 3.52 (2H, 
s, 3-CH2), 2.81 (3H, s, SOCH3) and 2.21 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 175.3 
(quat., C-4′′), 169.6 (quat., carboxyl), 163.6 (quat., d, J 246.6 Hz, C-5), 161.4 (quat., C-3′′), 
146.8 (quat., d, J 8.9 Hz, C-8), 145.7 (quat., C-4′), 141.9 (quat., C-1), 139.8 (quat., C-1′), 139.8 
(C-2, quat.), 134.0 (quat., C-6′′), 133.5 (CH, C-9′′), 132.7 (quat., C-3), 130.9 (CH × 2, C-
7′′,11′′), 130.6 (CH × 2, C-4′,6′), 130.5 (quat., C-9), 128.7 (CH, C-α), 124.1 (CH × 2, C-3′,5′), 
123.9 (CH, d, J 8.9 Hz, C-7), 121.8 (CH × 2, C-8′′,10′′), 111.1 (CH, d, J 22.6 Hz, C-6), 106.3 
(CH, d, J 24.1 Hz, C-4), 103.2 (CH, C-5′′), 64.7 (CH2, C-2′′), 44.2 (CH3, SOCH3), 39.5 (CH2, C-
1′′), 34.0 (CH2, 3-CH2) and 10.9 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -113.1; m/z 
(ES+) 609 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C31H27FN4NaO5S [M+Na]+ requires 
609.1584, found 609.1591; CHN Anal. calcd. for C31H27FN4O5S: C, 63.47; H, 4.64; N, 9.55. 
Found C, 63.50; H, 4.70; N, 9.59. 
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N-(((2-(2-((Z)-5-Fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetamido)ethoxy)carbamoyl)-3-phenylsydnonimine, 228 
 
 
 
 
Amine 222 (100 mg, 0.25 mmol) and N-((4-nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 
(82 mg, 0.25) were dissolved in acetonitrile (10 mL) and heated under reflux for 24 h. The 
solvent was removed under reduced pressure and the residue purified by silica gel 
chromatography, eluting with dichloromethane and methanol (100: 0 to 90:10), to provide (Z)-
5-(((2-(2-((Z)-5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-
yl)acetamido)ethoxy)-carbamoyl)-3-phenylsydnonimine 228 (126 mg, 0.22 mmol, 86%) as a 
yellow solid: Rf 0.53 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 118-120 °C; 
νmax (thin film)/cm−1 3428, 1728, 1632, 1602, 1526, 1468, 1368, 1295, 1136, 960; 1H NMR 
(400 MHz; CDCl3) δ 8.02 (1H, s, CH-5′′), 7.74-7.61 (9H, m, CH-2′,3′,5′,6′,7′′,8′′,9′′, 10′′,11′′), 
7.13 (1H, s, CH-α), 7.11 (1H, dd, J 8.3, 5.1 Hz, CH-7), 6.88 (1H, dd, J 8.8, 2.4 Hz, CH-4), 6.70 
(1H, s, br, NH), 6.47 (1H, ddd, J 9.0, 8.8, 2.4 Hz, CH-6), 5.78 (1H, s, br, NH), 3.50 (2H, s, 3-
CH2), 3.42-3.36 (4H, m, CH2-1′′, 2′′), 2.81 (3H, s, SOCH3) and 2.21 (3H, s, 2-CH3); 13C NMR 
(100 MHz; CDCl3) 173.0 (quat., C-4′′), 169.8 (quat., carboxyl), 163.6 (quat., d, J 248.0 Hz, C-
5), 162.9 (quat., C-3′′), 147.0 (quat., d, J 8.8 Hz, C-8), 145.8 (quat., C-4′), 141.9 (quat., C-1), 
139.9 (quat., C-1′), 138.9 (C-2, quat.), 134.2 (quat., C-6′′), 133.2 (CH, C-9′′), 133.0 (quat., C-3), 
130.7 (CH × 2, C-7′′,11′′), 130.5 (CH × 2, C-4′,6′) 129.9 (quat., C-9), 128.5 (CH, C-α), 124.1 
(CH × 2, C-3′,5′), 123.8 (CH, d, J 8.8 Hz, C-7), 121.7 (CH × 2, C-8′′,10′′), 111.0 (CH, d, J 22.5 
Hz, C-6), 106.3 (CH, d, J 23.2 Hz, C-4), 102.2 (CH, C-5′′), 44.2 (CH3, SOCH3), 41.1 (CH2, 
CH2, C-2′′), 40.6 (CH2, C-1′′), 34.1 (CH2, 3-CH2) and 10.9 (CH3, 2-CH3); 19F {1H} NMR (376 
MHz; CDCl3) δ -113.2; m/z (ES+) 608 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C31H28FN5NaO4S [M+Na]+ requires 608.1744, found 608.1745; CHN Anal. calcd. for 
C31H28FN5O4S: C, 63.58; H, 4.82; N, 11.96. Found C, 63.66; H, 4.89; N, 12.00. 
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N-(((2-(2-((Z)-5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetamido)ethoxy)carbonyl)-3-phenylsydnonimine, 229 
 
 
 
Alcohol 223 (100 mg, 0.26 mmol) and N-((4-nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 
(85 mg, 0.26) were dissolved in acetonitrile (10 mL) and heated under reflux for 60 h. The 
solvent was removed under reduced pressure and the residue purified by silica gel 
chromatography, eluting with dichloromethane and methanol (100:0 to 90:10), to provide N-
(((2-(2-((Z)-5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetamido)ethoxy)-
carbonyl)-3-phenylsydnonimine 229 (71 mg, 0.118 mmol, 56%) as a yellow solid: Rf 0.78 
(90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 81-83 °C; νmax (thin film)/cm−1 
1658, 1603, 1589, 1467, 1369, 1278, 1198, 1070, 970; 1H NMR (400 MHz; CDCl3) δ 8.03 (1H, 
s, CH-5′′), 7.80-7.62 (4H, m, CH-3′,5′,7′′,11′′), 7.47-7.42 (1H, m, CH-9′′), 7.40 (1H, dd, J 8.4, 
5.1 Hz, CH-7), 7.33-7.26 (4H, m, CH-2′,6′,8′′,10′′), 7.13 (1H, s, CH-α), 6.84 (1H, dd, J 9.0, 2.3 
Hz, CH-4), 6.48 (1H, ddd, J 9.0, 9.0, 2.3 Hz, CH-6), 6.30 (1H, t, J 5.7 Hz, NH), 4.20 (2H, t, J 
5.1 Hz, CH2-2′′), 3.57 (2H, q, J 5.4 Hz, CH2-1′′), 3.52 (2H, s, 3-CH2), 2.55 (3H, s, SCH3) and 
2.19 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 175.3 (quat., C-4′′), 169.9 (quat., 
carboxyl), 163.4 (quat., d, J 246.6 Hz, C-5), 161.4 (quat., C-3′′), 146.5 (quat., d, J 8.8 Hz, C-8), 
140.2 (quat., C-1), 140.0 (C-2, quat.), 139.5 (quat., C-4′), 139.4 (quat., C-1′), 134.0 (quat., C-
6′′), 133.5 (quat., C-3), 133.1 (CH, C-9′′), 130.8 (CH × 2, C-7′′,11′′), 130.5 (CH, C-α), 130.2 
(CH × 2, C-4′,6′), 130.1 (quat., C-9), 126.1 (CH × 2, C-3′,5′), 123.9 (CH, d, J 9.1 Hz, C-7), 
121.8 (CH × 2, C-8′′,10′′), 110.9 (CH, d, J 22.6 Hz, C-6), 105.9 (CH, d, J 23.7 Hz, C-4), 103.2 
(CH, C-5′′), 64.7 (CH2, C-2′′), 39.5 (CH2, C-1′′), 34.0 (CH2, 3-CH2), 15.6 (CH3, SCH3) and 10.9 
(CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -114.0; m/z (ES+) 593 ([M+Na]+, 100%); 
HRMS m/z (ES+) calcd. for C31H27FN4NaO4S [M+Na]+ requires 593.1635, found 593.1640; 
CHN Anal. calcd. for C31H27FN4O4S: C, 65.25; H, 4.77; N, 9.82. Found C, 65.30; H, 4.78; N, 
9.89. 
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N-(((2-(2-((Z)-5-Fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetamido)ethoxy)carbamoyl)-3-phenylsydnonimine, 230 
 
 
 
Amine 224 (100 mg, 0.26 mmol) and N-((4-nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 
(85 mg, 0.26) were dissolved in acetonitrile (10 mL) and heated under reflux for 24 h. The 
solvent was removed under reduced pressure and the residue purified by silica gel 
chromatography, eluting with dichloromethane and methanol (100: 0 to 90:10), to provide N-
(((2-(2-((Z)-5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-
yl)acetamido)ethoxy)carbamoyl)-3-phenylsydnonimine 230 (126 mg, 0.22 mmol, 86%) as a 
yellow solid: Rf 0.60 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 129-130 °C; 
νmax (thin film)/cm−1 1632, 1601, 1548, 1467, 1365, 1293, 1168, 1092, 966; 1H NMR (400 
MHz; d6-DMSO) δ 8.27 (1H, s, CH-5′′), 8.12 (1H, t, J 5.0 Hz, NH), 7.96 (2H, d, J 8.6 Hz, CH-
7′′,11′′), 7.57-7.66 (3H, m, CH- 3′,5′,9′′), 7.48-7.44 (2H, m, CH-8′′,10′′), 7.34-7.28 (3H, m, CH-
7,2′,6′), 7.23 (1H, s, CH-α), 7.06 (1H, dd, J 9.4, 2.5 Hz, CH-4), 6.96 (1H, t, J 5.3 Hz, NH), CH), 
6.70 (1H, m, CH-6), 3.40 (2H, s, 3-CH2), 3.14 (4H, app. s, CH2-1′′, 2′′), 2.51 (3H, s, SCH3) and 
2.15 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) 171.1 (quat., C-4′′), 169.4 (quat., carboxyl), 
162.7 (quat., d, J 242.9 Hz, C-5), 161.3 (quat., C-3′′), 147.3 (quat., d, J 8.9 Hz, C-8), 139.4 
(quat., C-1), 139.2 (quat., C-2), 138.3 (quat., C-4′), 134.0 (quat., C-6′′), 133.0 (CH, C-9′′), 132.9 
(quat., C-3), 132.8 (quat., C-9), 130.4 (quat., C-1′), 130.5 (CH × 2, C-4′,6′), 130.1 (CH × 2, C-
7′′,11′′), 129.8 (CH, C-α), 125.7 (CH × 2, C-3′,5′), 123.1 (CH, d, J 8.9 Hz, C-7), 122.3 (CH × 2, 
C-8′′,10′′), 111.3 (CH, d, J 22.8 Hz, C-6), 106.1 (CH, d, J 23.8 Hz, C-4), 102.5 (CH, C-5′′), 41.1 
(CH2, × 2 C-1′′,2′′), 33.0 (CH2, 3-CH2), 15.4 (CH3, SCH3) and 10.6 (CH3, 2-CH3); 19F {1H} 
NMR (376 MHz; CDCl3) δ -114.5; m/z (ES+) 592 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. 
for C31H28FN5NaO3S [M+Na]+ requires 592.1795, found 592.1801; CHN Anal. calcd. for 
C31H28FN5O3S: C, 65.36; H, 4.95; N, 12.29. Found C, 65.39; H, 4.40; N, 12.32. 
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N-(((2-(2-((Z)-5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetamido)ethoxy)carbonyl)-3-phenylsydnonimine, 231 
 
 
 
Alcohol 225 (100 mg, 0.25 mmol) and N-((4-nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 
(82 mg, 0.25) were dissolved in acetonitrile (10 mL) and heated under reflux for 24 h. The 
solvent was removed under reduced pressure and the residue purified by silica gel 
chromatography, eluting with dichloromethane and methanol (100: 0 to 90:10), to provide N-
(((2-(2-((Z)-5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetamido)-
ethoxy)carbonyl)-3-phenyl-sydnonimine 231 (84 mg, 0.15 mmol, 49%) as a yellow solid: Rf 
0.62 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 99-101 °C; νmax (thin 
film)/cm−1 1660, 1603, 1590, 1468, 1369, 1308, 1280, 1199, 1148, 970; 1H NMR (400 MHz; 
CDCl3) δ 8.06 (1H, s, CH-5′′), 8.01 (2H, d, J 8.4 Hz, CH-3′,5′), 7.88-7.81 (2H, m, CH-7′, 11′), 
7.74-7.66 (5H, m, CH-2′,6′,8′′,9′′,10′′), 7.13 (1H, s, CH-α), 7.04 (1H, dd, J 8.4, 5.1, CH-7), 6.85 
(1H, dd, J 8.8, 2.4 Hz, CH-4), 6.46 (1H, ddd, J 9.0, 8.8, 2.4 Hz, CH-6), 6.30 (1H, t, J 6.0 Hz, 
NH), 4.20 (2H, t, J 5.1 Hz, CH2-2′′), 3.59 (2H, q, J 6.0 Hz, CH2-1′′), 3.52 (2H, s, 3-CH2), 3.14 
(3H, s, SO2CH3) and 2.20 (3H, s, 2-CH3); 13C NMR (100 MHz; CDCl3) δ 175.3 (quat., C-4′′), 
169.5 (quat., carboxyl), 163.7 (quat., d, J 247.1 Hz, C-5), 161.4 (quat., C-3′′), 146.9 (quat., d, J 
8.6 Hz, C-8), 142.7 (quat., C-4′), 142.5 (quat., C-1′), 140.1 (quat., C-1), 138.9 (quat., C-2), 
134.0 (quat., C-6′′), 133.6 (CH, C-9′′), 133.3 (quat., C-3), 130.9 (CH × 2, C-7′′,11′′), 130.5 (CH 
× 2, C-4′,6′), 129.7 (quat., C-9), 128.7 (CH × 2, C-3′,5′), 127.7 (CH, C-α), 123.9 (CH, d, J 9.3 
Hz, C-7), 121.7 (CH × 2, C-8′′,10′′), 111.2 (CH, d, J 22.8 Hz, C-6), 106.5 (CH, d, J 23.7 Hz, C-
4), 103.1 (CH, C-5′′), 64.7 (CH2, C-2′′), 44.8 (CH3, SO2CH3), 39.4 (CH2, C-1′′), 34.0 (CH2, 3-
CH2) and 10.9 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -112.6; m/z (ES+) 625 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C31H27FN4NaO6S [M+Na]+ requires 625.1533, 
found 625.1535; CHN Anal. calcd. for C31H27FN4O6S: C, 61.78; H, 4.52; N, 9.30. Found C, 
61.80; H, 4.55; N, 9.33. 
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N-(((2-(2-((Z)-5-Fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetamido)ethoxy)carbamoyl)-3-phenylsydnonimine, 232 
 
 
 
Amine 226 (100 mg, 0.24 mmol) and N-((4-nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 
(79 mg, 0.24) were dissolved in acetonitrile (10 mL) and heated under reflux for 24 h. The 
solvent was removed under reduced pressure and the residue purified by silica gel 
chromatography, eluting with dichloromethane and methanol (100: 0 to 90:10), to provide N-
(((2-(2-((Z)-5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-
yl)acetamido)ethoxy)-carbamoyl)-3-phenyl-sydnonimine 232 (131 mg, 0.22 mmol, 90%) as a 
yellow solid: Rf 0.59 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 118-120 °C; 
νmax (thin film)/cm−1 1730, 1650, 1626, 1530, 1469, 1303, 1145, 1087; 1H NMR (400 MHz; d6-
DMSO) δ 8.34 (1H, s, CH-5′′), 8.12 (1H, t, J 5.0 Hz, NH), 8.01 (2H, d, J 8.3 Hz, CH-3′,5′), 
7.79-7.66 (7H, m, CH-2′,6′,7′′,8′′,9′′,10′′,11′′), 7.34 (1H, s, CH-α), 7.14-7.06 (2H, m, CH-7 and 
CH-4), 7.00 (1H, t, J 5.5 Hz, NH), 6.89 (1H, ddd, J 9.0, 8.6, 2.6 Hz, CH-6), 3.43 (2H, s, 3-CH2), 
3.29 (3H, s, SO2CH3), 3.16-3.13 (4H, m, CH2-1′′, 2′′) and 2.18 (3H, s, 2-CH3); 13C NMR (100 
MHz; d6-DMSO) 171.8 (quat., C-4′′), 168.8 (quat., carboxyl), 162.6 (quat., d, J 249.1 Hz, C-5), 
161.1 (quat., C-3′′), 147.4 (quat., d, J 9.8 Hz, C-8), 141.5 (quat., C-4′), 141.1 (quat., C-1′), 140.1 
(quat., C-1), 137.8 (quat., C-2), 134.1 (quat., C-3), 133.8 (quat., C-6′′), 132.6 (CH, C-9′′), 130.2 
(CH × 2, C-4′,6′), 130.0 (CH × 2, C-7′′,11′′), 127.2 (CH × 2, C-3′,5′), 129.3 (quat., C-9), 128.3 
(CH, C-α), 123.1 (CH, d, J 7.3 Hz, C-7), 122.1 (CH × 2, C-8′′,10′′), 110.3 (CH, d, J 23.2 Hz, C-
6), 106.3 (CH, d, J 25.4 Hz, C-4), 102.3 (CH, C-5′′), 44.3 (CH3, SO2CH3), 39.8 (CH2, × 2 C-1′′, 
C-2′′), 32.8 (CH2, 3-CH2) and 10.4 (CH3, 2-CH3); 19F {1H} NMR (376 MHz; CDCl3) δ -113.7; 
m/z (ES+) 624 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C31H28FN5NaO5S [M+Na]+ 
requires 624.1693, found 624.1700; CHN Anal. calcd. for C31H28FN5O5S: C, 61.89; H, 4.69; N, 
11.64. Found C, 61.90; H, 4.72; N, 11.64. 
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A.5 EXPERIMENTAL PROCEDURES FOR CHAPTER FOUR 
 
(3β)-3-(Acetyloxy)-5-androsten-17-one, 243402 
 
 
 
Boron trifluoride diethyl etherate (22 mg, 10 µL, 0.16 mmol) was added to a suspension of 
dehydroepiandrosterone 235 (1.00 g, 3.47 mmol) in dichloromethane (5 mL). Acetic anhydride 
(460 mg, 430 µL, 4.51 mmol) was added dropwise and the solution stirred for 4 h. Water (10 
mL) was added and the biphasic mixture stirred for 30 min. The aqueous layer was extracted 
with dichloromethane (15 mL). The organic layers were combined and washed with aq. Sodium 
hydrogen carbonate solution (saturated, 15 mL), dried over Na2SO4. The mixture was filtered 
and the solvent removed under reduced pressure to provide (3β)-3-(acetyloxy)-5-androsten-17-
one 243 (1.15 g, 3.47 mmol, quant.) as a white solid, which was used without any further 
purification: Rf 0.55 (20:80, EtOAc:cyclohexane, UV/cerium phosphomolybdate); m.p. 
(hexane) 171-172 °C, [Lit.403 172 °C]; [𝛂]𝐃𝟐𝟎 -6.9 (c = 2.0, CHCl3), [Lit.403 -7.0, (c = 2.0, 
CHCl3]; 1H NMR (300 MHz; CDCl3) δ 5.41 (1H, d, J 5.0 Hz, CH-6), 4.66-4.55 (1H, m, CH-3), 
2.51 (1H, dd, J 20.0, 9.0 Hz, CHAHB-16), 2.38-2.28 (2H, m, CH2-1), 2.17-2.05 (2H, m, CHAHB-
16, CHAHB-12), 2.03 (3H, s, CH3-21), 2.01-1.92 (1H, m, CHAHB-15), 1.92-1.79 (3H, m, 
CHAHB-7, CHAHB-4, CHAHB-2), 1.76-1.40 (6H, m, CHAHB-15, CHAHB-12, CH2-11, CH-8, 
CHAHB-2), 1.38-1.23 (2H, m, CH-9, CHAHB-7), 1.21-0.96 (5H, m, CH-14, CHAHB-4, CH3-18 
and CH3-19), 0.88 (3H, s, CH3-18); 13C NMR (100 MHz; CDCl3) δ 221.1 (quat., C-17), 170.5 
(quat., C-20), 139.9 (quat., C-5), 121.9 (CH, C-6), 73.7 (CH, C-3), 51.7 (CH, C-9), 49.5 (CH, 
C-14), 47.5 (quat., C-13), 40.0 (CH2, C-4), 38.1 (CH2, C-1), 36.8 (quat., C-10), 35.9 (CH2, C-
16), 31.5 (CH, C-8), 31.4 (CH2, C-7), 30.8 (CH2, C-12), 27.7 (CH2, C-2), 21.9 (CH2, C-15), 
21.4 (CH3, C-21), 20.3 (CH2, C-11), 19.4 (CH3, C-19), 13.6 (CH3, C-18); m/z (ES+) 353 
([M+Na]+, 100%). The data were in agreement with the literature values.402,403  
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(3β)-Acetyloxyandrosta-5-16-dien-17-yl trifluoromethanesulfonate, 244291 
 
 
 
Trifluoromethanesulfonic anhydride (1.71 g, 1.02 mL, 6.06 mmol) was added dropwise to a 
solution of (3β)-3-(acetyloxy)-5-androsten-17-one 243 (2.00 g, 6.06 mmol) and 2,6-di-tert-
butyl-4-methylpyridine (1.49 g, 7.27 mmol) and stirred at room temperature for 16 h. The 
suspension was filtered and the filtrate washed with water (4 mL), dried over MgSO4. The 
mixture was filtered and the solvent adsorbed onto silica gel. Purification by silica gel 
chromatography, eluting with petroleum ether and dichloromethane (95:5 to 60:40) provided 
(3β)-acetyloxyandrosta-5-16-dien-17-yl trifluoromethanesulfonate 244 (1.64 g, 3.51 mmol, 
58%) as an orange solid: Rf 0.67 (20:80, EtOAc:cyclohexane, UV/cerium phosphomolybdate); 
m.p. (hexane) 75-76 °C [Lit.291 75-76 °C]; [𝛂]𝐃𝟐𝟎 -34.8, (c = 1.0, CHCl3); 1H NMR (300 MHz; 
CDCl3) δ 5.58 (1H, dd, J 3.3, 1.7 Hz CH-16), 5.40-5.38 (1H, m, CH-6), 4.68-4.56 (1H, m, CH-
3), 2.37-2.31 (2H, m, CH2-1) 2.23 (1H, ddd, J 15.0, 6.3, 3.3 Hz, CHAHB-12), 2.03 (3H, s, CH3-
21), 2.02-1.98 (2H, m, CHAHB-15, CHAHB-12), 1.90-1.82 (2H, m, CHAHB-4, CHAHB-2), 1.71-
1.44 (7H, m, CHAHB-15, CH2-11, CH-9, CH-8, CHAHB-7, CHAHB-2), 1.18-1.08 (2H, m, CH-14, 
CHAHB-4), 1.05 (3H, s, CH3-19), 0.99 (3H, s, CH3-18); 13C NMR (100 MHz; CDCl3) δ 170.5 
(quat., C-20), 159.2 (quat., C-17), 140.1 (quat., C-5), 121.8 (CH, C-6), 117.3 (quat., C-22), 
114.5 (CH2, C-16), 73.7 (CH, C-3), 54.2 (CH, C-9), 50.3 (CH, C-14), 44.6 (quat., C-13), 38.1 
(CH2, C-1), 36.8 (CH2, C-4), 36.7 (quat., C-10), 32.7 (CH2, C-7), 30.5 (CH2, C-12), 29.9 (CH, 
C-8),  28.6 (CH2, C-15), 27.7 (CH2, C-2), 21.5 (CH3, C-21), 20.1 (CH2, C-11), 19.2 (CH3, C-
19), 15.1 (CH3, C-18); 19F {1H} -74.1 (CF3); m/z (ES+) 485 ([M+H]+, 100%). The data were in 
agreement with the literature values.291 
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3β-Acetoxy-17-(3-pyridyl)androsta-5,16-diene (abiraterone acetate), 246291 
 
 
 
Diethyl(3-pyridyl)borane (974 mg, 6.66 mmol) was added to a solution of vinyl triflate 244 
(2.00 g, 4.33 mmol) in THF (22 mL) containing bis(triphenylphosphine)palladium (II) chloride 
(60 mg, 0.09 mmol). Aqueous sodium carbonate (2 M, 8.6 mL) was added and the solution was 
stirred at 80 °C for 1 h. The biphasic mixture was partitioned between diethyl ether and water 
(1:1, 150 mL). The organic layer was separated and dried over Na2CO3. The mixture was 
filtered through a plug of silica gel and adsorbed onto silica gel. Purification by silica gel 
chromatography, eluting with petroleum ether and diethyl ether (85:15 to 40:60) provided 3β-
acetoxy-17-(3-pyridyl)androsta-5,16-diene 246 (abiraterone acetate) 246 (1.47 g, 3.76 mmol, 
87%) as a white solid: Rf 0.35 (20:80, EtOAc:cyclohexane, UV/cerium phosphomolybdate); 
m.p. 144-146 °C [Lit.291 144-145 °C]; [𝛂]𝐃𝟐𝟎-41.4, (c = 1.0, CHCl3); 1H NMR (300 MHz; 
CDCl3) δ 8.58 (1H, d, J 1.7 Hz, CH-2′), 8.41 (1H, dd, J 5.0, 1.8 Hz, CH-6′), 7.60 (1H, ddd, J 
8.0, 1.7, 1.8 Hz, CH-4′), 7.17 (1H, dd, J 8.0, 5.0 Hz, CH-5′), 5.95-5.94 (1H, m, CH-16), 5.37 
(1H, d, J 5.7 Hz, CH-6), 4.62-4.51 (1H, m, CH-3), 2.39-2.29 (2H, m, CH2-1), 2.22 (1H, ddd, J 
15.8, 6.4, 3.5 Hz, CHAHB-12), 2.06-1.97 (2H, m, CHAHB-12, CHAHB-7), 1.97 (3H, s, CH3-21), 
1.84-1.77 (2H, m, CHAHB-2, CHAHB-4), 1.76-1.38 (8H, m, CHAHB-2, CHAHB-7, CH-8, CH-9, 
CH2-11,15), 1.18-0.99 (2H, m, CHAHB-4, CH-14), 1.03 (3H, s, CH3-19), 1.00 (3H, s, CH3-18); 
13C NMR (100 MHz; CDCl3) δ 170.4 (quat., C-20), 151.6 (quat., C-17), 147.7 (quat. × 2, C-
2′,6′), 140.0 (quat., C-5), 133.7 (CH, C-4′), 132.9 (quat., C-1′), 129.5 (CH2, C-16), 123.0 (CH, 
C-5′), 122.3 (CH, C-6), 73.8 (CH, C-3), 57.4 (CH, C-9), 50.2 (CH, C-14), 47.3 (quat., C-13), 
38.1 (CH2, C-1), 36.9 (CH2, C-4), 36.8 (quat., C-10), 35.2 (CH2, C-7), 31.8 (CH2, C-12), 31.5 
(CH2, C-15), 30.4 (CH, C-8), 27.7 (CH2, C-2), 21.4 (CH3, OAc), 20.8 (CH2, C-11), 19.2 (CH3, 
C-19), 16.6 (CH3, C-18), m/z (ES+) 414 ([M+Na]+, 100%). The data were in agreement with the 
literature values.291 
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17-(3-Pyridyl)androsta-5,16-dien-3β-ol  (abiraterone), 106291 
 
 
 
 
KOH (10% w/v in MeOH, 3.4 mL) was added to a solution of abiraterone acetate 246 (500 mg, 
1.28 mmol) in MeOH (10 mL) and the resultant solution stirred for 1 hour. The suspension was 
added to water (50 mL), neutralised with aq. HCl (2 N) and rebasified with aq. sodium 
hydrogen carbonate solution (saturated). The aqueous froth was extracted with chloroform (3 × 
75 mL), dried over Na2SO4. The mixture was filtered and the solvent evaporated under reduced 
pressure, to afford 17-(3-pyridyl)androsta-5,16-dien-3β-ol (abiraterone) 106 (446 mg, 1.28 
mmol, quant.) as a white solid, which was used without any further purification: m.p. 228-230 
°C [Lit.291 228-229 °C]; Rf 0.29 (50:50, EtOAc:Cyclohexane, UV/cerium phosphomolybdate); [𝛂]𝐃𝟐𝟎 -47.6, (c = 1.0, CHCl3); 1H NMR (300 MHz; CDCl3) δ 8.61 (1H, d, J 1.9 Hz, CH-2′), 
8.45 (1H, dd, J 4.9, 1.6 Hz, CH-6′), 7.64 (1H, ddd, J 7.9, 1.9, 1.6, CH-4′), 7.21 (1H, dd, J 7.9, 
4.9 Hz, CH-5′), 5.99 (1H, d, J 3.8, 1.2 Hz, CH-16), 5.41-5.37 (1H, m, CH-6), 3.59-3.49 (1H, m, 
CH-3), 2.37-2.20 (3H, m, CH2-1, CHAHB-2), 2.13-1.99 (3H, m, CH2-12, CHAHB-7), 1.90-1.81 
(2H, m, CHAHB-2, CHAHB-4), 1.79-1.72 (1H, m, CH-8), 1.72-1.46 (6H, m, CHAHB-7, CH-9, 
CH2-11, CH2-15), 1.15-1.09 (2H, m, CHAHB-4, CH-7). 1.07 (3H, s, CH3-19), 1.04 (3H, s, CH3-
18); 13C NMR (100 MHz; CDCl3) δ 151.7 (quat., C-17), 147.9 (quat. × 2, C-2′,6′), 141.2 (quat., 
C-5), 133.7 (CH, C-4′), 133.0 (quat., C-1′), 129.3 (CH2, C-16), 123.0 (CH, C-5′), 121.6 (CH, C-
6), 71.7 (CH, C-3), 57.6 (CH, C-9), 50.4 (CH, C-14), 47.4 (quat., C-13), 42.3 (CH2, C-4), 37.2 
(CH2, C-1), 36.7 (quat., C-10), 35.3 (CH2, C-7), 31.8 (CH2, C-12), 31.7 (CH2, C-2), 31.5 (CH2, 
C-15), 30.5 (CH, C-8), 20.9 (CH2, C-11), 19.4 (CH3, C-19), 16.6 (CH3, C-18); m/z (ES+) 372 
([M+Na]+, 100%). The data were in agreement with the literature values.291 
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17-(3-Pyridyl)androsta-5,16-dien-3β-ol 3-butanoate, 250 
 
 
 
Butyric acid 250 (25 mg, 26 µL, 0.17 mmol) and DMAP (20 mg, 0.14 mmol) were added to a 
solution of abiraterone 106 (50 mg, 0.14 mmol) in dichloromethane (7 mL). EDCI.HCl (40 mg, 
0.210 mmol) was added in a single portion and the solution stirred for 4 h. The solution was 
washed with water (5 mL) and dried over MgSO4. The mixture was filtered and the solvent 
adsorbed onto silica gel. Purification by silica gel chromatography, eluting with ethyl acetate 
and petroleum ether (15:85 to 25:75), provided 17-(3-pyridyl)androsta-5,16-dien-3β-ol 3-
butanoate 250 (58 mg, 0.14, 97%) as a white solid: Rf 0.74 (50:50, EtOAc:cyclohexane, 
UV/cerium phosphomolybdate); m.p. 104-105 °C; [𝛂]𝐃𝟐𝟎 -14.8, (c = 1.0, CHCl3); νmax (thin 
film)/cm−1 1765, 1640, 1560, 1440, 1225, 1060, 751; 1H NMR (300 MHz; CDCl3) δ 8.61 (1H, 
d, J 1.9 Hz, CH-2′), 8.45 (1H, dd, J 4.8, 1.5 Hz, CH-6′), 7.65 (1H, dt, J 8.0, 1.9 Hz, CH-4′), 7.22 
(1H, dd, J 8.0, 4.8 Hz, CH-5′), 5.99 (1H, dd, J 3.2, 1.7 Hz, CH-16), 5.41 (1H, d, J 5.2 Hz, CH-
6), 4.66-4.59 (1H, m, CH-3), 2.36-2.31 (2H, m, CH2-1), 2.28-2.24 (3H, m, CH2-2′′, CHAHB-12), 
2.09-2.01 (2H, m, CHAHB-12, CHAHB-7), 1.88-1.84 (2H, m, CHAHB-2, CHAHB-4), 1.78-1.55 
(9H, m, CHAHB-2, CH2-3′′, CH-8,9, CH2-11,15), 1.48 (1H, td, J 24.9, 12.4, 5.2 Hz, CHAHB-7), 
1.27-1.12 (2H, m, CHAHB-4, CH-14), 1.08 (3H, s, CH3-19), 1.04 (3H, s, CH3-18) and 0.94 (3H, 
t, J 7.4 Hz, CH3-4′′); 13C NMR (100 MHz; CDCl3) δ 173.2 (quat., C-1′′), 151.6 (quat., C-17), 
147.7 (CH, C-2′), 147.7 (CH, C-6′), 140.1 (quat., C-5), 133.8 (CH, C-4′), 133.0 (quat., C-1′), 
129.3 (CH, C-16), 123.1 (CH, C-5′), 122.2 (CH, C-6), 73.6 (CH, C-3), 57.5 (CH, C-9), 50.3 
(CH, C-14), 47.3 (quat., C-13), 38.2 (CH2, C-1), 36.9 (CH2, C-4), 36.8 (quat., C-10), 35.2 (CH2, 
C-7), 31.8 (CH2, C-12), 31.5 (CH2, C-2′′), 31.5 (CH2, C-15), 30.4 (CH, C-8), 27.7 (CH2, C-2),  
20.8 (CH2, C-11), 19.3 (CH3, C-19), 18.6 (CH2, C-3′′), 16.6 (CH3, C-18) and 13.7 (CH3, C-4′′); 
m/z (ES+) 442 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C28H37NNaO2 [M+Na]+ requires 
442.2722, found 442.2725; CHN Anal. calcd. For C28H37NO2: C, 80.15; H, 8.89; N, 3.34. 
Found C, 80.22; H, 8.95; N, 3.35. 
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17-(3-Pyridyl)androsta-5,16-dien-3β-ol 3-(4-bromo)butanoate, 257 
  
 
 
4-Bromobutyric acid 256 (53 mg, 0.32 mmol) and DMAP (35 mg, 0.29 mmol) were added to a 
solution of abiraterone 106 (100 mg, 0.29 mmol) in chloroform (7 mL). EDCI.HCl (36 mg, 0.22 
mmol) was added in a single portion and the solution stirred for 4 h. The solution was washed 
with water and dried over MgSO4. The mixture was filtered and the solvent evaporated to yield 
17-(3-pyridyl)androsta-5,16-dien-3β-ol 3-(4-bromo)butanoate 257 (130 mg, 0.26, 92%) as an 
off white solid: Rf 0.61 (50:50, EtOAc:cyclohexane, UV/cerium phosphomolybdate); m.p. 94-
98 °C; [𝛂]𝐃𝟐𝟎+4.0, (c = 1.0, CHCl3); νmax (thin film)/cm−1 3040, 2939, 1772, 1727, 1650, 1601, 
1464, 1373, 1259, 1200, 1129, 1024, 996, 798, 735; 1H NMR (300 MHz; CDCl3) δ 8.52 (1H, s, 
CH-2′), 8.45 (1H, d, J 4.1 Hz, CH-6′), 7.64 (1H, dt, J 8.4, 1.7 Hz, CH-4′), 7.21 (1H, dd, J 7.9, 
4.8 Hz, CH-5′), 5.98 (1H, dd, J 2.7, 1.5 Hz, CH-16), 5.42 (1H, d, J 4.9 Hz, CH-6), 4.60-4.54 
(1H, m, CH-3), 3.44 (2H, t, J 7.1 Hz, CH2-4′′), 2.47 (2H, t, J 7.3 Hz, CH2-2′′), 2.35-2.30 (2H, m, 
CH2-1), 2.28-2.24 (1H, m, CHAHB-12), 2.16 (2H, pentet, J 7.1 Hz, CH2-3′′), 2.03-1.96 (2H, m, 
CHAHB-7, CHAHB-12), 1.83-1.78 (2H, m, CHAHB-2, CHAHB-4), 1.73-1.39 (8H, m, CHAHB-2, 
CHAHB-7, CH-8,9, CH2-11,15) 1.09-1.04 (2H, m, CHAHB-4, CH-14), 1.04 (3H, s, CH3-19) and 
1.00 (3H, s, CH3-18); 13C NMR (100 MHz; CDCl3) δ 172.0 (quat., C-1′′), 151.7 (quat., C-17), 
147.9 (CH, C-2′), 147.9 (CH, C-6′), 139.9 (quat., C-5), 133.7 (CH, C-4′), 132.9 (quat., C-1′), 
129.2 (CH, C-16), 123.0 (CH, C-5′), 122.4 (CH, C-6), 74.1 (CH, C-3), 57.4 (CH, C-9), 50.2 
(CH, C-14), 47.3 (quat., C-13), 38.1 (CH2, C-1), 36.9 (CH2, C-4), 36.8 (quat., C-10), 35.2 (CH2, 
C-7), 32.8 (CH2, C-2′′), 32.8 (CH2, C-4′′), 31.8 (CH2, C-12), 31.5 (CH2, C-15), 30.4 (CH, C-8), 
27.8 (CH2, C-3′′), 27.7 (CH2, C-2),  20.8 (CH2, C-11), 19.2 (CH3, C-19), 16.6 (CH3, C-18); m/z 
(ES+) 520 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C28H36BrNNaO2 [M+Na]+ requires 
520.1827, found 520.1825. 
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Methyl 4-bromobutanoate, 259404 
 
 
 
Acetyl chloride (576 mg, 550 µL, 7.34 mmol) was added to a solution of 4-bromobutyric acid 
256 (5.00 g, 30.0 mmol) in methanol (40 mL) cooled to 0 °C. The resulting solution was 
allowed to warm to room temperature and stirred for 18 h. The solution was evaporated under 
reduced pressure to yield methyl 4-bromobutanoate 259 (5.40 g, 30.0 mmol quant.) as a 
colourless oil, which was used without any further purification: 1H NMR (500 MHz; CDCl3) δ 
3.56 (3H, s, CH3-5), 3.35 (2H, t, J 6.6 Hz, CH2-1), 2.38 (2H, t, J 7.6 Hz, CH2-3), 2.04 (2H, tt, J 
7.4, 6.6, CH2-2); 13C NMR (125 MHz; CDCl3) δ 172.7 (quat., C-4), 51.5 (CH3, C-5), 32.7 (CH2, 
C-1), 32.0 (CH2, C-3), 27.7 (CH2, C-2); m/z (ES+) 203 ([M+Na]+, 100%). The data were in 
agreement with the literature values.405 
 
Methyl 4-(nitrooxy)butanoate, 260406 
 
 
 
Silver nitrate (7.0 g, 41.3 mmol) was added to a solution of methyl 4-bromobutanoate 259 (3.0 
g, 16.5 mmol) in dry acetonitrile (60 mL). The reaction was heated to 80 °C for 4 h, protected 
from light. The reaction mixture was filtered through Celite and the solvent removed under 
reduced pressure. The crude residue suspended in ethyl acetate (50 mL) and filtered through a 
silica plug. The organic layer was washed with water (100 mL) and brine (100 mL), dried over 
Na2SO4, filtered and the solvent removed under reduced pressure to 4-(nitrooxy)butanoate 260 
(2.6 g, 15.9 mmol, 97%) as a pale yellow oil, which was used without any further purification: 
1H NMR (300 MHz; CDCl3) δ 3.56 (3H, s, CH3-5), 3.35 (2H, t, J 6.6 Hz, CH2-1), 2.38 (2H, t, J 
7.4 Hz, CH2-3), 2.04 (2H, tt, J 7.4, 6.6 Hz, CH2-2); 13C NMR (100 MHz; CDCl3) δ 173.1 (quat., 
C-4), 72.4 (CH2, C-1), 52.2 (CH3, C-5), 30.3 (CH2, C-3), 22.6 (CH2, C-2); m/z (ES+) 186 
([M+Na]+, 100%). The data were in agreement with the literature values.406 
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4-(Nitrooxy)butanoic acid, 258406 
 
 
 
LiOH (2 N, 6.0 mL) was added to a solution of methyl 4-(nitrooxy)butanoate 260 (1.0 g, 6.1 
mmol) in methanol (25 mL) cooled to 0 °C. The suspension was stirred overnight at 5 °C. The 
pH of the solution was adjusted to pH = 2 with HCl (2 N) and the solution concentrated under 
reduced pressure. The aqueous layer was extracted with dichloromethane (50 mL). The organic 
layer was separated and dried over Na2SO4, filtered and the solvent removed under reduced 
pressure to yield 4-(nitrooxy)butanoic acid 258 (700 mg, 4.69 mmol, 77%) as a colourless oil, 
which was used without any further purification. 1H NMR (300 MHz; CDCl3) δ 8.88 (1H, s, br, 
CO2H-5), 4.52 (2H, t, J 6.3 Hz, CH2-1), 2.52 (2H, t, J 7.1 Hz, CH2-3), 2.07 (2H, tt, J 7.1, 6.3, 
CH2-2); 13C NMR (100 MHz; CDCl3) δ 178.3 (quat., C-4), 72.2 (CH2, C-1), 30.3 (CH2, C-3), 
22.4 (CH2, C-2); m/z (ES−) 148 ([M-H]−, 100%). The data were in agreement with the literature 
values.406 
 
17-(3-Pyridyl)androsta-5,16-dien-3β-ol 3-(4-nitrooxy)butanoate, 251 
 
 
 
4-(Nitrooxy)butanoic acid 258 (30 mg, 0.20 mmol) and DMAP (21 mg, 0.17 mmol) were added 
to a solution of abiraterone 106 (60 mg, 0.17 mmol) in dichloromethane (7 mL). EDCI.HCl (40 
mg, 0.210 mmol) was added in a single portion and the solution was stirred for 6 h. The solution 
was washed with water and dried over MgSO4. The mixture was filtered and the solvent 
adsorbed onto silica gel. Purification by silica gel chromatography, eluting with ethyl acetate 
and petroleum ether (15:85 to 25:75), provided 17-(3-pyridyl)androsta-5,16-dien-3β-ol 3-(4-
nitrooxy)butanoate 251 (78 mg, 0.16 mmol, 95%) as a white solid: Rf 0.70 (90:10, 
CH2Cl2:acetone, UV/cerium phosphomolybdate); m.p. 68-70 °C; [𝛂]𝐃𝟐𝟎-8.3, (c = 1.0, CHCl3); 
νmax (thin film)/cm−1 2937, 1730, 1630, 1441, 1410, 1375, 1280, 1177, 1026, 930, 868, 797, 
711;1H NMR (300 MHz; CDCl3) δ 8.63 (1H, s, br, CH-2′), 8.47 (1H, s, br, CH-6′), 7.71 (1H, 
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dt, J 8.1, 1.6 Hz, CH-4′), 7.28 (1H, dd, J 8.1, 5.0 Hz, CH-5′), 6.02 (1H, dd, J 3.1, 1.7 Hz, CH-
16), 5.41 (1H, d, J 5.2 Hz, CH-6), 4.69-4.59 (1H, m, CH-3), 4.51 (2H, t, J 6.3 Hz, CH2-4′′), 
2.52-2.23 (6H, m, CH2-1, CH2-2′′, CH2-12), 2.11-2.01 (5H, m, CH2-3′′, CHAHB-7, CH2-15), 
1.92-1.83 (2H, m, CHAHB-2, CHAHB-4), 1.80-1.44 (6H, m, CHAHB-2, CHAHB-7, CH-8, 9, CH2-
11,), 1.25-1.10 (2H, m, CHAHB-4, CH-14,), 1.08 (3H, s, CH3-19) and 1.04 (3H, s, CH3-18); 13C 
NMR (100 MHz; CDCl3) δ 171.7 (quat., C-1′′), 151.3 (quat., C-17), 146.9 (CH, C-2′), 146.9 
(CH, C-6′), 139.9 (quat., C-5), 134.5 (CH, C-4′), 133.0 (quat., C-1′), 129.9 (CH, C-16), 123.4 
(CH, C-5′), 122.4 (CH, C-6), 74.3 (CH, C-3), 72.1 (CH2, C-4′′), 57.5 (CH, C-9), 50.2 (CH, C-
14), 47.4 (quat., C-13), 38.1 (CH2, C-1), 36.9 (CH2, C-4), 36.8 (quat., C-10), 35.2 (CH2, C-7), 
31.5 (CH2, C-2′′), 31.9 (CH2, C-12), 31.5 (CH2, C-15), 30.4 (CH, C-8), 27.7 (CH2, C-2),  22.4 
(CH2, C-3′′), 20.8 (CH2, C-11), 19.3 (CH3, C-19), 16.6 (CH3, C-18); m/z (ES+) 503 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C28H36N2NaO5 [M+Na]+ requires 503.2522, found 
503.2530; CHN Anal. calcd. For C28H36N2O5: C, 69.98; H, 7.55; N, 5.83. Found C, 70.03; H, 
7.59; N, 5.88. 
 
17-(3-Pyridyl)androsta-5,16-dien-3β-nitrate, 252 
 
 
 
Zinc nitrate hexahydrate (85 mg, 0.29 mmol) was added to a solution of abiraterone 206 (100 
mg, 0.286 mmol) in acetonitrile and dichloromethane (1:1, 10 mL). EDCI.HCl (110 mg, 0.57 
mmol) was added in a single portion and the solution stirred for 18 h. The solution was washed 
with water and dried over MgSO4. The mixture was filtered and the solvent adsorbed onto silica 
gel. Purification by silica gel chromatography, eluting with ethyl acetate and petroleum ether 
(15:85 to 25:75), provided 17-(3-pyridyl)androsta-5,16-dien-3β-nitrate 252 (39 mg, 0.10 mmol, 
35%, 88% b.r.s.m) as a white solid: Rf 0.77 (90:10, EtOAc:PE, UV/cerium phosphomolybdate); 
m.p. 91-94 °C; [𝛂]𝐃𝟐𝟎-9.9, (c = 1.0, CHCl3); νmax (thin film)/cm−1 1729, 1669, 1627, 1464, 1378, 
1279, 1176, 1012, 867, 748; 1H NMR (300 MHz; CDCl3) δ 8.62 (1H, d, J 1.5 Hz, CH-2′), 8.46 
(1H, dd, J 4.8, 1.3 Hz, CH-6′), 7.64 (1H, dt, J 7.8, 1.8 Hz, CH-4′), 7.22 (1H, dd, J 7.8, 4.8 Hz, 
CH-5′), 6.00 (1H, dd, J 3.2, 1.7 Hz, CH-16), 5.49 (1H, d, J 5.4 Hz, CH-6), 4.85-4.78 (1H, m, 
CH-3), 2.49 (1H, ddd, J 13.0, 4.9, 2.2 Hz, CHAHB-11), 2.45-2.38 (1H, m, CHAHB-11), 2.27 (1H, 
ddd, J 15.9, 6.5, 3.3 Hz, CHAHB-12), 2.12-1.93 (4H, m, CHAHB-2, CHAHB-4, CHAHB-7, 
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CHAHB-12), 1,82-1.56 (6H, m, CHAHB-2, CH-9, CH2-11, CH2-15), 1.49 (1H, ddd, J 24.0, 12.0, 
5.1 Hz, CHAHB-7), 1.26-1.18 (2H, m, CHAHB-4, CH-8), 1.13-1.09 (1H, m, CH-14), 1.08 (CH3, 
s, CH3-19) and 1.05 (CH3, s, CH3-18); 13C NMR (100 MHz; CDCl3) δ 151.6 (quat., C-17), 
147.9 (quat. × 2, C-2′,6′), 138.8 (quat., C-5), 133.7 (CH, C-4′), 132.9 (quat., C-1′), 129.3 (CH2, 
C-16), 123.6 (CH, C-5′), 123.0 (CH, C-6), 83.3 (CH, C-3), 57.4 (CH, C-9), 50.2 (CH, C-14), 
47.3 (quat., C-13), 36.9 (CH2, C-4), 36.7 (quat., C-10), 36.3 (CH2, C-1), 35.1 (CH2, C-7), 31.8 
(CH2, C-12), 31.5 (CH2, C-15), 30.3 (CH, C-8), 25.9 (CH2, C-2), 20.8 (CH2, C-11), 19.2 (CH3, 
C-19), 16.6 (CH3, C-18); m/z (ES+) 417 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C24H30N2NaO3 [M+Na]+ requires 417.2154, found 417.2150. 
 
Succinic acid mono-tert-butyl ester, 264407 
 
 
 
Succinic anhydride 263 (10 g, 100 mmol), N-hydroxysuccinimide (3.34 g, 0.30 mmol), and 
DMAP (1.17 g, 1.00 mmol) were dissolved in toluene (50 mL). tert-Butanol (11.7 mL, 124 
mmol) and Et3N (3.03 g, 4.17 mL, 30.0 mmol) were added sequentially. The suspension was 
heated under reflux for 24 h. The solution was cooled and diluted with EtOAc (50 mL) and was 
washed with citric acid (10% w/v, 100 mL) and brine (100 mL), dried over Na2SO4, and 
concentrated to give a brown solid. The solid was recrystallised with ether and petroleum ether 
(10:90) at -20 °C to give succinic acid mono-tert-butyl ester 264 (13.3 g, 76.4 mmol, 77%) as 
fawn crystals: m.p. 50-52 °C (PE) [Lit.408 49-52 °C]; 1H NMR (500 MHz; CDCl3) δ 11.30 (1H, 
s, br, CO2H), 2.60 (2H, t, J 6.0 Hz, CH2-5), 2.50 (2H, t, J 6.0 Hz, CH2-4), 1.42 (9H, s, 3 × CH3-
1); 13C NMR (100 MHz; CDCl3) δ 178.7 (quat., C-6), 171.4 (quat., C-3), 81.0 (quat., C-2), 30.0 
(CH2), 29.9 (CH2), 28.1 (CH3 × 3, C-1); m/z (ES+) 175 ([M+H]+, 100%). The data were in 
agreement with the literature values.407,408 
 
tert-Butyl 4-hydroxybutanoate, 262409 
 
 
 
BH3.Me2S (2.0 M in THF, 6.6 mL, 13.2 mmol) was added dropwise to a solution of carboxylic 
acid 264 (2.12 g, 12.2 mmol) in dry THF (20 mL) cooled to 0° C. The solution was allowed to 
OH65
4
3
O
O
2
1
1
1
O
OH
6
5
4
3
O
O
2
1
1
1
Appendix: Experimental 
 
	   268	  
warm to room temperature and stirred for 24 h. EtOAc (100 mL) was added and the organic 
layer separated and washed with water (70 mL) and brine (70 mL), dried over MgSO4, filtered 
and the solvent removed under reduced pressure to give tert-butyl 4-hydroxybutanoate 262 
(1.92 g, 12.2 mmol, quant.), which was used without any further purification as a pale yellow 
oil: 1H NMR (500 MHz; CDCl3) δ 3.65 (2H, t, J 6.1 Hz, CH2-4), 2.33 (2H, t, J 7.3 Hz, CH2-4), 
2.17 (1H, s, br, OH), 1.82 (2H, tt, J 7.7, 7.4, CH2-5) and 1.44 (9H, s, 3 × CH3-1); 13C NMR 
(100 MHz; CDCl3) δ 173.5 (quat., C-3), 80.5 (quat., C-2), 62.2 (CH2, C-6), 32.4 (CH2, C-4), 
28.1 (CH3 × 3, C-1) and 27.8 (CH2, C-5); m/z (ES+) 183 ([M+Na]+, 100%). The data were in 
agreement with the literature values.409 
 
4-(4-(tert-Butoxy)-4-oxobutoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 265 
 
 
 
DBU (971 µL, 6.00 mmol) was added to a solution of tert-butyl 4-hydroxybutanoate 262 (480 
mg, 3.00 mmol) in dichloromethane (15 mL) and the solution was stirred vigorously. 
Bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 53 (732 mg, 2.00 mmol) was added and stirring 
continued for 2 h. The reaction mixture was washed with distilled water (20 mL) and with HCl 
(2 N, 2 × 15 mL) and brine (20 mL). The organic layer was dried over Na2SO4, filtered and the 
solvent removed under reduced pressure to give the crude product. This product was purified by 
silica gel chromatography, eluting with dichloromethane, to give 4-(4-(tert-butoxy)-4-
oxobutoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 265 (595 mg, 1.71 mmol, 86%) as a 
colourless oil which solidified on standing; Rf 0.76 (30:70, EtOAc:PE, UV/KMnO4); m.p. 
95-97 °C; νmax  (thin film)/cm−1 2098, 1616, 1550, 1449, 1358, 1166; 1H NMR (500 MHz; 
CDCl3) δ 8.03 (2H, d, J 8.7 Hz, CH-10,14), 7.74 (1H, tt, J 7.4, 1.2 Hz, CH-12), 7.61 (2H, t, J 
8.7 Hz, CH-11,13), 4.43 (2H, t, J 6.3 Hz, CH2-6), 2.40 (2H, t, J 7.3 Hz, CH2-4), 2.12 (2H, dt, J 
7.3, 6.3 Hz, CH2-5) and 1.44 (9H, s, 3 × CH3-1); 13C NMR (75 MHz; CDCl3) δ 170.7 (quat., 
C-3), 158.9 (quat., C-7), 138.0 (quat., C-9), 135.7 (CH, C-12), 129.7 (CH × 2, C-11,13), 128.5 
(CH × 2, C-10,14), 110.5 (quat., C-8), 80.8 (quat., C-2), 70.5 (CH2, C-6), 31.3 (CH2, C-4), 28.1 
(CH3 × 3, C-1) and 24.0 (CH2, C-5); m/z (ES+) 385 ([M+H]+, 100%); HRMS m/z (ES+) calcd. 
for C16H21N2NaO7S [M+H]+ requires 385.1069, found 385.1072. 
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4-(3-Carboxypropoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 261 
 
 
 
Trifluoroacetic acid (2 mL) was added to a solution of 4-(4-(tert-butoxy)-4-oxobutoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 265 (200 mg, 0.52 mmol) in dichloromethane 
(10  mL) and stirred at room temperature overnight. The solvent was removed under reduced 
pressure to provide 4-(3-carboxypropoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 261 
(164 mg, 0.50 mmol, 96%) as a white solid, which was used without any further purification: Rf 
0.11 (50:50, EtOAc:PE, UV/KMnO4); m.p. 129-130 °C, [Lit.342 130-131 °C]; 1H NMR (400 
MHz; CDCl3) δ 8.77 (1H, s, br, CO2H), 8.04 (2H, d, J 8.3 Hz, CH-8,12), 7.75 (1H, tt, J 7.5, 1.4 
Hz, CH-10), 7.61 (2H, t, J 8.0 Hz, CH-9,11), 4.49 (2H, t, J 6.2 Hz, CH2-4), 2.60 (2H, t, J 7.0 
Hz, CH2-2), 2.21 (2H, t, J 6.7 Hz, CH2-3); 13C NMR (100 MHz; CDCl3) δ 178.4 (quat., C-1′′), 
158.8 (quat., C-6), 138.0 (quat., C-7), 135.7 (CH, C-10), 129.7 (CH × 2, C-9,11), 128.5 (CH × 
2, C-8,12), 110.4 (quat., C-5), 70.2 (CH2, C-4), 30.1 (CH2, C-2), 23.6 (CH2, C-3); m/z (ES+) 351 
([M+Na]+, 100%). The data were in agreement with the literature values.342 
 
17-(3-Pyridyl)androsta-5,16-dien-3β-ol 3-(4-oxo-(phenylsulfonyl)-1,2,5-oxadiazole 
2-oxide))butanoate, 253 
 
 
 
 
4-(3-Carboxypropoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 261 (53 mg, 0.16 mmol) 
and DMAP (20 mg, 0.16 mmol) were added to a solution of abiraterone 106 (51 mg, 0.15 
mmol) in dichloromethane (7 mL). EDCI.HCl (36 mg, 0.22 mmol) was added in a single 
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portion and the solution stirred for 36 h. The solution was washed with water (5 mL) and dried 
over MgSO4. The mixture was filtered and the solvent adsorbed onto silica gel. Purification by 
silica gel chromatography, eluting with diethyl ether, provided (((17-(3-pyridyl)androsta-5,16-
dien-3β-yl)oxy)-4-oxobutoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 253 (62 mg, 0.09 
mmol, 64%) as a fawn solid: Rf 0.62 (50:50, EtOAc:cyclohexane, UV/cerium 
phosphomolybdate); m.p. 60-61 °C; [𝛂]𝐃𝟐𝟎 -13.0, (c = 1.0, CHCl3); νmax (thin film)/cm−1 2936, 
2855, 1727, 1616, 1522, 1450, 1369, 1260, 1171, 1087, 1023, 999, 799, 734; 1H NMR (300 
MHz; CDCl3) δ 8.60 (1H, d, J 1.7 Hz, CH-2′), 8.44 (1H, d, J 4.5 Hz, CH-6′), 8.04 (2H, d, J 8.0 
Hz, CH-8′′,12′′), 7.76 (1H, tt, J 7.4, 1.3 Hz, CH-10′′), 7.66-7.61 (3H, m, CH-4′,9′′,11′′), 7.21 
(1H, dd, J 8.0, 5.1 Hz, CH-5′), 6.00 (1H, dd, J 3.9, 1.7 Hz, CH-16), 5.38 (1H, d, J 4.9 Hz, CH-
6), 4.68-4.61 (1H, m, CH-3), 4.48 (2H, t, J 7.2 Hz, CH2-4′′), 2.50 (2H, t, J 7.2 Hz, CH2-2′′), 
2.33-2.23 (3H, m, CH2-1, CHAHB-12), 2.20 (2H, pentet, J 6.7 Hz, CH2-3′′), 2.09-2.00 (2H, m, 
CHAHB-7, CHAHB-12,), 1.88-1.83 (2H, m, CHAHB-2, CHAHB-4), 1.75 (1H, td, J 22.0, 11.0, 5.0 
Hz, CH-8), 1.69-1.44 (7H, m, CHAHB-2, CHAHB-7, CH-9, CH2-11, CH2-15), 1.16-1.10 (2H, m, 
CHAHB-4, CH-14), 1.06 (3H, s, CH3-19), 1.04 (3H, s, CH3-18); 13C NMR (100 MHz; CDCl3) δ 
171.6 (quat., C-1′′), 158.9 (quat., C-5′′), 151.6 (quat., C-17), 147.9 (CH, C-2′), 147.8 (CH, C-6′), 
139.9 (quat., C-5), 138.1 (quat., C-7′′), 135.7 (CH, C-10′′), 133.8  (CH, C-4′), 133.0 (quat., C-
1′), 129.7 (CH × 2, C-9′′,11′′), 129.3 (CH, C-16), 128.6 (CH × 2, C-8′′,12′′), 123.1 (CH, C-5), 
122.4 (CH, C-6), 110.5 (quat., C-6′′), 74.4 (CH, C-3), 70.4 (CH2, C-4′′), 57.5 (CH, C-9), 50.3 
(CH, C-14), 47.3 (quat., C-13), 38.1 (CH2, C-1), 36.9 (CH2, C-4), 36.8 (quat., C-10), 35.2 (CH2, 
C-7), 31.8 (CH2, C-12), 31.5 (CH2, C-15), 30.4 (CH, C-8), 30.4 (CH2, C-2′′), 27.8 (CH2, C-2), 
23.9 (CH2, C-3′′), 20.8 (CH2, C-11), 19.3 (CH3, C-19), 16.6 (CH3, C-18); m/z (ES+) 618 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C36H41N3NaO5 [M+Na]+ requires 618.2944, 
found 618.2954; CHN Anal. calcd. For C36H41N3O5: C, 72.58; H, 6.95; N, 7.05. Found C, 
72.66; H, 7.01; N, 7.11. 
 
N-((4-(tert-Butoxy)-4-oxobutoxy)carbonyl)-3-phenylsydnonimine, 267 
 
 
 
Alcohol 262 (500 mg, 3.12 mmol) and N-((4-nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 
(1.11 g, 3.44) were dissolved in acetonitrile (25 mL) and heated under reflux for 24 h. The 
solvent was removed under reduced pressure and the residue adsorbed onto silica gel.  
Purification by silica gel chromatography, eluting with dichloromethane and acetone (100: 0 to 
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90:10), provided N-((4-(tert-butoxy)-4-oxobutoxy)carbonyl)-3-phenylsydnonimine 267 (726 mg, 
2.09 mmol, 67%) as an amber solid: Rf 0.37 (90:10, CH2Cl2:acetone, UV/cerium 
phosphomolybdate); m.p. 45-47 °C; νmax (thin film)/cm−1 2977, 1884, 1726, 1631, 1496, 1394, 
1368, 1259, 1158, 766; 1H NMR (300 MHz; CDCl3) δ 8.14 (1H, s CH-9), 7.80 (2H, d, J 8.4 Hz, 
CH-11,15), 7.75-7.63 (3H, m, CH-12,13,14), 4.16 (2H, t, J 6.4 Hz, CH2-6), 2.39 (2H, t, J 7.7 
Hz, CH2-4), 1.98 (2H, dt, J 7.7, 6.4, CH2-5), and 1.43 (9H, s, 3 × CH3-1); 13C NMR (100 MHz; 
CDCl3) δ 175.2 (quat., C-8), 172.6 (quat., C-3), 161.7 (quat., C-7), 133.9 (quat., C-10), 133.2 
(CH, C-13), 130.1 (CH × 2, C-11,15), 121.6 (CH × 2, C-12,14), 102.8 (CH, C-9), 80.3 (quat., 
C-2), 64.7 (CH2, C-6), 32.1 (CH2, C-4), 28.1 (CH3 × 3, C-1) and 24.5 (CH2, C-5); m/z (ES+) 370 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C17H21N3NaO5 [M+Na]+ requires 370.1379, 
found 370.1382. 
 
N-((3-Carboxypropoxy)carbonyl)-3-phenylsydnonimine, 266 
 
 
 
Trifluoroacetic acid (800 µL) was added to a solution of N-((4-(tert-butoxy)-4-
oxobutoxy)carbonyl)-3-phenylsydnonimine 267 (53 mg, 0.153 mmol) in CH2Cl2 (3 mL) at 0 °C. 
The solution was allowed to warm to room temperature and stirred for 18 h. The solvent was 
evaporated under reduced pressure and the residue azeotroped with toluene. The residue was 
uptaken in dichloromethane and adsorbed onto silica gel. Purification by silica gel 
chromatography, eluting with dichloromethane and methanol (100: 0 to 97:3), provided N-((3-
carboxypropxy)carbonyl)-3-phenylsydnonimine 266 (46 mg, 0.153 mmol, quant.): Rf 0.37 
(90:10, CH2Cl2:acetone, UV/cerium phosphomolybdate); m.p. 99-101 °C; νmax (thin film)/cm−1 
3479, 2977, 1796, 1725, 1597, 1532, 1458, 1369, 1158, 915, 845; 1H NMR (300 MHz; CDCl3) 
δ 8.51 (1H, s CH-7), 8.30 (1H, s, br, CO2H), 7.76 (2H, d, J 8.2 Hz, CH-9,13), 7.75-7.63 (3H, m, 
CH-10,11,12), 4.16 (2H, t, J 6.4 Hz, CH2-4), 2.39 (2H, t, J 7.7 Hz, CH2-2) and 1.98 (2H, dt, J 
7.7, 6.4 Hz, CH2-3); 13C NMR (100 MHz; CDCl3) δ 176.9 (quat., C-6), 168.8 (quat., C-1), 
153.6 (quat., C-5), 134.7 (CH, C-11), 132.8 (quat., C-8), 131.1 (CH × 2, C-9,13), 122.1 (CH × 
2, C-10,12), 106.3 (CH, C-7), 67.1 (CH2, C-4), 31.1 (CH2, C-2), and 24.1 (CH2-3); m/z (ES+) 
314 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C13H13N3NaO5 [M+Na]+ requires 314.0753, 
found 314.0760. 
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17-(3-Pyridyl)androsta-5,16-dien-3β-ol 3-(N-((4-oxobutoxy)carbonyl)-3-phenyl-
sydnonimine), 254 
 
 
N-((3-Carboxypropoxy)carbonyl)-3-phenylsydnonimine 266 (46 mg, 0.16 mmol) and DMAP 
(17 mg, 0.17 mmol) were added to a solution of abiraterone 106 (50 mg, 0.143 mmol) in 
dichloromethane (7 mL). EDCI.HCl (40 mg, 0.21 mmol) was added in a single portion and the 
solution stirred for 6 h. The solution was washed with water and dried over MgSO4. The 
mixture was filtered and the solvent adsorbed onto silica gel. Purification by silica gel 
chromatography, eluting with ethyl acetate and petroleum ether (15:85 to 25:75), provided 17-
(3-pyridyl)androsta-5,16-dienyl-3β-(N-((4-oxobutoxy)carbonyl)-3-phenylsydnonimine) 254 (67 
mg, 0.11 mmol, 76%) as an off-white solid: Rf 0.45 (90:10, CH2Cl2:acetone, UV/cerium 
phosphomolybdate); m.p. 55-58 °C; [𝛂]𝐃𝟐𝟎-7.4, (c = 1.0, CHCl3); νmax (thin film)/cm−1 3333, 
1728, 1651, 1587, 1557, 1509, 1451, 1367, 1214, 1190, 1155, 971, 846; 1H NMR (300 MHz; 
CDCl3) δ 8.61 (1H, d, J 1.8 Hz, CH-2′), 8.45 (1H, dd, J 4.9, 1.5 Hz, CH-6′), 8.12 (1H, s, CH-
7′′), 7.82-7.78 (2H, m, CH-9′′,13′′), 7.72-7.62 (4H, m, CH-4′,10′′,11′′,12′′), 7.21 (1H, ddd, J 7.9, 
4.8, 0.6 Hz, CH-5′), 5.99 (1H, dd, J 3.2, 1.7 Hz, CH-16), 5.41 (1H, d, J 5.0 Hz, CH-6), 4.68-
4.57 (1H, m, CH-3), 4.18 (2H, t, J 6.2 Hz, CH2-4′′), 2.47 (2H, t, J 7.5 Hz, CH2-2′′), 2.39-2.22 
(3H, m, CH2-1, CHAHB-12), 2.10-1.99 (4H, m, CH2-3′′, CHAHB-7, CHAHB-12), 1.88-1.81 (2H, 
m, CHAHB-2, CHAHB-4), 1.77-1.44 (8H, m, CHAHB-2, CHAHB-7, CH-8, CH-9, CH2-11, CH2-
15), 1.21-1.10 (2H, m, CHAHB-4, CH-14), 1.07 (3H, s, CH3-19) and 1.04 (3H, s, CH3-18); 13C 
NMR (100 MHz; CDCl3) δ 175.3 (quat., C-6′′), 172.6 (quat., C-1′′), 153.5 (quat., C-5′′), 151.7 
(quat., C-17), 147.9 (CH, C-2′), 147.9 (CH, C-6′), 140.0 (quat., C-5), 135.4 (CH, C-11′′), 133.9 
(CH, C-4′), 133.2 (quat., C-8′′), 133.0 (quat., C-1′), 130.6 (CH × 2, C-9′′, C-13′′), 129.3 (CH, C-
16), 123.0 (CH, C-5′), 122.2 (CH, C-6), 121.6 (CH × 2, C-19′′, C-12′′), 101.4 (CH, C-7′′), 73.8 
(CH, C-3), 64.6 (CH2, C-4′′), 57.5 (CH, C-9), 50.3 (CH, C-14), 47.4 (quat., C-13), 38.2 (CH2, 
C-1), 36.9 (CH2, C-4), 36.8 (quat., C-10), 35.2 (CH2, C-7), 31.6 (CH2, C-2′′), 31.8 (CH2, C-12), 
31.5 (CH2, C-15), 30.4 (CH, C-8), 27.7 (CH2, C-2),  24.5 (CH2, C-3′′), 20.8 (CH2, C-11), 19.3 
(CH3, C-19), 16.6 (CH3, C-18); m/z (ES+) 645 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C37H42N4NaO5 [M+Na]+ requires 645.3053, found 645.3065; CHN Anal. calcd. For 
C37H42N4O5: C, 71.36; H, 6.80; N, 9.09. Found C, 71.42; H, 6.82; N, 9.09. 
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A.6 EXPERIMENTAL PROCEDURES FOR CHAPTER FIVE 
 
(S)-Tyrosine methyl ester hydrochloride, 292370 
 
 
 
Acetyl chloride (15.5 g, 14 mL, 196 mmol) was added dropwise to methanol (110 mL) cooled 
to 0 °C. Tyrosine 283 (5.4 g, 27.6 mmol) was added and the resulting suspension heated to 
reflux for 18 h. The resultant solution was cooled to room temperature and the solvent removed 
under reduced pressure to give a white solid. This was suspended in methanol and the solvent 
removed under reduced pressure. This procedure was repeated three times to yield (S)-tyrosine 
methyl ester hydrochloride 292 (5.4 g, 27.6 mmol, quant.) as a white solid, which was used 
without any further purification: m.p. 190-193 °C (ethanol), [Lit.410 189-190 °C]; [𝛂]𝐃𝟐𝟎+13.0, (c 
= 2, MeOH), [Lit.411 +12.9 (c = 2, MeOH)]; 1H NMR (300 MHz; d6-DMSO) δ 8.70 (3H, s, br, 
NH2 .HCl), 6.99 (2H, d, J 8.4 Hz, CH-7,9), 6.72 (2H, d, J 8.4 Hz, CH-6,10), 5.08 (1H, s, br, 
OH), 4.13-4.07 (1H, m, CH-1), 3.62 (3H, s, CH3-3) and 3.03 (2H, dq, J 14.2, 5.2 Hz, CH2-4); 
13C NMR (100 MHz; d6-DMSO) δ 169.3 (quat., C-2), 156.6 (quat., C-8), 130.3 (CH × 2, C-
6,11), 124.3 (quat., C-7), 115.4 (CH × 2, C-7,9), 53.5 (CH2, C-4), 52.5 (CH3, C-3) and 35.0 
(CH, C-1); m/z (ES+) 196 ([M+H]+, 100%). The data were in agreement with the literature 
values.370 
 
N-tert-Butoxycarbonyl-(S)-tyrosine methyl ester, 293370 
 
 
 
Sodium bicarbonate (21.5 g, 256 mmol) was added to a solution of (S)-tyrosine methyl ester 
hydrochloride 293 (5.0 g, 25.6 mmol) in ethanol (100 mL). Di-tert-butyl dicarbonate (5.6 g, 
25.6 mmol) was added and the resulting suspension was stirred for 18 h at room temperature. 
The suspension was filtered and the solvent removed under reduced pressure to yield N-tert-
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butoxycarbonyl-(S)-tyrosine methyl ester 293 (6.00 g, 20.4 mmol, 80%) as a colourless oil that 
solidified on standing, which was used without any further purification: Rf 0.54 (50:50, 
EtOAc:PE, UV/cerium phosphomolybdate); m.p. 100-103 °C, [Lit.412 100-102 °C]; [𝛂]𝐃𝟐𝟎 
+46.0, (c = 1, CHCl3); [Lit.412 +47.0 (c = 1, CHCl3]; 1H NMR (300 MHz; CDCl3) δ 6.96 (2H, 
d, J 8.4 Hz, CH-10,12), 6.73 (2H, d, J 8.4 Hz, CH-9,13), 5.94 (1H, s, OH), 5.95-6.00 (1H, m, 
NH), 4.57-4.50 (1H, m, CH-4), 3.71 (3H, s, CH3-6), 3.06-2.92 (2H, m, CH2-7) and 1.41 (9H, s, 
3 × CH3-1); 13C NMR (100 MHz; CDCl3) δ 172.6 (quat., C-5), 155.3 (quat., C-3), 150.1 (quat., 
C-11), 130.4 (CH × 2, C-9,13), 121.3 (quat., C-8), 115.5 (CH × 2, C-10,12), 80.1 (quat., C-2), 
54.6 (CH2, C-7), 52.2 (CH3, C-6), 37.5 (CH, C-4) and 28.3 (CH3 × 3, C-1); m/z (ES+) 318 
([M+Na]+, 100%). The data were in agreement with the literature values.370 
 
(S)-4-Nitrophenylalanine methyl ester, 295371 
 
 
 
Thionyl chloride (7.5 g, 4.6 mL, 62.8 mmol) was added dropwise to methanol (50 mL) at 0 °C. 
(S)-4-Nitrophenylalanine 294 (6.2 g, 27.2 mmol) was added portionwise and the resulting 
solution was allowed to warm to room temperature and stirred for 18 h. The solvent and excess 
thionyl chloride was removed under reduced pressure to give a yellow residue. This was 
evaporated from methanol (5 × 100 mL) to give (S)-4-nitrophenylalanine methyl ester 
hydrochloride 295 (7.1 g, 27.2 mmol, quant.) as a pale yellow solid, which was used without 
any further purification: m.p. 209-212 °C, [Lit.413 221-224 °C];  [𝛂]𝐃𝟐𝟎+32.0, (c = 1.0, EtOH), 
[Lit.413 +32.2, (c = 1.0, EtOH)]; 1H NMR (500 MHz; d6-DMSO) δ 9.01 (3H, s, br, NH2.HCl), 
8.16 (2H, d, J 8.7 Hz, CH-7,9), 7.59 (2H, d, J 8.7 Hz, CH-6,10), 4.34 (1H, dd, J 7.6, 5.7 Hz, 
CH-1), 3.67 (3H, s, CH3-3), 3.42 (1H, dd, J 14.0, 5.6 Hz, CHAHB-4) and 3.30 (1H, dd, J 13.8, 
7.8 Hz, CHAHB-4); 13C NMR (75 MHz, d6-DMSO) δ 168.9 (quat., C-2), 146.7 (quat., C-5), 
143.0 (quat., C-8), 130.9 (CH × 2, C-6,10), 123.5 (CH × 2, C-7,9), 52.3 (CH, C-1) and 52.6 
(CH3, C-3); m/z (ES+) 225 ([M+H]+, 100%). The data were in agreement with the literature 
values.371  
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4-Nitro-N-tert-butoxycarbonyl-(S)-phenylalanine methyl ester, 296371 
 
 
 
Triethylamine (2.90 g, 4.0 mL, 28.7 mmol) and di-tert butyl dicarbonate (3.10, 14.1 mmol) was 
added to a suspension of (S)-methyl 4-nitrophenylalanine hydrochloride 295 (3.5 g, 13.4 mmol) 
in dichloromethane (25 mL). The resulting suspension was stirred at room temperature for 18 h. 
The reaction mixture was diluted with water (50 mL), and the organic layer separated. The 
aqueous layer was extracted with dichloromethane (50 mL). The organic extracts were 
combined and washed with brine (50 mL), dried over MgSO4. The mixture was filtered and the 
solvent removed under reduced pressure to give 4-nitro-N-tert-butoxycarbonyl-(S)-
phenylalanine methyl ester 296 (4.35 g, 13.4 mmol, quant.) as a white solid, which was used 
without any further purification: Rf 0.72 (30:70, EtOAc:PE, UV/cerium phosphomolybdate); 
m.p. 99-100 °C, [Lit.412 99-101 °C]; [𝛂]𝐃𝟐𝟎+52.9, (c = 1, CHCl3); [Lit.412 +53.0, (c = 1, CHCl3)]; 
1H NMR (500 MHz; CDCl3) δ 8.13 (2H, d, J 8.7 Hz, CH-10,12), 7.29 (2H, d, J 8.7 Hz, CH-
9,13), 5.09 (1H, d, J 7.5, NH), 4.63-4.57 (1H, m, CH-4), 3.71 (3H, s, CH3-6), 3.25 (1H, dd, J 
13.7, 5.7 Hz, CHAHB-7), 3.07 (1H, dd, J 14.0, 7.2 Hz, CHAHB-7) and 1.37 (9H, s, 3 × CH3-1); 
13C NMR (100 MHz; CDCl3) δ 171.6 (quat., C-5), 154.9 (quat., C-3), 147.2 (quat., C-11), 144.0 
(quat., C-8), 130.6 (CH × 2, C-9,13), 123.7 (CH × 2, C-10,12), 80.4 (quat., C-2), 54.1 (CH2, C-
7), 52.6 (CH3, C-6), 45.8 (CH, C-4) and 28.3 (CH3 × 3, C-1); m/z (ES+) 347 ([M+Na]+, 100%). 
The data were in agreement with the literature values.371 
 
4-Amino-N-tert-butoxycarbonyl-(S)-phenylalanine methyl ester, 297371 
 
 
 
10% Pd/C (15% in weight, 150 mg) was added to a solution of 4-nitro-N-tert-butoxycarbonyl-
(S)-phenylalanine methyl ester 296 (1.0 g, 3.09 mmol) and ammonium formate (1.27 g, 20.1 
mmol) in methanol (20 mL) and the suspension stirred for 3 h. The suspension was filtered 
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through Celite and the solvent evaporated. The residue was uptaken in ethyl acetate (50 mL) 
and washed with water (3 × 20 mL). The organic layer was dried over MgSO4, filtered and the 
solvent removed under reduced pressure to yield 4-amino-N-tert-butoxycarbonyl-(S)-
phenylalanine methyl ester 297 (0.91 g, 3.09 mmol, quant.) as a yellow solid, which was used 
without any further purification: Rf 0.41 (30:70, EtOAc: PE, UV/cerium phosphomolybdate); 
m.p. 85-90 °C, [Lit.414 85-87 °C];  [𝛂]𝐃𝟐𝟎 +42.1, (c = 1, CHCl3); [Lit.412 +42.0, (c = 1.0 Hz, 
CHCl3)]; 1H NMR (500 MHz; CDCl3) δ 6.89 (2H, d, J 8.0 Hz, CH-9,13), 6.61 (2H, d, J 8.0 Hz, 
CH-10,12), 4.96 (1H, d, J 8.3, NH), 4.52-4.48 (1H, m, CH-4), 3.70 (3H, s, CH3-6), 3.00-2.92 
(2H, m, CH2-7) and 1.41 (9H, s, 3 × CH3-1); 13C NMR (100 MHz; CDCl3) δ 172.6 (quat., C-5), 
155.2 (quat., C-3), 145.3 (quat., C-11), 130.1 (CH × 2, C-9,13), 125.7 (quat., C-8), 115.3 (CH × 
2, C-10,12), 79.8 (quat., C-2), 54.6 (CH2, C-7), 52.2 (CH3, C-6), 37.4 (CH, C-4) and 28.3 (CH3 
× 3, C-1); m/z (ES+) 317 ([M+Na]+, 100%). The data were in agreement with the literature 
values.371 
 
(S)-N-((4-(2-((tert-Butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyloxy)-
carbonyl)-3-phenylsydnonimine, 298 
 
 
N-tert-Butoxycarbonyl-(S)-tyrosine methyl ester 293 (532 mg, 1.80 mmol) and N-((4-
nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 (587 mg, 1.80 mmol) were dissolved in 
acetonitrile (15 mL) and heated under reflux for 24 h. The solvent was removed under reduced 
pressure and the residue uptaken in dichloromethane (10 mL) and adsorbed onto silica gel. 
Silica gel chromatography, eluting with CH2Cl2 and acetone (100: 0 to 90:10) provided  ((S)-N-
((4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3- oxopropyl)phenyloxy) carbonyl)-3-
phenylsydnonimine 298 (772 mg, 1.60 mmol, 89%) as a pale yellow crystalline solid: Rf 0.30 
(50:50, EtOAc:PE, UV/cerium phosphomolybdate); m.p. 58-60 °C;  [𝛂]𝐃𝟐𝟎  +31.0, (c = 1.0, 
CHCl3); νmax (thin film)/cm−1 1744, 1678, 1586, 1471, 1367, 1282, 1213, 971, 1018; 1H NMR 
(500 MHz; CDCl3) δ 8.17 (1H, s, 1H, CH-16), 7.79 (2H, d, J 8.0 Hz, CH-18,22), 7.71 (1H, t, J 
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7.4 Hz, CH-20), 7.65 (2H, t, J 8.0 Hz, CH-19,21), 7.13-7.09 (4H, m, CH-9, 10, 12, 13), 5.02 
(1H, d, J 8.4, NH-Boc), 4.55 (1H, dd, J 13.7, 6.0 Hz, CH-4), 3.69 (3H, s, CH3-6), 3.08 (1H, dd, 
J 14.0, 5.7 Hz, CHAHB-7), 3.03 (1H, dd, J 13.8, 6.1 Hz, CHAHB-7) and 1.40 (9H, s, 3 × CH3-1); 
13C NMR (125 MHz; CDCl3) δ 175.7 (quat., C-15), 172.4 (quat., C-5), 160.4 (quat., C-14), 
155.2 (quat., C-3), 151.1 (quat., C-11), 133.7 (quat., C-17), 133.3 (CH, C-20), 132.7 (quat., C-
8), 130.7 (CH × 2, C-9,13), 130.0 (CH × 2, C-18,22), 121.9 (CH × 2, C-10,12), 121.5 (CH × 2, 
C-19,21), 103.4 (CH, C-16), 80.0 (quat., C-2), 54.4 (CH, C-4), 52.3 (CH3, C-6), 37.6 (CH2, C-7) 
and 28.3 (CH3 × 3, C-1); m/z (ES+) 505 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C24H26N4NaO7 [M+Na]+ requires 505.1699, found 505.1672. 
 
(S)-N-((4-(2-((tert-Butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyl)-
carbamoyl)-3-phenylsydnonimine, 299 
 
 
4-Amino-N-tert-butoxycarbonyl-(S)-phenylalanine methyl ester 297 (186 mg, 0.63 mmol) and 
N-((4-nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 (206 mg, 0.63 mmol) were dissolved 
in acetonitrile (15 mL) and heated under reflux for 24 h. The solvent was removed under 
reduced pressure and the residue uptaken in dichloromethane (10 mL) and adsorbed onto silica 
gel. Silica gel chromatography, eluting with CH2Cl2 and acetone (100: 0 to 90:10) provided (S)-
N-((4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyl)-carbamoyl)-3-
phenylsydnonimine 299 (243 mg, 0.51 mmol, 88%) as a yellow solid: Rf 0.19 (50:50, 
EtOAc:PE, UV/cerium phosphomolybdate); m.p. 62-64 °C; [𝛂]𝐃𝟐𝟎 +30.3, (c = 1.0 , CHCl3); 
νmax (thin film)/cm−1 1740, 1708, 1650, 1591, 1517, 1411, 1365, 1244, 1166; 1H NMR (500 
MHz; CDCl3) δ 8.25 (1H, s, CH-16), 7.80-7.77 (2H, m, CH-18,22), 7.71-7.60 (3H, m, CH-19, 
20, 21), 7.45 (2H d, J 8.5 Hz, CH-10,12), 7.28 (1H, s, NH), 7.05-7.00 (2H, m, CH-9,13), 5.10-
5.01 (1H, m, NHBoc), 4.53 (1H, dd, J 13.3, 5.8 Hz, CH-4), 3.69 (3H, s, CH3-6), 3.08-2.94 
(CH2-7) and 1.40 (9H, s, 3 × CH3-1); 13C NMR (100 MHz; CDCl3) δ 173.4 (quat., C-15), 172.5 
(quat., C-5), 159.4 (quat., C-14), 155.2 (quat., C-3), 138.5 (quat., C-8), 134.0 (quat., C-17), 
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133.0 (CH, C-20), 130.5 (CH × 2, C-18,22), 130.1 (quat., C-11), 129.7 (CH × 2, C-9,13), 121.5 
(CH × 2, C-20, 21), 119.0 (CH × 2, C-10,12), 103.4 (CH, C-16), 80.1 (quat., C-2), 54.5 (CH2, 
C-7), 52.2 (CH3, C-6), 37.7 (CH, C-4) and 28.3 (CH3 × 3, C-1); m/z (ES+) 504 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C24H27N5NaO6 [M+Na]+ requires 504.1859, found 
504.1861. 
 
(S)-4-(4-(2-((tert-Butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 300 
 
 
 
DBU (544 µL, 3.64 mmol) was added to a solution of N-tert-butoxycarbonyl-(S)-tyrosine 
methyl ester 293 (537 mg, 1.82 mmol) in dichloromethane (10 mL) and the solution stirred 
vigorously. Bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 53 (666 mg, 1.82 mmol) was added 
and stirring continued for 2 h. The reaction mixture was washed with distilled water (20 mL) 
and with HCl (2 N, 2 × 15 mL) and with brine (20 mL), the organic layer was dried over 
Na2SO4. The mixture was filtered and the solvent removed under reduced pressure to give the 
crude product. This product was purified by silica gel chromatography, eluting with 
dichloromethane and hexane (50:50 to 100:0) to give (S)-4-(4-(2-((tert-butoxycarbonyl)amino)-
3-methoxy-3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 300 (595 mg, 
1.71 mmol, 86%) as a white solid; Rf 0.54 (30:70, EtOAc:PE, UV/cerium phosphomolybdate); 
m.p. 129-131 °C; [𝛂]𝐃𝟐𝟎 +29.2, (c = 1, CHCl3); νmax (thin film)/cm−1 1746, 1713, 1619, 1535, 
1449, 1366, 1275, 1200, 1167, 1019; 1H NMR (500 MHz; CDCl3) δ 8.06 (2H, d, J 8.2 Hz, CH-
17,21), 7.76 (1H, tt, J 7.5, 1.2 Hz, CH-19), 7.62 (2H, t, J 8.2 Hz, CH-18,20), 7.22-7.18 (4H, m, 
CH-9,10,12,13), 5.09 (1H, d, J 8.1, NH-Boc), 4.57 (1H, dd, J 13.9, 6.5 Hz, CH-4), 3.69 (3H, s, 
CH3-6), 3.14 (1H, dd, J 13.9, 5.8 Hz, CHAHB-7), 3.03 (1H, dd, J 13.9, 6.3 Hz, CHAHB-7) and 
1.39 (9H, s, 3 × CH3-1); 13C NMR (125 MHz; CDCl3) δ 172.1 (quat., C-5), 158.3 (quat., C-14), 
155.0 (quat., C-3), 151.6 (quat., C-11), 137.8 (quat., C-16), 135.9 (CH, C-19), 135.0 (quat., C-
8), 130.9 (CH × 2, C-9,13), 129.8 (CH × 2, C-17,21), 128.6 (CH × 2, C-18,20), 119.9 (CH × 2, 
C-10,12), 110.7 (quat., C-14), 80.1 (quat., C-2), 54.4 (CH, C-4), 52.4 (CH3, C-6), 37.7 (CH2, C-
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7) and 28.3 (CH3 × 3, C-1); m/z (ES+) 542 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C23H25N3NaO9S [M+Na]+ requires 542.1209, found 542.1210.  
 
N-(tert-Butoxycarbonyl)-L-serine methyl ester, 301373 
 
 
 
Thionyl chloride 11.9 g, 7.3 mL, 100 mmol) was added dropwise to a suspension of L-serine 
285 (10.0 g, 95 mmol) in methanol (150 mL) at 0 °C following the addition the solution was 
allowed to warm to room temperature and stirred overnight. The solvent was removed under 
reduced pressure, and the resulting solid was suspended in methanol and the solvent removed 
reduced pressure; this procedure was repeated a further two times. The solid was then 
suspended in diethyl ether, filtered and washed with diethyl ether and dried under vacuum to 
provide L-serine methyl ester 303 (11.3 g). L-serine methyl ester 303 (11.3 g) was suspended in 
acetonitrile (200 mL) and di-tert-butyl-dicarbonate (21.8 g, 100 mmol) in acetonitrile (100 mL) 
followed by triethylamine (19.3 g, 26.6 mL, 190 mmol) in acetonitrile (100 mL) in one portion 
and the resultant solution stirred at room temperature overnight. CH2Cl2 (1000 mL) was added 
and organics extracted with aq. HCl (1 N, 500 mL) and saturated sodium bicarbonate (100 mL). 
The organic layer was washed with brine (200 mL), dried over MgSO4, filtered and the solvent 
removed under reduced pressure to furnish N-(tert-butoxycarbonyl)-L-serine methyl ester 301 
(21.8 g, 95 mmol, quant) as a viscous colourless oil, which was used without any further 
purification: Rf 0.35 (80:20, EtOAc:PE); [𝛂]𝐃𝟐𝟎 +9.0, (c = 1.0 , CHCl3); [Lit.373 +9.0, (c = 1.0 , 
CHCl3]; 1H NMR (300 MHz; CDCl3) δ 5.52 (1H, d, J 7.0, br, NH-Boc), 4.37 (1H, s br, CH-4), 
4.01-3.81 (2H, m, CH2-5), 3.76 (3H, s, CH3-7), 2.78 (1H, t, J 5.9, br, OH) and 1.43 (9H, s, 3 × 
CH3); 13C NMR (100 MHz; CDCl3) δ 171.6 (quat.), 156.0 (quat.), 80.6 (quat.), 63.7 (CH2), 56.0 
(CH), 52.9 (CH3) and 28.5 (CH3 × 3); m/z (ES+) 242 ([M+Na]+, 100%). The data were in 
agreement with the literature values.373 
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(S)-Methyl 3-amino-2-(tert-butoxycarbonylamino)propanoate, 302374 
 
 
 
TMS-diazomethane solution (2.0 M in ether, 7.9 mL, 15.8 mmol) was added dropwise to a 
solution of (S)-2-((tert-butoxycarbonyl)amino)-3-aminopropionic acid 304 (3.0 g, 14.7 mmol) 
in dichloromethane (50 mL) and methanol (5 mL). The mixture was stirred at room temperature 
for 3 h, following this time a pale yellow solution had formed. The solvent was removed under 
reduced pressure to yield methyl 3-amino-2-(tert-butoxycarbonylamino)propanoate 302 (3.21 g, 
14.7 mmol, quant.) as a colourless oil, which was used without any further purification: Rf 0.35 
(90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate);  [𝛂]𝐃𝟐𝟎 -25.1, (c = 1, MeOH); [Lit.415 -
25.0, (c = 1, MeOH]; 1H NMR (500 MHz, CDCl3) δ 5.44 (1H, d, J 5.3, NH-Boc), 4.32-4.27 
(1H, m, CH-4), 3.75 (3H, s, CH3-7), 3.03 (2H, d, J 4.8 Hz, CH2-5), 1.43 (9H, s, 3 × CH3-1) and 
1.40-1.35 (2H, m, NH2); 13C NMR (125 MHz, CDCl3) δ 172.1 (quat., C-6), 155.5 (quat., C-3), 
80.0 (quat., C-2), 55.9 (CH, C-4), 52.4 (CH3, C-7), 43.9 (CH2, C-5) and 28.3 (CH3 × 3, C-1); 
m/z (ES+) 241 ([M+Na]+, 100%); m/z (ES+) 587 ([M+Na]+, 100%). The data were in agreement 
with the literature values.374  
 
(S)-N-((2-((tert-Butoxycarbonyl)amino)-3-methoxy-3-oxopropoxy)carbonyl)-3-
phenylsydnonimine, 305 
 
 
N-(tert-Butoxycarbonyl)-L-serine methyl ester 301 (250 mg, 1.14 mmol) and N-((4-
nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 (372 mg, 1.14 mmol) were dissolved in 
acetonitrile (15 mL) and heated under reflux for 24 h. The solvent was removed under reduced 
pressure and the residue uptaken in dichloromethane (10 mL) and adsorbed onto silica gel. 
Silica gel chromatography, eluting with CH2Cl2 and acetone (100: 0 to 90:10), provided (S)-N-
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(((2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropoxy)carbonyl)-3-phenylsydnonimine 
305 (272 mg, 0.67 mmol, 59%) as a colourless crystalline solid: Rf 0.24 (90:10, CH2Cl2:MeOH, 
UV/cerium phosphomolybdate); m.p. 40-41 °C;   [𝛂]𝐃𝟐𝟎 +17.9, (c = 1.0, CHCl3); νmax (thin 
film)/cm−1 2978, 1793, 1712, 1585, 1390, 1377, 1282, 1069, 972; 1H NMR (300 MHz; CDCl3) 
δ 8.12 (1H, s CH-10), 7.81 (2H, d, J 8.2 Hz, CH-12,16), 7.75 -7.69 (3H, m, CH-13,14,15), 5.52 
(1H, d, J 8.4, NH-Boc), 4.61-4.55 (2H, m, CH2-7), 4.41-4.35 (1H, m, CH-4), 3.77 (3H, s, CH3-
6) and 1.44 (9H, s, 3 × CH3); 13C NMR (100 MHz; CDCl3) δ 175.1 (quat), 170.5 (quat.), 160.1 
(quat), 155.3 (quat.), 133.6 (quat), 133.1 (CH), 130.5 (CH × 2), 121.4 (CH × 2), 103.0 (CH), 
89.8 (quat.), 65.2 (CH2), 53.1 (CH), 52.5 (CH3) and 28.1 (CH3 × 3); m/z (ES+) 429 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C18H22N4NaO7 [M+Na]+ requires 429.1386, found 
429.1390. 
 
(S)-N-((2-((tert-Butoxycarbonyl)amino)-3-methoxy-3-oxopropoxy)carbamoyl)-3-
phenylsydnonimine, 306 
 
 
(S)-Methyl 3-amino-2-(tert-butoxycarbonylamino)propanoate 302 (250 mg, 1.14 mmol) and N-
((4-nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 (372 mg, 1.14 mmol) were dissolved in 
acetonitrile (15 mL) and heated under reflux for 24 h. The solvent was removed under reduced 
pressure and the residue uptaken in dichloromethane (10 mL) and adsorbed onto silica gel. 
Silica gel chromatography, eluting with CH2Cl2 and acetone (100: 0 to 90:10), provided (S)-N-
((2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropoxy)carbamoyl)-3-phenylsydnonimine 
306 (254 mg, 0.627 mmol, 55%) as a yellow crystalline solid: Rf 0.13 (95:5, CH2Cl2:acetone, 
UV/cerium phosphomolybdate); m.p. 150 °C (decomp.);  [𝛂]𝐃𝟐𝟎 +18.1, (c = 1.0 , CHCl3); νmax 
(NaCl/thin film)/cm−1 1760, 1600, 1477, 1450, 1325, 1145, 1032, 980; 1H NMR (500 MHz, 
CDCl3) δ 8.16 (1H, s, CH-10), 7.79 (2H, d, J 7.8 Hz, CH-12,16), 7.69 (1H, t, J 7.3 Hz, CH-14), 
7.63 (2H, t, J 7.8 Hz, CH-13,15), 7.37 (1H, s, br, NH-urea), 5.87 (1H, t, J 7.2, NH-Boc), 4.41-
4.38 (1H, m, CH-4), 3.76-3.63 (5H, m, CH3-6, CH2-7) and 1.41 (9H, s, 3 × CH3-1); 13C NMR 
(125 MHz, CDCl3) δ 172.9 (quat., C-9), 171.6 (quat., C-5), 162.1 (quat., 8), 155. (quat., C-3), 
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134.0 (quat., C-14), 132.9 (CH, C-14), 130.5 (CH × 2, C-13,15), 121.6 (CH × 2, C-12,16), 
102.4 (CH, C-10), 79.9 (quat., C-2), 54.8 (CH, C-4), 52.5 (CH3, C-6), 42.2 (CH2, C-7) and 28.3 
(CH3 × 3, C-1); m/z (ES+) 428 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C18H23N5NaO6 
[M+Na]+ requires 428.1546, found 428.1550. 
 
(S)-N-((4-(2-Amino-3-methoxy-3-oxopropyl)phenoxy)carbonyl)-3-
phenylsydnonimine hydrochloride, 307 
 
 
HCl in dioxane (4M, 2 mL, 8.0 mmol) was added to a solution of (S)-N-((4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyloxy)carbonyl)-3-phenylsydnonimine 
298 (92 mg, 0.19 mmol) in dichloromethane (5 mL) cooled to 0 °C. The solution was stirred at 
0 °C for 3 h and the solvent evaporated under reduced pressure to yield a white residue. 
Trituration with diethyl ether provided (S)-N-((4-(2-amino-3-methoxy-3-
oxopropyl)phenoxy)carbonyl)-3-phenylsydnonimine hydrochloride 307 (78 mg, 0.19 mmol, 
quant.) as a white solid; m.p. 117-119 °C; [𝛂]𝐃𝟐𝟎+2.6, (c = 1.0, MeOH); νmax (thin film)/cm−1 
1780, 1734, 1515, 1313, 1247, 1227, 1068, 868; 1H NMR (500 MHz; CDCl3) δ 8.82-8.75 (4H, 
m, CH-13, NH2.HCl), 8.09 (2H, d, J 7.6 Hz, CH-15,19), 7.83-7.71 (3H, m, CH-16,17, 18), 7.28 
(2H d, J 8.4 Hz, CH-6,10), 7.13 (2H d, J 8.4 Hz, CH-7,9), 4.29-4.23 (1H, m, CH-1), 3.68 (3H, s, 
CH3-3), 3.22 (1H, dd, J 14.2, 5.7 Hz, CHAHB-4), and 3.12 (1H, dd, J 14.2, 7.1 Hz, CHAHB-4); 
13C NMR (75 MHz; d6-DMSO) δ 173.7 (quat., C-12), 169.3 (quat., C-2), 157.4 (quat., C-11), 
150.9 (quat., C-8), 133.4 (quat., C-5), 133.2 (CH, C-17), 131.3 (quat., C-14), 130.3 (CH × 4, C-
6,10,15,19), 122.6 (CH × 2, C-16,18), 121.8 (CH × 2, C-7,9), 105.4 (CH, C-13), 53.1 (CH, C-
1), 52.6 (CH3, C-3) and 35.1 (CH2, C-4); m/z (ES+) 383 ([M+H]+, 100%); HRMS m/z (ES+) 
calcd. for C19H19N4O5 [M+H]+ requires 383.1355, found 383.1360. 
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(S)-N-((4-(2-((tert-Butoxycarbonyl)amino)-2-carboxyethyl)phenoxy)carbonyl) -3-
phenylsydnonimine, 308 
 
 
Sodium hydroxide (17 mg, 0.42 mmol) was added to a solution of (S)-N-((4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyloxy)carbonyl)-3-phenylsydnonimine 
298 (100 mg, 0.21 mmol) in THF (2 mL) and water (2 mL). The resulting solution was stirred 
for 30 min and cooled to 0 °C. The solution was acidified (pH = 2) with aq. hydrochloric acid (2 
N) with continued stirring. The cooled solution was extracted with ethyl acetate (3 × 20 mL), 
and the combined organic extracts were washed with brine (20 mL), dried over Na2SO4. The 
mixture was filtered and the solvent removed under reduced pressure to yield (S)-5-((4-(2-((tert-
butoxycarbonyl)amino)-2-carboxyethyl)phenoxy)carbonyl)-3-phenylsydnonimine 308 (92 mg, 
0.20 mmol, 95%) as a white solid, which was used without any further purification: Rf 0.63 
(100:1, EtOAc:AcOH, UV/cerium phosphomolybdate); m.p. 115-118 °C; [𝛂]𝐃𝟐𝟎 -24.8, (c = 0.1 , 
MeOH); νmax (thin film)/cm−1 1727, 1623, 1580, 1502, 1469, 1365, 1295, 1250, 1187, 1166; 1H 
NMR (500 MHz; CDCl3) δ 8.62 (1H, s, CH-15), 8.06 (2H, d, J 7.6 Hz, CH-17,21), 7.80-7.70 
(3H, m, CH-18, 19, 20), 7.20 (2H d, J 8.3 Hz, CH-8, 12), 7.10 (2H d, J 8.4 Hz, CH-9, 11), 6.51 
(1H, s, br, NH), 4.01-3.96 (1H, m, CH-4), 3.06 (1H, dd, J 14.5, 4.9 Hz, CHAHB-6), 2.88 (1H, dd, 
J 13.4, 8.1 Hz, CHAHB-4) and 1.34 (9H, s, 3 × CH3-1); 13C NMR (75 MHz; d6-DMSO) δ 174.9 
(quat., C-15), 174.4 (quat., C-5), 158.0 (quat., C-13), 155.1 (quat., C-3), 150.3 (quat., C-10), 
135.0 (quat., C-7). 133.6 (quat., C-16), 133.0 (CH, C-19), 130.2 (CH × 2, C-17,21), 129.9 (CH 
× 2, C-8, 12), 122.4 (CH × 2, C-18,20), 121.2 (CH × 2, C-9, 11), 104.7 (CH, C-15), 77.7 (quat., 
C-2), 55.8 (CH, C-4), 36.2 (CH2, C-6) and 28.2 (CH3 × 3, C-1); m/z (ES+) 491 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C23H24N4NaO5 [M+Na]+ requires 491.1543, found 
491.1540.  
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(S)-N-((4-(2-Amino-2-carboxyethyl)phenyl)carbonyl)-3-phenylsydnonimine 
hydrochloride, 287 
 
 
Sodium hydroxide (17 g, 0.42 mmol) was added to a solution of (S)-N-((4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyloxy)carbonyl)-3-phenylsydnonimine 
298 (100 mg, 0.21 mmol) in THF (2 mL) and water (2 mL). The resulting solution was stirred 
for 30 min and cooled to 0 °C. The solution was acidified (pH = 2) with aq. hydrochloric acid (2 
N) with continued stirring. The cooled solution was extracted with ethyl acetate (3 × 20 mL), 
and the combined organic extracts were evaporated at reduced pressure. The residue was 
uptaken in dichloromethane (4 mL) and cooled to 0 °C. HCl in dioxane (4M, 1.5 mL, 6 mmol) 
was added dropwise and the solution stirred at 0 °C for 1 h. Following this time the solvent was 
evaporated under reduced pressure and the residue triturated with diethyl ether to give (S)-N-
((4-(2-amino-2-carboxyethyl)phenyl)carbonyl)-3-phenylsydnonimine hydrochloride 287 (65 mg, 
0.160 mmol, 77%) as a white powder: m.p. 108-111 °C; [𝛂]𝐃𝟐𝟎  -0.6, (c = 1.0 , MeOH); νmax 
(thin film)/cm−1 3036, 1755, 1629, 1597, 1544, 1507, 1368, 1256, 1216, 1193; 1H NMR (500 
MHz; CDCl3) δ 8.73 (1H, s, CH-12), 8.51 (3H, s, br, NH2.HCl), 8.03 (2H, d, J 8.0 Hz, CH-
14,18), 7.79 (1H, tt, J 7.5, 2.3 Hz, CH-16), 7.74 (2H, t, J 8.1 Hz, CH-15,17), 7.31 (2H d, J 8.5 
Hz, CH-5,9), 7.12 (2H d, J 8.5 Hz, CH-6,8), 4.16 (1H, dd, J 11.6, 5.9 Hz, CH-1) and 3.15 (2H, 
d, J 6.2 Hz, CH2-3); 13C NMR (125 MHz; d6-DMSO) δ 174.6 (quat., C-11), 170.8 (quat., C-2), 
158.3 (quat., C-10), 151.4 (quat., C-7),  133.9 (quat., C-13), 133.7 (CH, C-16), 132.0 (quat., C-
4), 130.8 (CH × 2, C-14,18), 130.8 (CH × 2, C-5,9), 123.1 (CH × 2, C-15,17), 122.3 (CH × 2, 
C-6,8), 105.8 (CH, C-15), 55.4 (CH, C-1) and 35.5 (CH2, C-3); m/z (ES+) 391 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C18H16N4NaO5 [M+Na]+ requires 391.1018, found 
391.1022.  
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(S)-N-((4-(2-Amino-3-methoxy-3-oxopropyl)phenyl)carbamoyl)-3-
phenylsydnonimine hydrochloride, 309 
 
 
HCl in dioxane (4M, 2 mL, 8.0 mmol) was added to a solution of (S)-N-((4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyl)carbamoyl)-3-phenylsydnonimine 299 
(100 mg, 0.21 mmol) in dichloromethane (5 mL) cooled to 0 °C. The solution was stirred at 0 
°C for 3 h and the solvent evaporated under reduced pressure to yield a yellow residue. 
Trituration with diethyl ether provided (S)-N-((4-(2-amino-3-methoxy-3-
oxopropyl)phenyl)carbamoyl)-3-phenylsydnonimine hydrochloride 309 (87 mg, 0.21 mmol, 
quant.) as a orange solid, which was used without any further purification: m.p. 160 °C 
(decomp.); [𝛂]𝐃𝟐𝟎  +5.2, (c = 0.8, MeOH); νmax (thin film)/cm−1 3334, 1738, 1706, 1650, 1591, 
1517, 1365, 1274, 1246, 1165; 1H NMR (500 MHz; CDCl3) δ 9.61 (1H, s, NH), 9.11 (1H, s, 
CH-13), 8.65 (3H, s, br, NH2.HCl), 8.13 (2H, m, CH-15,19), 7.86-7.74 (3H, m, CH-16,17,18), 
7.54 (2H d, J 8.3 Hz, CH-7,9), 7.18 (2H, d, J CH-6,10), 4.25-4.19 (1H, m, CH-1), 3.68 (3H, s, 
CH3-3) and 3.18-3.00 (2H, m, CH2-4); 13C NMR (75 MHz; d6-DMSO) δ 176.0 (quat., C-12), 
169.4 (quat., C-2), 159.5 (quat., C-11), 139.2 (quat., C-8), 133.5 (quat., C-5), 133.4 (quat., C-
17), 133.1 (CH, C-14), 130.4 (CH × 2, C-15,19), 127.2 (CH × 2, C-6,10), 122.6 (CH × 2, C-
16,18), 118.5 (CH × 2, C-7,9), 106.2 (CH, C-16), 53.2 (CH2, C-1), 52.6 (CH3, C-3) and 35.2 
(CH, C-4); m/z (ES+) 382 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C19H20N5O4 [M+H]+ 
requires 382.1515, found 382.1520. 
 
 
 
 
 
 
 
2
HCl. H2N 1
4
5
10
9
8 NH76
O
O
3
11
NO
12
13
NN
O
14 19
18
1716
15
Appendix: Experimental 
 
	   286	  
(S)-N-((4-(2-((tert-Butoxycarbonyl)amino)-2-carboxyethyl)phenoxy)carbamoyl) -3-
phenylsydnonimine, 310 
 
 
Sodium hydroxide (17 mg, 0.42 mmol) was added to a solution of (S)-N-((4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyl)carbamoyl)-3-phenylsydnonimine 299 
(100 mg, 0.21 mmol) in THF (2 mL) and water (2 mL). The resulting solution was stirred for 30 
min and cooled to 0 °C. The solution was acidified (pH = 2) with aq. hydrochloric acid (2 N) 
with continued stirring. The cooled solution was extracted with ethyl acetate (3 × 20 mL), and 
the combined organic extracts were washed with brine (20 mL), dried over Na2SO4. The 
mixture was filtered and the solvent removed under reduced pressure to yield (S)-N-((4-(2-
((tert-butoxycarbonyl)amino)-2-carboxyethyl)phenoxy)carbamoyl)-3-phenylsydnonimine 310 
(85 mg, 0.18 mmol, 88%) as a yellow solid, which was used without any further purification: Rf 
0.19 (80:20, CH2Cl2:acetone, UV/cerium phosphomolybdate); m.p. 151-154 °C; [𝛂]𝐃𝟐𝟎 +8.0, (c 
= 1, MeOH); νmax (thin film)/cm−1 1710, 1650, 1590, 1517, 1411, 1365, 1313, 1245, 1167, 963; 
1H NMR (500 MHz; CDCl3) δ 9.46 (1H, s, NH), 8.55 (1H, s, CH-15), 7.86 (2H, d, J 7.9 Hz, 
CH-17,21), 7.72 (1H, t, J 7.3 Hz, CH-19), 7.66 (2H, t, J 7.6 Hz, CH-18,20), 7.36 (2H, d, J 8.0 
Hz, CH-9, 11), 7.07 (2H, d, J 8.1 Hz, CH-8, 12), 5.16 (1H, d, J 7.7, NH), 4.78 (1H, dd, J 13.4, 
6.2 Hz, CH-4), 3.15-3.05 (2H, m, CH2-6) and 1.45 (9H, s, 3 × CH3-1); 13C NMR (125 MHz; 
CDCl3) δ 176.8 (quat., C-14), 175.9 (quat., C-5), 155.8 (quat., C-13), 155.3 (quat., C-3), 138.0 
(quat., C-7), 133.5 (quat., C-16), 133.3 (CH, C-19), 130.6 (CH × 2, C-17,21), 130.4 (quat., C-
10), 129.9 (CH × 2, C-8, 12), 121.7 (CH × 2, C-18,20), 119.0 (CH × 2, C-9, 11), 80.0 (quat., C-
2), 54.8 (CH, C-4), 37.7 (CH2, C-6) and 28.4 (CH3 × 3, C-1); m/z (ES+) 490 ([M+H]+, 100%); 
HRMS m/z (ES+) calcd. for C23H25N5NaO6 [M+H]+ requires 490.1703, found 490.1711. 
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(S)-N-((4-(2-Amino-2-carboxyethyl)phenyl)carbamoyl)-3-phenylsydnonimine 
hydrochloride, 288 
 
 
Sodium hydroxide (17 mg, 0.42 mmol) was added to a solution of (S)-N-((4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyl)carbamoyl)-3-phenylsydnonimine 299 
(100 mg, 0.21 mmol) in THF (2 mL) and water (2 mL). The resulting solution was stirred for 30 
min and cooled to 0 °C. The solution was acidified (pH = 2) with aq. hydrochloric acid (2 N) 
with continued stirring. The cooled solution was extracted with ethyl acetate (3 × 20 mL), and 
the combined organic extracts were evaporated at reduced pressure. The residue was uptaken in 
dichloromethane (4 mL) and cooled to 0 °C. HCl in dioxane (4M, 1.5 mL, 6 mmol) was added 
dropwise and the solution stirred at 0 °C for 1 h. Following this time the solvent was evaporated 
under reduced pressure and the residue triturated with diethyl ether to give (S)-N-((4-(2-amino-
2-carboxyethyl)phenyl)carbamoyl)-3-phenylsydnonimine 288 (63 mg, 0.16 mmol, 75%) as a 
yellow solid: m.p. 200 °C (decomp);   [𝛂]𝐃𝟐𝟎 -1.6, (c = 1.0 , MeOH); νmax (thin film)/cm−1 1700, 
1648, 1520, 1409, 1360, 1240, 970; 1H NMR (300 MHz; CDCl3) δ 9.59 (1H, s, NH), 9.11 (1H, 
s, CH-12), 8.42 (3H, s, br, NH2.HCl), 8.13 (2H, m, CH-14,18), 7.83 (1H, tt, J 7.5, 1.5 Hz, CH-
16), 7.76 (2H, d, J 7.8 Hz, CH-15,17), 7.54 (2H d, J 8.5 Hz, CH-6,8), 7.16 (2H, d, J 8.5 Hz, 
CH-5,9), 4.10-4.07 (1H, m, CH-1) and 3.11-3.06 (2H, m, CH2-3); 13C NMR (75 MHz; d6-
DMSO) δ 174.8 (quat., C-11), 170.3 (quat., C-2), 152.7 (quat., C-10), 139.0 (quat., C-7), 134.1 
(CH, C-16), 133.5 (quat., C-13), 130.4 (quat., C-4), 130.0 (CH × 2, C-14,18), 129.8 (CH × 2, C-
6,8), 123.3 (CH × 2, C-15,17), 117.8 (CH × 2, C-5,9), 106.2 (CH, C-12), 53.2 (CH2, C-1) and 
35.8 (CH, C-4); m/z (ES+) 390 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C23H25N5NaO6 
[M+H]+ requires 390.1178, found 490.1711. 
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(S)-4-(4-(2-Amino-3-methoxy-3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide hydrochloride, 311 
 
 
HCl in dioxane (4M, 2 mL, 8.0 mmol) was added to a solution of (S)-4-(4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 
2-oxide 300 (100 mg, 0.19) in dichloromethane (5 mL) cooled to 0 °C. The solution was stirred 
at 0 °C for 3 h and the solvent evaporated under reduced pressure to yield a white residue. 
Trituration with diethyl ether provided (S)-4-(4-(2-amino-3-methoxy-3-oxopropyl)phenoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide hydrochloride 311 (87 mg, 0.19 mmol, quant.) as a 
white solid: m.p. 174-177 °C; [𝛂]𝐃𝟐𝟎 +9.3, (c = 0.9, MeOH); νmax (thin film)/cm−1 1742, 1617, 
1503, 1357, 1275, 1275, 1161, 1017, 990; 1H NMR (300 MHz; d6-DMSO) δ 8.72 (3H, s, br, 
NH2.HCl), 8.05 (2H, d, J 8.1 Hz, CH-14,18), 7.92 (1H, tt, J 7.5, J 1.4 Hz, CH-16), 7.77 (2H, t, J 
7.9 Hz, CH-15,17), 7.41-7.35 (4H, m, CH-6,7,9,10), 4.31 (1H, t, J 6.1 Hz, CH-1), 3.68 (3H, s, 
CH3-3), 3.23 (1H, dd, J 6.1, J 14.2 Hz, CHAHB-4) and 3.14 (1H, dd, J 7.3, J 14.2 Hz, CHAHB-
4); 13C NMR (75 MHz; d6-DMSO) δ 169.3 (quat., C-2), 158.4 (quat., C-11), 151.8 (quat., C-8), 
136.9 (quat., C-5), 136.3 (CH, C-16), 133.1 (quat., C-13), 131.1 (CH × 2, C-6,10), 130.1 (CH × 
2, C-14, C-18), 128.5 (CH × 2, C-15,17), 119.8 (CH × 2, C-7,10), 111.2 (quat., C-12), 53.0 
(CH, C-1), 52.6 (CH3, C-3) and  35.0 (CH2, C-4); m/z (ES+) 420 ([M+H]+, 100%); HRMS m/z 
(ES+) calcd. for C18H18N3O7S [M+H]+ requires 420.0865, found 420.0870. 
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(S)-4-(4-(2-((tert-Butoxycarbonyl)amino)-2-carboxyethyl)phenoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 312 
 
 
Sodium hydroxide (15 mg, 0.39 mmol) was added to a solution of (S)-4-(4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 
2-oxide 300 (100 mg, 0.19 mmol) in THF (2 mL) and water (2 mL). The resulting solution was 
stirred for 30 min and cooled to 0 °C. The solution was acidified (pH = 2) with aq. hydrochloric 
acid (2 N) with continued stirring. The cooled solution was extracted with ethyl acetate (3 × 20 
mL), and the combined organic extracts were washed with brine (20 mL), dried over Na2SO4. 
The mixture was filtered and the solvent removed under reduced pressure to yield (S)-4-(4-(2-
((tert-butoxycarbonyl)amino)-2-carboxyethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-
oxide 312 (92 mg, 0.20 mmol, 90%) as a white solid, which was used without any further 
purification: Rf 0.48 (100:1, EtOAc:AcOH, UV/cerium phosphomolybdate); m.p. 66-68 
°C; [𝛂]𝐃𝟐𝟎 +6.4, (c = 1.0 , MeOH); νmax (thin film)/cm−1 1717, 1619, 1535, 1505, 1445, 1368, 
1267, 1167, 1019; 1H NMR (500 MHz; CDCl3) δ 8.10 (2H, d, J 8.4 Hz, CH-16,20), 7.89 (1H, 
tt, J 6.7, J 1.2 Hz, CH-18), 7.64 (2H, t, J 7.7 Hz, CH-17,19), 7.29-7.25 (4H m, CH-8,9,11,12), 
5.02 (1H, d, J 8.7, NH-Boc), 4.62 (1H, dd, J 11.9, 6.3 Hz, CH-4), 3.24 (1H, dd, J 14.3, 5.6 Hz, 
CHAHB-6), 3.09 (1H, dd, J 14.3, 6.6 Hz, CHAHB-4) and 1.42 (9H, s, 3 × CH3-1); 13C NMR (75 
MHz; d6-DMSO) δ 175.5 (quat., C-5), 158.4 (quat., C-13), 155.4 (quat., C-3), 151.6 (quat., C-
10), 137.9 (quat., C-7), 135.9 (CH, C-18), 134.7 (quat., C-15), 131.0 (CH × 2, C-8,12), 129.8 
(CH × 2, C-16, 20), 128.7 (CH × 2, C-17,19), 120.0 (CH × 2, C-9,11), 110.7 (quat., C-14), 80.6 
(quat., C-2), 54.2 (CH, C-4), 37.2 (CH2, C-6) and 28.3 (CH3 × 3, C-1); m/z (ES+) 528 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C22H23N3NaO9S [M+Na]+ requires 528.1053, found 
528.2050. 
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(S)-4-(4-(Amino-2-carboxyethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-
oxide, 289 
 
 
Sodium hydroxide (15 mg, 0.39 mmol) was added to a solution of (S)-4-(4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 
2-oxide 300 (100 mg, 0.19 mmol) in THF (2 mL) and water (2 mL). The resulting solution was 
stirred for 30 min and cooled to 0 °C. The solution was acidified (pH = 2) with aq. hydrochloric 
acid (2 N) with continued stirring. The cooled solution was extracted with ethyl acetate (3 × 20 
mL), and the combined organic extracts were evaporated at reduced pressure. The residue was 
uptaken in dichloromethane (4 mL) and cooled to 0 °C. HCl in dioxane (4M, 1.5 mL, 6 mmol) 
was added dropwise and the solution stirred at 0 °C for 1 h. Following this time the solvent was 
evaporated under reduced pressure and the residue triturated with diethyl ether to give (S)-4-(4-
(2-amino-2-carboxyethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 289 (68 mg, 
0.15 mmol, 80%) as a white powder: m.p. 250 °C (decomp);  [𝛂]𝐃𝟐𝟎  -0.52, (c = 0.7 , MeOH); 
νmax (thin film)/cm−1 1727, 1623, 1534, 1449, 1352, 1256, 1201, 1163, 1083; 1H NMR (300 
MHz; d6-DMSO) δ 8.57 (3H, s, br, NH2.HCl), 8.05 (2H, d, J 8.4 Hz, CH-13,17), 7.92 (1H, tt, J 
7.5, J 2.2 Hz, CH-15), 7.78 (2H, t, J 8.0 Hz, CH-14,16), 7.42-7.36 (4H, m, CH-5,6,8,9), 4.08 
(1H, t, J 7.2 Hz, CH-1) and 3.21 (2H, d, J 7.2 Hz, CH2-3); 13C NMR (75 MHz; d6-DMSO) δ 
174.6 (quat., C-2), 158.4 (quat., C-10), 152.1 (quat., C-7), 137.2 (quat., C-4), 135.4 (CH, C-15), 
134.1 (quat., C-13), 131.7 (CH × 2, C-5,9), 130.6 (CH × 2, C-14,18), 129.0 (CH × 2, C-14,16), 
120.0 (CH × 2, C-6,8), 108.8 (quat., C-11), 53.8 (CH., C-1) and  35.3 (CH2, C-3); m/z (ES+) 406 
([M+H]+, 100%); HRMS m/z (ES+) calcd. for C17H16N3O7S [M+H]+ requires 406.0709, found 
406.0713. 
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(S)-N-((2-Amino-3-methoxy-3-oxopropoxy)carbonyl)-3-phenylsydnonimine 
hydrochloride, 313 
 
 
HCl in dioxane (4M, 2 mL, 8.0 mmol) was added to a solution of (S)-N-(((2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropoxy)carbonyl)-3-phenylsydnonimine 305 (100 
mg mg, 0.225 mmol) in dichloromethane (5 mL) cooled to 0 °C. The solution was stirred at 0 
°C for 3 h and the solvent evaporated under reduced pressure to yield a tan residue. Trituration 
with diethyl ether provided (S)-N-(((2-amino-3-methoxy-3-oxopropoxy)carbonyl)-3-
phenylsydnonimine hydrochloride 313 (84 mg, 0.25 mmol, quant.) as an off-white solid: m.p. 
102-104 °C; [𝛂]𝐃𝟐𝟎 +9.4, (c = 0.9, MeOH); νmax (thin film)/cm−1 1682, 1583, 1519, 1471, 1366, 
1313, 1213 1187, 969;  1H NMR (300 MHz; d6-DMSO) δ 8.95 (3H, s, br, NH2.HCl), 8.78 (1H, 
s CH-7), 8.12-8.04 (2H, m, CH-9,13), 7.83-7.71 (3H, m, CH-10,11,12), 4.54-4.40 (3H, m, CH-
1, CH2-4) and 3.78 (3H, s, CH3-3); 13C NMR (100 MHz; d6-DMSO) δ 173.1 (quat., C-6), 167.6 
(quat., C-1), 157.5 (quat., C-5), 133.3 (CH, C-11), 130.3 (CH × 2, C-10,12), 122.5 (CH × 2, C-
9,13), 105.4 (CH, C-7), 62.8 (CH2, C-4), 53.1 (CH3, C-3) and 51.5 (CH, C-1); m/z (ES+) 307 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C13H15N4O5 [M+Na]+ requires 307.1042, found 
307.1049. 
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(S)-N-(((2-Amino-3-methoxy-3-oxopropoxy)carbonyl)-3-phenylsydnonimine 
hydrochloride, 314 
 
 
HCl in dioxane (4M, 2 mL, 8.0 mmol) was added to a solution of (S)-N-(((2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropoxy)carbamoyl)-3-phenylsydnonimine 306 (100 
mg, 0.25 mmol) in dichloromethane (5 mL) cooled to 0 °C. The solution was stirred at 0 °C for 
3 h and the solvent evaporated under reduced pressure to yield a tan residue. Trituration with 
diethyl ether provided (S)-N-(((2-amino-3-methoxy-3-oxopropoxy)carbamoyl)-3-
phenylsydnonimine hydrochloride 314 (84 mg, 0.25 mmol, quant.) as an off-white solid: m.p. 
150-152; [𝛂]𝐃𝟐𝟎 +11.0, (c = 1.0, MeOH); νmax (NaCl/thin film)/cm−1 1744, 1609, 1546, 1514, 
1495, 1416, 1315, 1237, 1050, 823; 1H NMR (500 MHz, d6-DMSO) δ 9.25 (1H, s, CH-7), 8.89-
8.79 (3H, s, br, NH2.HCl), 8.14 (2H, d, J 7.7 Hz, CH-9,13), 7.84-7.77 (3H, m, CH-10, 11, 12), 
4.14-4.09 (1H, s, br, CH-1) and 3.75-3.71 (5H, m, CH2-4, CH3-3); 13C NMR (125 MHz, d6-
DMSO) δ 176.5 (quat., C-6), 168.8 (quat., C-2), 167.7 (quat., C-5), 134.3 (CH, C-11), 133.3 
(quat., C-8), 130.9 (CH × 2, C-9,13), 123.4 (CH × 2, C-10,12), 107.5 (CH, C-7), 53.0 (CH3, C-
3), 52.2 (CH, C-1) and 39.9 (CH2, C-4); m/z (ES+) 306 ([M+Na]+, 100%); HRMS m/z (ES+) 
calcd. for C13H16N5O6 [M+H]+ requires 306.1202, found 306.1220.  
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N-(tert-Butoxycarbonyl)-L-serine tert-butyl ester, 317 
 
 
 
Aqueous sodium hydroxide (1 N, 19.5 mL) was added to a solution of L-serine 285 (1.00 g, 9.5 
mmol) in dioxane cooled to 0 °C. Di-tert-butyl dicarbonate (2.47 g, 1.13 mmol) was added 
portionwise and the resultant solution stirred overnight at room temperature. Aqueous citric acid 
(10%, 50 mL) was added slowly and the solution extracted with ethyl acetate (3 × 100 mL). The 
organic extracts were combined and washed with brine (100 mL), dried over MgSO4, filtered 
and the solvent removed under reduced pressure to furnish N-(tert-butoxycarbonyl)-L-serine 
(1.94 g) as a colourless oil. N,N-Dimethylformamide di-tert-butyl acetal (DMF-DBA, 5.27 g, 
6.2 mL, 26.9 mmol) was added to a solution of N-(tert-butoxycarbonyl)-L-serine (1.00 g, 4.89 
mmol) in toluene (8 mL). The solution was heated to reflux for 18 h. Aqueous sodium 
bicarbonate (5% of saturated, 20 mL) was added and the mixture stirred for 30 min. Methanol 
was added to the mixture until a homogenous layer was obtained. The solution was extracted 
with ethyl acetate (50 mL). The organic layer was washed with water (3 × 10 mL) and brine (20 
mL), dried over MgSO4, filtered and the solvent was removed under reduced pressure and the 
residue uptaken in dichloromethane and adsorbed onto silica gel. Silica gel chromatography, 
eluting with ethyl acetate and hexanes (50:50), furnished N-(tert-butoxycarbonyl)-L-serine tert-
butyl ester 317 (830 mg, 3.18 mmol, 65%, over two steps) as a colourless oil which solidified 
on standing: Rf 0.34 (50:50, EtOAc: PE, KMnO4); m.p. 79-82 °C [Lit.,416 79.0-83.5°C]; [𝛂]𝐃𝟐𝟎 -25.0, (c = 2, EtOH, [Lit.,417 -25.0, (c = 2, EtOH)]; 1H NMR (400 MHz; CDCl3) δ 5.43 
(1H, s, br, NH), 4.27-4.20 (1H, m, CH-4), 3.88 (2H, d, J 3.8 Hz, CH2-8), 2.25 (1H, s, OH), 1.47 
(9H, s, 3 × CH3-7) and 1.43 (9H, s, 3 × CH3-1); 13C NMR (75 MHz; CDCl3) δ 169.8 (quat., 
C-5), 155.9 (quat., C-3), 82.7 (quat., C-6), 80.2 (quat., C-2), 64.1 (CH2, C-8), 53.4 (CH, C-4), 
28.3 (9H, s, 3 × CH3-1) and 28.0 (9H, s, 3 × CH3-7); m/z (ES+) 262 ([M+H]+, 100%). The data 
were in agreement with the literature values.416 
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(S)-N-((3-(tert-Butoxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropoxy)carbonyl)-3-
phenylsydnonimine, 318 
 
 
N-(tert-butoxycarbonyl)-L-serine tert-butyl ester 317 (200 mg, 0.77 mmol) and N-((4-
nitrophenoxy)carbonyl)-3-phenylsydnonimine 218 (250 mg, 0.77 mmol) were dissolved in 
acetonitrile (15 mL) and heated under reflux for 24 h. The solvent was removed under reduced 
pressure and the residue uptaken in dichloromethane (10 mL) and adsorbed onto silica gel. 
Silica gel chromatography, eluting with CH2Cl2 and acetone (100: 0 to 90:10) provided (S)-N-
(((3-(tert-butoxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropoxy)carbonyl)-3-phenylsydnon-
imine 318 (206 mg, 0.46 mmol, 60%) as an orange gum: Rf 0.21 (95:5, CH2Cl2:acetone, 
UV/cerium phosphomolybdate);  [𝛂]𝐃𝟐𝟎 +34.6, (c = 1.0 , CHCl3); νmax (thin film)/cm−1 1722, 
1589, 1500, 1458, 1368, 1152, 1030, 972, 846; 1H NMR (300 MHz; CDCl3) δ 8.17 (1H, s CH-
11), 7.83 (2H, d, J 8.6 Hz, CH-13,17), 7.72 (1H, tt, J 8.7, 1.2 Hz, CH-15) 7.66 (2H, t, J 7.9 Hz, 
CH-14,16), 5.51 (1H, d, J 8.7, NH), 4.55 (1H, dd, J 10.9, 3.8 Hz, CHAHB-8), 4.46 (1H, m, CH-
4), 4.31 (1H, dd, J 10.9, 3.2 Hz, CHAHB-8), 1.45 (9H, s, 3 × CH3-1) and 1.43 (9H, s, 3 × CH3-
7); 13C NMR (100 MHz; CDCl3) δ 174.9 (quat., C-9), 169.1 (quat., C-5), 160.5 (quat., C-3), 
155.5 (quat., C-9), 133.7 (quat., C-12), 133.3 (CH, C-15), 130.6 (CH × 2, C-13,17), 121.4 (CH 
× 2, C-14,16), 103.1 (CH, C-11), 82.4 (quat., C-2), 79.7 (quat., C-6), 65.9 (CH2), 53.7 (CH), 
28.3 (CH3 × 3, C-1) and 28.1 (CH3 × 3, C-7); m/z (ES+) 471 ([M+Na]+, 100%); HRMS m/z 
(ES+) calcd. for C21H28N4NaO7 [M+Na]+ requires 471.1856, found 471.1862. 
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(S)-N-(((2-Amino-2-carboxyethoxy)carbonyl)-3-phenylsydnonimine 
trifluoroacetate, 319 
 
 
Trifluoroacetic acid (2 mL) was added to a solution of (S)-N-(((3-(tert-butoxy)-2-((tert-
butoxycarbonyl)amino)-3-oxopropoxy)carbonyl)-3-phenylsydnonimine 318 (200 mg, 0.45 
mmol) in dichloromethane (2 mL) at 0 °C. The resultant solution was stirred for 18 h and the 
solvent evaporated to yield (S)-N-(((2-amino-2-carboxyethyl)carbonyl)-3-phenylsydnonimine 
319 (183 mg, 0.45 mmol, quant.)  as an orange gum: Rf 0.14 (90:10, CH2Cl2:acetone, 
UV/cerium phosphomolybdate);  [𝛂]𝐃𝟐𝟎 +3.9, (c = 1, MeOH; νmax (NaCl/thin film)/cm−1 1736, 
1566, 1487, 1477, 1360, 1010, 956, 822; 1H NMR (400 MHz, d6-DMSO) δ 8.62 (1H, s, CH-6), 
8.51 (3H, s, br, NH2.CF3COOH), 8.08 (2H, d, J 8.0 Hz, CH-18,12), 7.81-7.72 (3H, m, CH-
9,10,11) and 4.42-4.31 (3H, m, CH2-3, CH-1); 13C NMR (100 MHz, d6-DMSO) δ 174.5 (quat., 
C-2), 174.2 (quat., CF3COOH), 168.8 (quat., C-5), 159.1 (quat., C-4), 133.5 (CH, C-10), 130.7 
(quat., C-7), 130.2 (CH × 2, C-8,12), 122.4 (CH × 2, C-9,11), 118.4 (quat., q, J  18.0 Hz, 
CF3COOH), 104.5 (CH, C-6), 62.8 (CH2, C-3) and 51.7 (CH, C-1); m/z (ES+) 315 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C12H12N4NaO5 [M+Na]+ requires 315.0705, found 
315.0700. 
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(S)-N-((2-((tert-Butoxycarbonyl)amino)-3-oxopropoxy)carbonyl)-3-
phenylsydnonimine, 320 
 
 
Boc2O (134 mg, 0.62 mmol) and NaHCO3 (52 mg, 0.62 mmol) were added to a solution of (S)-
N-(((2-amino-2-carboxyethoxy)carbonyl)-3-phenylsydnonimine trifluoroacetate 319 (100 mg, 
0.246 mmol) in H2O:dioxane (1:1, 2 mL) and stirred overnight at room temperature. The 
solution was extracted with diethyl ether (2 mL) and the aqueous layer separated. The solution 
was cooled to 0 °C and acidified (pH = 2) with aq. hydrochloric acid (2 N) with continued 
stirring. The cooled solution was extracted with ethyl acetate (3 × 2 mL), and the combined 
organic extracts were washed with brine (2 mL), dried over Na2SO4. The mixture was filtered 
and the solvent removed under reduced pressure to yield (S)-N-((2-((tert-
butoxycarbonyl)amino)-3-oxopropoxy)carbonyl)-3-phenylsydnonimine 320 as an orange gum 
(70 mg, 0.18 mmol, 72%): Rf 0.22 (100: 1, EtOAc:AcOH, UV, KMnO4); [𝛂]𝐃𝟐𝟎 +27.2 (c = 0.5, 
MeOH); 1H NMR (500 MHz, CD3CN) δ 8.68 (1H, s, CH-9), 8.01 (2H, d, J 8.7 Hz, CH-11,13), 
7.81-7.72 (3H, m, CH-12,13,14), 4.59-4.35 (3H, m, CH-4, CH2-6) and 1.53 (9H, s, 3 × CH3-1); 
13C NMR (125 MHz, CD3CN) δ 171.7 (quat., C-8), 170.5 (quat., C-5), 168.6 (quat., C-7), 153.3 
(quat., C-3), 134.4 (quat., C-10), 133.0 (CH, C-13), 130.7 (CH × 2, C-11,15), 122.8 (CH × 2, C-
12,14), 107.5 (CH, C-9), 85.5 (quat., C-2), 61.9 (CH2, C-6), 55.5 (CH, C-4) and 27.5 (CH3 × 3, 
C-1); νmax (NaCl/thin film)/cm−1 1751, 1710, 1630, 1557, 1494, 1451, 1403, 1216, 1050; m/z 
(ES+) 415 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C17H20N4NaO7 [M+Na]+ requires 
415.1230, found 415.1236. 
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(S)-N-(((4-(2-(((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-methoxy-3-
oxopropyl)phenoxy)carbonyl)-3-phenylsydnonimine, 321 
 
 
HCl in dioxane (4M, 2 mL, 8.0 mmol) was added to a solution of (S)-N-((4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyloxy)carbonyl)-3-phenylsydnonimine 
298 (320 mg, 0.66 mmol) in dichloromethane (10 mL) cooled to 0 °C. The solution was stirred 
at 0 °C for 3 h and the solvent evaporated under reduced pressure to yield a white residue which 
was triturated with diethyl ether. The white powder was suspended in THF (10 mL) and cooled 
to 0 °C. To this was added Fmoc-Cl (258 mg, 0.99 mmol) and triethylamine (201 mg, 280 µL, 
2.00 mmol) and the solution was stirred for 1 hour. The resultant suspension was diluted with 
ethyl acetate (40 mL). The solution was washed with aq. hydrochloric acid (2 N, 30 mL) and 
brine (30 mL), dried over Na2SO4. The mixture was filtered and the solvent removed under 
reduced pressure to yield a yellow residue. This was uptaken in dichloromethane (10 mL) and 
adsorbed onto silica gel. Purification by silica gel chromatography eluting with dichloromethane 
and acetone (100:0 to 90:10) provided (S)-N-(((4-(2-(((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)carbonyl)-3-phenylsydnonimine 
321  (356 mg, 0.59 mmol, 90%) as a white crystalline solid: Rf 0.58 (90:10, CH2Cl2:acetone, 
UV/cerium phosphomolybdate); m.p. 74-76 °C;   [𝛂]𝐃𝟐𝟎  +33.7, (c = 1, CHCl3); νmax (thin 
film)/cm−1 1742, 1720, 1675, 1587, 1508, 1471, 1450, 1366, 1281, 1213, 1190, 804; 1H NMR 
(400 MHz, CDCl3) δ 8.15 (1H, s, CH-28), 7.80-7.65 (7H, m, CH-2,12,30,31,32,33,34), 7.59 
(2H, d, J 7.6 Hz, CH-5,9), 7.40 (2H, t, J 7.5 Hz, CH-3,11), 7.31 (2H, tt, J 7.5, 1.0 Hz, CH-4,10), 
7.16 (2H, d, J 8.6 Hz, CH-21, 25), 7.09 (2H, d, J 8.6 Hz, CH-22, 24) 5.29 (1H, d, J 8.0, NH), 
4.67 (1H, ddd, J 13.8, 8.0, 5.6 Hz, CH-16), 4.45 (1H, dd, J 10.6, 7.2 Hz, CHAHB-14), 4.36 (1H, 
dd, J 10.0, 6.8 Hz, CHAHB-14), 4.22 (1H, t, J 7.1 Hz, CH-7), 3.74 (3H, s, CH2-18) and 3.12 (2H, 
J 5.7 Hz, CH2-19); 13C NMR (100 MHz, CDCl3) δ 175.7 (quat., C-27), 171.9 (quat., C-17), 
160.7 (quat., C-26), 155.7 (quat., C-15), 151.2 (quat., C-23), 143.9, 143.8 (quat. × 2, C-6,8), 
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141.3 (quat. × 2, C-1,13), 133.7 (quat., C-29), 133.3 (CH, C-32), 132.5 (quat., C-20), 130.7 (CH 
× 2, C-31,33), 130.1 (CH × 2, C-21,25), 127.7 (CH × 2, C-3,11), 127.1 (CH × 2, C-4,10), 125.2, 
125.1 (CH × 2, C-2,12), 122.0 (CH × 2, C-22,24), 121.6 (CH × 2, C-30,34), 120.0 (CH × 2, C-
2,12), 103.4 (CH, C-28), 67.0 (CH2, C-14), 54.8 (CH, C-16), 52.4 (CH3, C-18), 47.2 (CH, C-7) 
and 37.5 (CH2, C-19); m/z (ES+) 627 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C34H28N4NaO7 [M+Na]+ requires 627.1856, found 627.1841. 
 
(S)-N-(((4-(2-(((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-
carboxyethyl)phenoxy)-carbonyl)-3-phenylsydnonimine, 323 
 
 
Sodium hydroxide (30 mg, 0.75) was added to a solution of (S)-N-(((4-(2-(((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)carbonyl)-3-phenylsydnonimine 
321 (218 mg, 0.36 mmol) in THF (5 mL) and water (5 mL). The resulting solution was stirred 
for 30 min and cooled to 0 °C. The solution was acidified (pH = 2) with aq. hydrochloric acid (2 
N) with continued stirring. The cooled solution was extracted with ethyl acetate (3 × 20 mL), 
and the combined organic extracts were washed with brine (20 mL), dried over Na2SO4. The 
mixture was filtered and the solvent removed under reduced pressure to yield a yellow residue. 
The residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification by silica 
gel chromatography, eluting with dichloromethane and methanol (97:3), furnished (S)-N-(((4-
(2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-carboxyethyl)phenoxy)carbonyl)-3-
phenylsydnonimine 323 (170 mg, 0.29 mmol, 80%) as a pale yellow solid: Rf 0.29 (90:10, 
CH2Cl2:acetone, UV/cerium phosphomolybdate); m.p. 148-150 °C (decomp.), [𝛂]𝐃𝟐𝟎  +5.8, (c = 
0.5, MeOH); νmax (thin film)/cm−1 1712, 1584, 1508, 1471, 1450, 1368, 1296, 1212, 982; 1H 
NMR (500 MHz, d6-DMSO) δ 8.59 (1H, s, CH-27), 8.05 (2H, d, J 7.8 Hz, CH-29,33), 7.87 
(2H, d, J 6.7 Hz, CH-2,12), 7.77 (1H, tt, J 7.5, 2.4 Hz, CH-31), 7.71 (2H, t, J 8.0 Hz, CH-
30,32), 7.66 (2H, t, J 7.9 Hz, CH-5,9), 7.41-7.37 (2H, m, CH-3,11), 7.33-7.28 (2H, m, CH-
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4,10), 7.23 (2H, d, J 8.2 Hz, CH-20,24), 6.99 (2H, d, J 8.2 Hz, CH-21,23), 4.27-4.23 (1H, m, 
CHAHB-14), 4.20-4.15 (2H, m, CH-7, CHAHB-14), 4.07 (1H, dd, J 13.6, 8.6 Hz, CH-16), 3.11 
(1H, dd, J 13.6, 4.0 Hz CHAHB-18) and 2.90 (1H, dd, J 13.3, 9.0 Hz, CHAHB-18); 13C NMR (75 
MHz, d6-DMSO) δ 174.9 (quat., C-26), 173.4 (quat., C-17), 158.7 (quat., C-25), 155.6 (quat., C-
15), 150.3 (quat., C-22), 143.8 (quat., C-6,8), 140.6 (quat., C-1,13), 135.0 (quat., C-19), 133.6 
(quat., C-28), 133.0 (CH, C-31), 130.2 (CH × 2, C-29,33), 129.9 (CH × 2, C-20,24) 127.6 
(quat., C-3,11), 127.0 (quat., C-4,10), 125.3, 125.2 (quat., C-5,9), 122.4 (CH × 2, C-30,32), 
121.2 (CH × 2, C-21,23), 120.0 (quat., C-2,12), 104.7 (CH, C-27), 65.4 (CH2, C-14), 56.3 (CH, 
C-16), 46.6 (CH, C-7) and 36.3 (CH2, C-18); m/z (ES+) 613 ([M+Na]+, 100%); HRMS m/z 
(ES+) calcd. for C33H26N4NaO7 [M+Na]+ requires 613.1699, found 613.1677. 
 
(S)-N-((4-(2-((Allyloxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyloxy)-
carbonyl)-3-phenylsydnonimine, 322 
 
 
HCl in dioxane (4M, 0.5 mL, 2.0 mmol) was added to a solution of (S)-N-((4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyloxy)carbonyl)-3-phenylsydnonimine 
298 (100 mg, 0.21 mmol) in dichloromethane (5 mL) cooled to 0 °C. The solution was stirred at 
0 °C for 3 h and the solvent evaporated under reduced pressure to yield a white residue which 
was triturated with diethyl ether. The white powder was suspended in THF (8 mL) and cooled 
to 0 °C. To this was added allyl chloroformate (35 mg, 0.31 mmol) and triethylamine (63 mg, 
90 µL, 0.62 mmol) and the solution was stirred for 1 hour. The resultant suspension was diluted 
with ethyl acetate (40 mL). The solution was washed with aq. hydrochloric acid (2 N, 30 mL) 
and brine (30 mL), dried over Na2SO4. The mixture was filtered and the solvent removed under 
reduced pressure to yield a yellow residue. This was uptaken in dichloromethane (10 mL) and 
adsorbed onto silica gel. Purification by silica gel chromatography eluting with dichloromethane 
and acetone (100:0 to 90:10) provided (S)-N-((4-(2-((allyloxycarbonyl)amino)-3-methoxy-3-
oxopropyl)phenyloxy)carbonyl)-3-phenylsydnonimine 322 (82 mg, 0.18, 85%) as a white solid: 
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Rf 0.62 (90:10, CH2Cl2:acetone, UV/cerium phosphomolybdate); m.p. 101-104 °C ;   [𝛂]𝐃𝟐𝟎 
+23.7, (c = 1, CHCl3); νmax (NaCl/thin film)/cm−1 1718, 1585, 1508, 1495, 1448, 1403, 1368, 
1260, 1213, 1051, 941; 1H NMR (500 MHz, CDCl3) δ 8.16 (1H, s, CH-17), 7.80 (2H, d, J 8.4 
Hz, CH-19,23), 7.76-7.64 (3H, m, CH-20,21,22), 7.17-7.10 (4H, m, CH-10,11,13,14), 5.96-5.82 
(1H, m, CH-2), 5.29 (1H, d, J 17.1 Hz, CH-1-trans), 5.21 (1H, d, J 10.2 Hz, CH-1-cis), 4.65 
(1H, dd, J 13.7, 6.0 Hz, CH-5), 4.56 (2H, d, J 5.6 Hz, CH2-3), 3.72 (3H, s, CH3-7) and 3.11 (2H, 
d, J 5.5 Hz, CH2-8); 13C NMR (125 MHz, CDCl3) δ 175.7 (quat., C-16), 172.0 (quat., C-6), 
160.4 (quat., C-15), 155.6 (quat., C-4), 151.1 (quat., C-12), 133.7 (CH, C-21), 133.4 (quat., C-
9), 132.6 (quat., C-18), 132.4 (CH, C-2), 130.7 (CH × 2, C-19,23), 130.0 (CH × 2, C-10,14), 
122.0 (CH × 2, C-11,13), 121.5 (CH × 2, C-20,22),  117.7 (CH2, C-1), 103.2 (CH, C-17), 65.8 
(CH2, C-3), 54.7 (CH, C-5), 52.4 (CH3, C-7) and 37.5 (CH2, C-8); m/z (ES+) 489 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C23H22N4NaO7 [M+Na]+ requires 489.1386, found 
489.1392. 
 
(S)-N-((4-(2-((Allyloxy)amino)-2-carboxyethyl)phenoxy)carbonyl)-3-
phenylsydnonimine, 324 
 
 
Sodium hydroxide (9 mg, 0.22 mmol) was added to a solution of (S)-N-((4-(2-
((allyloxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyloxy)carbonyl)-3-phenylsydnonimine 
322 (50 mg, 0.11 mmol) in THF (2 mL) and water (2 mL). The resulting solution was stirred for 
30 min and cooled to 0 °C. The solution was acidified (pH = 2) with aq. hydrochloric acid (2 N) 
with continued stirring. The cooled solution was extracted with ethyl acetate (3 × 20 mL), and 
the combined organic extracts were washed with brine (20 mL), dried over Na2SO4. The 
mixture was filtered and the solvent removed under reduced pressure to yield (S)-N-((4-(2-
((allyloxycarbonyl)-2-carboxyethyl)phenoxy)carbonyl) -3-phenylsydnonimine 324 (39 mg, 0.09 
mmol, 80%) as a white solid, which was used without any further purification: Rf 0.28 (90:10, 
CH2Cl2:acetone, UV/cerium phosphomolybdate); m.p. 113-116 °C;  [𝛂]𝐃𝟐𝟎 +26.0, (c = 0.5 , 
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MeOH; νmax (NaCl/thin film)/cm−1 1647, 1605, 1580, 1494, 1451, 1400, 1256, 1200, 1050; 1H 
NMR (500 MHz, CD3CN) δ 8.57 (1H, s, CH-17), 8.06 (2H, d, J 7.6 Hz, CH-18,22), 7.93 (1H, t, 
J 7.4 Hz, CH-20), 7.85 (2H, t, J 8.2 Hz, CH-19,21), 7.41 (2H, d, J 8.4 Hz, CH-9,13), 7.24 (2H, 
d, J 8.4 Hz, CH-9,13), 6.06-5.92 (2H, m, CH-2, NH), 5.38 (1H, d, J 17.7 Hz, CH-1-trans), 5.29 
(1H, d, J 10.3 Hz, CH-1-cis), 4.63-4.57 (1H, m, CH2-3), 4.54 (1H, ddd, J 14.0, 9.0, 5.0 Hz, CH-
5), 3.33 (1H, dd, J 14.0, 5.4 Hz, CHAHB-7) and 3.08 (1H, dd, J 14.0, 9.0 Hz, CHAHB-7); 13C 
NMR (125 MHz, CD3CN) δ 173.0 (quat., C-15), 172.0 (quat., C-6), 163.2 (quat., C-14), 155.9 
(quat., C-4), 151.6 (quat., C-11), 136.2 (quat., C-8), 133.3 (CH, C-2), 130.2 (CH × 2, C-9,13), 
133.6 (quat., C-17), 133.5 (CH, C-20), 130.5 (CH × 2, C-18,22), 122.5 (CH × 2, C-19,21), 
121.7 (CH × 2, C-10,12), 116.6 (CH2, C-1), 102.7 (CH, C-16), 65.2 (CH3, C-3), 55.2 (CH, C-5) 
and 36.3 (CH2, C-7); m/z (ES+) 475 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C22H20N4NaO7 [M+Na]+ requires 475.1230, found 475.1238. 
 
(S)-4-(4-(2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-methoxy-3-
oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 325 
 
 
 
HCl in dioxane (4M, 2 mL, 8.0 mmol) was added to a solution of (S)-4-(4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 
2-oxide 300 (500 mg, 0.96 mmol) in dichloromethane (10 mL) cooled to 0 °C. The solution was 
stirred at 0 °C for 3 h and the solvent evaporated under reduced pressure to yield a white residue 
which was triturated with diethyl ether. The white powder was suspended in THF (30 mL) and 
cooled to 0 °C. To this was added Fmoc-Cl (374 mg, 1.45 mmol) and triethylamine (292 mg, 
410 µL, 2.00 mmol) the solution was stirred for 1 hour. The resultant suspension was diluted 
with ethyl acetate (20 mL). The solution was washed with aq. hydrochloric acid (2 N, 30 mL) 
and brine (30 mL), dried over Na2SO4. The mixture was filtered and the solvent removed under 
reduced pressure to yield a white residue. This was uptaken in dichloromethane and adsorbed 
onto silica gel. Purification by silica gel chromatography eluting with ethyl acetate and hexanes 
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(0:100 to 15:85) provided (S)-4-(4-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methoxy-
3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 325 (556 mg, 0.92 mmol, 
90%) as a white solid: Rf 0.50 (50:50, EtOAc:PE, UV/cerium phosphomolybdate); m.p. 141-
143 °C; [𝛂]𝐃𝟐𝟎 +25.4, (c = 1, CHCl3); νmax (thin film)/cm−1 1746, 1692, 1625, 1539, 1506, 1450, 
1357, 1260, 1165; 1H NMR (500 MHz, CDCl3) δ 8.10 (2H, d, J 8.3 Hz, CH-28, 32), 7.79-7.76 
(3H, m, CH-2,12, 30), 7.63 (2H, t, J 8.2 Hz, CH-29,31), 7.57 (2H, dd, J 7.4, 4.4 Hz, CH-5,9), 
7.40 (2H, t, J 7.2 Hz, CH-3,11), 7.32 (2H, t, J 7.6 Hz, CH-4,10). 7.22 (2H, d, J 8.5 Hz, CH-21, 
25), 7.15 (2H, d, J 8.5 Hz, CH-22, 24), 5.34 (1H, d, J 8.1, NH), 4.67 (1H, dd, J 13.6, 6.0 Hz, 
CH-16), 4.47 (1H, dd, J 10.6, 7.2 Hz, CHAHB-14), 4.37 (1H, dd, J 10.2, 6.7 Hz, CHAHB-14), 
4.20 (1H, t, J 5.8 Hz, CH-7), 3.73 (3H, s, CH2-18), 3.18 (1H, dd, J 14.0, 5.8 Hz, CHAHB-19) and 
3.09 (1H, dd, J 14.0, 6.2 Hz, CHAHB-19); 13C NMR (125 MHz, CDCl3) δ 171.7 (quat., C-17) 
158.3 (quat., C-26), 155.6 (quat., C-15), 151.6 (quat., C-23), 144.0, 143.7 (quat., × 2, C-6,8), 
141.3 (quat., C-1, 14), 137.9 (quat., C-28), 135.9 (CH, C-31), 130.9 (CH × 2, C-21,25), 129.8 
(CH × 2, C-29,33), 128.7 (CH × 2, C-30,32), 127.8 (CH × 2, C-3,11), 127.1 (CH × 2, C-4,10), 
125.1, 125.0 (CH × 2, C-5,9), 120.1 (CH × 2, C-2,12), 119.9 (CH × 2, C-22, 24) 110.7 (quat., 
C-27) and 66.9 (CH2, C-14), 54.7 (CH, C-16), 52.5 (CH3, C-18), 47.2 (CH, C-7) and 37.7 (CH2, 
C-19); m/z (ES+) 664 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C33H27N3NaO9S [M+Na]+ 
requires 664.1366, found 664.1359. 
 
(S)-4-(4-(2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-oxopropyl)phenoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 327 
 
 
 
Sodium hydroxide (30 mg, 0.75) was added to a solution of ((S)-4-(4-(2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide 325 (226 mg, 0.35 mmol) in THF (5 mL) and water (5 mL). The resulting 
solution was stirred for 30 min and cooled to 0 °C. The solution was acidified (pH = 2) with aq. 
hydrochloric acid (2 N) with continued stirring. The cooled solution was extracted with ethyl 
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acetate (3 × 20 mL), and the combined organic extracts were washed with brine (20 mL), dried 
over Na2SO4. The mixture was filtered and the solvent removed under reduced pressure to yield 
a yellow residue. The residue was uptaken in dichloromethane and adsorbed onto silica gel. 
Purification by silica gel chromatography, eluting with dichloromethane and methanol (97:3), 
furnished (S)-4-(4-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-oxopropyl)phenoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 325 (177 mg, 0.28 mmol, 80%) as a white solid; Rf 
0.33 (100:1, EtOAc:AcOH, UV/cerium phosphomolybdate); m.p. 189-191 °C;   [𝛂]𝐃𝟐𝟎 +3.9, (c = 
0.5, MeOH; νmax (thin film)/cm−1 1689, 1623, 1537, 1501, 1446, 1353, 1161, 1022; 1H NMR 
(500 MHz, d6-DMSO) δ 8.04 (2H, d, J 7.7 Hz, CH-28, 32), 7.90 (1H, t, J 7.4 Hz, CH-30), 7.86 
(2H, d, J 7.5 Hz, CH-2,12), 7.79-7.74 (3H, m, CH-29, 31, NH-Fmoc), 7.63 (2H, t, J 7.7 Hz, 
CH-5,9), 7.41-7.34 (4H, m, CH-3,11,20,24), 7.32-7.27 (4H, m, CH-4,10, 21, 23), 4.22-4.15 
(4H, m, CH-7, 16, CH2-14), 3.13 (1H, dd, J 13.9, 4.4 Hz, CHAHB-18) and 3.13 (1H, dd, J 13.6, 
10.9 Hz, CHAHB-18); 13C NMR (125 MHz, d6-DMSO) δ 173.7 (quat., C-17) 159.0 (quat., C-
25), 156.5 (quat., C-15), 151.7 (quat., C-22), 144.2 (quat., × 2, C-6,8), 141.2 (quat., C-1,13), 
137.9 (quat., C-27), 136.8 (CH, C-30), 131.1 (CH × 2, C-20,24), 130.5 (CH × 2, C-28,32), 
129.0 (CH × 2, C-29,31), 128.1 (CH × 2, C-3,11), 127.6 (CH × 2, C-4,10), 125.7 (CH × 2, C-
5,9), 120.6 (CH × 2, C-2,12), 119.9 (CH × 2, C-21,23) 111.7 (quat., C-26), 66.1 (CH2, C-14), 
55.8 (CH, C-16),  47.0 (CH, C-7) and 36.2 (CH2, C-19); m/z (ES+) 650 ([M+Na]+, 100%); 
HRMS m/z (ES+) calcd. for C32H25N3NaO9S [M+Na]+ requires 650.1209, found 650.1215. 
 
(S)-4-(4-(2-((Allyloxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide, 326 
 
 
 
HCl in dioxane (4M, 0.5 mL, 2.0 mmol) was added to a solution of (S)-4-(4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 
2-oxide 300 (227 mg, 0.44 mmol) in dichloromethane (5 mL) cooled to 0 °C. The solution was 
stirred at 0 °C for 3 h and the solvent evaporated under reduced pressure to yield a white residue 
which was triturated with diethyl ether. The white powder was suspended in THF (12 mL) and 
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cooled to 0 °C. To this was added allyl chloroformate (80 mg, 70 µL, 0.66 mmol) and 
triethylamine (132 mg, 180 µL, 1.31 mmol) the solution was stirred for 1 hour. The resultant 
suspension was diluted with ethyl acetate (20 mL). The solution was washed with aq. 
hydrochloric acid (2 N, 30 mL) and brine (30 mL), dried over Na2SO4. The mixture was filtered 
and the solvent removed under reduced pressure to yield a white residue. This was uptaken in 
dichloromethane and adsorbed onto silica gel. Purification by silica gel chromatography eluting 
with ethyl acetate and hexanes (0:100 to 15:85) provided (S)-4-(4-(2-((allyloxycarbonyl)amino)-
3-methoxy-3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide  326 (178 mg, 
0.35 mmol, 85%) as a white solid: Rf 0.62 (50:50, EtOAc:PE, UV/cerium phosphomolybdate); 
m.p. 78-80 °C; [𝛂]𝐃𝟐𝟎  +29.3, (c = 1, CHCl3); νmax (NaCl/thin film)/cm−1 1745, 1614, 1536, 1505, 
1449, 1439, 1314, 1257, 1211, 1167, 1019; 1H NMR (500 MHz, CDCl3) δ 8.09 (2H, d, J 8.3 
Hz, CH-18,22), 7.79 (1H, tt, J 6.7, 1.2 Hz, CH-20), 7.64 (2H, t, J 7.9 Hz, CH-19,21), 7.31-7.22 
(4H, m, CH-10, 11, 13, 14), 5.94-5.82 (1H, m, CH-2), 5.28 (1H, dd, J 17.2, 1.2 Hz, CH-1-
trans), 5.21 (1H, dd, J 10.2, 1.2 Hz, CH-1-cis), 4.68-4.35 (3H, m, CH2-3, CH-5), 3.72 (3H, s, 
CH3-7) and 3.21-3.05 (2H, m, CH2-8); 13C NMR (125 MHz, CDCl3) δ 171.7 (quat., C-6), 158.3 
(quat., C-15), 155.5 (quat., C-4), 151.6 (quat., C-12), 137.9 (quat., C-17), 135.9 (CH, C-20), 
134.7 (quat., C-9), 132.5 (CH, C-2), 130.8 (CH × 2, C-10,14), 129.8 (CH × 2, C-18,22), 128.6 
(CH × 2, C-19,21), 119.9 (CH × 2, C-11,13), 118.0 (CH2, C-1), 110.7 (quat., C-16), 65.9 (CH2, 
C-3), 54.7 (CH, C-5), 52.5 (CH3, C-7) and 37.7 (CH2, C-8); m/z (ES+) 526 ([M+Na]+, 100%); 
HRMS m/z (ES+) calcd. for C22H21N3NaO9S [M+Na]+ requires 526.0896, found 526.0902. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix: Experimental 
 
	   305	  
(S)-4-(4-(2-((Allyoxycarbonyl)amino)-2-carboxyethyl)phenoxy)-3-(phenylsulfonyl)-
1,2,5-oxadiazole 2-oxide, 328 
 
 
Sodium hydroxide (16 mg, 0.40 mmol) was added to a solution of (S)-4-(4-(2-
((allyloxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide 326 (100 mg, 0.20 mmol) in THF (2 mL) and water (2 mL). The resulting 
solution was stirred for 30 min and cooled to 0 °C. The solution was acidified (pH = 2) with aq. 
hydrochloric acid (2 N) with continued stirring. The cooled solution was extracted with ethyl 
acetate (3 × 20 mL), and the combined organic extracts were washed with brine (20 mL), dried 
over Na2SO4. The mixture was filtered and the solvent removed under reduced pressure to yield 
(S)-4-(4-(2-((Allyoxycarbonyl)amino)-2-carboxyethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide 328 (87 mg, 0.18 mmol, 90%) as a white solid, which was used without any 
further purification: Rf 0.41 (100:1, EtOAc:AcOH, UV/cerium phosphomolybdate); m.p. 138-
141 °C; [𝛂]𝐃𝟐𝟎 +23.5, (c = 0.7, MeOH; νmax (NaCl/thin film)/cm−1 2525, 1658, 1537, 1451, 
1404, 1260, 1201, 1112, 1020; 1H NMR (500 MHz, CD3CN) δ 8.18 (2H, d, J 7.9 Hz, CH-
17,21), 7.98 (1H, t, J 7.6 Hz, CH-19), 7.83 (2H, t, J 7.9 Hz, CH-18,20), 7.47-7.43 (2H, m, CH-
9,13) 7.36 (2H, d, J 7.5 Hz, CH-10,12), 6.05-5.95 (2H, m, CH-2, NH), 5.36 (1H, d, J 17.7 Hz, 
CH-1-trans), 5.28 (1H, dd, J 10.7 Hz, CH-1-cis), 4.59 (2H, d, J 5.3 Hz, CH2-3), 4.54 (1H, ddd, 
J 15.0, 9.1, 5.0 Hz, CH-5), 3.34 (1H, ddd, J 15.0, 5.0 Hz, CHAHB-7) and 3.09 (1H, ddd, J 15.0, 
9.1 Hz, CHAHB-7); 13C NMR (125 MHz, CD3CN) δ 172.2 (quat., C-6), 158.9 (quat., C-14), 
155.5 (quat., C-4), 151.7 (quat., C-11), 137.6 (quat., C-16), 136.1 (CH, C-19), 136.0 (quat., C-
8), 133.2 (CH, C-2), 131.0 (CH × 2, C-9,13), 129.9 (CH × 2, C-17,21), 128.7 (CH × 2, C-
18,20), 119.9 (CH × 2, C-10,12), 116.6 (CH2, C-1), 111.3 (quat., C-15), 65.1 (CH2, C-3), 54.9 
(CH, C-5) and 36.2 (CH2, C-7); m/z (ES+) 512 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for 
C21H19N3NaO9S [M+Na]+ requires 512.0740 found 512.0745. 
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Boc-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Val-OMe, 329 
 
 
 
HATU (442 mg, 1.16 mmol) was added to a solution of valine methyl ester hydrochloride (49 
mg, 0.35 mmol) and (S)-N-((4-(2-((tert-butoxycarbonyl)amino)-2-
carboxyethyl)phenoxy)carbonyl)-3-phenylsydnonimine 308 (150 mg, 0.32 mmol) in dry DMF 
(5 mL) cooled to 0 °C. The solution was stirred for 15 min and diisopropylethylamine (distilled, 
200 mg, 270 µL, 1.55 mmol) was added. The solution was allowed to warm to room 
temperature and stirred for 18 h. The resultant solution was diluted with ethyl acetate (50 mL) 
and water (50 mL). The organic layer was separated and washed with aq. hydrochloric acid (2 
N, 20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic layer was separated and 
dried over Na2SO4, filtered and the solvent removed under reduced pressure. The resultant 
residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification by silica gel 
chromatography, eluting with dichloromethane and methanol (100:0 to 97:3) provided Boc-
Tyr(O-carbonyl-N-3-phenylsydnonimine)-Val-OMe 329 (169 mg g, 0.29 mmol, 91%) as a white 
solid: Rf 0.62 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 139-140 °C;   [𝛂]𝐃𝟐𝟎 
+29.4, (c = 1, CHCl3); νmax (NaCl/thin film)/cm−1 1743, 1647, 1593, 1545, 1495, 1451, 1367, 
1251, 1215, 1050: 1H NMR (500 M, CHCl3) δ 8.17 (1H, s, CH-14), 7.79 (2H, d, J 7.9 Hz, CH-
16,20), 7.69 (1H, tt, J 7.5, 1.2 Hz, CH-18), 7.69 (2H, t, J 7.7 Hz, CH-17,19), 7.68 (2H, d, J 7.5 
Hz, CH-7,11), 7.16 (2H, d, J 7.8 Hz, CH-8,10), 7.09 (2H, d, J 8.40, CH-8,10), 6.55 (1H, s, br, 
NH-amide), 5.01 (1H, s, br, NH-Boc), 4.43 (1H, dd, J 8.6, 5.1 Hz, CH-22), 4.36-4.28 (1H, s, 
CH-4), 3.66 (3H, s, CH3-26), 3.07-2.93 (2H, m, CH2-5), 2.10-2.04 (1H, m, CH-23), 1.38 (9H, s, 
3 × CH3-1), 0.85 (3H, d, J 7.0 Hz, CH3-24) and 0.82 (3H, d, J 7.0 Hz, CH3-24); 13C NMR (125 
M, CHCl3) δ 175.7 (quat., C-13), 171.8 (quat., C-25), 171.2 (quat., C-21), 160.3 (quat., C-12), 
155.5 (quat., C-3), 151.0 (quat., C-9), 133.7 (quat., C-6), 133.4 (quat., C-15), 133.3 (CH, C-18), 
130.6 (CH × 2, C-16, 20), 130.1 (CH × 2, C-7,11), 121.9 (CH × 2, C-8,10), 121.3 (CH × 2, C-
17,19), 103.4 (CH, C-14), 80.2 (quat., C-2), 57.3 (CH, C-22), 55.8 (CH, C-4), 52.1 (CH3, C-26), 
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37.1 (CH2, C-5), 31.2 (CH, C-23), 28.3 (CH3 × 3, C-1) and 18.8, 17.8 (CH3 × 2, C-24); m/z 
(ES+) 604 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C29H35N5NaO8 [M+Na]+ requires 
604.2383, found 604.2395. 
 
Boc-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Phe-OMe, 330 
 
 
 
HATU (442 mg, 1.16 mmol) was added to a solution of phenylalanine methyl ester 
hydrochloride (76 mg, 0.352 mmol) and (S)-N-((4-(2-((tert-butoxycarbonyl)amino)-2-
carboxyethyl)phenoxy)carbonyl) -3-phenylsydnonimine 308 (150 mg, 0.32 mmol) in dry DMF 
(5 mL) cooled to 0 °C. The solution was stirred for 15 min and diisopropylethylamine (distilled, 
200 mg, 270 µL, 1.55 mmol) was added. The solution was allowed to warm to room 
temperature and stirred for 18 h. The resultant solution was diluted with ethyl acetate (50 mL) 
and water (50 mL). The organic layer was separated and washed with aq. hydrochloric acid (2 
N, 20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic layer was separated and 
dried over Na2SO4, filtered and the solvent removed under reduced pressure. The resultant 
residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification by silica gel 
chromatography, eluting with ethyl acetate and hexanes (10:90 to 25:75) provided Boc-Tyr(O-
carbonyl-N-3-phenylsydnonimine)-Phe-OMe 330 (191 mg, 0.30 mmol, 95%) as a fawn solid: Rf 
0.58 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 159-160 °C;  [𝛂]𝐃𝟐𝟎 +17.6, (c 
= 0.7 , CHCl3); νmax (NaCl/thin film)/cm−1 1733, 1677, 1587, 1508, 1438, 1368, 1215, 1167, 
1050; 1H NMR (500 MHz, CHCl3) δ 8.27 (1H, s, CH-14), 7.85 (2H, d, J 7.7 Hz, CH-16,20), 
7.76 (1H, t, J 7.4 Hz, CH-18), 7.76 (2H, t, J 7.7 Hz, CH-17, 19), 7.30-7.14 (7H, m, CH-
7,11,25,26,27,28,29), 7.07 (2H, d, J 7.6 Hz, CH-8,10), 6.55 (1H, d, J 7.9, NH-amide), 5.01 (1H, 
d, J 8.1, NH-Boc), 4.82 (1H, dd, J 13.4, 6.3 Hz, CH-22), 4.40-4.33 (1H, m, CH-4), 3.70 (3H, s, 
CH3-31), 3.14-3.03 (4H, m, CH2-5, 23), and 1.43 (9H, s, 3 × CH3-1); 13C NMR (125 MHz, 
21N
H
4
5
6
11
10
9 O87
O
H
N
12
NO
13
14
NN
O
15
20
19
1817
16
22 30
23
O
O
31
24
29
28
27
26
25
3O
O
21
1
1
Appendix: Experimental 
 
	   308	  
CHCl3) δ 175.7 (quat., C-13), 171.4 (quat., C-30), 170.9 (quat., C-21), 160.2 (quat., C-12), 
155.3 (quat., C-3), 151.0 (quat., C-9), 135.8 (CH, C-27), 129.2 (CH × 2, C-25, 29), 128.5 (CH × 
2, C-26, 28), 127.1 (quat., C-24), 121.9 (CH × 2, C-8,10), 121.6 (CH × 2, C-17, 19), 133.7 
(quat., C-6), 133.3 (CH, C-18), 133.3 (quat., C-15), 130.6 (CH × 2, C-16, 20), 130.1 (CH × 2, 
C-7, 11), 103.5 (CH, C-14), 80.2 (quat., C-2), 55.6 (CH, C-4), 53.4 (CH, C-22), 52.3 (CH3, C-
31), 37.9 (CH2, C-23), 37.4 (CH2, C-5) and 28.2 (CH3 × 3, C-1); m/z (ES+) 652 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C33H35N5NaO8 [M+Na]+ requires 652.2383, found 
652.2390. 
 
Fmoc-Arg(Pbf)-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Val-OMe, 331 
 
 
 
HCl in dioxane (4M, 3 mL, 12.0 mmol) was added to a solution of dipeptide 329 (186 mg, 0.32 
mmol) in dichloromethane (10 mL) cooled to 0 °C. The solution was stirred at 0 °C for 3 h and 
the solvent evaporated under reduced pressure to yield a white residue which was triturated with 
diethyl ether. The residue was dissolved in dry DMF (5 mL) and Fmoc-Arg(Pbf)-OH (208 mg, 
0.32 mmol) was added. The solution was cooled to 0 °C and stirred for 10 min. HATU (442 mg, 
1.297 mmol) was added and the solution stirred for a further 15 min. Diisopropylethylamine 
(distilled, 166 mg, 220 µL, 1.28 mmol) was added and the solution was allowed to warm to 
room temperature and stirred for 18 h. The resultant solution was diluted with ethyl acetate (50 
mL) and water (50 mL). The organic layer was separated and washed with aq. hydrochloric acid 
(2 N, 20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic layer was separated 
and dried over Na2SO4, filtered and the solvent removed under reduced pressure. The resultant 
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residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification by silica gel 
chromatography, eluting with dichloromethane and methanol (99:1) provided Fmoc-Arg(Pbf)-
Tyr(O-carbonyl-N-3-phenylsydnonimine)-Val-OMe 331 (312 mg, 0.28 mmol, 85%) as a white 
solid: Rf 0.59 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 115-119 
°C; [𝛂]𝐃𝟐𝟎+110 (c = 0.6 , CHCl3); νmax (NaCl/thin film)/cm−1 1725, 1651, 1553, 1451, 1404, 
1369, 1212, 1107, 1019, 974, 851; 1H NMR (500 MHz, CDCl3) δ 8.27 (1H, s, CH-44), 7.79 
(2H, d, J 7.7 Hz, CH-46,50), 7.75-7.67 (2H, m, CH-2,12), 7.63 (1H, t, J 7.5 Hz, CH-48), 7.55 
(2H, t, J 7.9 Hz, CH-47,49), 7.52 (2H, d, J 7.5 Hz, CH-5,9), 7.30 (2H, t, J 7.5 Hz, CH-3,11), 
7.21-7.16 (4H, m, CH-4,10,37,41), 7.10 (1H, s, br, NH-sulfonamide), 7.02 (2H, d, J 8.0 Hz, 
CH-38,40), 6.54-6.15 (5H, m, 2 × NH-amide, 2 × NH-guanidine, NH-Fmoc), 4.74 (1H, dd, J 
14.4, 8.0 Hz, CH-34), 4.36 (1H, dd, J 7.5, 5.8 Hz, CH-52), 4.31-4.23 (3H, m, CH-16, CH2-14), 
4.07 (1H, t, J 6.8 Hz, CH-7), 3.62 (3H, s, CH3-56), 3.26-3.10 (3H, m, CH2-17, CHAHB-35), 
3.04-2.98 (1H, m, CHAHB-35), 2.86 (2H, s, CH2-25), 2.58 (CH3, s, CH3-23), 2.50 (3H, s, CH3-
30), 2.05-2.01 (4H, m, CH3-32, CH-53), 1.73-1.65 (1H, m, CHAHB-19), 1.60-1.53 (1H, m, 
CHAHB-19), 1.41-1.35 (8H, m, CH2-18, 3 × CH3-27) and 0.83-0.80 (6H, m, 2 × CH3-54); 13C 
NMR (125 MHz, CDCl3) δ 175.5 (quat., C-43), 172.9 (quat., C-33), 171.8 (quat., C-55), 171.4 
(quat., C-51), 159.9 (quat., C-42), 158.7 (quat., C-20), 156.6 (quat., C-15), 156.4 (quat., C-28), 
150.6 (quat., C-39), 144.0, 143.6 (quat. × 2, C-1,13), 141.2, 141.1 (quat. × 2, C-6,8), 138.4 
(quat., C-21), 133.9 (quat., C-36), 133.6 (quat., C-45), 133.2 (CH, C-48), 133.0 (quat., C-24), 
132.3 (quat., C-29), 130.5 (CH × 2, C-46,50), 130.2 (CH × 2, C-37,41), 127.7 (CH × 2, C-1,13), 
127.1 (CH × 2, C-4,10), 125.3, 125.2 (CH × 2, C-5,9), 124.6 (quat., C-31), 121.8 (CH × 2, C-
38,40), 121.6 (CH × 2, C-47,49), 119.9 (CH × 2, C-1,13), 117.6 (quat., C-22), 103.4 (CH, C-
44), 86.3 (quat., C-26), 67.1 (CH2, C-14), 55.0 (CH, C-34), 54.7 (CH, C-16), 53.5 (CH, C-52), 
52.2 (CH3, C-56), 47.0 (CH, C-7), 43.5 (CH2, C-25), 39.9 (CH2, 17), 36.8 (CH2, C-35), 31.0 
(CH, C-53), 29.1 (CH2, C-19), 28.5 (quat. × 2, C-27),  25.5 (CH2, C-18), 19.4 (CH3, C-30), 19.0 
(CH3, C-32), 18.0 (CH3 × 2, C-54) and 12.5 (CH3, C-23); m/z (ES+) 1112 ([M+H]+, 100%); 
HRMS m/z (ES+) calcd. for C58H65N9O12S [M+H]+ requires 1112.4546, found 1112.4546. 
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Fmoc-Asp(OtBu)-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Phe-OMe, 332 
 
 
 
HCl in dioxane (4M, 3 mL, 12.0 mmol) was added to a solution of dipeptide 330 (201 mg, 0.32 
mmol) in dichloromethane (10 mL) cooled to 0 °C. The solution was stirred at 0 °C for 3 h and 
the solvent evaporated under reduced pressure to yield a white residue which was triturated with 
diethyl ether. The residue was dissolved in dry DMF (5 mL) and Fmoc-Asp(OtBu)-OH  (132 
mg, 0.32 mmol) was added. The solution was cooled to 0 °C and stirred for 10 min. HATU (442 
mg, 1.297 mmol) was added and the solution stirred for a further 15 min. 
Diisopropylethylamine (distilled, 166 mg, 220 µL, 1.28 mmol) was added and the solution was 
allowed to warm to room temperature and stirred for 18 h. The resultant solution was diluted 
with ethyl acetate (50 mL) and water (50 mL). The organic layer was separated and washed 
with aq. hydrochloric acid (2 N, 20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The 
organic layer was separated and dried over Na2SO4, filtered and the solvent removed under 
reduced pressure. The resultant residue was uptaken in dichloromethane and adsorbed onto 
silica gel. Purification by silica gel chromatography, eluting with dichloromethane and 
methanol (99:1) provided Fmoc-Asp(OtBu)-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Phe-OMe 
332 (250 mg, 0.27 mmol, 85%) as a white solid: Rf 0.59 (90:10, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); m.p. 116-117 °C; [𝛂]𝐃𝟐𝟎  +157, (c = 1.0 , CHCl3); νmax (NaCl/thin 
film)/cm−1 1734, 1670, 1603, 1588, 1513, 1495, 1451, 1368, 1216, 1050: 1H NMR (500 MHz, 
CDCl3) δ 8.20 (1H, s, CH-31), 7.82 (2H, d, J 7.9 Hz, CH-33,37), 7.75-7.67 (3H, m, CH-
2,12,35), 7.63-7.52 (4H, m, CH-5,9,34,36), 7.38-7.20 (7H, m, CH-3,4,10,11,43,44,45), 7.09-
7.05 (4H, m, CH-25,29,43,47), 6.91 (2H, d, J 8.1 Hz, CH-26,28), 6.74 (1H, d, J 8.1, NH-
amide), 6.60 (1H, d, J 7.6, NH-amide), 5.96 (1H, d, J 8.5, NH-Fmoc), 4.77 (1H, dd, J 13.4, 6.7 
Hz, CH-40), 4.64 (1H, dd, J 15.0, 7.9 Hz, CH-22), 4.47-4.40 (3H, m, CH-16, CH2-14), 4.19 
40N
H
23
24
25
30
29
28 O2726
O
H
N2216
O
41 49
42
O
O
50
H
N15
17
18
O
O
O
14
7
8
13
1
6
9
1011
12
2
3
4
5 O
19
20
20
20
43
48
47
46
45
44
31
O N
32
33
NN
O
34
39
38
3736
35
Appendix: Experimental 
 
	   311	  
(1H, t, J 6.5 Hz, CH-7), 3.67 (3H, s, CH3-49), 3.15-3.08 (2H, m, CHAHB-23, CHAHB-41), 3.00 
(1H, dd, J 13.8, 6.8 Hz, CHAHB-41), 2.91 (1H, dd, J 14.2, 8.2 Hz, CHAHB-23), 2.62 (1H, dd, J 
16.5, 5.6 Hz, CHAHB-16), 2.56 (1H, dd, J 16.5, 7.2 Hz, CHAHB-16) and 1.39 (9H, s, 3 × CH3-
19); 13C NMR (125 MHz, CDCl3) 175.8 (quat., C-31), 171.5 (quat., C-48), 170.8 (quat., C-39), 
170.8 (quat., C-21), 170.1 (quat., C-18), 160.6 (quat., C-30), 156.4 (quat., C-15), 151.0 (quat., 
C-27), 143.8, 143.7 (CH × 2, C-6,8), 141.3 (quat. × 2, C-1,13), 135.8 (quat., C-42), 133.7 (quat., 
C-33), 133.4 (CH, C-36), 133.4 (quat., C-24), 130.5 (CH × 2, C-34, 38), 130.1 (CH × 2, C-25, 
29), 129.2 (CH × 2, C-43,47), 128.6 (CH × 2, C-44,46), 127.8, 127.5 (CH × 2, C-4,10), 127.1 
(CH × 2, C-3,11), 127.0 (CH, C-45), 125.0, 124.9 (CH × 2, C-5,9), 122.2 (CH × 2, C-26,28), 
121.6 (CH × 2, C-35,37), 120.1, 120.0 (CH × 2, C-2,13), 103.6 (CH, C-32), 81.6 (quat., C-19), 
67.0 (CH2, C-14), 54.0 (CH, C-22), 53.4 (CH, C-40), 52.4 (CH3, C-49), 51.6 (CH, C-16), 47.1 
(CH, C-7), 37.8 (CH2, C-41), 37.2 (CH2, C-17), 36.8 (CH2, C-23) and 28.0 (CH3 × 3, C-20); m/z 
(ES+) 923 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C51H50N6O11 [M+H]+ requires 
923.3610, found 923.3614. 
 
Boc-Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide))-Val-OMe, 333 
 
 
HATU (113 mg, 0.30 mmol) was added to a solution of L-valine methyl ester hydrochloride  
(18 mg, 0.11 mmol) and (S)-4-(4-(2-((tert-butoxycarbonyl)amino)-2-carboxyethyl)phenoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 312 (50 mg, 0.11 mmol) in dry DMF (5 mL) cooled 
to 0 °C. The solution was stirred for 15 min and diisopropylethylamine (distilled, 51 mg, 70 µL, 
0.40 mmol) was added. The solution was allowed to warm to room temperature and stirred for 
18 h. The resultant solution was diluted with ethyl acetate (50 mL) and water (50 mL). The 
organic layer was separated and washed with aq. hydrochloric acid (2 N, 20 mL), saturated 
NaHCO3 (20 mL) and brine (20 mL). The organic layer was separated and dried over Na2SO4, 
filtered and the solvent removed under reduced pressure. The resultant residue was uptaken in 
dichloromethane and adsorbed onto silica gel. Purification by silica gel chromatography, eluting 
with ethyl acetate and hexanes (10:90 to 25:75) provided Boc-Tyr((O-(3-(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide))-Val-OMe 333 (55 mg, 0.09 mmol, 95%) as a white solid: Rf 0.60 (90:10, 
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CH2Cl2:MeOH); m.p. 126-128 °C;  [𝛂]𝐃𝟐𝟎-9.2, (c = 0.1, CHCl3); νmax (NaCl/thin film)/cm−1 
3019, 2927, 1741, 1699, 1678, 1618, 1533, 1505, 1449, 1438, 1368, 1215, 1168, 1018: 1H 
NMR (500 MHz, CDCl3) δ 8.15-8.09 (2H, d, J 8.3 Hz, CH-15,19), 7.78 (1H, t, J 7.6 Hz, CH-
17), 7.67-7.63 (2H, m, CH-16,18), 7.30-7.26 (2H, m, CH-7, 11), 7.23-7.19 (2H, m, CH-8,10), 
6.45-6.36 (1H, m, NH-amide), 5.05 (1H, s, br, NH-Boc), 4.46 (1H, dd, J 8.8, 5.0 Hz, CH-21), 
4.38-4.33 (1H, m, CH-4), 3.71-3.68 (3H, m, CH3-25), 3.15-3.10 (1H, m, CHAHB-5), 3.08-3.02 
(1H, m, CHAHB-5), 2.16-2.07 (1H, m, CH-22), 1.42 (9H, s, 3 × CH3-1), 0.89 (3H, d, J 6.9 Hz, 
CH3-23) and 0.86 (3H, d, J 6.9 Hz, CH3-23); 13C NMR (125 MHz, CD3CN) δ 171.8 (quat., C-
24), 170.8 (quat., C-20), 158.3, 160.6 (quat., C-12), 155.5 (quat., C-3), 151.7, 152.8 (quat., × 2, 
C-9), 137.9, 137.8 (quat., C-14), 135.8, 135.6 (CH, C-17), 135.5, 135.3 (quat., C-6), 130.9 (CH 
× 2, C-7, 11), 129.0 (CH × 2, C-16,18) 128.6 (CH × 2, C-15,19), 119.9, 119.3 (CH × 2, C-8,10), 
110.8 (quat., C-13), 80.5 (quat., C-2), 57.3 (CH, C-21), 55.7 (CH, C-4), 52.2 (CH3, C-25), 37.2 
(CH2, C-5), 31.2 (CH, C-22), 28.3 (CH3 × 3, C-1) and 18.6, 17.7 (CH3 × 2, C-23); m/z (ES+) 641 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C28H34N4NaO10S [M+Na]+ requires 641.1893, 
found 641.1900. 
 
Boc-Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide))-Phe-OMe, 334 
 
 
HATU (113 mg, 0.30 mmol) was added to a solution of phenylalanine methyl ester 
hydrochloride (872 mg, 1.66 mmol) and (S)-4-(4-(2-((tert-butoxycarbonyl)amino)-2-
carboxyethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 312 (50 mg, 0.10 mmol) in 
dry DMF (5 mL) cooled to 0 °C. The solution was stirred for 15 min and diisopropylethylamine 
(distilled, 51 mg, 70 µL, 0.40 mmol) was added. The solution was allowed to warm to room 
temperature and stirred for 18 h. The resultant solution was diluted with ethyl acetate (20 mL) 
and water (20 mL). The organic layer was separated and washed with aq. hydrochloric acid (2 
N, 20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic layer was separated and 
dried over Na2SO4, filtered and the solvent removed under reduced pressure. The resultant 
residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification by silica gel 
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chromatography, eluting with ethyl acetate and hexanes (10:90 to 25:75) provided Boc-Tyr((O-
(3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide))-Phe-OMe 334 (60 mg, 0.09 mmol, 95%) as a 
white solid: Rf  0.62 (90:10, CH2Cl2:MeOH); m.p. 118-121 °C;  [𝛂]𝐃𝟐𝟎 -22.0, (c =0.1 , CHCl3); 
νmax (NaCl/thin film)/cm−1 2960, 2924, 2853, 1741, 1658, 1617, 1535, 1505, 1450, 1366, 1259, 
1202, 1167, 1019; 1H NMR (500 M, CHCl3) δ 8.18-8.12 (2H, m, CH-15,19), 7.81 (1H, tt, J 7.5, 
1.2 Hz, CH-17), 7.67 (2H, t, J 8.0 Hz, CH-16,18), 7.28-7.20 (7H, m, CH-7,8,10,11,25,26,27), 
7.05 (2H, d, J 7.4 Hz, CH-24,28), 6.34 (1H, d, J 7.4, NH-amide), 4.99 (1H, s, br, NH-Boc), 4.81 
(1H, dd, J 13.3, 6.4 Hz, CH-21), 4.37-4.33 (1H, m, CH-4), 3.72 (3H, s, CH3-30), 3.14-3.02 (4H, 
m, CH2-5, 22) and 1.43 (9H, s, 3 × CH3-1); 13C NMR (125 M, CHCl3) δ 171.4 (quat., C-29), 
170.5 (quat., C-20), 158.4 (quat., C-12), 155.3 (quat., C-3), 151.6 (quat., C-9), 138.0 (quat., C-
14), 135.9 (CH, C-17), 135.5 (quat., C-6), 135.3 (quat., C-23), 130.9 (CH × 2, C-7,11), 129.8 
(CH, C-26), 129.2 (CH × 2, C-16,18), 128.6 (CH × 2, C-15,19), 128.6 (CH × 2, C-24,28), 127.2 
(CH × 2, C-25,27), 120.0 (CH × 2, C-8,10); 110.7 (quat., C-13),  80.3 (quat., C-2), 53.3 (CH, C-
21), 52.4 (CH3, C-30), 51.6 (CH, C-4), 37.9 (CH2, C-22), 37.6 (CH2, C-5) and 28.1 (CH3 × 3, C-
1); m/z (ES+) 667 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C32H35N4O10S [M+H]+ requires 
667.2074, found 667.2078. 
 
Fmoc-Asp(OtBu)-Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide))-Val-OMe, 
335 
 
 
HCl in dioxane (4M, 1 mL, 4.0 mmol) was added to a solution of dipeptide 333 (62 mg, 0.10 
mmol) in dichloromethane (10 mL) cooled to 0 °C. The solution was stirred at 0 °C for 3 h and 
the solvent evaporated under reduced pressure to yield a white residue which was triturated with 
diethyl ether. The residue was dissolved in dry DMF (5 mL) and Fmoc-Asp(OtBu)-OH (41 mg, 
0.10 mmol) was added. The solution was cooled to 0 °C and stirred for 10 min. HATU (113 mg, 
0.30 mmol) was added and the solution stirred for a further 15 min. Diisopropylethylamine 
(distilled, 39 mg, 50 µL, 0.30 mmol) was added and the solution was allowed to warm to room 
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temperature and stirred for 18 h. The resultant solution was diluted with ethyl acetate (50 mL) 
and water (50 mL). The organic layer was separated and washed with aq. hydrochloric acid (2 
N, 20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic layer was separated and 
dried over Na2SO4, filtered and the solvent removed under reduced pressure. The resultant 
residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification by silica gel 
chromatography, eluting with ethyl acetate and hexanes (10:90 to 25:75) provided Fmoc-
Asp(OtBu)-Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide))-Val-OMe 335 (72 mg, 0.08 
mmol, 80%) as a white solid: Rf 0.65 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); 
m.p. 135-139 °C (decomp.); [𝛂]𝐃𝟐𝟎 -22.0, (c = 0.1, CHCl3); νmax (NaCl/thin film)/cm−1 1733, 
1700, 1656, 1648, 1581, 1553, 1539, 1494, 1450, 1404, 1367, 1260, 1181; 1H NMR (500 MHz, 
CDCl3) δ 8.17-8.08 (2H, m, CH-33,37), 7.81-7.44 (3H, m, CH-5,9,35), 7.63 (2H, t, J 7.6 Hz, 
CH-34,36), 7.60-7.55 (2H, m, CH-4,10), 7.43-7.37 (2H, m, CH-2,12), 7.35-7.25 (4H, m, CH-
3,11,25, 29), 7.13-7.10 (2H, m, CH-26,28), 7.02-6.99 (1H, m, NH-amide), 6.43 (1H, s, br, NH-
amide), 5.78 (1H, dd, J 19.0, 8.3 NH-Fmoc), 4.64 (1H, t, J 6.7 Hz, CH-22), 4.49-4.34 (4H, m, 
CH-16, 39, CH2-14), 4.20 (1H, t, J 6.7 Hz, CH-7), 3.78-3.71 (3H, m, CH3-43), 3.17-3.04 (2H, 
m, CH2-23), 2.85-2.80 (1H, m, CHAHB-17), 2.61 (1H, dd, J 17.0, 5.8 Hz, CHAHB-17), 2.14-2.08 
(1H, m, CH-40), 1.41 (9H, s, 3 × CH3-20) and 0.86-0.83 (6H, m, 2 × CH3-41); 13C NMR (125 
MHz, CDCl3) δ 171.8 (quat., C-42), 171.0 (quat., C-38), 170.7 (quat., C-21), 169.9 (quat., C-
18), 160.7, 158.4 (quat., C-30) 156.1 (quat., C-15), 152.8, 151.4 (quat., C-27), 141.3 (quat., C-
6,8), 141.6 (quat. × 2, C-1,13), 137.8, 137.0 (quat., C-32), 135.8, 135.6 (CH, C-35), 135.2, 
135.1 (quat., C-24), 131.0 (CH × 2, C-25,29), 129.8 (CH × 2, C-34, 36), 129.1, 128.6 (CH × 2, 
C-33,37), 127.7 (CH × 2, C-3,11), 127.1 (CH × 2, C-4,10), 125.0 (CH × 2, C-5,9), 120.1 (CH × 
2, C-26,18), 119.4 (CH × 2, C-2,12), 110.7 (quat., C-31), 82.1 (quat., C-19), 67.2 (CH2, C-14), 
57.4 (CH, C-16), 54.4 (CH, C-22), 52.2 (CH3, C-43), 51.2 (CH, C-39), 47.1 (CH, C-7), 37.1 
(CH2, C-17), 36.9 (CH2, C-23), 31.0 (CH, C-40) 28.0 (CH × 3, C-20) and 18.9, 17.9 (CH3 × 2, 
C-41); m/z (ES+) 913 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C46H50N5O13S [M+H]+ 
requires 912.3125, found 912.3126. 
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Fmoc-Arg(Pbf)-Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide))-Phe-OMe, 
336 
 
 
 
HCl in dioxane (4M, 1 mL, 4.0 mmol) was added to a solution of dipeptide 334 (66 mg, 0.10 
mmol) in dichloromethane (10 mL) cooled to 0 °C. The solution was stirred at 0 °C for 3 h and 
the solvent evaporated under reduced pressure to yield a white residue which was triturated with 
diethyl ether. The residue was dissolved in dry DMF (5 mL) and Fmoc-Arg(Pbf)-OH (64 mg, 
0.10 mmol) was added. The solution was cooled to 0 °C and stirred for 10 min. HATU (113 mg, 
0.30 mmol) was added and the solution stirred for a further 15 min. Diisopropylethylamine 
(distilled, 39 mg, 50 µL, 0.30 mmol) was added and the solution was allowed to warm to room 
temperature and stirred for 18 h. The resultant solution was diluted with ethyl acetate (50 mL) 
and water (50 mL). The organic layer was separated and washed with aq. hydrochloric acid (2 
N, 20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic layer was separated and 
dried over Na2SO4, filtered and the solvent removed under reduced pressure. The resultant 
residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification by silica gel 
chromatography, eluting with ethyl acetate and hexanes (10:90 to 25:75) provided Fmoc-
Arg(Pbf)-Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide))-Phe-OMe 336 (103 mg, 0.09 
mmol, 85%) as a white solid: Rf 0.62 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); 
m.p. 109-110 °C; [𝛂]𝐃𝟐𝟎 -9.2, (c = 0.1 , CHCl3); νmax (NaCl/thin film)/cm−1 1752, 1730, 1635, 
1600, 1540, 1491, 1450, 1270, 1175, 1040; 1H NMR (500 MHz, CDCl3) δ 8.11-8.05 (2H, m, 
CH-45,49), 7.71-7.70 (3H, m, CH-5,9,47), 7.62-7.53 (4H, m, CH-4,10,46,48), 7.39-7.15 (8H, 
m, CH-2,3,11,12,54,55,58,57), 7.14-7.02 (5H, m, CH-30,37,38,41,56), 6.94 (1H, s, br, NH-
amide), 6.36 (2H, s, br, NH-guanidine), 5.95 (1H, s, br, NH-Fmoc), 4.70 (1H, dd, J 6.7, 13.9 
Hz, CH-51), 4.57 (1H, t, J 7.1 Hz, CH-34), 4.39-4.22 (3H, m, CH2-14, CH-16), 4.11 (1H, t, J 
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7.4 Hz, CH-7), 3.60 (3H, s, CH3-60), 3.17-2.85 (8H, m, CH2-17,25,35,52), 2.61 (3H, s, CH3-
23), 2.51 (3H, s, CH3-30), 2.07 (3H, s, CH-32), 1.82-1.74 (1H, m, CHAHB-19), 1.65-1.54 (1H, 
m, CHAHB-19) and 1.47-1.40 (8H, CH2-18, 3 × CH3-27); 13C NMR (125 MHz, CDCl3) δ 172.6 
(quat., C-33), 171.7 (quat., C-59), 170.9 (quat., C-50), 159.0 (quat., C-42), 158.3 (quat., C-28), 
156.6 (quat., C-20), 156.4 (quat., C-15), 151.3 (quat, C-39), 143.8, 143.7 (quat. × 2, C-6,8), 
141.2 (quat. × 2, C-1,13), 138.5 (quat., C-21), 138.0 (quat., C-44), 136.0 (quat., C-36), 135.8 
(CH, C-47), 135.4 (quat., C-53), 132.4 (quat., C-24), 132.3 (quat., C-29), 130.8 (CH × 2, C-37, 
41), 129.8 (CH × 2, C-55,57), 129.2 (CH × 2, C-45,49), 128.6 (CH × 2, C-46,48), 128.8 (CH, 
C-56), 128.7 (CH × 2, C-54,58), 127.7 (CH × 2, C-3,11), 127.1 (CH × 2, C-4,10), 125.2 (CH × 
2, C-5,9), 124.8 (quat., C-31), 120.0 (CH × 2, C-38 40), 119.9 (CH × 2, C-2,12), 117.7 (quat., 
C-22), 110.7 (quat., C-43), 86.5 (quat., C-26), 67.1 (CH2, C-14), 56.8 (CH, C-51), 53.7 (CH, C-
16) 55.5 (CH, C-34), 52.4 (CH3, C-60), 47.0 (CH, C-7), 43.2 (CH2, C-17), 43.2 (CH2, C-25), 
37.7 (CH2, C-35), 36.8 (CH2, C-52). 30.3 (CH2, C-19), 28.6 (quat. × 2, C-27), 25.2 (CH2, C-18), 
19.4 (CH3, C-30), 18.1 (CH3, C-32) and 12.5 (CH3, C-23); m/z (ES+) 1197 ([M+H]+, 100%); 
HRMS m/z (ES+) calcd. for C61H65N8O14S [M+H]+ requires 1197.4057, found 1197.4062. 
 
Cbz-Asp(OtBu)-OtBu, 340377 
 
 
 
Boron trifluoride diethyl etherate (930 µL, 7.5 mmol) was added to a suspension of Cbz-Asp-
OH 339 (10.0 g, 37.4 mmol) in tert-butyl acetate (55 mL), and the suspension stirred overnight. 
After ca. 3 h a clear solution was attained. The solution was quenched with water (25 mL), 
basified to pH 12 with aq. sodium hydroxide (4N) and extracted with ethyl acetate (3 × 50 mL). 
The ethyl acetate layer was separated and the solvent removed under reduced pressure to give 
Cbz-Asp(OtBu)-OtBu 340 (8.50 g, 22.4 mmol, 60%) as a colourless oil, which was used 
without any further purification: Rf 0.31 (90:10, EtOAc:PE, UV/KMnO4); [𝛂]𝐃𝟐𝟎 +4.6, (c = 1.0, 
dioxane, [Lit.418 +4.5 (c = 1.0, dioxane]; 1H NMR (500 MHz, CDCl3) δ 7.36-7.28 (5H, m, CH-
12,13,14,15,16), 5.75 (1H, d, J 8.7 Hz, NH-Cbz), 5.11 (2H, s, CH2-10), 4.19 (1H, dt, J 8.7, 4.4 
Hz, CH-4), 2.87 (1H, dd, J 17.1, 4.4 Hz, CHAHB-5), 2.70 (1H, dd, J 16.9, 4.3 Hz, CHAHB-5), 
1.45-1.52 (18H, m, 3 × CH3-1,3 × CH3-8); 13C NMR (125 MHz, CDCl3) δ 170.2, 169.9 (quat. × 
2, C-3,6), 156.1 (quat., C-9), 136.4 (quat., C-11), 128.5 (CH × 2, C-15,13), 128.1 (CH, C-4), 
128.0 (CH × 2, C-12,16), 82.3, 81.6 (quat. × 2, C-2,7), 66.9 (CH2, C-10), 51.0 (CH, C-4), 37.9 
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(CH2, C-5), 28.0, 27.9 (2 × CH3 × 3, C-1, C-8); m/z (ES+) 402 ([M+Na]+, 100%). The data were 
in agreement with the literature values.377 
 
NH2-Asp(OtBu)-OtBu hydrochloride, 338377 
 
 
 
Pd/C (10%, 830 mg, 10% w/w) was added to a solution of Cbz-Asp(OtBu)-OtBu 340 (8.25 g, 
21.8 mmol) and ammonium formate (34.3 g, 0.54 mol) in ethanol (20 mL) and the suspension 
stirred overnight at room temperature. The suspension was filtered through Celite and the 
solvent removed under reduced pressure. The resultant residue was uptaken in ethyl acetate and 
cooled to 0 °C and a saturated solution of HCl in ethyl acetate was added dropwise and the 
solution stirred for 15 min. The precipitated solid was filtered, washed with cold ethyl acetate 
and dried under vacuum to give NH2-Asp(OtBu)-OtBu hydrochloride, 338 (4.28 g, 17.4 mmol, 
80%) as a white solid, which was used without any further purification: m.p. 157-160 °C, 
[Lit.419 156-158 °C]; [𝛂]𝐃𝟐𝟎 +6.62, (c = 0.9, MeOH), [Lit.419 +6.6 (c = 0.9, MeOH)]; 1H NMR 
(300 MHz, d6-DMSO) δ 8.70 (3H, s, NH2.HCl), 4.07 (1H, t, J 5.4 Hz, CH-4), 2.89 (2H, d, J 5.4 
Hz, CH2-5), 1.41 (18H, s, 3 × CH3-1, 3 × CH3-8); 13C NMR (75 MHz, d6-DMSO) δ 168.9, 
167.7 (quat., × 2, C-3,6), 83.2, 81.7 (quat., C-2, 7), 49.1 (CH, C-4), 35.5 (CH2, C-5), 28.0, 27.8 
(2 × CH3 × 3, C-1,8); m/z (ES+) 246 ([M+H]+, 100%). The data were in agreement with the 
literature values. 377 
 
Fmoc-Gly-Asp(OtBu)-OtBu, 343376 
 
 
 
Diisopropylamine (1.31 g, 1.76 mL, 10.1 mmol) was added to a solution of Fmoc-Gly-OH 341 
(1.51 g, 5.05 mmol) and NH2-Asp(OtBu)-OtBu.HCl 338 (1.43 g, 5.05 mmol) in 
dichloromethane (50 mL) cooled to 0 °C . T3P® (50 wt% in EtOAc, 3.65 mL, 6.2 mmol) was 
added via syringe pump over 30 min. The solution was allowed to warm to room temperature 
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and stirred for 24 h. Water (50 mL) was added, and the organic layer separated and washed with 
NaHCO3 solution (saturated, 50 mL), aq. HCl (2 N, 50 mL) and brine (100 mL). The organic 
layer was dried over MgSO4, filtered and the solvent removed under reduced pressure to give 
Fmoc-Gly-Asp(OtBu)-OtBu 343 (2.52 g, 4.80 mmol, 95%) as a white foam, which was used 
without any further purification: m.p. 57-59 °C, [Lit.376 55.4-60.2 °C]; Rf 0.58 (90:10, 
CH2Cl2:MeOH, UV/cerium phosphomolydate); [𝛂]𝐃𝟐𝟎  +23.0, (c = 1.0, CHCl3, [Lit.376 +22.9 (c = 
1.0, CHCl3]; 1H NMR (500 MHz, CDCl3) δ 7.75 (2H, d, J 7.6 Hz, CH-18,21), 7.60 (2H, d, J 6.9 
Hz, CH-15,24), 7.38 (2H, t, J 7.5 Hz, CH-17,22), 7.30 (2H, t, J 7.6 Hz, CH-16,23), 6.96 (1H, s, 
br, NH-amide), 5.63 (1H, s, br, NH-Fmoc), 4.71 (1H, dt, J 8.4, 4.3 Hz, CH-4), 4.38 (2H, d, J 
7.1 Hz, CH2-12), 4.22 (1H, t, J 7.1 Hz, CH-13), 4.00-3.90 (2H, m, CH2-10), 2.89 (1H, dd, J 
17.2, 4.4 Hz, CHAHB-5), 2.72 (1H, dd, J 17.2, 4.1 Hz, CHAHB-5), 1.45-1.41 (18H, m, 3 × CH3-
1, 3 × CH3-8); 13C NMR (125 MHz, CDCl3) δ 171.2, 169.6, 168.7 (quat., C-3,6,9), 156.5 (quat., 
C-11), 143.8 (quat. × 2, C-14,25), 141.3 (quat. × 2, C-19,20), 127.7 (CH × 2, C-17,22), 127.1 
CH × 2, C-16,23), 125.2 (CH × 2, C-15,24), 119.9 (CH × 2, C-18,21), 82.5, 81.7  (quat., C-2,7), 
67.3 (CH2, C-12), 49.1 (CH, C-4), 47.1 (CH, C-13), 44.3 (CH2, C-10), 36.5 (CH2, C-5), 28.0, 
27.9 (CH3 × 6, C-1, 8), 25.2 (CH2, C-8); m/z (ES+) 547 ([M+Na]+, 100%). The data were in 
agreement with the literature values.376 
 
NH2-Gly-Asp(OtBu)-OtBu, 344376 
 
 
 
Piperidine (3 mL, 30.4 mmol) was added to a solution of Fmoc-Gly-Asp(OtBu)-OtBu 343 (1.70 
g, 3.24 mmol) in dry DMF (10 mL) cooled in an ice-bath. After addition, the ice-bath was 
removed and the solution stirred for 15 min. The solvent was evaporated under reduced pressure 
to yield a yellow residue. The residue suspended in dichloromethane and adsorbed onto silica 
gel. Purification by silica gel chromatography eluting with dichloromethane and methanol 
(100:0 to 90:0) provided NH2-Gly-Asp(OtBu)-OtBu 344 (855 mg, 2.83, 87%) as a colourless 
oil: Rf 0.25 (90:10, CH2Cl2:MeOH, ninhydrin); [𝛂]𝐃𝟐𝟎 +36.5, (c = 1.0, CHCl3, [Lit. +36.5 (c = 
1.0, CHCl3]; 1H NMR (500 MHz, CDCl3) δ 7.98 (1H, d, J 8.4 Hz, NH-amide), 4.70 (1H, dt, J 
8.8, 4.5 Hz, CH-4), 3.37 (2H, d, J 2.3 Hz, CH2-10), 2.88 (1H, dd, J 4.4 Hz, J 16.8 Hz, CHAHB-
5), 2.88 (1H, dd, J 4.5 Hz, J 16.9 Hz, CHAHB-5), 1.58 (2H, s, br, NH2) and 1.44-1.42 (18H, m, 3 
× CH3-1, 3 × CH3-8); 13C NMR (125 MHz, CDCl3) δ 173.0 (quat., C-9), 170.3, 170.1 (quat. × 
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2, C-3,6), 82.2, 81.8 (quat. × 2, C-2,7), 49.0 (CH, C-4), 45.0 (CH2, C-10), 38.1 (CH2, C-5) and 
28.3, 28.2 (CH3 × 6, C-1, 8); m/z (ES+) 303 ([M+H]+, 100%). The data were in agreement with 
the literature values. 376 
 
Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OtBu, 345376 
 
 
 
Diisopropylamine (1.31 g, 1.76 mL, 10.1 mmol) was added to a solution of Fmoc-Arg(Pbf)-OH, 
(2.17 g, 3.34 mmol) and NH2-Gly-Asp(OtBu)-OtBu 344 (1.01 g, 3.34 mmol) in 
dichloromethane (50 mL) cooled to 0 °C . T3P® (50 wt% in EtOAc, 2.50 mL, 4.25 mmol) was 
added via syringe pump over 30 min. The solution was allowed to warm to room temperature 
and stirred for 24 h. Water (50 mL) was added, and the organic layer separated and washed with 
aq. NaHCO3 solution (saturated, 50 mL), aq. HCl (2 N, 50 mL) and brine (100 mL). The 
organic layer was dried over MgSO4, filtered and the solvent removed under reduced pressure. 
The residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification by silica 
gel chromatography eluting with dichloromethane and methanol (99:1 to 95:5) provided Fmoc-
Arg(Pbf)-Gly-Asp(OtBu)-OtBu 345 (2.80 g 3.01 mmol, 90%) as a white foam: m.p. 116-119 
°C, [Lit.376 114.0-120.0 °C]; Rf 0.55 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolydate);   [𝛂]𝐃𝟐𝟎 +8.6, (c = 1.0, CHCl3, [Lit.376 +8.6 (c = 1.0, CHCl3]; 1H NMR (500 MHz, CDCl3) δ 7.73 
(2H, d, J 7.5 Hz, CH-36,39), 7.63 (1H, s, br, NH-Gly-Asp-amide), 7.58 (2H, d, J 6.3 Hz, CH-
33,42), 7.36 (2H, t, J 7.4 Hz, CH-35,40), 7.26 (2H, t, J 7.4 Hz, CH-34,41), 7.02 (1H, d, J 6.3, 
NH-Arg-Gly-amide), 6.31 (2H, s, br, NH-guanidine × 2), 6.12 (1H, s, br, NH-sulfonamide), 
6.01 (1H, d, J 5.7 Hz, NH-Fmoc), 4.64 (1H, dt, J 8.5, 4.3 Hz, CH-4), 4.40-4.33 (3H, m, CH-12, 
CH2-30), 4.17 (1H, t, J 7.0 Hz, CH-7), 4.06 (1H, dd, J 17.3, 5.7 Hz, CHAHB-10), 3.91 (1H, dd, J 
17.0, 5.7 Hz, CHAHB-10), 3.38-3.30 (1H, m, CHAHB-15), 3.24-3.17 (1H, m, CHAHB-15), 2.92 
(2H, s, CH2-29), 2.82 (1H, dd, J 17.1, 4.8 Hz, CHAHB-5), 2.67 (1H, dd, J 17.1, 4.4 Hz, CHAHB-
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5), 2.59 (3H, s, CH3-19), 2.51 (3H, s, CH3-21), 2.07 (3H, s, CH3-28), 1.76-1.68 (2H, m, CH2-
13), 1.64-1.54 (2H, m, CH2-14), 1.43 (6H, s, 2 × CH3-24), and 1.42-1.40 (18H, s, 3 × CH3-1, 3 
× CH3-8); 13C NMR (125 MHz, CDCl3) δ 172.7, 170.2, 169.9, 169.2 (quat. × 4, C-3,6,9,12), 
158.7 (quat., C-22), 156.6 (quat., C-16), 156.3 (quat., C-29), 143.9, 143.8 (quat. × 2, C-37, 38), 
141.3 (quat. × 2, C-32,43), 138.4 (quat., C-17), 132.8 (quat., C-26), 132.4 (quat., C-20), 127.7 
(CH × 2, C-35,40), 127.1 (CH × 2, C-34,41), 125.2 (CH × 2, C-33, 42), 124.6 (quat., C-18), 
119.9 (CH × 2, C-36,39), 117.5 (quat., C-27), 86.4 (quat., C-23), 82.7, 81.8 (quat. × 2, C-2, C-
7), 67.1 (CH2, C-30), 54.0 (CH, C-12), 49.4 (CH, C-4), 47.1 (CH, C-31), 43.2 (CH2, C-25), 42.8 
(CH2, C-10), 40.1 (CH2, C-15), 37.3 (CH2, C-5), 30.0 (CH2, C-13), 28.6 (CH3 × 2, C-24), 28.0, 
27.9 (2 × CH3 × 3, C-1,8), 25.0 (CH2, C-14), 19.3 (CH3, C-21), 18.0 (CH3, C-19) and 12.5 (CH3, 
C-28); m/z (ES+) 933 ([M+H]+, 100%). The data were in agreement with the literature values. 
376 
 
NH2-Arg(Pbf)-Gly-Asp(OtBu)-OtBu, 341376 
 
 
 
Piperidine (3.0 mL, 30.4 mmol) was added to a solution of Fmoc-Gly-Asp(OtBu)-OtBu, 345 
(2.80 g, 3.00) in dry DMF (10 mL) cooled in an ice-bath. After addition, the ice-bath was 
removed and the solution stirred for 15 min. The solvent was evaporated under reduced pressure 
to yield a yellow residue. The residue suspended in dichloromethane and adsorbed onto silica 
gel. Purification by silica gel chromatography eluting with dichloromethane and methanol 
(100:0 to 90:0) provided NH2-Arg(Pbf)-Gly-Asp(OtBu)-OtBu 341 (1.81 g, 2.55 mmol, 85%) as 
a colourless solid: m.p. 81-83°C, [Lit.376 83.0-84.0 °C]; Rf 0.33 (90:10, CH2Cl2:MeOH, 
UV/cerium phosphomolydate); [𝛂]𝐃𝟐𝟎 +18.1, (c = 1.0, CHCl3, [Lit.376 +18.2 (c = 1.0, CHCl3]; 
1H NMR (500 MHz, CDCl3) δ 8.10 (1H, t, J 6.5, NH-Gly-Arg amide), 7.28 (1H, d, J 7.7, NH-
Asp-Gly-amide), 6.46-6.33 (3H, m, NH-guanidine × 3), 4.65 (1H, dt, J 8.7, 4.6 Hz, CH-4), 4.00 
(1H, dd, J 16.8, 5.1 Hz, CHAHB-10), 3.94 (1H, dd, J 16.8, 5.1 Hz, CHAHB-10), 3.47 (1H, t, J 6.9 
Hz, CH-12), 3.24-3.19 (2H, m, CH2-15), 2.95 (2H, s, CH2-25), 2.83 (1H, dd, J 17.2, 4.9 Hz, 
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CHAHB-5), 2.70 (1H, dd, J 17.2, 4.4 Hz, CHAHB-5), 2.57 (3H, s, CH3-19), 2.49 (3H, s, CH3-21), 
2.17-2.05 (5H, m, CH3-28, NH2), 1.84-1.78 (1H, m, CHAHB-13), 1.65-1.55 (3H, m, CHAHB-13, 
CH2-14), 1.45 (6H, s, 9H, s, 2 × CH3-24) and 1.42-1.41 (18H, s, 3 × CH3-1, 3 × CH3-8); 13C 
NMR (125 MHz, CDCl3) δ 172.1 (quat., C-11), 170.2 (quat., C-6), 169.7 (quat., C-3), 169.3 
(quat., C-9), 158.6 (quat., C-22), 156.5 (quat., C-16), 138.2 (quat., C-17), 133.0 (quat., C-26), 
132.2 (quat., C-20), 124.6 (quat., C-18), 117.4 (quat., C-27), 86.3 (quat., C-23), 82.5, 81.6 (quat. 
× 2, C-2, C-7), 54.4 (CH, C-12), 49.2 (CH, C-4), 43.2 (CH2, C-25), 42.7 (CH2, C-10), 40.5 
(CH2, C-15), 37.3 (CH2, C-5), 31.9 (CH2, C-13), 28.6 (CH3 × 2, C-24), 28.0, 27.9 (2 × CH3 × 3, 
C-1, C-8), 25.4 (CH2, C-14), 19.3 (CH3, C-21), 18.0 (CH3, C-19) and 12.5 (CH3, C-28); m/z 
(ES+) 711 ([M+H]+, 100%). The data were in agreement with the literature values.376  
 
Boc-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-Asp(OtBu)-OtBu, 346 
 
 
 
Following general procedure B, with HATU (217 mg, 0.572 mmol), NH2-Arg(Pbf)-Gly-
Asp(OtBu)-OtBu 341 (203 mg, 0.286 mmol), (S)-N-((4-(2-((tert-butoxycarbonyl)amino)-2-
carboxyethyl)phenoxy)carbonyl)-3-phenylsydnonimine 308 (134 mg, 0.286 mmol) and 
diisopropylethylamine (distilled, 113 mg, 150 µL, 0.875 mmol). Purification by silica gel 
chromatography, eluting with dichloromethane and methanol (100:0 to 97:3) provided Boc-
Tyr(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-Asp(OtBu)-OtBu 346 (233 mg, 0.201 
mmol, 70%) as a pale yellow solid: Rf 0.65 (90:10, CH2Cl2:MeOH, UV/cerium 
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phosphomolydate); m.p. 138-141 °C; [𝛂]𝐃𝟐𝟎 +13.0, (c = 0.2, CHCl3); νmax (thin film)/cm−1 1734, 
1684, 1652, 1588, 1558, 1537, 1506, 1455, 1393, 1369, 1108, 973, 847; 1H NMR (500 MHz, 
CDCl3) δ 8.31 (1H, s, CH-40), 7.86 (2H, d, J 8.0 Hz, CH-42,46), 7.69-7.60 (4H, m, CH-
43,44,45, NH-Arg-Gly-amide), 7.35 (1H, s, br, NH-Gly-Asp-amide), 7.19 (2H, d, J 7.7 Hz, CH-
33,37), 7.06 (2H, d, J 8.0 Hz, CH-34,46), 6.40 (2H, s, br, NH-guanidine), 6.09 (1H, s, br, NH-
sulfonamide), 5.65 (1H, s, br, NH-Boc), 4.66 (1H, dd, 3H = 5.0, 13.6 Hz, CH-4), 4.46-4.36 (2H, 
m, CH-12, 30), 3.95-3.89 (2H, m, CH2-10), 3.21-3.13 (2H, m, CH2-15), 3.11-3.06 (1H, m, 
CHAHB-31), 3.00-2.95 (1H, m, CHAHB-31), 2.91 (2H, s, CH2-25), 2.79 (1H, dd, J 16.9, 5.4 Hz, 
CHAHB-5), 2.69 (1H, dd, J 17.2, 5.1 Hz, CHAHB-5), 2.53 (3H, s, CH3-19), 2.46 (3H, s, CH3-21), 
2.04 (3H, s, CH3-28), 1.90-1.82 (1H, m, CHAHB-13), 1.71-1.62 (1H, m, CHAHB-13), 1.49-1.30 
(35H, m, 3 × CH3-1, 3 × CH3-8 Hz, CH2-14, 2 × CH3-24, 3 × CH3-49); 13C NMR (125 MHz, 
CDCl3) δ 175.5 (quat., C-39), 172.5, 172.2, 170.0, 169.8, 169.2 (quat. × 5, C-3,6,9,11,29), 159.9 
(quat., C-38) 158.7 (quat., C-22) 156.4 (quat., C-16), 156.0 (quat., C-47), 150.8 (quat., C-35), 
138.4 (quat., C-17), 133.6 (quat., C-41), 133.2 (CH, C-44), 133.7 (quat., C-32), 132.9 (quat., C-
26), 132.3 (quat., C-20), 130.6 (CH × 2, C-42,46), 130.2 (CH × 2, C-33,37), 124.6 (quat., C-18), 
121.9 (CH × 3, C-34,36), 121.7 (CH × 2, C-43,45), 117.5 (quat., C-27), 103.9 (CH, C-40), 86.4 
(quat., C-23), 82.9 (quat., C-7), 81.5 (quat., C-2), 80.2 (quat., C-48), 53.2 (CH, C-12) 56.1 (CH, 
C-30), 49.4 (CH, C-4), 43.2 (CH2, C-25), 42.8 (CH2, C-10), 40.4 (CH2, C-15), 37.5 (CH2 × 2, C-
5,31), 29.0 (CH2, C-13), 28.6 (CH3 × 2, C-24), 28.3 (CH3 × 3, C-49), 28.0 (CH3 × 3, C-8) 27.9 
(CH3 × 3, C-1), 25.1 (CH2, C-14), 19.3 (quat., C-21), 18.0 (CH3, C-19), 12.5 (CH3, C-28); m/z 
(ES+) 1161 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C56H76N10O15S [M+H]+ requires 
1161.5286, found 1161.5266. 
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Boc-Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide))-Arg(Pbf)-Gly-
Asp(OtBu)-OtBu, 347 
 
 
Following general procedure B, with HATU (221 mg, 0.58), NH2-Arg(Pbf)-Gly-Asp(OtBu)-
OtBu 341 (207 mg, 0.29 mmol), (S)-4-(4-(2-((tert-butoxycarbonyl)amino)-2-
carboxyethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 312 (147 mg, 0.29 mmol) 
and diisopropylethylamine (distilled, 113 mg, 150 µL, 0.88 mmol). Purification by silica gel 
chromatography, eluting with dichloromethane and methanol (100:0 to 97:3) provided Boc-
Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide))-Arg(Pbf)-Gly-Asp(OtBu)-OtBu 347 (241 
mg, 0.20 mmol, 69%) as a white solid: Rf 0.69 (90:10, CH2Cl2:MeOH, UV/cerium 
phosphomolydate); m.p. 98-103 °C; [𝛂]𝐃𝟐𝟎 +8.6, (c = 0.2, CHCl3); νmax (thin film)/cm−1 1905, 
1734, 1700, 1683, 1654, 1639, 1498, 1456, 1103, 1020, 1051, 993, 970; 1H NMR (500 MHz, 
CDCl3) δ 8.08 (2H, d, J 7.7 Hz, CH-45,41), 7.79-7.74 (2H, m, CH-43, NH-Arg-Gly-amide), 
7.63 (2H, t, J 7.6 Hz, CH-42,44), 7.34 (1H, d, J 7.7, NH-Gly-Asp-amide), 7.28 2H, d, J 8.3 Hz, 
CH-33,37), 7.15 (2H, d, J 8.3 Hz, CH-34,36), 6.38 (2H, s, br, 2 × NH-guanidine), 6.10 (1H, s, 
br, NH-sulfonamide), 5.75 (1H, s, br, NH-Boc), 4.68-4.64 (1H, m, CH-4), 4.56-4.50 (1H, m, 
CH-12), 4.50-4.44 (1H, m, CH-30), 4.04-3.98 (2H, m, CH2-10), 3.34-3.13 (3H, m, CH2-15, 
CHAHB-31), 2.98-2.91 (3H, m, CH2-25, CHAHB-31), 2.82 (1H, dd, J 17.1, 5.5 Hz, CHAHB-5), 
2.69 (1H, dd, J 17.1, 5.0 Hz, CHAHB-5), 2.56 (3H, s, CH3-19), 2.49 (3H, s, CH3-21), 2.07 (3H, 
s, CH3-28), 1.94-1.86 (1H, m, CHAHB-13), 1.76-1.67 (1H, m, CHAHB-13), 1.64-1.55 (2H, m, 
CH2-14) and 1.44-1.32 (33H, m, 3 × CH3-1, 3 × CH3-8, 2 × CH3-24, 3 × CH3-48); 13C NMR 
(125 MHz, CDCl3) δ 172.2, 170.0, 169.9, 169.3 (quat. × 5, C-3,6,9,11,29), 158.8 (quat., C-35), 
158.5 (quat., C-39), 156.5 (quat., C-16), 156.0 (quat., C-46), 138.8 (quat., C-22), 138.5 (quat., 
C-17), 137.9 (quat., C-40), 136.0 (quat., C-32), 135.9 (CH, C-43), 132.7 (quat., C-26), 132.3 
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(quat., C-20), 131.0 (CH × 2, C-33,37), 129.8 (CH × 2, C-41,45), 128.6 (CH × 2, C-42,44), 
124.7 (quat., C-18), 119.8 (CH × 2, C-34,36), 117.6 (quat., C-27), 110.8 (quat., C-38), 86.5 
(quat., C-23), 82.5, 81.6 (quat. × 2, C-2,7), 80.1 (quat., C-47), 56.1 (CH, C-30), 53.1 (CH, C-
12), 49.5 (CH, C-4), 43.3 (CH2, C-25), 42.7 (C-10), 40.5 (CH2, C-15), 37.8 (CH2, C-31), 37.4 
(CH2, C-5), 29.3 (CH2, C-13), 28.6 (CH3 × 2, C-24), 28.3 (CH3 × 3, C-48), 28.0 and 27.9 (2 × 
CH3 × 3, C-1,8), 25.1 (CH2, C-14), 19.4 (CH3, C-21), 18.0 (CH3, C-19), 12.5 (CH3, C-28); m/z 
(ES+) 1198 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C55H75N9O17S2 [M+H]+ requires 
1198.4795, found 1198.4788. 
 
Tyr(O-carbonyl-N-3-phenylsydnonimine)-Arg-Gly-Asp trifluoroacetate, 348 
 
 
Following general procedure C with Boc-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-
Gly-Asp(OtBu)-OtBu 346 (60 mg, 52 µmol) and deprotecting cocktail (700 µL), to provide 
Tyr(O-carbonyl-N-3-phenylsydnonimine)-Arg-Gly-Asp trifluoroacetate 348 (38 mg, 48 µmol, 
92%) as a white powder: Rf. 0.00 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolydate); m.p. 
128-132 °C (decomp.); [𝛂]𝐃𝟐𝟎 +8.4, (c = 0.13, 1:1, H2O:MeOH; νmax (KBr disc)/cm−1 2953, 
2924, 2853, 1702, 1674, 1568, 1521, 1508, 1465, 1376, 1201, 1139, 1048; 1H NMR (500 MHz, 
d6-DMSO) δ 8.80 (1H, d, J 7.7 Hz, NH-Tyr-Arg), 8.62 (1H, s, CH-24), 8.38 (1H, t, J 5.2 Hz, 
NH-Arg-Gly), 8.22 (1H, d, J 7.4 Hz, NH-Gly-Asp), 8.07 (2H, d, J 7.7 Hz, CH-26,30), 7.79 (1H, 
tt. J 7.5, 2.5 Hz, CH-28), 7.73 (2H, t, J 8.0 Hz, CH-27,29), 7.35-7.01 (7H, m, CH-17,18,20,21, 3 
x NH-guanidine), 4.46 (1H, dd, J 12.2, 5.9 Hz, CH-2), 4.38 (1H, dd, J 13.0, 6.6, CH-8), 4.08 
(1H, t, J 7.7 Hz, CH-14), 3.87 (1H, dd, J 17.7, 5.7, CHAHB-6), 3.69 (1H, dd, J 16.2, 5.2 Hz, 
CHAHB-6), 3.15-3.07 (3H, m, CH2-11, CHAHB-15), 2.93 (1H, dd, J 15.0, 7.9 Hz, CHAHB-15), 
2.60 (2H, d, J 5.6 Hz, CH2-3), 1.80-1.73 (1H, m, CHAHB-9) and 1.67-1.48 (3H, m, CHAHB-9, 
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CH2-10); 13C NMR (125 MHz, d6-DMSO) δ 175.0 (quat., C-23), 172.6, 172.2, 171.0, 168.4, 
168.1 (quat., × 5, C-1,4,5,7,13),  158.7 (quat., C-22), 156.8 (quat., C-12), 151.2 (quat., C-19), 
133.6 (quat., C-25), 133.1 (CH, C-28), 131.3 (quat., C-16), 130.4 (CH × 2, C-17,21), 130.3 (CH 
× 2, C-27, 29), 122.6 (CH × 2, C-26,30), 121.8 (CH × 2, C-18,20), 104.9 (CH, C-24); 53.4 
(CH2, C-14), 52.5 (CH, C-8), 48.7 (CH, C-2), 41.6 (CH2, C-6), 40.5 (CH2, C-11), 36.7 (CH2, C-
3), 36.4 (CH2, C-15), 29.6 (CH2, C-9) and 24.8 (CH2, C-10); m/z (ES+) 697 ([M+H]+, 100%); 
HRMS m/z (ES+) calcd. for C30H37N10O10 [M+H]+ requires 697.2689, found 697.2684. 
 
Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide))-Arg-Gly-Asp 
trifluoroacetate, 349 
 
 
 
Following general procedure C with Boc-Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole-2-
oxide))-Arg(Pbf)-Gly-Asp(OtBu)-OtBu 347 (60 mg, 50 µmol) and deprotecting cocktail (700 
µL), to provide Tyr((O-(3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide))-Arg-Gly-Asp 
trifluoroacetate 349 (37 mg, 45 µmol, 90%) as a white solid: Rf. 0.00 (90:10, CH2Cl2:MeOH, 
UV/cerium phosphomolydate); m.p. 120-128 °C (decomp.); [𝛂]𝐃𝟐𝟎  +44.4, (c = 0.2, 1:1, 
H2O:MeOH; νmax (KBr)/cm−1 3417, 2952, 2923, 2853, 1726, 1659, 1602, 1566, 1468, 1369, 
1369, 1201, 1046; 1H NMR (500 MHz, d6-DMSO) δ 8.80 (1H, d, J 7.9 Hz, NH-Tyr-Arg), 8.44 
(1H, t, J 5.6 Hz, NH-Arg-Gly), 8.19 (1H, d, J 7.6 Hz, NH-Gly-Asp), 8.05 (2H, d, J 8.8 Hz, CH-
25,29), 7.93 (1H, tt, J 7.4, 1.3 Hz, CH-27), 7.77 (2H, t, J 8.0 Hz, CH-28,26), 7.40-7.14 (7H, m, 
CH-17,18,20,21, 3 × NH-guanidine), 4.40 (1H, dd, J 13.3, 6,1 Hz, CH-2), 4.37 (1H, dd, J 13.2, 
7.2, CH-8), 4.10 (1H, t, J 7.0 Hz, CH-14), 3.87 (1H, dd, J 16.6, 6.1 Hz, CHAHB-6), 3.77 (1H, 
dd, J 17.0, 5.4 Hz, CHAHB-6), 3.18-3.06 (3H m, CH2-11, CHAHB-15), 2.97 (1H, dd, J 14.0, 8.0 
Hz, CHAHB-15), 2.59 (2H, d, J 5.9, CH2-3) 1.84-1.74 (1H, m, CHAHB-9) and 1.66-1.48 (3H, m, 
CHAHB-9, CH2-10); 13C NMR (100 MHz, d6-DMSO) δ 172.6, 172.3, 171.1, 168.3, 168.0 (quat., 
× 5, C-1,4,5,7,13), 158.4 (quat., C-22), 156.9 (quat., C-12), 151.9 (quat., C-19), 136.7 (quat., C-
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24), 133.4 (quat., C-16), 131.3 (CH × 2, C-17,21), 130.1 (CH × 2, C-26,30), 128.6 (CH × 2, C-
25,29), 119.7 (CH × 2, C-18,20), 111.3 (quat., C-23), 53.3 (CH, C-14), 52.5 (CH, C-8), 48.7 
(CH, C-2), 41.7 (CH2, C-6), 40.5 (CH2, C-11), 36.9 (CH2, C-3), 36.3 (CH2, C-15), 29.6 (CH2, C-
9), 24.8 (CH2, C-10); m/z (ES+) 734 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for 
C29H36N9O12S [M+H]+ requires 734.2199, found 734.2194. 
 
Fmoc-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-Asp(OtBu)-OtBu, 
350 
 
 
 
Following general procedure B, with HATU (749 mg, 1.97 mmol), NH2-Arg(Pbf)-Gly-
Asp(OtBu)-OtBu 341 (700 mg, 0.99 mmol), (S)-N-(((4-(2-(((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-2-carboxyethyl)phenoxy)carbonyl)-3-phenylsydnonimine 321 
(581 mg, 0.99 mmol) and diisopropylethylamine (distilled, 381 mg, 510 µL, 2.95 mmol). 
Purification by silica gel chromatography, eluting with dichloromethane and methanol (100:0 to 
97:3) provided Fmoc-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-Asp(OtBu)-OtBu 
350 (965 mg, 0.75 mmol, 76%) as a white solid: Rf 0.71 (90:10, CH2Cl2:MeOH, UV/cerium 
phosphomolydate); m.p. 110-112 °C; [𝛂]𝐃𝟐𝟎 +7.6, (c = 1.0, CHCl3); νmax (thin film)/cm−1 2982, 
2934, 1723, 1699, 1685, 1668, 1603, 1587, 1539, 1509, 1369, 1265, 1217, 1191, 1106, 972; 1H 
NMR (500 MHz, CDCl3) δ 8.24 (1H, s, CH-40), 7.83 (2H, d, J 8.1 Hz, CH-54,57), 7.70 (2H, d, 
J 7.6 Hz, CH-42,46), 7.66 (1H, t, J 7.6 Hz, CH-44), 7.60 (2H, t, J 7.6 Hz, CH-43,45), 7.53 (2H, 
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d, J 7.4 Hz, CH-51,60), 7.35-7.31 (3H, m, CH-53,58, NH-Gly-Asp-amide), 7.26-7.22 (3H, m, 
CH-52,59, NH-Tyr-Arg), 7.19 (2H, d, J 8.0 Hz, CH-33,37), 7.07 (2H, d, J 8.0 Hz, CH-34, 36), 
6.36 (2H, s, br, NH-guanidine × 2), 6.01 (1H, s, br, NH-Fmoc), 4.66-4.62 (1H, m, CH-4), 4.59-
4.54 (1H, m, CH-30), 4.50-4.42 (1H, m, CH-12), 4.36 (1H, t, J 8.6 Hz, CHAHB-48), 4.20 (1H, t, 
J 8.6 Hz, CHAHB-48), 4.09 (1H, t, J 8.6 Hz, CH-49), 3.96-3.90 (2H, m, CH2-10),  3.18-3.06 
(4H, m, CH2-15, CH2-31), 2.88 (2H, s, CH2-25), 2.78 (1H, dd, J 17.6, 5.8 Hz, CHAHB-5), 2.67 
(1H, dd, J 17.6, 4.7 Hz, CHAHB-5), 2.53 (3H, s, CH3-19), 2.46 (3H, s, CH3-21), 2.02 (3H, s, 
CH3-28), 1.90-1.82 (1H, m, CHAHB-13), 1.70-1.62 (1H, m, CHAHB-13) and 1.45-1.35 (26H, m, 
3 × CH3-1, 3 × CH3-8 Hz, CH2-14, 2 × CH3-24); 13C NMR (125 MHz, CDCl3) δ 175.3 (quat., 
C-39), 172.1, 171.6, 169.8, 169.6, 169.0 (quat., × 5, C-3,6,9,11,29), 159.7 (quat., C-38), 158.4 
(quat., C-22), 156.2 (quat., C-16), 156.2 (quat., C-47), 150.6 (quat., C-35), 143.6 (quat., × 2, C-
55,56), 140.9 (quat., × 2, C-50,61), 138.0 (quat., C-17), 133.4 (quat., C-41), 133.4 (quat., C-32), 
132.9 (CH, C-44), 132.8 (quat., C-26), 132.0 (quat., C-20), 130.3 (CH × 2, C-42,46), 130.1 (CH 
× 2, C-33,37), 127.5 (CH × 2, C-53,58), 126.9 (CH × 2, C-52,59), 125.1 (CH × 2, C-51,60), 
124.4 (quat., C-18), 121.7 (CH × 2, C-34, 36), 121.5 (CH × 2, C-43,45), 119.7 (CH × 2, C-
54,57), 117.2 (quat., C-27), 103.6 (CH, C-40), 86.1 (quat., C-23), 82.1 (quat., C-7), 81.2 (quat., 
C-2), 67.1 (CH2, C-48), 56.1 (CH, C-30), 53.0 (CH, C-12), 49.3 (CH, C-4), 46.7 (CH, C-49), 
43.0 (CH2, C-25), 42.6 (CH2, C-10), 40.3 (CH2, C-15), 37.8 (CH2, C-31), 37.3 (CH2, C-5), 29.2 
(CH2, C-13), 28.4 (CH3 × 2, C-24), 27.8 (CH3 × 3, C-8), 27.7 (CH3 × 3, C-1), 25.1 (CH2, C-14), 
19.2 (CH3, C-21, 17.8 (CH3, C-19) and 12.3 (CH3, C-28); m/z (ES+) 1283 ([M+H]+, 100%); 
HRMS m/z (ES+) calcd. for C66H78N10O15S [M+H]+ requires 1283.5442, found 1283.5423. 
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NH2-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-Asp(OtBu)-OtBu, 351 
 
 
 
Piperidine (350 µL, 3.51 mmol) was added to a solution of Fmoc-tetrapeptide 350 (300 mg, 
0.23 mmol) in dry DMF (10 mL) cooled in an ice-bath. After addition, the ice-bath was 
removed and the solution stirred for 15 min. The solvent was evaporated under reduced pressure 
to yield a yellow residue. The residue suspended in dichloromethane and adsorbed onto silica 
gel. Purification by silica gel chromatography eluting with dichloromethane and methanol 
(100:0 to 90:0) provided amine 351 (224 mg, 0.211, 90%) as a pale yellow solid: Rf 0.44 
(90:10, CH2Cl2:MeOH, UV/cerium phosphomolydate); m.p. 116-120 °C; [𝛂]𝐃𝟐𝟎 -0.7, (c = 1.0, 
CHCl3); νmax (thin film)/cm−1 3334, 2976, 2932, 1728, 1698, 1654, 1583, 1554, 1509, 1419, 
1367, 1279, 1214, 1190, 1155, 972; 1H NMR (500 MHz, CDCl3) δ 8.31 (1H, s, CH-40), 7.87 
(2H, d, J 7.7 Hz, CH-42,46), 7.72-7.61 (4H, m, CH-43,44,45, NH-Tyr-Arg), 7.20-7.11 (3H, m, 
CH-33,37, NH-Gly-Asp), 7.07 (2H, d, J 8.0 Hz, CH-35,36), 6.48 (2H, s, br, NH-guanidine), 
6.12 (1H, s, br, NH-sulfonamide), 4.62 (1H, dt, J 8.5, 4.5 Hz, CH-4), 4.44-4.36 (1H, m, CH-12), 
3.96 (1H, dd, J 5.6 Hz, J 17.2 Hz, CHAHB-10), 3.86 (1H, dd, J 16.8, 5.6 Hz, CHAHB-10), 3.77-
3.74 (1H, m, CH-30), 3.19-3.13 (2H, m, CH2-15), 3.05-2.99 (1H, m, CHAHB-31), 2.95-2.88 
(3H, m, CH2-25, CHAHB-31), 2.80 (1H, dd, J 17.2, 4.3, CHAHB-5), 2.68 (1H, dd, J 17.2, 4.3 Hz, 
CHAHB-5), 2.55 (3H, s, CH3-19), 2.48 (3H, s, CH3-21), 2.06 (3H, s, CH3-28), 1.88-1.81 (1H, m, 
CHAHB-13), 1.66-1.58 (1H, m, CHAHB-13), 1.45-1.31 (26H, m, 3 × CH3-1, 3 × CH3-8 Hz, CH2-
14, 2 × CH3-24); 13C NMR (125 MHz, CDCl3) δ 175.7 (quat., C-39), 160.2 (quat., C-38), 158.6 
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(quat., C-22), 156.4 (quat., C-16), 150.7 (quat., C-35), 138.3 (quat., C-17), 134.0 (quat., C-32), 
133.7 (quat., C-41), 133.3 (CH, C-44), 133.1 (quat., C-26), 132.3 (quat., C-20), 130.6 (CH × 2, 
C-43,45), 130.4 (CH × 2, C-33,37), 124.6 (quat., C-18), 122.0 (CH × 2, C-34,36), 121.6 (CH × 
2, C-42,46), 117.4 (quat., C-27), 103.8 (CH, C-40), 86.3 (quat., C-23), 82.5 (quat., C-2), 81.6 
(quat., C-7), 56.0 (CH, 30), 52.6 (CH, C-12), 49.2 (CH, C-4), 43.2 (CH2, C-25), 42.8 (CH2, C-
10), 40.5 (CH2, C-15), 37.4 (CH2, C-5), 37.4 (CH2, C-31), 29.1 (CH2, C-13), 28.6 (CH3 × 2, C-
24), 28.0 (CH3 × 3, C-8), 27.9 (CH3 × 3, C-1), 25.2 (CH2, C-14), 19.3 (CH3, C-21), 18.0 (CH3, 
C-19) and 12.5 (CH3, C-28); m/z (ES+) 1061 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for 
C51H68N10O13S [M+H]+ requires 1061.4761, found 1061.4756. 
 
tert-Butyl-17-(3-Pyridyl)androsta-5,16-dien-3β-ol 3-hemisuccinate, 353 
 
 
 
tert-Butyl hemisuccinate 264 (279 mg, 1.60 mmol) and DMAP (170 mg, 1.70 mmol) were 
added to a solution of abiraterone 106 (500 mg, 1.43 mmol) in dichloromethane (20 mL). 
EDCI.HCl (400 mg, 2.10 mmol) was added in one portion and the solution stirred for 6 h. The 
solution was washed with water and dried over MgSO4. The mixture was filtered and the 
solvent adsorbed onto silica gel. Purification by silica gel chromatography, eluting with diethyl 
ether, provided tert-butyl-17-(3- pyridyl)androsta-5,16-dien-3β-ol 3-hemisuccinate 353 (686 
mg, 1.36 mmol, 95%) as an white solid: Rf 0.66 (50:50, EtOAc:Cyclohexane, UV/cerium 
phosphomolydate); m.p. 209-211 °C; [𝛂]𝐃𝟐𝟎 -14.8, (c = 1.0, CHCl3); νmax (thin film)/cm−1 1740, 
1705, 1619, 1540, 1541, 1320, 1170, 1015; 1H NMR (500 MHz, CDCl3) δ 8.56 (1H, d, J 1.5 
Hz, CH-2′), 8.40 (1H, dd, J 4.7, 1.3 Hz, CH-6′), 7.59 (1H, d, J 7.9, 1.7 Hz, CH-4′), 7.16 (1H, dd, 
J 7.9, 4.7 Hz, CH-5′), 5.93 (1H, dd, J 3.0, 1.8 Hz, CH-16), 5.35 (1H, d, J 4.9 Hz, CH-6), 4.61-
4.55 (1H, m, CH-3), 2.52-2.46 (4H, m, CH2-2′′,3′′), 2.33-2.24 (2H, m, CH2-1), 2.20 (1H, ddd, J 
15.8, 6.6, 3.3 Hz, CHAHB-12), 2.03-1.96 (3H, m, CHAHB-7, CHAHB-12, CHAHB-15), 1.85-1.78 
(2H, m, CHAHB-2, CHAHB-4), 1.74-1.36 (16H, m, CHAHB-2, 3 × CH3-6′′, CHAHB-7, CH-8,9, 
CH2-11, CHAHB-15) and  1.13-0.97 (8H, m, CHAHB-4, CH-14, CH3-18, CH3-19); 13C NMR 
(125 MHz, CDCl3) δ 172.9 (quat., C-1′′), 172.1 (quat., C-4′′), 151.6 (quat., C-17), 147.2 (CH × 
2, C-2′,6′), 139.9 (quat., C-5), 133.6 (CH, C-4′), 132.9 (quat., C-1′), 129.2 (CH, C-16), 123.0 
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(CH, C-5′), 122.3 (CH, C-6), 80.6 (quat., C-5′′), 74.0 (CH, C-3), 57.4 (CH, C-9), 50.2 (CH, C-
14), 47.2 (quat., C-13), 38.1 (CH2, C-1), 36.8 (CH2, C-4), 36.7 (quat., C-10), 35.1 (CH2, C-7), 
31.8 (CH2, C-12), 31.5 (CH2, C-15), 30.3 (CH, C-8), 29.6 (CH2 × 2, C-2′′,3′′), 28.0 (CH3 × 3, C-
6′′), 27.7 (CH2, C-2), 20.8 (CH2, C-11), 19.2 (CH3, C-19) and 16.5 (CH3, C-18); m/z (ES+) 1061 
([M+H]+, 100%); HRMS m/z (ES+) calcd. for C32H43NNaO4 [M+Na]+ requires 528.3084, found 
528.3090. 
 
17-(3-Pyridyl)androsta-5,16-dien-3β-ol  3-hemisuccinate, 352 
 
Trifluoroacetic acid (2 mL) was added to a solution of tert-butyl-17-(3-pyridyl)androsta-5,16-
dien-3β-ol 3-hemisuccinate 353 (200 mg, 0.40 mmol) in dichloromethane (10 mL) and stirred at 
room temperature overnight. The solvent was removed under reduced pressure to provide 17-(3-
pyridyl)androsta-5,16-dien-3β-ol  3-hemisuccinate 352 (164 mg, 0.50 mmol, 96%) as a white 
solid: Rf 0.00 (50:50, EtOAc:Cyclohexane, UV/KMnO4); m.p. 238-240 °C;   [𝛂]𝐃𝟐𝟎 +5.6, (c = 
1.0, CHCl3); νmax (thin film)/cm−1 3430, 1735, 1705, 1616, 1553, 1450, 1314, 1169, 1022;1H 
NMR (500 MHz, CDCl3) δ 8.64 (1H, s, br, CH-2′), 8.46 (1H, s, br, CH-6′), 7.71 (1H, dd, J 7.9, 
1.8 Hz, CH-4′), 7.28 (1H, dd, J 7.9, 5.0 Hz, CH-5′), 6.02 (1H, dd, J 2.9, 1.6 Hz, CH-16), 5.40 
(1H, d, J 4.6 Hz, CH-6), 4.68-4.61 (1H, m, CH-3), 2.70-2.60 (4H, m, CH2-2′′,3′′), 2.36-2.33 
(2H, m, CH2-1), 2.20 (1H, ddd, J 16.1, 6.4, 3.2 Hz, CHAHB-12), 2.09-2.01 (3H, m, CHAHB-7, 
CHAHB-12, CHAHB-15), 1.89-1.83 (2H, m, CHAHB-2, CHAHB-4), 1.74 (1H, ddd, J 21.8, 10.7, 
4.9 Hz, CH-8), 1.70-1.47 (6H, m, CHAHB-2, CHAHB-7, CH-9, CH2-11, CHAHB-15) and 1.18-
1.04 (8H, m, CHAHB-4, CH-14, CH3-18, CH3-19); 13C NMR (125 MHz, CDCl3) δ 175.9 (quat., 
C-4′′), 171.9 (quat., C-4′′), 151.2 (quat., C-17), 146.5 (CH × 2, C-2′,6′), 140.0 (quat., C-5), 
134.8 (CH, C-4′), 133.5 (quat., C-1′), 129.9 (CH, C-16), 123.5 (CH, C-5′), 122.3 (CH, C-6), 
74.2 (CH, C-3), 57.4 (CH, C-9), 50.2 (CH, C-14), 47.3 (quat., C-13), 38.1 (CH2, C-1), 36.9 
(CH2, C-4), 36.8 (quat., C-10), 35.1 (CH2, C-7), 31.8 (CH2, C-12), 31.5 (CH2, C-15), 30.4 (CH, 
C-8), 29.6, 29.3 (CH2 × 2, C-2′′,3′′), 27.7 (CH2, C-2), 20.8 (CH2, C-11), 19.3 (CH3, C-19) and 
16.6 (CH3, C-18); m/z (ES+) 1061 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C28H35NNaO4 
[M+Na]+ requires 472.2458, found 472.2466. 
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Pbf-(OtBu)2-RGD-abiraterone hemsuccinamide, 354 
 
 
Following general procedure B, with HATU (103 mg, 0.272 mmol), amine 351 (120 mg, 0.113 
mmol), abiraterone hemisuccinate (74 mg, 0.135 mmol) and diisopropylethylamine (distilled, 
59 mg, 75 µL, 0.453 mmol). Purification by silica gel chromatography, eluting with 
dichloromethane and methanol (100:0 to 97:3) provided hemisuccinamide 354 (167 mg, 0.11 
mmol, 83%) as pale yellow solid: Rf 0.78 (90:10, CH2Cl2, UV/cerium phosphomolybdate), m.p. 
45-49 °C, [𝛂]𝐃𝟐𝟎 -43.2, (c = 0.1, CHCl3, νmax (thin film)/cm−1 1931, 2975, 1843, 1731, 1684, 
1654, 1637, 1585, 1559, 1538, 1471, 1455, 1409, 1368, 1279, 1191, 1167; 1H NMR (500 MHz, 
CDCl3) δ 8.60 (1H, s, CH-21′), 8.45 (1H, d, J 4.8 Hz, CH-24′), 8.31 (1H, s, CH-40), 7.87 (2H, 
d, J 7.9 Hz, CH-42,46), 7.70-7.61 (4H, m, CH-43, 44,45,22′), 7.42 (1H, s, br, NH-amide), 7.32-
7.21 (6H, m, CH-33,34,36,37,23′, NH-amide), 6.48 (2H, s, br, NH-guanidine), 6.00-5.98 (1H, 
m, CH-16′), 5.33 (1H, d, J 4.6 Hz, CH-6′), 4.72 (1H, dt, J 13.1, 5.3 Hz, CH-4), 4.67-4.63 (1H, 
m, CH-30), 4.52 (1H, ddd, J 10.5, 5.4, 5.1 Hz, CH-3′), 4.26-4.18 (1H, m, CH-12), 3.93-3.87 
(2H, m, CH2-10), 3.22-3.14 (1H, m, CHAHB-31), 3.13-3.02 (3H, m CH2-15, CHAHB-31), 2.92 
(2H, s, CH2-25), 2.80 (1H, dd, J 17.0, 5.8, CHAHB-5), 2.73 (1H, dd, J 17.0, 5.1 Hz, CHAHB-5), 
2.69-2.65 (1H, m, CHAHB-49), 2.57-2.39 (9H, s, CH3-19, CH3-21, CH2-48, CHAHB-49), 2.31-
2.21 (3H, m, CH2-1′, CHAHB-12′), 2.11-1.79 (5H, m, CH3-28, CHAHB-7′, CHAHB-12′), 1.93-
1.21 (38H, m, 3 × CH3-1, 3 × CH3-8 , CH2-13, CH2-14, 2 × CH3-24, CH2-2′, CHAHB-4′, CHAHB-
7′, CH-8′, CH-9′ Hz, CH2-11′, CH2-15′) and 1.17-0.98 (8H, m, CHAHB-4′, CH-14′, CH3-18′, 
CH3-19′); 13C NMR (125 MHz, CDCl3) δ 175.6 (quat., C-39), 172.9, 172.9, 171.9, 171.8, 170.1, 
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169.8, 169.0 (quat., × 7, C-3,6,9,11,29,47,50), 160.0 (quat., C-38), 158.7 (quat., C-22), 156.3 
(quat., C-16), 151.4 (quat., C-17′), 150.7 (quat., C-35), 147.4 (CH, C-24′), 147.4 (CH, C-21′), 
139.7 (quat., C-5′), 138.3 (quat., C-17), 134.1 (CH, C-22′), 133.7 (quat., C-32), 133.6 (quat., C-
41), 133.3 (CH, C-44), 133.2 (quat., C-20′), 133.0 (quat., C-26), 132.2 (quat., C-20), 130.6 (CH 
× 2, C-43,45), 130.3 (CH × 2, C-34,36), 129.6 (CH, C-16′), 124.6 (quat., C-18), 123.2 (CH, C-
23′), 122.5 (CH, C-6′), 121.8 (CH × 2, C-33, 37), 121.6 (CH × 2, C-42,46), 103.8 (CH, C-40), 
86.4 (quat., C-23), 81.6 (quat., C-3), 81.4 (quat., C-7), 74.5 (CH, C-3′), 57.4 (CH, C-9′), 56.3 
(CH, C-30), 53.8 (CH, C-12), 50.9 (CH, C-14′), 49.4 (CH, C-4), 47.3 (quat., C-13′), 43.2 (CH2, 
C-25), 42.8 (CH2, C-10), 40.7 (CH2, C-15), 37.9 (CH2, C-1′), 37.5 (CH2, C-31), 37.5 (CH2, C-
5), 36.8 (CH2, C-4′), 36.7 (quat., C-10′), 35.1 (CH2, C-7′), 31.8 (CH2, C-12′), 31.5 (CH2, C-15′),  
30.3 (CH, C-8′), 29.8 (CH2, C-13), 29.6 (CH2, C-48), 29.6 (CH2, C-49), 28.6 (CH3 × 2, C-24), 
28.1 (CH3 × 3, C-1), 27.9 (CH3 × 3, C-8), 27.7 (CH2, C-2′), 25.5 (CH2, C-14), 20.8 (CH2, C-
11′), 19.3 (CH3, C-21), 19.2 (CH3, C-19′), 18.0 (CH3, C-19), 16.6 (CH3, C-18′),12.5 (CH3, C-
27); m/z (ES+) 1493 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C79H102N11O16S [M+H]+ 
requires 1492.7227, found 1492.7232. 
 
Abiraterone RGD-hemisuccinate, 355 
 
 
 
Following general procedure C with Pbf-(OtBu)2-RGD-abiraterone hemsuccinamide 354 (60 
mg, 49 µmol) and deprotecting cocktail (700 µL), to provide NO-abiraterone RGD-
hemisuccinate 355 (45 mg, 37 µmol, 75%) as a white powder: Rf 0.00 (90:10, CH2Cl2:MeOH, 
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UV/cerium phosphomolydate); m.p. 159-163 °C; [𝛂]𝐃𝟐𝟎 -10.0, (c = 0.4, 1:1 H2O:MeOH; νmax 
(KBr disc)/cm−1 2953, 2924, 2853, 1702, 1674, 1568, 1521, 1508, 1465, 1376, 1296, 1256, 
1201; 1H NMR (500 MHz, d6-DMSO) δ 8.78 (1H, s, br, CH-21′), 8.67-8.64 (2H, m, CH-24,24′), 
8.28-8.21 (3H, m, CH-22′, NH-Tyr-Arg, NH-Gly-Asp), 8.15 (1H, t, J 5.8 Hz, NH-Arg-Gly), 
8.08 (2H, d, J 8.5 Hz, CH-26,30), 7.79 (1H, tt, J 7.4, 2.5 Hz, CH-28), 7.76-7.72 (3H, m, CH-
27,29,23′), 7.52 (1H, t, J 5.2 Hz, NH-succinamide), 7.39-6.75 (7H, m, CH-17, 18, 20, 21, 3 × 
NH-guanidine), 6.35 (1H, t, J 2.8 Hz, CH-16′), 5.38 (1H, d, J 4.0 Hz, CH-6′), 4.59-4.53 (2H, m, 
CH-2, 14′), 4.48-4.41 (1H, m, CH-3′), 4.31 (1H, dd, J 13.8, 7.4 Hz, CH-8), 3.83-3.74 (2H, m, 
CH2-6), 3.12 (2H, dd, J 12.2, 6.3 Hz, CH2-11), 3.04 (1H, dd, J 14.3, 3.5 Hz, CHAHB-15), 2.78 
(1H, dd, J 13.9, 10.1 Hz, CHAHB-15), 2.70 (1H, dd, J 16.8, 5.9 Hz, CHAHB-3), 2.62 (1H, dd, J 
16.8, 6.9 Hz, CHAHB-3), 2.44-2.33 (4H, m, CH2-32,33), 2.29-2.22 (3H, m, CH2-1′, CHAHB-12′), 
2.14-1.96 (3H, m, CHAHB-7′, CHAHB-12′, CHAHB-15′), 1.86-1.31 (13H, m, CH2-9,10, CH2-1′, 
CHAHB-4′, CHAHB-7′, CH-8′,9′, CH2-11′, CHAHB-15′) and 1.15-0.98 (8H, m, CHAHB-4′, CH-
14′, CH3-18′,19′); 13C NMR (500 MHz, d6-DMSO) δ 174.9 (quat., C-23), 172.3, 171.7, 171.6, 
171.4, 171.4, 170.9, 168.5 (quat., × 7, C-1,4,5,7,13,31,34), 159.4 (quat., C-17′), 158.7 (quat., C-
22), 156.7 (quat., C-12), 150.5 (quat., C-19), 143.2 (CH, C-24′), 142.4 (CH, C-21′), 139.8 
(quat., C-5′), 138.2 (CH, C-22′), 134.3 (quat., C-16), 133.8 (quat., C-20′), 133.6 (quat., C-25), 
133.1 (CH, C-28), 132.0 (CH, C-16′), 130.3 (CH × 2, C-27,29), 129.8 (CH × 2, C-18,20), 125.4 
(CH, C-23′), 122.4 (CH × 2, C-26,30), 121.8 (CH, C-6′), 121.3 (CH × 2, C-17,21), 104.7 (CH, 
C-24), 73.3 (CH, C-3′), 56.9 (CH, C-9′), 54.9 (CH, C-13), 52.3 (CH, C-8), 50.0 (CH, C-14′), 
48.6 (CH, C-2), 46.7 (quat., C-13′), 41.6 (CH2, C-6), 40.5 (CH2, C-11), 37.7 (CH2, C-1′), 36.7 
(CH2, C-15), 36.4 (CH2, C-3), 36.3 (quat., C-10′), 36.1 (CH2, C-4′), 34.2 (CH2, C-7′), 31.5 (CH2, 
C-12′), 30.9 (CH, C-15′), 29.9 (CH2, C-9), 29.8 (CH, C-8′), 29.2, 29.1 (CH2 × 2, C-32,33), 27.3 
(CH2, C-2′), 25.0 (CH2, C-10), 20.3 (CH2, C-11′), 18.9 (CH3, C-19′) and 16.1 (CH3, C-18′); 
HRMS m/z (ES+) calcd. for C58H70N11O13 [M+H]+ requires 1128.5149, found 1128.5148. 
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Pbf-(OtBu)2-RGD-(4-nitrooxy)butyramide, 356 
 
 
Following general procedure B, with HATU (161 mg, 0.423 mmol), NH2-Arg(Pbf)-Gly-
Asp(OtBu)-OtBu 341 (150 mg, 0.320 mmol), 4-nitrooxybutanoic acid 258 (31 mg, 0.211 mmol) 
and diisopropylethylamine (distilled, 82 mg, 110 µL, 0.633 mmol). Purification by silica gel 
chromatography, eluting with dichloromethane and methanol (100:0 to 97:3) provided Pbf-
(OtBu)2-RGD-(4-nitrooxy)butyramide 356 (115 mg, 0.136 mmol, 65%) as a colourless glass: Rf 
0.61 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 78-81 °C; [𝛂]𝐃𝟐𝟎 -6.2, (c = 
0.1, CHCl3); νmax (thin film)/cm−1 1978, 2935, 1732, 1701, 1654, 1559, 1455, 1407, 1394, 1369, 
1279, 1258, 1154, 1108; 1H NMR (500 MHz, CDCl3) δ 7.76 (1H, t, J 5.0 Hz, NH-Arg-Gly), 
7.33-7.28 (2H, m, NH-Gly-Asp, NH-amide), 6.43-6.14 (3H, m, 3 × NH-guanidine), 4.65 (1H, 
dt, J 8.3, 4.5 Hz, CH-4), 4.52-4.45 (3H, m, CH-12, CH2-32), 3.97 (2H, d, J 5.1 Hz, CH2-10), 
3.30-3.17 (2H, m, CH2-15), 2.94 (2H, s, CH2-25), 2.80 (1H, dd, J 17.1, 5.3 Hz,  CHAHB-5), 2.67 
(1H, dd, J 17.1, 4.5 Hz, CHAHB-5), 2.55 (3H, s, CH3-28), 2.48 (3H, s, CH3-19), 2.39 (2H, t, J 
7.2, CH2-30), 2.07-2.01 (5H, m, CH3-21,31), 1.93-1.85 (1H, m, CHAHB-13), 1.77-1.67 (1H, m, 
CHAHB-13), 1.64-1.53 (2H, m, CH2-14), 1.46-1.38 (24H, m, 3 × CH3-1, 3 × CH3-8 Hz, 2 × CH3-
24); 13C NMR (125 MHz, CDCl3) δ 172.8, 172.5, 170.2, 170.1, 169.2 (quat. × 5, C-
3,6,9,11,29), 158.8 (quat., C-22), 156.6 (quat., C-16), 138.3 (quat., C-17), 132.7 (quat., C-26), 
132.2 (quat., C-20), 124.7 (quat., C-18), 117.5 (quat., C-27), 86.4, 82.6, 81.6 (quat. × 3, C-
2,7,23), 72.6 (CH2, C-32), 53.1 (CH, C-12), 49.4 (CH, C-4), 43.2 (CH2, C-25), 42.8 (CH2, C-
10), 40.4 (CH3, C-15), 37.3 (CH2, C-5), 31.8 (CH2, C-30), 29.2 (CH2, C-13), 28.6 (CH3 × 2, C-
24), 28.0, 27.9, (CH3 × 6, C-1,8), 25.3 (CH2, C-14), 22.6 (CH2, C-31), 19.3 (CH3, C-21), 18.0 
(CH3, C-19) and 12.5 (CH3, C-28); m/z (ES+) 842 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for 
C37H60N7O13S [M+H]+ requires 842.3964, found 842.3966. 
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Pbf-(OtBu)2-RGD-(4-(O-(3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide)butyramide, 
357 
 
 
 
Following general procedure B, with HATU (149 mg, 0.391 mmol), NH2-Arg(Pbf)-Gly-
Asp(OtBu)-OtBu 341 (139 mg, 0.195 mmol), 4-(3-carboxypropoxy)-3-(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide 261 (64 mg, 0.195 mmol) and diisopropylethylamine (distilled, 76 mg, 100 
µL, 0.586 mmol). Purification by silica gel chromatography, eluting with dichloromethane and 
methanol (100:0 to 97:3) provided peptide 357 (151 mg, 0.148 mmol, 76%) as a white solid: Rf 
0.64 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 69-71 °C, [𝛂]𝐃𝟐𝟎 +7.8, (c = 
0.1, CHCl3, νmax (thin film)/cm−1 2979, 2935, 1734, 1652, 1557, 1450, 1409, 1369, 1256, 1169, 
1167, 1089, 1107, 1023, 997; 1H NMR (500 MHz, CDCl3) δ 8.00 (2H, d, J 7.5 Hz, CH-36,40), 
7.80 (1H, s, br, NH-Arg-Gly), 7.69 (1H, t, J 7.7 Hz, CH-38), 7.56 (2H, t, J 7.8, CH-37,39), 
7.35-7.28 (2H, m, NH-Gly-Asp, NH-amide), 6.39-6.17 (3H, m, 3 × NH-guanidine), 4.64-4.60 
(1H, m, CH-4), 4.53-4.78 (1H, m, CH-12), 4.42-4.38 (2H, m, CH2-32), 4.00-3.92 (2H, m, CH2-
10), 3.30-3.14 (2H, m, CH2-15), 2.90 (2H, s, CH2-25), 2.77 (1H, dd, J 17.0, 5.3, CHAHB-5), 2.66 
(1H, dd, J 17.0, 3.7 Hz, CHAHB-5), 2.54-2.44 (8H, m, CH3-19, CH3-28,30), 2.17-2.11 (5H, m, 
CH3-21,31), 1.93-1.85 (1H, m, CHAHB-13), 1.75-1.65 (1H, m, CHAHB-13), 1.61-1.51 (2H, m, 
CH2-14) and 1.42-1.32 (24H, m, 3 × CH3-1, 3 × CH3-8, 2 × CH3-24); 13C NMR (125 MHz, 
CDCl3) δ 172.9, 172.6, 170.1, 169.8, 169.3 (quat. × 5, C-3,6,9,11,29), 158.9 (quat., C-34), 158.8 
(quat., C-22), 156.6 (quat., C-16), 138.3 (quat., C-17), 137.8 (CH, C-35), 135.8 (quat, C-38), 
132.7 (quat., C-26), 132.2 (quat., C-20), 129.7 (CH × 2, C-36,40), 128.5 (CH × 2, C-37,39), 
124.7 (quat., C-18), 117.5 (quat., C-27), 110.5 (CH, C-33), 86.4, 82.6, 81.6 (quat. × 3, C-
2,7,23), 70.7 (CH2, C-32), 53.1 (CH, C-12), 49.4 (CH, C-4), 43.2 (CH2, C-25), 42.8 (CH2, C-
10), 40.3 (CH3, C-15), 37.3 (CH2, C-5), 31.6 (CH2, C-30), 29.2 (CH2, C-13), 28.6 (CH3 × 2, C-
24), 28.0, 27.8, (CH3 × 6, C-1,8), 25.3 (CH2, C-14), 24.2 (CH2, C-31), 19.3 (CH3, C-21), 18.0 
(CH3, C-19), 12.5 (CH3, C-28); m/z (ES+) 1021 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for 
C45H65N8O15S2 [M+H]+ requires 1021.4005, found 1021.4008. 
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Pbf-(OtBu)2-RGD-(4-(O-carbonyl-N-3-phenylsydnonimine)butyramide, 358 
 
 
 
Following general procedure B, with HATU (145 mg, 0.38 mmol), NH2-Arg(Pbf)-Gly-
Asp(OtBu)-OtBu 341 (135 mg, 0.19 mmol), N-((3-carboxypropxy)carbonyl)-3-
phenylsydnonimine 266 (55 mg, 0.19 mmol) and diisopropylethylamine (distilled, 76 mg, 100 
µL, 0.59 mmol). Purification by silica gel chromatography, eluting with dichloromethane and 
methanol (100:0 to 97:3) provided Pbf-(OtBu)2-RGD-(4-(O-carbonyl-N-3-
phenylsydnonimine)butyramide 358 (150 mg, 0.16 mmol, 80%) as a pale yellow solid: Rf 0.64 
(90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 109-114 °C; [𝛂]𝐃𝟐𝟎 -23.9, (c = 
0.2, CHCl3, νmax (thin film)/cm−1 2934, 2978, 1734, 1700, 1684, 1654, 1651, 1635, 1575, 1561, 
1456, 1394, 1369, 1267, 1201, 1153, 1106; 1H NMR (500 MHz, CDCl3) δ 8.23 (1H, s, br, CH-
35), 8.03 (1H, s, br, NH-amide), 7.84 (2H, d, J 7.4 Hz, CH-37,41), 7.64 (1H, t, J 7.5 Hz, CH-
39), 7.59 (2H, t, J 7.8 Hz, CH-38,40), 7.40 (2H, s, br, NH-Arg-Gly, NH-Gly-Asp), 6.37-6.15 
(3H, m, 3 × NH-guanidine), 4.67-4.60 (1H, m, CH-4), 4.44-4.36 (1H, m, CH-12), 4.19-4.05 
(2H, m, CH2-32), 4.03-3.96 (1H, m, CHAHB-10), 3.94-3.88 (1H, m, CHAHB-10), 3.24-3.16 (2H, 
m, CH2-15), 2.90 (2H, s, CH2-25), 2.74 (1H, dd, J 17.6, 6.0 Hz, CHAHB-5), 2.66 (1H, dd, J 17.6, 
4.4 Hz, CHAHB-5), 2.51-2.49 (8H, m, CH3-19, CH3-28, CH2-30), 2.04-1.98 (5H, m, CH3-21, 
CH2-31), 1.89-1.84 (1H, m, CHAHB-13), 1.77-1.66 (1H, m, CHAHB-13), 1.65-1.53 (2H, m, CH2-
14) and 1.42-1.32 (24H, m, 3 × CH3-1, 3 × CH3-8, 2 × CH3-24); 13C NMR (125 MHz, CDCl3) δ 
175.0 (quat., C-34), 174.2, 173.4, 170.2, 170.1, 169.6 (quat. × 5, C-3,6,9,11,29), 161.2 (quat., 
C-33), 158.7 (quat., C-22), 156.5 (quat., C-16), 138.3 (quat., C-17), 133.7 (quat., C-26), 133.1 
(CH, C-39), 132.7 (quat, C-26), 132.2 (quat., C-20), 130.4 (CH × 2, C-37,41), 124.7 (quat., C-
18), 121.8 (CH × 2, C-38,40), 117.5 (quat., C-27), 103.7 (CH, C-35), 86.3, 86.2, 81.6 (quat. × 3, 
C-2,7,23), 65.0 (CH2, C-32), 53.8 (CH, C-12), 49.4 (CH, C-4), 43.2 (CH2, C-25), 42.8 (CH2, C-
10), 40.4 (CH3, C-15), 37.7 (CH2, C-5), 32.1 (CH2, C-30), 28.7 (CH2, C-13), 28.6 (CH3 × 2, C-
24), 28.0, 28.0, (CH3 × 6, C-1,8), 25.5 (CH2, C-14), 24.6 (CH2, C-31), 19.3 (CH3, C-21), 18.0 
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(CH3, C-19) and 12.5 (CH3, C-28); m/z (ES+) 984 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for 
C46H66N9O13S [M+H]+ requires 984.4495, found 984.4500. 
 
RGD-(4-Nitrooxy)butyramide trifluoroacetate, 359 
 
 
 
Following general procedure C with Pbf-(OtBu)2-RGD-(4-nitrooxy)butyramide 356 (60 mg, 71 
µmol) and deprotecting cocktail (700 µL), to provide RGD-(4-nitrooxy)butyramide 
trifluoroacetate 359 (35 mg, 61 µmol, 85%) as the white powder: Rf 0.00 (90:10, CH2Cl2, 
UV/cerium phosphomolybdate); m.p. 136 °C (decomp); [𝛂]𝐃𝟐𝟎 +4.2, (c = 0.3, 1:1 H2O:MeOH; 
νmax (KBr disc)/cm−1 3209, 1700, 1653, 1559, 1506, 1457, 1110; 1H NMR (500 MHz, d6-
DMSO) δ 11.85 (2H, s, br, 2 × CO2H), 8.25-8.13 (3H, m, 3 × NH-backbone), 7.54 (1H, s, br, 
NH-guanidine), 7.46-6.71 (4H, m, NH2-guanidine, NH-guanidine, CF3CO2H), 4.55-4.78 (3H, 
m, CH-2, CH2-16), 4.23 (1H, dd, J 13.4, 6.2 Hz, CH-8), 3.72 (2H, d, J 5.7 Hz, CH2-6), 3.08 
(1H, dd, J 13.0, 6.7 Hz, CH2-11), 2.66 (1H, dd, J 16.7, 6.7 Hz, CHAHB-3), 2.57 (1H, dd, J 16.7, 
6.4 Hz, CHAHB-3), 2.07 (2H, t, J 7.4 Hz, CH2-14), 1.89 (1H, tt, J 7.0, 6.8 Hz, CH2-15), 1.72-
1.62 (1H, m, CHAHB-9) and 1.54-1.43 (3H, m, CHAHB-9, CH2-10); 13C NMR (125 MHz, d6-
DMSO) 172.3, 171.8, 171.6, 171.5, 168.5 (quat. × 5, C-1,4,5,7,13), 156.6 (quat., C-12), 73.7 
(CH2, C-16), 53.4 (CH, C-8), 48.6 (CH, C-2), 41.6 (CH2, C-6), 40.5 (CH2, C-11), 36.1 (CH2, C-
3), 31.4 (CH2, C-14), 29.0 (CH2, C-9), 25.0 (CH2, C-10) and 22.3 (CH2, C-15); m/z (ES+) 697 
([M+H]+, 100%); HRMS m/z (ES+) calcd. for C18H28N7O10 [M+H]+ requires 479.1892, found 
478.1880. 
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RGD-(4-(O-(3-(Phenylsulfonyl)-1,2,5-oxadiazole 2-oxide)butyramide 
trifluoroacetate, 360 
 
 
 
Following general procedure C with Pbf-(OtBu)2-RGD-(4-(O-(3-(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide)butyramide 357 (90 mg, 88 µmol) and deprotecting cocktail (900 µL), to 
provide RGD-(4-(O-(3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide)butyramide trifluoroacetate 
360 (60 mg, 79 µmol, 90%) as a white powder: Rf 0.00 (90:10, CH2Cl2, UV/cerium 
phosphomolybdate); m.p. 115-121 °C (decomp); [𝛂]𝐃𝟐𝟎+11.4, (c = 0.1, 1:1 H2O:MeOH; νmax 
(KBr disc)/cm−1 2953, 2923, 2853, 1727, 1605, 1568, 1456, 1378, 1291, 1168, 1085; 1H NMR 
(500 MHz, d6-DMSO) δ 11.97 (2H, s, br, 2 × CO2H), 8.29 (1H, t, J 5.9 Hz, NH-Arg-Gly), 8.20-
8.16 (2H, m, NH-amide-Arg, NH-Gly-Asp), 8.04 (2H, d, J 7.6 Hz, CH-20,24), 7.92 (1H, tt, J 
8.0, 1.4 Hz, CH-22), 7.77 (2H, t, J 7.8 Hz, CH-21,23), 7.69 (1H, s, br, NH-guanidine), 7.35-
6.75 (4H, m, NH2-guanidine, NH-guanidine, CF3CO2H), 4.52 (1H, dd, J 13.8, 6.1 Hz, CH-2), 
4.42 (2H, t J 6.4 Hz, CH2-16), 4.29 (1H, dd, J 13.4, 6.2 Hz, CH-2), 3.79 (1H, dd, J 17.0, 5.5, 
CHAHB-6), 3.72 (1H, dd, J 16.9, 5.6 Hz, CHAHB-6), 3.11 (2H, dd, J 14.0, 7.9 Hz, CH2-11), 2.67 
(1H, dd, J 16.8, 6.1 Hz, CHAHB-3), 2.59 (1H, dd, J 16.8, 6.4 Hz, CHAHB-3), 2.33 (2H, t, J 7.5 
Hz, CH2-14), 2.00 (1H, tt, J 6.9, 6.8 Hz, CH2-15), 1.78-1.70 (1H, m, CHAHB-9) and 1.59-1.46 
(3H, m, CHAHB-9, CH2-10); 13C NMR (125 MHz, d6-DMSO) 172.4, 171.9, 171.8, 171.5, 168.5 
(quat. × 5, C-1,4,5,7,13), 158.9 (quat., C-17), 156.6 (quat., C-12), 137.1 (quat., C-19), 136.2 
(CH, C-22), 130.1 (CH × 2, C-20,24), 128.4 (CH × 2, C-21,23), 110.6 (quat., C-18), 71.0 (CH2, 
C-16), 52.3 (CH, C-8), 48.5 (CH, C-2), 41.6 (CH2, C-6), 40.5 (CH2, C-11), 36.4 (CH2, C-3), 
30.9 (CH2, C-14), 29.2 (CH2, C-9), 25.0 (CH2, C-10) and 24.2 (CH2, C-15); m/z (ES+) 657 
([M+H]+, 100%); HRMS m/z (ES+) calcd. for C24H33N8O12S [M+H]+ requires 657.1933, found 
657.1925. 
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RGD-(4-(O-Carbonyl-N-3-phenylsydnonimine)butyramide, 361 
 
 
 
Following general procedure C with Pbf-(OtBu)2-RGD-(4-(O-carbonyl-N-3-
phenylsydnonimine)butyramide 358 (60 mg, 61 µmol) and deprotecting cocktail (600 µL), to 
provide RGD-(4-(O-carbonyl-N-3-phenylsydnonimine)butyramide 361 (38 mg, 54 µmol, 88%) 
as a white powder: Rf 0.00 (90:10, CH2Cl2, UV/cerium phosphomolybdate); m.p. 158-160 °C 
(decomp); [𝛂]𝐃𝟐𝟎+8.0, (c = 0.2, 1:1 H2O:MeOH; νmax (KBr disc)/cm−1 2955, 2923, 2850, 1720, 
1604, 1577, 1450, 1362, 1301, 1150; 1H NMR (500 MHz, d6-DMSO) δ 8.63 (1H, s, CH-19), 
8.22-8.12 (3H, m, 3 × NH-backbone), 8.07 (2H, d, J 7.7 Hz, CH-21,25), 7.78 (1H, tt, J 6.4, 1.4 
Hz, CH-23), 7.73 (2H, t, J 8.0 Hz, CH-22,24), 7.48 (1H, t, J, NH-guanidine), 7.40-6.44 (4H, m, 
NH2-guanidine, NH-guanidine, CF3CO2H), 4.55 (1H, dd, J 14.2, 6.0 Hz, CH-2), 4.24 (1H, dd, J 
13.5, 6.3 Hz, CH-2), 4.03 (2H, t J 6.6 Hz, CH2-16), 3.73 (2H, d, J 5.9 Hz, CH2-6), 3.09 (2H, dd, 
J 13.2, 6.8 Hz, CH2-11), 2.68 (1H, dd, J 13.9, 6.1 Hz, CHAHB-3), 2.58 (1H, dd, J 16.6, 6.7 Hz, 
CHAHB-3), 2.52 (2H, t, J 7.5 Hz, CH2-14), 1.83 (1H, tt, J 7.2, 6.4 Hz, CH2-15), 1.73-1.65 (1H, 
m, CHAHB-9) and 1.56-1.44 (3H, m, CHAHB-9, CH2-10); 13C NMR (125 MHz, d6-DMSO) 
173.9 (quat., C-18), 172.3, 172.0, 171.8, 171.6, 168.6 (quat. × 5, C-1,4,5,7,13), 159.6 (quat., C-
17), 156.6 (quat., C-12), 133.6 (quat., C-20), 133.1 (CH, C-23), 130.3 (CH × 2, C-22,24), 122.5 
(CH × 2, C-21,25), 105.0 (CH, C-19), 64.3 (CH2, C-16), 52.3 (CH, C-8), 48.5 (CH, C-2), 41.6 
(CH2, C-6), 40.4 (CH2, C-11), 36.0 (CH2, C-3), 31.3 (CH2, C-14), 29.0 (CH2, C-9), 25.0 (CH2, 
C-10) and 24.7 (CH2, C-15); m/z (ES+) 620 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for 
C25H34N9O10 [M+H]+ requires 620.2423, found 620.2412. 
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NH2-Gly-OAll p-toluenesulfonate, 367420 
 
 
 
p-Toluenesulfonic acid (24.3 g, 135 mmol) was added to a solution of glycine 366 (9.4 g, 135 
mmol) in toluene (50 mL) and allyl alcohol (65 mL). The mixture was heated to reflux using a 
Dean-Stark trap overnight. The resultant solution was cooled to room temperature and the 
solvent removed under reduced pressure. The residue was cooled in an ice-bath and diethyl 
ether added. The precipitant was collected to afford NH2-Gly-OAll p-toluenesulfonate 367 (35.0 
g, 122 mmol, 90%) as an off-white solid, which was used without any further purification: m.p. 
130-132 °C; 1H NMR (500 MHz, CDCl3) δ 8.06 (3H, s, br, NH2.TsOH), 7.67 (2H, d, J 7.9 Hz, 
CH-8,12), 7.07 (2H, d, J 7.9 Hz, CH-9,11), 5.72 (1H, ddd, J 22.4, 10.5, 5.7 Hz, CH-4), 5.20 
(1H, dd, J 16.0, 1.2 Hz, CH-5-trans), 5.14 (1H, dd, J 10.5, 1.0 Hz, CH-5-cis), 4.46 (2H, d, J 5.7 
Hz, CH2-3), 3.72 (2H, s, CH2-1), 2.31 (3H, s, CH2-6); 13C NMR (125 MHz, CDCl3) δ 167.3 
(quat., C-2), 141.1 (quat., C-7), 140.5 (quat., C-10), 131.1 (CH, C-4), 129.0 (CH × 2, C-8,12), 
125.9 (CH × 2, C-9,11), 119.0 (CH2, C-5), 66.6 (CH2, C-3), 40.5 (CH2, C-1) and 21.3 (CH3, C-
6); m/z 138 ([M+Na]+, 100%). The data were in agreement with the literature values. 420 
 
Fmoc-Arg(Pbf)-Gly-OAll, 368 
 
 
 
HOBt hydrate (937 mg, 6.94 mmol) and triethylamine (702 mg, 1.0 mL, 6.94 mmol) were 
added to a solution of Fmoc-Arg(Pfb)-OH (1.5 g, 2.31 mmol) and NH2-Gly-OAll p-
toluenesulfonate 367 (995 mg, 3.47 mmol) in dry DMF (20 mL) cooled to 0 °C. After 15 min, 
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EDCI.HCl (1.33 g, 6.94 mmol) was stirred for a further 1 h at 0 °C. Following this time, the 
solution was allowed to warm to room temperature and stirred for 18 h. The resultant solution 
was poured into distilled water (200 mL) and extracted with ethyl acetate (4 × 30 mL). The 
organic layers were combined and washed with aq. HCl (2 N, 60 mL), saturated NaHCO3 
solution (60 mL), and brine (60 mL). The solution was dried over Na2SO4, filtered and the 
solvent removed under reduced pressure. The residue was uptaken in dichloromethane (50 mL) 
and adsorbed onto silica gel. Purification by silica gel chromatography eluting with 
dichloromethane and methanol (99:1 to 95:5) provided Fmoc-Arg(Pfb)-Gly-OAll 368 (1.54 g, 
2.07 mmol, 89%) as white crystalline solid: Rf 0.65 (90:10, CH2Cl2:MeOH); m.p. 65-69 °C, [𝛂]𝐃𝟐𝟎 -5.3 (c = 1.0, CHCl3); νmax (thin film)/cm−1 1730, 1690, 1550, 1451, 1410, 1380, 1245, 
1110, 1034, 994; 1H NMR (500 MHz, CDCl3) δ 7.73-7.69 (3H, m, CH-32,35, NH-Arg-Gly), 
7.54 (2H, dd, J 7.2, 4.1 Hz, CH-29,36), 7.34 (2H, t, J 7.5 Hz, CH-31,36), 7.23 (2H, ddd, J 15.0, 
7.5, J 2.9 Hz, CH-30, 37), 6.38 (2H, s, NH-guanidine, NH-sulfonamide), 6.19 (2H, , NH-Fmoc, 
NH-guanidine), 5.83 (1H, ddd, J 22.6, 11.1, 5.7 Hz, CH-2), 5.27 (1H, dd, J 16.5, 1.2 Hz, CH-1-
trans), 5.19 (1H, dd, J 10.5, 1.0 Hz, CH-1-cis), 4.55 (2H, d, J 5.5 Hz, CH2-3), 4.38 (1H, dd, J 
8.1, 12.8 Hz, CH-7), 4.30 (2H, d, J 6.9 Hz, CH2-26), 4.11 (1H, t, J 7.5 Hz, CH-27), 4.07 (1H, 
dd, J 18.0, 6.0 Hz, CHAHB-5), 3.92 (1H, dd, J 17.6, 5.5 Hz, CHAHB-5), 3.89-3.31 (1H, m, 
CHAHB-10), 3.24-3.17 (1H, m, CHAHB-10), 2.89 (2H, s, CH2-21), 2.57 (3H, s, CH2-24), 2.48 
(3H, s, CH2-14), 2.07 (3H, s, CH2-16), 1.98-1.91 (1H, m, CHAHB-9), 1.77-1.70 (1H, m, CHAHB-
9), 1.65-1.60 (2H, m,  CH2-8), 1.41 (6H, s, CH3 × 2, CH2-19, 20); 13C NMR (125 MHz, CDCl3) 
δ 173.0 (quat., C-4), 169.6 (quat., C-6), 158.8 (quat., C-22), 156.4 (quat., C-25), 156.3 (quat., C-
11), 143.9, 143.7 (quat., × 2, C-28,39), 141.2 (quat., × 2, C-33,34), 138.3 (quat., C-12), 132.6 
(quat., C-17), 132.3 (quat., C-15),  131.5 (CH, C-2), 127.7 (quat., × 2, C-31,36), 127.1 (quat., × 
2, C-30,37), 125.2 (quat., × 2, C-29,38), 124.8 (quat., C-13), 120.0 (quat., × 2, C-32,35), 118.8 
(CH2, C-1), 117.6 (quat., C-23), 86.5 (quat., C-18), 67.1 (CH2, C-26), 66.0 (CH2, C-3), 54.1 
(CH, C-7), 47.1 (CH, C-27), 43.2 (CH2, C-21), 41.2 (CH2, C-5), 40.2 (CH2, C-10), 30.0 (CH2, 
C-9), 28.6 (CH3 × 2, C-19, 20), 25.2 (CH2, C-8), 19.4 (CH3, C-16), 18.0 (CH3, C-14) and 12.3 
(CH3, C-24); m/z (ES+) 768 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C39H47N5NaO8S 
[M+Na]+ requires 768.3043, found 768.3047. 
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NH2-Arg(Pbf)-Gly-OAll, 369 
 
 
Piperidine (3 mL, 30.4 mmol) was added to a solution of Fmoc-Arg(Pfb)-Gly-OAll 368 (1.5 g, 
2.01 mmol) in dry DMF (15 mL) cooled in an ice-bath. After addition, the ice-bath was 
removed and the solution stirred for 15 min. The solvent was evaporated under reduced pressure 
to yield a yellow residue. The residue suspended in dichloromethane and adsorbed onto silica 
gel. Purification by silica gel chromatography eluting with dichloromethane and methanol 
(100:0 to 90:0) provided NH2-Arg(Pbf)-Gly-OAll 369 (1.0 g, 1.91 mmol, 95%) as a colourless 
glass: Rf 0.23 (90:10, CH2Cl2:MeOH); m.p. 48-51 °C; [𝛂]𝐃𝟐𝟎 -1.1 (c = 1.0, CHCl3); νmax (thin 
film)/cm−1 3337, 2973, 2932, 1746, 1683, 1651, 1455, 1253, 1105, 1034, 993; 1H NMR (500 
MHz, CDCl3) δ 8.02-7.99 (2H, m, NH × 2, NH-peptide, NH-guanidine), 6.40 (3H, s, br, NH2, 
NH-guanidine, 5.87 (1H, ddt, J 17.2, 10.4, 5.7, Hz, CH-2), 5.30 (1H, dd, J 17.2, 1.4 Hz, CH-1-
trans), 5.22 (1H, dd, J 10.4, 1.1 Hz, CH-1-cis), 4.59 (2H, d, J 5.7 Hz, CH2-3), 4.00 (2H, d, J 5.8 
Hz, CH2-5), 3.52 (1H, J 7.1 Hz, CH-7), 3.23-3.16 (2H, m, CH2-10), 2.93 (2H, s, CH2-21), 2.54 
(3H, s, CH2-24), 2.47 (3H, s, CH2-14), 2.05 (3H, s, CH2-16), 1.84-1.78 (1H, m, CHAHB-9), 1.65-
1.58 (3H, m, CH2-8, CHAHB-9) and 1.43 (6H, s, CH2-19, 20); 13C NMR (75 MHz, CDCl3) δ 
175.5 (quat., C-4) 169.8 (quat., C-6), 158.8 (quat., C-22), 156.5 (quat., C-11), 138.3 (quat., C-
12), 132.8 (quat., C-17), 132.2 (quat., C-15), 131.5 (CH, C-2), 124.7 (quat., C-13), 118.9 (CH2, 
C-1), 117.6 (quat., C-23), 86.5 (quat., C-18), 66.0 (CH2, C-3), 54.1 (CH, C-7), 43.2 (CH2, C-
21), 41.0 (CH2, C-5), 40.6 (CH2, C-10), 31.7 (CH2, C-9), 28.6 (CH3 × 2, C-19, 20), 25.3 (CH2, 
C-8), 19.3 (CH3, C-16), 18.0 (CH3, C-14) and 12.5 (quat., C-24); m/z (ES+) 546 ([M+Na]+, 
100%); HRMS m/z (ES+) calcd. for C24H37N5NaO6S [M+Na]+ requires 546.2362, found 
546.2356. 
 
 
 
 
 
6
H2N 7
8 9
10 NH
11
HN NH
O
H
N
S 12 23 22
1715
13
O
O 21
18O
24
14
16
19
20
5
4 O
O
3
2
1
Appendix: Experimental 
 
	   343	  
Fmoc-Tyr-(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-OAll, 370 
 
 
 
HATU (949 mg, 2.49 mmol) was added to a solution of NH2-Arg(Pbf)-Gly-OAll 369 (872 mg, 
1.66 mmol) and (S)-N-(((4-(2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-
carboxyethyl)phenoxy)carbonyl)-3-phenylsydnonimine  321 (982 mg, 1.66 mmol) in dry 
dichloromethane (30 mL) cooled to 0 °C. The solution was stirred for 15 min and 
diisopropylethylamine (distilled, 323 mg, 430 µL, 2.49 mmol) was added. The solution was 
allowed to warm to room temperature and stirred for 18 h. The resultant solution was diluted 
with dichloromethane (50 mL) and washed with aq. citric acid (10%, 100 mL), saturated 
NaHCO3 (100 mL) and brine (20 mL). The organic layer was separated and dried over Na2SO4, 
filtered and the solvent removed under reduced pressure. The resultant residue was uptaken in 
dichloromethane and adsorbed onto silica gel. Purification by silica gel chromatography eluting 
with dichloromethane and methanol (100:0, to 95.5:0.5, to 98:2) provided Fmoc-Tyr-(O-
carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-OAll 370 (1.59 g, 1.49 mmol, 87%) as a white 
solid: Rf 0.57 (90:10, CH2Cl2:MeOH); m.p. 128-131 °C; [𝛂]𝐃𝟐𝟎 +0.9 (c = 1.0, CHCl3); νmax (thin 
film)/cm−1 2361, 1701, 1656, 1580, 1539, 1509, 1470, 1451, 1368, 1276, 1191, 1105, 1033, 
1018, 941; 1H NMR (500 MHz, CDCl3) δ 8.23 (1H, s, CH-36), 7.80 (2H, d, J 8.2 Hz, CH-
50,53), 7.69 (2H, d, J 7.6 Hz, CH-38,42), 7.66 (1H, t, J 7.3 Hz, CH-40), 7.58 (2H, t, J 7.8 Hz, 
CH-39,41), 7.51 (2H, d, J 7.2 Hz, CH-47,56), 7.32 (2H, t, J 7.8 Hz, CH-49,54), 7.23 (2H, t, J 
7.3 Hz, CH-48,55), 7.17 (2H, d, J 8.1 Hz, CH-29,33), 7.07 (2H, d, J 8.1 Hz, CH-30,32), 6.40 
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(2H, s, br, NH-sulfonamide, NH-guanidine), 5.99 (1H, s, br, NH-Fmoc), 5.80 (1H, ddt, J 16.9, 
10.3, 5.1 Hz, CH-2), 5.23 (1H, d, J 16.9 Hz, CHAHB-1-trans), 5.15 (1H, d, J 10.3 Hz, CHAHB-1-
cis), 4.48-4.47 (4H, m, CH2-3, CH-7,26), 4.35 (1H, dd, J 10.6, 7.6 Hz, CHAHB-44), 4.19 (1H, 
dd, J 11.6, 7.6 Hz, CHAHB-44), 4.06 (1H, t, J 7.6 Hz, CH-45), 3.97-3.95 (2H, m, CH2-10), 3.17-
3.12 (2H, m, CH2-5), 3.07 (2H, d, J 4.2 Hz, CH2-27), 2.87 (2H, s, CH2-21), 2.52 (3H, s, CH2-
14), 2.46 (3H, s, CH2-16), 2.02 (3H, s, CH2-24), 1.90-1.82 (1H, m, CHAHB-8), 1.68-1.63 (1H, 
m, CHAHB-8) and 1.46-1.39 (8H, m, CH2-9, CH2-19,20); 13C NMR (75 MHz, CDCl3) δ 175.5 
(quat., × 2, C-4,35), 172.0 (quat., C-6), 171.6 (quat., C-25), 169.5 (quat., C-34), 159.8 (quat., C-
17), 159.7 (quat., C-11), 156.4 (quat., C-43), 150.8 (quat., C-31), 143.9, 143.7 (quat., × 2, C-46, 
57), 141.2 (quat., C-41, 52), 139.7 (quat., C-12), 133.6 (CH, C-40), 133.3 (quat., C-37), 133.1 
(quat., C-28), 132.8 (quat., C-22), 132.5 (quat., C-15), 131.6 (CH, C-2), 130.6 (CH × 2, C-
39,41), 130.1 (CH × 2, C-29,33), 127.7 (CH × 2, C-49,54), 127.1 (CH × 2, C-48,55), 125.1 (CH 
× 2, C-47,56), 124.8 (quat., C-13), 122.0 (CH × 2, C-30,32), 121.7 (CH × 2, C-38,42), 119.9 
(CH × 2, C-50,53), 118.7 (CH2, C-1), 117.6 (quat., C-23), 103.8 (CH, C-36), 86.5 (quat., C-18), 
67.2 (CH2, C-44), 65.9 (CH2, C-3), 54.3 (CH, C-26), 53.5 (CH, C-7), 47.0 (CH, C-45), 43.2 
(CH2, C-21), 41.2 (CH2, C-5), 40.6 (CH2, C-10), 37.7 (CH2, C-27), 29.6 (CH2, C-8), 28.6 (CH3 
× 2, C-19, 20), 25.1 (CH2, C-9), 19.3 (CH3, C-16), 18.0 (CH3, C-14) and 12.5 (CH3, C-24); m/z 
(ES+) 1118 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C57H61N9NaO12S [M+Na]+ requires 
1118.4058, found 1118.4062. 
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NH2-Tyr-(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-OAll, 364 
 
 
 
Piperidine (3.0 mL, 30.4 mmol) was added to a solution of Fmoc-Tyr-(O-carbonyl-N-3-
phenylsydnonimine)-Arg(Pbf)-Gly-OAll 370 (1.01 g, 0.92 mmol) in dry DMF (15 mL) cooled 
in an ice-bath. After addition, the ice-bath was removed and the solution stirred for 15 min. The 
solvent was evaporated under reduced pressure to yield a yellow residue. The residue suspended 
in dichloromethane and adsorbed onto silica gel. Purification by silica gel chromatography, 
eluting with dichloromethane and methanol (100:0 to 90:10), provided NH2-Tyr-(O-carbonyl-N-
3-phenylsydnonimine)-Arg(Pbf)-Gly-OAll 364 (725 mg, 0.83 mmol, 82%) as a yellow 
crystalline solid; Rf 0.31 (90:10, CH2Cl2:MeOH); m.p. 103-107 °C; [𝛂]𝐃𝟐𝟎 +13.3 = 1.0, CHCl3); 
νmax (thin film)/cm−1 2928, 2926, 2854, 1745, 1650, 1583, 1558, 1508, 1471, 1408, 1369, 1283, 
1193, 1106, 975, 852; 1H NMR (500 MHz, CDCl3) δ 8.41 (1H, s, CH-36), 8.02-7.83 (4H, m, 
NH2, CH-38, 42), 7.70-7.61 (4H, m, NH-Arg-Gly, CH-39,40,41), 7.17 (2H, d, J 7.2 Hz, CH-
29,33), 7.06 (2H, d, J 7.2 Hz, CH-30,32), 6.48 (2H, s, br, NH-sulfonamide, NH-guanidine), 
5.83 (1H, ddt, J 17.1, 10.3, 5.0 Hz, CH-2), 5.27 (1H, d, J 17.1 Hz, CHAHB-1-trans), 5.19 (1H, d, 
J 10.3 Hz, CHAHB-1-cis), 4.56-4.50 (3H, m, 3H, CH2-3, CH-7), 4.01-3.91 (2H, m, CH2-5), 3.76-
3.71 (1H, m, CH-26), 3.21-3.15 (2H, m, CH2-10), 2.94-2.90 (4H, m, CH2-27, CH2-21), 2.54 
(3H, s, CH-14), 2.47 (3H, s, CH2-16), 2.05 (3H, s, CH2-24), 1.89-1.84 (1H, m, CHAHB-8), 1.70-
1.64 (1H, m, CHAHB-8) and 1.46-1.41 (8H, m, CH2-9, CH2-19,20); 13C NMR (125 MHz, 
CDCl3) 175.5 (quat., C-35), 172.3 (quat., C-4), 170.3 (quat., × 2, C-6,25), 169.5 (quat., C-34), 
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158.7 (quat., C-17), 156.5 (quat., C-11), 150.8 (quat., C-31), 138.8 (quat., C-12), 133.7 (quat., 
C-37), 133.3 (CH, C-40), 133.1 (quat., C-28), 132.8 (quat., C-22), 132.3 (quat., C-15), 131.6 
(CH, C-2), 130.6 (CH × 4, C-29,33,38,42), 124.7 (quat., C-13), 122.1 (CH × 2, C-30,32), 121.6 
(CH × 2, C-39,41), 118.8 (CH2, C-1), 117.5 (quat., C-23), 104.0 (CH, C-46), 86.4 (quat., C-18), 
65.9 (CH2, C-3), 55.7 (CH, C-26), 52.6 (CH, C-7), 43.2 (CH2, C-21), 42.0 (CH2, C-5), 40.5 
(CH2, C-27), 41.2 (CH2, C-10), 29.8 (CH2, C-8), 28.6 (CH3 × 2, C-19, 20), 25.1 (CH2, C-9), 19.3 
(CH3, C-16), 18.0 (CH3, C-14) and 12.5 (CH3, C-24); m/z (ES+) 896 ([M+Na]+, 100%); HRMS 
m/z (ES+) calcd. for C42H11N9NaO10S [M+Na]+ requires 896.3372, found 896.3373. 
 
NH2-D-Phe-OBn p-toluenesulfonate, 371378 
 
 
 
p-Toluenesulfonic acid (6.9 g, 36.1 mmol) was added to a solution of D-phenylalanine 371 (5.0 
g, 30.4 mmol) in toluene (50 mL) and benzyl alcohol (65 mL). The mixture was heated to reflux 
using a Dean-Stark trap overnight. The resultant solution was cooled to room temperature and 
then in an ice-bath and diethyl ether added. The precipitant was collected to recrystallised from 
toluene to afford NH2-D-Phe-OBn p-toluenesulfonate 372 (10.8 g, 25 mmol, 81%) as white 
waxy crystals: m.p. 120-121 °C (toluene); [𝛂]𝐃𝟐𝟎-7.1, (c = 1.0, MeOH [S enantiomer, Lit.421 
+7.2, (c = 1.0, MeOH]; 1H NMR (500 MHz, CDCl3) δ 8.49 (3H, s, br, NH2.TosOH), 7.51 (2H, 
d, J 8.0 Hz, CH-19,23), 7.36-7.10 (10H, m, CH-4,5,6,7,8,12,13,14,15,16), 7.13 (2H, d, J 8.0 Hz, 
CH-20,22), 5.13 (2H, s, CH2-10), 4.38 (1H, t, J 6.7 Hz, CH-1), 3.16 (1H, dd, J 14.1, 6.0 Hz, 
CHAHB-2), 3.06 (1H, dd, J 13.8, 7.5 Hz, CHAHB-2), 2.85 (3H, s, CH2-17); 13C NMR (125 MHz, 
CDCl3) δ 169.4 (quat., C-9), 138.8 (quat., C-18), 138.3 (quat., C-21), 135.3 (CH, C-14), 134.9 
(CH, C-6), 129.1, 128.9, 128.6, 128.0 (CH × 6, C-4,5,8,7,19,23), 128.5 (CH × 2, CH-20,22), 
127.9 (quat., C-3), 127.7 (quat., C-11), 126.0 (CH × 2, CH-19,23), 67.6 (CH2, C-10), 53.7 (CH, 
C-1), 36.5 (CH2, C-2) and 21.3 (CH3, C-17); m/z 279 ([M+Na]+, 100%). The data were in 
agreement with the literature values.378 
 
 
 
 
 
9
H2N 1
O
O 21
18
22
20
23
19
17
S
O
O OH
10
2
3
8
7
6
5
4
11
16
15
14
13
12
Appendix: Experimental 
 
	   347	  
Fmoc-Asp(OtBu)-F, 374379 
 
 
 
Cyanuric fluoride (656 mg, 420 µL. 4.86 mmol) was added to a solution of Fmoc-Asp(OtBu)-
OH 373 (1.00 g, 2.43 mmol) in dry dichloromethane (13 mL). To this was added pyridine (200 
µL, 2.43 mmol) and the solution was stirred for 3 h. The resulting suspension was diluted with 
dichloromethane (10 mL) and washed with ice-cold water (20 mL × 2), dried over MgSO4. The 
mixture was filtered and the solvent removed under reduced pressure to give Fmoc-Asp(OtBu)-
F 374 (940 mg, 2.28 mmol, 94%) as a pale pink solid, which was used without any further 
purification: m.p. 74-76 °C, [Lit.379 74-75 °C]; [𝛂]𝐃𝟐𝟎 +3.9 (c = 0.5, EtOAc, [Lit.379 +4.0 (c = 
0.5, EtOAc]; 1H NMR (500 MHz, CDCl3) δ 7.77 (2H, d, J 7.6 Hz, CH-2,12), 7.59 (2H, d, J 7.4 
Hz, CH-5,9), 7.41 (2H, t, J 7.4 Hz, CH-3,11), 7.32 (2H, t, J 7.4 Hz, CH-4,10), 5.72 (1H, NH-
Fmoc), 4.83 (1H, ddd, J 12.0, 8.0, 4.0 Hz, CH-16), 4.48 (1H, dd, J 10.6, 7.2 Hz, CHAHB-14), 
4.39 (1H, dd, J 10.5, 7.3 Hz, CHAHB-14), 4.25 (1H, t, J 7.0 Hz, CH-7), 3.00 (1H, dd, J 17.7, 4.7 
Hz, CHAHB-17), 2.82 (1H, dd, J 17.7, 4.2 Hz, CHAHB-17) and 1.49 (9H, s, CH3 × 3, CH2-20); 
13C NMR (125 MHz, CDCl3) δ 169.6 (quat., C-18), 161.5 (quat., d, J 366.7 Hz, C-21), 155.4 
(quat., C-15), 143.6, 143.5 (quat., × 2, C-6,8), 141.3 (quat., × 2, C-1,13), 127.4 (CH × 2, C-
3,11), 125.4 (CH × 2, C-4,10), 120.1 (CH × 2, C-2,12), 83.0 (quat., C-19), 67.6 (CH2, C-14), 
49.4 (CH, d, J 60.8 Hz, C-16), 47.0 (CH, C-7), 37.3 (CH2, C-17) and 28.0 (CH3 × 3, CH2-20); 
19F NMR (376 MHz, CDCl3) δ 28.2 (s, COF); m/z (ES+) 414 ([M+H]+, 100%). The data were in 
agreement with the literature values.379  
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Fmoc-Asp(OtBu)-D-Phe-OBn, 375379 
 
 
 
Fmoc-Asp(OtBu)-F 374 (940 mg, 2.28 mmol in dry CH2Cl2, 10 mL) was added dropwise to a 
solution of NH2-D-Phe-OBn p-toluenesulfonate 372 (1.07 g, 2.51 mmol) and 
diispropylethylamine (distilled, 657 mg, 870 µL, 5.01 mmol) in dry dichloromethane (20 mL) 
cooled to -20 °C and stirred for 1 hour. The solution as diluted with dichloromethane (20 mL) 
and washed with saturated sodium bicarbonate (30 mL), brine (30 mL), dried over MgSO4. The 
mixture was filtered and the solvent evaporated under reduced pressure to give an off-white 
residue. The residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification 
by silica gel chromatography eluting with ethyl acetate and hexanes (5:95) provided Fmoc-
Asp(OtBu)-D-Phe-OBn 375 (1.00 g, 1.54 mmol, 68%) as a white crystalline solid: m.p. 79-81 
°C; Rf 0.85 (50:50, EtOAc:PE); [𝛂]𝐃𝟐𝟎 +10.1 (c = 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 
7.78 (2H, d, J 7.6 Hz, CH-2,12), 7.59-7.56 (2H, m, CH-5,9), 7.41 (2H, t, J 7.4 Hz, CH-3,11), 
7.36-7.27 (7H, m, CH-4,10,25,26,27,28,29), 7.21-7.16 (3H, m, CH-33,37, 35), 7.08-7.02 (3H, 
m, CH-34, 36, NH-Asp-Phe), 5.98 (2H, d, J 8.3, NH-Fmoc), 5.16 (1H, d, J 12.1 Hz, CHAHB-
31), 5.11 (1H, d, J 12.1 Hz, CHAHB-31), 4.91-4.85 (1H, m, CH-22), 4.58-4.53 (1H, m, CH-16), 
4.41-4.32 (2H, m, CH2-14), 4.21 (1H, dd, J 12.8, 6.3 Hz, CH-7), 3.17-3.06 (2H, m, CH2-23), 
2.89-2.84 (1H, m, CHAHB-17), 2.61-2.55 (1H, m, CHAHB-17) and 1.45 (9H, app, d, CH3 × 3, 
CH3-20, major and minor rotamer); 13C NMR (125 MHz, CDCl3) δ 171.3 (quat., C-30), 170.9 
(quat., C-21), 170.2 (quat., C-18), 156.0 (quat., C-15), 143.8, 143.7 (quat., × 2, C-6,8), 141.3 
(quat., × 2, C-1,13), 135.3 (CH, C-35), 135.1 (quat., C-32), 129.3 (CH × 4, C-26, 28, 34, 36), 
128.6 (CH × 5 and quat., C-24,25,29,27,33,37), 127.8 (CH × 2, C-3,11), 127.1 (CH × 2, C-
4,10), 125.2 (CH × 2, C-5,9), 120.1 (CH × 2, C-2,12), 82.0 (quat., C-19), 67.4 (CH2, C-31), 67.3 
(CH2, C-14), 53.5 (CH, C-16), 51.0 (CH, C-22), 47.1 (CH, C-7), 37.8 (CH2, C-23), 37.4 (CH2, 
C-17) and 28.0 (CH3 × 3, C-20 × 3); m/z (ES+) 671 ([M+Na]+, 100%). The data were in 
agreement with the literature values.380 
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Fmoc-Asp(OtBu)-D-Phe-OH, 365380 
 
Palladium on carbon (5%, 363 mg) was added to a solution of Fmoc-Asp(OtBu)-D-Phe-OBn 
375 (3.63 g, 5.60 mmol) and ammonium formate (1.06 g, 16.8 mmol) in THF:MeOH (1:1, 40 
mL) cooled in an ice-bath. The resulting suspension was stirred for 30 min. The resultant 
suspension was filtered through Celite and evaporated under reduced pressure to give a 
colourless residue. This was uptaken in dichloromethane and adsorbed onto silica gel. 
Purification by silica gel chromatography eluting with dichloromethane and methanol (90:10) 
provided Fmoc-Asp(OtBu)-D-Phe-OH 365 (2.81 g, 4.76 mmol, 85%) as a white crystalline solid 
as a mixture of rotamers: Rf 0.23 (50:50, EtOAc:PE); m.p. 160-162 °C [Lit.380 159-162 °C, 
Carpino et al.380); [𝛂]𝐃𝟐𝟎 -5.5, (c = 1.0, CHCl3); 1H NMR (500 MHz, d6-DMSO) δ 8.14 (1H, d, J 
8.0, NH-Fmoc, minor rotamer), 7.94 (1H, d, J 7.9, NH-Fmoc, major rotamer), 7.89 (2H, d, J 7.3 
Hz, CH-6,9), 7.70 (2H, t, J 6.7 Hz, CH-3,12), 7.62 (1H, d, J 8.6, NH-peptide, major rotamer), 
7.57 (1H, d, J 8.6, NH-peptide, minor rotamer), 7.41 (2H, d, J 7.3 Hz, CH-3,12), 7.31 (2H, t J 
7.3 Hz, CH-4, 11), 7.26-7.15 (5H, m, CH-25,26,27,28,29), 4.45-4.36 (2H, m, CH-16,22), 4.32-
4.20 (3H, m, CH2-14, CH-1), 3.08-3.02 (1H, m, CHAHB-23), 2.91 (1H, dd, J 8.6, J 13.8 Hz, 
CHAHB-23), 2.61 (1H, dd, J 15.9, 4.2 Hz, CHAHB-17), 2.41 (1H, dd, J 16.6, 9.0 Hz, CHAHB-17) 
and 1.36-1.35 (9H, m, CH2-20, major and minor rotamer.); 13C NMR (125 MHz, d6-DMSO) δ 
173.2 (quat., C-30), 171.2 (quat., C-21), 169.7 (quat., C-18), 156.2 (quat., C-15) 144.3, 144.2 
(quat., × 2, C-6,8), 141.2 (quat. × 2, C-1,13), 137.8 (quat., C-24), 129.7 (CH × 2, C-26,28), 
128.7 (CH × 2, C-25, 29), 128.2 (CH, C-27), 127.6 (CH × 2, C-3,11), 126.9 (CH × 2, C-4,10), 
125.8 (CH × 2, C-5,9), 120.6 (CH × 2, C-2,12), 80.6 (quat., C-19), 66.3 (CH2, C-14), 53.9 (CH, 
C-16), 51.8 (CH, C-22), 47.0 (CH, C-7), 38.0 (CH2, C-23), 37.1 (CH2, C-17) and 28.2 (CH3 × 3, 
C-20 × 3); m/z (ES+) 557 ([M-H]+, 100%). The data were in agreement with the literature 
values.380 
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Fmoc-Asp(OtBu)-D-Phe-Tyr-(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-
OAll, 376 
 
HATU (431 mg, 1.13 mmol) was added to a solution of NH2-Tyr-(O-carbonyl-N-3-
phenylsydnonimine)-Arg(Pbf)-Gly-OAll 374 (660 mg. 0.756 mmol) and Fmoc-Asp(OtBu)-D-
Phe-OH 375 (422 mg, 0.756 mmol) in dry dichloromethane (50 mL) cooled to 0 °C. The 
solution was stirred for 15 min and diisopropylethylamine (distilled, 147 mg, 200 µL, 1.13 
mmol) was added. The solution was allowed to warm to room temperature and stirred for 18 h. 
The resultant solution was diluted with dichloromethane (50 mL) and washed with aq. citric 
acid (10%, 50 mL), saturated NaHCO3 (50 mL) and brine (50 mL). The organic layer was 
separated and dried over Na2SO4, filtered and the solvent removed under reduced pressure. The 
resultant residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification by 
silica gel chromatography eluting with dichloromethane and methanol (100:0, to 97:3) provided 
Fmoc-Asp(OtBu)-D-Phe-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-OAll 376 (880 
mg, 0.622 mmol, 82%) as a pale yellow solid: Rf 0.78 (90:10, CH2Cl2:MeOH); m.p. 138-143 
°C; [𝛂]𝐃𝟐𝟎-20.1, (c = 1.0, CHCl3); νmax (thin film)/cm−1 2926, 2852, 1729, 1884, 1654, 1651, 
1635, 1586, 1537, 1508, 1471, 1367, 1280, 1212, 1191, 1168, 1106, 1033, 971; 1H NMR (500 
MHz, CDCl3) δ 8.18-8.17 (1H, m, CH-36), 7.80-7.78 (2H, m, CH-38,42), 7.75-7.72 (2H, m, 
CH-65,68), 7.71-7.67 (1H, m, CH-40), 7.64-7.61 (2H, m, CH-39,41), 7.59-7.55 (2H, m, CH-
62,71), 7.39-7.36 (2H, m, CH-64,69), 7.31-7.28 (2H, m, CH-63,70), 7.26-7.15 (4H, m, CH-
47,48,50,51), 7.13-7.03 (5H, m, CH-29,30,32,33,49), 6.34-6.30 (2H, m, 2 × NH-guanidine), 
5.90-5.71 (1H, m, CH-2), 5.30 (1H, d, J 17.2 Hz, CH-1-trans), 5.21 (1H, d, J 12.6 Hz, CH-1-
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cis), 4.61-4.47 (4H, m, CH2-3, CH-26,53), 4.42-4.37 (2H, m, CH-7,44), 4.35-4.28 (2H, m, CH2-
59), 4.21-4.11 (3H, m, CH2-5, CH-60), 3.87 (1H, dd, J 13.5, 5.0 Hz, CHAHB-10), 3.79 (1H, dd, 
J 15.7, 6.0 Hz, CHAHB-10), 3.24-3.15 (2H, m, CH2-17), 3.10-2.88 (6H, m, CH2-21,45,54), 2.57-
2.55 (3H, m, CH3-14), 2.51-2.49 (3H, m, CH3-16), 2.06 (3H, s, CH3-24), 1.93-1.85 (2H, m, 
CH2-9) and 1.56-1.38 (17H, m, CH2-8, CH3-19,20, 3 × CH3-57); 13C NMR (125 MHz, CDCl3) δ 
175.7 (quat., C-35), 175.6 (quat., C-4), 172.1 (quat., C-53), 171.4 (quat., C-6), 171.3 (quat., C-
25), 170.9 (quat., C-43), 170.2 (quat., C-50), 160.1 (quat., C-17), 159.6 (quat., C-34), 158.7 
(quat., C-11), 156.9 (quat., C-58), 151.0 (quat., C-31), 143.7, 143.6 (quat. × 2, C-61,72), 141.1 
(quat. × 2, C-66,67), 138.4 (quat., C-12), 133.7 (quat., C-37), 133.3 (CH, C-40), 133.2 (quat., C-
28), 132.4 (quat. × 2, C-15,22), 131.7 (quat., C-46), 131.4 (CH, C-2), 130.7 (CH × 2, C-39,41), 
130.1 (CH × 2, C-29,33), 129.7 (CH, C-49), 129.2 (CH × 2, C-47,51), 128.8 (CH × 2, C-47,51), 
127.8 (quat. × 2, C-64,69), 127.1 (quat. × 2, C-63,70), 125.2 (quat. × 2, C-62,71), 123.6 (quat., 
C-13), 122.2 (CH × 2, C-30,32), 121.7 (CH × 2, C-38,42), 120.0 (quat. × 2, C-65,68), 118.8 
(CH2, C-1), 117.5 (quat., C-23) 103.6 (CH, C-36), 86.4 (quat., C-18), 82.0 (quat., C-54); 67.4 
(CH2, C-59), 66.0 (CH3, C-3), 55.9 (CH, C-26), 55.7 (CH, C-51), 53.1 (CH, C-7), 50.5 (CH, C-
44), 46.9 (CH, C-60), 43.1 (CH3, C-21), 41.3 (CH2, C-5), 40.8 (CH3, C-10), 40.7 (CH2, C-27), 
36.2 (CH2, C-45), 35.9 (CH2, C-52), 28.6 (CH3 × 2, C-19,20), 28.2 (CH2, C-8), 28.1 (CH3 × 3, 
C-28), 25.4 (CH2, C-9), 19.3 (CH3, C-16) 18.0 (CH3, C-14) and 12.5 (CH3, C-24); m/z (ES+) 
1414 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C74H84N11O16S [M+H]+ requires 1414.5813, 
found 1414.5780. 
 
Fmoc-Arg(Pbf)-Gly-OH, 377 
 
Palladium tetrakis(triphenylphosphine) (16 mg, 0.013 mmol, 5 mol%) and dimedone (94 mg, 
0.670 mmol) was added to a solution of Fmoc-Arg(Pbf)-Gly-OAll 368 (200 mg, 0.268 mmol) in 
dry THF (15 mL), and the solution stirred at room temperature for 3 h. Dichloromethane (20 
mL) was added and the solution was washed with aq. HCl (2 N, 4 mL) and brine (5 mL), dried 
over MgSO4, filtered and evaporated. The resultant residue was uptaken in dichloromethane and 
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adsorbed onto silica gel. Purification by silica gel chromatography, eluting with 
dichloromethane, methanol and acetic acid (98:2, 95:5:1), furnished Fmoc-Arg(Pbf)-Gly-OH 
377 (180 g, 0.255 mmol, 95%) as a white solid: Rf 0.54 (90:10:0.5, CH2Cl2:MeOH:AcOH); 
m.p. 128-131 °C; [𝛂]𝐃𝟐𝟎 -3.2, (c = 1.0, CHCl3, MeOH; νmax (thin film)/cm−1 2926, 2854, 2528, 
1719, 1684, 1669, 1653, 1621, 1560, 1451, 1407, 1370, 1250, 1105, 1034, 994; 1H NMR (500 
MHz, d6-DMSO) δ 8.21 (1H, t, J 5.4, NH-Arg-Gly), 7.90 (2H, d, J 7.6 Hz, CH-29,32), 7.75 
(2H, t, J 6.8 Hz, CH-26,35), 7.56 (1H, d, J 8.4, NH-Fmoc), 7.43 (2H t, J 6.8 Hz, CH-28,33), 
7.34 (2H, t, J 6.4 Hz, CH-27,34), 6.78 (1H, s, NH-sulfonamide), 6.44 (1H, s, NH-guanidine), 
4.32-4.21 (3H, m, CH2-23, CH-24), 4.04 (1H, dd, J 13.5, 8.6 Hz, CH-4), 3.80 (1H, dd, J 17.5, 
5.8 Hz, CHAHB-2), 3.74 (1H, dd, J 5.6, J 17.5 Hz, CHAHB-2), 3.06 (2H, dd, J 12.3, 6.7 Hz, CH2-
7), 2.95 (2H, s, CH2-18), 2.52 (3H, s, CH2-21), 2.44 (3H, s, CH2-11), 2.02 (3H, s, CH2-13), 
1.72-1.66 (1H, m, CHAHB-5) and 1.54-1.39 (9H, m, CHAHB-5, CH2-9, CH2-16,17); 13C NMR 
(125 MHz, d6-DMSO) δ 173.0 (quat., C-1), 171.6 (quat., C-3), 157.8 (quat., C-14), 156.6 (quat., 
C-8), 156.4 (quat., C-22), 144.4, 144.2 (quat., × 2, C-25,36), 137.8 (quat., C-9), 134.8 (quat., C-
19), 131.9 (quat., C-12), 131.1 (quat., × 2, C-30,31), 128.1 (quat., × 2, C-28,33) 127.6 (quat., × 
2, C-27,34), 125.8 (quat., × 2, C-26, 35), 124.8 (quat., C-10), 120.6 (quat., × 2, C-29, 23), 116.8 
(quat., C-20), 86.8 (quat., C-15), 66.1 (CH2, C-23), 54.6 (CH, C-4), 41.2 (CH2, C-2), 40.4 (CH2, 
C-7), 29.8 (CH2, C-5), 28.7 (CH3 × 2, C-16,17), 26.0 (CH2, C-6), 19.5 (CH3, C-13), 18.1 (CH3, 
C-11), 12.8 (CH3, C-21), 47.1 (CH, C-24), 42.8 (CH2, C-18); m/z (ES−) 704 ([M-H]−, 100%); 
HRMS m/z (ES+) calcd. for C36H42N5O8S [M+H]+ requires 704.2760, found 704.2766. 
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Fmoc-Tyr(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-OH, 378 
 
 
 
Palladium tetrakis(triphenylphosphine) (4 mg, 0.004 mmol, 6.7 mol%) and dimedone (64 mg, 
0.46 mmol) was added to a solution of Fmoc-Tyr(O-carbonyl-N-3-phenylsydnonimine)-
Arg(Pbf)-Gly-OAll 370 (100 mg, 0.09 mmol) in dry THF (10 mL), and the solution stirred at 
room temperature for 3 h. Dichloromethane (20 mL) was added and the solution was washed 
with aq. HCl (2 N, 10 mL) and brine (10 mL), dried over MgSO4, filtered and evaporated. The 
resultant residue was uptaken in dichloromethane and adsorbed onto silica gel. Purification by 
silica gel chromatography, eluting with dichloromethane, methanol and acetic acid (98:2, 
95:5:1), furnished Fmoc-Arg(Pbf)-Gly-OH 378 (85 g, 0.08 mmol, 88%) as a pale yellow solid. 
Rf 0.60 (90:10:0.5, CH2Cl2:MeOH:AcOH); m.p. 195-200 °C; [𝛂]𝐃𝟐𝟎 -7.9, (c = 1.0, CHCl3, 
MeOH; νmax (thin film)/cm−1 3347, 2977, 2932, 1730, 1652, 1584, 1508, 1471, 1368, 1285, 
1192, 1166, 1107, 1018, 974, 846; 1H NMR (500 MHz, d6-DMSO) δ 8.57 (1H, s, CH-33), 8.19 
(1H, d, J 6.5 Hz, NH-Fmoc), 8.10 (1H, s, br, NH-Tyr-Arg), 8.05 (2H, d, J 7.8 Hz, CH-25,39), 
7.85 (2H, d, J 7.6 Hz, CH-47,50), 7.77 (1H, t, J 7.1 Hz, CH-37), 7.72 (2H, t, J 7.6 Hz, CH-
36,38), 7.66-7.63 (3H, m, CH-44,53, NH-Arg-Gly), 7.40-7.36 (2H, m, CH-46,51), 7.32-7.26 
(4H, m, CH-26,30,45,52), 7.07 (1H, t, J 7.4 Hz, NH-guanidine), 7.01 (2H, d, J 8.1, CH-27,29), 
6.51 (2H, s, br, NH-guanidine, NH-sulfonamide), 4.35-4.26 (2H, m, CH-4,23), 4.20-4.11 (3H, 
m, CH-41,42), 3.72-3.63 (2H, m, CH2-2), 3.06-3.01 (3H, m, CH2-7, CHAHB-24), 3.92 (2H, s, 
CH2-18), 2.80-2.75 (1H, m, CHAHB-24), 2.57 (3H, s, CH3-21), 2.41 (3H, s, CH3-11), 1.98 (3H, 
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s, CH3-13), 1.73-1.68 (1H, m, CHAHB-5), 1.57-1.60 (1H,  m, CHAHB-5) and 1.46-1.37 (8H, m, 
CH2-6, CH3-16,17); 13C NMR (125 MHz, d6-DMSO) δ 175.4 (quat., C-32), 172.5 (quat., C-1), 
171.8 (quat., C-3), 171.9 (quat., C-22), 157.8 (quat., C-31), 157.9 (quat., C-14), 156.6 (quat., C-
8), 156.2 (quat., C-40), 150.9 (quat., C-28), 144.3, 144.2 (quat. × 2, C-43,54), 141.1 (quat. × 2, 
C-48,49), 137.7 (quat., C-9), 134.6 (quat., C-19), 134.4 (quat., C-34), 134.1 (quat., C-25), 133.5 
(CH, C-38), 131.9 (quat., C-12), 130.7 (CH × 2, C-36,38), 130.6 (CH × 2, C-27,39), 128.1 (CH 
× 2, C-46,51), 127.5 (CH × 2, C-45,52), 125.8, 125.7 (CH × 2, C-44 53), 124.8 (quat., C-10), 
122.9 (CH × 2, C-35,39), 121.7 (CH × 2, C-26,30), 120.5 (CH × 2, C-47,50), 116.7 (quat., C-
20), 105.2 (CH, C-33), 86.7 (quat, C-15), 66.1 (CH2, C-41), 56.6 (CH, C-23), 55.4 (CH, C-4), 
47.0 (CH, C-42), 42.9 (CH2, C-18), 41.9 (CH2, C-2), 40.1 (CH2, C-7), 37.2 (CH2, C-24), 30.0 
(CH2, C-5), 28.7 (CH3 × 2, C-16, 17), 25.6 (CH2, C-6), 19.4 (CH3, C-13), 18.0 (CH3, C-11) and 
12.7 (CH3, C-21); m/z (ES−) 1054 ([M-H]−, 100%); HRMS m/z (ES−) calcd. for C54H56N9O12S 
[M-H]− requires 1054.3775, found 1054.3772. 
 
 
Fmoc-Asp(OtBu)-D-Phe-Tyr-(O-carbonyl-N-3-phenylsydnonimine)-Arg(Pbf)-Gly-
OH, 379 
 
Palladium tetrakis(triphenylphosphine) (2 mg, 0.0018 mmol, 5 mol%) and dimedone (25 mg, 
0.176 mmol) was added to a solution of 376 (50 mg, 0.035 mmol) in dry THF (3 mL), and the 
solution stirred at room temperature for 3 h. Dichloromethane (20 mL) was added and the 
solution was washed with aq. HCl (2 N, 4 mL) and brine (5 mL), dried over MgSO4, filtered and 
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evaporated. The resultant residue was uptaken in dichloromethane and adsorbed onto silica gel. 
Purification by silica gel chromatography eluting with dichloromethane, methanol and acetic 
acid (100:0:0, to 97:3:0 to 95:5:1) provided Fmoc-Asp(OtBu)-D-Phe-Tyr-(O-carbonyl-N-3-
phenylsydnonimine)-Arg(Pbf)-Gly-OH 379 (37 mg, 0.027 mmol, 77%) as a pale yellow solid: Rf 
0.54 (90:10:1, CH2Cl2:MeOH:AcOH); m.p. 159-165 °C; [𝛂]𝐃𝟐𝟎+9.2 (c = 0.75, MeOH; νmax (thin 
film)/cm−1 2362, 2342, 2335, 1701, 1696, 1688, 1654, 1559, 1561, 1512, 1464, 1274, 1267, 
1261, 764; 1H NMR (500 MHz, d6-DMSO) δ 8.62-8.57 (1H, m, CH-33), 1.44 (1H, d, J 9.2 Hz, 
NH-amide), 8.31 (1H, d, J 9.0 Hz, NH-amide), 8.22 -8.13 (1H, m, NH-Fmoc), 8.06 (2H, d, J 7.1 
Hz, CH-35, 39), 8.00-7.83 (3H, m, CH-62, 65, NH-amide), 7.78 (1H, t, J 7.6 Hz, CH-37), 7.74-
7.66 (4H, m, CH-36,38,59,68), 7.62-7.54 (1H, m, NH-amide), 7.42-7.38 (2H, m, CH-61, 66), 
7.30-7.24 (4H, m, CH-26,30,60,67), 7.14-7.09 (4H, m, CH-44, 45,47,48), 7.03 (2H, d, J 7.9 Hz, 
CH-27,29), 7.00-6.98 (1H, m, CH-46), 6.75 (1H, m, NH-guanidine), 6.41 (2H, m, NH-
guanidine, NH-sulfonamide), 4.63-4.48 (3H, m, CH-4, 23,41), 4.35-4.17 (4H, m, CH-50,57, 
CH2-56), 3.80-3.17 (2H, m, CH2-2), 3.09-3.01 (4H, m, CH2-7, CH2-24), 2.94 (2H, s, CH2-18), 
2.77-2.72 (1H, m, CHAHB-42), 2.58-2.31 (8H, m, CH3-11, 21, CHAHB-42, CHAHB-51), 2.17 
(1H, dd, J 15.4, 10.7 Hz, CHAHB-51), 1.99 (3H, s, CH3-13), 1.73-1.67 (1H, m, CHAHB-5) and 
1.57-1.33 (18H, m, CHAHB-5, CH2-6, CH3-16,17, 3 × CH3-54); 13C NMR (125 MHz, d6-
DMSO) δ 175.4 (quat., C-32), 172.0, 171.6, 171.1, 171.0, 170.8, 169.6 (quat. × 6, C-
1,3,22,40,49,52), 157.9 (quat., C-14), 157.9 (quat., C-31), 156.6 (quat., C-8), 156.2 (quat., C-
55), 150.0 (quat., C-28), 144.3, 144.1 (quat., C-58,69), 141.1 (quat. × 2, C-59,68), 137.8 (quat., 
C-9), 134.7 (quat., C-19), 134.4 (quat., C-34), 134.1 (quat., C-25), 134.0 (CH, C-37), 131.9 
(quat., C-12), 130.7 (CH × 2, C-35,39), 130.5 (CH × 2, C-27, 29), 130.4 (CH × 2, C-45,47), 
129.7 (CH × 2, C-44,48), 128.3 (quat., C-43), 128.1 (CH × 2, C-61,66), 127.5 (CH × 2, C-
60,67), 126.6 (CH, C-46), 125.7 (CH × 2, C-59,68), 124.8 (quat., C-10), 122.9 (CH × 2, C-
35,39), 121.7 (CH × 2, C-26,30), 120.5 (CH × 2, C-52,65), 116.7 (quat., C-20), 105.2 (CH, C-
33), 86.7 (quat., C-15), 80.5 (quat., C-53), 66.2 (CH2, C-56), 54.3 (CH, C-4), 54.1 (CH, C-23), 
52.6 (CH, C-41), 51.9 (CH, C-50), 47.0 (CH, C-57), 42.9 (CH2, C-18), 41.3 (CH2, C-2), 40.6 
(CH2, C-7), 38.4 (CH2, C-42), 38.1 (CH2, C-51), 37.4 (CH2, C-24), 30.0 (CH2, C-5), 28.8 (CH2 
× 2, CH3-16,17), 28.1 (CH3 × 3, C-54), 25.8 (CH2, C-6), 19.4 (CH3, C-13), 18.1 (CH3, C-11) 
and 12.7 (CH3, C-21); HRMS m/z (ES+) calcd. for C54H56N9O12S [M+Na]+ requires 1396.5319, 
found 1396.5321. 
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1,5-Di-tert-butyl (2S)-2-((((2S)-6-(((benzyloxy)carbonyl)amino)-1-(tert-butoxy)-1-
oxohexan-2-yl)carbamoyl)amino)pentanedioate, 382257 
 
 
 
A solution of N-ε-Cbz-lysine tert-butyl ester hydrochloride 384 (0.91 g, 2.70 mmol) and 
diisopropylethylamine (0.79 g, 1.05 mL, 6.00 mmol) in dry dichloromethane (5 mL) was added 
via syringe pump over 1 hour to a solution of triphosgene (0.29 g, 1.00 mmol) in dry 
dichloromethane (5 mL) at 0 °C. The solution was stirred for a further hour at 0 C. After this 
time a solution of glutamic acid di-tert-butyl ester hydrochloride 383 (0.80 g, 2.70 mmol) and 
diisopropylethylamine (0.79 g, 1.05 mL, 6.00 mmol) in dry dichloromethane (5 mL) was added 
in one portion. The solution was allowed to warm to room temperature and stirred for a further 
two h. The solvent was removed under reduced pressure and the residue diluted with ethyl 
acetate (50 mL), washed with aq. HCl (2 N, 2 × 50 mL), brine (100 mL), dried over Na2SO4. 
The solvent was removed under reduced pressure and the residue uptaken in dichloromethane 
and adsorbed onto silica gel. Silica gel chromatography, eluting with ethyl acetate and hexane 
(10:90 to 40:60) provided 1,5-di-tert-butyl (2S)-2-((((2S)-6-(((benzyloxy)carbonyl)amino)-1-
(tert-butoxy)-1-oxohexan-2-yl)carbamoyl)amino)pentanedioate 382 (1.31 g, 2.11 mmol) as a 
colourless oil: Rf 0.69 (50:50, EtOAc:PE, weakly UV active/KMnO4); [𝛂]𝐃𝟐𝟎 +8.4, (c = 1, 
CHCl3); 1H NMR (500 MHz; CDCl3) δ 7.34-7.25 (5H, m, CH-22,23,24,25,26), 5.56-5.55 (2H, 
m, NH-Cbz, NH-Glu-urea), 5.47 (1H, d, J 5.6, NH-Lys-urea), 5.13-5.03 (2H, m, CH2-20), 4.36 
(1H, dd, J 12.2, 7.4 Hz, CH-4), 4.30 (1H, dd, J 11.2, 6.3 Hz, CH-11), 3.14 (2H, dt, J 7.2, 6.3 
Hz, CH2-18), 2.27-2.21 (2H, m, CH2-6), 2.04-1.98 (1H, m, CHAHB-5), 1.81-1.74 (1H, m, 
CHAHB-5), 1.73-1.66 (1H, m, CHAHB-15), 1.60-1.52 (1H, m, CHAHB-15), 1.45-1.37 (29H, CH2-
17, 3 × CH3-1, 3 × CH3-9, 3 × CH3-14) and 1.33-1.24 (2H, m, CH2-16); 13C NMR (125 MHz; 
CDCl3) δ 173.0 (quat., C-3), 172.7 (quat., C-7), 172.3 (quat., C-12), 156.7 (quat., C-19), 157.2 
(quat., C-10), 136.8 (quat., C-21), 128.0 (CH × 2, C-22,26), 127.9 (CH, C-21), 123.4 (CH × 2, 
C-23,25), 82.0 (quat., C-2), 82.0 (quat., C-13), 80.4 (quat., C-8), 66.4 (CH2, C-20), 53.3 (CH, C-
11), 52.8 (CH, C-4), 40.7 (CH2, C-18), 32.6 (CH2, C-15), 31.6 (CH2, C-6), 29.3 (CH2, C-16), 
28.3 (CH2, C-5), 28.0 (CH3 × 6, C-1, 9), 28.0 (CH3 × 3, C-14), 22.4 (CH2, C-17); m/z (ES+) 644 
([M+Na]+, 100%). The data were in agreement with the literature values.257 
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1,5-Di-tert-butyl (2S)-2-((((2S)-6-amino-1-(tert-butoxy)-1-oxohexan-2-
yl)carbamoyl)-amino)pentanedioate, 385257 
 
 
 
A solution of Cbz amine 382 (500 mg, 0.80 mmol) in methanol (27 mL, 0.03 M) was 
hydrogenated at room temperature in flow (H-Cube, 1 mL min−1) over a 10% Pd/C carbon 
cartridge. The solvent was evaporated under reduced pressure to yield 385 (406 mg, 0.80 mmol, 
quant.) as a waxy solid which was used immediately: Rf = 0.00 (50:50, EtOAc:PE, KMnO4); 1H 
NMR (500 MHz; CDCl3) δ 5.35-5.32 (2H, m, NH-urea × 2), 4.34-4.29 (2H, m, CH-4,11), 2.66 
(2H, t, J 6.5 Hz, CH2-18), 2.34-2.21 (2H, m, CH2-6), 2.07-2.00 (1H, m, CHAHB-5), 1.85-1.70 
(2H, m, CHAHB-5, CHAHB-15), 1.62-1.54 (1H, m, CHAHB-15), 1.56-1.30 (31H, 3 × CH3-1, 3 × 
CH3-9, 3 × CH3-14, CH2-16, CH2-17); 13C NMR (125 MHz; CDCl3) δ 172.7, 172.5, 172.3 
(quat., × 3, C-3,7,18), 156.9 (quat., C-10), 82.0, 81.6, 80.5 (quat. × 3, C-2,8,13), 53.1 (CH, C-4), 
53.0 (CH2, C-11),  41.8 (CH2, C-18), 33.1 (CH2, C-6), 32.9 (CH2, C-15), 31.6 (CH2, C-17), 28.4 
(CH2, C-5), 28.1, 28.0, 28.0 (CH3 × 9, C-1,9,14), 22.4 (CH2, C-16); m/z (ES+) 510 ([M+Na]+, 
100%). The data were in agreement with the literature values.257 
 
1, 5-Di-tert-butyl (2S)-2-((((2S)-1-(tert-butoxy)-6-(4-(nitrooxy)butanamido)-1-
oxohexan-2-yl)carbamoyl)amino)pentanedioate, 386 
 
 
 
Following general procedure B with HATU (510 mg, 1.34 mmol), 4-(nitrooxy)butanoic acid 
258 (100 mg, 0.67 mmol), amine 385 (218 mg, 0.45 mmol) and diisopropylethylamine 
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(distilled, 231 mg, 310 µL, 1.79 mmol). Purification by silica gel chromatography, eluting with 
dichloromethane and methanol (98:2) provided 1, 5-di-tert-butyl (2S)-2-((((2S)-1-(tert-butoxy)-
6-(4-(nitrooxy)butanamido)-1-oxohexan-2-yl)carbamoyl)amino)pentanedioate 386 (194 mg, 
0.31 mmol, 70%) as an amber gum: Rf 0.58 (90:10, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); [𝛂]𝟐𝟎𝐃  +9.2, (c = 0.1, CHCl3); νmax (thin film)/cm−1 1730, 1635, 1561, 1458, 
1368, 1277, 1257, 1153, 1036, 846, 748, 665; 1H NMR (500 MHz; CDCl3) δ 7.04 (1H, t, J 5.4, 
NH-amide), 5.84 (1H, d, J 7.6, NH-urea-Lys), 5.50 (1H, d, J 6.2, NH-urea-Glu), 4.50 (2H, t, J 
7.6 Hz, CH2-22), 4.30 (1H, dt, J 8.6, 5.0 Hz, CH-11), 4.17-4.11 (1H, m, CH-4), 3.33-3.25 (1H, 
m, CHAHB-18), 3.16-3.09 (1H, m, CHAHB-18), 2.37-2.29 (4H, m, CH2-6, 20), 2.08-2.02 (3H, m, 
CHAHB-5, CH2-21,), 1.85-1.77 (1H, m, CHAHB-5), 1.74-1.67 (1H, m, CHAHB-15), 1.55-1.49 
(1H, m, CHAHB-15); 1.48-1.36 (29H, m, 3 × CH3-1, 3 × CH3-9, 3 × CH3-14, CH2-17), 1.31-1.24 
(2H, m, CH2-16); 13C NMR (125 MHz; CDCl3) δ 172.4, 172.2, 171.8 (quat. × 3, C-3,7,12), 
157.5 (quat., C-10), 82.6, 81.5, 80.7 (quat. × 3, C-2,8,13), 72.8 (CH2, C-22), 53.7 (CH, C-4), 
53.1 (CH, C-11), 39.0 (CH2, C-18), 32.4 (CH2 × 2, C-6, C-20), 31.6 (CH2, C-17), 28.8 (CH2, C-
5), 28.0 (CH3 × 9, C-1,9,14), 27.9 (CH2, C-15), 23.2 (CH2, C-21) and  22.9 (CH2, C-16); m/z 
(ES+) 556 ([M−ONO3]+, 100%), 641 ([M+Na]+, 50%); HRMS m/z (ES+) calcd. for 
C28H50N4NaO11 [M+Na]+ requires 641.3374, found 641.3354. 
 
1, 5-Di-tert-butyl (2S)-2-((((2S)-1-(tert-butoxy)-6-(4-((3-phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide)oxy)butanamido)-1-oxohexan-2-yl)carbamoyl)amino) 
pentanedioate, 387 
 
 
 
Following general procedure B with HATU (468 mg, 1.23 mmol), 4-(3-carboxypropoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 261 (148 mg, 0.45 mmol), amine 385 (200 mg, 0.41 
mmol) and diisopropylethylamine (distilled, 212 mg, 281 µL, 1.64 mmol). Purification by silica 
gel chromatography, eluting with dichloromethane and methanol (98:2) provided 1, 5-di-tert-
butyl (2S)-2-((((2S)-1-(tert-butoxy)-6-(4-((3-phenylsulfonyl)-1,2,5-oxadiazole 2-
oxide)oxy)butanamido)-1-oxohexan-2-yl)carbamoyl)amino) pentanedioate 387 (229 mg, 0.29 
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mmol, 70%) as a white solid: Rf 0.60 (90:10, CH2Cl2:MeOH, UV/cerium phosphomolybdate); 
m.p. 94-97 °C; [𝛂]𝟐𝟎𝐃  +13.6, (c = 0.1, CHCl3); νmax (thin film)/cm−1 1733, 1633, 1552, 1451, 
1367, 1257, 1157, 1086, 1021, 958, 899, 848, 748; 1H NMR (500 MHz; CDCl3) δ 8.04 (2H, d, 
J 7.6 Hz, CH-26,30), 7.75 (1H, t, J 7.3 Hz, CH-28), 7.62 (2H, t, J 7.8 Hz, CH-27,29), 6.61 (1H, 
t, J 5.4, NH-amide), 5.57 (1H, d, J 8.0, NH-urea-Lys), 5.44 (1H, d, J 7.7, NH-urea-Glu), 4.48 
(2H, t, J 6.2 Hz, CH2-22), 4.31 (1H, dt, J 8.0, 5.0 Hz, CH-11), 4.24 (1H, dt, J 7.7, 4.4 Hz, CH-
4), 3.33-3.37 (1H, m, CHAHB-18), 3.20-3.14 (1H, m, CHAHB-18), 2.41 (2H, t, J 6.9 Hz, CH2-
20), 2.34-2.26 (2H, m, CH2-6), 2.21 (2H, tt, J 6.9, 6.2 Hz, CH2-21), 2.09-2.01 (1H, m, CHAHB-
5), 1.86-1.79 (1H, m, CHAHB-5), 1.78-1.71 (1H, m, CHAHB-15), 1.61-1.30 (32H, m, 3 × CH3-1, 
3 × CH3-9, 3 × CH3-14, CHAHB-15, CH2-16,17); 13C NMR (125 MHz; CDCl3) δ 173.1, 172.4, 
172.3, 171.9 (quat. × 4, C-3,7,12,19),158.9 (quat., C-24), 157.3 (quat., C-10), 137.9 (quat., C-
25), 135.7 (CH, C-28), 129.7 (CH × 2, CH-26,30), 128.5 (CH × 2, CH-27, 29), 110.5 (quat., C-
23), 82.3, 81.6, 80.6 (quat. × 3, C-2,8,13), 70.8 (CH3, C-22), 53.4 (CH, C-4), 53.0 (CH, C-11), 
39.0 (CH2, C-18), 32.4 (CH2, C-6), 31.9 (CH2, C-20), 31.5 (CH2, C-17) 28.8 (CH2, C-5), 28.1 
(CH2, C-15), 28.0 (3 × CH3 × 3, C-1,9,14), 24.5 (CH2, C-21) and 22.6 (CH2, C-16); m/z 820 
([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C36H55N5NaO13 [M+Na]+ requires 820.3415, 
found 820.3392. 
 
N-(((3-(((5S)-5-((((2S)-1,5-Bis(tert-butoxy)-1,4-dioxopentan-2-yl)carbamoyl)amino)-
6-(tert-butoxy)-6-oxohexyl)carbamoyl)propoxy)carbonyl)-3-phenylsydnonimine, 
388 
 
 
 
Following general procedure B with HATU (304 mg, 0.80 mmol), N-((3-
carboxypropxy)carbonyl)-3-phenylsydnonimine 266 (96 mg, 0.29 mmol), amine 385 (130 mg, 
0.27 mmol) and diisopropylethylamine (distilled, 137 mg, 190 µL, 1.08 mmol). Purification by 
silica gel chromatography, eluting with dichloromethane and methanol (98:2) provided N-(((3-
(((5S)-5-((((2S)-1,5-bis(tert-butoxy)-1,4-dioxopentan-2-yl)carbamoyl)amino)-6-(tert-butoxy)-6-
oxohexyl)carbamoyl)propoxy)carbonyl)-3-phenylsydnonimine 388 (148 mg, 0.19 mmol, 66%) 
as an amber solid: Rf 0.69 (90:10, CH2Cl2:MeOH,, UV/cerium phosphomolybdate); m.p. 44-46 
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°C; [𝛂]𝐃𝟐𝟎 +13.6, (c = 0.1, CHCl3); νmax (thin film)/cm−1 1735, 1649, 1550, 1428, 1370, 1265, 
1150, 1099, 900; 1H NMR (500 MHz; CDCl3) δ 8.42 (1H, s, CH-25), 7.93 (2H, d, J 8.5 Hz, 
CH-27,31), 7.70 (1H, tt, J 7.5, 1.2 Hz, CH-29), 7.64 (2H, t, J 8.5 Hz, CH-28,30), 6.71 (1H, t, J 
5.8, NH-amide), 6.10 (1H, d, J 9.1, NH-urea-Lys), 5.92 (1H, d, J 8.8, NH-urea-Glu), 4.42 (1H, 
ddd, J 13.1, 8.8, 4.3 Hz, CH-11), 4.30-4.20 (2H, m, CH-4, CHAHB-22), 4.15-4.09 (1H, m, 
CHAHB-22), 3.54-3.47 (1H, m, CHAHB-18), 2.98-2.90 (1H, m, CHAHB-18), 2.36-2.27 (4H, m, 
CH2-6, CH2-20), 2.18-1.98 (3H, m, CHAHB-15, CH2-21), 1.86-1.76 (2H, m, CHAHB-15, CHAHB-
17), 1.47-1.29 (32H, 3 × CH3-1, CH2-5, 3 × CH3-9, 3 × CH3-14, CH2-16, CHAHB-17); 13C NMR 
(125 MHz; CDCl3) δ 175.1 (quat., C-24), 173.3, 172.9, 172.7, 172.2 (quat., × 5, C-3,7,12,19), 
161.7 (quat., C-23), 157.8 (quat., C-10), 133.8 (quat., C-26), 133.1 (CH, C-29), 130.5 (CH × 2, 
C-19,23), 121.8 (CH × 2, C-27,31), 103.7 (CH, C-25) 64.8 (CH2, C-22), 53.3 (CH, C-4), 52.8 
(CH, C-11), 38.7 (CH2, C-18), 32.7 (CH2, C-20), 32.5 (CH2, C-6), 31.9 (CH2, C-17), 28.5 (CH2, 
C-5), 28.0, 28.0, 28.0 (CH3 × 9, C-1,9,14), 27.7 (CH2, C-15), 21.7 (CH2, C-16) and 25.0 (CH2, 
C-21),; m/z 783 ([M+Na]+, 100%); HRMS m/z (ES+) calcd. for C37H56N6NaO11 [M+Na]+ 
requires 783.3899, found 783.3900. 
 
(2S)-2-((((2S)-1-Carboxy-5-(4-(nitrooxy)butanamido)pentyl)carbamoyl)amino) 
pentanedioic acid, 389 
 
 
Trifluoroacetic acid (1 mL, 13.1 mmol) was added to a solution of amide 386 (100 mg, 0.16 
mmol) in dichloromethane (4 mL) cooled in an ice-bath. The solution was stirred for 18 h. The 
solvent was removed under reduced pressure and the residue evaporated from toluene, 
methanol, and dichloromethane. The residue was triturated with cold acetonitrile to furnish 
(2S)-2-((((2S)-1-carboxy-5-(4-(nitrooxy)butanamido)pentyl)carbamoyl)amino) pentanedioic 
acid 389 (66 mg, 0.15 mmol, 90%) as a colourless gum: Rf = 0.00 (CH2Cl2, cerium 
phosphomolybdate); νmax (KBr disc)/cm−1 2930, 2909, 1725, 1600, 1478, 1300, 1270, 1257, 
1140, 1H NMR (500 MHz, d6-DMSO) δ 12.47 (3H, s, br, 3 × COOH), 7.87 (1H, t, J 4.9 Hz, 
NH-amide), 6.36-6.30 (2H, m, 2 × NH-urea), 4.51 (2H, t, J 6.0 Hz, CH2-16), 4.12-4.04 (2H, m, 
CH-2, 7), 3.01 (2H, dd, J 12.8, 6.6 Hz, CH2-12), 2.32-2.14 (4H, m, CH2-4, CH2-14), 1.96-1.84 
(3H, m, CHAHB-3, CH2-15), 1.74-1.48 (3H, m, CHAHB-3, CH2-9) and 1.41-1.22 (4H, m, CH2-
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11, CH2-10); 13C NMR (125 MHz, d6-DMSO) δ 175.0, 174.6, 174.2, 171.2 (quat. × 4, C-
1,5,8,13), 157.7 (quat., C-6), 73.8 (CH2, C-16), 52.6, 52.1 (CH × 2, C-2,7), 38.8 (CH2, C-12), 
32.3 (CH2, C-9), 31.7 (CH2, C-4), 30.4 (CH2, C-14), 29.3 (CH2, C-11), 28.0 (CH2, C-3), 23.0 
(CH2, C-10) and 22.7 (CH2, C-15); m/z (ES−) 449 ([M-H]−, 100%); HRMS m/z (ES−) calcd. for 
C16H25N4O11 [M-H]− requires 449.1525, found 449.1530. 
 
(2S)-2-((((2S)-1-Carboxy-5-(4-((3-phenylsulfonyl)-1,2,5-oxadiazole 2-
oxide)oxy)butan-amido)pentyl)carbamoyl)amino) pentanedioic acid, 390 
 
 
Trifluoroacetic acid (1 mL, 13.1 mmol) was added to a solution of amide 387 (100 mg, 0.13 
mmol) in dichloromethane (4 mL) cooled in an ice-bath. The solution was stirred for 18 h. The 
solvent was removed under reduced pressure and the residue evaporated from toluene, 
methanol, and dichloromethane. The residue was triturated with cold acetonitrile to furnish 
(2S)-2-((((2S)-1-carboxy-5-(4-((3-phenylsulfonyl)-1,2,5-oxadiazole 2-oxide)oxy)butanamido)-
pentyl)carbamoyl)amino) pentanedioic acid 390 (73 mg, 0.12 mmol, 92%) as a white solid: Rf 
= 0.00 (CH2Cl2, UV/cerium phosphomolybdate); m.p. 77 °C (decomp.); νmax (KBr disc)/cm−1 
2944, 2908, 1730, 1622, 1500, 1388, 1257, 1158, 1091, 1022, 900; 1H NMR (500 MHz, d6-
DMSO) δ 12.45 (3H, s, br, 3 × COOH), 8.03 (2H, d, J 7.7 Hz, CH-20,24), 7.92-7.87 (2H, m, 
CH-22, NH-amide), 7.75 (2H, t, J 7.7 Hz, CH-21,23), 6.37-6.27 (2H, m, 2 × NH-urea), 4.40 
(2H, t, J 6.2 Hz, CH2-16), 4.12-4.02 (2H, m, CH-2, 7), 3.03 (2H, dd, J 13.3, 6.8 Hz, CH2-12), 
2.30-2.19 (4H, m, CH2-4, CH2-14), 2.01-1.87 (3H, m, CHAHB-3, CH2-15), 1.75-1.60 (3H, m, 
CHAHB-3, CH2-9), 1.43-1.38 (2H, m, CH-11) and 1.32-1.25 (2H, m, CH2-10); 13C NMR (125 
MHz, d6-DMSO) δ 175.0, 174.3, 174.2, 171.4 (quat. × 4, C-1, 5, 8, 13), 159.3 (quat., C-17), 
157.7 (quat., C-6), 137.6 (quat., C-19), 136.6 (CH, C-22), 130.5 (CH × 2, C-21,23), 128.8 (CH 
× 2, C-21,23), 110.0 (quat., C-18), 79.6 (CH2, C-16), 52.7, 52.0 (CH × 2, C-2, 7), 38.8 (CH2, C-
12), 32.3 (CH2, C-9), 31.5 (CH2, C-4), 30.4 (CH2, C-14), 29.3 (CH2, C-11), 28.0 (CH2, C-3), 
24.7 (CH2, C-15) and 23.1 (CH2, C-10); m/z (ES+) 628 ([M-H]−, 100%); HRMS m/z (ES+) 
calcd. for C24H30N5O13S [M-H]− requires 628.1566, found 628.1576. 
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5-(((3-((((5S)-5-Carboxy-5-((((1S)-1,3-dicarboxypropyl)carbamoyl)amino)-pentyl)-
carbamoyl)propoxy)carbonyl)-3-phenylsydnonimine, 391 
 
 
 
Trifluoroacetic acid (1 mL, 13.1 mmol) was added to a solution of amide 388 (100 mg, 0.13 
mmol) in dichloromethane (4 mL) cooled in an ice-bath. The solution was stirred for 18 h. The 
solvent was removed under reduced pressure and the residue evaporated from toluene, 
methanol, and dichloromethane. The residue was triturated with cold acetonitrile to furnish 5-
(((3-((((5S)-5-carboxy-5-((((1S)-1,3-dicarboxypropyl)carbamoyl)amino)pentyl)carbamoyl)-
propoxy)carbonyl)-3-phenylsydnonimine 391 (62 mg, 0.11 mmol, 80%) as a off-white solid: Rf 
= 0.00 (CH2Cl2, UV/cerium phosphomolybdate); m.p. 82 °C (decomp.); νmax (KBr disc)/cm−1 
1724, 1701, 1615, 1462, 1395, 1249, 1160, 1090, 1025, 898; 1H NMR (500 MHz, d6-DMSO) δ 
12.35 (3H, s, br, 3 × CO2H), 8.56 (1H, s, CH-19), 8.07 (2H, d, J 7.5 Hz, CH-21, 25), 7.85 (1H, 
t, J 5.3 Hz, NH-amide), 7.78 (1H, tt, J 7.3, 1.2 Hz, CH-23), 7.73 (2H, t, J 7.3 Hz, CH-22,24), 
6.34-6.25 (2H, m, 2 × NH-urea), 4.11-3.98 (4H, m, CH-2, 7, CH2-16), 3.01 (2H, dd, J 12.4, 6.3 
Hz, CH2-12), 2.30-2.12 (4H, m, CH2-4,14), 1.94-1.87 (1H, m, CHAHB-3), 1.81 (2H, dd, J 7.3, 
7.3 Hz, CH2-15), 1.76-1.68 (1H, m, CHAHB-3), 1.67-1.60 (1H, m, CHAHB-9), 1.54-1.47 (1H, m, 
CHAHB-9), 1.41-1.34 (2H, m, CH2-11) and 1.31-1.25 (2H, m, CH2-10); 13C NMR (125 MHz, 
d6-DMSO) δ) 13C NMR (125 MHz, d6-DMSO) δ 175.4 (quat., C-18), 175.0, 174.7, 173.3, 171.8 
(quat. × 4, C-1,5,8,13), 160.8 (quat., C-17), 157.8 (quat., C-6), 134.2 (quat., C-20), 133.5 (CH, 
133.5), 130.7 (CH × 2, C-22,24), 122.9 (CH × 2, C-21,25), 104.5 (quat., C-19), 64.5 (CH2, C-
16), 52.9, 52.5 (CH × 2, C-2,7), 38.9 (CH2, C-12), 32.3 (CH2, C-9), 31.8 (CH2, C-4), 30.8 (CH2, 
C-14), 29.4 (CH2, C-11), 29.0 (CH2, C-3), 25.3 (CH2, C-15) and 23.2 (CH2, C-10); m/z (ES+) 
591 ([M-H]−, 100%); HRMS m/z (ES+) calcd. for C25H31N6O11 [M-H]− requires 591.2056, found 
591.2060. 
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N-((4-(((2S)-2-((((9H-Fluoren-9-ylmethoxy)carbonyl)amino)-3-fluoro-3-oxopropyl)-
phenoxycarbonyl)-3-phenylsydnonimine, 392 
 
 
 
 
Cyanuric fluoride (114 mg, 73 µL, 0.85 mmol) was added to a solution of (S)-N-(((4-(2-(((9H-
fluoren-9-yl)methoxy)carbonyl)amino)-2-carboxyethyl)phenoxy)carbonyl)-3-
phenylsydnonimine 321 (250 mg, 0.42 mmol) in dry dichloromethane (8 mL). To this was 
added pyridine (35 µL, 0.42 mmol) and the solution was stirred for 3 h. The resulting 
suspension was diluted with dichloromethane (10 mL) and washed with ice-cold water (20 mL 
× 2), dried over MgSO4. The mixture was filtered and the solvent removed under reduced 
pressure to give N-((4-(((2S)-2-((((9H-fluoren-9-ylmethoxy)carbonyl)amino)-3-fluoro-3-
oxopropyl)phenoxycarbonyl)-3-phenylsydnonimine 392 (247 mg, 0.41 mmol, quant.) as an 
orange solid: m.p. 109-113 °C, [𝛂]𝐃𝟐𝟎 +31.6 (c = 1.0, CHCl3); νmax  (KBr disc)/cm−1 1840, 1740, 
1680, 1586, 1510, 1469, 1450, 1350, 1215, 1190; 1H NMR (500 MHz, d6-DMSO) δ 8.52 (1H, 
s, CH-27), 8.17 (1H, d, J 7.3, NH-Fmoc), 8.01 (2H, d, J 7.9 Hz, CH-2,12), 7.85 (2H, d, J 7.5 
Hz, CH-29,33), 7.76 (1H, t, J 7.4 Hz, CH-31), 7.70 (2H, t, J 8.0 Hz, CH-30,32), 7.61 (2H, t, J 
7.0 Hz, CH-5,9), 7.39 (2H, d, J 7.5 Hz, CH-3,11), 7.30 (2H, J 6.2, CH-4,10), 7.23 (2H, d, J 8.5 
Hz, CH-20,24), 7.02 (2H, d, J 8.5 Hz, CH-21,23), 4.55-4.50 (1H, m, CH-16), 4.38 (1H, dd, J 
10.6, 6.9 Hz, CHAHB-14), 4.30 (1H, dd, J 10.6, 6.6 Hz, CHAHB-14), 4.18 (1H, t, J 6.7 Hz, CH-
7), 3.12 (1H, dd, J 13.8, 5.0 Hz CHAHB-18) and 2.99 (1H, dd, J 13.8, 10.2 Hz, CHAHB-18; 13C 
NMR (125 MHz, d6-DMSO) δ 175.4 (quat., C-26), 174.6 (quat., J 192.7 Hz C-17), 159.3 (quat., 
C-25), 156.6 (quat., C-15), 150.9 (quat., C-22), 147.1 (quat., C-6,8), 141.1 (quat., C-1,13), 
133.9 (quat., C-19), 134.8 (quat., C-28), 133.6 (CH, C-31), 130.9 (CH × 2, C-30,32), 130.3 (CH 
× 2, C-20,24) 128.2 (quat., C-3,11), 127.6 (quat., C-4,10), 125.6 (quat., C-5,9), 122.8 (CH × 2, 
C-29,33), 122.0 (CH × 2, C-21,23), 120.5 (quat., C-2,12), 105.2 (CH, C-27), 66.1 (CH2, C-14), 
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56.0 (CH, C-16), 47.0 (CH, C-7) and 36.6 (CH2, C-18); 19F NMR (376 MHz, d6-DMSO) δ 
+30.5 (COF); m/z (ES+) 593 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C33H26N4O6 [M+H]+ 
requires 593.1831, found 593.1839. 
 
N-((4-(((2S)-2-((((5S)-5-((((2S)-1,5-Bis(tert-butoxy)-1,5-dioxopentan-1-
yl)carbamoyl)-amino-6-(tert-butoxy)-6-oxohexyl)carbamoyl)-2-((((9H-fluoren-9-
ylmethoxy)-carbonyl)amino)ethyl)phenoxycarbonyl)-3-phenylsydnonimine, 393 
 
 
 
Acyl fluoride 392 (458 mg, 0.77 mmol in dry CH2Cl2, 10 mL) was added dropwise to a solution 
of amine 385 (344 mg, 0.71 mmol) and diispropylethylamine (distilled, 200 mg, 266 µL, 1.55 
mmol) in dry dichloromethane (20 mL) cooled to -20 °C and stirred for 1 hour. The solution as 
diluted with dichloromethane (20 mL) and washed with saturated sodium bicarbonate (30 mL), 
brine (30 mL). The organic layer was separated and dried over Na2SO4, filtered and the solvent 
removed under reduced pressure. The resultant residue was uptaken in dichloromethane and 
adsorbed onto silica gel. Purification by silica gel chromatography eluting with dichloromethane 
and methanol (98:2) provided N-((4-(((2S)-2-((((5S)-5-((((2S)-1,5-bis(tert-butoxy)-1,5-
dioxopentan-1-yl)carbamoyl)amino-6-(tert-butoxy)-6-oxohexyl)carbamoyl)-2-((((9H-fluoren-9-
ylmethoxy)carbonyl)amino)ethyl)phenoxycarbonyl)-3-phenylsydnonimine 393 (585 mg, 5.51 
mmol, 78%) as a translucent yellow solid: Rf 0.81 (90:10, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); m.p. 46-49 °C; [𝛂]𝐃𝟐𝟎 +23.8, (c = 0.6, CHCl3); νmax (thin film)/cm−1 2931, 
2853, 1728, 1669, 1616, 1552, 1449, 1364, 1260, 1169, 1085, 1024, 799, 733, 598; 1H NMR 
(500 MHz; CDCl3) δ 8.14 (1H, s, CH-30), 7.81 (2H, d, J 8.2 Hz, CH-32,36), 7.68-7.64 (3H, m, 
CH-34,44,47), 7.60 (2H, t, J 8.0 Hz, CH-33, 35), 7.47-7.44 (2H, m, CH-41,50), 7.32-7.21 (4H, 
m, CH-42,43,48,49), 7.18 (2H, d, J 8.4 Hz, CH-23, 27), 7.07 (2H, d, J 8.4 Hz, CH-24,26), 6.77 
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(1H, s, br, NH-amide), 6.12 (1H, d, J 7.6, NH-Fmoc), 4.74 (1H, dd, J 16.9, 8.5 Hz, CH-20), 
4.61-4.57 (1H, m, CH-4), 4.37 (1H, dd, J 14.0, 5.7 Hz, CH-11), 4.28 (1H, dd, J 13.0, 11.0 Hz, 
CHAHB-38), 4.15-4.09 (2H, m, CHAHB-38, CH-39), 3.39-3.12 (1H, m, CHAHB-18), 3.03-2.94 
(3H, m, CHAHB-18, CH2-21), 2.41-2.28 (2H, m, CH2-6), 2.15-2.06 (1H, m, CHAHB-5), 1.90-
1.80 (1H, m, CHAHB-5) and 1.59-1.05 (33H, m, 3 × CH3-1, 3 × CH3-9, 3 × CH3-14, CH2-15, 
CH2-16, CH2-17); 13C NMR (125 MHz; CDCl3) δ 175.5 (quat., C-29), 174.5, 173.6, 172.5, 
172.4 (quat. × 4, C-3,7,12,19), 160.1 (quat., C-28), 157.7 (quat., C-10), 157.4 (quat., C-37), 
150.9 (quat., C-25), 144.0, 143.6 (quat. × 2, C-40,51), 141.1 (quat. × 2, C-45,46), 133.8 (quat., 
C-22), 133.7 (quat., C-31), 133.2 (CH, C-34), 130.6 (CH × 2, C-33,35), 130.1 (CH × 2, C-
23,27), 127.7, 127.6 (CH × 2, C-43,48), 127.4, 127.3 (CH × 2, C-42,49), 125.2, 125.3 (CH × 2, 
C-41,50), 122.0 (CH × 2, C-24,26), 121.8 (CH × 2, C-32,36), 119.8 (CH × 2, C-44,47), 103.3 
(CH, C-30), 82.3, 80.9, 80.3 (quat. × 3, C-2,8,13), 67.7 (CH2, C-38), 56.7 (CH, C-20), 53.0 
(CH, C-11), 52.4 (CH, C-4), 46.7 (CH, C-39), 39.9 (CH2, C-18), 38.5 (CH2, C-21), 32.7 (CH2, 
C-15), 31.6 (CH2, C-6), 29.8 (CH2, C-5), 29.3 (CH2, C-16), 28.0 (3 × CH3 × 3, C-1, C-9, C-14), 
22.8 (CH2, C-8); m/z (ES+) 1060 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C57H70N7O13S 
[M+H]+ requires 1060.5010, found 1060.5026. 
 
N-((4-(((2S)-2-Amino-2-((((5S)-5-((((2S)-1,5-bis(tert-butoxy)-1,5-dioxopentan-2-
yl)carbamoyl)amino)-6-(tert-butoxy)-6-oxohexyl]carbamoyl)ethyl)-
phenoxycarbonyl)-3-phenylsydnonimine, 394 
 
 
 
Piperidine (100 µL, 1.01 mmol) was added to a solution of Fmoc amine 393 (122 mg, 0.12 
mmol) in dry DMF (5 mL) cooled in an ice-bath. After addition, the ice-bath was removed and 
the solution stirred for 15 min. The solvent was evaporated under reduced pressure to yield a 
yellow residue. The residue suspended in dichloromethane and adsorbed onto silica gel. 
Purification by silica gel chromatography eluting with dichloromethane and methanol (100:0 to 
90:0) provided amine 394 (87 mg, 0.10 mmol, 90%) as a pale yellow solid: Rf 0.46 (90:10, 
CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 74-76 °C; [𝛂]𝐃𝟐𝟎 -26.1, (c = 0.3, CHCl3); 
νmax (thin film)/cm−1 2976, 2935, 1728, 1652, 1585, 1508, 1455, 1367, 1281,, 1257, 1211, 1191, 
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1155, 974, 846; 1H NMR (500 MHz; CDCl3) δ 8.53 (1H, s, CH-30), 7.91 (2H, d, J 7.7 Hz, CH-
32,36), 7.69 (1H, tt, J 7.6, 1.4 Hz, CH-34), 7.63 (2H, t, J 8.0, CH-33,35), 7.36 (1H, s, br, NH-
amide), 7.20 (2H, d, J 8.7 Hz, CH-23,27), 7.11 (2H, d, J 8.7 Hz, CH-24,26), 5.76 (1H, d, J 8.9, 
NH-urea-Lys), 5.35 (1H, d, J 7.0, NH-urea-Glu), 4.28-4.20 (2H, m, CH-4, 11), 3.65 (1H, t, J 5.6 
Hz, CH-20), 3.51 (1H, dd, J 13.5, 6.0 Hz, CHAHB-21), 3.19 (1H, dd, J 13.7, 6.2 Hz, CHAHB-18), 
2.98 (1H, dd, J 13.0, 4.9 Hz, CHAHB-21), 2.93 (1H, dd, J 13.6, 5.2 Hz, CHAHB-18), 2.25-2.16 
(2H, m, CH2-17), 2.01-1.94 (1H, m, CHAHB-5), 1.81-1.67 (2H, m, CHAHB-5, CHAHB-6), 1.53-
1.20 (32H, m, 3 × CH3-1, 3 × CH3-9, 3 × CH3-14, CHAHB-6, CH2-15, CH2-16); 13C NMR (125 
MHz; CDCl3) δ 175.9 (quat., C-29), 173.9, 173.1, 172.2 (quat., × 4, C-3,7,12,19), 160.9 (quat., 
C-28), 157.5 (quat., C-10), 150.8 (quat., C-25), 133.9 (quat., C-22), 133.8 (quat., C-31), 133.1 
(CH, C-4), 130.8 (CH × 2, C-33,35), 130.5 (CH × 2, C-23, 27), 121.9 (CH × 2, C-24,26), 121.8 
(CH × 2, C-32,36), 104.1 (CH, C-30), 81.6, 81.2, 80.5 (quat., × 3, C-2,8,13), 55.7 (CH, C-20), 
52.8 (CH, C-4), 52.8 (CH, C-11), 39.7 (CH2, C-18), 38.6 (CH2, C-21), 32.1 (CH2, C-6), 31.6 
(CH2, C-17), 28.5 (CH2, C-5), 28.4 (CH2, C-15), 28.0 (3 × CH3 × 3, C-1,9,14), 22.5 (CH2, C-
16); m/z (ES+) 838 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C42H60N7O11 [M+H]+ requires 
838.4345, found 838.4346. 
 
(OtBu)3-PSMA-abiraterone conjugate, 395 
 
 
Following general procedure C with HATU (459 mg, 1.21 mmol), abiraterone hemisuccinate 
352 (329 mg, 0.60 mmol), amine 394 (334 mg, 0.40 mmol) and diisopropylethylamine 
(distilled, 208 mg, 275 µL, 1.61 mmol). Purification by silica gel chromatography, eluting with 
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dichloromethane and methanol (98:2) provided (OtBu)3-PSMA-abiraterone conjugate 395 (464 
mg, 0.37 mmol, 91%) as a translucent yellow solid: Rf 0.76 (90:10, CH2Cl2:MeOH, UV/cerium 
phosphomolybdate); m.p. 109-111 °C; [𝛂]𝐃𝟐𝟎+7.7, (c = 0.7, CHCl3); νmax (thin film)/cm−1 3377, 
3054, 2984, 2305, 1726, 1641, 1589, 1554, 1509, 1422, 1368, 1265, 1217, 1192, 1155, 972, 
996, 846, 739; 1H NMR (500 MHz; CDCl3) δ 8.61 (1H, s, CH-21′), 8.46 (1H, s, CH-24′), 8.25 
(1H, s, CH-30), 7.87 (2H, d, J 7.8 Hz, CH-33,36), 7.70-7.62 (4H, m, CH-33,34,35,22′), 7.25 
(1H, s, br, CH-23′), 7.19-7.09 (4H, m, CH-23,24, 26,27), 6.04 (1H, d, J 5.8, NH-urea-Lys), 
6.00-6.98 (1H, m, CH-16′), 5.23 (1H, d, J 3.7 Hz, CH-6′), 5.11-4.98 (1H, m, CH-20), 4.64-4.48 
(2H, m, CH-11,3′), 4.39 (1H, m, CH-4), 3.46-3.99 (1H, m, CHAHB-18), 3.07-2.88 (2H, m, 
CHAHB-18, CH2-21), 2.47-2.20 (9H, m, CH2-6, CH2-38, CH2-29, CH2-1′, CHAHB-12′), 2.17-
2.09 (1H, m, CHAHB-5), 2.07-1.95 (2H, m, CHAHB-7′, CHAHB-12′), 1.91-1.14 (43H, m, 3 × 
CH3-1, CHAHB-5, 3 × CH3-9, 3 × CH3-14, CH2-15,16, CHAHB-17, CH2-2′, CHAHB-4′, CHAHB-
7′, CH2-9′,11′,15′) and 1.10-1.97 (9H, m, CHAHB-17, CHAHB-4′, CH-14, CH3-18′,19′); 13C 
NMR (125 MHz; CDCl3) δ 175.7 (quat., C-29), 174.7, 174.7, 172.8, 172.6, 172.3, 171,7 (quat., 
× 6, C-3,7,12,19,37,40), 160.2 (quat., C-28), 157.7 (quat., C-10), 151.4 (quat., C-17′), 150.9 
(quat., C-25), 147.1 (CH, C-24′), 147.1 (CH, C-21′), 140.0 (quat., C-5′), 134.3 (CH, C-22′), 
133.9 (quat., C-22), 133.7 (quat., C-31), 133.3 (quat., C-20′), 133.1 (CH, C-34), 130.6 (CH × 2, 
C-23,35), 130.1 (CH × 2, C-23,27), 129.8 (CH, C-16′), 123.4 (CH, C-23′), 122.1 (CH, C-6′), 
122.0 (CH × 2, C-24,26), 121.8 (CH × 2, C-32,36), 103.6 (CH, C-30), 82.5, 80.8, 80.4 (quat., × 
6, C-2,8,13), 73.9 (CH, C-3′), 57.4 (CH, C-9′), 54.8 (CH, C-20), 53.0 (CH, C-11), 52.3 (CH, C-
4), 50.1 (CH, C-14′), 47.3 (quat., C-13′), 39.8 (CH2, C-18), 38.3 (CH2, C-21), 38.1 (CH2, C-1′), 
36.8 (CH2, C-4′), 36.7 (quat., C-10′), 35.2 (CH2, C-7′), 32.6 (CH2, C-15), 31.5 (CH2, C-15′), 
31.8 (CH2, C-12′), 31.7 (CH2, C-6), 30.3 (CH2, C-8′), 30.0 (CH2, C-16), 29.7 (CH2 × 2, C-
38,39), 29.0 (CH2, C-5), 28.1, 28.1, 28.0 (3 × CH3 × 3, C-1,9,14), 27.7 (CH2, C-2′), 22.4 (CH2, 
C-17), 20.7 (CH2, C-11′), 19.2 (CH3, C-19′), 16.6 (CH3, C-18′); m/z (ES+) 1291 ([M+Na]+, 
15%), 1269 ([M+H]+, 100%); HRMS m/z (ES+) calcd. for C70H93N8O14 [M+H]+ requires 
1269.6806, found 1269.6777. 
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PSMA-abiraterone conjugate, 396 
 
 
Trifluoroacetic acid (1 mL, 13.1 mmol) was added to a solution of amide 395 (100 mg, 0.08 
mmol) in dichloromethane (4 mL) cooled in an ice-bath. The solution was stirred for 18 h. The 
solvent was removed under reduced pressure and the residue evaporated from toluene, 
methanol, and dichloromethane. The residue was triturated with cold acetonitrile to furnish 
PSMA-abiraterone conjugate 396 (76 mg, 0.07, 88%) as a white solid: Rf 0.00 (90:10, 
CH2Cl2:MeOH, UV/cerium phosphomolybdate); m.p. 95 °C (decomp.); νmax (thin film)/cm−1 
2923, 2852, 1716, 1674, 1456, 1377, 1157, 895′ 1H NMR (500 MHz, d6-DMSO) δ 8.75 (1H, s, 
br, CH-21′), 8.64-8.61 (2H, m, CH-24,24′), 8.23 (1H, d, J 7.5 Hz, CH-22′), 8.16 (1H, d, J 8.4 
Hz, NH-succinamide), 8.05 (2H, d, J 7.6 Hz, CH-26, 30), 7.93 (1H, t, J 7.1 Hz, NH-amide), 
7.78-7.69 (4H, m, CH-27, 28, 29, 23′), 7.21 (2H, d, J 8.3 Hz, CH-18,20), 7.01 (2H, d, J 8.3 Hz, 
CH-17, 20), 6.34-6.26 (3H, m, 2 × NH-urea, CH-16′), 5.36 (1H, d, J 3.9, CH-6′), 4.45-4.37 (2H, 
m, CH-2, 7), 3.06-2.92 (3H, m, CH2-12, CHAHB-15), 2.74 (1H, dd, J 13.1, 9.6 Hz, CHAHB-15), 
2.44-2.15 (9H, m, CH2-4,32,33, CHAHB-12), 2.12-1.44 (16H, m, CH2-3, CH2-9, CH2-2′, 
CHAHB-4′, CHAHB-7′, CH-8′, CH-9′, CH2-11′, CHAHB-12′, CH2-15′), 1.41-1.31 (3H, m, CH2-11, 
CHAHB-7′), 1.25 (2H, dt, J 7.5, 6.9, CH2-10), 1.07-0.99 (8H, m, CHAHB-4′, CH-14′, CH3-
18′,19′); 13C NMR (125 MHz, d6-DMSO) δ 175.3 (quat., C-23), 175.2, 174.8, 174.3, 172.4, 
171.4, 171.3 (quat. × 6, C-1,5,7,13,31,34), 159.3 (quat., C-22), 157.9 (quat., C-6), 151.0 (quat., 
C-19), 149.7 (quat., C-17′), 143.7 (CH, C-24′), 142.8 (CH, C-21′), 140.4 (quat., C-5′), 139.3 
(CH, C-22′), 134.9 (quat., C-16), 134.6 (quat., C-20′), 134.1 (quat., C-25), 133.6 (CH, C-28), 
132.9 (CH, C-16′), 130.9 (CH × 2, C-27,29), 130.3 (CH × 2, C-18,20), 126.2 (CH, C-23′), 122.9 
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(CH × 2, C-26,30), 122.4 (CH, C-6′), 121.9 (CH × 2, C-17,21), 105.3 (CH, C-24), 73.8 (CH, C-
3′), 57.9 (CH, C-9′), 54.7 (CH, C-14), 52.8, 52.2 (CH × 2, C-2,7), 50.1 (CH, C-14′), 47.2 (quat., 
C-13′), 39.0 (CH2, C-12), 38.2 (CH2, C-1′), 37.8 (CH2, C-15), 36.9 (quat., C-10′), 36.8 (CH2, C-
4′), 34.7 (CH2, C-7′), 32.3 (CH2, C-9), 32.0 (CH2, C-12′), 31.4 (CH2, C-4), 30.4 (CH2, C-15′), 
29.9 (CH, C-8′), 29.2 (CH2, C-11), 28.2 (CH2 × 2, C-32,33), 28.1 (CH2, C-3), 27.8 (CH2, C-2′), 
23.2 (CH2, C-10), 21.0 (CH2, C-11′), 19.5 (CH3, C-19′) and 16.6 (CH3, C-18′); m/z (ES+) 1101 
([M+H]+, 100%); HRMS m/z (ES+) calcd. for C58H69N8O14 [M+H]+ requires 1101.4933, found 
1101.4945. 
 
 
6.7 MATERIALS AND METHODS 
 
Procedure adapted from that detailed in nitrite/nitrate determination kit purchased from Sigma 
Aldrich. All solutions used were from this kit. Buffer solution (pH 7.6, containing 6 mmol GST, 
4557 U mL−1, superoxide dismutase or pH 7.6 buffer) was added to the substrate (1 mmol). 
The mixture was incubated at room temperature for 1 h. Griess reagent A (1% sulfanilamide, 
5% H3PO4 in distilled H2O) was added and incubated for 5 min. Griess reagent B (N-1-
naphthyl)ethylenediamine dihydrochloride in  distilled H2O) was added and the mixture 
incubated for 10 min. The final concentration of substrate was 400 µM. UV absorbance at 568 
nm was measured using a Multiskan FC Microplate Photometer and calibrated using a standard 
curve prepared from a standard solution of NaNO2 to give nitrite concentration. Measurements 
were made in triplicate. 
References 
 
	   370	  
REFERENCES  
 
(1)  Altshuller, A. P.; Bufalini, J. J. Environ. Sci. Technol. 1971, 5, 39–64. 
(2)  Barton, C. H.; Ni, Z.; Vaziri, N. C. Am. J. Hypertens. 2003, 16, 1043–1048. 
(3)  Dawson, T. M.; Dawson, V. L. Neuroscientist 1995, 1, 7–18. 
(4)  Ignarro, L. J. Nitric Oxide, Biology and Pathobiology; Academic Press: San Diego, 1000. 
(5)  Kröncke, K.-D.; Fehsel, K.; Kolb-Bachofen, V. Nitric Oxide 1997, 1, 107–112. 
(6)  Koshland, D. E. Science 1992, 258, 1861. 
(7)  Recipients:; Furchgott, R. F.; Ignarro, L. J.; Murad, F. 1998. 
(8)  Zacharia, I. G.; Deen, W. M. Ann. Biomed. Eng. 2005, 33, 214–222. 
(9)  Andrew, P. J.; Mayer, B. Cardiovasc. Res. 1999, 43, 521–531. 
(10)  Gray, H. Anatomy of the human body; Warren, H. L., Ed.; 20th ed.; Bartleby: Philadelphia, 2000. 
(11)  Ignarro, L. J.; Bush, P. A.; Buga, G. M.; Wood, K. S.; Fukuto, J. M.; Rajfer, J. Biochem. Biophys. 
Res. Commun. 1990, 170, 843–850. 
(12)  Furchgott, R. F.; Zawadzki, J. V. Nature 1980, 288, 373–376. 
(13)  Parker, J. O.; Vankoughnett, K. A.; Farrell, B. Am. J. Cardiol. 1986, 57, 1–5. 
(14)  Yeh, B. K.; Gosselin, A. J.; Swaye, P. S.; Larsen, P. B.; Gentsch, T. O.; Traad, E. A.; Faraldo, A. 
R. Am. Heart. J. 1977, 93, 610–616. 
(15)  Ignarro, L. J.; Buga, G. M.; Wood, K. S.; Byrns, R. E.; Chaudhuri, G. Proc. Natl. Acad. Sci. 
U.S.A. 1987, 84, 9265–9269. 
(16)  Palmer, R. M. J.; Ferrige, A. G.; Moncada, S. Nature 1987, 327, 524–526. 
(17)  Rall, T. W.; Sutherland, E. W. J. Biol. Chem. 1958, 232, 1056–1076. 
(18)  Arnold, W. P.; Mittal, C. K.; Katsuki, S.; Murad, F. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 3203–
3207. 
(19)  Schultz, K.-D.; Schultz, K.; Schultz, G. Nature 1977, 265, 750–751. 
(20)  Martin, E.; Berka, V.; Tsai, A. L.; Murad, F. Methods Enzymol. 2005, 396, 478–492. 
(21)  Zabel, U.; Weeger, M.; La, M.; Schmidt, H. H. Biochem. J. 1998, 335, 51–57. 
(22)  Allerston, C. K.; Von Delft, F.; Gileadi, O. PLoS ONE 2013, 8, e57644. 
(23)  Stone, J. R.; Marletta, M. A. Biochemistry 1996, 35, 1093–1099. 
References 
 
	   371	  
(24)  Perutz, M. F.; Rossmann,, M. G.; Cullis, A. N. N. F.; Muirhead, H.; Will, G.; North, A. C. T. 
Nature 1960, 185, 416–422. 
(25)  Atkins, P.; Overton, T.; Rourke, J.; Weller, M.; Armstrong, F. Shriver and Atkins’ Inorganic 
Chemistry; Oxford University Press, 2010; p. Chapter 21. 
(26)  Hayton, T. W.; Legzdins, P.; Sharp, W. B. Chem. Rev. 2002, 102, 935–992. 
(27)  Dierks, E. A.; Hu, S.; Vogel, K. M.; Yu, A. E.; Spiro, T. G.; Burstyn, J. N. J. Am. Chem. Soc. 
1997, 119, 7316–7323. 
(28)  Ignarro, L. J.; Ballot, B.; Wood, K. S. J. Biol. Chem. 1984, 259, 6201–6207. 
(29)  Vanhoutte, P. M. Hypertension 1989, 13 , 658–667. 
(30)  Stasch, J.-P.; Pacher, P.; Evgenov, O. V Circulation 2011, 123 , 2263–2273. 
(31)  Langford, E. J.; Wainwright, R. J.; Martin, J. F. Arterioscler. Thromb. Vasc. Biol. 1996, 16, 51–
55. 
(32)  Hensley, L. E.; Geisbert, T. W. Thromb. Haemostasis 2005, 94, 254–261. 
(33)  Lee, J.-W.; Bae, S.-H.; Jeong, J.-W.; Kim, S.-H.; Kim, K.-W. Exp. Mol. Med. 2004, 36, 1–12. 
(34)  Vaupel, P.; Thews, O.; Hoeckel, M. Med. Oncol. 2001, 18, 243–259. 
(35)  Brown, J. M.; Giaccia, A. J. Cancer Res. 1998, 58, 1408–1416. 
(36)  Dewhirst, M. W.; Kimura, H.; Rehmus, S. W. E.; Braun, R. D.; Papahadjopoulos, D.; Hong, K.; 
Secomb, T. W. Br. J. Cancer 1996, 74 Suppl., S247–S251. 
(37)  Vaupel, P.; Kelleher, D. K.; Hockel, M. Semin. Oncol. 2001, 28, 29–35. 
(38)  Overgaard, J. J. Clin. Oncol. 2007, 25, 4066–4074. 
(39)  Bruick, R. K. Genes. Dev. 2003, 17, 2614–2623. 
(40)  Ke, Q.; Costa, M. Mol. Pharmacol. 2006, 70, 1469–1480. 
(41)  Wang, G. L.; Jiang, B. H.; Rue, E. A.; Semenza, G. L. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 
5510–5514. 
(42)  Carroll, V. A.; M., A. Exp. Rev. Mol. Med. 2005, 7, 1. 
(43)  Huang, L. E.; Gu, J.; Schau, M.; Bunn, H. F. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 7987–7992. 
(44)  Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J. M.; Lane, W. 
S.; Kaelin Jr., W. G. Science 2001, 292 , 464–468. 
(45)  Jaakkola, P.; Mole, D. R.; Tian, Y.-M.; Wilson, M. I.; Gielbert, J.; Gaskell, S. J.; Kriegsheim, A. 
von; Hebestreit, H. F.; Mukherji, M.; Schofield, C. J.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. 
J. Science 2001, 292, 468–472. 
(46)  Ebert, B. L.; Bunn, H. F. Blood 1999, 94 , 1864–1877. 
References 
 
	   372	  
(47)  Carmeliet, P.; Dor, Y.; Herbert, J.-M.; Fukumura, D.; Brusselmans, K.; Dewerchin, M.; Neeman, 
M.; Bono, F.; Abramovitch, R.; Maxwell, P.; Koch, C. J.; Ratcliffe, P.; Moons, L.; Jain, R. K.; 
Collen, D.; Keshet, E. Nature 1998, 394, 485–490. 
(48)  Sowter, H. M.; Ratcliffe, P. J.; Watson, P.; Greenberg, A. H.; Harris, A. L. Cancer Res. 2001, 61, 
6669–6673. 
(49)  Mateo, J.; García-Lecea, M.; Cadenas, S.; Hernández, C.; Moncada, S. Biochem. J. 2003, 376, 
537–544. 
(50)  Chandel, N. S.; Maltepe, E.; Goldwasser, E.; Mathieu, C. E.; Simon, M. C.; Schumacker, P. T. 
Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 11715–11720. 
(51)  Schroedl, C.; McClintock, D. S.; Budinger, G. R. S.; Chandel, N. S. Am. J. Physiol-Lung C 2002, 
283, L922–L931. 
(52)  Hagen, T.; Taylor, C. T.; Lam, F.; Moncada, S. Science 2003, 302 , 1975–1978. 
(53)  Pepke-Zaba, J.; Higenbottam, T. W.; Dinh-Xuan, A. T.; Stone, D.; Wallwork, J. Lancet 1991, 
338, 1173–1174. 
(54)  Smyth, R. L. Thorax 2000, 55 Suppl., S51–S55. 
(55)  Skimming, J. W.; Bender, K. A.; Hutchison, A. A.; Drummond, W. H. J. Pediatr. 1997, 130, 
225–230. 
(56)  Fukumura, D.; Kashiwagi, S.; Jain, R. K. Nat. Rev. Cancer 2006, 6, 521–534. 
(57)  Coulter, J. A.; Page, N. L.; Worthington, J.; Robson, T.; Hirst, D. G.; McCarthy, H. O. J. Gene. 
Med. 2010, 12, 755–765. 
(58)  Wink, D. A.; Cook, J. A.; Krishna, M. C.; Hanbauer, I.; Degraff, W.; Gamson, J.; Mitchell, J. B. 
Arch. Biochem. Biophys. 1995, 319, 402–407. 
(59)  Wink, D. A.; Hanbauer, I.; Krishna, M. C.; DeGraff, W.; Gamson, J.; Mitchell, J. B. Proc. Natl. 
Acad. Sci. U.S.A. 1993, 90, 9813–9817. 
(60)  Struck, A. T.; Hogg, N.; Thomas, J. P.; Kalyanaraman, B. FEBS Lett. 1995, 361, 291–294. 
(61)  Godoy, L. C.; Anderson, C. T. M.; Chowdhury, R.; Trudel, L. J.; Wogan, G. N. Proc. Natl. Acad. 
Sci. U.S.A. 2012. 
(62)  Stupp, R.; Mason, W. P.; Van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J. B.; 
Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, 
S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O. 
New Eng. J. Med. 2005, 352, 987–996. 
(63)  Eyler, C. E.; Wu, Q.; Yan, K.; MacSwords, J. M.; Chandler-Militello, D.; Misuraca, K. L.; 
Lathia, J. D.; Forrester, M. T.; Lee, J.; Stamler, J. S.; Goldman, S. A.; Bredel, M.; McLendon, R. 
E.; Sloan, A. E.; Hjelmeland, A. B.; Rich, J. N. Cell 2011, 146, 53–66. 
(64)  Thomsen, L. L.; Miles, D. W.; Happerfield, L.; Bobrow, L. G.; Knowles, R. G.; Moncada, S. Br. 
J. Cancer 1995, 72, 41–44. 
(65)  Vakkala, M.; Kahlos, K.; Lakari, E.; Pääkkö, P.; Kinnula, V.; Soini, Y. Clin. Cancer Res. 2000, 6, 
2408–2416. 
References 
 
	   373	  
(66)  Loibl, S.; Von Minckwitz, G.; Weber, S.; Sinn, H.-P.; Schini-Kerth, V. B.; Lobysheva, I.; 
Nepveu, F.; Wolf, G.; Strebhardt, K.; Kaufmann, M. Cancer 2002, 95, 1191–1198. 
(67)  Xu, W.; Liu, L. Z.; Loizidou, M.; Ahmed, M.; Charles, I. G. Cell Res. 2002, 12, 311–320. 
(68)  Burney, S.; Caulfield, J. L.; Niles, J. C.; Wishnok, J. S.; Tannenbaum, S. R. Mutat. Res.-Fund. 
Mol. M. 1999, 424, 37–49. 
(69)  Kelman, D. J.; Christodoulou, D.; Wink, D. A.; Keefer, L. K.; Srinivasan, A.; Dipple, A. 
Carcinogenesis 1997, 18 , 1045–1048. 
(70)  Niles, J. C.; Wishnok, J. S.; Tannenbaum, S. R. Nitric Oxide 2006, 14, 109–121. 
(71)  Huie, R. E.; Padmaja, S. Free Radical Res. Commun. 1993, 18, 195–199. 
(72)  Traylor, T. G.; Sharma, V. A. Biochemistry 1992, 31, 2847–2849. 
(73)  McCord, J. M.; Fridovich, I. Free Radical Biol. Med. 1988, 5, 363–369. 
(74)  Yun, B. H.; Geacintov, N. E.; Shafirovich, V. Chem. Res. Tox. 2011, 24, 1144–1152. 
(75)  Pieper, A. A.; Verma, A.; Zhang, J.; Snyder, S. H. Trends Pharmacol. Sci. 1999, 20, 171–181. 
(76)  Langelier, M.-F.; Planck, J. L.; Roy, S.; Pascal, J. M. J. Biol. Chem. 2011, 286, 10690–10701. 
(77)  Yu, X.; Hathout, Y.; Fenselau, C.; Sowder 2nd, R. C.; Henderson, L. E.; Rice, W. G.; 
Mendeleyev, J.; E., K. Chem. Res. Toxicol. 1995, 8, 586–590. 
(78)  Men, L.; Roginskaya, M.; Zou, Y.; Wang, Y. Rapid. Commun. Mass Sp. 2007, 21, 2743–2749. 
(79)  Jones, M. K.; Tsugawa, K.; Tarnawski, A. S.; Baatar, D. Biochem. Biophys. Res. Commun. 2004, 
318, 520–528. 
(80)  Wang, P. G.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A. J. Chem. Rev. 2002, 102, 
1091–1134. 
(81)  Cachofeiro, V.; Sakakibara, T.; Nasjletti, A. Hypertension 1992, 19, 138–145. 
(82)  Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A. M. Nature 1999, 
399, 601–605. 
(83)  Dhein, S.; Salameh, A. Circulation 1999, 100 , 1011–1015. 
(84)  Boschan, R.; Merrow, R. T.; Van Dolah, R. W. Chem. Rev. 1955, 55, 485–510. 
(85)  Doyle, M. P.; Terpstra, J. W.; Pickering, R. A.; LePoire, D. M. J. Org. Chem. 1983, 48, 3379–
3382. 
(86)  Lijinsky, W. Chemistry and Biology of N-Nitroso Compounds; Cambridge University Press: New 
York, 1992. 
(87)  Alston, T. A.; Porter, D. J.; Bright, H. J. J. Biol. Chem. 1985, 260, 4069–4074. 
(88)  Challis, B. C.; Challis, J. A. In Amino, Nitroso and Nitro Compounds and Their Derivatives 
(1982); John Wiley & Sons, Ltd., 2010; pp. 1151–1223. 
References 
 
	   374	  
(89)  Al-Sa’Doni, H.; Ferro, A. Clin. Sci. 2000, 98, 507–520. 
(90)  Chakrapani, H.; Bartberger, M. D.; Toone, E. J. J. Org. Chem. 2009, 74, 1450–1453. 
(91)  Gooden, D. M.; Chakrapani, H.; Toone, E. J. Curr. Top. Med. Chem. 2005, 7, 687–705. 
(92)  Gasco, A.; Fruttero, R.; Sorba, G.; Di Stilo, A.; Calvino, R. Pure Appl. Chem. 2004, 76, 973–981. 
(93)  Kankaanranta, H.; Rydell, E.; Petersson, A.-S.; Holm, P.; Moilanen, E.; Corell, T.; Karup, G.; 
Vuorinen, P.; Pedersen, S. B.; Wennmalm, Å. R.; Metsä-Ketelä, T. Br. J. Pharmacol. 1996, 117, 
401–406. 
(94)  Beal, E. N.; Turnbull, K. Synth. Commun. 1992, 22, 673–676. 
(95)  Kato, M.; Nishino, S.; Ohno, M.; Fukuyama, S.; Kita, Y.; Hirasawa, Y.; Nakanishi, I.; Takasugi, 
H.; Sakane, K. Bioorg. Med. Chem. Lett. 1996, 6, 33–38. 
(96)  DeMaster, E. G.; Raij, L.; Stephen, L. A.; Weir, E. K. Biochem. Biophys. Res. Commun. 1989, 
163, 527–533. 
(97)  Zhang, Q.; Kulczynska, A.; Webb, D. J.; Megson, I. L.; Botting, N. P. Chem. Commun. 2013, 49, 
1389–1391. 
(98)  King, S. B. Free Radical Biol. Med. 2004, 37, 737–744. 
(99)  Samuni, Y.; Samuni, U.; Goldstein, S. Biochem. Biophys. Acta 2012, 1820, 1560–1566. 
(100)  Lange, K.; Koenig, A.; Roegler, C.; Seeling, A.; Lehmann, J. Bioorg. Med. Chem. Lett. 2009, 19, 
3141–3144. 
(101)  Bolla, M.; Almirante, N.; Benedini, F. Curr. Top. Med. Chem. 2005, 5, 707–720. 
(102)  Philips, H. C. Preparation of Nitrocellulose 1950, US 2510834. 
(103)  Wheeler, W. H.; Whittaker, H.; Pike, H. H. M. J. Inst. Fuel 1947, 20, 137–156/159. 
(104)  Diplock, B. R.; Lofts, D. L.; Grimston, R. A. Aeronaut. Soc. 1953, 57, 19–28. 
(105)  Grewer, T.; Rogers, R. L. Thermochim. Acta 1993, 225, 289–301. 
(106)  Serkov, I. V; Bezuglov, V. V Chem. Nat. Comp. 2008, 44, 67–68. 
(107)  Oldham, J. W. H.; Rutherford, J. K. J. Am. Chem. Soc. 1932, 54, 366–378. 
(108)  Ferris, A. F.; McLean, K. W.; Marks, I. G.; Emmons, W. D. J. Am. Chem. Soc. 1953, 75, 4078. 
(109)  Fieser, L. F.; Doering, W. von E. J. Am. Chem. Soc. 1946, 68, 2252–2253. 
(110)  Baker, J. W.; Easty, D. M. Nature 1950, 166, 156. 
(111)  Cainelli, G.; Manescalchi, F.; Martelli, G.; Panunzio, M.; Plessi, L. Tetrahedron Lett. 1985, 26, 
3369–3372. 
(112)  Welsch, T.; Tran, H.-A.; Witulski, B. Org. Lett. 2010, 12, 5644–5647. 
References 
 
	   375	  
(113)  Hwu, J. R.; Vyas, K. A.; Patel, H. V; Lin, C.-H.; Yang, J.-C. Synthesis 1994, 471–473. 
(114)  Lucas, G. R.; Hammett, L. P. J. Am. Chem. Soc. 1942, 64, 1928–1937. 
(115)  Baker, J. W. J. Chem. Soc. 1934, 987–992. 
(116)  Capellos, C.; Fisco, W. J.; Ribaudo, C.; Hogan, V. D.; Campisi, J.; Murphy, F. X.; Castorina, T. 
C.; Rosenblatt, D. H. Int. J. Chem. Kinet. 1984, 16, 1027–1051. 
(117)  Ignarro, L. J.; Lippton, H.; Edwards, J. C.; Baricos, W. H.; Hyman, A. L.; Kadowitz, P. J.; 
Gruetter, C. A. J. Pharmacol. Exp. Ther. 1981, 218, 739–749. 
(118)  Tsou, P.-S.; Page, N.; Lee, S.; Fung, S.; Keung, W.; Fung, H.-L. AAPS J. 2011, 13, 548–555. 
(119)  Doel, J. J.; Godber, B. L. J.; Goult, T. A.; Eisenthal, R.; Harrison, R. Biochem. Biophys. Res. 
Commun. 2000, 270, 880–885. 
(120)  Keen, J. H.; Habig, W. H.; Jakoby, W. B. J. Biol. Chem. 1976, 251, 6183–6188. 
(121)  Zheng, H.; Wisedchaisri, G.; Gonen, T. Nature 2013, 497, 647–651. 
(122)  Yeates, R. A. Arzneim.-Forsch/Drug Res. 1992, 1314–1317. 
(123)  Artz, J. D.; Toader, V.; Zavorin, S. I.; Bennett, B. M.; Thatcher, G. R. J. Biochemistry 2001, 40, 
9256–9264. 
(124)  Bertinaria, M.; Rolando, B.; Giorgis, M.; Montanaro, G.; Marini, E.; Collino, M.; Benetti, E.; 
Daniele, P. G.; Fruttero, R.; Gasco, A. Eur. J. Med. Chem. 2012, 54, 103–112. 
(125)  Qin, Z.; Luo, J.; VandeVrede, L.; Tavassoli, E.; Fa’, M.; Teich, A. F.; Arancio, O.; Thatcher, G. 
R. J. J. Med. Chem. 2012, 55, 6784–6801. 
(126)  Caravaggi, A. M.; Sardi, A.; Balodi, E.; Di Francesco, G. F.; C., L. T. Arch. Int. Pharmocodyn. 
Ther. 1977, 226, 139–148. 
(127)  Kawashima, Y.; Ikemoto, T.; Horiguchi, A.; Hayashi, M.; Matsumoto, K.; Kawarasaki, K.; 
Yamazaki, R.; Okuyama, S.; Hatayama, K. J. Med. Chem. 1993, 36, 815–819. 
(128)  Gasco, A.; Boulton, A. J. Adv. Heterocyl. Chem. 1981, 29, 251–340. 
(129)  Wieland, H.; Semper, L. Leibigs. Ann. Chem. 1908, 358, 36–70. 
(130)  Godovikova, T. I.; Golova, S. P.; Streienko, Y. A.; Antipin, M. Y.; Struchkov, Y. T.; 
Khmeĺnitskii, L. I. Mendeleev Commun. 1994, 4, 7–9. 
(131)  Thakore, A. N.; Buchshriber, J.; Oehlschlager, A. C. Can. J. Chem. 1973, 51, 2406–2414. 
(132)  Emmons, W. D.; Freeman, J. P. J. Org. Chem. 1957, 22, 456–457. 
(133)  Armani, V.; Dell’Erba, C.; Marino, N.; Petrillo, G.; Tavani, C. Tetrahedron 1997, 53, 1751–1758. 
(134)  Boulton, A. J.; Hadjimihalakis, P.; Katritzky, A. R.; Hamid, A. M. J. Chem. Soc. C. 1969, 1901–
1903. 
(135)  Grundman, G.; Grünanget, P. The Nitrile Oxides; Springer-Verlag: Berlin and New York, 1971. 
References 
 
	   376	  
(136)  Mukaiyama, T.; Nambu, H.; Okamoto, M. J. Org. Chem. 1962, 27, 3651–3654. 
(137)  Whitney, R. A.; Nicholas, E. S. Tetrahedron Lett. 1981, 22, 3371–3374. 
(138)  Fruttero, R.; Sorba, G.; Ermondi, G.; Lolli, M.; Gasco, A. Il Farmaco 1997, 52, 405–410. 
(139)  Feelisch, M.; Schönafingeri, K.; Noack, H. Bio. Pharmacol. 1992, 44, 1149–1157. 
(140)  Feelisch, M.; Ostrowski, J.; Noack, E. J. Cardiovascl. Pharmacol. 1989, 14, S13–22. 
(141)  Fruttero, R.; Boschi, D.; Di Stilo, A.; Gasco, A. J. Med. Chem. 1995, 4944–4949. 
(142)  Boschi, D.; Di Stilo, A.; Cena, C.; Lolli, M.; Fruttero, R.; Gasco, A. Pharm. Res. 1997, 1750–
1758. 
(143)  Cena, C.; Visentin, S.; Di Stilo, A.; Boschi, D.; Fruttero, R.; Gasco, A. Pharm. Res. 2001, 157–
165. 
(144)  Mu, L.; Feng, S. S.; Go, M. L. Chem. Pharm. Bull. 2000, 48, 808–816. 
(145)  Turnbull, C. M.; Cena, C.; Fruttero, R.; Gasco, A.; Rossi, A. G.; Megson, I. L. Br. J. Pharmacol. 
2006, 148, 517–526. 
(146)  Lolli, M. L.; Cena, C.; Medana, C.; Lazzarato, L.; Morini, G.; Coruzzi, G.; Manarini, S.; Fruttero, 
R.; Gasco, A. J. Med. Chem. 2001, 44, 3463–3468. 
(147)  Visentin, S.; Amiel, P.; Fruttero, R.; Boschi, D.; Roussel, C.; Giusta, L.; Carbone, E.; Gasco, A. 
J. Med. Chem. 1999, 42, 1422–1427. 
(148)  Bertinaria, M.; Galli, U.; Sorba, G.; Fruttero, R.; Gasco, A.; Brenciaglia, M. I.; Scaltrito, M. M.; 
Dubini, F. Drug. Dev. Res. 2003, 60, 225–239. 
(149)  Bertinaria, M.; Sorba, G.; Medana, C.; Cena, C.; Adami, M.; Morini, G.; Pozzoli, C.; Coruzzi, G.; 
Gasco, A. Helv. Chim. Acta 2000, 83, 287–299. 
(150)  Tosco, P.; Bertinaria, M.; Stilo, A. Di; Cena, C.; Sorba, G.; Fruttero, R.; Gasco, A. Bioorg. Med. 
Chem. 2005, 13, 4750–4759. 
(151)  Moharram, S.; Zhou, A.; Wiebe, L. I.; Knaus, E. E. J. Med. Chem. 2004, 47, 1840–1846. 
(152)  Wang, T.; Zhang, Y.-H.; Kong, X.-W.; Lai, Y.-S.; Ji, H.; Chen, Y.-P.; Peng, S.-X. Chem. 
Biodivers. 2009, 6, 466–74. 
(153)  Min, T.; Yi, B.; Zhang, P.; Liu, J.; Zhang, C.; Zhou, H. Med. Chem. Res. 2009, 18, 495–510. 
(154)  Lai, Y.; Shen, L.; Zhang, Z.; Liu, W.; Zhang, Y.; Ji, H.; Tian, J. Bioorg. Med. Chem. Lett. 2010, 
20, 6416–6420. 
(155)  Buonsanti, M. F.; Bertinaria, M.; Di Stilo, A.; Cena, C.; Fruttero, R.; Gasco, A. J. Med. Chem. 
2007, 50, 5003–5011. 
(156)  Lolli, M. L.; Rolando, B.; Tosco, P.; Chaurasia, S.; Stilo, A. Di; Lazzarato, L.; Gorassini, E.; 
Ferracini, R.; Oliaro-Bosso, S.; Fruttero, R.; Gasco, A. J. Med. Chem. 2010, 18, 2428–2438. 
(157)  Schiefer, I. T.; VandeVrede, L.; Fa’, M.; Arancio, O.; Thatcher, G. R. J. J. Med. Chem. 2012, 55, 
3076–3087. 
References 
 
	   377	  
(158)  Peng, S.; Wuu, J.; Mufson, E. J.; Fahnestock, M. J. Neurochem. 2005, 93, 1412–1421. 
(159)  Montanaro, G.; Bertinaria, M.; Rolando, B.; Fruttero, R.; Lucas, C. D.; Dorward, D. A.; Rossi, A. 
G.; Megson, I. L.; Gasco, A. Bioorg. Med. Chem. 2013, 21, 2107–2116. 
(160)  Brookes, P.; Walker, J. J. Chem. Soc. 1957, 4409–4416. 
(161)  Fischer, E. Justus Leibigs Ann. Chem. 1882, 316–339. 
(162)  Kato, H.; Hashimoto, H.; Ohta, M. Nippon Kagaku Zasshi 1957, 707. 
(163)  Bartsch, H.; Montesano, R. Carcinogenesis 1984, 5, 1381–1393. 
(164)  Daeniker, H. U.; Druey, J. Helv. Chim. Acta 1962, 45, 2441–2462. 
(165)  Ruxer, J. M.; Mauger, J.; Bénard, D.; Lachoux, C. J. Heterocycl. Chem. 1995, 32, 643–654. 
(166)  Ohta, M.; Sato, S. Bull. Chem. Soc. Jpn. 1966, 39, 1269–1273. 
(167)  Parshin, V. A.; Olovyanishnikova, Z. A.; Yashunskii, V. G.; Mashkovskii, M. D. Pharm. Chem. 
Journal. 1981, 15, 333–337. 
(168)  Boehringer Sohm Ingelheim: Sydnonimine Derivatives 1969, GB1219254. 
(169)  Götz, M.; Grozinger, K.; Oliver, J. T. J. Med. Chem. 1973, 16, 671–3. 
(170)  Bohn, H.; Schönafinger, K. J. Cardiovascl. Pharmacol. 1989, 14, Suppl 11 S6–12. 
(171)  Khmel’nitskaya, E.Y., Trukhacheva, L.A., Grigoriev, N.B., Kalinin, V.N., Cherepanov, I.A., 
Lebedev, S.N., and Granik, V. G. Russ. Chem. Bull. Int. Ed. 2004, 53, 2840–2844. 
(172)  Holm, P.; Kankaanranta, H.; Metsä-Ketelä, T.; Moilanen, E. Eur. J. Pharmacol. 1998, 346, 97–
102. 
(173)  Chernov, V. A.; Yashunskii, V. G. Dokl. Akad. Nauk SSSR 1964, 155, 216. 
(174)  Oehme, P.; Gores, K.; K., S.; Petsch, G.; Faulhaber, H.; P., L. Acta. Biol. Med. Ger. 1965, 14, 
369. 
(175)  Yashunskii, V. G.; Kholodov, L. E. Russ. Chem. Rev. 1980, 28–45. 
(176)  Balakumaran, K.; Hugenholtz, P. G.; Tijssen, J. G. P.; Chadha, D. E. V. R. Eur. Heart. J. 1983, 4, 
655–661. 
(177)  Bohn, H.; Beyerle, R.; Martorana, P. A.; Schönafinger, K. J. Cardiovascl. Pharmacol. 1991, 18. 
(178)  Soulère, L.; Bringaud, F.; Hoffmann, P. J. Heterocycl. Chem. 2003, 40, 943–947. 
(179)  Hagos, A.; Goddeeris, B. M.; Yilkal, K.; Alemu, T.; Fikru, R.; Yacob, H. T.; Feseha, G.; Claes, F. 
Vet. Parasitol. 2010, 171, 200–206. 
(180)  Cai, T. B.; Lu, D.; Tang, X.; Zhang, Y.; Landerholm, M.; Wang, P. G. J. Org. Chem. 2005, 70, 
3518–3524. 
(181)  Tang, X.; Cai, T.; Wang, P. G. Bioorg. Med. Chem. Lett. 2003, 13, 1687–1690. 
References 
 
	   378	  
(182)  Maples, K.; Sandstrom, T.; Su, Y.; Henderson, R. Am. J. Respir. Cell. Mol. Biol. 1992, 4, 538–
543. 
(183)  Arroyo, C.; Kohno, M. Free Radical Res. Commun. 1991, 145–155. 
(184)  Greenberg, S. S.; Wilcox, D. E.; Rubanyi, G. M. Circ. Res. 1990, 67, 1446–1452. 
(185)  Wang, Q.; Jacobs, J.; DeLeo, J.; Kruszyna, H.; Kruszyna, R.; Smith, R.; Wilcox, D. Life Sci. 
1991, 49, PL55–PL60. 
(186)  Westernberger, U.; Thanner, S.; Ruf, H.; Gersonde, K.; Sutter, G.; Trentz, O. Free Radical Res. 
Commun. 1990, 11, 167–178. 
(187)  Kelm, M.; Feelisch, M.; Spahr, R.; Piper, H.-M.; Noack, E.; Schrader, J. Biochem. Biophys. Res. 
Commun. 1988, 154, 236–244. 
(188)  Tsikas, D. J. Chromatogr. B. 2007, 851, 51–70. 
(189)  Zafiriou, O. C.; McFarland, M. Anal. Chem. 1980, 52, 1662–1667. 
(190)  Menon, N.; Wolf, A.; Zehetgruber, M.; Bing, R. Proc. Soc. Exp. Biol. Med. 1989, 191, 316–319. 
(191)  Lee, C. H.; Akin-Olugbade, O.; Kirschenbaum, A. Endocrin. Metab. Clin. North. Am. 2011, 40, 
565–575. 
(192)  Balk, S. P.; Ko, Y.-J.; Bubley, G. J. J. Clin. Oncol. 2003, 21, 383–391. 
(193)  Gnanapragasam, V. J.; Robson, C. N.; Leung, H. Y.; Neal, D. E. BJU Int. 2000, 86, 1001–1013. 
(194)  Mooradian, A. D.; Morley, J. E.; Korenman, S. G. Endocr. Rev. 1987, 8, 1–28. 
(195)  Thomas, L. N.; Douglas, R. C.; Rittmaster, R. S.; Too, C. K. L. Prostate 2009, 69, 595–602. 
(196)  Carter, B. S.; Beaty, T. H.; Steinberg, G. D.; Childs, B.; Walsh, P. C. Proc. Natl. Acad. Sci. 
U.S.A. 1992, 89, 3367–3371. 
(197)  Sakr, W. J.; Grignon, D. J.; Haas, G. P.; Heilbrun, L. K.; Pontes, J. E.; Crissman, J. D. Cancer 
Risk Management Programme information for Primary Care, PSA testing for asymptomatic men; 
2008; p. NHS Cancer Screening Programmes: Sheffield. 
(198)  Huggins, C.; Hodges, C. V. Cancer Res. 1941, 1, 293–297. 
(199)  Hessels, D.; Schalken, J. A. Asian J. Androl. 2013, 15, 333–339. 
(200)  Wang, L.; Scherr, D.; Shariat, S. In Prostate Cancer Diagnosis SE-7; Jones, J. S., Ed.; Humana 
Press, 2013; pp. 73–84. 
(201)  Quinn, D.; Swanson, G. In Biomarkers in Oncology SE  - 9; Lenz, H.-J., Ed.; Springer New York, 
2013; pp. 189–247. 
(202)  Schröder, F. H.; Hermanek, P.; Denis, L.; Fair, W. R.; Gospodarowicz, M. K.; Pavone-Macaluso, 
M. Prostate 1992, 21, 129–138. 
(203)  Barry, M. J. New Eng. J. Med. 2001, 344, 1373–1377. 
(204)  Carlin, B. I.; Andriole, G. L. Cancer 2000, 88, 2989–1994. 
References 
 
	   379	  
(205)  Bubendorf, L.; Schöpfer, A.; Wagner, U.; Sauter, G.; Moch, H.; Willi, N.; Gasser, T. C.; 
Mihatsch, M. J. Hum. Pathol. 2000, 31, 578–583. 
(206)  Steinberg, G. D.; Carter, B. S.; Beaty, T. H.; Childs, B.; Walsh, P. C. Prostate 1990, 17, 337–347. 
(207)  Smith, J. R.; Freije, D.; Carpten, J. D.; Grönberg, H.; Xu, J.; Isaacs, S. D.; Brownstein, M. J.; 
Bova, G. S.; Guo, H.; Bujnovszky, P.; Nusskern, D. R.; Damber, J.-E.; Bergh, A.; Emanuelsson, 
M.; Kallioniemi, O. P.; Walker-Daniels, J.; Bailey-Wilson, J. E.; Beaty, T. H.; Meyers, D. A.; 
Walsh, P. C.; Collins, F. S.; Trent, J. M.; Isaacs, W. B. Science 1996, 274 , 1371–1374. 
(208)  McIndoe, R. A.; Stanford, J. L.; Gibbs, M.; Jarvik, G. P.; Brandzel, S.; Neal, C. L.; Li, S.; 
Gammack, J. T.; Gay, A. A.; Goode, E. L.; Hood, L.; Ostrander, E. A. Am. J. Hum. Genet. 1997, 
61, 347–353. 
(209)  Jarvik, G. P.; Stanford, J. L.; Goode, E. L.; McIndoe, R.; Kolb, S.; Gibbs, M.; Hood, L.; 
Ostrander, E. A. J. Natl. Cancer Inst. Monogr. 1999, 1999, 81–87. 
(210)  Cooney, K. A.; Huang, L.; Sandler, H. M.; Lange, E.; Lange, K.; Miesfeldt, S.; McCarthy, J. D.; 
Montie, J. E.; Oesterling, J. E. J. Natl. Cancer Inst. 1997, 89, 955–959. 
(211)  Grönberg, H.; Smith, J.; Emanuelsson, M.; Jonsson, B.-A.; Bergh, A.; Carpten, J.; Isaacs, W.; Xu, 
J.; Meyers, D.; Trent, J.; Damber, J.-E. Am. J. Hum. Genet. 1999, 65, 134–140. 
(212)  Gurel, B.; Alexander, R.; Cheng, L.; Marzo, A. In Molecular Surgical Pathology SE  - 10; Cheng, 
L.; Eble, J. N., Eds.; Springer New York, 2013; pp. 213–228. 
(213)  Peehl, D. M. Cancer 1993, 71, 1159–1164. 
(214)  Castro, E.; Goh, C.; Olmos, D.; Saunders, E.; Leongamornlert, D.; Tymrakiewicz, M.; Mahmud, 
N.; Dadaev, T.; Govindasami, K.; Guy, M.; Sawyer, E.; Wilkinson, R.; Ardern-Jones, A.; Ellis, 
S.; Frost, D.; Peock, S.; Evans, D. G.; Tischkowitz, M.; Cole, T.; Davidson, R.; Eccles, D.; 
Brewer, C.; Douglas, F.; Porteous, M. E.; Donaldson, A.; Dorkins, H.; Izatt, L.; Cook, J.; 
Hodgson, S.; Kennedy, M. J.; Side, L. E.; Eason, J.; Murray, A.; Antoniou, A. C.; Easton, D. F.; 
Kote-Jarai, Z.; Eeles, R. J. Clin. Oncol. 2013. 
(215)  Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P. A.; Harshman, K.; Tavtigian, S.; Liu, Q.; 
Cochran, C.; Bennett, L. M.; Ding, W.; et, al. Science 1994, 266 , 66–71. 
(216)  King, M.-C.; Marks, J. H.; Mandell, J. B.; Group, T. N. Y. B. C. S. Science 2003, 302, 643–646. 
(217)  Karayi, M. K.; Neal, D. E.; Markham, A. F. BJU Int. 2000, 86, 659–669. 
(218)  Heinlein, C. A.; Chang, C. Endocr. Rev. 2004, 25, 276–308. 
(219)  Pereira de Jésus-Tran, K.; Côté, P.-L.; Cantin, L.; Blanchet, J.; Labrie, F.; Breton, R. Protein Sci. 
2006, 15, 987–999. 
(220)  Brinkmann, A. O.; Faber, P. W.; Van Rooij, H. C. J.; Kuiper, G. G. J. M.; Ris, C.; Klaassen, P.; 
Van der Korput, J. A. G. M.; Voorhorst, M. M.; Van Laar, J. H.; Mulder, E.; Trapman, J. J. 
Steroid Biochem. Mol. Biol. 1989, 34, 307–310. 
(221)  Smith, D. F.; Toft, D. O. Mol. Endocrinol. 2008, 22, 2229–2240. 
(222)  Clark, P. A.; Rogol, A. D. Endocrin. Metab. Clin. North. Am. 1996, 25, 665–681. 
(223)  De Marzo, A. M.; Nelson, W. F.; Meeker, A.; Coffey, D. S. J. Urol. 1998, 160, 2381–2392. 
References 
 
	   380	  
(224)  Sadi, M. V; Walsh, P. C.; Barrack, E. R. Cancer 1991, 67, 3057–3064. 
(225)  English, H. F.; Kyprianou, N.; Isaacs, J. T. Prostate 1989, 15, 233–250. 
(226)  Ruizeveld De Winter, J. A.; Janssen, P. J.; Sleddens, H. M.; Verleun-Mooijman, M. C.; Trapman, 
J.; Brinkmann, A. O.; Santerse, A. B.; Schröder, F. H.; Van Der Kwast, T. H. Am. J. Pathol. 
1994, 144, 735–746. 
(227)  Zegarra-Moro, O. L.; Schmidt, L. J.; Huang, H.; Tindall, D. J. Cancer Res. 2002, 62, 1008–1013. 
(228)  Feldman, B. J.; Feldman, D. Nat. Rev. Cancer 2001, 1, 34–45. 
(229)  Linja, M. J.; Savinainen, K. J.; Saramäki, O. R.; Tammela, T. L. J.; Vessella, R. L.; Visakorpi, T. 
Cancer Res. 2001, 61, 3550–3555. 
(230)  Visakorpi, T.; Hyytinen, E.; Koivisto, P.; Tanner, M.; Keinanen, R.; Palmberg, C.; Palotie, A.; 
Tammela, T.; Isola, J.; Kallioniemi, O.-P. Nat. Genet. 1995, 9, 401–406. 
(231)  Cher, M. L.; Bova, G. S.; Moore, D. H.; Small, E. J.; Carroll, P. R.; Pin, S. S.; Epstein, J. I.; 
Isaacs, W. B.; Jensen, R. H. Cancer Res. 1996, 56, 3091–3102. 
(232)  Zong, Y.; Goldstein, A. S. Nat. Rev. Urol. 2013, 10, 90–98. 
(233)  Labrie, A.; Dupont, A.; Bélanger, A.; St-Arnaud, R.; Giguère, M.; Lacourcière, Y.; Emond, J.; 
Monfette, G. Endocr. Rev. 1986, 7, 67–74. 
(234)  Tan, J.; Sharief, Y.; Hamil, K. G.; Gregory, C. W.; Zang, D.-Y.; Sar, M.; Gumerlock, P. H.; 
deVere White, R. W.; Pretlow, T. G.; Harris, S. E.; Wilson, E. M.; Mohler, J. L.; French, F. S. 
Mol. Endocrinol. 1997, 11, 450–459. 
(235)  Veldscholte, J.; Voorhorst-Ogink, M. M.; Bolt-de Vries, J.; Van Rooij, H. C. J.; Trapman, J.; 
Mulder, E. BBA- Mol. Cell. Res. 1990, 1052, 187–194. 
(236)  Culig, Z.; Hobisch, A.; Cronauer, M. V; Cato, A. C.; Hittmair, A.; Radmayr, C.; Eberle, J.; 
Bartsch, G.; Klocker, H. Mol. Endocrinol. 1993, 7, 1541–1550. 
(237)  Miyamoto, H.; Yeh, S.; Wilding, G.; Chang, C. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 7379–
7384. 
(238)  Terekawa, T.; Miyake, H.; Kumano, M.; Sakai, I.; Fujisawa, M. Oncol. Rep. 2010, 25, 1395–
1399. 
(239)  Jenster, G. J. Pathol. 2000, 191, 227–228. 
(240)  Shi, X.-B.; Ma, A.-H.; Xia, L.; Kung, H.-J.; De Vere White, R. W. Cancer Res. 2002, 62, 1496–
1502. 
(241)  Yeh, S.; Lin, H.-K.; Kang, H.-Y.; Thin, T. H.; Lin, M.-F.; Chang, C. Proc. Natl. Acad. Sci. U.S.A. 
1999, 96, 5458–5463. 
(242)  Shukla, S.; MacLennan, G. T.; Hartman, D. J.; Fu, P.; Resnick, M. I.; Gupta, S. Int. J. Cancer 
2007, 121, 1424–1432. 
(243)  Bélanger, A.; Van Halbeek, H.; Graves, H. C. B.; Grandbois, K.; Stamey, T. A.; Huang, L.; 
Poppe, I.; Labrie, F. Prostate 1995, 27, 187–197. 
References 
 
	   381	  
(244)  Stenman, U.-H.; Leinonen, J.; Zhang, W.-M.; Finne, P. Semin. Cancer. Biol. 1999, 9, 83–93. 
(245)  Moyer, V. A. Ann. Intern. Med. 2012, 157, 120–134. 
(246)  Folkman, J. Nat. Med. Med. 1995, 1, 27–31. 
(247)  Cleutjens, K. B. J. M.; Van Eekelen, C. C. E. M.; Van der Korput, H. A. G. M.; Brinkmann, A. 
O.; Trapman, J. J. Biol. Chem. 1996, 271, 6379–6388. 
(248)  Bostwick, D. G.; Pacelli, A.; Blute, M.; Roche, P.; Murphy, G. P. Cancer 1998, 82, 2256–2261. 
(249)  Kawakami, M.; Nakayama, J. Cancer Res. 1997, 57, 2321–2324. 
(250)  Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C. Clin. Cancer Res. 1997, 
3, 81–85. 
(251)  Davis, M. I.; Bennett, M. J.; Thomas, L. M.; Bjorkman, P. J. Proc. Natl. Acad. Sci. U.S.A. 2005, 
102, 5981–5986. 
(252)  Pinto, J. T.; Suffoletto, B. P.; Berzin, T. M.; Qiao, C. H.; Lin, S.; Tong, W. P.; May, F.; 
Mukherjee, B.; Heston, W. D. Clin. Cancer Res. 1996, 2, 1445–1451. 
(253)  Liu, H.; Rajasekaran, A. K.; Moy, P.; Xia, Y.; Kim, S.; Navarro, V.; Rahmati, R.; Bander, N. H. 
Cancer Res. 1998, 58, 4055–4060. 
(254)  Murphy, G. P.; Elgamal, A. A.; Su, S. L.; Bostwick, D. G.; Holmes, E. H. Cancer 1998, 83, 
2259–2269. 
(255)  Smith-Jones, P. M.; Vallabahajosula, S.; Goldsmith, S. J.; Navarro, V.; Hunter, C. J.; Bastidas, 
D.; Bander, N. H. Cancer Res. 2000, 60, 5237. 
(256)  Kozikowski, A. P.; Nan, F.; Conti, P.; Zhang, J.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; 
Neale, J. H.; Pshenichkin, S.; Wroblewski, J. T. J. Med. Chem. 2001, 44, 298–301. 
(257)  Maresca, K. P.; Hillier, S. M.; Femia, F. J.; Keith, D.; Barone, C.; Joyal, J. L.; Zimmerman, C. 
N.; Kozikowski, A. P.; Barrett, J. A.; Eckelman, W. C.; Babich, J. W. J. Med. Chem. 2008, 52, 
347–357. 
(258)  Fleming, C.; Wasson, J. H.; Albertsen, P. C. JAMA 1993, 269, 2650–2658. 
(259)  Young, H. H. J. Urol. 1905, 168, 914–21. 
(260)  Millin, T. J. Urol. 1948, 59, 267–280. 
(261)  Walsh, P. C.; Partin, A. W.; Epstein, J. I. J. Urol. 1994, 152, 1831–1836. 
(262)  Liss, M. A.; Lusch, A.; Morales, B.; Beheshti, N.; Skarecky, D.; Narula, N.; Osann, K.; Ahlering, 
T. E. J. Urol. 2012, 188, 2205–2211. 
(263)  Eisenberger, M. A.; Blumenstein, B. A.; Crawford, E. D.; Miller, G.; McLeod, D. G.; Loehrer, P. 
J.; Wilding, G.; Sears, K.; Culkin, D. J.; Thompson, I. M.; Bueschen, A. J.; Lowe, B. A. New 
Eng. J. Med. 1998, 339, 1036–1042. 
(264)  Pollack, A.; Smith, L. G.; Von Eschenbach, A. C. Int. J. Radiat. Oncol. 2000, 48, 507–512. 
References 
 
	   382	  
(265)  Vicini M.D., F. A.; Horwitz M.D., E. M.; Kini M.D., V. R.; Stromberg M.D., J. S.; Martinez 
M.D. Alvaro A, F. Int. J. Radiat. Oncol. Biol. Phys. 1998, 40, 1101–1110. 
(266)  Zelefsky, M. J.; Fuks, Z.; Hunt, M.; Lee, H. J.; Lombardi, D.; Ling, C. C.; Reuter, V. E.; 
Venkatraman, E. S.; Leibel, S. A. J. Urol. 2001, 166, 876–881. 
(267)  Wallner, K. Oncology 1991, 5, 115–122. 
(268)  Blasko, J. C.; Grimm, P. D.; Sylvester, J. E.; Badiozamani, K. R.; Hoak, D.; Cavanagh, W. Int. J. 
Radiat. Oncol. Biol. Phys. 2000, 46, 839–850. 
(269)  Murphy, M. K.; Piper, R. K.; Greenwood, L. R.; Mitch, M. G.; Lamperti, P. J.; Seltzer, S. M.; 
Bales, M. J.; Phillips, M. H. Med. Phys. 2004, 31, 1529–1538. 
(270)  Chin, Y. S.; Bullard, J.; Bryant, L.; Bownes, P.; Ostler, P.; Hoskin, P. J. Clin. Oncol. 2006, 18, 
474–479. 
(271)  Parker, C.; Heinrich, D.; O’Sullivan, J. M.; Fossa, S.; Chodacki, A.; Demkow, T.; Cross, A.; 
Bolstad, B.; Garcia-Vargas, J.; Sartor, O. Eur. J. Cancer 2011, 47, 3. 
(272)  Hafeez, S.; Parker, C. Exp. Opin. Exp. Drug 2013, 22, 379–387. 
(273)  McLeod, D. G.; Crawford, E. D.; DeAntoni, E. P. Eur. Urol. 1997, 32 Suppl 3, 70–77. 
(274)  Borgmann, V.; Hardt, W.; Schmidt-Gollwitzer, M.; Adenauer, H.; Nagel, R. Lancet 1982, 319, 
1097–1099. 
(275)  Karten, M. J.; Rivier, J. E. Endocr. Rev. 1986, 7, 44–66. 
(276)  Thompson, I. M. Rev. Urol. 2001, Suppl. 3, S10–S14. 
(277)  Labrie, F. Cancer 1993, 72, 3816–3827. 
(278)  Neumann, F. J. Steroid Biochem. Mol. Biol.id 1983, 19, 391–402. 
(279)  Rabe, T.; Feldmann, K.; Heinemann, L.; Runnebaum, B. Drug Safety 1996, 14, 25–38. 
(280)  Holdaway, I. M.; Croxson, M. S.; Evans, M. C.; France, J.; Sheehan, A.; Wilson, T.; Ibbertson, 
H. K. Acta Endocrinol.-COP 1983, 104, 222–226. 
(281)  Tyrrell, C. J.; Kaisary, A. V; Iversen, P.; Anderson, J. B.; Baert, L.; Tammela, T.; Chamberlain, 
M.; Webster, A.; Blackledge, G. Eur. Urol. 1998, 33, 447–456. 
(282)  Katchen, B.; Buxbaum, S. J. Clin. Endocrinol. Metab. 1975, 41, 373–379. 
(283)  Kassouf, W.; Tanguay, S.; Aprikian, A. G. J. Urol. 2003, 169, 1742–1744. 
(284)  Tucker, H.; Crook, J. W.; Chesterson, G. J. J. Med. Chem. 1988, 31, 954–959. 
(285)  Yin, D.; He, Y.; Perera, M. A.; Hong, S. S.; Marhefka, C.; Stourman, N.; Kirkovsky, L.; Miller, 
D. D.; Dalton, J. T. Mol. Pharmacol. 2003, 63, 211–223. 
(286)  Cook, T.; Sheridan, W. P. The Oncologist 2000, 5 , 162–168. 
(287)  Klotz, L.; Boccon-Gibod, L.; Shore, N. D.; Andreou, C.; Persson, B.-E.; Cantor, P.; Jensen, J.-K.; 
Olesen, T. K.; Schröder, F. H. BJU Int. 2008, 102, 1531–1538. 
References 
 
	   383	  
(288)  Reid, A. H. M.; Attard, G.; Barrie, E.; De Bono, J. S. Nat. Clin. Pract. Oncol. 2008, 5, 610–620. 
(289)  Van Wauwe, J. P.; Janssen, P. A. J. J. Med. Chem. 1989, 32, 2231–2239. 
(290)  Stanbrough, M.; Bubley, G. J.; Ross, K.; Golub, T. R.; Rubin, M. A.; Penning, T. M.; Febbo, P. 
G.; Balk, S. P. Cancer Res. 2006, 66, 2815–2825. 
(291)  Potter, G. A.; Barrie, S. E.; Jarman, M.; Rowlands, M. G. J. Med. Chem. 1995, 38, 2463–2471. 
(292)  Denis, L. J.; Griffiths, K. Semin. Surg. Oncol. 2000, 18, 52–74. 
(293)  Forti, G.; Salerno, R.; Moneti, G.; Zoppi, S.; Fiorelli, G.; Marinoni, T.; Natali, A.; Costantini, A.; 
Serio, M.; Martini, L.; Motta, M. JCEM 1989, 68, 461–468. 
(294)  Russell, P. J.; Bennett, S.; Stricker, P. Clin. Chem. 1998, 44, 705–723. 
(295)  Buttyan, R.; Ghafar, M. A.; Shabsigh, A. Curr. Opin. Urol. 2000, 10. 
(296)  Gilligan, T.; Kantoff, P. W. Urology 2002, 60, 94–100. 
(297)  Petrylak, D. P.; Tangen, C. M.; Hussain, M. H. A.; Lara, P. N.; Jones, J. A.; Taplin, M. E.; Burch, 
P. A.; Berry, D.; Moinpour, C.; Kohli, M.; Benson, M. C.; Small, E. J.; Raghavan, D.; Crawford, 
E. D. New Eng. J. Med. 2004, 351, 1513–1520. 
(298)  Stewart, G. D.; Nanda, J.; Brown, D. J. G.; Riddick, A. C. P.; Ross, J. A.; Habib, F. K. Int. J. 
Cancer 2009, 124, 223–32. 
(299)  Kaighn, M. E.; Narayan, K. S.; Ohnuki, Y.; Lechner, J. F.; W., J. L. Invest. Urol. 1979, 17, 16–
23. 
(300)  Pulukuri, S. M.; Gondi, C. S.; Lakka, S. S.; Jutla, A.; Estes, N.; Gujrati, M.; Rao, J. S. J. Biol. 
Chem. 2005, 280, 36529–36540. 
(301)  Sun, H.-L.; Liu, Y.-N.; Huang, Y.-T.; Pan, S.-L.; Huang, D.-Y.; Guh, J.-H.; Lee, F.-Y.; Kuo, S.-
C.; Teng, C.-M. Oncogene 2007, 26, 3941–3951. 
(302)  Zhong, H.; Agani, F.; Baccala, A. A.; Laughner, E.; Rioseco-Camacho, N.; Isaacs, W. B.; 
Simons, J. W.; Semenza, G. L. Cancer Res. 1998, 58, 5280–5284. 
(303)  Zundel, W.; Schindler, C.; Haas-Kogan, D.; Koong, A.; Kaper, F.; Chen, E.; Gottschalk, A. R.; 
Ryan, H. E.; Johnson, R. S.; Jefferson, A. B.; Stokoe, D.; Giaccia, A. J. Genes. Dev. 2000, 14, 
391–396. 
(304)  Stewart, G. D.; Nanda, J.; Katz, E.; Bowman, K. J.; Christie, J. G.; Brown, D. J. G.; McLaren, D. 
B.; Riddick, A. C. P.; Ross, J. A.; Jones, G. D. D.; Habib, F. K. Biochem. Pharmacol. 2011, 81, 
203–210. 
(305)  Royle, J. S.; Ross, J. A.; Ansell, I. A. N.; Bollina, P.; Tulloch, D. N.; K., H. F. J. Urol. 2004, 172, 
338–344. 
(306)  Goluboff, E. T.; Shabsigh, A.; Saidi, J. A.; Weinstein, I. B.; Mitra, N.; Heitjan, D.; Piazza, G. A.; 
Pamukcu, R.; Buttyan, R.; Olsson, C. A. Urology 1999, 53, 440–445. 
(307)  Sinicrope, F. A.; Penington, R. C. Mol. Cancer. Ther. 2005, 4, 1475–1483. 
References 
 
	   384	  
(308)  Fogli, S.; Banti, I.; Stefanelli, F.; Picchianti, L.; Digiacomo, M.; Macchia, M.; Breschi, M. C.; 
Lapucci, A. Eur. J. Med. Chem. 2010, 45, 5100–5107. 
(309)  Kikuchi, S.; Konishi, H.; Hashimoto, Y. Tetrahedron 2005, 61, 3587–3591. 
(310)  5 g of ca. 3 mmol/g at a cost of £130.00 (Sigma Aldrich, 93093-5G, June 2013). 
(311)  Trost, B. M. Strategy and Efficienty in Modern Chemistry: Reduction v. 8; Pergamon, 1992; pp. 
404–407. 
(312)  Neises, B.; Steglich, W. Angew. Chem. Int. Ed. 1978, 17, 522–524. 
(313)  Keck, G. E.; Heumann, S. A. Org. Lett. 2008, 10, 4783–4786. 
(314)  Treves, K.; Shragina, L.; Rudich, Y. J. Phys. Chem. A 2002, 106, 5902–5907. 
(315)  Nortcliffe, A. Towards N-diazeniumdiolate analogues of Sulindac, MSc Thesis, University of 
Edinburgh, 2010. 
(316)  Taillier, C.; Gille, B.; Bellosta, V.; Cossy, J. J. Org. Chem. 2005, 70, 2097–2108. 
(317)  Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis; 3rd ed.; John Wiley & 
Sons, Inc., 1991. 
(318)  Biava, M.; Porretta, G. C.; Poce, G.; Battilocchio, C.; Alfonso, S.; Rovini, M.; Valenti, S.; Giorgi, 
G.; Calderone, V.; Martelli, A.; Testai, L.; Sautebin, L.; Rossi, A.; Papa, G.; Ghelardini, C.; Di 
Cesare Mannelli, L.; Giordani, A.; Anzellotti, P.; Bruno, A.; Patrignani, P.; Anzini, M. J. Med. 
Chem. 2011, 54, 7759–7771. 
(319)  Shan, R.; Velazquez, C.; Knaus, E. E. J. Med. Chem. 2003, 47, 254–261. 
(320)  Mayants, A. G.; Pyreseva, K. G.; Gordeichuk, S. S. Zhurnal Organicheskoi Khimii 1986, 22, 
2120–2123. 
(321)  Farrar, W. V J. Chem. Soc. 1964, 904. 
(322)  Nitromed 2007, p. WO2007/59311 A2 p62–63. 
(323)  Bahrami, K.; Khodaei, M. M.; Sheikh Arabi, M. J. Org. Chem. 2010, 75, 6208–6213. 
(324)  Lautens, M.; Paquin, J.-F.; Piguel, S. J. Org. Chem. 2002, 67, 3972–3974. 
(325)  Woo, Y.-H.; Fernandes, R. P. M.; Proteau, J. P. Bioorg. Med. Chem. 2006, 14, 2375–2385. 
(326)  Leclerc, E.; Vrancken, E.; Mangeney, P. J. Org. Chem. 2002, 67, 8928–37. 
(327)  Halder, S.; Satyam, A. Tetrahedron Lett. 2001, 52, 1179–1182. 
(328)  Stefaniak, L.; Witanowski, M.; Kamienski, B.; Webb, G. A. Org. Mag. Res. 1980, 13, 274–276. 
(329)  Sun, C.; Zhu, J.; Wang, H.; Jin, J.; Yang, D.; Xing, J. Eur. J. Med. Chem. 2011, 46, 11–20. 
(330)  Schröder, F.; Crawford, E. D.; Axcrona, K.; Payne, H.; Keane, T. E. BJU Int. 2012, 109, 1–12. 
(331)  Seruga, B.; Ocana, A.; Tannock, I. F. Nat. Rev. Clin. Oncol. 2011, 8, 12–23. 
References 
 
	   385	  
(332)  Reid, A. H. M.; Attard, G.; Barrie, E.; Bono, J. S. De Nat. Clin. Pract. Oncol. 2008, 5, 610–620. 
(333)  Small, E. J.; Halabi, S.; Dawson, N. A.; Stadler, W. M.; Rini, B. I.; Picus, J.; Gable, P.; Torti, F. 
M.; Kaplan, E.; Vogelzang, N. J. J. Clin. Oncol. 2004, 22, 1025–1033. 
(334)  McCague, R.; Rowlands, M. G.; Barrie, S. E.; Houghton, J. J. Med. Chem. 1990, 33, 3050–3055. 
(335)  Laughton, C. A.; Neidle, S. J. Med. Chem. 1990, 33, 3055–3060. 
(336)  Mak, A. Y.; Swinney, D. C. J. Am. Chem. Soc. 1992, 114, 8309–8310. 
(337)  Hosaka, M.; Oshima, H.; Troen, P. Acta Endocrinol. 1980, 94, 389–396. 
(338)  De Bono, J. S.; Logothetis, C. J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K. N.; Jones, R. 
J.; Goodman, O. B.; Saad, F.; Staffurth, J. N.; Mainwaring, P.; Harland, S.; Flaig, T. W.; Hutson, 
T. E.; Cheng, T.; Patterson, H.; Hainsworth, J. D.; Ryan, C. J.; Sternberg, C. N.; Ellard, S. L.; 
Fléchon, A.; Saleh, M.; Scholz, M.; Efstathiou, E.; Zivi, A.; Bianchini, D.; Loriot, Y.; Chieffo, 
N.; Kheoh, T.; Haqq, C. M.; Scher, H. I. New Eng. J. Med. 2011, 364, 1995–2005. 
(339)  Habib, F. K. University of Edinburgh, Personal Communication. 
(340)  Handratta, V. D.; Vasaitis, T. S.; Njar, V. C. O.; Gediya, L. K.; Kataria, R.; Chopra, P.; Newman, 
D.; Farquhar, R.; Guo, Z.; Qiu, Y.; Brodie, A. M. H. J. Med. Chem. 2005, 48, 2972–2984. 
(341)  Sarma, J. C. Ind. J. Chem. Section B. 1994, 33, 790–791. 
(342)  De Nanteuil, G.; Portevin, B.; Gloanec, P.; Parmentier, J.-G.; Benoist, A.; Verbeuren, T.; Rupin, 
A.; Courchay, C.; Simonet, S. US2009082393A1.pdf 2009, US 2009/0082393 A1. 
(343)  Tanrikulu, Y.; Krüger, B.; Proschak, E. Drug Discovery Today 2013, 18, 358–364. 
(344)  Murray, C. W.; Rees, D. C. Nat. Chem. 2009, 1, 187–192. 
(345)  Love, R. R.; Leventhal, H.; Easterling, D. V; Nerenz, D. R. Cancer 1989, 63, 604–612. 
(346)  Lesch, H. P.; Kaikkonen, M. U.; Pikkarainen, J. T.; Ylä-Herttuala, S. Exp. Opin. Drug. Del. 2010, 
7, 551–564. 
(347)  Zhao, X.; Li, H.; Lee, R. J. Exp. Opin. Drug. Del. 2008, 5, 309–319. 
(348)  Huang, C.-M.; Wu, Y.-T.; Chen, S.-T. Chemistry & Biology 2000, 7, 453–461. 
(349)  Ruoslahti, E. Annual Review of Cell and Developmental Biology 1996, 12, 697–715. 
(350)  Rojanasakul, Y. Adv. Drug Deliv. Rev. 1996, 18, 115–131. 
(351)  Shin, S. U.; Friden, P.; Moran, M.; Olson, T.; Kang, Y. S.; Pardridge, W. M.; Morrison, S. L. 
Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2820–2824. 
(352)  Ting, R.; Harwig, C.; auf dem Kebller, U.; McCormick, S.; Austin, P.; Overall, C. M.; Adam, M. 
J.; Ruth, T. J.; Perrin, D. M. J. Am. Chem. Soc. 2008, 130, 12045–12055. 
(353)  Dal Pozzo, A.; Ni, M.-H.; Esposito, E.; Dallavalle, S.; Musso, L.; Bargiotti, A.; Pisano, C.; Vesci, 
L.; Bucci, F.; Castorina, M.; Foderà, R.; Giannini, G.; Aulicino, C.; Penco, S. Bioorg. Med. 
Chem. 2010, 18, 64–72. 
References 
 
	   386	  
(354)  Pierschbacher, M. D.; Ruoslahti, E. Nature 1984, 309, 30–33. 
(355)  Gumbiner, B. M. Cell 1996, 84, 345–357. 
(356)  Danhier, F.; Breton, A. Le; Préat, V. Mol. Pharmaceut. 2012, 9, 2961–2973. 
(357)  Pierschbacher, M. D.; Polarek, J. W.; Craig, W. S.; Tschopp, J. F.; Sipes, N. J.; Harper, J. R. J. 
Cell. Biochem. 1994, 56, 150–154. 
(358)  Desgrosellier, J. S.; Cheresh, D. A. Nat. Rev. Cancer 2010, 10, 9–22. 
(359)  Takayama, S.; Ishii, S.; Ikeda, T.; Masamura, S.; Doi, M.; Kitajima, M. Anticancer Res. 2005, 25, 
79. 
(360)  Furger, K. A.; Allan, A. L.; Wilson, S. M.; Hota, C.; Vantyghem, S. A.; Postenka, C. O.; Al-
Katib, W.; Chambers, A. F.; Tuck, A. B. Mol. Cancer Res. 2003, 1, 810. 
(361)  Sheldrake, H. M.; Patterson, L. H. Curr. Cancer Drug Targets 2009, 9, 519. 
(362)  Hosotani, R.; Kawaguchi, M.; Masui, T.; Koshiba, T.; Ida, J.; Fujimoto, K.; Wada, M.; Doi, R.; 
Imamura, M. Pancreas 2002, 25, e30–35. 
(363)  Humphries, M. J.; Akiyama, S. K.; Komoriya, A.; Olden, K.; M., Y. K. J. Cell. Biol. 1986, 103, 
2637–2647. 
(364)  Saiki, I.; J., M.; Matsuno, K.; Ogawa, R.; Nishi, N.; Tokura, S.; Azuma, I. Jpn. J. Cancer. Res. 
1990, 81, 660–667. 
(365)  Gehlsen, K. R.; Argraves, W. S.; Pierschbacher, M. D.; Ruoslahti, E. J. Cell. Biol. 1988, 106, 
925–930. 
(366)  Cheng, Z.; Levi, J.; Xiong, Z.; Gheysens, O.; Keren, S.; Chen, X.; Gambhir, S. S. Bioconjug. 
Chem. 2006, 17, 662–669. 
(367)  Dall’Angelo, S.; Zhang, Q.; Fleming, I. N.; Piras, M.; Schweiger, L. F.; O’Hagan, D.; Zanda, M. 
Org. Biomol. Chem. 2013, 11, 4551–4558. 
(368)  Mukhopadhyay, S.; Barnés, C. M.; Haskel, A.; Short, S. M.; Barnes, K. R.; Lippard, S. J. 
Bioconjug. Chem. 2007, 19, 39–49. 
(369)  Hertzberg, R. P.; Caranfa, M. J.; Hecht, S. M. Biochemistry 1989, 28, 4629–4638. 
(370)  Richter, J. M.; Whitefield, B. W.; Maimone, T. J.; Lin, D. W.; Castroviejo, M. P.; Baran, P. S. J. 
Am. Chem. Soc. 2007, 129, 12857–12869. 
(371)  Lassoie, M.-A.; Broeders, F.; Collart, P.; Defrère, L.; De Laveleye-Defais, F.; Demaude, T.; 
Gassama, A.; Guillaumet, G.; Hayez, J.-C.; Kiss, L.; Knerr, L.; Nicolas, J.-M.; Norsikian, S.; 
Quéré, L.; Routier, S.; Verbois, V.; Provins, L. Bioorg. Med. Chem. Lett. 2007, 17, 142–146. 
(372)  Fruttero, R.; Crosetti, M.; Chegaev, K.; Guglielmo, S.; Gasco, A.; Berardi, F.; Niso, M.; Perrone, 
R.; Panaro, M. A.; Colabufo, N. A. J. Med. Chem. 2010, 53, 5467–5475. 
(373)  Torrini, I.; Zecchini, P. Z.; Agrosi, F.; Paradisi, M. P. J. Heterocycl. Chem. 1986, 23, 1459–1463. 
(374)  Wang, A. X.; Zheng, B. Z.; D’Andrea, S.; Meanwell, Nicholas, A.; Scola, P. M. 2008, 
WO2008064057 (A1). 
References 
 
	   387	  
(375)  Gurevich, V. S.; Lominadze, D. G.; Adeagbo, A. S. O.; Burov, S. V; Popov, Y. G.; Leko, M. V; 
Miller, F. N.; Schuschke, D. A. Pharmacol. 1997, 55, 1–9. 
(376)  Welsh, D. J.; Smith, D. K. Org. Biomol. Chem. 2011, 9, 4795–4801. 
(377)  Allen, D. R.; Kyung-Lee, S.-H. Preparation of protected amino acids 2003, US2003/235430 A1. 
(378)  Deal, K. A.; Welch, M. J. J. Med. Chem. 1997, 40, 3986–3989. 
(379)  Carpino, L. A.; Sadat-Aalaee, D.; Chao, H. G.; DeSelms, R. H. J. Am. Chem. Soc. 1990, 112, 
1515–1521. 
(380)  Carpino, L. A.; El-Faham, A. Tetrahedron 1999, 55, 6813–6830. 
(381)  Marin, J.; Briand, J.-P.; Guichard, G. Eur. J. Org. Chem. 2008, 2008, 1005–1012. 
(382)  Machauer, R.; Waldmann, H. Angew. Chem. Int. Ed. 2000, 39, 1449–1453. 
(383)  Wen, S.; Packham, G.; Ganesan, A. J. Org. Chem. 2008, 73, 9353–9361. 
(384)  Dijkgraaf, I.; Rijnders, A. Y.; Soede, A.; Dechesne, A. C.; Van Esse, G. W.; Brouwer, A. J.; 
Corstens, F. H. M.; Boerman, O. C.; Rijkers, D. T. S.; Liskamp, R. M. J. Org. Biomol. Chem. 
2007, 5, 935–944. 
(385)  Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S. L.; Jonczyk, A.; Kessler, H. J. Am. Chem. 
Soc. 1996, 118, 7461–7472. 
(386)  Nortcliffe, A.; Botting, N. P.; O’Hagan, D. Org. Biomol. Chem. 2013, 11, 4657–4671. 
(387)  Nagib, D. A.; MacMillan, D. W. C. Nature 2011, 480, 224–228. 
(388)  Ji, Y.; Brueckl, T.; Baxter, R. D.; Fujiwara, Y.; Seiple, I. B.; Su, S.; Blackmond, D. G.; Baran, P. 
S. Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 14411–14415. 
(389)  Li, X.-G.; Dall’Angelo, S.; Schweiger, L. F.; Zanda, M.; O’Hagan, D. Chem. Commun. 2012, 48, 
5247–5249. 
(390)  Dall’Angelo, S.; Bandaranayaka, N.; Windhorst, A. D.; Vugts, D. J.; Van der Born, D.; Onega, 
M.; Schweiger, L. F.; Zanda, M.; O’Hagan, D. Nucl. Med. Biol. 2013, 40, 464–470. 
(391)  Kularatne, S. A.; Wang, K.; Santhapuram, H.-K. R.; Low, P. S. Molecular Pharmaceutics 2009, 
6, 780–789. 
(392)  Banerjee, S. R.; Foss, C. A.; Castanares, M.; Mease, R. C.; Byun, Y.; Fox, J. J.; Hilton, J.; 
Lupold, S. E.; Kozikowski, A. P.; Pomper, M. G. J. Med. Chem. 2008, 51, 4504–4517. 
(393)  Nitromed 2005, p. WO2005/30135 A2. 
(394)  Greenwald, R. B.; Choe, Y. H.; Conover, C. D.; Shum, K.; Wu, D.; Royzen, M. J. Med. Chem. 
2000, 43, 475–487. 
(395)  Codelli, J. A.; Baskin, J. M.; Agard, N. J.; Bertozzi, C. R. J. Am. Chem. Soc. 2008, 130, 11486–
11493. 
(396)  Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923–2925. 
References 
 
	   388	  
(397)  Armarego, W. L. F.; Chai, C. L. L. Purification of Laboratory Chemicals; 6th ed.; Butterworth-
Heinemann, 2009. 
(398)  Douglas, A. W. Can. J. Chem. 1978, 56, 2129–2133. 
(399)  Bahrami, K.; Khodaei, M. M.; Khedri, M. Chem. Lett. 2007, 36, 1324–1325. 
(400)  Sakai, H.; Ito, K.; Sekiya, M. Chem. Pharm. Bull. 1873, 21, 2257–2264. 
(401)  Mukaiyama, T.; T., T.; Watanabe, K. Chem. Lett. 1978, 7, 1057–1060. 
(402)  Okabe, M.; Sun, R.-C.; Scalone, M.; Jibilian, C. H.; Hutchings, S. D. J. Org. Chem. 1995, 60, 
767–771. 
(403)  Barton, D. H. R.; Cox, J. D. J. Chem. Soc. 1948, 783–793. 
(404)  Miyaoka, H.; Tamura, M.; Yamada, Y. Tetrahedron 2000, 56, 8083–8094. 
(405)  Hu, M.; Li, L.; Wu, H.; Su, Y.; Yang, P.-Y.; Uttamchandani, M.; Xu, Q.-H.; Yao, S. Q. J. Am. 
Chem. Soc 2011, 133, 12009–12020. 
(406)  NICOX 2011, WO2011/29065 A1 p76. 
(407)  Colombo, R.; Mingozzi, M.; Belvisi, L.; Arosio, D.; Piarulli, U.; Carenini, N.; Perego, P.; 
Zaffaroni, N.; De Cesare, M.; Castiglioni, V.; Scanziani, E.; Gennari, C. J. Med. Chem. 2012, 55, 
10460–10474. 
(408)  Buechi, G.; Roberts, E. C. J. Org. Chem. 1968, 33, 460–462. 
(409)  Liu, F.; Zha, H.-Y.; Yao, Z.-J. J. Org. Chem. 2003, 68, 6679–6684. 
(410)  Jung, M. E.; Rohloff, J. C. J. Org. Chem. 1985, 50, 4909–4913. 
(411)  Wünsch, E.; Fries, G.; Zwick, A. Chem. Ber. 1958, 91, 542–547. 
(412)  Ross, A. J.; Lang, H. L.; Jackson, R. F. W. J. Org. Chem. 2009, 75, 245–248. 
(413)  Gerisch, S.; Jakubke, H.-D.; Kreuzfeld, H.-J. Tetrahedron: Asymmetry 1995, 6, 3039–3045. 
(414)  Szymańska, A.; Wegner, K.; Łankiewicz, L. Helv. Chim. Acta 2003, 86, 3326–3331. 
(415)  Couturier, C.; Blanchet, J.; Schlama, T.; Zhu, J. Org. Lett. 2006, 8, 2183–2186. 
(416)  Ikegame, F.; Yamamoto, A.; Sekine, T.; Ishikawa, T.; Kusame-Eguchi, K.; Kusama, T.; 
Watanabe, K. Chem. Pharm. Bull. 2000, 48, 278–280. 
(417)  Strazzolini, P.; Melloni, T.; Giumanini, A. G. Tetrahedron 2001, 57, 9033–9043. 
(418)  ChemImpex Int. Catalogue #: 12219, CAS: 42417-76-5. 
(419)  Schwyzer, R.; Iselin, B.; Kappeler, H.; Riniker, B.; Rittel, W.; Zuber, H. Helv. Chim. Acta 1963, 
46, 1975–1996. 
(420)  Xia, Z.; Smith, C. D. J. Org. Chem. 2001, 66, 5241–5244. 
References 
 
	   389	  
(421)  Zervas, L.; Winitz, M.; Greenstein, J. P. J. Org. Chem. 1957, 22, 1515–1521.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  
